{"title": "PDF", "author": "PDF", "url": "https://ddd.uab.cat/pub/tesis/2014/hdl_10803_285046/arm1de1.pdf", "hostname": "PDF", "description": "PDF", "sitename": "PDF", "date": "PDF", "id": "PDF", "license": "PDF", "body": "PDF", "comments": "PDF", "commentsbody": "PDF", "raw_text": "PDF", "text": "Tesis\u00a0Doctoral \u00a0\n\u00a0\nAAPPLLIICCAACCII\u00d3\u00d3NN\u00a0\u00a0DDEE\u00a0\u00a0TTEESSTTSS\u00a0\u00a0SSEERROOLL\u00d3\u00d3GGIICCOOSS\u00a0\u00a0\nPPAARRAA\u00a0\u00a0LLAA\u00a0\u00a0IIDDEENNTTIIFFIICCAACCII\u00d3\u00d3NN\u00a0\u00a0DDEE\u00a0\u00a0IINNFFEECCCCIIOONNEESS\u00a0\u00a0RREECCIIEENNTTEESS\u00a0\u00a0\n\u00a0\u00a0PPOORR\u00a0\u00a0VVIIHH\u00a0\u00a0EENN\u00a0\u00a0CCAATTAALLUU\u00d1\u00d1AA\u00a0\u00a0\n \nMemoria presentada por Anabel Romero Morales para optar al grado de Doctora por la Universidad Aut\u00f3noma de Barcelona \n\u00a0\nDoctoranda:\u00a0\nAnabel\u00a0Romero\u00a0 Morales\u00a0\n\u00a0\nDirectora:\u00a0\nDra.\u00a0Anna\u00a0Esteve\u00a0G\u00f3mez\u00a0\n\u00a0\nTutor:\u00a0\u00a0\nDr.\u00a0Jordi\u00a0 Casabona \u00a0Barbar\u00e0  \n \nPrograma \u00a0de\u00a0Doctorado \u00a0en\u00a0Salud\u00a0P\u00fablica\u00a0y\u00a0Metodolog\u00eda \u00a0de\u00a0la\u00a0investigaci\u00f3n \u00a0\nBiom\u00e9dica \u00a0\nDepartamento \u00a0de\u00a0Pediatr\u00eda,\u00a0Obstetricia \u00a0y\u00a0Ginecolog\u00eda\u00a0y \u00a0Medicina \u00a0Preventiva. \u00a0\nFacultad\u00a0de \u00a0Medicina \u00a0\u2013\u00a0Universidad \u00a0Aut\u00f3noma \u00a0de\u00a0Barcelona\u00a0\n\u00a0\n\u00a0\nBarcelona, \u00a02014\u00a0\n II\u00a0\n \n               \n \n                            AGRADECIMIENTOS\u00a0\n -  IIIAGRADECIMIENTOS \u00a0\n\u00a0\n\u00a0\nEn\u00a0 primer\u00a0 lugar\u00a0 me\u00a0 gustar\u00eda\u00a0 dar\u00a0 las\u00a0 gracias\u00a0 a\u00a0 la\u00a0 directora\u00a0 y\u00a0 el \u00a0t u t o r \u00a0d e \u00a0m i \u00a0t e s i s \u00a0p o r \u00a0l a \u00a0\noportunidad\u00a0que\u00a0me\u00a0han\u00a0ofrecido\u00a0 al\u00a0poder\u00a0realizar\u00a0esta\u00a0tesis:\u00a0A nna\u00a0Esteve\u00a0y\u00a0Jordi\u00a0Casabona.\u00a0\u00a0\n\u00a0\nEn\u00a0segundo\u00a0lugar\u00a0debo\u00a0dar\u00a0las\u00a0gracias\u00a0al\u00a0Servicio\u00a0de\u00a0Microbiolo g\u00eda\u00a0del\u00a0Hospital\u00a0Universitari\u00a0\nGermans\u00a0Trias\u00a0i\u00a0Pujol.\u00a0En\u00a0especial\u00a0a\u00a0Victoria\u00a0Gonz\u00e1lez,\u00a0por\u00a0hab er\u00a0analizado\u00a0las\u00a0m\u00e1s\u00a0de\u00a05.000\u00a0\nmuestras\u00a0que\u00a0han\u00a0dado\u00a0lugar\u00a0a\u00a0los\u00a0trabajos\u00a0que\u00a0conforman\u00a0esta\u00a0t esis.\u00a0Y\u00a0tambi\u00e9n\u00a0muchas\u00a0gracias\u00a0a\u00a0\nElisa\u00a0Martr\u00f3\u00a0y.\u00a0Lurdes\u00a0Matas.\u00a0\n\u00a0\nQuiero\u00a0dar\u00a0las\u00a0gracias\u00a0de\u00a0manera\u00a0especial\u00a0a\u00a0Jos\u00e9\u00a0M\u00aa\u00a0Mir\u00f3\u00a0y\u00a0a\u00a0To m\u00e1s\u00a0Pumarola,\u00a0as\u00ed\u00a0como\u00a0al\u00a0resto\u00a0\ndel\u00a0equipo\u00a0del\u00a0Hospital\u00a0Cl\u00ednic\u00a0por\u00a0su\u00a0implicaci\u00f3n\u00a0en\u00a0el\u00a0proyect o\u00a0AERI,\u00a0especialmente\u00a0en\u00a0el\u00a0trabajo\u00a0\nde\u00a0Resistencias,\u00a0pero\u00a0tambi\u00e9n\u00a0en\u00a0cada\u00a0uno\u00a0de\u00a0los\u00a0trabajos\u00a0que\u00a0c onforman\u00a0esta\u00a0tesis.\u00a0Muchas\u00a0\ngracias\u00a0Fernando,\u00a0Mar\u00eda\u00a0y\u00a0Christian.\u00a0Y\u00a0muchas\u00a0gracias\u00a0Omar,\u00a0por que\u00a0a\u00a0pesar\u00a0de\u00a0estar\u00a0al\u00a0otro\u00a0lado\u00a0\ndel\u00a0oc\u00e9ano\u00a0fue\u00a0muy\u00a0f\u00e1cil\u00a0trabajar\u00a0contigo.\u00a0\n\u00a0El\u00a0trabajo\u00a0de\u00a0resistencias\u00a0no\u00a0hubiera\u00a0sido\u00a0posible\u00a0tampoco\u00a0sin\u00a0 la\u00a0colaboraci\u00f3n\u00a0de\u00a0la\u00a0Fundaci\u00f3\u00a0\nIrsiCaixa.\u00a0Muchas\u00a0gracias\u00a0Teresa \u00a0por\u00a0tu\u00a0tiempo\u00a0y\u00a0dedicaci\u00f3n\u00a0al\u00a0 genotipado\u00a0de\u00a0las\u00a0muestras\u00a0del\u00a0\nproyecto\u00a0AERI,\u00a0y\u00a0por\u00a0estar\u00a0siemp re\u00a0disponible\u00a0para\u00a0resolver\u00a0mis\u00a0dudas\u00a0sobre\u00a0resistencias.\u00a0\n\u00a0Debo\u00a0dar\u00a0las\u00a0gracias\u00a0a\u00a0todo\u00a0el\u00a0grupo\u00a0de\u00a0estudio\u00a0AERI,\u00a0a\u00a0los\u00a0que \u00a0participaron\u00a0del\u00a02003\u00a0al\u00a02005\u00a0y\u00a0\ntambi\u00e9n\u00a0a\u00a0los\u00a0que\u00a0siguieron\u00a0participando\u00a0de\u00a0manera\u00a0voluntaria\u00a0a \u00a0partir\u00a0del\u00a02006.\u00a0Y\u00a0muchas\u00a0\ngracias\u00a0tambi\u00e9n\u00a0a\u00a0las\u00a0personas\u00a0de l\u00a0CEEISCAT\u00a0que\u00a0trabajaron\u00a0en\u00a0l os\u00a0inicios\u00a0del\u00a0proyecto\u00a0AERI:\u00a0Cris,\u00a0\nXus,\u00a0Diana,\u00a0Meritxell,\u00a0Vanessa.\u00a0\n\u00a0Muchas\u00a0 gracias\u00a0 a\u00a0 Meritxell\u00a0 y\u00a0 Berta\u00a0 por\u00a0 confiar\u00a0 en\u00a0 mi\u00a0 desde\u00a0 el\u00a0 primer\u00a0 momento.\u00a0 Gracias\u00a0\ntambi\u00e9n\u00a0al\u00a0resto\u00a0de\u00a0compa\u00f1eras\u00a0y\u00a0compa\u00f1eros\u00a0con\u00a0los\u00a0que\u00a0compart \u00ed\u00a0mi\u00a0tiempo\u00a0en\u00a0el\u00a0CEEISCAT:\u00a0\nCinta,\u00a0Laura,\u00a0Cristina,\u00a0Laia\u00a0Ferrer,\u00a0Eva\u00a0Loureiro,\u00a0Eva\u00a0Puchol,\u00a0 Rossie,\u00a0Evelin,\u00a0N\u00faria\u00a0Murtra,\u00a0Nuria\u00a0\nVives,\u00a0Esteve,\u00a0Lidia,\u00a0Jordi\u00a0Figuerola,\u00a0Aitor,\u00a0Joan,\u00a0Alexandra,\u00a0 Laia\u00a0Carrasco\u00a0y\u00a0Montse.\u00a0Y\u00a0menci\u00f3n\u00a0\nespecial\u00a0para\u00a0Rafa,\u00a0por\u00a0haberse\u00a0 encargado\u00a0tan\u00a0bien\u00a0de\u00a0llevar\u00a0de \u00a0un\u00a0lado\u00a0para\u00a0otro\u00a0las\u00a0m\u00e1s\u00a0de\u00a05.000\u00a0\nmuestras\u00a0de\u00a0esta\u00a0tesis.\u00a0\u00a0\n\u00a0AGRADECIMIENTOS\u00a0\u00a0\n IVQuiero\u00a0dar\u00a0las\u00a0gracias\u00a0a\u00a0Mar\u00eda\u00a0Sala\u00a0y\u00a0a\u00a0Xavier\u00a0Castells\u00a0del\u00a0Ser vicio\u00a0de\u00a0Epidemiolog\u00eda\u00a0del\u00a0Hospital\u00a0\ndel\u00a0Mar,\u00a0por\u00a0abrirme\u00a0las\u00a0puertas\u00a0de\u00a0la\u00a0investigaci\u00f3n\u00a0en\u00a0cribado \u00a0de\u00a0c\u00e1ncer\u00a0de\u00a0mama.\u00a0Gracias\u00a0a\u00a0mis\u00a0\ncompa\u00f1eras\u00a0de\u00a0despacho:\u00a0Laia,\u00a0Marta\u00a0y\u00a0Jordi,\u00a0por\u00a0formar\u00a0un\u00a0aut\u00e9 ntico\u00a0equipo,\u00a0y\u00a0por\u00a0hacer\u00a0del\u00a0\ntrabajo\u00a0un\u00a0lugar\u00a0agradable.\u00a0Y\u00a0tambi\u00e9n\u00a0muchas\u00a0gracias\u00a0al\u00a0resto\u00a0d el\u00a0personal\u00a0del\u00a0servicio,\u00a0sobretodo\u00a0\na\u00a0Esther\u00a0y\u00a0Merc\u00e8.\u00a0Fue\u00a0un\u00a0aut\u00e9ntico\u00a0placer\u00a0trabajar\u00a0con\u00a0todos\u00a0vo sotros.\u00a0\n\u00a0\nMuch\u00edsimas\u00a0gracias\u00a0a\u00a0Mireia\u00a0Espallargues\u00a0y\u00a0Joan\u00a0Pons\u00a0por\u00a0acoger me\u00a0en\u00a0la\u00a0Agencia\u00a0de\u00a0Calidad\u00a0y\u00a0\nEvaluaci\u00f3n\u00a0Santiarias\u00a0de\u00a0Catalu\u00f1a.\u00a0Muchas\u00a0gracias\u00a0Dolors\u00a0Estrad a\u00a0por\u00a0tu\u00a0energ\u00eda\u00a0y\u00a0ganas\u00a0de\u00a0\nense\u00f1arme.\u00a0Muchas\u00a0gracias\u00a0Noem\u00ed,\u00a0por\u00a0ser\u00a0mi\u00a0psic\u00f3loga\u00a0particular\u00a0y\u00a0por\u00a0compartir\u00a0caf\u00e9s\u00a0y\u00a0pizzas.\u00a0Y\u00a0muchas\u00a0gracias\u00a0al\u00a0resto\u00a0de\u00a0compa\u00f1eras\u00a0de\u00a0la\u00a0agencia:\u00a0J\u00falia,\u00a0D olors\u00a0Ben\u00edtez,\u00a0Ana,\u00a0Marta,\u00a0Vicky,\u00a0\nMarie.\u00a0Realmente\u00a0es\u00a0estupendo\u00a0 trabajar\u00a0con\u00a0todas\u00a0vosotras.\u00a0\n\u00a0\nMuchas\u00a0gracias\u00a0a\u00a0mis\u00a0bellas\u00a0amig as:\u00a0Bea,\u00a0Diana,\u00a0Cris,\u00a0Raquel,\u00a0G emma,\u00a0Davinia,\u00a0Carmen,\u00a0Esther,\u00a0\nLaura,\u00a0Zulema,\u00a0Sara,\u00a0Noem\u00ed,\u00a0Irene\u00a0y\u00a0Silvia.\u00a0Y\u00a0especialmente,\u00a0gr acias\u00a0a\u00a0Gemma\u00a0Arnaiz,\u00a0por\u00a0haber\u00a0\ncreado\u00a0una\u00a0portada\u00a0tan\u00a0bonita.\u00a0Gr acias\u00a0Marga\u00a0por\u00a0esos\u00a0buenos\u00a0ra tos\u00a0de\u00a0costura\u00a0y\u00a0patronaje.\u00a0\n\u00a0\nMuchas\u00a0gracias\u00a0N\u00faria,\u00a0por\u00a0ofrecerme\u00a0tu\u00a0amistad,\u00a0en\u00a0el\u00a0CEEISCAT, \u00a0en\u00a0el\u00a0PRBB\u00a0y\u00a0m\u00e1s\u00a0all\u00e1!\u00a0Ser\u00eda\u00a0\nestupendo\u00a0volver\u00a0a\u00a0coincidir\u00a0c omo\u00a0compa\u00f1eras\u00a0de\u00a0trabajo.\u00a0\n\u00a0\nMuch\u00edsimas\u00a0gracias\u00a0a\u00a0mi\u00a0familia:\u00a0mis\u00a0padres,\u00a0mi\u00a0hermana,\u00a0mi\u00a0sob rino,...Pero,\u00a0sobretodo,\u00a0gracias\u00a0\ninfinitas\u00a0a\u00a0mi\u00a0madre,\u00a0por\u00a0demostrarme\u00a0que\u00a0todo\u00a0es\u00a0posible.\u00a0Mam\u00e1 ,\u00a0eres\u00a0la\u00a0mejor.\u00a0Y\u00a0muchas\u00a0\ngracias\u00a0a\u00a0Ingrid\u00a0y\u00a0al\u00a0resto\u00a0del\u00a0 Servicio\u00a0de\u00a0Cardiolog\u00eda\u00a0del\u00a0Hos pital\u00a0Joan\u00a0XXIII\u00a0por\u00a0hacerlo\u00a0posible.\u00a0\n\u00a0Vull\u00a0donar\u00a0les\u00a0gr\u00e0cies\u00a0de\u00a0manera\u00a0 molt\u00a0especial\u00a0al\u00a0Lloren\u00e7,\u00a0per\u00a0 ser\u00a0tan\u00a0bon\u00a0nen\u00a0i\u00a0 estimar\u2010me\u00a0tant.\u00a0\nGr\u00e0cies\u00a0Josep,\u00a0perqu\u00e8\u00a0has\u00a0viscut\u00a0aquesta\u00a0tesis\u00a0amb\u00a0mi\u00a0des\u00a0del\u00a0m inut\u00a00\u00a0i\u00a0en\u00a0tot\u00a0moment\u00a0m\u2019has\u00a0\nrecolzat\u00a0i\u00a0m\u2019has\u00a0ajudat\u00a0a\u00a0que\u00a0arrib\u00e9s\u00a0a\u00a0bon\u00a0port.\u00a0I,\u00a0per\u00a0\u00faltim, \u00a0gr\u00e0cies\u00a0a\u00a0tu,\u00a0Laia!\u00a0Qu\u00e8\u00a0bonica\u00a0\u00e9s\u00a0la\u00a0\nvida,\u00a0ara\u00a0que\u00a0est\u00e0s\u00a0a\u00a0punt\u00a0d\u2019arri bar\u00a0al\u00a0m\u00f3n.\u00a0Aquesta\u00a0tesis\u00a0\u00e9s\u00a0p er\u00a0a\u00a0tu.\u00a0\u00a0\u00a0\n\u00a0PRESENTACI\u00d3N\u00a0\n -  VPRESENTACI\u00d3N \u00a0\n\u00a0\n\u00a0\nEsta\u00a0tesis\u00a0doctoral\u00a0es\u00a0el\u00a0resultado\u00a0de\u00a0la\u00a0aplicaci\u00f3n\u00a0de\u00a0los\u00a0tes ts\u00a0serol\u00f3gicos\u00a0para\u00a0identificar\u00a0\ninfecciones\u00a0recientes\u00a0entre\u00a0los\u00a0nuevos\u00a0diagn\u00f3sticos\u00a0de\u00a0VIH,\u00a0y\u00a0e st\u00e1\u00a0formada\u00a0por\u00a0cuatro\u00a0trabajos\u00a0\nque\u00a0han\u00a0dado\u00a0lugar\u00a0a\u00a0cuatro\u00a0publicaciones,\u00a0dos\u00a0de\u00a0ellas\u00a0publica das\u00a0en\u00a0revistas\u00a0internacionales.\u00a0\nLos\u00a0trabajos\u00a0que\u00a0se\u00a0presentan\u00a0han\u00a0sido\u00a0coordinados\u00a0por\u00a0el\u00a0Centr e\u00a0d'Estudis\u00a0Epidemiol\u00f2gics\u00a0sobre\u00a0\nles\u00a0Infeccions\u00a0de\u00a0Transmissi\u00f3\u00a0Sexual\u00a0i\u00a0Sida\u00a0de\u00a0Catalunya\u00a0(CEEIS CAT),\u00a0y\u00a0han\u00a0participado\u00a0un\u00a0total\u00a0\nde\u00a019\u00a0hospitales,\u00a07\u00a0laboratorios\u00a0de\u00a0atenci\u00f3n\u00a0primaria,\u00a0una\u00a0cl\u00ednica\u00a0de\u00a0infecciones\u00a0de\u00a0transmisi\u00f3n\u00a0\ns e x u a l \u00a0( I T S ) \u00a0y \u00a08 \u00a0c e n t r o s \u00a0d e \u00a0c r i b a d o \u00a0a l t e r n a t i v o s . \u00a0L a \u00a0m a y o r \u00ed a \u00a0d e \u00a0c e n t r o s \u00a0p a r t i c i p a n t e s \u00a0e s t \u00e1 n \u00a0\nubicados\u00a0en\u00a0Catalu\u00f1a,\u00a0pero\u00a0tambi\u00e9n\u00a0han\u00a0participado\u00a0centros\u00a0de\u00a0M adrid,\u00a0la\u00a0Rioja,\u00a0San\u00a0Sebasti\u00e1n\u00a0y\u00a0\nGranada.\u00a0El\u00a0laboratorio\u00a0responsable\u00a0de\u00a0analizar\u00a0las\u00a0muestras\u00a0me diante\u00a0los\u00a0tests\u00a0para\u00a0identificar\u00a0\ninfecciones\u00a0recientes\u00a0fue\u00a0el\u00a0Servicio\u00a0de\u00a0Microbiolog\u00eda\u00a0del\u00a0Hosp ital\u00a0Univesitari\u00a0Germans\u00a0Trias\u00a0i\u00a0\nPujol.\u00a0\u00a0\nEn\u00a0la\u00a0introducci\u00f3n\u00a0se\u00a0describen\u00a0brevemente\u00a0los\u00a0aspectos\u00a0relacio nados\u00a0con\u00a0la\u00a0infecci\u00f3n\u00a0por\u00a0VIH:\u00a0\nla\u00a0biolog\u00eda\u00a0del\u00a0virus,\u00a0la\u00a0historia\u00a0natural,\u00a0el\u00a0diagn\u00f3stico,\u00a0los \u00a0tratamientos\u00a0y\u00a0las\u00a0resistencias\u00a0del\u00a0VIH\u00a0a\u00a0\nlos\u00a0antirretrovirales.\u00a0Tambi\u00e9n\u00a0se\u00a0hace\u00a0una\u00a0revisi\u00f3n\u00a0de\u00a0la\u00a0situaci\u00f3n\u00a0actual\u00a0de\u00a0la\u00a0epidemia\u00a0del\u00a0VIH\u00a0en\u00a0 el\u00a0 mundo,\u00a0 as\u00ed\u00a0 como\u00a0 en\u00a0 Espa\u00f1a\u00a0 y\u00a0 Catalu\u00f1a.\u00a0 En\u00a0 la\u00a0 tercera\u00a0 secci \u00f3n\u00a0 de\u00a0 la\u00a0 introducci\u00f3n,\u00a0 se\u00a0\npresentan\u00a0 los\u00a0 tests\u00a0 serol\u00f3gicos\u00a0 para\u00a0 identificar\u00a0 infecciones\u00a0 re cientes,\u00a0 se\u00a0 comentan\u00a0 sus\u00a0\nfundamentos,\u00a0los\u00a0distintos\u00a0tipos\u00a0de\u00a0tests\u00a0existentes,\u00a0y\u00a0tambi\u00e9n\u00a0se\u00a0comentan\u00a0sus\u00a0limitaciones.\u00a0En\u00a0la\u00a0\n\u00faltima\u00a0secci\u00f3n\u00a0de\u00a0la\u00a0introducci\u00f3n\u00a0se\u00a0exponen\u00a0algunas\u00a0de\u00a0las\u00a0apl icaciones\u00a0m\u00e1s\u00a0frecuentes\u00a0de\u00a0estos\u00a0\ntests\u00a0 en\u00a0 Salud\u00a0 P\u00fablica:\u00a0 expresar\u00a0 la\u00a0 proporci\u00f3n\u00a0 de\u00a0 infecciones\u00a0 r ecientes,\u00a0 describir\u00a0 las\u00a0\ncaracter\u00edsticas\u00a0de\u00a0las\u00a0personas\u00a0infectadas\u00a0recientemente\u00a0y\u00a0esti mar\u00a0la\u00a0prevalencia\u00a0de\u00a0resistencias\u00a0\ntransmitidas\u00a0entre\u00a0los\u00a0pacientes\u00a0con\u00a0infecci\u00f3n\u00a0reciente.\u00a0\nEn\u00a0 el\u00a0 primer\u00a0 art\u00edculo\u00a0 se\u00a0 introduce\u00a0 el\u00a0 Serological\u00a0 Testing\u00a0Algorithm \u00a0for\u00a0Recent\u00a0 HIV\u00a0\nSeroconversions\u00a0(STARHS)\u00a0por\u00a0primera\u00a0vez\u00a0en\u00a0Espa\u00f1a.\u00a0Este\u00a0test\u00a0permite\u00a0identifi car\u00a0los\u00a0pacientes\u00a0\ncon\u00a0 infecci\u00f3n\u00a0 reciente\u00a0 por\u00a0 VIH.\u00a0 Aplicando\u00a0 este\u00a0 test\u00a0 se\u00a0 han\u00a0 desc rito\u00a0 las\u00a0 caracter\u00edsticas\u00a0\nepidemiol\u00f3gicas\u00a0de\u00a0los\u00a0pacientes\u00a0con\u00a0infecci\u00f3n\u00a0reciente\u00a0por\u00a0VIH .\u00a0Este\u00a0proyecto,\u00a0conocido\u00a0con\u00a0el\u00a0\nnombre\u00a0de\u00a0Algoritme\u00a0Estandarditzat\u00a0per\u00a0la\u00a0detecci\u00f3\u00a0de\u00a0Recent\u00a0Infectats\u00a0pel\u00a0VIH\u00a0(AERI\u2010VIH),\u00a0fue\u00a0\nf i n a n c i a d o \u00a0p o r \u00a0l a \u00a0F u n d a c i \u00f3 \u00a0L a \u00a0M a r a t \u00f3 \u00a0d e \u00a0T V 3 , \u00a0y \u00a0p a r t i c i p a r o n \u00a0c e n tros\u00a0 situados\u00a0 en\u00a0 Catalu\u00f1a,\u00a0\nMadrid,\u00a0San\u00a0Sebasti\u00e1n,\u00a0Granada\u00a0y\u00a0La\u00a0Rioja.\u00a0\u00a0\nA\u00a0partir\u00a0del\u00a0mismo\u00a0estudio\u00a0AERI,\u00a0realizado\u00a0entre\u00a0los\u00a0a\u00f1os\u00a02003\u00a0 \u2013\u00a02005,\u00a0los\u00a0laboratorios\u00a0del\u00a0\nHospital\u00a0 Cl\u00ednic\u00a0 y\u00a0 de\u00a0 la\u00a0 Fundaci\u00f3\u00a0 IrsiCaixa\u00a0 realizaron\u00a0 el\u00a0 genoti pado\u00a0 de\u00a0 las\u00a0 muestras\u00a0PRESENTACI\u00d3N\u00a0\n VIcorrespondientes\u00a0 a\u00a0 los\u00a0 pacientes\u00a0 i dentificados\u00a0 mediante\u00a0 el\u00a0 test \u00a0 STARHS\u00a0 como\u00a0 infecciones\u00a0\nrecientes.\u00a0A\u00a0partir\u00a0de\u00a0esos\u00a0genotipados\u00a0se\u00a0estim\u00f3\u00a0la\u00a0prevalenci a\u00a0de\u00a0resistencias\u00a0transmitidas\u00a0y\u00a0de\u00a0\nsubtipos\u00a0de\u00a0VIH\u20101\u00a0no\u00a0B.\u00a0De\u00a0este\u00a0t rabajo\u00a0surgi\u00f3\u00a0el\u00a0segundo\u00a0art\u00edc ulo\u00a0de\u00a0esta\u00a0tesis\u00a0doctoral.\u00a0\nDespu\u00e9s\u00a0de\u00a0estos\u00a0dos\u00a0trabajos\u00a0realizados\u00a0con\u00a0muestras\u00a0recogidas \u00a0entre\u00a0los\u00a0a\u00f1os\u00a02003\u00a0y\u00a02005,\u00a0\nse\u00a0 incorpor\u00f3\u00a0 la\u00a0 identificaci\u00f3n\u00a0 de\u00a0 infecciones\u00a0 recientes\u00a0 por\u00a0 VIH \u00a0 al\u00a0 Sistema\u00a0 Integrado\u00a0 de\u00a0 la\u00a0\nVigilancia\u00a0Epidemiol\u00f3gica\u00a0del\u00a0SI DA/VIH/ITS\u00a0(SIVES)\u00a0de\u00a0Catalu\u00f1a. \u00a0Para\u00a0este\u00a0nuevo\u00a0periodo\u00a0de\u00a0\nestudio,\u00a0 debido\u00a0 a\u00a0 que\u00a0 el\u00a0 test\u00a0 us ado\u00a0 en\u00a0 el\u00a0 primer\u00a0 estudio,\u00a0 el\u00a0 te st\u00a0 Vironostika,\u00a0 dej\u00f3\u00a0 de\u00a0 estar\u00a0\ndisponible\u00a0comercialmente,\u00a0el\u00a0laboratorio\u00a0empez\u00f3\u00a0a\u00a0usar\u00a0un\u00a0nuev o\u00a0test,\u00a0el\u00a0test\u00a0BED\u2010CEIA.\u00a0Para\u00a0\nasegurar\u00a0que\u00a0los\u00a0resultados\u00a0obtenidos\u00a0por\u00a0ambos\u00a0tests\u00a0eran\u00a0comp arables,\u00a0se\u00a0realiz\u00f3\u00a0un\u00a0estudio\u00a0de\u00a0\nconcordancia.\u00a0El\u00a0tercer\u00a0cap\u00edtulo\u00a0de\u00a0esta\u00a0tesis\u00a0doctoral\u00a0present a\u00a0los\u00a0resultados\u00a0de\u00a0este\u00a0estudio\u00a0de\u00a0\nconcordancia.\u00a0\nEn\u00a0el\u00a0siguiente\u00a0cap\u00edtulo\u00a0de\u00a0la\u00a0tesis\u00a0doctoral,\u00a0se\u00a0presentan\u00a0los \u00a0resultados\u00a0de\u00a0la\u00a0incorporaci\u00f3n\u00a0del\u00a0\ntest\u00a0para\u00a0identificar\u00a0infecciones\u00a0recientes\u00a0en\u00a0el\u00a0sistema\u00a0de\u00a0vi gilancia\u00a0del\u00a0VIH\u00a0en\u00a0Catalu\u00f1a,\u00a0durante\u00a0\nel\u00a0 periodo\u00a0 2006\u20102008.\u00a0 En\u00a0 este\u00a0 estud io\u00a0 participaron\u00a0 14\u00a0 hospitale s\u00a0 y\u00a0 8\u00a0 centros\u00a0 de\u00a0 cribado\u00a0\nalternativos\u00a0situados\u00a0en\u00a0su\u00a0mayor\u00eda\u00a0en\u00a0Barcelona\u00a0y\u00a0su\u00a0\u00e1mbito\u00a0me tropolitano,\u00a0y\u00a0tambi\u00e9n\u00a0en\u00a0Lleida,\u00a0\nReus,\u00a0Tortosa,\u00a0Vilafra nca,\u00a0Vic\u00a0y\u00a0Palam\u00f3s.\u00a0\u00a0\nComo\u00a0anexo\u00a0de\u00a0la\u00a0tesis,\u00a0se\u00a0presenta\u00a0un\u00a0trabajo\u00a0en\u00a0el\u00a0cual\u00a0se\u00a0ut ilizaron\u00a0los\u00a0tests\u00a0serol\u00f3gicos\u00a0para\u00a0\nidentificar\u00a0infecciones\u00a0recientes\u00a0para\u00a0obtener\u00a0una\u00a0estimaci\u00f3n\u00a0d e\u00a0la\u00a0incidencia\u00a0de\u00a0VIH\u00a0en\u00a0nuestro\u00a0\nmedio.\u00a0Se\u00a0us\u00f3\u00a0la\u00a0informaci\u00f3n\u00a0procedente\u00a0de\u00a0los\u00a0nuevos\u00a0diagn\u00f3sti cos\u00a0de\u00a0VIH\u00a0identificados\u00a0en\u00a0los\u00a0\nhospitales\u00a0y\u00a0centros\u00a0de\u00a0cribado\u00a0alternativos\u00a0que\u00a0participaron\u00a0e n\u00a0el\u00a0estudio\u00a0AERI,\u00a0a\u00a0lo\u00a0largo\u00a0del\u00a0\nperiodo\u00a02003\u00a0\u2013\u00a02008.\u00a0\n\u00a0\u00a0\n\u00a0\n\u00a0\n\u00a0\u00a0\n\u00a0\n\u00a0FINANCIACI\u00d3N\u00a0\n -  VIIFINANCIACI\u00d3N \u00a0\n\u00a0\n\u00a0\nLa\u00a0Fundaci\u00f3\u00a0La\u00a0Marat\u00f3\u00a0de\u00a0TV3\u00a0otorg\u00f3\u00a0al\u00a0CEEISCAT\u00a0una\u00a0beca\u00a0para\u00a0d esarrollar\u00a0el\u00a0proyecto\u00a0AERI\u2010\nVIH,\u00a0 proyecto\u00a0 de\u00a0 investigaci\u00f3n\u00a0 epidemiol\u00f3gica\u00a0 en\u00a0 SIDA\u00a0 aplicando\u00a0 el\u00a0 test\u00a0 STARHS\u00a0 (proyecto\u00a0\n#022010).\u00a0Este\u00a0trabajo\u00a0fue\u00a0parcialmente\u00a0financiado\u00a0por\u00a0la\u00a0Direc ci\u00f3\u00a0General\u00a0de\u00a0Salut\u00a0P\u00fablica\u00a0de\u00a0la\u00a0\nGeneralitat\u00a0de\u00a0Catalunya\u00a0y\u00a0por\u00a0la\u00a0Fundaci\u00f3n\u00a0para\u00a0la\u00a0Investigaci \u00f3n\u00a0y\u00a0Prevenci\u00f3n\u00a0del\u00a0SIDA\u00a0en\u00a0\nE s p a \u00f1 a \u00a0( F I P S E , \u00a0M a d r i d , \u00a0P l a n \u00a0N a c i onal\u00a0 del\u00a0 SIDA,\u00a0 Secretariado\u00a0 del \u00a0 Ministerio\u00a0 de\u00a0 Sanidad\u00a0 de\u00a0\nEspa\u00f1a),\u00a0el\u00a0Ministerio\u00a0de\u00a0Sanidad\u00a0y\u00a0Consumo,\u00a0Instituto\u00a0de\u00a0salud \u00a0Carlos\u00a0III\u00a0y\u00a0la\u00a0Red\u00a0Espa\u00f1ola\u00a0de\u00a0\nInvestigaci\u00f3n\u00a0en\u00a0SIDA\u00a0(RIS;\u00a0ISCIII\u2010RETIC\u00a0RD06/006).\u00a0\n\u00a0\n\u00a0\u00a0\n\u00a0\n\u00a0\u00a0\n VIII\u00cdNDICE\u00a0\n -  IX\u00cdNDICE\u00a0\n \nAGRADECIMIENTOS................................................................................................................ .........III  \nPRESENTA CI\u00d3N ................................................................................................................... ................V  \nFINANCIA CI\u00d3N ................................................................................................................... ...............VII \n\u00cdNDICE................................................................................................................................................... IX \nABREVIATURAS................................................................................................................... .............. XI  \nLISTADO \u00a0DE\u00a0FIGURAS \u00a0Y\u00a0TABLAS .............................................................................................. XIII  \nINTRODUCCI\u00d3N................................................................................................................... ................1  \n1........La\u00a0infecci\u00f3n \u00a0por\u00a0VIH..............................................................................................................2  \n1.1. Biolog\u00eda \u00a0del\u00a0VIH............................................................................................................2  \n1.2. Historia\u00a0natural\u00a0de\u00a0la\u00a0infecci\u00f3n\u00a0por \u00a0VIH..............................................................5  \n1.3. Diagn\u00f3stico \u00a0de\u00a0la\u00a0infecci\u00f3n\u00a0por\u00a0VIH ......................................................................6  \n1.4. Tratamientos \u00a0Antirretrovirales .............................................................................8  \n1.5. Resistencias\u00a0del \u00a0VIH\u20101\u00a0a\u00a0los\u00a0antirretroviral es................................................ 10  \n2........Epidemiolog\u00eda \u00a0de\u00a0la\u00a0infecci\u00f3n\u00a0por \u00a0VIH........................................................................ 13  \n2.1. La\u00a0pandemia \u00a0del\u00a0VIH................................................................................................ 13  \n2.2. Caracter\u00edsticas \u00a0de\u00a0la\u00a0epidemia \u00a0de\u00a0VIH\u00a0en\u00a0Catalu\u00f1a \u00a0y\u00a0Espa\u00f1a.................... 14  \n2.3. Inmigraci\u00f3n \u00a0y\u00a0VIH\u00a0en\u00a0Catalu\u00f1a \u00a0y\u00a0Espa\u00f1a.......................................................... 16  \n2.4. Epidemiolog\u00eda \u00a0de\u00a0las\u00a0resistencias \u00a0transmitidas............................................ 17  \n2.5. Distribuci\u00f3n \u00a0de\u00a0los\u00a0subtipos \u00a0del\u00a0VIH\u20101 ............................................................. 19  \n3........Tests\u00a0para\u00a0la\u00a0identificaci\u00f3n \u00a0de\u00a0infecciones \u00a0recientes \u00a0por\u00a0VIH \u20101 ........................ 21  \n3.1. Antecedentes.............................................................................................................. 21  \n3.2. Serological \u00a0Testing\u00a0 Algorithm\u00a0 for\u00a0 Recent\u00a0HIV\u00a0 Seroconversions\u00a0 y\u00a0\nenzimoimmunoensayo \u00a0de\u00a0captura \u00a0BED............................................................ 22  \n3.3. Otros\u00a0tests\u00a0serol\u00f3gicos............................................................................................ 25  \n3.4. Limitaciones ............................................................................................................... 27  \n4........Aplicaciones \u00a0de\u00a0los\u00a0tests \u00a0serol\u00f3gicos \u00a0para\u00a0identificar\u00a0infecciones \u00a0recientes \u00a0en\u00a0\nSalud\u00a0P\u00fablica........................................................................................................................ 29 \n4.1. Terminol og\u00eda.............................................................................................................. 29  \n4.2. Algoritmos \u00a0para\u00a0identificar \u00a0infecciones \u00a0recientes ....................................... 29  \u00cdNDICE\u00a0\n X4.3. Epidemiolog\u00eda \u00a0de\u00a0las\u00a0infecciones \u00a0recientes..................................................... 33  \n4.4. Resistencias \u00a0transmitidas \u00a0en\u00a0pacientes \u00a0identificados \u00a0con\u00a0 infecci\u00f3n\u00a0\nreciente ....................................................................................................................... .3 5 \nJUSTIFIC ACI\u00d3N.................................................................................................................................. 37  \nOBJETI VOS...................................................................................................................... .................... 39  \nM\u00c9TODOS \u00a0Y\u00a0RESULTADOS............................................................................................................ 43  \nART\u00cdCULO\u00a0 I .............................................................................................................................. .......... 45 \nART\u00cdCULO\u00a0 II............................................................................................................................. .......... 55 \nART\u00cdCULO\u00a0 III ............................................................................................................................ ......... 67 \nART\u00cdCULO\u00a0 IV............................................................................................................................. ......... 75 \nANEXO.......................................................................................................................... ........................ 87  \nDISCUSI \u00d3N...................................................................................................................... ..................109 \nCONCLUSI ONES................................................................................................................... ............119 \nRECOMENDAC IONES................................................................................................................ .....125  \nBIBLIOGRAF\u00cdA ................................................................................................................... .............129 \n\u00a0\n \n\u00a0\n\u00a0\n\u00a0ABREVIATURAS\u00a0\n -  XIABREVIATURAS \u00a0\n\u00a0\n\u00a0\nADN:\u00a0\u00c1cido\u00a0Desoxirribunocleico\u00a0\nARN:\u00a0\u00c1cido\u00a0Ribonucleico  \nAZT:\u00a0Zidovudina\u00a0\nBED\u2010CEIA:\u00a0Enzimoimmunoensayo\u00a0de\u00a0captura\u00a0BED\u00a0\nCDC:\u00a0 Centers\u00a0 for\u00a0Disease\u00a0Control\u00a0and\u00a0Prevention\u00a0\nCEEISCAT:\u00a0Centre\u00a0d'Estudis\u00a0Epide miol\u00f2gics\u00a0sobre\u00a0les\u00a0\u00a0Infeccions \u00a0de\u00a0Transmissi\u00f3\u00a0Sexual\u00a0i\u00a0Sida\u00a0de\u00a0\nCatalunya\u00a0\nCRF:\u00a0Forma\u00a0Recombinante\u00a0Circulante\u00a0( Circulating \u00a0Recombinant \u00a0Form)\u00a0\nDO:\u00a0Densidad\u00a0\u00d3ptica\u00a0\nECDC:\u00a0 European \u00a0Center\u00a0for\u00a0Disease\u00a0Prevention\u00a0 and\u00a0Control\u00a0\nEIA:\u00a0Enzimoimmunoensayo\u00a0FRR:\u00a0Tasa\u00a0de\u00a0Falsos\u00a0Positivos\u00a0( False\u00a0Recent\u00a0 Rate)\u00a0\nHSH:\u00a0Hombres\u00a0que\u00a0tienen\u00a0Sexo\u00a0con\u00a0Hombres\u00a0IAS:\u00a0 International \u00a0AIDS\u00a0Society\u00a0\nIP:\u00a0Inhibidores\u00a0de\u00a0la\u00a0Proteasa\u00a0ITIAN:\u00a0Inhibidores\u00a0de\u00a0la\u00a0Transcri ptasa\u00a0Inversa\u00a0An\u00e1logos\u00a0de\u00a0Nucl e\u00f3sidos\u00a0\nITINAN:\u00a0Inhibidores\u00a0de\u00a0la\u00a0Transcriptasa\u00a0Inversa\u00a0No\u00a0An\u00e1logos\u00a0de\u00a0 Nucle\u00f3sidos\u00a0\nITS:\u00a0Infecci\u00f3n\u00a0de\u00a0Transmisi\u00f3n\u00a0Sexual\u00a0\nMAA:\u00a0Algoritmo\u00a0Multi\u2010Ensayo \u00a0(Multi\u2010Assay\u00a0Algorithm) \u00a0\nOMS\u00a0/ WHO:\u00a0Organizaci\u00f3n\u00a0Mundial\u00a0de\u00a0la\u00a0Salud\u00a0/\u00a0World \u00a0Health\u00a0Organization \u00a0\nPCR:\u00a0Reacci\u00f3n\u00a0en\u00a0Cadena\u00a0de\u00a0la\u00a0Polimerasa\u00a0( Polymerase\u00a0 Chain\u00a0 Reaction)\u00a0\nRITA:\u00a0Algoritmo\u00a0para\u00a0Identif icar\u00a0Infecciones\u00a0Recientes\u00a0( Recent\u00a0 Infection\u00a0 Testing\u00a0Algorithm) \u00a0\nRT:\u00a0Resistencias\u00a0Transmitidas\u00a0\nSIDA:\u00a0S\u00edndrome\u00a0de\u00a0Inmunodeficiencia\u00a0Adquirida\u00a0SIVES:\u00a0Sistema\u00a0Integrado\u00a0de\u00a0Vigi lancia\u00a0Epidemiol\u00f3gica\u00a0del\u00a0SIDA/ VIH/ITS\u00a0\nSTARHS:\u00a0 Serological\u00a0 Testing\u00a0Algorithm \u00a0for\u00a0Recent\u00a0 HIV\u00a0Seroconversions\u00a0\nTARGA:\u00a0Tratamiento\u00a0Antirretroviral\u00a0de\u00a0Gran\u00a0Actividad\u00a0TI:\u00a0Transcriptasa\u00a0Inversa\u00a0\nTRI:\u00a0Test\u00a0para\u00a0detectar\u00a0Infecciones\u00a0Recientes\u00a0( Test\u00a0for\u00a0Recent\u00a0 Infection)\u00a0\nUDVP:\u00a0Usuarios\u00a0de\u00a0Droga\u00a0por\u00a0V\u00eda\u00a0Parenteral\u00a0ABREVIATURAS\u00a0\n XIIUNAIDS:\u00a0 Joint\u00a0United\u00a0Nations\u00a0 Programme \u00a0on\u00a0HIV/AIDS \u00a0\nURF:\u00a0Forma\u00a0Recombinante\u00a0\u00danica\u00a0( Unique\u00a0Recombinant \u00a0Form)\u00a0\nVIH\u20101:\u00a0Virus\u00a0de\u00a0la\u00a0Inmunod eficiencia\u00a0Humana\u00a0tipo\u00a01\u00a0\nVIH\u20102:\u00a0Virus\u00a0de\u00a0la\u00a0Inmunod eficiencia\u00a0Humana\u00a0tipo\u00a02\u00a0FIGURAS\u00a0Y\u00a0TABLAS\u00a0\n -  XIIILISTADO \u00a0DE\u00a0FIGURAS \u00a0Y\u00a0TABLAS\u00a0\n\u00a0\nFigura\u00a01.\u00a0Estructura\u00a0de\u00a0la\u00a0part\u00ed cula\u00a0de\u00a0VIH\u00a0y\u00a0prote\u00ednas\u00a0codific adas\u00a0por\u00a0el\u00a0virus.......................................2  \nFigura\u00a02.\u00a0Estructura\u00a0codific ante\u00a0del\u00a0genoma\u00a0del\u00a0VIH............ ................................................................................2  \nFigura\u00a03.\u00a0Ciclo\u00a0 vital\u00a0del\u00a0VIH.................................. ............................................................................................................3  \nFigura\u00a04.\u00a0Evoluci\u00f3n\u00a0de\u00a0los\u00a0par\u00e1m etros\u00a0virol\u00f3gicos\u00a0e\u00a0inmunol\u00f3gic os\u00a0durante\u00a0la\u00a0infecci\u00f3n\u00a0por\u00a0VIH...6  \nFigura\u00a05.\u00a0Evoluci\u00f3n\u00a0de\u00a0los\u00a0par\u00e1metros\u00a0virol\u00f3gicos\u00a0e\u00a0inmunol\u00f3gic os\u00a0durante\u00a0la\u00a0infecci\u00f3n\u00a0aguda\u00a0y\u00a0\nreciente\u00a0p or\u00a0VIH............................................... ..........................................................................................................7  \nFigura\u00a06.\u00a0Cronograma\u00a0de\u00a0las\u00a0estrategias\u00a0terap\u00e9uticas\u00a0frente\u00a0el\u00a0VIH\u20101\u00a0desde\u00a0los\u00a0inicios\u00a0de\u00a0la\u00a0\nepidemia....................................................... .................................................................................................................8  \nTabla\u00a01.\u00a0F\u00e1rmacos\u00a0 antirretrovirale s\u00a0por\u00a0familias............... ....................................................................................9  \nFigura\u00a07.\u00a0Ejemplo\u00a0de\u00a0una\u00a0secuencia\u00a0gen\u00e9tica\u00a0de\u00a0VIH\u00a0en\u00a0formato\u00a0FASTA...................................................12 \nFigura\u00a08.\u00a0Nomenclatura \u00a0de\u00a0las\u00a0mu taciones....................... ............................................................... .......................12  \nFigura\u00a09.\u00a0Prevalencia\u00a0 global\u00a0de\u00a0VIH,\u00a02012...................... ............................................................... .........................13 \nFigura\u00a010.\u00a0Evoluci\u00f3n\u00a0de\u00a0los\u00a0nuevos\u00a0diagn\u00f3sticos\u00a0de\u00a0VIH\u00a0por\u00a0v\u00eda\u00a0 de\u00a0transmisi\u00f3n,\u00a0Catalu\u00f1a\u00a0(2001\u00a0\u2013\u00a0\n2011).......................................................... ............................................................... ...................................................15  \nFigura\u00a011.Evoluci\u00f3n\u00a0del\u00a0diagn\u00f3stico\u00a0tard\u00edo\u00a0y\u00a0enfermedad\u00a0avanzad a\u00a0en\u00a0los\u00a0nuevos\u00a0diagn\u00f3sticos\u00a0de\u00a0\ninfecci\u00f3n\u00a0por\u00a0VIH\u00a0en\u00a0la\u00a0cohorte\u00a0PISCIS\u00a0(1998\u00a0\u2013\u00a02011)........... ............................................................... ..16 \nFigura\u00a012.\u00a0Distribuci\u00f3n\u00a0de\u00a0subtipos\u00a0y\u00a0CRFs\u00a0del\u00a0VIH\u20101\u00a0en\u00a0el\u00a0mund o.............................................................2 0 \nFigura\u00a013.\u00a0Cin\u00e9tica\u00a0de\u00a0los\u00a0marca dores\u00a0virol\u00f3gicos\u00a0y\u00a0la\u00a0respuest a\u00a0inmunitaria\u00a0usados\u00a0para\u00a0definir\u00a0\nestados\u00a0transitorios\u00a0en\u00a0las\u00a0primeras\u00a0fases\u00a0de\u00a0la\u00a0infecci\u00f3n\u00a0por\u00a0 VIH...................................................22  \nFigura\u00a014.\u00a0Fundamento\u00a0del\u00a0test\u00a0STARHS.......................... ............................................................... ........................23  \nFuente:\u00a0Adaptado\u00a0de.\u00a0Murphy\u00a0G,\u00a0 et\u00a0al.\u00a02008\u00a0(71)................................................................................................23  \nFigura\u00a015.  Esquema\u00a0de\u00a0las \u00a0diferentes\u00a0etapas\u00a0d el\u00a0test\u00a0BED\u2010CEIA............. ......................................................25  \nTabla\u00a02.\u00a0Tests\u00a0para\u00a0la\u00a0identific aci\u00f3n\u00a0de\u00a0infecciones\u00a0recientes\u00a0 por\u00a0VIH.......................................................2 6 \nFigura\u00a016.\u00a0Pr\nincipios\u00a0que\u00a0sustentan\u00a0los\u00a0tests\u00a0se rol\u00f3gicos\u00a0para\u00a0 identificar\u00a0infecciones\u00a0recientes...28  \nFigura\u00a017.\u00a0Ejemplo\u00a0de\u00a0un\u00a0R ITA\u00a0que\u00a0s\u00f3lo\u00a0usa\u00a0un\u00a0TRI.............. ............................................................... ..............30  \nFigura\u00a018.\u00a0Ejemplo\u00a0de\u00a0un\u00a0RITA\u00a0que\u00a0usa\u00a0un\u00a0TRI\u00a0e\u00a0informaci\u00f3n\u00a0cl\u00edn ica\u00a0y\u00a0de\u00a0lab oratorio......................31  \nFigura\u00a019.\u00a0Ejemplo\u00a0de\u00a0un\u00a0RITA,\u00a0usando\u00a0dos\u00a0TRIs\u00a0e\u00a0informaci\u00f3n\u00a0cl \u00ednica\u00a0y\u00a0de\u00a0lab oratorio..................32 \nTabla\u00a03\u00a0Prevalencias\u00a0d e\u00a0infecci\u00f3n\u00a0reciente..................... ............................................................... .........................34 \nTabla\u00a04.\u00a0Prevalencias\u00a0de\u00a0resiste ncias\u00a0transmitidas\u00a0en\u00a0pacientes\u00a0con\u00a0infecci\u00f3n\u00a0reciente\u00a0por\u00a0VIH...36  \nTabla\u00a05.\u00a0Estimaciones\u00a0de\u00a0inciden cia\u00a0de\u00a0VIH,\u00a0usando\u00a0tests\u00a0serol\u00f3 gicos\u00a0para\u00a0identificar\u00a0infecciones\u00a0\nrecientes\u00a0..................................................... ............................................................... ................................................91 \u00a0\u00a0\n -  1\u00a0\n\u00a0\n \n     \n\u00a0\n\u00a0\n\u00a0\u00a0\n\u00a0\n\u00a0\n\u00a0\nINTRODUCCI\u00d3N\u00a0\n \n                   INTRODUCCI\u00d3N\u00a0\n 21.\u00a0La\u00a0infecci\u00f3n \u00a0por\u00a0VIH\u00a0\n1.1.\u00a0Biolog\u00eda \u00a0del\u00a0VIH\u00a0\nEl\u00a0Virus\u00a0de\u00a0la\u00a0Inmunodeficiencia\u00a0Humana\u00a0(VIH)\u00a0pertenece\u00a0a\u00a0la\u00a0familia\u00a0 Retroviridae ,\u00a0virus\u00a0ARN\u00a0\nque\u00a0replican\u00a0a\u00a0trav\u00e9s\u00a0de\u00a0un\u00a0intermediario\u00a0de\u00a0ADN\u00a0mediante\u00a0una\u00a0t ranscriptasa\u00a0inversa.\u00a0Dentro\u00a0de\u00a0\nlos\u00a0retrovirus,\u00a0pertenece\u00a0a\u00a0la\u00a0subfamilia\u00a0 Lentiviridae .\u00a0Es\u00a0una\u00a0part\u00edcula\u00a0esf\u00e9rica\u00a0de\u00a080\u00a0a\u00a0100\u00a0nm,\u00a0\nestructurada\u00a0en\u00a0tres\u00a0capas:\u00a0la\u00a0capa\u00a0interna\u00a0o\u00a0nucleoide,\u00a0que\u00a0co ntiene\u00a0ARN,\u00a0la\u00a0nucleoprote\u00edna\u00a0y\u00a0\nalgunos\u00a0enzimas,\u00a0una\u00a0c\u00e1pside\u00a0icos a\u00e9drica\u00a0y\u00a0un\u00a0envoltorio\u00a0deriva do\u00a0de\u00a0la\u00a0c\u00e9lula\u00a0anfitriona,\u00a0donde\u00a0\nse\u00a0insertan\u00a0las\u00a0glicoprote\u00ednas\u00a0en\u00a072\u00a0proyecciones\u00a0externas\u00a0y\u00a0lo s\u00a0ant\u00edgenos\u00a0de\u00a0histocompatibilidad\u00a0\nde\u00a0clases\u00a0I\u00a0y\u00a0II\u00a0que\u00a0derivan\u00a0de\u00a0la\u00a0c\u00e9lula\u00a0anfitriona.\u00a0El\u00a0genoma \u00a0del\u00a0virus\u00a0es\u00a0ARN\u00a0de\u00a0cadena\u00a0\u00fanica,\u00a0\nformado\u00a0por\u00a0dos\u00a0hebras\u00a0id\u00e9nticas ,\u00a0de\u00a0polaridad\u00a0positiva\u00a0(Figura \u00a01)(1).\u00a0\n\u00a0\n \nFigura\u00a01.\u00a0Estructura \u00a0de\u00a0la\u00a0part\u00edcula\u00a0 de\u00a0VIH\u00a0y\u00a0prote\u00ednas \u00a0codificadas \u00a0por\u00a0el\u00a0virus\u00a0\nFuente:\u00a0http://commons.wikimedia.org/w iki/File:Niaid\u2010hiv\u2010virion.jpg \u00a0\u00a0\n\u00a0\n\u00a0\nEl\u00a0virus\u00a0del\u00a0VIH\u00a0(tipos\u00a01\u00a0y\u00a02)\u00a0posee\u00a0una\u00a0gran\u00a0variedad\u00a0de\u00a0genes \u00a0y\u00a0prote\u00ednas\u00a0reguladoras\u00a0(Figura\u00a0\n2),\u00a0que\u00a0condicionan\u00a0la\u00a0interacci\u00f3n\u00a0virus\u2010c\u00e9lula\u00a0y,\u00a0por\u00a0tanto,\u00a0l a\u00a0patogenia\u00a0de\u00a0la\u00a0enfermedad.\u00a0(1).\u00a0\n\u00a0\n \nFigura\u00a02 .\u00a0Estructura \u00a0codificante \u00a0del\u00a0genoma\u00a0del\u00a0VIH\u00a0\nFuente:\u00a0http://commons.wikimedia.org/wik i/File:HIV_genome.png?uselang=e s\u00a0\u00a0INTRODUCCI\u00d3N\u00a0\n -  3El\u00a0ciclo\u00a0vital\u00a0del\u00a0VIH\u00a0consta\u00a0de\u00a0diferentes\u00a0etapas.\u00a0En\u00a0primer\u00a0l ugar,\u00a0el\u00a0virus\u00a0se\u00a0une\u00a0a\u00a0su\u00a0receptor\u00a0\ncelular,\u00a0la\u00a0prote\u00edna\u00a0CD4\u00a0presente\u00a0en\u00a0la\u00a0superficie\u00a0de\u00a0los\u00a0linfocitos\u00a0T.\u00a0Esta\u00a0uni\u00f3n\u00a0no\u00a0es\u00a0suficiente\u00a0\npara\u00a0la\u00a0fusi\u00f3n\u00a0de\u00a0las\u00a0membranas,\u00a0 y\u00a0es\u00a0necesaria\u00a0la\u00a0participaci\u00f3n\u00a0del\u00a0co\u2010receptor\u00a0CCR5\u00a0o\u00a0CXCr4.\u00a0La\u00a0\nuni\u00f3n\u00a0induce\u00a0cambios\u00a0estructurales\u00a0que\u00a0permiten\u00a0la\u00a0fusi\u00f3n\u00a0de\u00a0la s\u00a0membranas\u00a0y\u00a0es\u00a0entonces\u00a0\ncuando\u00a0el\u00a0material\u00a0gen\u00e9tico\u00a0entra\u00a0en\u00a0la\u00a0c\u00e9lula.\u00a0A\u00a0continuaci\u00f3n\u00a0 la\u00a0transcriptasa\u00a0inversa\u00a0cataliza\u00a0la\u00a0\nformaci\u00f3n\u00a0del\u00a0provirus\u00a0en\u00a0forma\u00a0de\u00a0doble\u00a0cadena\u00a0de\u00a0ADN,\u00a0que\u00a0se\u00a0 integra\u00a0en\u00a0el\u00a0genoma\u00a0de\u00a0la\u00a0c\u00e9lula\u00a0\nanfitriona.\u00a0A\u00a0partir\u00a0del\u00a0provirus\u00a0se\u00a0transcriben\u00a0los\u00a0ARN\u00a0mensaj eros\u00a0que\u00a0codificar\u00e1n\u00a0las\u00a0prote\u00ednas\u00a0\ncorrespondientes,\u00a0que\u00a0se\u00a0unir\u00e1n\u00a0al\u00a0ARN\u00a0gen\u00f3mico\u00a0v\u00edrico,\u00a0constit uyendo\u00a0la\u00a0part\u00edcula\u00a0que\u00a0emerge\u00a0\npor\u00a0gemaci\u00f3n\u00a0a\u00a0trav\u00e9s\u00a0de\u00a0la\u00a0membrana\u00a0celular.\u00a0(Figura\u00a03)(1)\u00a0.\u00a0\n\u00a0\n \n\u00a0\nFigura\u00a03.\u00a0Ciclo\u00a0 vital\u00a0del\u00a0VIH\u00a0\u00a0\nFuente:\u00a0Taylor\u00a0BS,\u00a0 et\u00a0al.\u00a02008\u00a0(2).\u00a0\n\u00a0Hay\u00a0dos\u00a0tipos\u00a0de\u00a0VIH:\u00a0el\u00a0VIH\u20101\u00a0y\u00a0el\u00a0VIH\u20102,\u00a0siendo\u00a0el\u00a0VIH\u20101\u00a0el\u00a0v irus\u00a0m\u00e1s\u00a0extendido\u00a0y\u00a0virulento.\u00a0\nAn\u00e1lisis\u00a0filogen\u00e9ticos\u00a0sugieren\u00a0que\u00a0se\u00a0produjeron\u00a0tres\u00a0eventos\u00a0 de\u00a0transmisi\u00f3n\u00a0independientes\u00a0a\u00a0\nprincipios\u00a0del\u00a0siglo\u00a0XX,\u00a0dando\u00a0lugar\u00a0a\u00a0tres\u00a0grupos\u00a0de\u00a0VIH\u20101:\u00a0el \u00a0grupo\u00a0M\u00a0(entre\u00a01915\u00a0y\u00a01941),\u00a0el\u00a0\nmayoritario\u00a0en\u00a0la\u00a0pandemia\u00a0del\u00a0S\u00edndrome\u00a0de\u00a0Inmunodeficiencia\u00a0Ad quirida\u00a0(SIDA),\u00a0el\u00a0grupo\u00a0O\u00a0\n(outlier\u00a0o\u00a0marginal)\u00a0del\u00a0que\u00a0se\u00a0han\u00a0descrito\u00a0algunos\u00a0cientos\u00a0de \u00a0casos,\u00a0la\u00a0mayor\u00eda\u00a0procedentes\u00a0de\u00a0\nCamer\u00fan,\u00a0y\u00a0el\u00a0grupo\u00a0N\u00a0(no\u00a0mayoritario\u00a0y\u00a0no\u00a0marginal),\u00a0del\u00a0que\u00a0s \u00f3lo\u00a0hay\u00a06\u00a0casos\u00a0caracterizados\u00a0en\u00a0\nCamer\u00fan.\u00a0Se\u00a0especula\u00a0en\u00a0que\u00a0el\u00a0VIH\u20101\u00a0se\u00a0extendi\u00f3\u00a0entre\u00a0los\u00a0huma nos\u00a0a\u00a0lo\u00a0largo\u00a0del\u00a0r\u00edo\u00a0Congo\u00a0\nhasta\u00a0Kinshasa,\u00a0Zaire,\u00a0donde\u00a0se\u00a0ha\u00a0trazado\u00a0el\u00a0primer\u00a0caso\u00a0docum entado\u00a0de\u00a0infecci\u00f3n\u00a0por\u00a0VIH\u20101\u00a0\n(dentro\u00a0del\u00a0grupo\u00a0M)\u00a0en\u00a0humanos\u00a0en\u00a0una\u00a0muestra\u00a0de\u00a0sangre\u00a0de\u00a0195 9\u00a0(1).\u00a0El\u00a0VIH\u20102\u00a0es\u00a0menos\u00a0\nvirulento\u00a0y\u00a0est\u00e1\u00a0extendido\u00a0principalmente\u00a0por\u00a0\u00c1frica\u00a0Occidental ,\u00a0aunque\u00a0tambi\u00e9n\u00a0en\u00a0Portugal,\u00a0\nAngola,\u00a0Mozambique\u00a0e\u00a0India.\u00a0(3).\u00a0El\u00a0grupo\u00a0M\u00a0es\u00a0el\u00a0grupo\u00a0de\u00a0VIH\u2010 1\u00a0circulante\u00a0mayoritario.\u00a0Se\u00a0ha\u00a0\ndividido\u00a0en\u00a0subtipos,\u00a0llamados\u00a0con\u00a0letras,\u00a0y\u00a0sub\u2010subtipos,\u00a0llam ados\u00a0con\u00a0n\u00fameros.\u00a0Los\u00a0subtipos\u00a0A1,\u00a0\nA2,\u00a0A3,\u00a0A4,\u00a0B,\u00a0C,\u00a0D,\u00a0F1,\u00a0F2,\u00a0G,\u00a0 H,\u00a0J,\u00a0y\u00a0K\u00a0son\u00a0los\u00a0subtipos\u00a0de\u00a0V IH\u20101\u00a0actualmente\u00a0reconocidos\u00a0(4).\u00a0\u00a0\u00a0INTRODUCCI\u00d3N\u00a0\n 4Adem\u00e1s\u00a0 de\u00a0 los\u00a0 distintos\u00a0 subtipos,\u00a0 tambi\u00e9n\u00a0 se\u00a0 pueden\u00a0 identificar \u00a0 Formas\u00a0 Recombinantes\u00a0\nCirculantes\u00a0(CRFs)\u00a0y\u00a0Formas\u00a0Recombinantes\u00a0\u00danicas\u00a0(URFs).  Las\u00a0CRFs\u00a0y\u00a0URFs\u00a0son\u00a0el\u00a0resultado\u00a0de\u00a0\nla\u00a0recombinaci\u00f3n\u00a0entre\u00a0dos\u00a0subtipos\u00a0dentro\u00a0de\u00a0una\u00a0persona\u00a0infec tada\u00a0por\u00a0dos\u00a0subtipos,\u00a0y\u00a0a\u00a0partir  \nde la\u00a0cual\u00a0las\u00a0formas\u00a0recombinantes\u00a0son\u00a0transmitidas\u00a0a\u00a0otras\u00a0perso nas.\u00a0La\u00a0progenie\u00a0recombinante\u00a0\nse\u00a0 clasifica\u00a0 como\u00a0 CRF\u00a0 si\u00a0 se\u00a0 identifican\u00a0 en\u00a0 tres\u00a0 o\u00a0 m\u00e1s\u00a0 personas\u00a0 que\u00a0 no\u00a0 tienen\u00a0 un\u00a0 v\u00ednculo\u00a0\nepidemiol\u00f3gico\u00a0directo;\u00a0y\u00a0si\u00a0no\u00a0 es\u00a0as\u00ed,\u00a0se\u00a0describen\u00a0como\u00a0URFs\u00a0 (2).  \nLa\u00a0 transmisi\u00f3n\u00a0 del\u00a0 virus\u00a0 del\u00a0 VIH\u00a0 se\u00a0 conoce\u00a0 que\u00a0 es\u00a0 posible\u00a0 a\u00a0 tra v\u00e9s\u00a0 de\u00a0 tres\u00a0 v\u00edas:\u00a0 por\u00a0 v\u00eda\u00a0\nparenteral\u00a0(transfusiones,\u00a0uso\u00a0de\u00a0drogas\u00a0por\u00a0v\u00eda\u00a0parenteral),\u00a0por\u00a0v\u00eda\u00a0perinatal\u00a0o\u00a0maternoinfantil\u00a0\n(transmisi\u00f3n\u00a0transplacentaria,\u00a0durante\u00a0el\u00a0parto\u00a0o\u00a0a\u00a0trav\u00e9s\u00a0de\u00a0l a\u00a0leche\u00a0materna)\u00a0o\u00a0a\u00a0trav\u00e9s\u00a0de\u00a0las\u00a0\nmucosas\u00a0(relaciones\u00a0sexuales)\u00a0(1,\u00a05).\u00a0La\u00a0eficiencia\u00a0de\u00a0la\u00a0trans misi\u00f3n\u00a0del\u00a0virus\u00a0mediante\u00a0el\u00a0acto\u00a0de\u00a0\ncompartir\u00a0el\u00a0material\u00a0de\u00a0inyecci\u00f3n\u00a0entre\u00a0los\u00a0usuarios\u00a0de\u00a0droga\u00a0 por\u00a0v\u00eda\u00a0parenteral\u00a0(UDVP)\u00a0es\u00a0\nmayor\u00a0que\u00a0la\u00a0de\u00a0las\u00a0relaciones\u00a0sexuales\u00a0(6).\u00a0Otras\u00a0v\u00edas\u00a0conside radas\u00a0de\u00a0contagio\u00a0parenteral\u00a0son\u00a0\nlos\u00a0accidentes\u00a0por\u00a0pinchazo,\u00a0aunque\u00a0con\u00a0un\u00a0riesgo\u00a0muy\u00a0bajo\u00a0de\u00a0t ransmisi\u00f3n\u00a0(7,\u00a08);\u00a0as\u00ed\u00a0como\u00a0los\u00a0\ncasos\u00a0espor\u00e1dicos,\u00a0descritos\u00a0en\u00a0l a\u00a0literatura,\u00a0infectados\u00a0a\u00a0trav\u00e9s\u00a0de\u00a0posibles\u00a0heridas\u00a0microsc\u00f3picas\u00a0\nen\u00a0piel\u00a0y\u00a0por\u00a0mordiscos\u00a0(9,\u00a010).\u00a0\u00a0\nEn\u00a0cuanto\u00a0a\u00a0la\u00a0transmisi\u00f3n\u00a0sexual\u00a0del\u00a0virus,\u00a0se\u00a0conoce\u00a0que\u00a0la\u00a0t ransmisi\u00f3n\u00a0entre\u00a0hombres\u00a0que\u00a0\ntienen\u00a0sexo\u00a0con\u00a0hombres\u00a0(HSH)\u00a0es\u00a0mayor\u00a0que\u00a0la\u00a0heterosexual,\u00a0deb ido\u00a0a\u00a0las\u00a0caracter\u00edsticas\u00a0de\u00a0su\u00a0\nconducta\u00a0sexual;\u00a0en\u00a0general,\u00a0un\u00a0 mayor\u00a0n\u00famero\u00a0de\u00a0parejas,\u00a0y\u00a0pr\u00e1c ticas\u00a0con\u00a0mayor\u00a0potencial\u00a0de\u00a0\nlesionar\u00a0 las\u00a0 mucosas\u00a0 (11,\u00a0 12).\u00a0 En\u00a0 cuanto\u00a0 a\u00a0 la\u00a0 transmisi\u00f3n\u00a0 heter osexual\u00a0 es\u00a0 m\u00e1s\u00a0 eficiente\u00a0 de\u00a0\nhombre\u00a0a\u00a0mujer;\u00a0debido\u00a0a\u00a0un\u00a0mayor\u00a0volumen\u00a0y\u00a0concentraci\u00f3n\u00a0de\u00a0vi rus\u00a0en\u00a0el\u00a0semen\u00a0que\u00a0en\u00a0el\u00a0\nfluido\u00a0c\u00e9rvico\u2010vaginal,\u00a0y\u00a0mayor\u00a0tiempo\u00a0de\u00a0exposici\u00f3n\u00a0en\u00a0el\u00a0caso \u00a0de\u00a0la\u00a0mujer\u00a0(6).\u00a0Otros\u00a0factores\u00a0que\u00a0\nal\u00a0margen\u00a0de\u00a0las\u00a0caracter\u00edsticas \u00a0de\u00a0la\u00a0relaci\u00f3n\u00a0sexual\u00a0pueden\u00a0estar\u00a0asociados\u00a0a\u00a0un\u00a0mayor\u00a0riesgo\u00a0de\u00a0\ntransmisi\u00f3n\u00a0del\u00a0VIH\u00a0son\u00a0las\u00a0co \u2010infecciones\u00a0con\u00a0otras\u00a0infeccione s\u00a0de\u00a0transmisi\u00f3n\u00a0sexual\u00a0(ITS)\u00a0(13).\u00a0\nLa\u00a0presencia\u00a0de\u00a0\u00falceras\u00a0genitale s\u00a0hace\u00a0que\u00a0la\u00a0transmisi\u00f3n\u00a0del\u00a0v irus\u00a0sea\u00a0m\u00e1s\u00a0f\u00e1cil\u00a0(14).\u00a0\nLa\u00a0 transmisi\u00f3n\u00a0 madre\u2010hijo\u00a0 es\u00a0 posible\u00a0 en\u00a0 tres\u00a0 niveles:\u00a0 durante\u00a0 l a\u00a0 gestaci\u00f3n\u00a0 (transmisi\u00f3n\u00a0\nplacentaria),\u00a0durante\u00a0el\u00a0parto\u00a0y\u00a0post\u2010natal,\u00a0mediante\u00a0la\u00a0leche\u00a0 materna\u00a0(15).\u00a0Entre\u00a0los\u00a0factores\u00a0de\u00a0\nriesgo\u00a0que\u00a0favorecen\u00a0la\u00a0transmis i\u00f3n\u00a0se\u00a0han\u00a0descrito\u00a0los\u00a0siguientes:\u00a0\nA)\u00a0 Relacionados\u00a0con\u00a0la\u00a0madre:\u00a0enfermedad\u00a0avanzada,\u00a0cargas\u00a0v\u00edric as\u00a0plasm\u00e1ticas\u00a0elevadas,\u00a0\ntabaquismo,\u00a0uso\u00a0de\u00a0drogas\u00a0por\u00a0v\u00eda\u00a0parenteral.\u00a0\nB)\u00a0 Relacionados\u00a0con\u00a0problemas\u00a0obst \u00e9tricos:\u00a0ruptura\u00a0de\u00a0membranas \u00a0prolongada\u00a0durante\u00a0m\u00e1s\u00a0\nde\u00a04\u00a0horas,\u00a0presencia\u00a0de\u00a0corioamnionitis,\u00a0parto\u00a0vaginal.\u00a0\nC)\u00a0 Relacionados\u00a0con\u00a0el\u00a0feto\u00a0o\u00a0el\u00a0reci\u00e9n\u00a0nacido:\u00a0ingesta\u00a0de\u00a0lech e\u00a0materna,\u00a0prematuridad,\u00a0baja\u00a0\nedad\u00a0gestacional.\u00a0\n\u00a0INTRODUCCI\u00d3N\u00a0\n -  51.2.\u00a0Historia\u00a0natural\u00a0de\u00a0la\u00a0infecci\u00f3n\u00a0 por\u00a0VIH\u00a0\nEl\u00a0VIH\u00a0es\u00a0el\u00a0agente\u00a0causal\u00a0de\u00a0una\u00a0enfermedad\u00a0de\u00a0curso\u00a0m\u00e1s\u00a0o\u00a0men os\u00a0prolongado\u00a0que\u00a0culmina\u00a0\ncon\u00a0una\u00a0destrucci\u00f3n\u00a0pr\u00e1cticamente\u00a0completa\u00a0de\u00a0los\u00a0linfocitos\u00a0CD 4+.\u00a0Una\u00a0vez\u00a0el\u00a0virus\u00a0ha\u00a0entrado\u00a0\nen\u00a0 el\u00a0 organismo,\u00a0 se\u00a0 inicia\u00a0 una\u00a0 infecci\u00f3n\u00a0 en\u00a0 la\u00a0 que\u00a0 se\u00a0 pueden\u00a0 di ferenciar\u00a0 distintas\u00a0 fases\u00a0\nrelativamente\u00a0bien\u00a0definidas,\u00a0aunque\u00a0no\u00a0siempre\u00a0se\u00a0identifican\u00a0 cl\u00ednicamente,\u00a0y\u00a0con\u00a0una\u00a0duraci\u00f3n\u00a0\nvariable\u00a0que\u00a0depende\u00a0de\u00a0diferentes\u00a0factores\u00a0relacionados\u00a0con\u00a0el \u00a0virus\u00a0y\u00a0con\u00a0el\u00a0hospedador\u00a0(1).\u00a0La\u00a0\nhistoria\u00a0natural\u00a0de\u00a0la\u00a0infecci\u00f3n\u00a0puede\u00a0diferenciarse\u00a0en\u00a0las\u00a0sig uientes\u00a0fases:\u00a0(i)\u00a0fase\u00a0aguda,\u00a0desde\u00a0el\u00a0\nmomento\u00a0de\u00a0la\u00a0infecci\u00f3n\u00a0hasta\u00a0que\u00a0se\u00a0produce\u00a0la\u00a0seroconversi\u00f3n; \u00a0(ii)\u00a0fase\u00a0cr\u00f3nica,\u00a0que\u00a0puede\u00a0ser\u00a0\nm\u00e1s\u00a0o\u00a0menos\u00a0sintom\u00e1tica\u00a0y\u00a0de\u00a0duraci\u00f3n\u00a0variable;\u00a0y\u00a0(iii)\u00a0fase\u00a0fi nal,\u00a0a\u00a0partir\u00a0del\u00a0diagn\u00f3stico\u00a0de\u00a0SIDA.  \nLa\u00a0fase\u00a0aguda\u00a0(tambi\u00e9n\u00a0conocida\u00a0como\u00a0primoinfecci\u00f3n,\u00a0o\u00a0infecci\u00f3 n\u00a0primaria)\u00a0comprende\u00a0las\u00a0\nprimeras\u00a02\u00a0\u2013\u00a04\u00a0semanas\u00a0despu\u00e9s\u00a0de\u00a0la\u00a0entrada\u00a0del\u00a0virus\u00a0en\u00a0el\u00a0or ganismo,\u00a0y\u00a0en\u00a0m\u00e1s\u00a0de\u00a0un\u00a050%\u00a0de\u00a0\nlos\u00a0casos\u00a0se\u00a0produce\u00a0un\u00a0cuadro\u00a0cl\u00ednico\u00a0de\u00a0infecci\u00f3n\u00a0aguda\u00a0de\u00a0in tensidad\u00a0variable\u00a0y\u00a0caracterizado\u00a0\nnormalmente\u00a0 por\u00a0 fiebre,\u00a0 cefalea,\u00a0 adenopat\u00edas,\u00a0 mialgias\u00a0 y\u00a0 rash\u00a0 denominado\u00a0 s\u00edndrome\u00a0\nmononucle\u00f3sido\u00a0por\u00a0su\u00a0similitud\u00a0con\u00a0la\u00a0mononucleosis\u00a0infecciosa \u00a0producida\u00a0por\u00a0el\u00a0virus\u00a0Epstein\u2010\nBarr\u00a0(16).\u00a0A\u00a0la\u00a0semana\u00a0del\u00a0inicio\u00a0de\u00a0los\u00a0s\u00edntomas\u00a0se\u00a0puede\u00a0detectar\u00a0en\u00a0el\u00a0plasma\u00a0cargas\u00a0v\u00edricas\u00a0\nelevadas\u00a0 (entre\u00a0 105\u00a0y \u00a01 07\u00a0 copias/ml)\u00a0 (17),\u00a0 y\u00a0 en\u00a0 un\u00a0 tiempo\u00a0 aproximado\u00a0 de\u00a0 19\u00a0 semanas\u00a0 se\u00a0\ndesencadena\u00a0la\u00a0respuesta\u00a0inmunitaria\u00a0espec\u00edfica\u00a0(18),\u00a0que\u00a0reduce\u00a0la\u00a0carga\u00a0v\u00edrica\u00a0plasm\u00e1tica,\u00a0de\u00a0manera\u00a0temporal,\u00a0hasta\u00a0alcanzar\u00a0una\u00a0situaci\u00f3n\u00a0de \u00a0equilibrio\u00a0a\u00a0los\u00a06\u00a0y\u00a012\u00a0meses, \u00a0y\u00a0que\u00a0situar\u00e1\u00a0la\u00a0\ncarga\u00a0v\u00edrica\u00a0plasm\u00e1tica\u00a0entre\u00a010\n2\u00a0y\u00a0106\u00a0copias/ml\u00a0(16)\u00a0(Figura\u00a04). \u00a0A\u00a0partir\u00a0de\u00a0este\u00a0momento\u00a0se\u00a0\ninicia\u00a0la\u00a0fase\u00a0cr\u00f3nica.\u00a0En\u00a0esta\u00a0fase\u00a0la\u00a0carga\u00a0v\u00edrica\u00a0plasm\u00e1tica \u00a0se\u00a0reduce\u00a0aproximadamente\u00a0100\u00a0\nveces\u00a0con\u00a0el\u00a0desarrollo\u00a0de\u00a0la\u00a0respuesta\u00a0inmunitaria\u00a0(19).\u00a0La\u00a0ve locidad\u00a0de\u00a0progresi\u00f3n\u00a0a\u00a0SIDA\u00a0no\u00a0es\u00a0\nla\u00a0misma\u00a0para\u00a0todos\u00a0los\u00a0pacientes,\u00a0siendo\u00a0la\u00a0carga\u00a0v\u00edrica\u00a0plasm \u00e1tica\u00a0el\u00a0principal\u00a0factor\u00a0pron\u00f3stico\u00a0\ndel\u00a0tiempo\u00a0de\u00a0evoluci\u00f3n.\u00a0Se\u00a0pueden\u00a0definir\u00a0tres\u00a0grupos\u00a0de\u00a0velocidades\u00a0de\u00a0progresi\u00f3n:\u00a0progresores\u00a0r\u00e1pidos\u00a0(5\u00a0\u2013\u00a010%),\u00a0progresores\u00a0t\u00edpicos\u00a0(80\u00a0\u2013\u00a090%)\u00a0y\u00a0progresores \u00a0lentos\u00a0(tambi\u00e9n\u00a0conocidos\u00a0como\u00a0\nelite\u00a0controllers \u00a0o\u00a0long\u2010term\u00a0non\u2010progressors )\u00a0(5\u00a0\u2013\u00a010%)\u00a0(1).\u00a0\u00a0\n\u00a0INTRODUCCI\u00d3N\u00a0\n 6\n\u00a0\n\u00a0\nFigura\u00a04 .\u00a0Evoluci\u00f3n \u00a0de\u00a0los\u00a0par\u00e1metros \u00a0virol\u00f3gicos \u00a0e\u00a0inmunol\u00f3gicos \u00a0durante\u00a0la\u00a0infecci\u00f3n \u00a0por\u00a0VIH\u00a0\u00a0\nFuente:\u00a0http://pathmicro.med.sc.edu/lecture/hiv3.htm \u00a0\n\u00a0\nLa\u00a0fase\u00a0final\u00a0de\u00a0la\u00a0infecci\u00f3n\u00a0o\u00a0SIDA\u00a0se\u00a0caracteriza\u00a0por\u00a0ser\u00a0una \u00a0fase\u00a0con\u00a0recuentos\u00a0de\u00a0linfocitos\u00a0\nCD4+\u00a0inferiores\u00a0a\u00a0200\u00a0c\u00e9lulas/ \uf06dl,\u00a0aumento\u00a0de\u00a0la\u00a0tasa\u00a0de\u00a0replicaci\u00f3n\u00a0v\u00edrica\u00a0y\u00a0descenso\u00a0de\u00a0la\u00a0\nactividad\u00a0 de\u00a0 los\u00a0 linfocitos\u00a0 T\u00a0 citot\u00f3xicos\u00a0 anti\u2010VIH\u00a0 (1).\u00a0 El\u00a0 dete rioro\u00a0 del\u00a0 sistema\u00a0 inmunitario\u00a0\nprovocado\u00a0por\u00a0el\u00a0VIH\u00a0hace\u00a0que\u00a0el\u00a0individuo\u00a0sea\u00a0susceptible\u00a0a\u00a0in fecciones\u00a0oportunistas\u00a0(infecci\u00f3n\u00a0\npor\u00a0Pneumocystis \u00a0jirovecii,\u00a0tuberculosis,\u00a0entre\u00a0otras)\u00a0u\u00a0otros\u00a0signos\u00a0o\u00a0s\u00edntomas\u00a0cl\u00ednicos ,\u00a0as\u00ed\u00a0como\u00a0\nc\u00e1nceres\u00a0definitorios\u00a0de\u00a0SIDA\u00a0(S arcoma\u00a0de\u00a0Kaposi,\u00a0por\u00a0ejemplo)\u00a0 (20).\u00a0\n\u00a0\n\u00a0\n1.3.\u00a0Diagn\u00f3stico \u00a0de\u00a0la\u00a0infecci\u00f3n\u00a0 por\u00a0VIH\u00a0\nEl\u00a0 diagn\u00f3stico\u00a0 de\u00a0 la\u00a0 infecci\u00f3n\u00a0 por\u00a0 VIH\u00a0 s\u00f3lo\u00a0 puede\u00a0 establecerse\u00a0 de\u00a0 manera\u00a0 definitiva\u00a0 por\u00a0\nm\u00e9todos\u00a0de\u00a0laboratorio,\u00a0ya\u00a0que\u00a0l as\u00a0manifestaciones\u00a0cl\u00ednicas\u00a0son \u00a0inespec\u00edficas\u00a0en\u00a0cualquier\u00a0estad\u00edo\u00a0\nde\u00a0la\u00a0enfermedad\u00a0(1).\u00a0La\u00a0seropos itividad\u00a0se\u00a0define\u00a0mediante\u00a0la\u00a0 demostraci\u00f3n\u00a0de\u00a0anticuerpos\u00a0\nfrente\u00a0a\u00a0las\u00a0prote\u00ednas\u00a0v\u00edricas,\u00a0con\u00a0reactividad\u00a0repetida\u00a0en\u00a0las\u00a0pruebas\u00a0de\u00a0cribado\u00a0y\u00a0adem\u00e1s\u00a0con\u00a0las\u00a0pruebas\u00a0de\u00a0confirmaci\u00f3n\u00a0(21).\u00a0\nEl\u00a0primer\u00a0marcador\u00a0biol\u00f3gico\u00a0que\u00a0 podemos\u00a0detectar\u00a0es\u00a0la\u00a0viremia \u00a0plasm\u00e1tica\u00a0(presencia\u00a0de\u00a0\nARN\u00a0del\u00a0virus\u00a0en\u00a0el\u00a0plasma),\u00a0que\u00a0ocurre\u00a0hacia\u00a0el\u00a0s\u00e9ptimo\u00a0d\u00eda\u00a0despu\u00e9s\u00a0de\u00a0la\u00a0infecci\u00f3n.\u00a0El\u00a0ARN\u00a0del\u00a0INTRODUCCI\u00d3N\u00a0\n -  7virus\u00a0se\u00a0detecta\u00a0mediante\u00a0la\u00a0t\u00e9cnica\u00a0de\u00a0la\u00a0reacci\u00f3n\u00a0en\u00a0cadena\u00a0d e\u00a0la\u00a0polimerasa\u00a0(PCR).\u00a0Estas\u00a0\nt\u00e9cnicas\u00a0est\u00e1n\u00a0basadas\u00a0en\u00a0las\u00a0propiedades\u00a0del\u00a0ARN\u00a0y\u00a0del\u00a0ADN,\u00a0qu e\u00a0es\u00a0la\u00a0complementariedad\u00a0de\u00a0la\u00a0\nsecuencia\u00a0 (22).\u00a0 Los\u00a0 tests\u00a0 que\u00a0 incorporan\u00a0 la\u00a0 detecci\u00f3n\u00a0 de\u00a0 ant\u00edge no\u00a0 p24\u00a0 son\u00a0 positivos\u00a0 7\u00a0 d\u00edas\u00a0\ndespu\u00e9s\u00a0de\u00a0observarse\u00a0viremia,\u00a0mientras\u00a0que\u00a0los\u00a0basados\u00a0en\u00a0la\u00a0i dentificaci\u00f3n\u00a0de\u00a0anticuerpos\u00a0son\u00a0\npositivos\u00a0de\u00a021\u00a0a\u00a028\u00a0d\u00edas\u00a0despu\u00e9s\u00a0del\u00a0episodio\u00a0de\u00a0primoinfecci\u00f3n\u00a0(23).\u00a0El\u00a0resto\u00a0de\u00a0anticuerpos\u00a0\naparecen\u00a0de\u00a0manera\u00a0progresiva\u00a0en\u00a0las\u00a0siguientes\u00a0semanas,\u00a0siendo \u00a0el\u00a0dirigido\u00a0frente\u00a0a\u00a0la\u00a0prote\u00edna\u00a0\np31\u00a0el\u00a0\u00faltimo\u00a0en\u00a0aparecer\u00a0(Figura\u00a05)\u00a0(24).\u00a0\n\u00a0\n\u00a0\n\u00a0\nFigura\u00a05.\u00a0Evoluci\u00f3n \u00a0de\u00a0los\u00a0par\u00e1metros \u00a0virol\u00f3gicos \u00a0e\u00a0inmunol\u00f3gicos \u00a0durante\u00a0la\u00a0infecci\u00f3n \u00a0aguda\u00a0y\u00a0\nreciente \u00a0por\u00a0VIH\u00a0\nFuente:\u00a0Cohen\u00a0 et\u00a0al.\u00a02011\u00a0(24)\u00a0\n\u00a0\nLa\u00a0determinaci\u00f3n\u00a0de\u00a0anticuerpos\u00a0m ediante\u00a0enzimoimmunoensayos\u00a0(E IA)\u00a0es\u00a0la\u00a0metodolog\u00eda\u00a0\nm\u00e1s\u00a0utilizada\u00a0para\u00a0la\u00a0identificaci\u00f3n\u00a0de\u00a0individuos\u00a0infectados\u00a0p or\u00a0VIH,\u00a0y\u00a0es\u00a0la\u00a0estrategia\u00a0que\u00a0se\u00a0\nutiliza\u00a0como\u00a0prueba\u00a0de\u00a0cribado.\u00a0 Un\u00a0concepto\u00a0importante\u00a0en\u00a0el\u00a0di agn\u00f3stico\u00a0del\u00a0VIH\u00a0es\u00a0el\u00a0de\u00a0periodo\u00a0\nventana,\u00a0que\u00a0es\u00a0el\u00a0tiempo\u00a0que\u00a0transcurre\u00a0entre\u00a0la\u00a0infecci\u00f3n\u00a0por \u00a0VIH\u00a0y\u00a0la\u00a0producci\u00f3n\u00a0de\u00a0un\u00a0nivel\u00a0de\u00a0\nanticuerpos\u00a0detectable\u00a0por\u00a0el\u00a0EIA\u00a0(24).\u00a0\nUna\u00a0vez\u00a0se\u00a0obtiene\u00a0un\u00a0resultado\u00a0positivo\u00a0en\u00a0el\u00a0EIA\u00a0de\u00a0cribado,\u00a0 es\u00a0necesario\u00a0realizar\u00a0la\u00a0prueba\u00a0\nconfirmatoria.\u00a0El\u00a0Western\u00a0blot\u00a0o\u00a0el\u00a0Inno\u2010lia\u00a0son\u00a0los\u00a0m\u00e9todos\u00a0m\u00e1 s\u00a0utilizados\u00a0para\u00a0la\u00a0confirmaci\u00f3n\u00a0\nde\u00a0los\u00a0resultados\u00a0obtenidos\u00a0con\u00a0 las\u00a0pruebas\u00a0de\u00a0cribado.\u00a0Estas\u00a0t \u00e9cnicas\u00a0detectan\u00a0los\u00a0ant\u00edgenos\u00a0\nv\u00edricos,\u00a0es\u00a0decir\u00a0las\u00a0prote\u00ednas\u00a0 que\u00a0forman\u00a0parte\u00a0del\u00a0virus\u00a0(1). \u00a0INTRODUCCI\u00d3N\u00a0\n 81.4.\u00a0Tratamientos \u00a0Antirretrovirales \u00a0\u00a0\nEl\u00a0primer\u00a0ensayo\u00a0cl\u00ednico\u00a0con\u00a0un\u00a0medicamento\u00a0con\u00a0actividad\u00a0antir retroviral\u00a0(la\u00a0zidovudina,\u00a0o\u00a0\nAZT),\u00a0un\u00a0nucle\u00f3sido\u00a0an\u00e1logo\u00a0de\u00a0la\u00a0timidina\u00a0que\u00a0inhibe\u00a0la\u00a0transc riptasa\u00a0inversa,\u00a0se\u00a0realiz\u00f3\u00a0en\u00a01986\u00a0\n(25).\u00a0Se\u00a0incluyeron\u00a0pacientes\u00a0con\u00a0una\u00a0infecci\u00f3n\u00a0por\u00a0el\u00a0VIH\u20101\u00a0en \u00a0fase\u00a0muy\u00a0avanzada\u00a0y\u00a0se\u00a0demostr\u00f3\u00a0\nuna\u00a0reducci\u00f3n\u00a0significativa\u00a0de\u00a0la\u00a0mortalidad\u00a0frente\u00a0a\u00a0la\u00a0rama\u00a0p lacebo,\u00a0lo\u00a0que\u00a0oblig\u00f3\u00a0a\u00a0interrumpir\u00a0\nel\u00a0ensayo\u00a0cl\u00ednico\u00a0cuando\u00a0la\u00a0duraci\u00f3n\u00a0del\u00a0seguimiento\u00a0s\u00f3lo\u00a0era\u00a0d e\u00a06\u00a0meses.\u00a0Sin\u00a0embargo,\u00a0pronto\u00a0se\u00a0\npondr\u00eda\u00a0en\u00a0evidencia\u00a0que\u00a0se\u00a0trataba\u00a0de\u00a0un\u00a0efecto\u00a0transitorio.\u00a0D esde\u00a0entonces,\u00a0han\u00a0tenido\u00a0que\u00a0\npasar\u00a0m\u00e1s\u00a0de\u00a020\u00a0a\u00f1os\u00a0para\u00a0que\u00a0se\u00a0llegaran\u00a0a\u00a0comercializar\u00a0m\u00e1s\u00a0d e\u00a020\u00a0medicamentos\u00a0con\u00a0actividad\u00a0\nfrente\u00a0al\u00a0VIH\u20101\u00a0(1).\u00a0En\u00a0la\u00a0Figura\u00a06\u00a0se\u00a0representan\u00a0las\u00a0diferent es\u00a0estrategias\u00a0terap\u00e9uticas\u00a0frente\u00a0al\u00a0\nVIH\u20101\u00a0a\u00a0lo\u00a0largo\u00a0del\u00a0tiempo.\u00a0\u00a0\n\u00a0\n\u00a0\n\u00a0\nFigura\u00a06.\u00a0Cronograma \u00a0de\u00a0las\u00a0estrategias \u00a0terap\u00e9uticas \u00a0frente\u00a0el\u00a0VIH\u20101\u00a0desde\u00a0 los\u00a0inicios\u00a0de\u00a0la\u00a0epidemia \u00a0\n\u00a0\nActualmente\u00a0se\u00a0dispone\u00a0de\u00a0m\u00e1s\u00a0de \u00a020\u00a0f\u00e1rmacos\u00a0antirretrovirales\u00a0 comercializados\u00a0en\u00a0Espa\u00f1a,\u00a0\nque\u00a0se\u00a0agrupan\u00a0por\u00a0familias\u00a0en\u00a0funci\u00f3n\u00a0de\u00a0la\u00a0diana\u00a0terap\u00e9utica\u00a0sobre\u00a0la\u00a0que\u00a0act\u00faan\u00a0(Tabla\u00a01)\u00a0(1).\u00a0\nLos\u00a0f\u00e1rmacos\u00a0antirretrovirales\u00a0que\u00a0inhiben\u00a0la\u00a0transcriptasa\u00a0inversa\u00a0del\u00a0VIH\u20101\u00a0reciben\u00a0el\u00a0nombre\u00a0\nde\u00a0inhibidores\u00a0de\u00a0la\u00a0transcriptas a\u00a0inversa\u00a0an\u00e1logos\u00a0o\u00a0no\u00a0an\u00e1log os\u00a0de\u00a0los\u00a0nucle\u00f3sidos\u00a0(ITIAN\u00a0o\u00a0\nITINAN)\u00a0seg\u00fan\u00a0sea\u00a0su\u00a0estructura\u00a0qu\u00edmica;\u00a0y\u00a0los\u00a0que\u00a0inhiben\u00a0la\u00a0a ctividad\u00a0de\u00a0la\u00a0proteasa\u00a0se\u00a0conocen\u00a0\ncomo\u00a0 inhibidores\u00a0 de\u00a0 la\u00a0 proteasa\u00a0 (IP).\u00a0 Los\u00a0 IP\u00a0 act\u00faan\u00a0 de\u00a0 forma\u00a0 espec\u00edfica\u00a0 bloqueando\u00a0 el\u00a0procesamiento\u00a0por\u00a0parte\u00a0de\u00a0la\u00a0proteasa\u00a0v\u00edrica\u00a0de\u00a0mol\u00e9culas\u00a0poli pept\u00eddicas,\u00a0necesarias\u00a0para\u00a0la\u00a0\nmaduraci\u00f3n\u00a0 completa\u00a0 del\u00a0 virus\u00a0 y\u00a0 la\u00a0 formaci\u00f3n\u00a0 de\u00a0 part\u00edculas\u00a0 infe cciosas\u00a0 Los\u00a0 an\u00e1logos\u00a0 de\u00a0\nnucle\u00f3sidos\u00a0act\u00faan\u00a0compitiendo\u00a0por\u00a0el\u00a0sustrato\u00a0natural\u00a0del\u00a0enzi ma,\u00a0los\u00a0deoxinucle\u00f3sidos.\u00a0La\u00a0INTRODUCCI\u00d3N\u00a0\n -  9incorporaci\u00f3n\u00a0de\u00a0un\u00a0an\u00e1logo\u00a0de\u00a0nucle\u00f3sido\u00a0al\u00a0centro\u00a0activo\u00a0de\u00a0l a\u00a0transcriptasa\u00a0inversa\u00a0bloquea\u00a0la\u00a0\nentrada\u00a0de\u00a0nuevos\u00a0deoxinucle\u00f3sidos\u00a0y\u00a0la\u00a0elongaci\u00f3n\u00a0de\u00a0la\u00a0cadena \u00a0de\u00a0ADN\u00a0en\u00a0curso.\u00a0En\u00a0cambio,\u00a0los\u00a0\nno\u00a0an\u00e1logos\u00a0de\u00a0nucle\u00f3sidos\u00a0no\u00a0compiten\u00a0por\u00a0el\u00a0centro\u00a0activo\u00a0de\u00a0la\u00a0transcriptasa\u00a0inversa,\u00a0sino\u00a0que\u00a0\ninteraccionan\u00a0 en\u00a0 un\u00a0 dominio\u00a0 pr\u00f3ximo\u00a0 al\u00a0 centro\u00a0 activo,\u00a0 dificulta ndo\u00a0 la\u00a0 movilidad\u00a0 de\u00a0 la\u00a0\ntranscriptasa\u00a0inversa\u00a0y\u00a0bloqueando\u00a0la\u00a0polimerizaci\u00f3n\u00a0del\u00a0ADN.\u00a0( 26).\u00a0\n\u00a0\u00a0\u00a0\n\u00a0\n\u00a0\u00a0\u00a0\n\u00a0\n\u00a0\u00a0\n\u00a0\n\u00a0\u00a0\u00a0\n\u00a0\n\u00a0\u00a0\u00a0\nTabla\u00a01 .\u00a0F\u00e1rmacos \u00a0antirretrovirales \u00a0por\u00a0familias\u00a0\u00a0\nFuente:\u00a0Gatell\u00a0JM,\u00a0et \u00a0al.\u00a02007\u00a0(1)\u00a0\n\u00a0\nTambi\u00e9n\u00a0se\u00a0ha\u00a0conseguido\u00a0inhibir\u00a0la\u00a0replicaci\u00f3n\u00a0del\u00a0VIH\u20101\u00a0media nte\u00a0medicamentos\u00a0dirigidos\u00a0a\u00a0\notras\u00a0dianas,\u00a0como\u00a0pueden\u00a0ser\u00a0lo s\u00a0complejos\u00a0procesos\u00a0de\u00a0adheren cia\u00a0v\u00edrica\u00a0y\u00a0fusi\u00f3n\u00a0con\u00a0las\u00a0\nc\u00e9lulas\u00a0del\u00a0hospedador\u00a0(inhibidores\u00a0de\u00a0la\u00a0fusi\u00f3n),\u00a0as\u00ed\u00a0como\u00a0la\u00a0integraci\u00f3n\u00a0del\u00a0ADN\u00a0prov\u00edrico\u00a0en\u00a0el\u00a0ADN\u00a0celular\u00a0(inhibidores\u00a0de\u00a0la\u00a0integrasa)\u00a0(27).\u00a0Por\u00a0\u00faltimo\u00a0tamb i\u00e9n\u00a0se\u00a0ha\u00a0conseguido\u00a0inhibir\u00a0la\u00a0\nentrada\u00a0del\u00a0VIH\u20101\u00a0al\u00a0bloquear\u00a0la\u00a0entrada\u00a0de\u00a0uno\u00a0de\u00a0los\u00a0co\u2010recep tores\u00a0de\u00a0quimiocinas\u00a0(CCR5)\u00a0(28).\u00a0\nEn\u00a01996\u00a0se\u00a0empezaron\u00a0a\u00a0comercializar\u00a0los\u00a0inhibidores\u00a0de\u00a0la\u00a0proteasa,\u00a0y\u00a0fue\u00a0entonces\u00a0cuando\u00a0se\u00a0\npropuso\u00a0un\u00a0cambio\u00a0de\u00a0estrategia\u00a0consistente\u00a0en\u00a0combinar\u00a0siempre \u00a0tres\u00a0o\u00a0m\u00e1s\u00a0medicamentos\u00a0\n(Figura\u00a06).\u00a0Esta\u00a0nueva\u00a0estrategia\u00a0se\u00a0conoce\u00a0como\u00a0Tratamiento\u00a0An tirretroviral\u00a0de\u00a0Gran\u00a0Actividad\u00a0Familia\u00a0 F\u00e1rmaco \u00a0\nZidovudina\u00a0(AZT)\u00a0\nDidanosina\u00a0(ddl)\u00a0\nEstavudina\u00a0(d4T)\u00a0Lamivudina\u00a0(3TC)\u00a0Emtricitabina\u00a0(FTC)\u00a0Abacavir\u00a0(ABC)\u00a0ITIAN\u00a0\n \nTenofovir\u00a0(TDF)\u00a0\nNevirapina\u00a0\nEfavirenz\u00a0ITINAN\u00a0\nEtravirina\u00a0Indinavir\u00a0\nRitonavir\u00a0\nSaquinavir\u00a0\nFosamprenavir\u00a0\nLopinavir\u00a0Atazanavir\u00a0Darunavir\u00a0IP\u00a0\nTipranavir\u00a0\nInhibidores\u00a0de\u00a0la\u00a0fusi\u00f3n\u00a0 Enfuvirtida\u00a0(T20)\u00a0\nInhibidores\u00a0de\u00a0la\u00a0integrasa\u00a0 Raltegravir\u00a0\nAntagonistas\u00a0del\u00a0correceptor\u00a0CCR5\u00a0 Maraviroc\u00a0INTRODUCCI\u00d3N\u00a0\n 10(TARGA),\u00a0y\u00a0supuso\u00a0un\u00a0aumento\u00a0del\u00a0tiempo\u00a0de\u00a0progresi\u00f3n\u00a0a\u00a0SIDA,\u00a0a s\u00ed\u00a0como\u00a0la\u00a0disminuci\u00f3n\u00a0de\u00a0la\u00a0\nmortalidad\u00a0relacionada\u00a0con\u00a0infe cciones\u00a0oportunistas\u00a0y\u00a0las\u00a0neopl asias\u00a0asociadas\u00a0al\u00a0SIDA\u00a0(29,\u00a030)\u00a0.\u00a0\u00a0\n\u00a0\n\u00a0\n1.5.\u00a0Resistencias \u00a0del\u00a0VIH\u20101\u00a0a\u00a0los\u00a0antirretrovirales \u00a0\u00a0\nEl\u00a0desarrollo\u00a0de\u00a0resistencias\u00a0es\u00a0consecuencia,\u00a0sobretodo,\u00a0de\u00a0la \u00a0alta\u00a0din\u00e1mica\u00a0de\u00a0replicaci\u00f3n\u00a0del\u00a0\nVIH\u20101\u00a0que\u00a0se\u00a0produce\u00a0durante\u00a0todo\u00a0el\u00a0proceso\u00a0de\u00a0la\u00a0enfermedad.\u00a0Adem\u00e1s,\u00a0el\u00a0VIH\u20101\u00a0no\u00a0tiene\u00a0la\u00a0\nactividad\u00a0 correctora\u00a0 de\u00a0 las\u00a0 ADN\u2010polimerasas\u00a0 que\u00a0 preservan\u00a0 la\u00a0 co mposici\u00f3n\u00a0 gen\u00e9tica\u00a0 de\u00a0 los\u00a0\norganismos\u00a0de\u00a0ADN\u00a0de\u00a0doble\u00a0cadena\u00a0(1).\u00a0Estos\u00a0factores\u00a0conllevan \u00a0a\u00a0la\u00a0alta\u00a0diversidad\u00a0gen\u00e9tica\u00a0de\u00a0\nla\u00a0poblaci\u00f3n\u00a0de\u00a0virus\u00a0VIH\u20101\u00a0que\u00a0se\u00a0encuentran\u00a0en\u00a0un\u00a0individuo\u00a0i nfectado.\u00a0Este\u00a0conjunto\u00a0de\u00a0cepas\u00a0\nde\u00a0VIH\u00a0distintas\u00a0gen\u00e9ticamente\u00a0se\u00a0conoce\u00a0con\u00a0el\u00a0nombre\u00a0de\u00a0cuasi especies\u00a0(31).\u00a0\u00a0\nLas\u00a0mutaciones\u00a0(cambios\u00a0en\u00a0la\u00a0secuencia\u00a0de\u00a0nucle\u00f3tidos\u00a0del\u00a0ADN) \u00a0en\u00a0el\u00a0genoma\u00a0del\u00a0virus\u00a0\npueden\u00a0tener\u00a0distintos\u00a0efectos\u00a0sobre\u00a0el\u00a0 fitness\u00a0(la\u00a0capacidad\u00a0replicativa\u00a0del\u00a0virus).\u00a0Uno\u00a0de\u00a0ellos\u00a0es\u00a0\nel\u00a0de\u00a0provocar\u00a0un\u00a0efecto\u00a0neutral,\u00a0por\u00a0lo\u00a0que\u00a0no\u00a0afecta\u00a0a\u00a0la\u00a0cap acidad\u00a0replicativa\u00a0del\u00a0virus.\u00a0Otro\u00a0\nser\u00eda\u00a0un\u00a0efecto\u00a0delet\u00e9reo,\u00a0esto\u00a0quiere\u00a0decir\u00a0que\u00a0las\u00a0variantes\u00a0v\u00edricas\u00a0se\u00a0replican\u00a0con\u00a0una\u00a0menor\u00a0\neficiencia\u00a0respecto\u00a0la\u00a0cepa\u00a0sin\u00a0mutaciones\u00a0(o\u00a0 wild\u00a0type).\u00a0Finalmente,\u00a0las\u00a0mutaciones\u00a0tambi\u00e9n\u00a0\npueden\u00a0tener\u00a0un\u00a0efecto\u00a0resistente,\u00a0lo\u00a0cual\u00a0significa\u00a0que\u00a0las\u00a0ce pas\u00a0son\u00a0capaces\u00a0de\u00a0replicarse\u00a0bajo\u00a0\npresi\u00f3n\u00a0farmacol\u00f3gica.\u00a0Es\u00a0import ante\u00a0destacar\u00a0que\u00a0las\u00a0cepas\u00a0con \u00a0mutaciones\u00a0con\u00a0efecto\u00a0resistente\u00a0\npresentan\u00a0un\u00a0menor\u00a0 fitness\u00a0que\u00a0las\u00a0cepas\u00a0 wild\u00a0type\u00a0(31).\u00a0\nLa\u00a0supresi\u00f3n\u00a0incompleta\u00a0de\u00a0la\u00a0replicaci\u00f3n\u00a0v\u00edrica\u00a0en\u00a0individuos\u00a0 que\u00a0est\u00e1n\u00a0recibiendo\u00a0terapias\u00a0\nsub\u00f3ptimas,\u00a0que\u00a0presentan\u00a0baja\u00a0adherencia\u00a0al\u00a0tratamiento\u00a0o\u00a0por\u00a0 fen\u00f3menos\u00a0de\u00a0mala\u00a0absorci\u00f3n,\u00a0es\u00a0\nuno\u00a0 de\u00a0 los\u00a0 factores\u00a0 implicados\u00a0 en\u00a0 la\u00a0 emergencia\u00a0 y\u00a0 evoluci\u00f3n\u00a0 de\u00a0 cepas\u00a0 resistentes\u00a0 a\u00a0 los\u00a0\nantirretrovirales.\u00a0 Las\u00a0 mutaciones\u00a0 que\u00a0 surgen\u00a0 y\u00a0 se\u00a0 seleccionan\u00a0 b ajo\u00a0 terapia\u00a0 antirretroviral\u00a0\npermiten\u00a0al\u00a0virus\u00a0resistente\u00a0esc apar\u00a0del\u00a0efecto\u00a0inhibitorio\u00a0del\u00a0f\u00e1rmaco\u00a0sobre\u00a0su\u00a0replicaci\u00f3n\u00a0(31).\u00a0\u00a0\nSeg\u00fan\u00a0el\u00a0momento\u00a0de\u00a0adquisici\u00f3n\u00a0de\u00a0las\u00a0resistencias\u00a0podemos\u00a0dif erenciar\u00a0entre\u00a0resistencias\u00a0\ntransmitidas,\u00a0 detectadas\u00a0 en\u00a0 pacientes\u00a0 que\u00a0 no\u00a0 han\u00a0 recibido\u00a0 tratamiento\u00a0 antirretroviral,\u00a0 y\u00a0resistencias\u00a0adquiridas,\u00a0detecta das\u00a0en\u00a0pacientes\u00a0que\u00a0han\u00a0recibido\u00a0tratamiento\u00a0antirretroviral.\u00a0\u00a0\nLas\u00a0mutaciones\u00a0tambi\u00e9n\u00a0se\u00a0pueden\u00a0 clasificar\u00a0seg\u00fan\u00a0el\u00a0momento\u00a0en\u00a0que\u00a0se\u00a0desarrollan\u00a0las\u00a0\nresistencias,\u00a0a\u00a0partir\u00a0de\u00a0la\u00a0pre si\u00f3n\u00a0farmacol\u00f3gica,\u00a0dando\u00a0lugar \u00a0a\u00a0dos\u00a0definiciones:\u00a0\n- Mutaciones\u00a0primarias:\u00a0son\u00a0aquella s\u00a0mutaciones\u00a0seleccionadas\u00a0en\u00a0 el\u00a0inicio\u00a0del\u00a0proceso\u00a0del\u00a0\ndesarrollo\u00a0 de\u00a0 resistencias\u00a0 a\u00a0 un\u00a0 f\u00e1rmaco.\u00a0 Estas\u00a0 mutaciones\u00a0 puede n\u00a0 estar\u00a0 seleccionadas\u00a0 o\u00a0\nfavorecidas\u00a0despu\u00e9s\u00a0de\u00a0la\u00a0aparic i\u00f3n\u00a0de\u00a0mutaciones\u00a0secundarias,\u00a0 y\u00a0presentan\u00a0un\u00a0alto\u00a0grado\u00a0de\u00a0\nespecificidad\u00a0por\u00a0un\u00a0tipo\u00a0de\u00a0f\u00e1rmaco\u00a0que\u00a0compromete\u00a0significativamente\u00a0la\u00a0susceptibilidad\u00a0del\u00a0virus\u00a0frente\u00a0a\u00a0ese\u00a0f\u00e1rmaco.\u00a0INTRODUCCI\u00d3N\u00a0\n -  11- Mutaciones\u00a0secundarias:\u00a0son\u00a0mutaciones\u00a0que\u00a0tienden\u00a0a\u00a0acumularse \u00a0en\u00a0el\u00a0genoma\u00a0v\u00edrico\u00a0\nque\u00a0ya\u00a0contiene\u00a0una\u00a0o\u00a0m\u00e1s\u00a0mutaciones\u00a0primarias\u00a0previas.\u00a0Estas\u00a0m utaciones\u00a0pueden\u00a0tener\u00a0un\u00a0\ncierto\u00a0efecto\u00a0o\u00a0ninguno\u00a0sobre\u00a0el\u00a0nivel\u00a0de\u00a0resistencia.\u00a0Algunas\u00a0 mutaciones\u00a0secundarias\u00a0pueden\u00a0\nfavorecer\u00a0la\u00a0replicaci\u00f3n\u00a0v\u00edrica\u00a0aumentando\u00a0la\u00a0capacidad\u00a0replica tiva\u00a0del\u00a0virus.\u00a0\nLas\u00a0mutaciones\u00a0asociadas\u00a0a\u00a0resist encia\u00a0tambi\u00e9n\u00a0pueden\u00a0clasificarse\u00a0seg\u00fan\u00a0la\u00a0familia\u00a0de\u00a0f\u00e1rmaco\u00a0\nantirretroviral\u00a0 que\u00a0 las\u00a0 ha\u00a0 seleccionado,\u00a0 y\u00a0 podemos\u00a0 hablar\u00a0 de\u00a0 mu taciones\u00a0 resistentes\u00a0 a\u00a0 los\u00a0\ninhibidores\u00a0de\u00a0la\u00a0transcriptasa\u00a0inversa\u00a0(an\u00e1logos\u00a0o\u00a0no\u00a0an\u00e1logos )\u00a0y\u00a0mutaciones\u00a0resistentes\u00a0a\u00a0los\u00a0\ninhibidores\u00a0de\u00a0la\u00a0proteasa\u00a0(31).\u00a0En\u00a0relaci\u00f3n\u00a0con\u00a0las\u00a0familias\u00a0d e\u00a0f\u00e1rmacos\u00a0que\u00a0se\u00a0han\u00a0introducido\u00a0\nde\u00a0manera\u00a0m\u00e1s\u00a0reciente,\u00a0ya\u00a0existen\u00a0algunos\u00a0estudios\u00a0que\u00a0reporta n\u00a0la\u00a0presencia\u00a0de\u00a0cepas\u00a0de\u00a0VIH\u20101\u00a0\ncon\u00a0resistencias\u00a0a\u00a0los\u00a0antagonistas\u00a0del\u00a0co\u2010receptor\u00a0CCR5\u00a0(Marav iroc)\u00a0(32),\u00a0a\u00a0los\u00a0inhibidores\u00a0de\u00a0la\u00a0\nfusi\u00f3n\u00a0(Enfuvirtida)\u00a0(33)\u00a0y\u00a0tambi \u00e9n\u00a0a\u00a0los\u00a0inhibidores\u00a0de\u00a0la\u00a0int egrasa\u00a0(Raltegravir)\u00a0(34).\u00a0\nLa\u00a0barrera\u00a0gen\u00e9tica\u00a0es\u00a0el\u00a0n\u00famero\u00a0de\u00a0mutaciones\u00a0necesario\u00a0para\u00a0reducir\u00a0la\u00a0actividad\u00a0antiviral\u00a0de\u00a0\nun\u00a0f\u00e1rmaco,\u00a0y\u00a0se\u00a0puede\u00a0clasificar\u00a0en\u00a0baja\u00a0(la\u00a0p\u00e9rdida\u00a0de\u00a0activi dad\u00a0antiv\u00edrica\u00a0se\u00a0pierde\u00a0por\u00a0la\u00a0\naparici\u00f3n\u00a0o\u00a0selecci\u00f3n\u00a0de\u00a0una\u00a0\u00fanica\u00a0mutaci\u00f3n)\u00a0o\u00a0alta\u00a0(la\u00a0p\u00e9rdida \u00a0de\u00a0actividad\u00a0antiv\u00edrica\u00a0se\u00a0pierde\u00a0\ndespu\u00e9s\u00a0de\u00a0la\u00a0aparici\u00f3n\u00a0o\u00a0selecci \u00f3n\u00a0de\u00a0m\u00faltiples\u00a0mutaciones)\u00a0(31).\u00a0\u00a0\u00a0\nEn\u00a0general,\u00a0la\u00a0resistencia\u00a0a\u00a0un\u00a0determinado\u00a0f\u00e1rmaco\u00a0es\u00a0el\u00a0resul tado\u00a0de\u00a0mutaciones\u00a0en\u00a0un\u00a0\nn\u00famero\u00a0de\u00a0posiciones\u00a0determinadas\u00a0en\u00a0el\u00a0gen\u00a0que\u00a0codifica\u00a0la\u00a0pro te\u00edna\u00a0sobre\u00a0la\u00a0que\u00a0act\u00faa\u00a0dicho\u00a0\nf\u00e1rmaco.\u00a0Por\u00a0lo\u00a0tanto,\u00a0determinando\u00a0la\u00a0composici\u00f3n\u00a0de\u00a0amino\u00e1cid os\u00a0en\u00a0un\u00a0n\u00famero\u00a0de\u00a0posiciones\u00a0\nen\u00a0 el\u00a0 genoma\u00a0 del\u00a0 VIH\u20101,\u00a0 es\u00a0 posible\u00a0 deducir\u00a0 el\u00a0 nivel\u00a0 de\u00a0 resisten cia.\u00a0 Los\u00a0 tests\u00a0 genot\u00edpicos\u00a0\ndeterminan\u00a0la\u00a0secuencia\u00a0gen\u00e9tica,\u00a0mediante\u00a0t\u00e9cnicas\u00a0de\u00a0secuenci aci\u00f3n\u00a0de\u00a0ADN,\u00a0de\u00a0una\u00a0gran\u00a0parte\u00a0\ndel\u00a0gen\u00a0 pol,\u00a0en\u00a0la\u00a0que\u00a0que\u00a0se\u00a0codifican\u00a0la\u00a0retrotranscriptasa\u00a0inversa\u00a0y\u00a0la \u00a0proteasa.\u00a0Estas\u00a0t\u00e9cnicas\u00a0\npermiten\u00a0obtener\u00a0la\u00a0secuencia\u00a0de\u00a0nucle\u00f3tidos\u00a0del\u00a0virus\u00a0en\u00a0un\u00a0fo rmato\u00a0conocido\u00a0como\u00a0secuencia\u00a0\nFASTA.\u00a0Este\u00a0formato\u00a0consiste\u00a0en\u00a0un\u00a0fichero\u00a0inform\u00e1tico\u00a0de\u00a0texto\u00a0que\u00a0contiene\u00a0la\u00a0secuencia\u00a0de\u00a0\nnucle\u00f3tidos\u00a0del\u00a0virus.\u00a0Cada\u00a0nucle\u00f3tido\u00a0est\u00e1\u00a0representado\u00a0por\u00a0un a\u00a0letra,\u00a0y\u00a0ocupa\u00a0la\u00a0misma\u00a0posici\u00f3n\u00a0\nque\u00a0ocupar\u00eda\u00a0en\u00a0el\u00a0gen\u00a0(Figura\u00a07).\u00a0\nMediante\u00a0un\u00a0algoritmo\u00a0de\u00a0interpretaci\u00f3n\u00a0es\u00a0posible\u00a0obtener\u00a0las\u00a0 mutaciones\u00a0observadas\u00a0en\u00a0la\u00a0\nsecuencia\u00a0 de\u00a0 inter\u00e9s,\u00a0 con\u00a0 relaci\u00f3n\u00a0 a\u00a0 una\u00a0 secuencia\u00a0 consenso\u00a0 de\u00a0 VIH\u20101.\u00a0 Estas\u00a0 mutaciones\u00a0 se\u00a0\nexpresan\u00a0 por\u00a0 la\u00a0 posici\u00f3n\u00a0 que\u00a0 ocupan\u00a0 en\u00a0 el\u00a0 gen,\u00a0 precedido\u00a0 por\u00a0 la \u00a0 letra\u00a0 correspondiente\u00a0 al\u00a0\namino\u00e1cido\u00a0encontrado\u00a0en\u00a0el\u00a0virus\u00a0 wild\u2010type,\u00a0y\u00a0seguido\u00a0por\u00a0el\u00a0amino\u00e1cido\u00a0mutado\u00a0(Figura\u00a08).\u00a0\nActualmente\u00a0existen\u00a0numerosos\u00a0algoritmos\u00a0disponibles\u00a0 on\u2010line\u00a0para\u00a0interpretar\u00a0las\u00a0secuencias\u00a0en\u00a0\nformato\u00a0FASTA,\u00a0y\u00a0muchos\u00a0de\u00a0ellos\u00a0 son\u00a0de\u00a0libre\u00a0acceso,\u00a0como\u00a0el\u00a0p roporcionado\u00a0por\u00a0la\u00a0Universidad\u00a0\nde\u00a0Stanford\u00a0(disponible\u00a0en\u00a0 http://sierra2.stanford.edu/sierra/servlet/JSierra )\u00a0(31).\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\n\u00a0\n\u00a0INTRODUCCI\u00d3N\u00a0\n 12\u00a0\n\u00a0\n\u00a0\nFigura\u00a07.\u00a0Ejemplo \u00a0de\u00a0una\u00a0secuencia \u00a0gen\u00e9tica \u00a0de\u00a0VIH\u00a0en\u00a0formato\u00a0FASTA\u00a0\nFuente:\u00a0hivdb.stanford.edu\u00a0\u00a0\u00a0\n\u00a0\u00a0\nNOMENCLATURA DE LAS MUTACIONES\nPrimera letra N\u00famero \u00daltima letra\nAmino\u00e1cido \npresente en la \nprote\u00edna wild-typeCod\u00f3n mutado Amino\u00e1cido \npresente en la prote\u00edna mutanteAMINO\u00c1CIDOS\nA AlaninaR ArgininaN AsparaginaD \u00c1cido asp\u00e1rtico\nC Ciste\u00edna\nQ GlutaminaE \u00c1cido glut\u00e1micoG Glicina\nH Histidina\nI IsoleucinaL LeucinaK Lisina\nM Metionina\nF FenilalaninaP ProlinaS Serina\nT Treonina\nW Tript\u00f3fanoY TirosinaV Valina\nEjemplos:\nL90M Cambio de leucina a metionina en el cod\u00f3n 90 del gen de   \nla proteasa\nM184V Cambio de metionina a valina en el cod\u00f3n 184 del gen de \nla retrotranscriptasa\u00a0\n\u00a0\nFigura\u00a08.\u00a0Nomenclatura\u00a0 de\u00a0las\u00a0mutaciones\u00a0\nFuente:\u00a0Clotet\u00a0 et\u00a0al.\u00a02008\u00a0(31)\u00a0INTRODUCCI\u00d3N\u00a0\n -  132.\u00a0Epidemiolog\u00eda \u00a0de\u00a0la\u00a0infecci\u00f3n \u00a0por\u00a0VIH\u00a0\u00a0\n2.1.\u00a0La\u00a0pandemia \u00a0del\u00a0VIH\u00a0\nLos\u00a0primeros\u00a0casos\u00a0de\u00a0SIDA\u00a0se\u00a0describieron\u00a0hace\u00a0m\u00e1s\u00a0de\u00a030\u00a0a\u00f1os\u00a0 en\u00a0las\u00a0ciudades\u00a0de\u00a0Los\u00a0\n\u00c1ngeles\u00a0 y\u00a0 Nueva\u00a0 York\u00a0 (35,\u00a0 36).\u00a0 Desde\u00a0 entonces,\u00a0 la\u00a0 epidemia\u00a0 de\u00a0 l a\u00a0 infecci\u00f3n\u00a0 por\u00a0 VIH\u00a0 se\u00a0 ha\u00a0\npropagado\u00a0por\u00a0todo\u00a0el\u00a0mundo,\u00a0de\u00a0manera\u00a0que\u00a0es\u00a0posible\u00a0hablar\u00a0de \u00a0pandemia\u00a0del\u00a0VIH\u00a0(1).\u00a0El\u00a0\nprograma\u00a0de\u00a0SIDA\u00a0de\u00a0las\u00a0Naciones\u00a0Unidas\u00a0(UNAIDS)\u00a0estima\u00a0que\u00a0has ta\u00a0diciembre\u00a0de\u00a02012\u00a0el\u00a0\nn\u00famero\u00a0de\u00a0personas\u00a0en\u00a0el\u00a0mundo\u00a0que\u00a0viven\u00a0con\u00a0VIH\u00a0es\u00a0de\u00a035,3\u00a0mil lones,\u00a0de\u00a0las\u00a0cuales\u00a025,0\u00a0\nmillones\u00a0(71%)\u00a0se\u00a0encuentran\u00a0en\u00a0l a\u00a0regi\u00f3n\u00a0del\u00a0\u00c1frica\u00a0Subsaharia na\u00a0(Figura\u00a09)\u00a0(38).\u00a0\u00a0\u00a0\n\u00a0\n\u00a0\n\u00a0\nFigura\u00a09.\u00a0Prevalencia \u00a0global\u00a0de\u00a0VIH,\u00a02012\u00a0\nFuente:\u00a0Informe\u00a0UNAIDS\u00a02013\u00a0(38)\u00a0\n\u00a0\nGlobalmente,\u00a0en\u00a0el\u00a0a\u00f1o\u00a02012\u00a0el\u00a0n\u00famero\u00a0anual\u00a0de\u00a0nuevas\u00a0infeccion es\u00a0por\u00a0VIH\u00a0ha\u00a0disminuido\u00a0\nrespecto\u00a0a\u00f1os\u00a0anteriores.\u00a0En\u00a0el\u00a0a\u00f1o\u00a02012\u00a0se\u00a0estima\u00a0que\u00a0se\u00a0produjeron\u00a02,3\u00a0millones\u00a0de\u00a0nuevas\u00a0infecciones,\u00a0un\u00a0valor\u00a0inferior\u00a0al\u00a0del\u00a0a\u00f1o\u00a01999\u00a0(3,1\u00a0millones),\u00a0 y\u00a0al\u00a0del\u00a01997\u00a0(3,2\u00a0millones).\u00a0A\u00fan\u00a0as\u00ed,\u00a0a\u00a0\npesar\u00a0 de\u00a0 la\u00a0 disminuci\u00f3n\u00a0 en\u00a0 el\u00a0 n\u00famero\u00a0 de\u00a0 nuevas\u00a0 infecciones,\u00a0 la\u00a0 magnitud\u00a0 de\u00a0 las\u00a0 nuevas\u00a0\ninfecciones\u00a0 sigue\u00a0 siendo\u00a0 considerablemente\u00a0 alta.\u00a0 Este\u00a0 hecho,\u00a0 ju nto\u00a0 con\u00a0 la\u00a0 reducci\u00f3n\u00a0 de\u00a0 la\u00a0\nmortalidad\u00a0relacionada\u00a0con\u00a0el\u00a0SIDA,\u00a0hace\u00a0que\u00a0el\u00a0n\u00famero\u00a0de\u00a0perso nas\u00a0que\u00a0viven\u00a0con\u00a0VIH\u00a0siga\u00a0\naumentado\u00a0en\u00a0todo\u00a0el\u00a0mundo\u00a0(39).\u00a0\u00a0INTRODUCCI\u00d3N\u00a0\n 14En\u00a0 relaci\u00f3n\u00a0 con\u00a0 la\u00a0 principal\u00a0 forma\u00a0 de\u00a0 transmisi\u00f3n\u00a0 del\u00a0 VIH,\u00a0 actu almente\u00a0 la\u00a0 mayor\u00eda\u00a0 de\u00a0\ntransmisiones\u00a0se\u00a0producen\u00a0a\u00a0trav\u00e9s\u00a0de\u00a0las\u00a0relaciones\u00a0sexuales\u00a0desprotegidas.\u00a0En\u00a0la\u00a0regi\u00f3n\u00a0del\u00a0\n\u00c1frica\u00a0Subsahariana\u00a0la\u00a0transmisi \u00f3n\u00a0del\u00a0virus\u00a0se\u00a0produce\u00a0princip almente\u00a0por\u00a0v\u00eda\u00a0heterosexual,\u00a0\nmientras\u00a0que\u00a0en\u00a0los\u00a0pa\u00edses\u00a0desarrollados\u00a0(Norte\u00a0de\u00a0Am\u00e9rica\u00a0y\u00a0Europa\u00a0Occidental)\u00a0la\u00a0epidemia\u00a0de\u00a0VIH\u00a0entre\u00a0HSH\u00a0est\u00e1\u00a0experimentando\u00a0una\u00a0resurgencia\u00a0(40).\u00a0En\u00a0la\u00a0regi\u00f3n\u00a0de\u00a0Europa\u00a0del\u00a0Este\u00a0el\u00a0\nn\u00famero\u00a0de\u00a0casos\u00a0ha\u00a0aumentado\u00a0sus tancialmente,\u00a0principalmente\u00a0de bido\u00a0a\u00a0un\u00a0aumento\u00a0de\u00a0los\u00a0\ncasos\u00a0 adquiridos\u00a0 por\u00a0 los\u00a0 UDVP,\u00a0 pero\u00a0 tambi\u00e9n\u00a0 se\u00a0 est\u00e1\u00a0 observando\u00a0 un\u00a0 aumento\u00a0 de\u00a0 los\u00a0 casos\u00a0\nadquiridos\u00a0por\u00a0v\u00eda\u00a0heterosexual\u00a0(41).\u00a0\n\u00a0\u00a0\n2.2.\u00a0Caracter\u00edsticas \u00a0de\u00a0la\u00a0epidemia \u00a0de\u00a0VIH\u00a0en\u00a0Catalu\u00f1a\u00a0 y\u00a0Espa\u00f1a\u00a0\u00a0\nEn\u00a0sus\u00a0inicios,\u00a0tanto\u00a0en\u00a0Catalu\u00f1a\u00a0como\u00a0en\u00a0Espa\u00f1a,\u00a0la\u00a0epidemia\u00a0e stuvo\u00a0fuertemente\u00a0ligada\u00a0a\u00a0los\u00a0\nh\u00e1bitos\u00a0 de\u00a0 inyecci\u00f3n\u00a0 de\u00a0 drogas\u00a0 ( 42).\u00a0 Paulatinamente,\u00a0 la\u00a0 transmisi\u00f3n\u00a0 del\u00a0 virus\u00a0 se\u00a0 ha\u00a0 ido\u00a0\ndesplazando\u00a0hacia\u00a0la\u00a0v\u00eda\u00a0sexual, \u00a0y\u00a0actualmente\u00a0la\u00a0mayor\u00eda\u00a0de\u00a0nu evas\u00a0infecciones\u00a0se\u00a0adquieren\u00a0por\u00a0\nesta\u00a0 v\u00eda.\u00a0 En\u00a0 Espa\u00f1a,\u00a0 en\u00a0 el\u00a0 a\u00f1o\u00a0 2012\u00a0 se\u00a0 notificaron\u00a0 3.210\u00a0 nuevos \u00a0d i a g n \u00f3 s t i c o s \u00a0d e \u00a0V I H , \u00a0\nrepresentando\u00a0una\u00a0tasa\u00a0de\u00a08,5\u00a0por\u00a0100.000\u00a0habitantes.\u00a0La\u00a0mayor\u00eda\u00a0de\u00a0nuevos\u00a0diagn\u00f3sticos\u00a0eran\u00a0hombres\u00a0 (85%),\u00a0 ten\u00edan\u00a0 36\u00a0 a\u00f1os\u00a0 de\u00a0 mediana\u00a0de\u00a0edad,\u00a0y\u00a0en\u00a0el\u00a051%\u00a0d e\u00a0los\u00a0casos\u00a0el\u00a0virus\u00a0se\u00a0\ntransmiti\u00f3\u00a0a\u00a0trav\u00e9s\u00a0de\u00a0relaciones\u00a0entre\u00a0HSH\u00a0(43).\u00a0\u00a0\u00a0\u00a0\nEn\u00a0Catalu\u00f1a,\u00a0la\u00a0epidemia\u00a0por\u00a0VIH\u00a0presenta\u00a0caracter\u00edsticas\u00a0simil ares\u00a0a\u00a0las\u00a0de\u00a0la\u00a0epidemia\u00a0en\u00a0el\u00a0\nresto\u00a0de\u00a0Espa\u00f1a.\u00a0En\u00a0el\u00a0registro\u00a0de\u00a0enfermedades\u00a0de\u00a0declaraci\u00f3n\u00a0 individualizadas\u00a0de\u00a0Catalu\u00f1a,\u00a0el\u00a0\na\u00f1o\u00a02011\u00a0se\u00a0notificaron\u00a0609\u00a0diagn\u00f3sticos\u00a0de\u00a0VIH,\u00a0que\u00a0representa\u00a0una\u00a0tasa\u00a0global\u00a0de\u00a08,5\u00a0casos\u00a0por\u00a0\n100.000\u00a0habitantes.\u00a0La\u00a0tasa\u00a0de\u00a0diagn\u00f3sticos\u00a0de\u00a0VIH\u00a0se\u00a0ha\u00a0manten ido\u00a0pr\u00e1cticamente\u00a0constate\u00a0\ndurante\u00a0todo\u00a0el\u00a0periodo\u00a0(44).\u00a0Del\u00a0total\u00a0de\u00a0nuevos\u00a0diagn\u00f3sticos\u00a0 notificados\u00a0el\u00a0a\u00f1o\u00a02011,\u00a0la\u00a0mayor\u00eda\u00a0\neran\u00a0hombres\u00a0(85,9%),\u00a0y\u00a0en\u00a0el\u00a064,6%\u00a0de\u00a0los\u00a0casos\u00a0se\u00a0hab\u00edan\u00a0decl arado\u00a0en\u00a0personas\u00a0entre\u00a0los\u00a020\u00a0y\u00a0\n39\u00a0a\u00f1os.\u00a0En\u00a0cuanto\u00a0a\u00a0la\u00a0transmisi\u00f3n\u00a0de\u00a0la\u00a0infecci\u00f3n,\u00a0las\u00a0v\u00edas\u00a0m \u00e1s\u00a0probables\u00a0de\u00a0transmisi\u00f3n\u00a0del\u00a0\nvirus\u00a0 fueron\u00a0 las\u00a0 relaciones\u00a0 entre\u00a0 HSH\u00a0 (61,5%),\u00a0 seguidas\u00a0 por\u00a0 las \u00a0 relaciones\u00a0 heterosexuales\u00a0\n(25,4%),\u00a0y\u00a0la\u00a0transmisi\u00f3n\u00a0entre\u00a0los\u00a0UDVP\u00a0(3,8%).\u00a0En\u00a0un\u00a09,3%\u00a0de\u00a0 los\u00a0casos\u00a0la\u00a0v\u00eda\u00a0de\u00a0transmisi\u00f3n\u00a0no\u00a0\npudo\u00a0identificarse.\u00a0\n\u00a0En\u00a0el\u00a0per\u00edodo\u00a02001\u00a0\u2010\u00a02010\u00a0se\u00a0ha\u00a0observado\u00a0un\u00a0aumento\u00a0del\u00a0n\u00famer o\u00a0de\u00a0diagn\u00f3sticos\u00a0en\u00a0HSH\u00a0\nentre\u00a0los\u00a0nuevos\u00a0diagn\u00f3sticos\u00a0de\u00a0VIH,\u00a0experimentando\u00a0un\u00a0increme nto\u00a0del\u00a088%.\u00a0En\u00a0cambio,\u00a0en\u00a0las\u00a0\ntransmisiones\u00a0heterosexuales\u00a0se\u00a0ha\u00a0observado\u00a0un\u00a0descenso\u00a0en\u00a0el\u00a0 n\u00famero\u00a0de\u00a0diagn\u00f3sticos\u00a0de\u00a0VIH.\u00a0\nEste\u00a0 descenso\u00a0 ha\u00a0 sido\u00a0 del\u00a0 55%\u00a0 en\u00a0 los\u00a0 hombres\u00a0 heterosexuales,\u00a0 y\u00a0 del\u00a0 43%\u00a0 en\u00a0 las\u00a0 mujeres\u00a0\nheterosexuales.\u00a0En\u00a0la\u00a0v\u00eda\u00a0de\u00a0transmisi\u00f3n\u00a0a\u00a0trav\u00e9s\u00a0del\u00a0uso\u00a0de\u00a0dr ogas\u00a0por\u00a0v\u00eda\u00a0parenteral\u00a0se\u00a0ha\u00a0\nobservado\u00a0un\u00a0importante\u00a0descenso \u00a0(86%)\u00a0tambi\u00e9n\u00a0para\u00a0el\u00a0mismo\u00a0pe riodo\u00a0(Figura\u00a010)\u00a0(44).\u00a0INTRODUCCI\u00d3N\u00a0\n -  15\u00a0\n \n \nFigura\u00a010.\u00a0 Evoluci\u00f3n \u00a0de\u00a0los\u00a0nuevos\u00a0 diagn\u00f3sticos \u00a0de\u00a0VIH\u00a0por\u00a0v\u00eda\u00a0de\u00a0transmisi\u00f3n, \u00a0Catalu\u00f1a \u00a0(2001\u00a0\u2013\u00a0\n2011)\u00a0\u00a0\nFuente:\u00a0Informe\u00a0SIVES\u00a02012\u00a0(44)\u00a0\u00a0\n\u00a0\nOtro\u00a0indicador\u00a0de\u00a0la\u00a0magnitud\u00a0de\u00a0la\u00a0epidemia\u00a0en\u00a0Catalu\u00f1a\u00a0es\u00a0el\u00a0 n\u00famero\u00a0de\u00a0personas\u00a0vivas\u00a0con\u00a0\ninfecci\u00f3n\u00a0por\u00a0VIH.\u00a0Para\u00a0el\u00a0a\u00f1o\u00a02011\u00a0se\u00a0estim\u00f3\u00a0que\u00a0el\u00a0n\u00famero\u00a0tot al\u00a0de\u00a0personas\u00a0vivas\u00a0con\u00a0infecci\u00f3n\u00a0\npor\u00a0VIH\u00a0era\u00a0de\u00a033.000.\u00a0Esta\u00a0estimaci\u00f3n\u00a0nos\u00a0indica\u00a0que\u00a0la\u00a0preval encia\u00a0de\u00a0la\u00a0infecci\u00f3n\u00a0por\u00a0VIH\u00a0en\u00a0el\u00a0\nconjunto\u00a0de\u00a0la\u00a0poblaci\u00f3n\u00a0genera l\u00a0fue\u00a0de\u00a04,5\u00a0por\u00a0cada\u00a01.000\u00a0pers onas\u00a0(44).\u00a0\nEl\u00a0retraso\u00a0en\u00a0el\u00a0diagn\u00f3stico\u00a0(o\u00a0diagn\u00f3stico\u00a0tard\u00edo)\u00a0es\u00a0un\u00a0aspec to\u00a0de\u00a0especial\u00a0inter\u00e9s\u00a0en\u00a0Salud\u00a0\nP\u00fablica.\u00a0A\u00a0nivel\u00a0individual,\u00a0los\u00a0pacientes\u00a0que\u00a0reciben\u00a0el\u00a0diagn \u00f3stico\u00a0de\u00a0VIH\u00a0tard\u00edamente\u00a0presentan\u00a0\nuna\u00a0peor\u00a0respuesta\u00a0al\u00a0TARGA\u00a0(45),\u00a0y\u00a0tienen\u00a0un\u00a0mayor\u00a0riesgo\u00a0de\u00a0p resentar\u00a0SIDA\u00a0o\u00a0morir\u00a0(46,\u00a047),\u00a0\ndebido\u00a0a\u00a0su\u00a0avanzada\u00a0inmunosupresi\u00f3n.\u00a0Por\u00a0otro\u00a0lado,\u00a0cuanto\u00a0m\u00e1s \u00a0tiempo\u00a0transcurre\u00a0entre\u00a0el\u00a0\nmomento\u00a0de\u00a0la\u00a0infecci\u00f3n\u00a0y\u00a0el\u00a0diagn\u00f3stico,\u00a0mayor\u00a0probabilidad\u00a0de \u00a0transmitir\u00a0el\u00a0VIH;\u00a0ya\u00a0que,\u00a0al\u00a0no\u00a0\nconocer\u00a0 que\u00a0 est\u00e1\u00a0 infectado,\u00a0 es\u00a0 po sible\u00a0 que\u00a0 el\u00a0 individuo\u00a0 no\u00a0 adop te\u00a0 medidas\u00a0 para\u00a0 evitar\u00a0 la\u00a0\ntransmisi\u00f3n\u00a0del\u00a0virus\u00a0(48).\u00a0Recientemente,\u00a0el\u00a0grupo\u00a0de\u00a0trabajo\u00a0 europeo\u00a0para\u00a0el\u00a0consenso\u00a0del\u00a0\ndiagn\u00f3stico\u00a0tard\u00edo\u00a0ha\u00a0propuesto\u00a0una\u00a0nueva\u00a0definici\u00f3n\u00a0para\u00a0ident ificar\u00a0aquellos\u00a0pacientes\u00a0en\u00a0los\u00a0\nque\u00a0el\u00a0diagn\u00f3stico\u00a0de\u00a0VIH\u00a0se\u00a0produjo\u00a0tard\u00edamente:\u00a0(i)\u00a0presentac i\u00f3n\u00a0tard\u00eda,\u00a0personas\u00a0que\u00a0en\u00a0el\u00a0\nmomento\u00a0del\u00a0diagn\u00f3stico\u00a0presentaron\u00a0recuentos\u00a0de\u00a0c\u00e9lulas\u00a0CD4+\u00a0i nferiores\u00a0a\u00a0350\u00a0c\u00e9lulas/\u03bcl;\u00a0o\u00a0(ii)\u00a0\npresentaci\u00f3n\u00a0de\u00a0enfermedad\u00a0avanzada\u00a0de\u00a0VIH,\u00a0personas\u00a0que\u00a0en\u00a0el\u00a0 momento\u00a0del\u00a0diagn\u00f3stico\u00a0\npresentaron\u00a0recuentos\u00a0de\u00a0c\u00e9lulas\u00a0CD4+\u00a0inferiores\u00a0a\u00a0200\u00a0c\u00e9lulas/\u03bcl\u00a0(49).\u00a0En\u00a0Catalu\u00f1a,\u00a0usando\u00a0la\u00a0\ninformaci\u00f3n\u00a0 proporcionada\u00a0 por\u00a0 la\u00a0 cohorte\u00a0 PISCIS\u00a0 (una\u00a0 cohorte\u00a0 pr ospectiva,\u00a0 longitudinal\u00a0 y\u00a0INTRODUCCI\u00d3N\u00a0\n 16multic\u00e9ntrica\u00a0de\u00a0individuos\u00a0infectados\u00a0por\u00a0el\u00a0VIH\u00a0en\u00a0Catalu\u00f1a\u00a0y\u00a0las\u00a0Islas\u00a0Baleares),\u00a0se\u00a0ha\u00a0analizado\u00a0\nel\u00a0retraso\u00a0diagn\u00f3stico\u00a0teniendo\u00a0en\u00a0cuenta\u00a0estas\u00a0nuevas\u00a0definici ones\u00a0(49).\u00a0Para\u00a0el\u00a0a\u00f1o\u00a02010,\u00a0entre\u00a0\nlos\u00a0nuevos\u00a0diagn\u00f3sticos\u00a0de\u00a0VIH\u00a0de\u00a0la\u00a0cohorte\u00a0PISCIS\u00a0el\u00a041,8%\u00a0presentaron\u00a0diagn\u00f3stico\u00a0tard\u00edo,\u00a0y\u00a0un\u00a0\n21,8%\u00a0diagn\u00f3stico\u00a0tard\u00edo\u00a0con\u00a0enfe rmedad\u00a0avanzada\u00a0de\u00a0VIH.\u00a0Se\u00a0observ\u00f3\u00a0un\u00a0descenso\u00a0significativo\u00a0\nen\u00a0los\u00a0casos\u00a0de\u00a0diagn\u00f3stico\u00a0tard\u00ed o,\u00a0pasando\u00a0del\u00a057,5%\u00a0en\u00a0el\u00a0199 8\u00a0al\u00a044,4%\u00a0en\u00a0el\u00a02010\u00a0y\u00a038,3%\u00a0en\u00a0\nel\u00a02011\u00a0(Figura\u00a011)\u00a0(44).\u00a0\n\u00a0\n\u00a0\n\u00a0\nFigura\u00a011.Evoluci\u00f3n \u00a0del\u00a0diagn\u00f3stico \u00a0tard\u00edo\u00a0y\u00a0enfermedad \u00a0avanzada \u00a0en\u00a0los\u00a0nuevos\u00a0 diagn\u00f3sticos \u00a0de\u00a0\ninfecci\u00f3n \u00a0por\u00a0VIH\u00a0en\u00a0la\u00a0cohorte\u00a0PISCIS\u00a0(1998\u00a0\u2013\u00a02011)\u00a0\nFuente:\u00a0Informe\u00a0SIVES\u00a02012\u00a0(44)\u00a0\u00a0\n\u00a0\n\u00a0\n2.3.\u00a0Inmigraci\u00f3n \u00a0y\u00a0VIH\u00a0en\u00a0Catalu\u00f1a\u00a0 y\u00a0Espa\u00f1a\u00a0\nEn\u00a0Espa\u00f1a\u00a0y\u00a0Catalu\u00f1a\u00a0la\u00a0proporci\u00f3n\u00a0de\u00a0inmigrantes\u00a0entre\u00a0los\u00a0nue vos\u00a0diagn\u00f3sticos\u00a0de\u00a0VIH\u00a0es\u00a0\ncreciente.\u00a0 Se\u00a0 ha\u00a0 pasado\u00a0 de\u00a0 tener\u00a0 en\u00a0 la\u00a0 d\u00e9cada\u00a0 de\u00a0 los\u00a0 a\u00f1os\u00a0 90\u00a0 un a\u00a0 epidemia\u00a0 de\u00a0 grandes\u00a0\nproporciones,\u00a0concentrada\u00a0fundamentalmente\u00a0en\u00a0UDVP\u00a0espa\u00f1oles,\u00a0a \u00a0una\u00a0epidemia\u00a0estabilizada\u00a0\nen\u00a0la\u00a0que\u00a0predomina\u00a0la\u00a0transmisi\u00f3n\u00a0sexual,\u00a0y\u00a0en\u00a0la\u00a0que,\u00a0debido\u00a0 a\u00a0la\u00a0disminuci\u00f3n\u00a0en\u00a0el\u00a0n\u00famero\u00a0de\u00a0\ncasos\u00a0espa\u00f1oles\u00a0y\u00a0al\u00a0fen\u00f3meno\u00a0de\u00a0la\u00a0inmigraci\u00f3n,\u00a0los\u00a0inmigrante s\u00a0conforman\u00a0una\u00a0proporci\u00f3n\u00a0cada\u00a0\nvez\u00a0mayor\u00a0(43,\u00a050).\u00a0\nA\u00a0diferencia\u00a0de\u00a0otros\u00a0pa\u00edses\u00a0europeos,\u00a0la\u00a0inmigraci\u00f3n\u00a0en\u00a0Espa\u00f1a \u00a0es\u00a0un\u00a0fen\u00f3meno\u00a0relativamente\u00a0\nreciente,\u00a0experimentando\u00a0un\u00a0fuerte\u00a0aumento\u00a0a\u00a0partir\u00a0de\u00a0finales\u00a0de\u00a0la\u00a0d\u00e9cada\u00a0de\u00a0los\u00a090.\u00a0Entre\u00a01998\u00a0\ny\u00a0 2006\u00a0 el\u00a0 n\u00famero\u00a0 de\u00a0 extranjeros\u00a0 empadronados\u00a0 en\u00a0 Espa\u00f1a\u00a0 se\u00a0 multi plic\u00f3\u00a0 por\u00a0 m\u00e1s\u00a0 de\u00a0 6,\u00a0INTRODUCCI\u00d3N\u00a0\n -  17representando\u00a0en\u00a0el\u00a0a\u00f1o\u00a02006\u00a0el\u00a019,3%\u00a0de\u00a0la\u00a0poblaci\u00f3n\u00a0total,\u00a0y\u00a0el\u00a011%\u00a0de\u00a0la\u00a0poblaci\u00f3n\u00a0de\u00a0entre\u00a015\u00a0\ny\u00a064\u00a0a\u00f1os.\u00a0Las\u00a0procedencias\u00a0m\u00e1s\u00a0frecuentes\u00a0han\u00a0sido\u00a0Am\u00e9rica\u00a0del \u00a0Sur,\u00a0seguida\u00a0de\u00a0otros\u00a0pa\u00edses\u00a0de\u00a0\nEuropa\u00a0Occidental,\u00a0Europa\u00a0del\u00a0Este\u00a0y\u00a0Rusia\u00a0y\u00a0\u00c1frica\u00a0del\u00a0Norte.\u00a0 Las\u00a0personas\u00a0procedentes\u00a0de\u00a0\u00c1frica\u00a0\nSubsahariana\u00a0representan\u00a0el\u00a00, 4%\u00a0de\u00a0los\u00a0empadronados\u00a0(51).\u00a0\nEn\u00a0una\u00a0cohorte\u00a0de\u00a019\u00a0hospitales\u00a0espa\u00f1oles,\u00a0incluyendo\u00a0nuevos\u00a0di agn\u00f3sticos\u00a0de\u00a0VIH\u00a0entre\u00a02004\u00a0\ny\u00a02006\u00a0se\u00a0describi\u00f3\u00a0el\u00a0perfil\u00a0cl\u00ednico\u2010epidemiol\u00f3gico\u00a0de\u00a0los\u00a0pac ientes\u00a0en\u00a0funci\u00f3n\u00a0del\u00a0lugar\u00a0de\u00a0\norigen.\u00a0Del\u00a0total\u00a0de\u00a0pacientes\u00a0incluidos\u00a0en\u00a0el\u00a0estudio\u00a0la\u00a0terce ra\u00a0parte\u00a0eran\u00a0extranjeros,\u00a0siendo\u00a0\nAm\u00e9rica\u00a0del\u00a0Sur\u00a0la\u00a0procedencia\u00a0m \u00e1s\u00a0frecuente,\u00a0representando\u00a0un\u00a0 56%\u00a0de\u00a0todos\u00a0los\u00a0inmigrantes.\u00a0\nLas\u00a0 caracter\u00edsticas\u00a0 epidemiol\u00f3gicas\u00a0 y\u00a0 sociodemogr\u00e1ficas\u00a0 de\u00a0 los\u00a0 diferentes\u00a0 grupos\u00a0 reflejan\u00a0 la\u00a0\nsituaci\u00f3n\u00a0 del\u00a0 VIH\u00a0 en\u00a0 sus\u00a0 lugares\u00a0 de\u00a0 origen.\u00a0 El\u00a0 n\u00famero\u00a0 de\u00a0 sujeto s\u00a0 procedentes\u00a0 del\u00a0 \u00c1frica\u00a0\nSubsahariana\u00a0 fue\u00a0 proporcionalmente\u00a0 mayor\u00a0 respecto\u00a0 a\u00a0 la\u00a0 poblaci\u00f3 n\u00a0 general.\u00a0 Esto\u00a0 refleja\u00a0\nprobablemente\u00a0las\u00a0altas\u00a0prevalen cias\u00a0de\u00a0la\u00a0infecci\u00f3n\u00a0en\u00a0sus\u00a0lugares\u00a0de\u00a0origen\u00a0(51).\u00a0\nLa\u00a0 proporci\u00f3n\u00a0 de\u00a0 inmigrantes\u00a0 entre\u00a0 los\u00a0 nuevos\u00a0 diagn\u00f3sticos\u00a0 de\u00a0 V IH\u00a0 en\u00a0 Catalu\u00f1a\u00a0 ha\u00a0 ido\u00a0\naumentando\u00a0en\u00a0el\u00a0periodo\u00a02001\u20102011,\u00a0de\u00a0un\u00a024,7%\u00a0en\u00a02001\u00a0hasta\u00a0u n\u00a046,1%\u00a0en\u00a02011.\u00a0En\u00a0global,\u00a0\nel\u00a062,3%\u00a0proced\u00edan\u00a0de\u00a0Am\u00e9rica\u00a0del\u00a0Sur,\u00a0el\u00a014,6%\u00a0de\u00a0Europa\u00a0Occid ental\u00a0y\u00a0el\u00a013,2%\u00a0de\u00a0\u00c1frica\u00a0\nSubsahariana\u00a0(44).\u00a0\n\u00a0\n\u00a0\n2.4.\u00a0Epidemiolog\u00eda \u00a0de\u00a0las\u00a0resistencias \u00a0transmitidas \u00a0\nEl\u00a0fen\u00f3meno\u00a0de\u00a0las\u00a0resistencias\u00a0transmitidas\u00a0aparece\u00a0como\u00a0una\u00a0a menaza\u00a0potencial\u00a0al\u00a0\u00e9xito\u00a0de\u00a0\nlas\u00a0terapias\u00a0antirretrovirales.\u00a0La\u00a0transmisi\u00f3n\u00a0de\u00a0virus\u00a0resiste ntes\u00a0se\u00a0produce\u00a0por\u00a0diferentes\u00a0v\u00edas\u00a0\nde\u00a0transmisi\u00f3n,\u00a0incluyendo\u00a0contactos\u00a0sexuales,\u00a0mediante\u00a0el\u00a0uso\u00a0 de\u00a0drogas\u00a0por\u00a0v\u00eda\u00a0parenteral\u00a0y\u00a0\ntambi\u00e9n\u00a0en\u00a0la\u00a0transmisi\u00f3n\u00a0vertical\u00a0(52).\u00a0\u00a0\nEn\u00a0noviembre\u00a0de\u00a02005\u00a0un\u00a0estudio\u00a0publicado\u00a0por\u00a0Sax\u00a0 et\u00a0al.\u00a0(53)\u00a0demostr\u00f3\u00a0que\u00a0la\u00a0determinaci\u00f3n\u00a0\nde\u00a0resistencias\u00a0transmitidas\u00a0en\u00a0los\u00a0nuevos\u00a0diagn\u00f3sticos\u00a0de\u00a0VIH\u00a0 era\u00a0coste\u2010efectiva\u00a0en\u00a0poblaciones\u00a0\nen\u00a0 las\u00a0 que\u00a0 la\u00a0 prevalencia\u00a0 de\u00a0 resistencias\u00a0 era\u00a0 superior\u00a0 al\u00a0 1%.\u00a0 A\u00a0p a r t i r \u00a0d e \u00a0e s e \u00a0e s t u d i o , \u00a0l a \u00a0\ndeterminaci\u00f3n\u00a0de\u00a0resistencias\u00a0transmitidas\u00a0en\u00a0los\u00a0nuevos\u00a0diagn\u00f3sticos\u00a0es\u00a0una\u00a0recomendaci\u00f3n\u00a0incluida\u00a0en\u00a0las\u00a0principales\u00a0gu\u00edas \u00a0de\u00a0tratamiento\u00a0antirretrovira l\u00a0(54\u201056).\u00a0\nLas\u00a0estimaciones\u00a0de\u00a0prevalencia\u00a0d e\u00a0resistencias\u00a0transmitidas\u00a0pu eden\u00a0variar\u00a0en\u00a0funci\u00f3n\u00a0del\u00a0tipo\u00a0\nde\u00a0estudio,\u00a0la\u00a0localizaci\u00f3n\u00a0geogr\u00e1fica\u00a0y\u00a0la\u00a0poblaci\u00f3n\u00a0de\u00a0estudi o,\u00a0as\u00ed\u00a0como\u00a0los\u00a0m\u00e9todos\u00a0usados\u00a0para\u00a0\ndetectar\u00a0 resistencias.\u00a0 La\u00a0 eficacia\u00a0 de\u00a0 los\u00a0 tratamientos\u00a0 antirret rovirales\u00a0 influye\u00a0 de\u00a0 manera\u00a0\nimportante\u00a0en\u00a0las\u00a0prevalencias\u00a0de\u00a0resistencias\u00a0transmitidas.\u00a0En \u00a0un\u00a0estudio\u00a0se\u00a0demostr\u00f3\u00a0que\u00a0la\u00a0\nprevalencia\u00a0de\u00a0resistencias\u00a0transmitidas\u00a0en\u00a0los\u00a0pacientes\u00a0con\u00a0i nfecci\u00f3n\u00a0reciente\u00a0se\u00a0correlacionaba\u00a0INTRODUCCI\u00d3N\u00a0\n 18de\u00a0manera\u00a0inversa\u00a0con\u00a0la\u00a0proporci\u00f3n\u00a0de\u00a0individuos\u00a0con\u00a0infecci\u00f3n \u00a0cr\u00f3nica\u00a0que\u00a0ten\u00edan\u00a0cargas\u00a0v\u00edricas\u00a0\nindetectables\u00a0(57).\u00a0\nOtra\u00a0 consideraci\u00f3n\u00a0 importante\u00a0 en\u00a0 la\u00a0 interpretaci\u00f3n\u00a0 de\u00a0las\u00a0estim aciones\u00a0 de\u00a0 prevalencia\u00a0 de\u00a0\nresistencias\u00a0transmitidas\u00a0es\u00a0el\u00a0m\u00e9todo\u00a0usado\u00a0para\u00a0definir\u00a0resis tencia.\u00a0Hasta\u00a0hace\u00a0relativamente\u00a0\npoco\u00a0tiempo,\u00a0el\u00a0enfoque\u00a0m\u00e1s\u00a0utilizado\u00a0era\u00a0el\u00a0listado\u00a0publicado\u00a0 por\u00a0el\u00a0panel\u00a0de\u00a0expertos\u00a0de\u00a0la\u00a0\nInternational \u00a0AIDS\u00a0Society\u00a0(58).\u00a0 Este\u00a0 listado\u00a0 proporciona\u00a0 una\u00a0 indicaci\u00f3n\u00a0 de\u00a0 las\u00a0 mutaciones \u00a0\nresistentes\u00a0observadas\u00a0bajo\u00a0presi\u00f3n\u00a0farmacol\u00f3gica\u00a0y\u00a0no\u00a0est\u00e1\u00a0esp ecialmente\u00a0dise\u00f1ado\u00a0para\u00a0la\u00a0\nvigilancia\u00a0de\u00a0las\u00a0resistencias\u00a0transmitidas.\u00a0Este\u00a0listado\u00a0se\u00a0ha\u00a0dejado\u00a0de\u00a0utilizar\u00a0a\u00a0favor\u00a0del\u00a0listado\u00a0\npublicado\u00a0 por\u00a0 la\u00a0 Organizaci\u00f3n\u00a0 Mundial\u00a0 de\u00a0 la\u00a0 Salud\u00a0 (OMS)\u00a0 (59),\u00a0 y a\u00a0 que\u00a0 presenta\u00a0 un\u00a0 listado\u00a0\nestandarizado\u00a0de\u00a0mutaciones\u00a0que\u00a0 hace\u00a0posible\u00a0la\u00a0comparaci\u00f3n\u00a0de\u00a0 prevalencias\u00a0de\u00a0resistencias\u00a0\ntransmitidas\u00a0en\u00a0diferentes\u00a0momentos\u00a0y\u00a0regiones,\u00a0facilitando\u00a0el\u00a0meta\u2010an\u00e1lisis\u00a0de\u00a0los\u00a0datos\u00a0de\u00a0\nvigilancia\u00a0recogidos\u00a0por\u00a0diferen tes\u00a0grupos\u00a0en\u00a0diferentes\u00a0moment os.\u00a0Este\u00a0listado\u00a0cumple\u00a0cuatro\u00a0\ncriterios\u00a0para\u00a0identificar\u00a0las\u00a0mu taciones\u00a0asociadas\u00a0a\u00a0resistencias:\u00a0\n1 .\u00a0 L a \u00a0m u ta ci\u00f3 n \u00a0h a \u00a0de \u00a0ca u sa r\u00a0o \u00a0co n trib u ir\u00a0a \u00a0la \u00a0re siste n cia \u00a0a \u00a0u n \u00a0 f\u00e1rmaco;\u00a0 ha\u00a0 de\u00a0 estar\u00a0\npresente\u00a0en\u00a0tres\u00a0o\u00a0m\u00e1s\u00a0de\u00a0las\u00a0cinco\u00a0listas\u00a0de\u00a0mutaciones\u00a0resist entes\u00a0de\u00a0paneles\u00a0de\u00a0\nexpertos.\u00a0\n2.\u00a0 Las\u00a0mutaciones\u00a0no\u00a0han\u00a0de\u00a0ser\u00a0polimorfismos\u00a0(variantes\u00a0de\u00a0la\u00a0 secuencia\u00a0gen\u00e9tica\u00a0en\u00a0un\u00a0\ndeterminado\u00a0 lugar\u00a0 del\u00a0 ADN)\u00a0 y\u00a0 no\u00a0 se\u00a0 han\u00a0 de\u00a0 producir\u00a0 en\u00a0 posicione s\u00a0 altamente\u00a0\npolim\u00f3rficas.\u00a0\n3.\u00a0 El\u00a0listado\u00a0de\u00a0mutaciones\u00a0debe\u00a0ser\u00a0aplicable\u00a0en\u00a0los\u00a0ocho\u00a0subtipos\u00a0m\u00e1s\u00a0comunes\u00a0de\u00a0VIH\u2010\n1.\u00a0\n4.\u00a0 El\u00a0 listado\u00a0 debe\u00a0 ser\u00a0 parsimonioso,\u00a0 excluyendo\u00a0 mutaciones\u00a0 que\u00a0 resultan\u00a0\nextremadamente\u00a0raras\u00a0a\u00a0partir\u00a0 de\u00a0la\u00a0presi\u00f3n\u00a0farmacol\u00f3gica.\u00a0\nEstudios\u00a0publicados\u00a0entre\u00a0el\u00a02005\u00a0y\u00a02006\u00a0reportan\u00a0prevalencias\u00a0 de\u00a0resistencias\u00a0transmitidas\u00a0\nentre\u00a00%\u00a0en\u00a0Suecia\u00a0y\u00a0Chile,\u00a0hasta\u00a024,5%\u00a0en\u00a0San\u00a0Diego\u00a0(52).\u00a0Inic ialmente,\u00a0las\u00a0prevalencias\u00a0m\u00e1s\u00a0\naltas\u00a0 de\u00a0 resistencias\u00a0 transmitidas\u00a0 se\u00a0 observan\u00a0 en\u00a0 regiones\u00a0 y\u00a0 po blaciones\u00a0 con\u00a0 un\u00a0 uso\u00a0 bien\u00a0\nestablecido\u00a0de\u00a0las\u00a0terapias\u00a0antirretrovirales,\u00a0incluyendo\u00a0Europa\u00a0Occidental,\u00a0Norte\u00a0de\u00a0Am\u00e9rica\u00a0y\u00a0algunas\u00a0regiones\u00a0de\u00a0Am\u00e9rica\u00a0del\u00a0Sur.\u00a0En\u00a0estas\u00a0poblaciones,\u00a0el\u00a0u so\u00a0de\u00a0monoterapias\u00a0y\u00a0biterapias\u00a0en\u00a0\nla\u00a0era\u00a0pre\u2010TARGA,\u00a0los\u00a0posteriore s\u00a0reg\u00edmenes\u00a0sub\u00f3ptimos\u00a0en\u00a0los\u00a0i nicios\u00a0de\u00a0la\u00a0era\u00a0TARGA\u00a0y\u00a0las\u00a0\ndificultades\u00a0con\u00a0la\u00a0adherencia\u00a0y\u00a0la\u00a0tolerancia\u00a0llevaron\u00a0a\u00a0la\u00a0ac umulaci\u00f3n\u00a0de\u00a0resistencias\u00a0en\u00a0los\u00a0\npacientes\u00a0con\u00a0experiencia\u00a0antirretroviral\u00a0y,\u00a0como\u00a0consecuencia, \u00a0a\u00a0la\u00a0expansi\u00f3n\u00a0de\u00a0resistencias\u00a0\ntransmitidas.\u00a0Actualmente\u00a0existe\u00a0evidencia\u00a0de\u00a0una\u00a0estabilizaci\u00f3 n\u00a0de\u00a0las\u00a0resistencias\u00a0transmitidas\u00a0\nen\u00a0Europa\u00a0(60),\u00a0y\u00a0en\u00a0algunos\u00a0casos,\u00a0incluso\u00a0se\u00a0confirma\u00a0una\u00a0tendencia\u00a0descendiente\u00a0(61).\u00a0En\u00a0una\u00a0\nreciente\u00a0revisi\u00f3n,\u00a0se\u00a0estim\u00f3\u00a0que \u00a0la\u00a0prevalencia\u00a0global\u00a0de\u00a0resis tencias\u00a0transmitidas\u00a0en\u00a0Espa\u00f1a,\u00a0INTRODUCCI\u00d3N\u00a0\n -  19entre\u00a01997\u00a0y\u00a02008,\u00a0fue\u00a0del\u00a010,6%,\u00a0similar\u00a0a\u00a0la\u00a0del\u00a0resto\u00a0de\u00a0Eur opa\u00a0(62).\u00a0Por\u00a0otro\u00a0lado,\u00a0en\u00a0las\u00a0\u00e1reas\u00a0\ndonde\u00a0la\u00a0introducci\u00f3n\u00a0de\u00a0los\u00a0tratamientos\u00a0antirretrovirales\u00a0se\u00a0ha\u00a0producido\u00a0recientemente,\u00a0se\u00a0\nest\u00e1\u00a0observando\u00a0una\u00a0emergencia\u00a0de\u00a0las\u00a0resistencias.\u00a0En\u00a0una\u00a0revi si\u00f3n\u00a0sistem\u00e1tica\u00a0publicada\u00a0en\u00a0\n2011,\u00a0 incluyendo\u00a0 38\u00a0 estudios\u00a0 reali zados\u00a0 en\u00a0 23\u00a0 pa\u00edses\u00a0 africanos, \u00a0l o s \u00a0v a l o r e s \u00a0o b s e r v a d o s \u00a0d e \u00a0\nprevalencias\u00a0de\u00a0resistencias\u00a0tra nsmitidas\u00a0oscilaban\u00a0entre\u00a00%\u00a0y\u00a08,6%.\u00a0(63).\u00a0\u00a0\n\u00a0\n\u00a0\n2.5.\u00a0Distribuci\u00f3n \u00a0de\u00a0los\u00a0subtipos\u00a0 del\u00a0VIH\u20101\u00a0\nEl\u00a0subtipo\u00a0de\u00a0VIH\u00a0m\u00e1s\u00a0prevalente\u00a0en\u00a0Europa\u00a0Occidental,\u00a0en\u00a0el\u00a0No rte\u00a0de\u00a0Am\u00e9rica,\u00a0Australia\u00a0y\u00a0\nalgunos\u00a0pa\u00edses\u00a0de\u00a0Am\u00e9rica\u00a0del\u00a0Sur\u00a0es\u00a0el\u00a0B.\u00a0En\u00a0cambio,\u00a0el\u00a0subtip o\u00a0CRF01_AE\u00a0domina\u00a0el\u00a0Sureste\u00a0\nAsi\u00e1tico,\u00a0mientras\u00a0que\u00a0en\u00a0\u00c1frica\u00a0Subsahariana\u00a0existe\u00a0una\u00a0gran\u00a0d iversidad\u00a0de\u00a0subtipos\u00a0y\u00a0CRFs,\u00a0\n(Figura\u00a012)\u00a0(2).\u00a0\nEn\u00a0Espa\u00f1a,\u00a0el\u00a0subtipo\u00a0de\u00a0VIH\u20101\u00a0m\u00e1s\u00a0prevalente\u00a0ha\u00a0sido\u00a0el\u00a0B,\u00a0aun que\u00a0estudios\u00a0recientes\u00a0han\u00a0\ndescrito\u00a0 una\u00a0 progresi\u00f3n\u00a0 r\u00e1pida\u00a0 de\u00a0 otros\u00a0 subtipos\u00a0 (64\u201066).\u00a0 Este\u00a0 hecho\u00a0 es\u00a0 resultado\u00a0 de\u00a0\nmovimientos\u00a0poblacionales\u00a0como\u00a0la\u00a0inmigraci\u00f3n,\u00a0los\u00a0viajes\u00a0inter nacionales\u00a0y\u00a0el\u00a0contacto\u00a0sexual\u00a0\ncon\u00a0individuos\u00a0infectados\u00a0en\u00a0pa\u00edses\u00a0donde\u00a0otros\u00a0subtipos\u00a0no\u2010B\u00a0s on\u00a0altamente\u00a0prevalentes.\u00a0En\u00a0un\u00a0\nestudio\u00a0realizado\u00a0en\u00a0Espa\u00f1a\u00a0entre\u00a0los\u00a0a\u00f1os\u00a01995\u00a0y\u00a02003,\u00a0se\u00a0demo str\u00f3\u00a0que\u00a0un\u00a043.2%\u00a0de\u00a0los\u00a0\npacientes\u00a0sospechosos\u00a0de\u00a0estar\u00a0i nfectados\u00a0por\u00a0un\u00a0subtipo\u00a0no\u2010B\u00a0( extranjeros,\u00a0aut\u00f3ctonos\u00a0que\u00a0\nhab\u00edan\u00a0viajado\u00a0a\u00a0pa\u00edses\u00a0donde\u00a0variantes\u00a0no\u2010B\u00a0son\u00a0end\u00e9micas\u00a0y\u00a0qu e\u00a0hab\u00edan\u00a0admitido\u00a0mantener\u00a0\nrelaciones\u00a0de\u00a0riesgo,\u00a0aut\u00f3ctonos\u00a0que\u00a0hab\u00edan\u00a0mantenido\u00a0contactos \u00a0sexuales\u00a0con\u00a0personas\u00a0de\u00a0estas\u00a0\n\u00e1reas,\u00a0o\u00a0aut\u00f3ctonos\u00a0que\u00a0presentaban\u00a0una\u00a0reducci\u00f3n\u00a0significativa\u00a0de\u00a0los\u00a0niveles\u00a0de\u00a0CD4+\u00a0a\u00a0pesar\u00a0de\u00a0\ntener\u00a0 cargas\u00a0 v\u00edricas\u00a0 bajas)\u00a0 realmente\u00a0 lo\u00a0 estaban.\u00a0 Estos\u00a0 investi gadores\u00a0 encontraron\u00a0 una\u00a0 gran\u00a0\ndiversidad\u00a0en\u00a0las\u00a0variantes\u00a0y\u00a0formas\u00a0recombinantes\u00a0del\u00a0VIH\u20101\u00a0ci rculantes\u00a0en\u00a0Espa\u00f1a\u00a0(66).\u00a0\n\u00a0\n\u00a0\n\u00a0\u00a0\u00a0\n\u00a0\n\u00a0\u00a0\n\u00a0\n\u00a0\u00a0INTRODUCCI\u00d3N\u00a0\n 20\u00a0\n\u00a0\n\u00a0\nFigura\u00a012 .\u00a0Distribuci\u00f3n \u00a0de\u00a0subtipos \u00a0y\u00a0CRFs\u00a0del\u00a0VIH\u20101\u00a0en\u00a0el\u00a0mundo\u00a0\nFuente:  Taylor BS, et al. 2008 (2)\u00a0\n\u00a0INTRODUCCI\u00d3N\u00a0\n -  213.\u00a0Tests\u00a0para\u00a0la\u00a0identificaci\u00f3n \u00a0de\u00a0infecciones\u00a0 recientes \u00a0por\u00a0VIH\u20101\u00a0\u00a0\u00a0\u00a0\n3.1.\u00a0Antecedentes \u00a0\nPuesto\u00a0que\u00a0el\u00a0tiempo\u00a0que\u00a0transcurre\u00a0entre\u00a0el\u00a0momento\u00a0de\u00a0la\u00a0infe cci\u00f3n\u00a0y\u00a0el\u00a0del\u00a0diagn\u00f3stico\u00a0\npuede\u00a0ser\u00a0extremadamente\u00a0variabl e\u00a0de\u00a0unos\u00a0individuos\u00a0a\u00a0otros,\u00a0d escribir\u00a0las\u00a0caracter\u00edsticas\u00a0y\u00a0\ntendencias\u00a0de\u00a0los\u00a0nuevos\u00a0diagn\u00f3s ticos\u00a0de\u00a0VIH,\u00a0o\u00a0los\u00a0casos\u00a0de\u00a0SI DA,\u00a0no\u00a0revela\u00a0necesariamente\u00a0los\u00a0\npatrones\u00a0actuales\u00a0de\u00a0transmisi\u00f3n\u00a0del\u00a0virus.\u00a0Es\u00a0por\u00a0ello\u00a0que,\u00a0de sde\u00a0el\u00a0punto\u00a0de\u00a0vista\u00a0de\u00a0la\u00a0Salud\u00a0\nP\u00fablica\u00a0y\u00a0en\u00a0el\u00a0\u00e1mbito\u00a0de\u00a0la\u00a0vigilancia\u00a0epidemiol\u00f3gica\u00a0del\u00a0VIH, \u00a0es\u00a0especialmente\u00a0relevante\u00a0poder\u00a0\ndiscernir\u00a0de\u00a0entre\u00a0los\u00a0pacientes\u00a0que\u00a0presentan\u00a0un\u00a0nuevo\u00a0diagn\u00f3stico,\u00a0las\u00a0infecciones\u00a0ocurridas\u00a0\nrecientemente\u00a0de\u00a0las\u00a0establecidas\u00a0o\u00a0cr\u00f3nicas.\u00a0\u00a0\nEn\u00a0 1995,\u00a0 Brookmeyer\u00a0 y\u00a0 Quinn\u00a0 presentaron\u00a0 una\u00a0 estrategia\u00a0 para\u00a0 identificar\u00a0 infecciones\u00a0\nrecientes,\u00a0antes\u00a0del\u00a0momento\u00a0de\u00a0la\u00a0seroconversi\u00f3n.\u00a0A\u00a0partir\u00a0de\u00a0 una\u00a0muestra\u00a0de\u00a0suero\u00a0usaron\u00a0un\u00a0\nalgoritmo\u00a0de\u00a0dos\u00a0pasos\u00a0combinando\u00a0tests\u00a0diagn\u00f3sticos\u00a0para\u00a0la\u00a0de tecci\u00f3n\u00a0del\u00a0ant\u00edgeno\u00a0p24\u00a0y\u00a0\nanticuerpos\u00a0frente\u00a0al\u00a0VIH.\u00a0Usando\u00a0este\u00a0enfoque\u00a0se\u00a0considera\u00a0que \u00a0un\u00a0paciente\u00a0ha\u00a0seroconvertido\u00a0\nrecientemente\u00a0si\u00a0se\u00a0obtiene\u00a0un\u00a0resultado\u00a0positivo\u00a0en\u00a0la\u00a0detecci \u00f3n\u00a0del\u00a0ant\u00edgeno\u00a0p24\u00a0y\u00a0negativo\u00a0en\u00a0\nla\u00a0detecci\u00f3n\u00a0de\u00a0anticuerpos\u00a0frente\u00a0al\u00a0VIH\u00a0(67).\u00a0\nPosteriormente,\u00a0 se\u00a0 propuso\u00a0 el\u00a0 ARN\u00a0 v\u00edrico\u00a0 como\u00a0 otro\u00a0 marcador\u00a0 vir ol\u00f3gico\u00a0 para\u00a0 identificar\u00a0\ninfecciones\u00a0recientes.\u00a0El\u00a0ARN\u00a0v\u00edri co\u00a0puede\u00a0detectarse\u00a0mediante\u00a0 PCR\u00a0antes\u00a0que\u00a0el\u00a0ant\u00edgeno\u00a0p24,\u00a0y\u00a0\nel\u00a0 uso\u00a0 mediante\u00a0 pools\u00a0 (analizar\u00a0 muestras\u00a0 procedentes\u00a0 de\u00a0 muchos\u00a0 pacientes\u00a0 en\u00a0 una\u00a0 mism a\u00a0\nal\u00edcuota)\u00a0disminuye\u00a0sustancialmente\u00a0los\u00a0costes\u00a0(68,\u00a069).\u00a0La\u00a0des ventaja\u00a0de\u00a0este\u00a0enfoque\u00a0es\u00a0que\u00a0el\u00a0\ntiempo\u00a0durante\u00a0el\u00a0cual\u00a0el\u00a0ant\u00edgeno\u00a0p24\u00a0o\u00a0el\u00a0ARN\u00a0v\u00edrico\u00a0son\u00a0dete ctables\u00a0antes\u00a0de\u00a0la\u00a0seroconversi\u00f3n\u00a0\nes\u00a0muy\u00a0corto,\u00a0menos\u00a0de\u00a050\u00a0d\u00edas\u00a0(Figura\u00a013).\u00a0En\u00a0consecuencia,\u00a0se \u00a0requiere\u00a0un\u00a0gran\u00a0volumen\u00a0de\u00a0\nm u e s t r a s , \u00a0o \u00a0b i e n \u00a0u n a \u00a0e l e v a d a \u00a0i n c idencia\u00a0 de\u00a0 VIH\u00a0 para\u00a0 identificar \u00a0 un\u00a0 nombre\u00a0 suficiente\u00a0 de\u00a0\nindividuos\u00a0con\u00a0ant\u00edgeno\u00a0p24\u00a0o\u00a0ARN\u00a0v\u00edrico\u00a0detectable\u00a0que\u00a0no\u00a0haya n\u00a0seroconvertido\u00a0(68).\u00a0\u00a0\nPosteriormente,\u00a0en\u00a01998\u00a0Janssen\u00a0 et\u00a0al.\u00a0describieron\u00a0otra\u00a0estrategia\u00a0para\u00a0identificar\u00a0infecciones\u00a0\nrecientes,\u00a0 el\u00a0 m\u00e9todo\u00a0 conocido\u00a0 como\u00a0 STARHS\u00a0 ( Serological\u00a0 Testing\u00a0Algorithm \u00a0for\u00a0Recent\u00a0 HIV\u00a0\nSeroconversion) .\u00a0Siguiendo\u00a0el\u00a0mismo\u00a0principio,\u00a0se\u00a0han\u00a0desarrollado\u00a0otros\u00a0tests \u00a0serol\u00f3gicos\u00a0para\u00a0\nidentificar\u00a0infecciones\u00a0recientes\u00a0 a\u00a0partir\u00a0de\u00a0estudios\u00a0transver sales\u00a0(70,\u00a071)\u00a0\n\u00a0\n\u00a0\u00a0INTRODUCCI\u00d3N\u00a0\n 22\n\u00a0\n\u00a0\nFigura\u00a013.\u00a0 Cin\u00e9tica\u00a0 de\u00a0los\u00a0marcadores \u00a0virol\u00f3gicos \u00a0y\u00a0la\u00a0respuesta \u00a0inmunitaria \u00a0usados\u00a0para\u00a0definir\u00a0\nestados\u00a0transitorios \u00a0en\u00a0las\u00a0primeras \u00a0fases\u00a0de\u00a0la\u00a0infecci\u00f3n \u00a0por\u00a0VIH\u00a0\u00a0\nFuente:\u00a0Le\u00a0Vu\u00a0S,\u00a0 et\u00a0al.\u00a02008\u00a0(70).\u00a0\n\u00a0\n\u00a0\n3.2.\u00a0Serological \u00a0Testing\u00a0Algorithm \u00a0for\u00a0Recent\u00a0HIV\u00a0 Seroconversions \u00a0y\u00a0\nenzimoimmunoensayo\u00a0 de\u00a0captura\u00a0BED\u00a0\nEn\u00a0relaci\u00f3n\u00a0al\u00a0m\u00e9todo\u00a0propuesto\u00a0por\u00a0Brookmeyer\u00a0 et\u00a0al.,\u00a0el\u00a0STARHS\u00a0ofrec\u00eda\u00a0la\u00a0ventaja\u00a0de\u00a0testar\u00a0\ns\u00f3lo\u00a0 individuos\u00a0 VIH\u00a0 positivos\u00a0 y\u00a0 definir\u00a0 un\u00a0 periodo\u00a0 suficienteme nte\u00a0 corto\u00a0 para\u00a0 considerar\u00a0\ninfecciones\u00a0recientes:\u00a0129\u00a0d\u00edas\u00a0(IC\u00a095%:\u00a0109\u00a0\u2013149)\u00a0para\u00a0un\u00a0 cut\u00a0off\u00a0(punto\u00a0de\u00a0corte) \u00a0de\u00a00,75\u00a0\ndensidades\u00a0\u00f3pticas\u00a0(DO)\u00a0(72).\u00a0Los\u00a0fundamentos\u00a0del\u00a0STARHS\u00a0se\u00a0bas an\u00a0en\u00a0el\u00a0aumento\u00a0progresivo\u00a0\ndel\u00a0nivel\u00a0de\u00a0anticuerpos\u00a0IgG\u00a0frente\u00a0al\u00a0VIH\u00a0a\u00a0partir\u00a0del\u00a0momento \u00a0de\u00a0la\u00a0infecci\u00f3n.\u00a0Despu\u00e9s\u00a0de\u00a0unos\u00a0\nseis\u00a0meses\u00a0de\u00a0producirse\u00a0la\u00a0infecci\u00f3n,\u00a0se\u00a0llega\u00a0a\u00a0un\u00a0nivel\u00a0m\u00e1xi mo\u00a0de\u00a0anticuerpos.\u00a0El\u00a0STARHS\u00a0\nconsiste\u00a0en\u00a0aplicar\u00a0un\u00a0algoritmo\u00a0diagn\u00f3stico\u00a0a\u00a0una\u00a0muestra\u00a0de\u00a0s uero.\u00a0En\u00a0primer\u00a0lugar\u00a0se\u00a0aplica\u00a0un\u00a0\ntest\u00a0est\u00e1ndar\u00a0(test\u00a0sensible)\u00a0que\u00a0resultar\u00e1\u00a0reactivo\u00a0en\u00a0cualquier\u00a0paciente\u00a0infectado\u00a0por\u00a0VIH.\u00a0El\u00a0segundo\u00a0test\u00a0se\u00a0ha\u00a0modificado\u00a0para\u00a0que\u00a0sea\u00a0menos\u00a0sensible,\u00a0de\u00a0m anera\u00a0que\u00a0un\u00a0paciente\u00a0con\u00a0\ninfecci\u00f3n\u00a0reciente\u00a0no\u00a0habr\u00e1\u00a0alcanzado\u00a0el\u00a0nivel\u00a0m\u00e1ximo\u00a0de\u00a0anticu erpos\u00a0y\u00a0dar\u00e1\u00a0un\u00a0resultado\u00a0no\u2010INTRODUCCI\u00d3N\u00a0\n -  23reactivo\u00a0 en\u00a0 ese\u00a0 segundo\u00a0 test\u00a0 Por \u00a0 lo\u00a0 tanto,\u00a0 el\u00a0 STARHS\u00a0 considera\u00a0 que\u00a0 la\u00a0 muestra\u00a0 analizada\u00a0\ncorresponde\u00a0a\u00a0un\u00a0individuo\u00a0con\u00a0infecci\u00f3n\u00a0reciente\u00a0si\u00a0se\u00a0obtiene \u00a0un\u00a0resultado\u00a0reactivo\u00a0en\u00a0el\u00a0test\u00a0\nsensible\u00a0y\u00a0no\u00a0reactivo\u00a0en\u00a0el\u00a0tes t\u00a0menos\u00a0sensible.\u00a0(Figura\u00a014).\u00a0\n\u00a0\n\u00a0\n\u00a0\nFigura\u00a014 .\u00a0Fundamento \u00a0del\u00a0test\u00a0STARHS\u00a0\u00a0\nFuente:\u00a0Adaptado\u00a0de.\u00a0Murphy\u00a0G,\u00a0 et\u00a0al.\u00a02008\u00a0(71) \u00a0\n\u00a0\nLa\u00a0duraci\u00f3n\u00a0del\u00a0periodo\u00a0ventana\u00a0entre\u00a0la\u00a0seroconversi\u00f3n\u00a0en\u00a0el\u00a0test\u00a0sensible,\u00a0y\u00a0la\u00a0conversi\u00f3n\u00a0(de\u00a0\nreciente\u00a0a\u00a0cr\u00f3nica)\u00a0en\u00a0el\u00a0test\u00a0menos\u00a0sensible,\u00a0se\u00a0calcula\u00a0con\u00a0p aneles\u00a0de\u00a0muestras\u00a0de\u00a0individuos\u00a0\ncon\u00a0fecha\u00a0de\u00a0seroconversi\u00f3n\u00a0conocida\u00a0(71).\u00a0\nEl\u00a0STARHS\u00a0se\u00a0us\u00f3\u00a0por\u00a0primera\u00a0vez\u00a0con\u00a0el\u00a0test\u00a0Abbott\u00a0HIV\u00a03A11\u00a0as say\u00a0( Abbott\u00a0 Laboratories, \u00a0\nAbbott\u00a0 Park,\u00a0Chicago,\u00a0Illinois,\u00a0USA)(72),\u00a0y\u00a0m\u00e1s\u00a0tarde\u00a0se\u00a0sustituy\u00f3\u00a0por\u00a0el\u00a0Vironostika\u2010LS\u00a0(Less\u00a0\nSensitive)\u00a0HIV\u20101\u00a0Microelisa\u00a0System\u00a0( bioM\u00e9rieux \u00a0SA,\u00a0Marcy\u00a0l'Etoile,\u00a0France)(73).\u00a0\nVironostika \u2010LS\u00a0HIV\u20101\u00a0Microelisa \u00a0System\u00a0\nE n \u00a0e s t e \u00a0t e s t \u00a0l a \u00a0d i l u c i \u00f3 n \u00a0d e \u00a0l a \u00a0m u e s t r a , \u00a0y \u00a0l o s \u00a0t i e m p o s \u00a0d e \u00a0i n c u b a ci\u00f3n\u00a0 de\u00a0 la\u00a0 muestra\u00a0 y\u00a0 el\u00a0\nconjugado\u00a0se\u00a0han\u00a0modificado\u00a0para\u00a0que\u00a0el\u00a0test\u00a0sea\u00a0menos\u00a0sensible:\u00a0los\u00a0tiempos\u00a0de\u00a0incubaci\u00f3n\u00a0se\u00a0\nhan\u00a0reducido\u00a0y\u00a0la\u00a0muestra\u00a0se\u00a0ha\u00a0diluido\u00a0hasta\u00a0una\u00a0proporci\u00f3n\u00a01/ 20.000\u00a0(73).\u00a0Las\u00a0DO\u00a0est\u00e1ndar\u00a0se\u00a0\ncalculan\u00a0de\u00a0la\u00a0siguiente\u00a0manera:\u00a0(DO\u00a0muestra\u00a0\u2013\u00a0DO\u00a0mediana\u00a0del\u00a0c ontrol\u00a0negativo\u00a0/\u00a0DO\u00a0mediana\u00a0INTRODUCCI\u00d3N\u00a0\n 24del\u00a0calibrador\u00a0\u2013\u00a0DO\u00a0mediana\u00a0del\u00a0control\u00a0negativo).\u00a0Las\u00a0muestras \u00a0se\u00a0testan\u00a0con\u00a0el\u00a0primer\u00a0test\u00a0\nsensible,\u00a0en\u00a0el\u00a0que\u00a0cualquier\u00a0mu estra\u00a0VIH\u00a0positiva\u00a0obtendr\u00eda\u00a0un \u00a0resultado\u00a0reactivo.\u00a0\nEn\u00a0el\u00a0test\u00a0menos\u00a0sensible,\u00a0las\u00a0muestras\u00a0con\u00a0una\u00a0DO\u00a0est\u00e1ndar\u00a0cal culada\u00a0inferior\u00a0a\u00a02,0\u00a0se\u00a0\nvuelven\u00a0a\u00a0re\u2010testar\u00a0en\u00a0triplic ado.\u00a0La\u00a0duraci\u00f3n\u00a0de\u00a0la\u00a0infecci\u00f3n\u00a0 se\u00a0define\u00a0como\u00a0reciente\u00a0para\u00a0aquellas\u00a0\nmuestras\u00a0re\u2010testadas\u00a0con\u00a0una\u00a0DO\u00a0est\u00e1ndar\u00a0inferior\u00a0a\u00a01,0\u00a0y\u00a0no\u00a0re ciente\u00a0para\u00a0aquellas\u00a0con\u00a0una\u00a0DO\u00a0\nest\u00e1ndar\u00a0 superior\u00a0 o\u00a0 igual\u00a0 a\u00a0 1, 0.\u00a0 Los\u00a0 pacientes\u00a0 con\u00a0 infecci\u00f3n\u00a0 re ciente\u00a0 se\u00a0 estima\u00a0 que\u00a0 han\u00a0\nseroconvertido\u00a0dentro\u00a0de\u00a0los\u00a0\u00faltimos\u00a0170\u00a0d\u00edas\u00a0(IC\u00a095%:\u00a0144\u00a0\u2013\u00a020 0).\u00a0El\u00a0periodo\u00a0ventana\u00a0del\u00a0test\u00a0se\u00a0\nd e f i n e \u00a0c o m o \u00a0e l \u00a0p e r i o d o \u00a0d e \u00a0t i e m p o \u00a0m e d i o \u00a0d u r a n t e \u00a0e l \u00a0c u a l \u00a0l a s \u00a0p e r s onas\u00a0 reci\u00e9n\u00a0 infectadas\u00a0\npermanecen\u00a0bajo\u00a0el\u00a0umbral\u00a0del\u00a0 cut\u00a0off\u00a0del\u00a0test\u00a0(73).\u00a0El\u00a0test\u00a0Vironostika\u00a0dej\u00f3\u00a0de\u00a0comercializarse\u00a0\nhacia\u00a0el\u00a0a\u00f1o\u00a02007,\u00a0por\u00a0lo\u00a0que\u00a0actu almente\u00a0no\u00a0se\u00a0encuentra\u00a0dispo nible.\u00a0\nEnzimoinmunoensayo \u00a0de\u00a0Captura \u00a0BED\u00a0\u00a0\nEl\u00a0test\u00a0BED\u2010CEIA\u00a0(Enzimoinmunoensayo\u00a0de\u00a0Captura\u00a0BED)\u00a0( Calypte\u00a0Biomedical \u00a0Corporation, \u00a0\nPorland,\u00a0Oregon,\u00a0USA)\u00a0fue\u00a0descrito\u00a0por\u00a0Parekh\u00a0 et\u00a0al.\u00a0en\u00a02002\u00a0(74).Utiliza\u00a0un\u00a0p\u00e9ptido\u00a0que\u00a0incluye\u00a0la\u00a0\nsecuencia\u00a0gp41\u00a0inmunodominante\u00a0de\u00a0diferentes\u00a0subtipos\u00a0de\u00a0VIH\u20101\u00a0 (B,\u00a0E\u00a0y\u00a0D)\u00a0estableciendo\u00a0una\u00a0\ndetecci\u00f3n\u00a0similar\u00a0de\u00a0los\u00a0anticuerpos\u00a0espec\u00edficos\u00a0para\u00a0VIH\u00a0entre \u00a0diferentes\u00a0subtipos.\u00a0En\u00a0la\u00a0Figura\u00a0\n15\u00a0se\u00a0muestran\u00a0las\u00a0diferentes\u00a0eta pas\u00a0del\u00a0test.\u00a0Al\u00a0ser\u00a0un\u00a0EIA\u00a0de \u00a0captura,\u00a0se\u00a0observa\u00a0un\u00a0incremento\u00a0\ngradual\u00a0en\u00a0la\u00a0proporci\u00f3n\u00a0de\u00a0IgG\u00a0espec\u00edficas\u00a0de\u00a0VIH\u20101\u00a0respecto\u00a0el\u00a0total\u00a0de\u00a0IgG\u00a0despu\u00e9s\u00a0de\u00a0la\u00a0\nseroconversi\u00f3n.\u00a0 Las\u00a0 DO\u00a0 normalizada s\u00a0 se\u00a0 calculan\u00a0 de\u00a0 la\u00a0 siguiente \u00a0 manera:\u00a0 DO\u00a0 muestra/DO\u00a0\ncalibrador.\u00a0Los\u00a0estudios\u00a0iniciales\u00a0indicaron\u00a0que\u00a0usando\u00a0un\u00a0 cut\u00a0off\u00a0de\u00a01,0\u00a0la\u00a0duraci\u00f3n\u00a0del\u00a0periodo\u00a0\nventana\u00a0era\u00a0de\u00a0160\u00a0d\u00edas\u00a0(74).\u00a0An\u00e1l isis\u00a0posteriores\u00a0usando\u00a0panel es\u00a0con\u00a0virus\u00a0de\u00a0otros\u00a0subtipos\u00a0\nsugieren\u00a0un\u00a0 cut\u00a0off\u00a0de\u00a00,8,\u00a0que\u00a0corresponde\u00a0con\u00a0una\u00a0duraci\u00f3n\u00a0del\u00a0periodo\u00a0ventana\u00a0de \u00a0155\u00a0d\u00edas\u00a0\n(75).\u00a0\nLos\u00a0CDC\u00a0( Centers\u00a0 for\u00a0Disease\u00a0Control\u00a0and\u00a0Prevention)\u00a0desarrollaron\u00a0estos\u00a0tests\u00a0(Vironostika\u00a0y\u00a0\nBED\u2010CEIA)\u00a0con\u00a0el\u00a0prop\u00f3sito\u00a0expreso\u00a0de\u00a0estimar\u00a0incidencia\u00a0de\u00a0VIH \u00a0a\u00a0nivel\u00a0poblacional,\u00a0no\u00a0para\u00a0\nprop\u00f3sitos\u00a0 diagn\u00f3sticos\u00a0 o\u00a0 cl\u00ednicos.\u00a0 Su\u00a0 utilidad\u00a0 a\u00a0 nivel\u00a0 individ ual\u00a0 no\u00a0 ha\u00a0 sido\u00a0 determinada\u00a0 ni\u00a0\naprobada\u00a0por\u00a0la\u00a0FDA\u00a0( Food\u00a0and\u00a0Drug\u00a0Administration),\u00a0por\u00a0lo\u00a0que\u00a0no\u00a0recomiendan\u00a0su\u00a0uso\u00a0para\u00a0el\u00a0\ndiagn\u00f3stico\u00a0individual\u00a0(75).\u00a0\u00a0\n\u00a0\u00a0\n\u00a0\n\u00a0\u00a0\u00a0INTRODUCCI\u00d3N\u00a0\n -  25 \n        \n \n           \nFigura\u00a0 15. Esquema \u00a0de\u00a0las\u00a0diferentes \u00a0etapas\u00a0del\u00a0test\u00a0BED\u2010CEIA\u00a0\nFuente:\u00a0Parekh\u00a0BS,\u00a0et \u00a0al.\u00a02001.\u00a0(76)\u00a0\n\u00a0\n\u00a0\n3.3.\u00a0Otros\u00a0tests\u00a0 serol\u00f3gicos \u00a0\u00a0\nAdem\u00e1s\u00a0de\u00a0los\u00a0tests\u00a0desarrollado s\u00a0por\u00a0Janssen\u00a0y\u00a0Parekh,\u00a0otros\u00a0a utores\u00a0han\u00a0descrito\u00a0otros\u00a0tests\u00a0\nserol\u00f3gicos\u00a0para\u00a0identificar\u00a0inf ecciones\u00a0recientes\u00a0(77).\u00a0En\u00a0Italia,\u00a0Suligoi\u00a0 et\u00a0al.\u00a0desarrollaron\u00a0un\u00a0test\u00a0\nque\u00a0valoraba\u00a0la\u00a0respuesta\u00a0de\u00a0los\u00a0anticuerpos\u00a0frente\u00a0al\u00a0VIH\u00a0inve stigando\u00a0su\u00a0avidez\u00a0(78).\u00a0Los\u00a0\nanticuerpos\u00a0de\u00a0baja\u00a0avidez\u00a0son\u00a0indicativos\u00a0de\u00a0infecci\u00f3n\u00a0recient e,\u00a0mientras\u00a0que\u00a0los\u00a0anticuerpos\u00a0con\u00a0\nmayor\u00a0avidez\u00a0indican\u00a0infecci\u00f3n\u00a0cr\u00f3nica.\u00a0El\u00a0m\u00e9todo\u00a0de\u00a0Suligoi\u00a0es \u00a0una\u00a0modificaci\u00f3n\u00a0de\u00a0un\u00a0test\u00a0\nserol\u00f3gico\u00a0anti\u2010VIH\u20101/2\u00a0de\u00a0tercera\u00a0generaci\u00f3n\u00a0que\u00a0usa\u00a0el\u00a0autoan alizador\u00a0de\u00a0Abbott\u00a0AxSYM,\u00a0por\u00a0lo\u00a0\nque\u00a0 es\u00a0 f\u00e1cil\u00a0 de\u00a0 realizar.\u00a0 Utiliza\u00a0 un\u00a0 m\u00e9todo\u00a0 donde\u00a0 la\u00a0 muestra\u00a0 se \u00a0 pre\u2010incuba\u00a0 con\u00a0 el\u00a0 agente\u00a0\ncaotr\u00f3pico\u00a0(guanidina\u00a0clorhidrato).\u00a0El\u00a0tratamiento\u00a0con\u00a0guanidin a\u00a0rompe\u00a0los\u00a0puentes\u00a0de\u00a0hidr\u00f3geno\u00a0\nque\u00a0ayudan\u00a0a\u00a0determinar\u00a0la\u00a0estructura\u00a0secundaria\u00a0del\u00a0anticuerpo ,\u00a0por\u00a0lo\u00a0que\u00a0puede\u00a0tener\u00a0un\u00a0\nefecto\u00a0en\u00a0la\u00a0subsecuente\u00a0interacci\u00f3n\u00a0anticuerpo\u2010ant\u00edgeno.\u00a0El\u00a0tr atamiento\u00a0tiene\u00a0un\u00a0mayor\u00a0efecto\u00a0\nsobre\u00a0los\u00a0anticuerpos\u00a0generados\u00a0al\u00a0principio\u00a0de\u00a0la\u00a0infecci\u00f3n,\u00a0p or\u00a0lo\u00a0que\u00a0se\u00a0puede\u00a0unir\u00a0con\u00a0menor\u00a0\nintensidad\u00a0a\u00a0su\u00a0ant\u00edgeno,\u00a0reducie ndo\u00a0as\u00ed\u00a0la\u00a0se\u00f1al.\u00a0A\u00a0medida\u00a0que \u00a0la\u00a0respuesta\u00a0madura,\u00a0el\u00a0sitio\u00a0\nactivo\u00a0se\u00a0hace\u00a0m\u00e1s\u00a0resistente\u00a0a\u00a0la\u00a0ruptura\u00a0(78). \u00a0En\u00a0un\u00a0estudio\u00a0se\u00a0compararon\u00a0el\u00a0test\u00a0de\u00a0avidez\u00a0y\u00a0el\u00a0\nVironostika,\u00a0y\u00a0los\u00a0resultados\u00a0obtenidos\u00a0demostraron\u00a0que\u00a0ambos\u00a0t ests\u00a0identificaban\u00a0de\u00a0manera\u00a0\nINTRODUCCI\u00d3N\u00a0\n 26similar\u00a0las\u00a0infecciones\u00a0recientes,\u00a0aunque\u00a0el\u00a0Vironostika\u00a0tend\u00eda\u00a0a\u00a0clasificar\u00a0m\u00e1s\u00a0pacientes\u00a0con\u00a0\ninfecci\u00f3n\u00a0cr\u00f3nica\u00a0como\u00a0recientes\u00a0(79) .\u00a0\nEn\u00a0Francia\u00a0Barin\u00a0et \u00a0al.\u00a0dise\u00f1aron\u00a0un\u00a0test\u00a0para\u00a0identificar\u00a0infecciones\u00a0recientes\u00a0por\u00a0VIH\u20101\u00a0en\u00a0muestras\u00a0\nde\u00a0 sangre\u00a0 seca,\u00a0 conocido\u00a0 como\u00a0 IDE/V3\u00a0 (80).\u00a0 Para\u00a0 dise\u00f1ar\u00a0 el\u00a0 test ,\u00a0 seleccionaron\u00a0 3\u00a0 ant\u00edgenos\u00a0 que\u00a0\ncumpl\u00edan\u00a0cuatro\u00a0criterios.\u00a0(i)\u00a0Los\u00a0ant\u00edgenos\u00a0deben\u00a0ser\u00a0reconoci dos\u00a0por\u00a0los\u00a0anticuerpos\u00a0presentes\u00a0en\u00a0\ntodos\u00a0los\u00a0pacientes\u00a0infectados\u00a0por\u00a0VIH.\u00a0(ii)\u00a0Deben\u00a0estar\u00a0altame nte\u00a0conservados\u00a0independientemente\u00a0\ndel\u00a0subtipo,\u00a0(iii)\u00a0obtenerse\u00a0f\u00e1cilmente\u00a0sin\u00a0que\u00a0cambien\u00a0sus\u00a0pro piedades\u00a0y\u00a0(iv)\u00a0los\u00a0anticuerpos\u00a0de\u00a0esos\u00a0\nant\u00edgenos\u00a0 deben\u00a0 detectarse\u00a0 con\u00a0 algo\u00a0 de\u00a0 retraso\u00a0 despu\u00e9s\u00a0 de\u00a0 la\u00a0 se roconversi\u00f3n.\u00a0 El\u00a0 ep\u00edtopo\u00a0\ninmunodominante\u00a0de\u00a0gp41\u00a0(IDE)\u00a0y\u00a0una\u00a0mezcla\u00a0de\u00a0cinco\u00a0p\u00e9ptidos\u00a0V3 \u00a0que\u00a0representan\u00a0secuencias\u00a0\nconsenso\u00a0de\u00a0los\u00a0subtipos\u00a0A,\u00a0B,\u00a0C,\u00a0D\u00a0y\u00a0CRF01\u2010AE\u00a0resultaron\u00a0ser\u00a0l os\u00a0que\u00a0mejor\u00a0discriminaban\u00a0entre\u00a0los\u00a0\nanticuerpos\u00a0presentes\u00a0en\u00a0suero\u00a0de\u00a0los\u00a0individuos\u00a0infectados\u00a0rec ientemente\u00a0(\u22646\u00a0meses)\u00a0de\u00a0aquellos\u00a0con\u00a0\ninfecci\u00f3n\u00a0cr\u00f3nica\u00a0(80).\u00a0\nEn\u00a0la\u00a0Tabla\u00a02\u00a0se\u00a0muestran\u00a0algunas\u00a0de\u00a0las\u00a0caracter\u00edsticas\u00a0de\u00a0cua tro\u00a0tests\u00a0para\u00a0identificar\u00a0infecciones\u00a0\nrecientes:\u00a0STARHS,\u00a0BED\u2010CEIA,\u00a0Avidez\u00a0e\u00a0IDE/V3.\u00a0\n\u00a0\n\u00a0\nTabla\u00a02.\u00a0Tests\u00a0para\u00a0la\u00a0identificaci\u00f3n \u00a0de\u00a0infecciones \u00a0recientes\u00a0 por\u00a0VIH\u00a0\nFuente:\u00a0Mastro\u00a0TD\u00a0 et\u00a0al.\u00a0J\u00a0HIV\u00a0AIDS\u00a0Surveill\u00a0Epidemiol\u00a02010  \u00a0(81)\u00a0\n \u00a0 STARHS\u00a0\u00a0\n(Vironostika-LS HIV-1 \nMicroelisa System )\u00a0BED\u2010CEIA\u00a0\n\u00a0(Calypte\u00a9\u00a0 HIV\u20101\u00a0BED\u00a0\nIncidence \u00a0EIA)\u00a0Avidez\u00a0\u00a0\n(Abbott\u00a0AxSYM\u00a0HIV\u00a0\n1/2/gO) \u00a0IDE/V3\u00a0\nFactor\u00a0 \u00a0\u00a0\u00a0\u00a0\nTipo\u00a0de\u00a0anticuerpo \u00a0\nmedido\u00a0Cantidad\u00a0de\u00a0anti\u2010VIH\u00a0Cantidad\u00a0de\u00a0anti\u2010VIH\u00a0\ngp\u201041\u00a0(como\u00a0\nproporci\u00f3n\u00a0del\u00a0total\u00a0de\u00a0\nIgG)\u00a0Calidad\u00a0anti\u2010VIH\u00a0\n(avidez\u00a0del\u00a0anticuerpo)\u00a0Cantidad\u00a0de\u00a0anti\u2010VIH\u00a0\ngp41\u00a0y\u00a0V3\u00a0\u00a0\nDisponibilidad\u00a0\ncomercial \u00a0S\u00ed\u00a0(procedimiento\u00a0modificado\u00a0del\u00a0prospecto\u00a0del\u00a0producto)\u00a0S\u00ed\u00a0S\u00ed\u00a0(procedimiento\u00a0modificado\u00a0del\u00a0prospecto\u00a0del\u00a0producto)\u00a0No\u00a0(test\u00a0 in\u2010house,\u00a0los\u00a0\nreactivos\u00a0se\u00a0pueden\u00a0conseguir\u00a0comercialmente)\u00a0\nDisponibilidad\u00a0 del\u00a0test\u00a0Ya\u00a0no\u00a0est\u00e1\u00a0disponible\u00a0 En\u00a0todo\u00a0el\u00a0mundo\u00a0Europa,\u00a0y\u00a0algunos\u00a0\npa\u00edses\u00a0no\u00a0europeos\u00a0Los\u00a0reactivos\u00a0est\u00e1n\u00a0\ngeneralmente\u00a0\ndisponibles\u00a0\u2013\u00a0algunos\u00a0\ncomponentes\u00a0pueden\u00a0\ntener\u00a0disponibilidad\u00a0\nlimitada\u00a0\nRequerimiento \u00a0de\u00a0\nequipos\u00a0especiales \u00a0No\u00a0 No\u00a0 S\u00ed\u00a0(Analizador\u00a0AxSYM)\u00a0 No\u00a0\nDiluci\u00f3n \u00a0de\u00a0trabajo\u00a01:20,000\u00a0 1:101\u00a0 1:10\u00a0 1:100\u00a0\nAutomatizaci\u00f3n \u00a0Es\u00a0posible\u00a0una\u00a0automatizaci\u00f3n\u00a0parcial\u00a0Es\u00a0posible\u00a0una\u00a0automatizaci\u00f3n\u00a0parcial\u00a0S\u00ed\u00a0 No\u00a0\nDuraci\u00f3n \u00a0del\u00a0test\u00a0 90\u00a0minutos\u00a0por\u00a0placa\u00a0 245\u00a0minutos\u00a0por\u00a0placa\u00a0M\u00ednimo\u00a0de\u00a060\u00a0minutos;\u00a0\n2\u20103\u00a0minutos\u00a0por\u00a0cada\u00a0\nmuestra\u00a0adicional\u00a0por\u00a0\nencima\u00a0de\u00a010\u00a02\u00a0horas\u00a0\nAlgoritmo \u00a0\nconfirmatorio \u00a0S\u00ed,\u00a0por\u00a0triplicado\u00a0 S\u00ed,\u00a0por\u00a0triplicado\u00a0 No\u00a0 No\u00a0\n%\u00a0casos\u00a0 de\u00a0SIDA\u00a0\nclasificados \u00a0\nerr\u00f3neamente \u00a0como\u00a0\nrecientes \u00a02,4%\u00a0 2\u20103%\u00a0 Desconocido\u00a0 9%\u00a0INTRODUCCI\u00d3N\u00a0\n -  273.4.\u00a0Limitaciones \u00a0\u00a0\nLas\u00a0limitaciones\u00a0de\u00a0estos\u00a0tests \u00a0se\u00a0enumeran\u00a0a\u00a0continuaci\u00f3n.\u00a0\nSubtipo\u00a0de\u00a0VIH\u00a0\nLa\u00a0mayor\u00eda\u00a0de\u00a0tests\u00a0se\u00a0han\u00a0desarrollado\u00a0bas\u00e1ndose\u00a0en\u00a0el\u00a0uso\u00a0del \u00a0subtipo\u00a0B.\u00a0Puesto\u00a0que\u00a0los\u00a0\nep\u00edtopos\u00a0(regi\u00f3n\u00a0del\u00a0ant\u00edgeno\u00a0reconocida\u00a0espec\u00edficamente\u00a0por\u00a0el \u00a0anticuerpo)\u00a0difieren\u00a0entre\u00a0los\u00a0\ndiferentes\u00a0 subtipos\u00a0 de\u00a0 VIH,\u00a0 es\u00a0 probable\u00a0 que\u00a0 la\u00a0 respuesta\u00a0 de\u00a0 los \u00a0 anticuerpos\u00a0 de\u00a0 pacientes\u00a0\ninfectados\u00a0por\u00a0subtipos\u00a0no\u00a0B\u00a0pueda\u00a0mostrar\u00a0una\u00a0menor\u00a0afinidad\u00a0p or\u00a0el\u00a0ant\u00edgeno,\u00a0lo\u00a0cual\u00a0puede\u00a0\nalterar\u00a0al\u00a0periodo\u00a0ventana\u00a0del\u00a0test\u00a0(en\u00a0la\u00a0mayor\u00eda\u00a0de\u00a0los\u00a0casos \u00a0extendi\u00e9ndolo).\u00a0Estudios\u00a0realizados\u00a0\npara\u00a0evaluar\u00a0las\u00a0caracter\u00edsticas\u00a0de\u00a0estos\u00a0tests,\u00a0en\u00a0pacientes\u00a0infectados\u00a0con\u00a0subtipos\u00a0no\u00a0B,\u00a0han\u00a0\nmostrado\u00a0 que\u00a0 el\u00a0 periodo\u00a0 durante\u00a0 el\u00a0 cual\u00a0 una\u00a0 infecci\u00f3n\u00a0 se\u00a0 puede\u00a0 detectar\u00a0 como\u00a0 reciente\u00a0 es\u00a0\nsignificativamente\u00a0diferente\u00a0seg\u00fan\u00a0el\u00a0subtipo\u00a0estudiado.\u00a0Concre tamente,\u00a0para\u00a0el\u00a0test\u00a0Vironostika\u00a0\nusando\u00a0un\u00a0 cut\u00a0off\u00a0de\u00a01,0\u00a0DO,\u00a0el\u00a0periodo\u00a0ventana\u00a0es\u00a0de\u00a0170\u00a0d\u00edas\u00a0para\u00a0los\u00a0subtipos \u00a0B,\u00a0mientras\u00a0que\u00a0\npara\u00a0la\u00a0CRF_01\u00a0AE\u00a0es\u00a0de\u00a0356\u00a0d\u00edas\u00a0(82).\u00a0En\u00a0una\u00a0reciente\u00a0evaluaci \u00f3n\u00a0usando\u00a0el\u00a0test\u00a0BED\u2010CEIA,\u00a0\nusando\u00a0un\u00a0 cut\u00a0off\u00a0de\u00a00,8\u00a0DO,\u00a0se\u00a0estim\u00f3\u00a0que\u00a0el\u00a0periodo\u00a0ventana\u00a0para\u00a0los\u00a0subtipos\u00a0 no\u2010B\u00a0presentaban\u00a0\nvariaciones,\u00a0desde\u00a0127\u00a0d\u00edas\u00a0en\u00a0el\u00a0subtipo\u00a0AE\u00a0tailand\u00e9s,\u00a0hasta\u00a02 36\u00a0d\u00edas\u00a0en\u00a0los\u00a0subtipos\u00a0AG\u00a0y\u00a0AD\u00a0\n(83).\u00a0\nBajo\u00a0nivel\u00a0de\u00a0anticuerpos \u00a0\n1.\u00a0Estad\u00edos \u00a0avanzados \u00a0de\u00a0la\u00a0enfermedad \u00a0\nEl\u00a0deterioro\u00a0del\u00a0sistema\u00a0inmunitario\u00a0asociado\u00a0a\u00a0estad\u00edos\u00a0avanza dos\u00a0de\u00a0la\u00a0enfermedad\u00a0est\u00e1\u00a0\nasociado\u00a0a\u00a0un\u00a0descenso\u00a0en\u00a0los\u00a0niveles\u00a0de\u00a0anticuerpos\u00a0anti\u2010VIH\u00a0( 84),\u00a0y\u00a0por\u00a0lo\u00a0tanto\u00a0se\u00a0espera\u00a0que\u00a0\ntenga\u00a0un\u00a0cierto\u00a0impacto\u00a0en\u00a0la\u00a0es pecificidad\u00a0de\u00a0aquellos\u00a0tests\u00a0q ue\u00a0dependen\u00a0de\u00a0la\u00a0cuantificaci\u00f3n\u00a0de\u00a0\nlos\u00a0 anticuerpos.\u00a0 Se\u00a0 ha\u00a0 reportado\u00a0 un\u00a0 porcentaje\u00a0 de\u00a0 falsos\u00a0 positi v o s \u00a0d e \u00a0e n t r e \u00a0e l \u00a05 % \u00a0( p a r a \u00a0e l \u00a0\nVironostika)\u00a0(73)\u00a0y\u00a0de\u00a0entre\u00a0el\u00a02\u20103%\u00a0para\u00a0el\u00a0test\u00a0BED\u2010CEIA\u00a0(75) .\u00a0Por\u00a0otro\u00a0lado,\u00a0puesto\u00a0que\u00a0la\u00a0\navidez\u00a0del\u00a0anticuerpo\u00a0por\u00a0el\u00a0ant\u00edgeno\u00a0no\u00a0est\u00e1\u00a0relacionada\u00a0con\u00a0l a\u00a0cantidad\u00a0de\u00a0anticuerpos,\u00a0se\u00a0\nespera\u00a0que\u00a0el\u00a0test\u00a0de\u00a0avidez\u00a0no\u00a0 se\u00a0vea\u00a0tan\u00a0afectado\u00a0por\u00a0este\u00a0supuesto\u00a0(71).\u00a0\n2.\u00a0Terapia\u00a0antirretroviral\u00a0\nEl\u00a0tratamiento\u00a0antirretroviral\u00a0suprime\u00a0la\u00a0replicaci\u00f3n\u00a0v\u00edrica\u00a0hasta\u00a0tal\u00a0punto\u00a0que\u00a0el\u00a0est\u00edmulo\u00a0\ncr\u00f3nico\u00a0 de\u00a0 la\u00a0 respuesta\u00a0 inmunitaria\u00a0 se\u00a0 elimina,\u00a0 llevando\u00a0 a\u00a0 un\u00a0 d escenso\u00a0 en\u00a0 el\u00a0 nivel\u00a0 de\u00a0 de\u00a0\nanticuerpos\u00a0frente\u00a0al\u00a0VIH.\u00a0El\u00a0efecto\u00a0es\u00a0m\u00e1s\u00a0pronunciado\u00a0durante \u00a0los\u00a0primeros\u00a0meses\u00a0despu\u00e9s\u00a0del\u00a0\ninicio\u00a0del\u00a0tratamiento.\u00a0Por\u00a0tant o,\u00a0tambi\u00e9n\u00a0puede\u00a0llevar\u00a0a\u00a0una\u00a0d isminuci\u00f3n\u00a0en\u00a0la\u00a0especificidad\u00a0(71).\u00a0\n3.\u00a0Variabilidad \u00a0interpersonal \u00a0\nLa\u00a0 velocidad\u00a0 de\u00a0 progresi\u00f3n\u00a0 a\u00a0 SIDA\u00a0 es\u00a0 diferente\u00a0 para\u00a0 cada\u00a0 pacien t e , \u00a0y \u00a0e n \u00a0f u n c i \u00f3 n \u00a0d e \u00a0e s a \u00a0\nvelocidad\u00a0 podemos\u00a0 definir\u00a0 tres\u00a0 tipos\u00a0 de\u00a0 pacientes:\u00a0 los\u00a0 progreso res\u00a0 r\u00e1pidos,\u00a0 los\u00a0 progresores\u00a0\nt\u00edpicos\u00a0\ny\u00a0 los\u00a0 progresores\u00a0 lentos\u00a0 (tambi\u00e9n\u00a0 conocidos\u00a0 como\u00a0 elite\u00a0controllers \u00a0o \u00a0long\u2010term\u00a0non\u2010INTRODUCCI\u00d3N\u00a0\n 28progressors )\u00a0(1).\u00a0Los\u00a0progresores\u00a0lentos\u00a0pu eden\u00a0presentar\u00a0niveles\u00a0de\u00a0antic uerpos\u00a0frente\u00a0al\u00a0VIH\u00a0\nbajos,\u00a0mucho\u00a0tiempo\u00a0despu\u00e9s\u00a0de l\u00a0momento\u00a0de\u00a0la\u00a0infecci\u00f3n\u00a0(81).\u00a0 \u00a0\nAdem\u00e1s,\u00a0hay\u00a0que\u00a0tener\u00a0en\u00a0cuenta\u00a0que\u00a0el\u00a0periodo\u00a0ventana\u00a0se\u00a0deter mina\u00a0mediante\u00a0paneles\u00a0de\u00a0\nmuestras\u00a0pertenecientes\u00a0a\u00a0individuos\u00a0cuya\u00a0fecha\u00a0de\u00a0seroconversi \u00f3n\u00a0es\u00a0conocida.\u00a0Modelando\u00a0estos\u00a0\ndatos\u00a0se\u00a0obtiene\u00a0la\u00a0relaci\u00f3n\u00a0entre\u00a0el\u00a0momento\u00a0de\u00a0seroconversi\u00f3n \u00a0y\u00a0el\u00a0promedio\u00a0de\u00a0la\u00a0se\u00f1al\u00a0\nesperada\u00a0en\u00a0el\u00a0test\u00a0para\u00a0detectar\u00a0infecciones\u00a0recientes.\u00a0Este\u00a0periodo\u00a0est\u00e1\u00a0limitado\u00a0por\u00a0los\u00a0efectos\u00a0\nd e \u00a0l a \u00a0v a r i a c i \u00f3 n \u00a0i n d i v i d u a l \u00a0e n \u00a0l a \u00a0r e s p u e s t a \u00a0d e \u00a0l o s \u00a0a n t i c u e r p o s , \u00a0 existiendo\u00a0 individuos\u00a0 que\u00a0\ndesarrollan\u00a0r\u00e1pidamente\u00a0la\u00a0respues ta\u00a0y\u00a0otros\u00a0individuos\u00a0que\u00a0res ponden\u00a0de\u00a0manera\u00a0lenta\u00a0(Figura\u00a0\n16)\u00a0(71)\u00a0\n \n \n \nFigura\u00a016.\u00a0 Principios \u00a0que\u00a0sustentan\u00a0 los\u00a0tests\u00a0serol\u00f3gicos \u00a0para\u00a0identificar \u00a0infecciones \u00a0recientes\u00a0\nFuente:.\u00a0Murphy\u00a0G,\u00a0 et\u00a0al.\u00a02008\u00a0.\u00a0(71).\u00a0\n \n \u00a0\n -  294.\u00a0Aplicaciones \u00a0de\u00a0los\u00a0tests\u00a0serol\u00f3gicos \u00a0para\u00a0identificar \u00a0infecciones\u00a0\nrecientes \u00a0en\u00a0Salud\u00a0P\u00fablica  \n4.1.\u00a0Terminolog\u00eda  \nEn\u00a0relaci\u00f3n\u00a0a\u00a0la\u00a0identificaci\u00f3n\u00a0de\u00a0infecciones\u00a0recientes\u00a0por\u00a0VI H\u00a0mediante\u00a0tests\u00a0serol\u00f3gicos,\u00a0\npodemos\u00a0encontrar\u00a0en\u00a0la\u00a0literatura\u00a0diferentes\u00a0t\u00e9rminos.\u00a0El\u00a0t\u00e9rm ino\u00a0STARHS\u00a0ha\u00a0sido\u00a0utilizado\u00a0por\u00a0\na lg u n o s\u00a0a u to re s\u00a0pa ra \u00a0h a ce r\u00a0re f e re n cia \u00a0a \u00a0cu a lq u ie r\u00a0te st\u00a0de \u00a0la b o r atorio\u00a0 usado\u00a0 para\u00a0identificar\u00a0\ninfecciones\u00a0recientes\u00a0(71).\u00a0Actualmente,\u00a0el\u00a0t\u00e9rmino\u00a0STARHS\u00a0s\u00f3lo \u00a0se\u00a0utiliza\u00a0para\u00a0hacer\u00a0referencia\u00a0\nal\u00a0m\u00e9todo\u00a0descrito\u00a0por\u00a0Janssen\u00a0 et\u00a0al.\u00a0en\u00a01998,\u00a0usando\u00a0el\u00a0test\u00a0de\u00a0Abbott\u00a0(72)\u00a0y\u00a0tambi\u00e9n\u00a0el\u00a0test\u00a0\nVironostika\u00a0(73).\u00a0Algunos\u00a0autores\u00a0tambi\u00e9n\u00a0hacen\u00a0referencia\u00a0al\u00a0t est\u00a0descrito\u00a0por\u00a0Janssen\u00a0como\u00a0\nDetuned\u00a0( 8 5 ) . \u00a0E n \u00a0l a \u00a0l i t e r a t u r a \u00a0m \u00e1 s \u00a0r e c i e n t e \u00a0e n c o n t r a m o s \u00a0e l \u00a0t \u00e9 r m i n o \u00a0T R I ,\u00a0de\u00a0 Test\u00a0for\u00a0Recent\u00a0\nInfection,\u00a0para\u00a0hacer\u00a0referencia\u00a0a\u00a0cualquier\u00a0test\u00a0serol\u00f3gico\u00a0utilizado\u00a0p ara\u00a0identificar\u00a0infecciones\u00a0\nrecientes\u00a0(81),\u00a0o\u00a0tambi\u00e9n\u00a0el\u00a0t\u00e9rmino\u00a0 HIV\u00a0incidence \u00a0assays\u00a0(86).\u00a0\u00a0\nEl\u00a0WHO\u00a0Technical \u00a0Working\u00a0Group\u00a0on\u00a0HIV\u00a0Incidence\u00a0ha\u00a0introducido\u00a0recientemente\u00a0el\u00a0t\u00e9rmino\u00a0\nHIV\u2010\u00a0RITA\u00a0( Recent\u00a0 Infection\u00a0Testing\u00a0Algorithm )\u00a0(89).\u00a0Un\u00a0RITA\u00a0es\u00a0un\u00a0algoritmo\u00a0que\u00a0utiliza\u00a0siempre\u00a0\nun\u00a0TRI,\u00a0y,\u00a0adem\u00e1s,\u00a0puede\u00a0incluir\u00a0tambi\u00e9n\u00a0informaci\u00f3n\u00a0cl\u00ednica\u00a0y/ o\u00a0de\u00a0laboratorio\u00a0para\u00a0identificar\u00a0\nlas\u00a0infecciones\u00a0recientes.\u00a0Como\u00a0veremos\u00a0a\u00a0continuaci\u00f3n,\u00a0algunos \u00a0RITA\u00a0pueden\u00a0usar\u00a0dos\u00a0TRIs\u00a0\ndistintos.\u00a0Un\u00a0RITA\u00a0que\u00a0usa\u00a0dos\u00a0TRIs\u00a0tambi\u00e9n\u00a0se\u00a0conoce\u00a0como\u00a0 Multi\u00a0Assay\u00a0Algorithm \u00a0(MAA)\u00a0(87,\u00a0\n88).\u00a0\u00a0\n\u00a0\n\u00a0\n4.2.\u00a0Algoritmos \u00a0para\u00a0 identificar \u00a0infecciones \u00a0recientes \u00a0\nAntes\u00a0de\u00a0aplicar\u00a0un\u00a0RITA\u00a0en\u00a0una\u00a0poblaci\u00f3n\u00a0de\u00a0nuevos\u00a0diagn\u00f3stico s\u00a0de\u00a0VIH,\u00a0es\u00a0importante\u00a0\nconsiderar\u00a0la\u00a0factibilidad\u00a0log\u00eds tica\u00a0y\u00a0el\u00a0coste\u00a0que\u00a0supone\u00a0la\u00a0a plicaci\u00f3n\u00a0de\u00a0cada\u00a0algoritmo,\u00a0as\u00ed\u00a0como\u00a0\nsus\u00a0 limitaciones.\u00a0 Tal\u00a0 y\u00a0 como\u00a0 se\u00a0 ha\u00a0 comentado\u00a0 anteriormente,\u00a0 los \u00a0TRIs\u00a0pueden\u00a0usarse\u00a0como\u00a0\nherramienta\u00a0\u00fanica\u00a0para\u00a0identifi car\u00a0infecciones\u00a0recientes\u00a0(Figur a\u00a017),\u00a0o\u00a0tambi\u00e9n\u00a0en\u00a0combinaci\u00f3n\u00a0\ncon\u00a0informaci\u00f3n\u00a0de\u00a0biomarcadores\u00a0(recuento\u00a0de\u00a0c\u00e9lulas\u00a0CD4+,\u00a0det ecci\u00f3n\u00a0de\u00a0antirretrovirales\u00a0en\u00a0el\u00a0\nsuero)\u00a0o\u00a0de\u00a0la\u00a0historia\u00a0cl\u00ednica\u00a0del\u00a0paciente\u00a0(presencia\u00a0de\u00a0enfe rmedades\u00a0definitorias\u00a0de\u00a0SIDA,\u00a0\nrealizaci\u00f3n\u00a0de\u00a0tests\u00a0VIH\u00a0con\u00a0ante rioridad\u00a0al\u00a0diagn\u00f3stico).\u00a0El\u00a0u so\u00a0de\u00a0biomarcadores\u00a0adicionales\u00a0\nasociados\u00a0con\u00a0la\u00a0fase\u00a0cr\u00f3nica\u00a0de\u00a0la\u00a0infecci\u00f3n\u00a0por\u00a0VIH,\u00a0as\u00ed\u00a0como \u00a0informaci\u00f3n\u00a0de\u00a0la\u00a0historia\u00a0cl\u00ednica\u00a0\ndel\u00a0paciente,\u00a0mejora\u00a0la\u00a0especificidad,\u00a0ya\u00a0que\u00a0as\u00ed\u00a0se\u00a0minimiza\u00a0e l\u00a0error\u00a0de\u00a0clasificaci\u00f3n\u00a0en\u00a0los\u00a0falsos\u00a0\npositivos\u00a0(pacientes\u00a0con\u00a0infecci \u00f3n\u00a0no\u00a0reciente\u00a0clasificados\u00a0por \u00a0el\u00a0algoritmo\u00a0como\u00a0recientes)\u00a0(81).\u00a0\u00a0\n 30\n\u00a0\n\u00a0\nFigura\u00a017. \u00a0Ejemplo \u00a0de\u00a0un\u00a0RITA\u00a0que\u00a0s\u00f3lo\u00a0usa\u00a0un\u00a0TRI\u00a0\nFuente:\u00a0UNAIDS/WHO\u00a0Working\u00a0group\u00a0 on\u00a0Global\u00a0HIV/AIDS\u00a0and\u00a0STI\u00a0Sur veillance.\u00a02011.\u00a0(89)\u00a0\n\u00a0\nTambi\u00e9n\u00a0se\u00a0ha\u00a0propuesto\u00a0el\u00a0uso\u00a0de\u00a0m\u00e1s\u00a0de\u00a0un\u00a0TRI,\u00a0junto\u00a0con\u00a0la\u00a0i nformaci\u00f3n\u00a0de\u00a0biomarcadores\u00a0y\u00a0\ncl\u00ednica\u00a0para\u00a0identificar\u00a0infecciones\u00a0recientes.\u00a0Concretamente,\u00a0 Laeyendecker\u00a0 et\u00a0al.\u00a0han\u00a0propuesto\u00a0\nusar\u00a0un\u00a0algoritmo\u00a0con\u00a0los\u00a0tests\u00a0BED\u2010CEIA\u00a0y\u00a0Avidez,\u00a0adem\u00e1s\u00a0de\u00a0a\u00f1 adir\u00a0marcadores\u00a0virol\u00f3gicos\u00a0y\u00a0\nbiol\u00f3gicos\u00a0(carga\u00a0v\u00edrica\u00a0y\u00a0CD4+) ,\u00a0obteniendo\u00a0una\u00a0especificidad\u00a0 del\u00a099,2%\u00a0(88,\u00a087,\u00a090).\u00a0\u00a0\u00a0\nEn\u00a0la\u00a0Figura\u00a018,\u00a0podemos\u00a0ver\u00a0un\u00a0ejemplo\u00a0de\u00a0un\u00a0RITA\u00a0que\u00a0usa\u00a0un\u00a0T RI\u00a0junto\u00a0con\u00a0informaci\u00f3n\u00a0\nsobre\u00a0biomarcadores\u00a0(recuento\u00a0de\u00a0c\u00e9lulas\u00a0CD4+\u00a0y\u00a0detecci\u00f3n\u00a0de\u00a0antirretrovirales\u00a0en\u00a0el\u00a0suero)\u00a0e\u00a0informaci\u00f3n\u00a0de\u00a0la\u00a0historia\u00a0cl\u00ednica\u00a0(enfermedades\u00a0definitorias\u00a0de\u00a0SIDA\u00a0y\u00a0tests\u00a0de\u00a0VIH\u00a0previos\u00a0al\u00a0diagn\u00f3stico).\u00a0En\u00a0este\u00a0ejemplo,\u00a0el\u00a0primer\u00a0paso\u00a0del\u00a0algoritmo\u00a0es\u00a0 analizar\u00a0la\u00a0muestra\u00a0del\u00a0paciente\u00a0\nVIH\u00a0positivo\u00a0con\u00a0el\u00a0TRI.\u00a0En\u00a0caso\u00a0de\u00a0obtener\u00a0un\u00a0resultado\u00a0que\u00a0in dique\u00a0infecci\u00f3n\u00a0reciente,\u00a0se\u00a0sigue\u00a0\nel\u00a0algoritmo\u00a0teniendo\u00a0en\u00a0cuenta\u00a0el\u00a0resto\u00a0de\u00a0informaci\u00f3n.\u00a0Con\u00a0es ta\u00a0estrategia,\u00a0es\u00a0posible\u00a0obtener\u00a0la\u00a0\ntasa\u00a0de\u00a0falsos\u00a0positivos\u00a0en\u00a0la\u00a0poblaci\u00f3n\u00a0de\u00a0muestras\u00a0analizadas ,\u00a0tambi\u00e9n\u00a0conocida\u00a0como\u00a0 False\u00a0\nRecent\u00a0 Rate.\u00a0T a l \u00a0y \u00a0c o m o \u00a0s e \u00a0c o m e n t a r \u00e1 \u00a0m \u00e1 s \u00a0a d e l a n t e \u00a0e n \u00a0e l \u00a0a p a r t a d o \u00a04 . 5 , \u00a0e s t e \u00a0 par\u00e1metro\u00a0 es\u00a0\nnecesario\u00a0para\u00a0poder\u00a0estimar \u00a0la\u00a0incidencia\u00a0por\u00a0VIH\u00a0(89).\u00a0\nTambi\u00e9n\u00a0ser\u00eda\u00a0posible\u00a0considerar \u00a0en\u00a0primer\u00a0lugar\u00a0la\u00a0informaci\u00f3n \u00a0sobre\u00a0tests\u00a0previos\u00a0de\u00a0VIH,\u00a0\nrecuentos\u00a0de\u00a0CD4+\u00a0en\u00a0el\u00a0momento\u00a0del\u00a0diagn\u00f3stico\u00a0o\u00a0presencia\u00a0de\u00a0enfermedades\u00a0definitorias\u00a0de\u00a0\nSIDA,\u00a0por\u00a0ejemplo,\u00a0y\u00a0posteriorme nte\u00a0analizar\u00a0la\u00a0muestra\u00a0mediant e\u00a0el\u00a0TRI.\u00a0De\u00a0este\u00a0modo\u00a0s\u00f3lo\u00a0se\u00a0\nanalizar\u00edan\u00a0las\u00a0muestras\u00a0de\u00a0los\u00a0pacientes\u00a0que\u00a0cumplen\u00a0 a\u00a0priori\u00a0las\u00a0caracter\u00edsticas\u00a0de\u00a0los\u00a0pacientes\u00a0\ncon\u00a0infecci\u00f3n\u00a0reciente:\u00a0\u00a0\n\uf0b7\uf020CD4+\u00a0>\u00a0200\u00a0c\u00e9lulas/\u03bcl\u00a0\n\uf0b7\uf020Primer\u00a0test\u00a0VIH\u00a0positivo\u00a0<6\u00a0meses\u00a0\n\uf0b7\uf020Ausencia\u00a0de\u00a0enfermedades\u00a0definitorias\u00a0de\u00a0SIDA\u00a0\n\u00a0\u00a0\n -  31\n \n\u00a0\nFigura\u00a018.\u00a0 Ejemplo \u00a0de\u00a0un\u00a0RITA\u00a0que\u00a0usa\u00a0un\u00a0TRI\u00a0e\u00a0informaci\u00f3n \u00a0cl\u00ednica\u00a0 y\u00a0de\u00a0laboratorio \u00a0\u00a0\u00a0\u00a0\nFuente:\u00a0UNAIDS/WHO\u00a0Working\u00a0group\u00a0 on\u00a0Global\u00a0HIV/AIDS\u00a0and\u00a0STI\u00a0Sur veillance.\u00a02011.\u00a0(89)\u00a0\n\u00a0\nEn\u00a0la\u00a0Figura\u00a019\u00a0podemos\u00a0ver\u00a0otro\u00a0ejemplo\u00a0de\u00a0RITA\u00a0que\u00a0incorpora\u00a0 dos\u00a0TRIs.\u00a0En\u00a0este\u00a0caso,\u00a0\nprimero\u00a0se\u00a0excluyen\u00a0todos\u00a0los\u00a0pacientes\u00a0con\u00a0un\u00a0recuento\u00a0de\u00a0c\u00e9lu las\u00a0CD4+\u00a0bajo\u00a0(<200\u00a0c\u00e9lulas/\u03bcl).\u00a0\nDespu\u00e9s\u00a0las\u00a0muestras\u00a0se\u00a0analizan\u00a0mediante\u00a0el\u00a0test\u00a0BED\u2010CEIA,\u00a0com o\u00a0herramienta\u00a0inicial\u00a0de\u00a0cribado\u00a0\npara\u00a0identificar\u00a0aquellas\u00a0muestr as\u00a0que\u00a0corresponden\u00a0a\u00a0infeccion es\u00a0recientes.\u00a0Posteriormente,\u00a0\naquellas\u00a0en\u00a0las\u00a0que\u00a0se\u00a0obtiene\u00a0un\u00a0resultado\u00a0de\u00a0infecci\u00f3n\u00a0recien te,\u00a0se\u00a0vuelven\u00a0a\u00a0analizar\u00a0con\u00a0otro\u00a0\nTRI\u00a0m\u00e1s\u00a0espec\u00edfico,\u00a0que\u00a0usa\u00a0un\u00a0principio\u00a0biol\u00f3gico\u00a0diferente\u00a0al \u00a0del\u00a0TRI\u00a0inicial\u00a0(en\u00a0este\u00a0caso\u00a0se\u00a0\nutiliza\u00a0el\u00a0test\u00a0Avidez).\u00a0En\u00a0aquellas\u00a0muestras\u00a0que\u00a0tambi\u00e9n\u00a0se\u00a0id entifican\u00a0como\u00a0infecciones\u00a0recientes\u00a0\u00a0\n 32usando\u00a0este\u00a0segundo\u00a0TRI,\u00a0se\u00a0determina\u00a0la\u00a0presencia\u00a0del\u00a0ARN\u00a0v\u00edri co.\u00a0Aquellas\u00a0muestras\u00a0en\u00a0que\u00a0no\u00a0\nse\u00a0 detecta\u00a0 ARN\u00a0 v\u00edrico\u00a0 se\u00a0 consideran\u00a0 como\u00a0 infecciones\u00a0 no\u00a0 recient es.\u00a0A\u00a0continuaci\u00f3n,\u00a0en\u00a0esas\u00a0\nmismas\u00a0 muestras\u00a0 correspondientes \u00a0 a\u00a0 infecciones\u00a0 no\u00a0 recientes\u00a0 se\u00a0 determina\u00a0 la\u00a0 presencia\u00a0 de\u00a0\nantirretrovirales\u00a0en\u00a0el\u00a0suero.\u00a0En\u00a0aquellos\u00a0casos\u00a0que\u00a0no\u00a0se\u00a0dete ctan\u00a0antirretrovirales,\u00a0se\u00a0considera\u00a0\nque\u00a0pueden\u00a0tratarse\u00a0de\u00a0pacientes\u00a0VIH\u00a0positivos\u00a0 elite\u00a0controllers .\u00a0Y\u00a0en\u00a0las\u00a0muestras\u00a0que\u00a0se\u00a0detecta\u00a0\npresencia\u00a0de\u00a0antirretrovirales,\u00a0se\u00a0considera\u00a0que\u00a0corresponden\u00a0a \u00a0pacientes\u00a0con\u00a0infecci\u00f3n\u00a0cr\u00f3nica\u00a0\nque\u00a0est\u00e1n\u00a0recibiendo\u00a0tratamiento\u00a0antirretroviral.\u00a0(81).\u00a0\n\u00a0\n\u00a0\n\u00a0\nFigura\u00a019.\u00a0 Ejemplo \u00a0de\u00a0un\u00a0RITA,\u00a0usando\u00a0dos\u00a0TRIs\u00a0e\u00a0informaci\u00f3n \u00a0cl\u00ednica\u00a0 y\u00a0de\u00a0laboratorio \u00a0\nFuente:\u00a0Mastro\u00a0 et\u00a0al.\u00a02010\u00a0(81)\u00a0\n\u00a0\nDesde\u00a0 la\u00a0 perspectiva\u00a0 de\u00a0 Salud\u00a0 P\u00fablica,\u00a0 estos\u00a0 algoritmos\u00a0 se\u00a0 han\u00a0 utilizado\u00a0 con\u00a0 diferentes\u00a0\nprop\u00f3sitos.\u00a0Entre\u00a0los\u00a0m\u00e1s\u00a0relevantes,\u00a0podemos\u00a0destacar\u00a0los\u00a0sigu ientes:\u00a0(i)\u00a0estimar\u00a0la\u00a0proporci\u00f3n\u00a0\nde\u00a0 infecciones\u00a0 recientes\u00a0 entre\u00a0 lo s\u00a0 nuevos\u00a0 diagn\u00f3sticos\u00a0 y\u00a0 descri bir\u00a0 epidemiol\u00f3gicamente\u00a0 los\u00a0\npacientes\u00a0 identificados\u00a0 con\u00a0 infecci\u00f3n\u00a0 reciente,\u00a0 (ii)\u00a0 conocer\u00a0 la \u00a0 prevalencia\u00a0 de\u00a0 resistencias\u00a0\u00a0\n -  33transmitidas\u00a0en\u00a0la\u00a0poblaci\u00f3n\u00a0de\u00a0infectados\u00a0recientemente\u00a0y\u00a0(iii )\u00a0estimar\u00a0la\u00a0tasa\u00a0de\u00a0incidencia\u00a0por\u00a0\nVIH.\u00a0A\u00a0continuaci\u00f3n\u00a0describiremo s\u00a0cada\u00a0una\u00a0de\u00a0estas\u00a0aplicacione s.\u00a0\n\u00a0\n\u00a0\n4.3.\u00a0Epidemiolog\u00eda \u00a0de\u00a0las\u00a0infecciones \u00a0recientes \u00a0\nConocer\u00a0las\u00a0caracter\u00edsticas\u00a0epidemiol\u00f3gicas\u00a0de\u00a0los\u00a0pacientes\u00a0in fectados\u00a0recientemente\u00a0es\u00a0una\u00a0\ninformaci\u00f3n\u00a0\u00fatil\u00a0para\u00a0mejorar\u00a0los\u00a0programas\u00a0de\u00a0prevenci\u00f3n\u00a0y\u00a0con trol\u00a0del\u00a0VIH\u00a0y\u00a0las\u00a0ITS,\u00a0evitando\u00a0\nas\u00ed\u00a0la\u00a0transmisi\u00f3n\u00a0de\u00a0estas\u00a0infecciones.\u00a0Los\u00a0diferentes\u00a0TRIs\u00a0se \u00a0han\u00a0utilizado\u00a0en\u00a0todo\u00a0el\u00a0mundo,\u00a0con\u00a0\nel\u00a0objetivo\u00a0de\u00a0describir\u00a0las\u00a0cara cter\u00edsticas\u00a0y\u00a0la\u00a0magnitud\u00a0de\u00a0l as\u00a0infecciones\u00a0recientes\u00a0e\u00a0identificar\u00a0\nlos\u00a0factores\u00a0asociados\u00a0a\u00a0la\u00a0infecci\u00f3n\u00a0reciente.\u00a0Algunos\u00a0pa\u00edses\u00a0 como\u00a0Francia,\u00a0Estados\u00a0Unidos,\u00a0o\u00a0\nAlemania\u00a0 han\u00a0 implementado\u00a0 en\u00a0 sus\u00a0 sistemas\u00a0 de\u00a0 vigilancia\u00a0 la\u00a0 iden tificaci\u00f3n\u00a0 de\u00a0 infecciones\u00a0\nrecientes\u00a0entre\u00a0los\u00a0nuevos\u00a0diag n\u00f3sticos\u00a0de\u00a0VIH,\u00a0mediante\u00a0TRIs\u00a0( 91\u201095).\u00a0\u00a0\nLos\u00a0 porcentajes\u00a0 de\u00a0 infecciones\u00a0 recientes\u00a0 (n\u00famero\u00a0 de\u00a0 infecciones \u00a0r e c i e n t e s \u00a0/ \u00a0t o t a l \u00a0n u e v o s \u00a0\ndiagn\u00f3sticos\u00a0de\u00a0VIH)\u00a0oscilan\u00a0entre\u00a0el\u00a09,6%\u00a0(en\u00a0un\u00a0estudio\u00a0realizado\u00a0en\u00a0poblaci\u00f3n\u00a0general)\u00a0(96)\u00a0\nhasta\u00a0el\u00a051,9%\u00a0(97)\u00a0o\u00a0el\u00a054.0%\u00a0(en \u00a0estudios\u00a0realizados\u00a0en\u00a0pobla ci\u00f3n\u00a0de\u00a0HSH)\u00a0(91).\u00a0Esta\u00a0variaci\u00f3n\u00a0\ndepende\u00a0del\u00a0lugar\u00a0de\u00a0realizaci\u00f3n\u00a0 del\u00a0estudio,\u00a0as\u00ed\u00a0como\u00a0del\u00a0tipo \u00a0de\u00a0poblaci\u00f3n\u00a0analizada\u00a0(Tabla\u00a03).\u00a0\nEn\u00a0la\u00a0interpretaci\u00f3n\u00a0de\u00a0los\u00a0resultados\u00a0es\u00a0importante\u00a0tener\u00a0en\u00a0c uenta\u00a0que\u00a0la\u00a0identificaci\u00f3n\u00a0de\u00a0\ninfecciones\u00a0recientes\u00a0va\u00a0ligada\u00a0al\u00a0momento\u00a0en\u00a0que\u00a0se\u00a0realiza\u00a0el \u00a0diagn\u00f3stico\u00a0de\u00a0VIH.\u00a0Aquellos\u00a0\ni n d i v i d u o s \u00a0q u e \u00a0s e \u00a0r e a l i z a n \u00a0e l \u00a0t e s t \u00a0d e l \u00a0V I H \u00a0d e \u00a0m a n e r a \u00a0f r e c u e n t e \u00a0 ser\u00e1n\u00a0 identificados\u00a0 como\u00a0\ninfectados\u00a0recientemente\u00a0con\u00a0una\u00a0mayor\u00a0probabilidad,\u00a0respecto\u00a0a quellos\u00a0individuos\u00a0que\u00a0s\u00f3lo\u00a0se\u00a0\nhayan\u00a0realizado\u00a0la\u00a0prueba\u00a0en\u00a0una\u00a0ocasi\u00f3n\u00a0(98).\u00a0\nEn\u00a0general,\u00a0en\u00a0los\u00a0pa\u00edses\u00a0europeos\u00a0y\u00a0en\u00a0Estados\u00a0Unidos,\u00a0se\u00a0encu entran\u00a0las\u00a0prevalencias\u00a0de\u00a0\ninfecci\u00f3n\u00a0reciente\u00a0m\u00e1s\u00a0altas,\u00a0y\u00a0el\u00a0factor\u00a0de\u00a0riesgo\u00a0que\u00a0se\u00a0asoc ia\u00a0con\u00a0m\u00e1s\u00a0frecuencia\u00a0a\u00a0la\u00a0infecci\u00f3n\u00a0\nreciente\u00a0es\u00a0infectarse\u00a0a\u00a0trav\u00e9s\u00a0de\u00a0relaciones\u00a0sexuales\u00a0entre\u00a0HS H\u00a0(91,\u00a092,\u00a099,\u00a0100)\u00a0.\u00a0Adem\u00e1s\u00a0de\u00a0este\u00a0\nfactor\u00a0de\u00a0riesgo,\u00a0la\u00a0edad\u00a0tambi\u00e9n\u00a0se\u00a0identifica\u00a0como\u00a0uno\u00a0de\u00a0los \u00a0factores\u00a0asociados\u00a0a\u00a0la\u00a0infecci\u00f3n\u00a0\nreciente\u00a0por\u00a0VIH\u00a0(91,\u00a0101,\u00a0102).\u00a0En\u00a0un\u00a0estudio\u00a0realizado\u00a0en\u00a0Sao \u00a0Paulo,\u00a0Brasil,\u00a0encontraron\u00a0que\u00a0la\u00a0\nedad\u00a0era\u00a0la\u00a0\u00fanica\u00a0variable\u00a0que\u00a0manten\u00eda\u00a0su\u00a0asociaci\u00f3n\u00a0significa tiva\u00a0con\u00a0la\u00a0infecci\u00f3n\u00a0reciente\u00a0en\u00a0el\u00a0\nan\u00e1lisis\u00a0multivariable;\u00a0siendo\u00a0m\u00e1s\u00a0frecuente\u00a0entre\u00a0los\u00a0individu os\u00a0menores\u00a0de\u00a025\u00a0a\u00f1os\u00a0(102).\u00a0\u00a0\nEn\u00a0la\u00a0regi\u00f3n\u00a0del\u00a0\u00c1frica\u00a0Subsahariana\u00a0tambi\u00e9n\u00a0se\u00a0han\u00a0realizado\u00a0d iferentes\u00a0estudios\u00a0aplicando\u00a0\nTRIs.\u00a0En\u00a0uno\u00a0de\u00a0esos\u00a0estudios,\u00a0el\u00a0porcentaje\u00a0de\u00a0infecci\u00f3n\u00a0recie nte\u00a0fue\u00a0del\u00a09,6%,\u00a0y\u00a0encontraron\u00a0que\u00a0\nlas\u00a0mujeres\u00a0j\u00f3venes\u00a0se\u00a0infectaban\u00a0a\u00a0una\u00a0edad\u00a0m\u00e1s\u00a0temprana\u00a0que\u00a0l os\u00a0hombres\u00a0(96).\u00a0En\u00a0Uganda\u00a0se\u00a0\nrealiz\u00f3\u00a0un\u00a0estudio\u00a0de\u00a0\u00e1mbito\u00a0nacional\u00a0en\u00a0el\u00a0que\u00a0se\u00a0identificaron\u00a0varios\u00a0factores\u00a0de\u00a0riesgo\u00a0para\u00a0la\u00a0infecci\u00f3n\u00a0reciente.\u00a0Entre\u00a0estos\u00a0factores\u00a0de\u00a0riesgo\u00a0encontraron\u00a0 los\u00a0siguientes:\u00a0ser\u00a0mujer,\u00a0el\u00a0estado\u00a0\u00a0\n 34civil\u00a0(las\u00a0personas\u00a0viudas\u00a0o\u00a0divorciadas\u00a0presentaban\u00a0un\u00a0mayor\u00a0r iesgo),\u00a0el\u00a0n\u00famero\u00a0de\u00a0parejas\u00a0en\u00a0el\u00a0\na\u00f1o\u00a0pasado\u00a0(las\u00a0personas\u00a0que\u00a0dura nte\u00a0el\u00a0a\u00f1o\u00a0pasado\u00a0tuvieron\u00a0dos\u00a0o\u00a0m\u00e1s\u00a0parejas\u00a0sexuales\u00a0ten\u00edan\u00a0\nm\u00e1s\u00a0riesgo\u00a0de\u00a0infecci\u00f3n\u00a0reciente)\u00a0y\u00a0la\u00a0regi\u00f3n\u00a0(vivir\u00a0en\u00a0la\u00a0regi \u00f3n\u00a0norte\u2010centro\u00a0se\u00a0asociaba\u00a0con\u00a0un\u00a0\nmayor\u00a0riesgo\u00a0de\u00a0infecci\u00f3n\u00a0reciente)\u00a0(103).\u00a0\u00a0\n\u00a0\n\u00a0\nTabla\u00a03\u00a0Prevalencias \u00a0de\u00a0infecci\u00f3n \u00a0reciente \u00a0\n*Porcentaje\u00a0entre\u00a0el\u00a0grupo\u00a0de\u00a0HSH ,\u00a0\u2020Porcentaje\u00a0entre\u00a0el\u00a0grupo\u00a0d e\u00a0heterosexuales\u00a0\n\u00a0\n\u00a0\n\u00a0\n\u00a0\u00a0\n\u00a0\n\u00a0\u00a0\u00a0\n\u00a0Lugar\u00a0 Periodo\u00a0%\u00a0\nInfecci\u00f3n\nReciente \u00a0Centros\u00a0 Poblaci\u00f3n\u00a0 T\u00e9cnica\u00a0Referencia \u00a0\nBangkok\u00a0 1996\u00a0 19\u00a0Centros\u00a0 de\u00a0 Salud\u00a0 para\u00a0\nUDVPs\u00a0UDVP\u00a0 BED\u2010CEIA\u00a0 Hu\u00a0DJ\u00a0 et\u00a0al.\u00a0\u00a0\n10\u00a0ciudades\u00a0\nEEUU\u00a01997\u20102001\u00a0 20\u00a0Cl\u00ednicas\u00a0de\u00a0VIH\u00a0y\u00a0Centros\u00a0de\u00a0cribado\u00a0y\u00a0consejo\u00a0Adultos\u00a0 Vironostika\u00a0 Schwarcz\u00a0S\u00a0 et\u00a0al.\u00a0\u00a0\nLos\u00a0\u00c1ngeles,\u00a0\nEEUU\u00a02002\u20102004\u00a0 16,2\u00a0Cl\u00ednicas\u00a0de\u00a0ITS\u00a0y\u00a0VIH\u00a0Hombres\u00a0con\u00a0s\u00edfilis\u00a0\nprimaria\u00a0Vironostika\u00a0Taylor\u00a0MM\u00a0 et\u00a0al.\u00a0\u00a0\nSeattle,\u00a0EEUU\u00a02002\u00a0\u2010\u00a02005\u00a0 51.9\u00a0 Cl\u00ednicas\u00a0de\u00a0ITS\u00a0y\u00a0VIH\u00a0 HSH\u00a0 Vironostika\u00a0 Thiede\u00a0H \u00a0et\u00a0al.\u00a0\u00a0\nS\u00e3o\u00a0Paulo,\u00a0Brasil\u00a0 2002\u20102004\u00a0 12\u00a0Centros\u00a0de\u00a0cribado\u00a0\u00a0 Adultos\u00a0 Vironostika\u00a0 Bassichetto\u00a0KC\u00a0 et\u00a0al.\u00a0\u00a0\nKenya\u00a0 2002\u20102003\u00a0 9,6\u00a0Hospital\u00a0y\u00a0centro\u00a0de\u00a0testaje\u00a0y\u00a0consejo\u00a0de\u00a0VIH\u00a0Adultos\u00a0 Vironostika\u00a0 Oyugi\u00a0JO\u00a0 et\u00a0al.\u00a0\u00a0\nUganda\u00a0 2005\u00a0 17\u00a0\u00a0\nEncuesta\u00a0poblacional\u00a0\n\u00a0Adultos\u00a0 BED\u2010CEIA\u00a0 Mermin\u00a0J\u00a0 et\u00a0al.\u00a0\u00a0\nReino\u00a0Unido\u00a0 1996\u00a0\u2010\u00a02005\u00a0 26,0\u00a0 Hospit ales\u00a0 Adultos\u00a0 Vironostika\u00a0 Fis her\u00a0M\u00a0 et\u00a0al.\u00a0\u00a0\nFrancia\u00a0 2003\u20102008\u00a0 47,6\u00a0Registro\u00a0de\u00a0nuevos\u00a0\ndiagn\u00f3sticos\u00a0de\u00a0VIH\u00a0HSH\u00a0 IDE\u2010V3\u00a0 Semaille\u00a0C\u00a0 et\u00a0al.\u00a0\u00a0\nPortugal,\u00a0Lisboa\u00a0 2004\u00a0 28,6\u00a0 Cl\u00ednica\u00a0 de\u00a0ITS\u00a0 Adultos\u00a0 Avidez\u00a0 Cortes \u00a0Martins\u00a0H\u00a0 et\u00a0al.\u00a0\u00a0\nBerl\u00edn,\u00a0Alemania\u00a0 2005\u20102007\u00a054,0*\u00a0\n16,0\u2020\u00a0Cl\u00ednicas\u00a0y\u00a0consultas\u00a0\nprivadas\u00a0de\u00a0VIH\u00a0Adultos\u00a0 BED\u2010CEIA\u00a0 Batzing\u2010Feigenbaum\u00a0J\u00a0et \u00a0al.\u00a0\nSan\u00a0Petersburgo,\u00a0Rusia\u00a02005\u00a0\u2010\u00a02008\u00a0 19,5\u00a0Centros\u00a0de\u00a0Salud\u00a0para\u00a0UDVPs\u00a0UDVP\u00a0 BED\u2010CEIA\u00a0 Niccolai\u00a0LM\u00a0 et\u00a0al.\u00a0\u00a0\u00a0\n -  354.4.\u00a0Resistencias \u00a0transmitidas \u00a0en\u00a0pacientes\u00a0 identificados \u00a0con\u00a0\ninfecci\u00f3n\u00a0 reciente \u00a0\u00a0\u00a0\nInicialmente\u00a0los\u00a0CDC\u00a0no\u00a0recomendaron\u00a0el\u00a0uso\u00a0de\u00a0los\u00a0TRIs\u00a0para\u00a0el \u00a0diagn\u00f3stico\u00a0individual.\u00a0A\u00fan\u00a0\nas\u00ed,\u00a0algunos\u00a0autores\u00a0han\u00a0propuesto\u00a0el\u00a0uso\u00a0de\u00a0los\u00a0TRIs\u00a0para\u00a0iden tificar\u00a0infecciones\u00a0recientes\u00a0a\u00a0nivel\u00a0\nindividual,\u00a0 ya\u00a0 sea\u00a0 para\u00a0 el\u00a0 manejo\u00a0 cl\u00ednico\u00a0 del\u00a0 paciente,\u00a0 como\u00a0 her r a m i e n t a \u00a0e n \u00a0e l \u00a0e s t u d i o \u00a0d e \u00a0\ncontactos,\u00a0 o\u00a0 para\u00a0 estimar\u00a0 la\u00a0 prevalencia\u00a0 de\u00a0 resistencias\u00a0 transm i t i d a s \u00a0e n t r e \u00a0l o s \u00a0p a c i e n t e s \u00a0\nidentificados\u00a0como\u00a0recientes\u00a0por\u00a0el\u00a0test\u00a0(108,\u00a070).\u00a0\u00a0\nLas\u00a0personas\u00a0reci\u00e9n\u00a0infectadas\u00a0son\u00a0una\u00a0fuente\u00a0importante\u00a0de\u00a0tra nsmisores\u00a0de\u00a0virus,\u00a0de\u00a0manera\u00a0\nque\u00a0la\u00a0prevalencia\u00a0de\u00a0resistencias\u00a0transmitidas\u00a0en\u00a0estos\u00a0indivi duos\u00a0es\u00a0un\u00a0indicador\u00a0importante\u00a0en\u00a0\nla\u00a0 vigilancia\u00a0 de\u00a0 la\u00a0 epidemia.\u00a0 Hay\u00a0 que\u00a0 tener\u00a0 presente\u00a0 que\u00a0 la\u00a0 pre valencia\u00a0 de\u00a0 resistencias\u00a0\ntransmitidas\u00a0 en\u00a0 pacientes\u00a0 con\u00a0 infecci\u00f3n\u00a0 reciente\u00a0 normalmente\u00a0 es \u00a0m \u00e1 s \u00a0a l t a \u00a0q u e \u00a0e n \u00a0a q u e l l o s \u00a0\npacientes\u00a0 con\u00a0 infecci\u00f3n\u00a0 cr\u00f3nica\u00a0 (109).\u00a0 En\u00a0 los\u00a0 pacientes\u00a0 infecta dos\u00a0 con\u00a0 cepas\u00a0 resistentes,\u00a0 en\u00a0\nausencia\u00a0de\u00a0presi\u00f3n\u00a0farmacol\u00f3gica,\u00a0con\u00a0el\u00a0paso\u00a0del\u00a0tiempo,\u00a0las\u00a0 cepas\u00a0minoritarias\u00a0 wild\u00a0type,\u00a0\nllegar\u00e1n\u00a0a\u00a0ser\u00a0la\u00a0cuasiespecie\u00a0mayoritaria,\u00a0ya\u00a0que\u00a0tienen\u00a0un\u00a0ma yor\u00a0 fitness\u00a0que\u00a0las\u00a0cepas\u00a0con\u00a0\nresistencias\u00a0(52).\u00a0\u00a0\nLas\u00a0 prevalencias\u00a0 de\u00a0 resistencias\u00a0 transmitidas\u00a0 en\u00a0 los\u00a0 pacientes\u00a0 con\u00a0 infecci\u00f3n\u00a0 reciente\u00a0\n(identificados\u00a0mediante\u00a0TRIs)\u00a0os cilan\u00a0entre\u00a0el\u00a021,0%,\u00a0en\u00a0un\u00a0est udio\u00a0realizado\u00a0en\u00a0Honduras\u00a0entre\u00a0\nlos\u00a0a\u00f1os\u00a02004\u00a0y\u00a02007,\u00a0hasta\u00a0el\u00a06,25%,\u00a0en\u00a0un\u00a0estudio\u00a0realizado\u00a0e n\u00a0una\u00a0regi\u00f3n\u00a0de\u00a0China\u00a0durante\u00a0el\u00a0\na\u00f1o\u00a02006\u00a0(Tabla\u00a04).\u00a0\u00a0\nLa\u00a0presencia\u00a0de\u00a0niveles\u00a0elevados\u00a0de\u00a0cepas\u00a0VIH\u20101\u00a0con\u00a0resistencia s\u00a0transmitidas\u00a0en\u00a0una\u00a0poblaci\u00f3n\u00a0\nes\u00a0un\u00a0indicador\u00a0sensible\u00a0del\u00a0\u00e9xito\u00a0de\u00a0las\u00a0terapias\u00a0antirretrovirales.\u00a0Desde\u00a0la\u00a0perspectiva\u00a0de\u00a0Salud\u00a0\nP\u00fablica,\u00a0nos\u00a0indica\u00a0la\u00a0presencia\u00a0de\u00a0pacientes\u00a0que\u00a0reciben\u00a0tratamiento\u00a0antirretroviral,\u00a0y\u00a0que\u00a0no\u00a0toman\u00a0 medidas\u00a0 preventivas\u00a0 efecti vas\u00a0 para\u00a0 evitar\u00a0 la\u00a0 transmisi\u00f3n\u00a0 del\u00a0 virus.\u00a0 Por\u00a0 lo\u00a0 tanto,\u00a0 la\u00a0\nvigilancia\u00a0 poblacional\u00a0 de\u00a0 las\u00a0 res istencias\u00a0 transmitidas\u00a0 en\u00a0 reci \u00e9n\u00a0 infectados\u00a0 es\u00a0 un\u00a0 elemento\u00a0\nesencial\u00a0en\u00a0la\u00a0evaluaci\u00f3n\u00a0global \u00a0de\u00a0las\u00a0resistencias\u00a0a\u00a0los\u00a0anti rretrovirales\u00a0(59).\u00a0\n\u00a0\u00a0\n 36\u00a0\nTabla\u00a04.\u00a0Prevalencias \u00a0de\u00a0resistencias \u00a0transmitidas \u00a0en\u00a0pacientes \u00a0con\u00a0infecci\u00f3n \u00a0reciente \u00a0por\u00a0VIH\u00a0\u00a0\n*Pacientes\u00a0identificados\u00a0con\u00a0inf ecci\u00f3n\u00a0aguda\u00a0(Anticuerpos\u00a0negat ivos\u00a0+\u00a0ARN\u00a0positivo)\u00a0e\u00a0infecci\u00f3n\u00a0reciente\u00a0(\u00faltimo\u00a0VIH\u00a0negativo, \u00a0\nVironostika\u00a0o\u00a0Avidez).\u00a0IR:\u00a0Infe cci\u00f3n\u00a0Reciente,\u00a0RT:\u00a0Resistencias \u00a0Transmitidas\u2010 \u00a0\n\u00a0\n\u00a0\n\u00a0\n\u00a0\n\u00a0Lugar\u00a0 Periodo\u00a0Total\u00a0\u00a0\u00a0\nVIH+\u00a0%IR\u00a0%\u00a0RT\u00a0\u2010\u00a0\nRECIENTES \u00a0%RT\u00a0\u2010\u00a0\nCR\u00d3NICAS \u00a0TRI\u00a0 Referencia \u00a0\nHonduras\u00a0 2004\u00a0\u2010\u00a02007\u00a0 200\u00a0 12,0\u00a0 21,0\u00a0 5,0\u00a0 BED\u2010CEIA\u00a0 Murillo\u00a0W\u00a0 et\u00a0al.\u00a0\u00a0\nNorht\u00a0Carolina\u00a0\n(EEUU)\u00a01998\u00a0\u2010\u00a02007\u00a0 253*\u00a0 _\u00a0 17,8\u00a0 _\u00a0Vironostika\u00a0y\u00a0\nAvidez\u00a0Hurt\u00a0CB\u00a0 et\u00a0al.\u00a0\u00a0\nDehong\u00a0(China)\u00a0 2006\u00a0 1048\u00a0 6,1\u00a0 6,25\u00a0 _\u00a0 BED\u2010CEIA\u00a0 Wang\u00a0MJ\u00a0 et\u00a0al.\u00a0\u00a0\nCanad\u00e1\u00a0\u00a0 2000\u00a0\u2010\u00a02001\u00a0 715\u00a0 30,9\u00a0 12,2\u00a0 6,1\u00a0 Vironostika\u00a0 Jayaraman\u00a0GC\u00a0 et\u00a0al.\u00a0\u00a0\u00a0\n -  37\u00a0\nJUSTIFICACI\u00d3N\u00a0\n\u00a0\n\u00a0\nLa\u00a0 infecci\u00f3n\u00a0 por\u00a0 VIH\u00a0 sigue\u00a0 siendo\u00a0 un\u00a0 problema\u00a0 importante\u00a0 de\u00a0 Sal ud\u00a0 P\u00fablica\u00a0 en\u00a0 nuestro\u00a0\nentorno.\u00a0Para\u00a0el\u00a0a\u00f1o\u00a02011,\u00a0en\u00a0Catalu\u00f1a,\u00a0se\u00a0estim\u00f3\u00a0que,\u00a0aproximadamente,\u00a0el\u00a0n\u00famero\u00a0total\u00a0de\u00a0\npersonas\u00a0vivas\u00a0con\u00a0infecci\u00f3n\u00a0por\u00a0VIH\u00a0era\u00a0de\u00a033.000.\u00a0La\u00a0estimaci \u00f3n\u00a0de\u00a0la\u00a0incidencia\u00a0de\u00a0VIH\u00a0en\u00a0\npoblaci\u00f3n\u00a0general\u00a0en\u00a0Catalu\u00f1a,\u00a0calculada\u00a0utilizando\u00a0t\u00e9cnicas\u00a0de\u00a0modelizaci\u00f3n\u00a0matem\u00e1tica,\u00a0mostr\u00f3\u00a0\nuna\u00a0tasa\u00a0de\u00a0incidencia\u00a0de\u00a00,2\u00a0nu evos\u00a0casos\u00a0por\u00a0cada\u00a01.000\u00a0personas\u00a0en\u00a0el\u00a0a\u00f1o\u00a02011.\u00a0Por\u00a0tanto,\u00a0es\u00a0\nimportante\u00a0seguir\u00a0trabajando\u00a0en\u00a0 las\u00a0pol\u00edticas\u00a0de\u00a0prevenci\u00f3n\u00a0de\u00a0 la\u00a0infecci\u00f3n\u00a0por\u00a0VIH\u00a0para\u00a0evitar\u00a0\nque\u00a0se\u00a0produzcan\u00a0nuevas\u00a0infecciones.\u00a0Para\u00a0detener\u00a0el\u00a0avance\u00a0de\u00a0 la\u00a0epidemia\u00a0es\u00a0esencial\u00a0conocer\u00a0\nen\u00a0qu\u00e9\u00a0poblaciones\u00a0se\u00a0est\u00e1\u00a0transmitiendo\u00a0la\u00a0infecci\u00f3n,\u00a0y\u00a0as\u00ed\u00a0po der\u00a0dise\u00f1ar\u00a0acciones\u00a0preventivas\u00a0\nm\u00e1s\u00a0efectivas.\u00a0\nEn\u00a0los\u00a0inicios\u00a0de\u00a0la\u00a0epidemia,\u00a0conocer\u00a0la\u00a0incidencia\u00a0de\u00a0casos\u00a0d e\u00a0SIDA\u00a0permiti\u00f3,\u00a0a\u00a0trav\u00e9s\u00a0de\u00a0los\u00a0\nregistros\u00a0de\u00a0SIDA,\u00a0la\u00a0descripci\u00f3n\u00a0epidemiol\u00f3gica\u00a0de\u00a0la\u00a0enfermedad\u00a0y\u00a0de\u00a0las\u00a0personas\u00a0infectadas\u00a0en\u00a0los\u00a0 pa\u00edses\u00a0 desarrollados.\u00a0 En\u00a0 ausencia\u00a0 de\u00a0 tratamientos\u00a0 efectivos , \u00a0e l \u00a0p e r i o d o \u00a0m e d i o \u00a0e n t r e \u00a0e l \u00a0\nmomento\u00a0de\u00a0la\u00a0infecci\u00f3n\u00a0por\u00a0VIH\u00a0y\u00a0el\u00a0diagn\u00f3stico\u00a0de\u00a0SIDA\u00a0era\u00a0ap roximadamente\u00a0de\u00a0diez\u00a0a\u00f1os,\u00a0lo\u00a0\nque\u00a0hac\u00eda\u00a0posible\u00a0estimar\u00a0la\u00a0incidencia\u00a0de\u00a0VIH\u00a0extrapol\u00e1ndola\u00a0d e\u00a0la\u00a0incidencia\u00a0de\u00a0SIDA,\u00a0y\u00a0as\u00ed\u00a0\ndescribir\u00a0la\u00a0epidemiolog\u00eda\u00a0de\u00a0la \u00a0enfermedad\u00a0y\u00a0de\u00a0los\u00a0infectados.\u00a0La\u00a0introducci\u00f3n\u00a0del\u00a0TARGA\u00a0en\u00a0\n1996\u00a0modific\u00f3\u00a0la\u00a0historia\u00a0natural\u00a0de\u00a0la\u00a0infecci\u00f3n\u00a0por\u00a0VIH,\u00a0aumentando\u00a0tanto\u00a0el\u00a0tiempo\u00a0desde\u00a0el\u00a0\nmomento\u00a0de\u00a0la\u00a0infecci\u00f3n\u00a0hasta\u00a0el\u00a0diagn\u00f3stico\u00a0de\u00a0SIDA,\u00a0as\u00ed\u00a0como\u00a0 reduciendo\u00a0dr\u00e1sticamente\u00a0la\u00a0\nincidencia\u00a0de\u00a0las\u00a0comorbilidades \u00a0y\u00a0la\u00a0mortalidad\u00a0asociada\u00a0al\u00a0VI H.\u00a0El\u00a0impacto\u00a0de\u00a0los\u00a0tratamientos\u00a0\nevidenci\u00f3\u00a0las\u00a0limitaciones\u00a0de\u00a0los\u00a0sistemas\u00a0de\u00a0vigilancia\u00a0basado s\u00a0en\u00a0los\u00a0casos\u00a0de\u00a0sida\u00a0y\u00a0favoreci\u00f3\u00a0las\u00a0\nrecomendaciones\u00a0orientadas\u00a0a\u00a0incorporar\u00a0la\u00a0notificaci\u00f3n\u00a0de\u00a0nuev os\u00a0diagn\u00f3sticos\u00a0de\u00a0VIH\u00a0en\u00a0los\u00a0\nsistemas\u00a0de\u00a0vigilancia\u00a0de\u00a0la\u00a0epidemia\u00a0en\u00a0los\u00a0pa\u00edses\u00a0con\u00a0acceso\u00a0 universal\u00a0al\u00a0tratamiento.\u00a0Siguiendo\u00a0\nestas\u00a0recomendaciones,\u00a0en\u00a0Catalu\u00f1a,\u00a0la\u00a0notificaci\u00f3n\u00a0de\u00a0casos\u00a0de \u00a0VIH\u00a0se\u00a0introdujo\u00a0en\u00a0el\u00a0Sistema\u00a0de\u00a0\nVigilancia\u00a0 de\u00a0 manera\u00a0 voluntaria\u00a0 y\u00a0 an\u00f3nima\u00a0 en\u00a0 el\u00a0 a\u00f1o\u00a0 2001,\u00a0 y\u00a0 a\u00a0 p artir\u00a0 del\u00a0 2010\u00a0 de\u00a0 manera\u00a0\nobligatoria.\u00a0\u00a0\nEn\u00a0Europa,\u00a0en\u00a0el\u00a0a\u00f1o\u00a02011\u00a0se\u00a0notificaron\u00a053.974\u00a0diagn\u00f3sticos\u00a0de \u00a0VIH,\u00a0lo\u00a0que\u00a0supone\u00a0una\u00a0tasa\u00a0de\u00a0\nnuevos\u00a0diagn\u00f3sticos\u00a0de\u00a0VIH\u00a0de\u00a07,6\u00a0casos\u00a0por\u00a0cada\u00a0100.000\u00a0habitantes.\u00a0Entre\u00a0el\u00a0total\u00a0de\u00a0nuevos\u00a0\ndiagn\u00f3sticos\u00a0de\u00a0VIH\u00a0podemos\u00a0encontrar\u00a0pacientes\u00a0que\u00a0se\u00a0infectar on\u00a0mucho\u00a0tiempo\u00a0atr\u00e1s\u00a0y\u00a0han\u00a0\nsido\u00a0diagnosticados\u00a0tard\u00edamente\u00a0 (cuando\u00a0la\u00a0cifra\u00a0de\u00a0linfocitos\u00a0 CD4+\u00a0m\u00e1s\u00a0cercana\u00a0al\u00a0momento\u00a0del\u00a0\ndiagn\u00f3stico\u00a0es\u00a0inferior\u00a0a\u00a0350\u00a0c\u00e9lulas/\u03bcl\u00a0y/o\u00a0presenta\u00a0una\u00a0enfer medad\u00a0definitoria\u00a0de\u00a0SIDA).\u00a0Por\u00a0lo\u00a0\u00a0\n 38tanto,\u00a0la\u00a0tasa\u00a0de\u00a0nuevos\u00a0diagn\u00f3sticos\u00a0no\u00a0refleja\u00a0de\u00a0manera\u00a0exac ta\u00a0la\u00a0magnitud\u00a0ni\u00a0las\u00a0caracter\u00edsticas\u00a0\nde\u00a0las\u00a0infecciones\u00a0que\u00a0se\u00a0est\u00e1n\u00a0produciendo\u00a0en\u00a0el\u00a0momento\u00a0actua l.\u00a0\nEl\u00a0hecho\u00a0de\u00a0identificar\u00a0entre\u00a0los\u00a0nuevos\u00a0diagn\u00f3sticos\u00a0de\u00a0VIH\u00a0qu \u00e9\u00a0infecciones\u00a0se\u00a0han\u00a0producido\u00a0\nrecientemente\u00a0s\u00ed\u00a0que\u00a0proporcionar\u00eda\u00a0una\u00a0descripci\u00f3n\u00a0m\u00e1s\u00a0precisa\u00a0de\u00a0los\u00a0patrones\u00a0actuales\u00a0de\u00a0la\u00a0\nepidemia,\u00a0y\u00a0con\u00a0esta\u00a0informaci\u00f3n\u00a0 se\u00a0podr\u00edan\u00a0dise\u00f1ar\u00a0intervencio nes\u00a0preventivas\u00a0adecuadas\u00a0para\u00a0\nevitar\u00a0nuevas\u00a0infecciones\u00a0de\u00a0VIH.\u00a0 Adem\u00e1s,\u00a0en\u00a0el\u00a0caso\u00a0de\u00a0los\u00a0pac ientes\u00a0infectados\u00a0por\u00a0el\u00a0VIH\u00a0de\u00a0\norigen\u00a0inmigrante,\u00a0si\u00a0se\u00a0conoce\u00a0 la\u00a0fecha\u00a0de\u00a0llegada\u00a0al\u00a0pa\u00eds,\u00a0la \u00a0aplicaci\u00f3n\u00a0de\u00a0estos\u00a0tests\u00a0puede\u00a0\nayudar\u00a0a\u00a0conocer\u00a0si\u00a0adquirieron\u00a0la\u00a0infecci\u00f3n\u00a0localmente,\u00a0o,\u00a0por \u00a0el\u00a0contrario,\u00a0la\u00a0adquirieron\u00a0cuando\u00a0\ntodav\u00eda\u00a0se\u00a0encontraban\u00a0en\u00a0su\u00a0pa\u00eds\u00a0de\u00a0origen.\u00a0\u00a0\nMediante\u00a0 el\u00a0 uso\u00a0 de\u00a0 estos\u00a0 tests\u00a0 serol\u00f3gicos,\u00a0 adem\u00e1s\u00a0 de\u00a0 describir\u00a0 las\u00a0 caracter\u00edsticas\u00a0\nepidemiol\u00f3gicas\u00a0y\u00a0conocer\u00a0la\u00a0magnitud\u00a0de\u00a0las\u00a0infecciones\u00a0recien tes\u00a0por\u00a0VIH,\u00a0es\u00a0posible\u00a0conocer\u00a0la\u00a0\nprevalencia\u00a0de\u00a0resistencias\u00a0transmitidas\u00a0en\u00a0los\u00a0pacientes\u00a0ident ificados\u00a0como\u00a0reci\u00e9n\u00a0infectados.\u00a0\nEsta\u00a0informaci\u00f3n\u00a0es\u00a0muy\u00a0\u00fatil,\u00a0tanto\u00a0desde\u00a0la\u00a0perspectiva\u00a0de\u00a0Sal ud\u00a0P\u00fablica\u00a0como\u00a0la\u00a0cl\u00ednica,\u00a0ya\u00a0que\u00a0la\u00a0\ntransmisi\u00f3n\u00a0 de\u00a0 virus\u00a0 resistentes\u00a0 puede\u00a0 tener\u00a0 un\u00a0 impacto\u00a0 negativo\u00a0 en\u00a0 la\u00a0 respuesta\u00a0 a\u00a0 los\u00a0tratamientos\u00a0antirretrovirales.\u00a0Adem\u00e1s,\u00a0disponer\u00a0de\u00a0esta\u00a0inform aci\u00f3n\u00a0en\u00a0los\u00a0pacientes\u00a0reci\u00e9n\u00a0\ninfectados,\u00a0respecto\u00a0a\u00a0tenerla\u00a0en\u00a0los\u00a0nuevos\u00a0diagn\u00f3sticos,\u00a0pres enta\u00a0una\u00a0ventaja\u00a0importante,\u00a0ya\u00a0que\u00a0\nen\u00a0el\u00a0conjunto\u00a0de\u00a0nuevos\u00a0diagn\u00f3sticos\u00a0la\u00a0prevalencia\u00a0de\u00a0resiste ncias\u00a0transmitidas\u00a0no\u00a0refleja\u00a0los\u00a0\npatrones\u00a0actuales\u00a0de\u00a0transmisi\u00f3n\u00a0 de\u00a0resistencias.\u00a0Por\u00a0lo\u00a0tanto, \u00a0desde\u00a0el\u00a0punto\u00a0de\u00a0vista\u00a0de\u00a0Salud\u00a0\nP\u00fablica\u00a0es\u00a0importante\u00a0poder\u00a0monitorizar\u00a0este\u00a0indicador\u00a0en\u00a0la\u00a0poblaci\u00f3n\u00a0de\u00a0reci\u00e9n\u00a0infectados\u00a0por\u00a0\nVIH.\u00a0\nFinalmente,\u00a0 mediante\u00a0 la\u00a0 aplicaci\u00f3n\u00a0 de\u00a0 los\u00a0 tests\u00a0 serol\u00f3gicos\u00a0 par a\u00a0 identificar\u00a0 infecciones\u00a0\nrecientes\u00a0es\u00a0posible\u00a0estimar\u00a0la\u00a0incidencia\u00a0de\u00a0VIH\u00a0en\u00a0una\u00a0poblac i\u00f3n.\u00a0Hasta\u00a0el\u00a0momento,\u00a0el\u00a0m\u00e9todo\u00a0\nconsiderado\u00a0como\u00a0gold\u00a0est\u00e1ndar\u00a0p ara\u00a0estimar\u00a0incidencia\u00a0ha\u00a0sido\u00a0 a\u00a0trav\u00e9s\u00a0del\u00a0seguimiento\u00a0de\u00a0\ncohortes\u00a0de\u00a0personas\u00a0VIH\u00a0negativas\u00a0que\u00a0se\u00a0realizan\u00a0de\u00a0manera\u00a0pe ri\u00f3dica\u00a0el\u00a0test\u00a0de\u00a0cribado\u00a0del\u00a0\nVIH.\u00a0Este\u00a0m\u00e9todo\u00a0presenta\u00a0ciertas\u00a0dificultades\u00a0log\u00edsticas,\u00a0y,\u00a0adem\u00e1s,\u00a0estas\u00a0cohortes\u00a0suelen\u00a0no\u00a0ser\u00a0\nrepresentativas\u00a0de\u00a0una\u00a0gran\u00a0poblaci\u00f3n.\u00a0De\u00a0modo\u00a0que\u00a0los\u00a0tests\u00a0se rol\u00f3gicos\u00a0aparecen\u00a0como\u00a0una\u00a0\nalternativa\u00a0 menos\u00a0 costosa\u00a0 para\u00a0 poder\u00a0 conocer\u00a0 el\u00a0 n\u00famero\u00a0 de\u00a0 nueva s\u00a0 infecciones\u00a0 producidas\u00a0\ndurante\u00a0un\u00a0periodo\u00a0de\u00a0tiempo,\u00a0en\u00a0el\u00a0contexto\u00a0de\u00a0un\u00a0estudio\u00a0transversal.\u00a0Por\u00a0otro\u00a0lado,\u00a0si\u00a0se\u00a0aplican\u00a0dentro\u00a0de\u00a0un\u00a0sistema\u00a0de\u00a0vigilancia\u00a0de\u00a0nuevos\u00a0diagn\u00f3stic os\u00a0de\u00a0VIH,\u00a0ser\u00eda\u00a0posible\u00a0estimar\u00a0la\u00a0\nincidencia\u00a0de\u00a0VIH\u00a0poblacional.\u00a0\u00a0\u00a0\nPor\u00a0tanto,\u00a0la\u00a0aplicaci\u00f3n\u00a0de\u00a0los\u00a0t ests\u00a0serol\u00f3gicos\u00a0para\u00a0identifi car\u00a0infecciones\u00a0recientes\u00a0por\u00a0VIH\u00a0\nproporcionar\u00e1\u00a0informaci\u00f3n\u00a0precisa\u00a0 sobre\u00a0c\u00f3mo\u00a0se\u00a0est\u00e1\u00a0transmitie ndo\u00a0la\u00a0infecci\u00f3n\u00a0por\u00a0VIH\u00a0en\u00a0el\u00a0\nmomento\u00a0actual,\u00a0cu\u00e1l\u00a0es\u00a0la\u00a0magnitud\u00a0de\u00a0la\u00a0transmisi\u00f3n\u00a0de\u00a0cepas\u00a0 de\u00a0VIH\u00a0resistentes\u00a0y\u00a0cual\u00a0es\u00a0la\u00a0\ntasa\u00a0de\u00a0incidencia\u00a0de\u00a0VIH\u00a0en\u00a0nuestro\u00a0medio.\u00a0\u00a0\u00a0\u00a0\u00a0\n -  39\u00a0\n\u00a0\n\u00a0\n\u00a0\n\u00a0\u00a0\n\u00a0\n\u00a0\u00a0\n\u00a0\n\u00a0\n\u00a0\n\u00a0\u00a0\n\u00a0\nOBJETIVOS\u00a0\u00a0\n\u00a0\n\u00a0\u00a0\u00a0\u00a0\n 40\u00a0\n\u00a0\u00a0\u00a0\u00a0\u00a0\n\u00a0\n\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\n\u00a0\n\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\n\u00a0OBJETIVOS\u00a0\n -  41Objetivos \u00a0generales\u00a0 y\u00a0espec\u00edficos \u00a0\n\u00a0\nObjetivo \u00a0general\u00a01:\u00a0Estimar\u00a0la\u00a0viabilidad\u00a0y\u00a0aplicabi lidad\u00a0de\u00a0la\u00a0introducci\u00f3n\u00a0de\u00a0los \u00a0\ntests\u00a0serol\u00f3gicos\u00a0para\u00a0identific ar\u00a0infecciones\u00a0recientes\u00a0por\u00a0VI H\u20101\u00a0en\u00a0nuestro\u00a0medio\u00a0\nObjetivos \u00a0espec\u00edficos \u00a0\n1.1)\u00a0 Estimar\u00a0la\u00a0prevalencia\u00a0de\u00a0infecci\u00f3n\u00a0reciente\u00a0entre\u00a0una\u00a0mue stra\u00a0de\u00a0nuevos\u00a0diagn\u00f3sticos\u00a0de\u00a0\nVIH\u00a0\n1.2)\u00a0 Describir\u00a0las\u00a0caracter\u00edstica s\u00a0epidemiol\u00f3gicas\u00a0de\u00a0los\u00a0pacie ntes\u00a0con\u00a0infecci\u00f3n\u00a0reciente\u00a0\n1.3)\u00a0 Identificar\u00a0los\u00a0determinant es\u00a0asociados\u00a0a\u00a0la\u00a0infecci\u00f3n\u00a0reciente\u00a0por\u00a0VIH\u00a0\n\u00a0\nObjetivo \u00a0general\u00a02:\u00a0Estudiar\u00a0las\u00a0resistencias\u00a0transmitidas\u00a0a\u00a0los\u00a0antirretrovirales \u00a0y\u00a0la\u00a0\ndistribuci\u00f3n\u00a0de\u00a0subtipos\u00a0de\u00a0VIH\u2010 1\u00a0en\u00a0los\u00a0pacientes\u00a0identificado s\u00a0con\u00a0infecci\u00f3n\u00a0reciente\u00a0\nObjetivos \u00a0espec\u00edficos \u00a0\n2.1)\u00a0 Estimar\u00a0la\u00a0prevalencia\u00a0de\u00a0r esistencias\u00a0transmitidas\u00a0y\u00a0de\u00a0subtipos\u00a0no\u00a0B\u00a0entre\u00a0los\u00a0pacientes\u00a0\nreci\u00e9n\u00a0infectados\u00a0\n2.2)\u00a0 Identificar\u00a0factores\u00a0asociados\u00a0a\u00a0las\u00a0resistencias\u00a0transmit idas\u00a0y\u00a0a\u00a0la\u00a0infecci\u00f3n\u00a0por\u00a0subtipo\u00a0\nno\u00a0B\u00a0\n \nObjetivo \u00a0general\u00a03: Evaluar\u00a0los\u00a0tests\u00a0serol\u00f3gicos\u00a0para\u00a0detectar\u00a0infecciones\u00a0recientes\u00a0\nutilizados\u00a0en\u00a0nuestro\u00a0medio:\u00a0Vironostika\u2010LS\u00a0y\u00a0BED\u2010CEIA.\u00a0\nObjetivos \u00a0espec\u00edficos \u00a0\n3.1)\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0Comparar\u00a0los\u00a0tests\u00a0mediante\u00a0un\u00a0estudio\u00a0de\u00a0concordanc ia.\u00a0\n3.2)\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0Estimar\u00a0la\u00a0sensibilidad\u00a0y \u00a0especificidad\u00a0de\u00a0los\u00a0tests .\u00a0\n \n\u00a0\n\u00a0\n\u00a0\n\u00a0\n\u00a0\n\u00a0\u00a0\n\u00a0OBJETIVOS\u00a0\n 42Trabajos \u00a0que\u00a0conforman \u00a0la\u00a0tesis,\u00a0y\u00a0relaci\u00f3n \u00a0de\u00a0objetivos \u00a0a\u00a0los\u00a0que \u00a0dan\u00a0respuesta \u00a0\n \n        \n  Objetivo \u00a0 \u00a0\u00a0\n1.1\u00a0\n1.2\u00a0Art\u00edculo\u00a0I: \u00a0\nRecently\u00a0Acquired\u00a0HI V\u00a0Infection\u00a0in\u00a0Spain\u00a0\n(2003\u20102005).\u00a0Introduction\u00a0of\u00a0the\u00a0Serological\u00a0\nTesting\u00a0Algorithm\u00a0for\u00a0Recent\u00a0HIV\u00a0\nSeroconversion\u00a0\n1.3\u00a0\u00a0\n\u00a0Art\u00edculo\u00a0IV: \u00a0\nIdentification\u00a0o f\u00a0recent\u00a0HIV\u20101\u00a0\ninfection\u00a0among\u00a0newly\u00a0diagnosed\u00a0\ncases\u00a0in\u00a0Catalonia,\u00a0Spain\u00a0(2006\u20102008) \u00a0\u00a0\n\u00a0\n\u00a0\n\u00a0\u00a0 \u00a0\n2.1\u00a0 \u00a0\n2.2\u00a0Art\u00edculo\u00a0II: \u00a0\nPrevalence\u00a0of\u00a0Transmitted\u00a0HIV\u20101\u00a0Drug\u00a0\nResistance\u00a0and\u00a0Distribution\u00a0of\u00a0HIV\u20101\u00a0\nSubtypes\u00a0Among\u00a0Patients\u00a0With\u00a0Recent\u00a0\nInfection\u00a0in\u00a0Catalonia\u00a0(Spain)\u00a0Between\u00a02003\u00a0\nand\u00a02005\u00a0\u00a0\n\u00a0 \u00a0\u00a0\n3.1\u00a0 \u00a0\n3.2\u00a0Art\u00edculo\u00a0III: \u00a0\nComparison\u00a0of\u00a0Two\u00a0Serological\u00a0Tests\u00a0for\u00a0the\u00a0\nIdentification\u00a0of\u00a0Re cent\u00a0HIV\u00a0Infection:\u00a0\nVironostika\u00a0HIV\u20101\u00a0Microelisa\u00a0and\u00a0BED\u2010CEIA\u00a0\nCapture\u00a0Enzyme\u00a0Immunoassay\u00a0\u00a0\n\u00a0 \u00a0\u00a0\u00a0\n -  43\u00a0\n\u00a0\n\u00a0\n\u00a0\n\u00a0\u00a0\n\u00a0\n\u00a0\u00a0\n\u00a0\n\u00a0\n\u00a0\n\u00a0\u00a0\n\u00a0\nM\u00c9TODOS \u00a0Y\u00a0RESULTADOS \u00a0\n\u00a0M\u00c9TODOS\u00a0Y\u00a0RESULTADOS\u00a0\n 44A\u00a0continuaci\u00f3n\u00a0se\u00a0presentan\u00a0los\u00a0c uatro\u00a0trabajos\u00a0que\u00a0conforman\u00a0esta\u00a0tesis:\u00a0\nART\u00cdCULO \u00a0I:\u00a0 Recently\u00a0 Acquired\u00a0 HIV\u00a0 Infection\u00a0 in\u00a0 Spain\u00a0 (2003\u20102005).\u00a0 Introdu ction\u00a0 of\u00a0 the\u00a0\nSerological\u00a0Testing\u00a0Algorithm\u00a0for\u00a0Recent\u00a0HIV\u00a0Seroconversion\u00a0\nART\u00cdCULO \u00a0II:\u00a0Prevalence\u00a0of\u00a0Transmitted\u00a0HIV\u20101\u00a0Drug\u00a0Resistance\u00a0and\u00a0Distribution\u00a0of\u00a0HIV\u20101\u00a0\nSubtypes\u00a0Among\u00a0Patients\u00a0With\u00a0Recent\u00a0Infection\u00a0in\u00a0Catalonia\u00a0(Spa in)\u00a0Between\u00a02003\u00a0and\u00a02005\u00a0\nART\u00cdCULO \u00a0III:\u00a0 Comparison\u00a0 of\u00a0 Two\u00a0 Serological\u00a0 T ests\u00a0 for\u00a0 the\u00a0 Identification\u00a0 of \u00a0 Recent\u00a0 HIV\u00a0\nInfection:\u00a0Vironostika\u00a0HIV\u20101\u00a0Microelisa\u00a0and\u00a0BED\u2010CEIA\u00a0Capture\u00a0En zyme\u00a0Immunoassay\u00a0\nART\u00cdCULO \u00a0IV:\u00a0 Identification\u00a0 of\u00a0 recent\u00a0 HIV\u20101\u00a0 infection\u00a0 among\u00a0 newly\u00a0 diagnosed \u00a0c a s e s \u00a0i n \u00a0\nCatalonia,\u00a0Spain\u00a0(2006\u20102008)\u00a0\n\u00a0\n\u00a0\n\u00a0M\u00c9TODOS\u00a0Y\u00a0RESULTADOS\u00a0\n -  45ART\u00cdCULO \u00a0I\u00a0\n\u00a0\n\u00a0\n\u00a0\n\u00a0\u00a0\n\u00a0\nRReecceennttllyy\u00a0\u00a0AAccqquuiirreedd\u00a0\u00a0HHIIVV\u00a0\u00a0IInnffeeccttiioonn\u00a0\u00a0iinn\u00a0\u00a0SSppaaiinn\u00a0\u00a0((22000033\u2010\u201022000055))..\u00a0\u00a0IInnttrroodduuccttiioonn\u00a0\u00a0\nooff\u00a0\u00a0tthhee\u00a0\u00a0SSeerroollooggiiccaall\u00a0\u00a0TTeessttiinngg\u00a0\u00a0AAllggoorriitthhmm\u00a0\u00a0ffoorr\u00a0\u00a0RReecceenntt\u00a0\u00a0HHIIVV\u00a0\u00a0SSeerrooccoonnvveerrssiioonn\u00a0\n\u00a0\nAnabel\u00a0Romero,\u00a0Victoria\u00a0Gonz\u00e1lez,,\u00a0Meritxell\u00a0Granell, \u00a0Lurdes\u00a0Matas\u00a0,\u00a0Anna\u00a0Esteve, \u00a0\u00a0\nElisa\u00a0Martr\u00f3,\u00a0Isabel\u00a0Rodrigo, \u00a0Tom\u00e0s\u00a0Pumarola, \u00a0Jos\u00e9\u00a0M.\u00a0Mir\u00f3,\u00a0Aurora\u00a0Casanova, \u00a0Elena\u00a0Ferrer, \u00a0\nCristina\u00a0Tural,\u00a0Jorge\u00a0del \u00a0Romero,\u00a0Carmen\u00a0Rodr\u00edguez, \u00a0Estrella\u00a0Caballero, \u00a0Esteve\u00a0Ribera,\u00a0\u00a0\nJordi\u00a0Casabona\u00a0\u00a0\nand\u00a0the\u00a0Standardized \u00a0Algorithm \u00a0for\u00a0Recent\u00a0HIV\u00a0Infections\u00a0(AERIVIH) \u00a0study\u00a0group\u00a0\n\u00a0\nSex\u00a0Transm\u00a0Infect.\u00a02009\u00a0Apr;85(2):106\u201010.\u00a0\n \n \n \n \n \n \n               M\u00c9TODOS\u00a0Y\u00a0RESULTADOS\u00a0\n 46M\u00c9TODOS\u00a0Y\u00a0RESULTADOS\u00a0\n -  47RESUMEN \u00a0\n \nEl\u00a0estudio\u00a0que\u00a0se\u00a0presenta\u00a0a\u00a0continuaci\u00f3n\u00a0muestra\u00a0la\u00a0primera\u00a0ap licaci\u00f3n\u00a0del\u00a0test\u00a0STARHS\u00a0en\u00a0\nEspa\u00f1a.\u00a0A\u00a0trav\u00e9s\u00a0de\u00a0la\u00a0aplicaci\u00f3n\u00a0del\u00a0test\u00a0STARHS,\u00a0es\u00a0posible\u00a0i dentificar\u00a0aquellas\u00a0infecciones\u00a0que\u00a0\nse\u00a0han\u00a0producido\u00a0recientemente,\u00a0y\u00a0de\u00a0ese\u00a0modo,\u00a0describir\u00a0las\u00a0caracter\u00edsticas\u00a0de\u00a0los\u00a0pacientes\u00a0con\u00a0\ninfecci\u00f3n\u00a0reciente.\u00a0Esta\u00a0descripci\u00f3n\u00a0proporciona\u00a0informaci\u00f3n\u00a0precisa\u00a0sobre\u00a0los\u00a0patrones\u00a0actuales\u00a0de\u00a0transmisi\u00f3n\u00a0del\u00a0VIH\u00a0y,\u00a0en\u00a0cons ecuencia,\u00a0puede\u00a0ayudar\u00a0a\u00a0dise\u00f1 ar\u00a0intervenciones\u00a0preventivas\u00a0\nadecuadas.\u00a0\nEl\u00a0objetivo\u00a0de\u00a0este\u00a0estudio\u00a0fue\u00a0estimar\u00a0la\u00a0viabilidad\u00a0de\u00a0la\u00a0int roducci\u00f3n\u00a0del\u00a0test\u00a0STARHS\u00a0en\u00a0\nnuestro\u00a0medio\u00a0y\u00a0describir\u00a0la\u00a0frecuencia\u00a0y\u00a0las\u00a0caracter\u00edsticas\u00a0epidemiol\u00f3gicas\u00a0de\u00a0las\u00a0personas\u00a0infectadas\u00a0recientemente.\u00a0\nSe\u00a0dise\u00f1\u00f3\u00a0un\u00a0estudio\u00a0transversal,\u00a0y\u00a0se\u00a0incluyeron\u00a0individuos\u00a0di agnosticados\u00a0con\u00a0VIH\u00a0entre\u00a0los\u00a0\na\u00f1os\u00a02003\u00a0y\u00a02005.\u00a0De\u00a0todos\u00a0los\u00a0pacientes\u00a0incluidos\u00a0en\u00a0el\u00a0estudi o,\u00a0se\u00a0recuperaron\u00a0muestras\u00a0de\u00a0\nsuero\u00a0que\u00a0hab\u00edan\u00a0sido\u00a0extra\u00eddas\u00a0 con\u00a0prop\u00f3sitos\u00a0diagn\u00f3sticos.\u00a0La s\u00a0muestras\u00a0de\u00a0pacientes\u00a0con\u00a0una\u00a0\nprueba\u00a0 de\u00a0 VIH\u00a0 positiva\u00a0 anterior\u00a0 a\u00a0 6\u00a0 meses\u00a0 (desde\u00a0 la\u00a0 fecha\u00a0 de\u00a0 extracci\u00f3n\u00a0 de\u00a0 la\u00a0 muestra\u00a0\nrecuperada)\u00a0 y\u00a0 edad\u00a0 inferior\u00a0 a\u00a0 18\u00a0 a\u00f1os\u00a0 fueron\u00a0 excluidas\u00a0 del\u00a0 an\u00e1l isis.\u00a0 Las\u00a0 muestras\u00a0\ncorrespondientes\u00a0a\u00a0pacientes\u00a0con\u00a0recuentos\u00a0inferiores\u00a0a\u00a0200\u00a0c\u00e9l ulas\u00a0CD4+/\u00b5l,\u00a0o\u00a0criterios\u00a0cl\u00ednicos\u00a0\nde\u00a0SIDA\u00a0se\u00a0consideraron\u00a0como\u00a0infecciones\u00a0no\u00a0recientes.\u00a0\nParticiparon\u00a0diferentes\u00a0tipos\u00a0de\u00a0centros:\u00a019\u00a0hospitales,\u00a07\u00a0laboratorios\u00a0de\u00a0atenci\u00f3n\u00a0primaria,\u00a0\nuna\u00a0cl\u00ednica\u00a0de\u00a0infecciones\u00a0de\u00a0tra nsmisi\u00f3n\u00a0sexual\u00a0y\u00a08\u00a0centros\u00a0de \u00a0cribado\u00a0alternativos.\u00a0\u00a0\nSe\u00a0 analizaron\u00a0 un\u00a0 total\u00a0 de\u00a0 3.444\u00a0 mu estras\u00a0 usando\u00a0 el\u00a0 test\u00a0 STARHS. \u00a0 El\u00a0 test\u00a0 identific\u00f3\u00a0 como\u00a0\ninfecciones\u00a0recientes\u00a0(ocurridas\u00a0en\u00a0los\u00a0\u00faltimos\u00a0170\u00a0d\u00edas)\u00a0660\u00a0( 19,2%)\u00a0muestras.\u00a0Seg\u00fan\u00a0el\u00a0lugar\u00a0\ndonde\u00a0el\u00a0paciente\u00a0fue\u00a0diagnosticado,\u00a0se\u00a0observ\u00f3\u00a0que\u00a0el\u00a0porcenta je\u00a0de\u00a0infecciones\u00a0reciente\u00a0fue\u00a0\nmayor\u00a0en\u00a0los\u00a0centros\u00a0de\u00a0atenci\u00f3n\u00a0primaria\u00a0(21,5%),\u00a0en\u00a0la\u00a0cl\u00ednica\u00a0de\u00a0ITS\u00a0(23,4%)\u00a0y\u00a0en\u00a0los\u00a0centros\u00a0\nde\u00a0cribado\u00a0alternativos\u00a0(21,3%);\u00a0respecto\u00a0al\u00a0porcentaje\u00a0de\u00a0infe cciones\u00a0recientes\u00a0estimado\u00a0en\u00a0los\u00a0\nhospitales\u00a0(16,5%).\u00a0La\u00a0mayor\u00eda\u00a0de \u00a0personas\u00a0identificadas\u00a0con\u00a0in fecci\u00f3n\u00a0reciente\u00a0eran\u00a0hombres\u00a0\n(79,8%)\u00a0con\u00a0una\u00a0mediana\u00a0de\u00a0edad\u00a0de\u00a033,1\u00a0a\u00f1os,\u00a0y\u00a0el\u00a062,5%\u00a0se\u00a0tra nsmitieron\u00a0entre\u00a0HSH.\u00a0Entre\u00a0los\u00a0\nindividuos\u00a0 con\u00a0 infecci\u00f3n\u00a0 reciente,\u00a0 el\u00a0 26,5%\u00a0 eran\u00a0 de\u00a0 origen\u00a0 inmigrante,\u00a0 siendo\u00a0 un\u00a0 48,7%\u00a0procedentes\u00a0de\u00a0Am\u00e9rica\u00a0del\u00a0Sur.\u00a0Adem\u00e1s,\u00a0en\u00a0algunos\u00a0casos\u00a0se\u00a0pud o\u00a0obtener\u00a0informaci\u00f3n\u00a0sobre\u00a0la\u00a0\nfecha\u00a0de\u00a0llegada\u00a0a\u00a0nuestro\u00a0pa\u00eds.\u00a0La\u00a0mayor\u00eda\u00a0de\u00a0inmigrantes\u00a0iden tificados\u00a0con\u00a0infecci\u00f3n\u00a0reciente\u00a0(y\u00a0\ncon\u00a0informaci\u00f3n\u00a0sobre\u00a0la\u00a0fecha\u00a0de\u00a0llegada\u00a0a\u00a0Espa\u00f1a)\u00a0llevaban\u00a0en \u00a0Espa\u00f1a\u00a0m\u00e1s\u00a0de\u00a0un\u00a0a\u00f1o\u00a0cuando\u00a0\nrecibieron\u00a0el\u00a0diagn\u00f3stico\u00a0de\u00a0VIH,\u00a0y\u00a0por\u00a0tanto,\u00a0adquirieron\u00a0la\u00a0infecci\u00f3n\u00a0de\u00a0VIH\u00a0en\u00a0nuestro\u00a0pa\u00eds.\u00a0En\u00a0relaci\u00f3n\u00a0a\u00a0la\u00a0presencia\u00a0de\u00a0otras\u00a0ITS\u00a0durante\u00a0el\u00a0a\u00f1o\u00a0previo\u00a0al\u00a0d iagn\u00f3stico,\u00a0se\u00a0observ\u00f3\u00a0que,\u00a0como\u00a0M\u00c9TODOS\u00a0Y\u00a0RESULTADOS\u00a0\n 48m\u00ednimo,\u00a0un\u00a016,5%\u00a0de\u00a0los\u00a0pacientes\u00a0con\u00a0infecci\u00f3n\u00a0reciente\u00a0hab\u00edan \u00a0declarado\u00a0tener\u00a0otra\u00a0ITS\u00a0durante\u00a0\nel\u00a0a\u00f1o\u00a0previo\u00a0al\u00a0diagn\u00f3stico\u00a0de\u00a0VIH.\u00a0\nEl\u00a0estudio\u00a0ha\u00a0demostrado\u00a0que\u00a0la\u00a0implementaci\u00f3n\u00a0del\u00a0test\u00a0STARHS\u00a0 en\u00a0nuestro\u00a0medio\u00a0es\u00a0factible.\u00a0\nGracias\u00a0a\u00a0la\u00a0aplicaci\u00f3n\u00a0de\u00a0este\u00a0test\u00a0ha\u00a0sido\u00a0posible\u00a0identificar\u00a0entre\u00a0los\u00a0nuevos\u00a0diagn\u00f3sticos\u00a0de\u00a0VIH\u00a0\naquellas\u00a0infecciones\u00a0que\u00a0se\u00a0produjeron\u00a0en\u00a0los\u00a0\u00faltimos\u00a0seis\u00a0mese s,\u00a0y\u00a0se\u00a0han\u00a0podido\u00a0describir\u00a0las\u00a0\ncaracter\u00edsticas\u00a0 de\u00a0 las\u00a0 personas\u00a0 que\u00a0 adquirieron\u00a0 la\u00a0 infecci\u00f3n\u00a0 po r\u00a0 VIH\u00a0 recientemente.\u00a0 Esa\u00a0\ndescripci\u00f3n\u00a0ha\u00a0permitido\u00a0poner\u00a0de \u00a0manifiesto\u00a0importantes\u00a0caracter\u00edsticas\u00a0de\u00a0la\u00a0epidemia\u00a0local\u00a0de\u00a0\nVIH,\u00a0como\u00a0la\u00a0propagaci\u00f3n\u00a0activa\u00a0del\u00a0VIH\u00a0entre\u00a0los\u00a0HSH,\u00a0el\u00a0papel\u00a0importante\u00a0de\u00a0las\u00a0ITS,\u00a0y\u00a0la\u00a0\nvulnerabilidad\u00a0de\u00a0los\u00a0inmigrante s\u00a0como\u00a0una\u00a0nueva\u00a0poblaci\u00f3n\u00a0dian a.\u00a0\n\u00a0\n\u00a0Recently acquired HIV infection in Spain\n(2003\u20132005): introduction of the serological testing\nalgorithm for recent HIV seroconversion\nA Romero,1,2,3V Gonza \u00b4lez,1,2,4M Granell,1L Matas,2,4A Esteve,1,2E Martro \u00b4,2,4\nI Rodrigo,5T Pumarola,6J M Miro \u00b4,6A Casanova,7E Ferrer,7C Tural,8J del Romero,9\nC Rodr\u0131 \u00b4 guez,9E Caballero,10E Ribera,10J Casabona1,2,3and the Standardized Algorithm\nfor Recent HIV Infections (AERIVIH) study group\n1Center for Epidemiological\nStudies on HIV/AIDS and STI of\nCatalonia (CEEISCAT), InstitutCatala ` d\u2019Oncologia/HealthDepartment, Generalitat deCatalunya, Spain;\n2CIBER\nEpidemiolog\u0131 \u00b4 a y Salud Pu \u00b4blica(CIBERESP), Spain;3Department\nof Paediatrics, Obstetrics andGynaecology, and PreventiveMedicine, Universitat Auto `nomade Barcelona, Barcelona, Spain;\n4Microbiology Service, Hospital\nUniversitari Germans Trias iPujol, Departament de Gene `tica iMicrobiologia, UniversitatAuto `noma de Barcelona,Badalona, Spain;\n5Laboratori\nCl\u0131 \u00b4 nic Manso, Barcelona, Spain;\n6Hospital Cl\u0131 \u00b4 nic \u2013 IDIBAPS,\nUniversity of Barcelona,Barcelona, Spain;7Hospital\nUniversitari de Bellvitge \u2013IDIBELL, l\u2019Hospitalet deLlobregat, Barcelona, Spain;\n8Hospital Universitari Germans\nTrias i Pujol, UniversitatAuto `noma de Barcelona,Badalona, Spain;\n9Centro\nSanitario Sandoval, Madrid,Spain;10Hospital Universitari\nVall Hebron, Universitat\nAuto `noma de Barcelona,\nBarcelona, Spain\nCorrespondence to:\nJordi Casabona, Center for\nEpidemiological Studies on HIV/aids and STI of Catalonia\n(CEEISCAT), Hospital Universitari\nGermans Trias i Pujol, Carreterade Canyet s/n, 08916 Badalona,\nSpain; jcb.ceescat.\ngermanstrias@gencat.cat\nAccepted 10 October 2008\nPublished Online First\n5 November 2008ABSTRACT\nBackground: Identification of recent HIV infections\nprovides a description of the current pattern of HIV\ntransmission and, consequently, can help to design better\npreventive interventions. Our study shows the first\nimplementation in Spain of the Serologic Testing\nAlgorithm for Recent HIV Seroconversion (STARHS)\nstrategy. We assess the viability of introducing STARHS in\nour setting and describe the frequency and epidemiolo-\ngical characteristics of recent infections (RIs).\nMethods: Between 2003 and 2005, HIV-positive blood\nsamples drawn for diagnostic purposes were collected\nfrom 28 Spanish laboratories to be tested using STARHS.\nSamples from patients with a previous HIV diagnosis, age\n,18 years, ,200 CD4 cells/ mL or clinical AIDS criteria\nwere excluded from the analysis.\nResults: A total of 660 (19.2%) samples were classified as\nRI. Most people identified with RI were male (79.8%) with a\nmedian age of 33.1 years, and 62.5% occurred among men\nwho have sex with men (MSM). Immigrants made up\n26.5% of individuals identified with RIs, with 48.7% coming\nfrom South America. Among the individuals with RI, at least\n16.5% had reported another sexually transmitted infection\n(STI) during the year before the HIV diagnosis.\nConclusion: The study shows that the implementation of\nSTARHS in our setting is feasible and has highlighted\nimportant features of the local HIV epidemic, such as the\nongoing spread of HIV among MSM, the potential role of\nSTIs in RIs and the vulnerability of immigrants as a newtarget population.\nHIV infection remains a major public health\nproblem in Europe and there is evidence ofincreasing transmission among vulnerable popula-\ntions in different countries.\n1Spain has the fifth\nhighest incidence rate of AIDS in Europe, with 36.0cases per million people.\n2Since the introduction\nand widespread use of highly active antiretroviraltherapy (HAART) in 1996, both the incidence of\nAIDS and HIV-related mortality rates have\ndecreased dramatically. Therefore, AIDS data are\nless indicative of the underlying trends in HIV\ninfection and many European countries have\nintroduced HIV reporting as part of their surveil-\nlance systems. Data from eight Spanish regions\nwith HIV reporting systems show a shift from\nparenteral to sexual transmission of HIV infec-\ntion.\n3In Catalonia, Spain, data generated by the\nIntegrated AIDS/HIV/STI Surveillance System(SIVES) suggest an increase in the incidence ofHIV among men who have sex with men (MSM)\nand immigrants.\n4Nevertheless, since new diag-\nnoses of HIV can include infections that occurred\nmany years ago, they may not reflect the\nmagnitude or characteristics of recent infections\n(RIs). Identification of RIs provides an accuratedescription of current epidemic patterns and\nenables us to better tailor preventive interventions.\nThe Serological Testing Algorithm for Recent HIVSeroconversion (STARHS) was first described in1998 as a tool to differentiate RIs from long-\nstanding infection (LSI).\n5STARHS has been used\nin different settings to estimate incidence6\u201311and\ndescribe RIs.12 13In Spain, HIV testing is offered\nfree at national health hospitals, primary health\ncentres (PHC), sexually transmitted infection (STI)units and several community-based voluntary\ncounselling and testing sites (CBVCTS), which\noffer free anonymous counselling and testingservices regardless of the user\u2019s health insuranceor residence status. Current policies promote\ntesting in vulnerable populations and young adults\non a voluntary basis. The objectives of this studyare to assess the viability of introducing STARHS\nin our setting and to describe the frequency and\nepidemiological characteristics of people with RI.\nMETHODS\nStudy design\nThree-year cross-sectional study (2003\u20132005).\nInclusion criteria\nConfirmed HIV-positive test samples from\npatients aged 18 years or over without a previousconfirmed HIV diagnosis during the 6 months\nbefore extraction.\nSettings\nSamples were collected from 28 laboratories: 19 athospital outpatient clinics, one from a STI clinic, 7\nlaboratories covering 163 PHCs and 1 STI unit, and1 laboratory collecting samples from 8 CBVCTS.\nCentres were selected on a voluntary basis.\nTwenty-two of these laboratories were fromCatalonia, three from Madrid and three from\nAndalusia, La Rioja, and the Basque Country.Epidemiology\n106 Sex Transm Infect 2009; 85:106\u2013110. doi:10.1136/sti.2008.031864 on 3 April 2009 sti.bmj.com Downloaded from Specimen collection\nResidual volumes of serum specimens collected for diagnostic\npurposes were sent by the participating laboratories to the\ncoordinating centre (Centre d\u2019Estudis Epidemiolo `gics sobre lesITS i la Sida de Catalunya, CEEISCAT). All personal identifiers\nwere removed from the samples, which were sent to the\ncoordinating centre with a study number. Only the recruitmentcentre had access to personal identifiers. Specific testing was\nperformed at the Microbiology Service of the Hospital\nUniversitari Germans Trias i Pujol.\nLaboratory methods\nSamples were additionally tested for HIV by a conventional sensitiveenzyme immunoassay (EIA) (Anti-HIV TETRA Elisa, Biotest,Dreieich, Germany) to double-check that all the samples were HIV\npositive. Positive specimens were then tested using a modified\nversion of the Vironostika HIV-1 EIA (bioMe \u00b4rieux, Durham, NorthCarolina, USA) in which sample dilution and sample and conjugate\nincubation times were modified to render it less sensitive. Standard\noptical density (OD) was calculated as follows:\nsample OD \u2013 median negative control OD/median calibrator OD \u2013\nmedian negative control OD.\nSpecimens with a standard OD ,2.0 were retested in triplicate.\nDuration of infection was defined as recent for retested specimenswith a standard OD ,1.0 and longstanding for those with a\nstandard OD >1.0. People with RI can be presumed to have\nseroconverted within the past 170 days (95% CI 144 to 200).\n14\nSince 2000, CEEISCAT and the microbiology service of the\nHospital Universitari Germans Trias i Pujol have been partici-\npating in an international STARHS quality control programme\nestablished by the Centers for Disease Control and Prevention(FDA BB-IND #8193).\nInterpretation of results\nAn infection was considered recent if the sample reacted with\nthe sensitive EIA but not with the modified less sensitive EIA\n(that is, had low HIV antibody titres). Since antibody titres mayfall in advanced stages of HIV infection, patients whose samplesdid not react and who presented clinical criteria for AIDS or a\nCD4+T cell count ,200 cells/ mL were considered as having LSI.\nData collection\nA data collection form, including CD4 +T cell counts, HIV viral\nloads and previous HIV testing, was filled out by the laboratory\nstaff. A second data collection form, compiled by the patient\u2019s\nphysician or a designated person, with demographical and clinical-\nepidemiological variables (sex, date of birth, country of origin,date of arrival in Spain, sexual orientation, use of injected drugs,STI diagnoses, HIV infection status at the time of diagnosis anduse of antiretrovirals) was used only for diagnosis of RI.\nThe total number of HIV tests performed and the positive\nresults were recorded for each centre.\nStatistical analysis\nThe normal approximation 95% CI was calculated, as was the exactCI when appropriate. Differences in the distribution of several\ncharacteristicsbetweendiagnosissites wereassessedusingPearson\u2019s\nx\n2test with a Bonferroni correction for multiple comparisons.\nRESULTS\nThe number of HIV tests performed at recruitment sites was\nhigher in hospitals, but STI clinic and CBVCTSs had the highest\nprevalence of HIV. We studied 59% of all the positive samplesfrom each centre between January 2003 and December 2005.\nThe samples studied as a percentage of all positive samples per\ntype of centre were distributed as follows: hospitals 50%; PHCs71%; STI clinic 77%; CBVCTSs 89% (table 1).\nWe collected 4172 samples, of which 728 did not meet the\ninclusion criteria and were excluded from the analysis. Out of theremaining 3444 specimens, 713 were non-reactive by the lesssensitive assay, but 53 samples were from patients with ,200\nCD4+T cells/mL or clinical criteria for AIDS and were considered to\nbe LSIs. Therefore, 660 (19.2%) samples were considered RIs (fig 1).\nOf the samples, 50.2% (n = 1728) were from hospitals, 37.3%\n(n = 1285) from PHCs, 10.2% (n = 351) from STI clinic and2.3% (n = 80) from CBVCTSs. The RI percentage differed withthe type of centre: 16.5% (n = 285; 95% CI 14.7 to 18.2) at\nhospitals, 21.5% (n = 276; 95% CI 19.2 to 23.7) at PHCs, 23.4%\n(n = 82; 95% CI 18.9 to 27.8) at STI clinic and 21.3% (n = 17;95% CI 12.9 to 31.8) at CBVCTSs. The percentage of RI in\nhospitals was significantly lower than in PHC and STI clinic\n(p(0.001) (table 1).\nThe characteristics of individuals with RI are shown in Table 2.\nMost were male (79.8%), median age was 33.1, MSM was the\nmain HIV transmission group (62.5%) and 38.8% reported at least\none STI within the 12 months before HIV diagnosis. Country oforigin was known in 426 cases and 26.5% were immigrants,\nmainly from South America (48.7%). The date of arrival in Spain\nwas collected in only 71 cases; 59 (83%) of which arrived morethan 12 months before the time of HIV diagnosis (median 39\nmonths; interquartile range 21\u201360). We found statistically\nsignificant differences by gender, origin, transmission group andcoinfection with other STIs according to the site of diagnosis.\nDISCUSSION\nTo our knowledge, this is the first time the STARHS techniquehas been used in Spain. The percentages of HIV diagnosis varybetween the centres. The number of samples from Catalonian\nTable 1 Distribution of HIV tests performed by centre (2003\u20132005)\nTotal Hospitals PHCs STI clinic CBVCTSs\nHIV tests performed* 478 932 250 398 210 359 14 962 3213\nPositive HIV tests { 5800 (1.2%) 3455 (1.4%) 1805 (0.9%) 451 (3.0%) 89 (2.8%)\nSamples collected* 4172 2305 1404 374 89\nSamples studied { 3444 (59.4%) 1728 (50.0%) 1285 (71.2%) 351 (77.8%) 80 (89.9%)\nRecent infections \" 660 (19.2%) 285 (16.5%) 276 (21.5%) 82 (23.4%) 17 (21.3%)\n*Number\u2014this number does not represent single persons; {number of positive HIV tests performed and prevalence (percentage) of positive HIV tests\u2014this number does not\nrepresent single persons. Out of 5800 positive HIV tests, 1628 were not collected for the study (mostly because of insufficient volume). Prevalence was calculated as follows:\nnumber of HIV tests performed divided by the total number of HIV tests performed; {number of samples included in the study and percentage of studied samples over the total of\npositive HIV tests by each centre\u2014this number represents single persons; \"number and percentage of recent infections\u2014this number represents single persons. Percentages of\nrecent infections by site of diagnosis were computed over the total number of samples with the inclusion criteria studied from each centre.\nCBVCTSs, community-based voluntary counselling and testing sites; PHCs, primary health centres; STI, sexually transmitted infection.Epidemiology\nSex Transm Infect 2009; 85:106\u2013110. doi:10.1136/sti.2008.031864 107 on 3 April 2009 sti.bmj.com Downloaded from centres\u2014when compared with the HIV reporting system of\nCatalonia\u2014represents 74% of all HIV cases reported during the\nsame period. Therefore, although not representative, we\nconsider the diagnoses of HIV in the study population to be\nindicative of those currently made in our setting. According to\nour results, 19.2% of new diagnoses had acquired the infection\nduring the 6 months before the test and this is consistent with\nthe results of a recently published study from 10 United States\ncities.12The percentage of RIs varied according to the type of\nrecruitment centre and the differences were statisticallysignificant. Although a lower percentage of positive samples\nfrom hospitals were included in the study, the fact that this\ngroup had the lowest percentage of RIs suggests that PHCs, STIclinic and CBVCTSs receive a high number of RIs because they\nare the first line of referral and, therefore, much closer to the\ncommunity. Given the increasing evidence that people who are\ndiagnosed with HIV reduce risk behaviour and, thus, HIV\ntransmission,\n15 16this finding clearly supports the need to\nimprove the offer of HIV testing and reinforce the activity ofCBVCTSs, including implementation of rapid HIV testing.\n17\nData from regional HIV reporting systems in Spain show that\n46% and 31% of all new diagnoses correspond to heterosexual\nindividuals and MSM, respectively.3The high proportion of MSM\namong RIs in our study (62.5%) may be attributable to several\nfactors. Although a potential selection bias may have occurred\nbecause the STI clinic in Madrid, which also has a voluntary\ncounselling and testing service, attends a high proportion of\npatients who are MSM, even if this centre is removed from the\nanalysis, MSM account for 56% of all individuals identified as\nhaving RI. Therefore, other factors should be considered. First,\nconcern among the gay community about infection means that\nthey test more often and sooner after a potential exposure. In\nSpain, 39.4% of the general population had taken an HIV test\nonce,18whereas for MSM this percentage was 81.0%.4\nAccordingly, MSM is the group with the lowest percentage ofdiagnoses made with ,200 CD4 cells/ mL.\n4Second, the incidenceof sexual risk practices and STIs are increasing among MSM in our\nsetting,4 19\u201321suggesting that the incidence of HIV is higher among\nthis group and that the likelihood of diagnosing infection at an\nearlier stage could increase. Our results also support that the HIVepidemic is growing again among the local gay community.\nAlmost 39% of all individuals with RI reported at least one\nSTI diagnosed over the previous 12 months, the highestpercentage being at PHCs (75%). This finding should beinterpreted with caution because of the high number of missing\nvalues for this variable. While there was information on co-\ninfection for all RIs identified at STI clinics, this was availablefor only 53.0%, 13.0% and 70.6% of RIs from hospitals, PHCsand CBVCTSs, respectively. Moreover, one laboratory receivingsamples from PHCs in Barcelona also serves as a STI unit and\nthis may contribute to the high percentage of co-infection at\nthis site. However, even assuming that all patients from whomwe have no information on STI co-infection were not infected,the percentage of patients with a RI and a STI during the yearbefore HIV diagnosis would be 17% (table 2). Consistent with\nthose of other studies,\n4 20 21our results suggest that STI may\nplay a role in the transmission of HIV in our setting.\nAlthough we only had information on the country of origin\nfor 65% of the individuals with RI, more than a quarter of those\ninfected were immigrants. The proportion of immigrants withRI was much higher (78.6%) at CBVCTSs than at the othersites. Since we have no information on LSI, it is difficult tointerpret this data; however, if we assume a similar proportion\nof immigrants among the LSI, it may reflect a preference for\nnon-official sites that offer anonymous voluntary counsellingand testing to this population. Otherwise, it could reflect ahigher incidence of HIV infection among this group. Toascertain whether these infections were imported or locally\nacquired, we recorded the date of arrival in Spain. Of 71\nimmigrants with RI for whom this variable was available, 59(83%) arrived in Spain more than 1 year before they werediagnosed with HIV. Although the finding cannot be extra-polated, it does suggest that in Spain most HIV infections\namong immigrants are locally acquired. This is consistent with\nthe fact that in our setting, unlike the UK, immigrants comemainly from countries with a low prevalence HIV, such asMorocco, Romania and Latin America.\n22\nA possible limitation of our study was the difficulty in retrieving\nclinical-epidemiological data from all the patients whose sampleswere studied. On the one hand, we could not systematise thecollection of additional data from the samples studied and had to\nlimit it to RI. On the other, samples from laboratories correspond-\ning to outside clinics could not be linked to clinical records becauseof confidentiality issues. Therefore, the characteristics of indivi-duals with RI were not compared with the characteristics ofindividuals with LSI and this has resulted in a relatively high\npercentage of missing values in some variables from patients with\nRI. Another limitation was the differences in sample recruitmentbetween the different centres. Whereas some centres collected 90%of all positive samples, others collected 50%. Nevertheless, ourresults are consistent with other studies and with the epidemio-\nlogical trends identified using other information sources.\n4\nThe limitations of STARHS are well-known, especially\nmisclassification of advanced disease stage, AIDS or patientson antiretroviral treatment as RIs. Nevertheless, access to\nclinical and laboratory information allowed us to detect andexclude misclassifications.\n23The Vironostika HIV-1 EIA is based\non subtype B antigens. Therefore, when used to detect RI, thisassay performs differently on B and non-B subtypes,\n24with a\nlonger window period on non-B subtypes. Although few studiesFigure 1 Algorithm for the identification of recently infected samples.\n*Of the 728 samples excluded, 75.0% belonged to patients whose HIV\ninfection was diagnosed more than 6 months before sample collection,11.1% were duplicate samples, 9.2% were HIV-negative samples, 2.7%\ndid not have enough volume, 1.4% were negative by Western blot and\n0.5% were from patients aged under 18 years.Epidemiology\n108 Sex Transm Infect 2009; 85:106\u2013110. doi:10.1136/sti.2008.031864 on 3 April 2009 sti.bmj.com Downloaded from have analysed the distribution of HIV subtypes in Spain, only\n7.6% of all clinically diagnosed acute HIV infections may be\nnon-B subtypes.25However, given that most immigrants come\nfrom South America,22it is unlikely that non-B HIV subtypes\nhave significantly affected the results of this study. In any case,they would have produced a slight overestimation of the\npercentage of RI. Nevertheless, since 2008 our laboratory has\nbeen using the BED assay, which has a similar window period for\nHIV subtypes A to E\n26 27and better reproducibility since it is based\non the HIV IgG to non-HIV IgG ratio and uses a simple 1:100\ndilution, which performs better in subtypes B, E and D.26 27\nIn summary, the study showed that implementing STARHS in\nour setting is feasible and, more importantly, that in order toimprove the use of the data collected, it is necessary to implement\nthese studies in settings where more complete clinical-epidemio-\nlogical data are available. Consequently, since 2006, STARHS has\nbeen included in the Integrated AIDS/HIV/STI Surveillance\nSystem in Catalonia by systematically testing all new HIVdiagnoses made in 14 hospitals, nine of them participating in anopen cohort (PISCIS) of people who are HIV positive,\n28 29as well as\nthroughout the CBVCTS network of the region.4Eventually, this\nshould enable us to collect data from patients with LSI and to\nestimate incidence rates. This study highlights important epide-\nmiological features of local HIV infection, such as the ongoing\nspread of HIV among MSM, the potential role of STIs in new HIV\ninfections and the vulnerability of immigrants as a new target\npopulation, which should be taken into account in national HIV\nand STI prevention strategies.\nAcknowledgements: We thank Joanne V Mei (Centers for Disease Control and\nPrevention, Atlanta, Georgia, USA) for technical assistance and advice.\nFunding: \u2018\u2018La Marato \u00b4 de TV3\u2019\u2019 Foundation awarded the CEEISCAT a grant for the\ndevelopment of the AERI-HIV (Algoritme Estandartditzat per la deteccio \u00b4 de Recent\nInfectats pel VIH) project for epidemiological research on AIDS by applying the\nSTARHS technique (project #022010). This work was partially funded by the Direccio \u00b4\nGeneral de Salut Pu \u00b4blica de la Generalitat de Catalunya and by the Fundacio \u00b4n para la\nInvestigacio \u00b4n y Prevencio \u00b4n del Sida en Espan \u02dca (FIPSE, Madrid Spain, National AIDSPlan Secretariat of the Spanish Ministry of Health), the Ministerio de Sanidad y\nConsumo, Instituto de Salud Carlos III and the Spanish Network for AIDS Research\n(RIS; ISCIII-RETIC RD06/006). JMM was a recipient of a research grant from the\nInstitut d\u2019Investigacions Biome `diques August Pi i Sunyer (IDIBAPS) and the Conselleria\nde Salut de la Generalitat de Catalunya, Barcelona, Spain. The Centers for DiseasesControl and Prevention (CDC) has provided the samples for the quality control\nprogramme (FDA BB-IND #8193).\nCompeting interests: None.\nEthics approval: The protocol was approved by the ethics committees of all the\nparticipating centres.\nContributors: Project concept, design, interpretation of results: J Casabona, J Masip,\nN Vives, B Ortiga, A Alque \u00b4zar, A Romero, M Granell, D Puente, M\naJ Casado, A `Jaen.\nQuality control programme :J Almeda. Statistical analysis :A Esteve, A Montoliu,\nN Ortega. Computer support: E Puchol. Management and storage of specimens:\nR Mun \u02dcoz. Technical support: V Espurz.Table 2 Characteristics of people with recent infection (2003\u20132005) by site of diagnosis\nTotal n (%) Hospitals n (%) PHCs n (%) STI clinic n (%) CBVCTSs n (%) p Value 1\nGender (n = 639)* ,0.001**\nMen 510 (79.8) 227 (80.2) 188 (73.2) 78 (95.1) 17 (100.0)\nOrigin (n = 426)* ,0.001{{\nSpain 313 (73.5) 180 (73.2) 73 (83.0) 57 (73.1) 3 (21.4)\nImmigrants 113 (26.5) 66 (26.8) 15 (17.0) 21 (26.9) 11 (78.6)\nSouth and Central America 62 (54.9) 33 (50.0) 8 (60.0) 13 (61.9) 7 (63.6)\nWestern and Central Europe 18 (15.9) 7 (10.6) 4 (26.7) 7 (33.3) 0 (0.0)\nMiddle East and North Africa 11 (9.7) 6 (9.1) 1 (6.7) 1 (4.8) 3 (27.3)\nSub-Saharan Africa 10 (8.8) 9 (13.6) 1 (6.7) 0 (0.0) 0 (0.0)\nEastern Europe and Central Asia 8 (7.1) 7 (10.6) 0 (0.0) 0 (0.0) 1 (9.1)\nOther 4 (3.5) 4 (6.1) 1 (6.7) 0 (0.0) 0 (0.0)\nAge, y{(n = 623)* 32.9 33.2 33.0 31.8 30.1 0.741\n,30 225 (36.1) 105 (38.2) 83 (33.1) 29 (36.3) 8 (47.1)\n30\u201340 274 (44.0) 113 (41.1) 116 (46.2) 38 (47.5) 7 (41.2)\n40\u201350 93 (14.9) 40 (14.5) 42 (16.7) 10 (12.5) 1 (5.9)\n.50 31 (5.0) 17 (6.2) 10 (4.0) 3 (3.8) 1 (5.9)\nTransmission group (n = 389)* ,0.001{{\nMSM 243 (62.5) 125 (54.8) 41 (62.1) 73 (90.1) 7 (50.0)\nHeterosexual 90 (23.1) 64 (28.1) 15 (22.7) 7 (8.6) 1 (7.1)\nInjection drug users 56 (14.4) 39 (17.1) 10 (15.2) 1 (1.2) 6 (42.9)\nSTI{(n = 281)* 109 (38.8) 54 (35.8%) 27 (75%) 27 (32.9%) 1 (8.3%) ,0.001 11\nNon-specified syphilis \" 52 (47.7) 27 (50.0) 18 (66.7) 7 (25.9) 0 (0.0)\nGonococci 10 (9.2) 4 (7.4) 3 (11.1) 3 (11.1) 0 (0.0)\nHerpes 5 (4.6) 2 (3.7) 1 (3.7) 2 (7.4) 0 (0.0)\nChlamydia 3 (2.7) 2 (3.7) 0 (0.0) 1 (3.7) 0 (0.0)\nOther/non-specified 39 (35.8) 19 (35.2) 5 (18.5) 14 (51.9) 1 (100.0)\n*The number of samples with available information for each variable. Stratified subtotals may not match the total number of RI because missing values were excluded from each\nvariable; {median; {having a diagnosis of a sexually transmitted infection (STI) within 12 months before study inclusion; 1p value, Pearson\u2019s x2test;\"the diagnosis of syphilis was\nself-reported by the patient, during the last 12 months, before study inclusion; **differences between hospitals and STI clinic and primary health centres (PHC); {{differences\nbetween community-based voluntary counselling and testing sites (CBVCTSs) and each of the other sites; {{differences between STI clinics and each of the other sites;\n11differences between PHCs and each of the other sites.\nKey messages\ncSerologic Testing Algorithm for Recent HIV Seroconversion\n(STARHS) is feasible and it helps to identify local\nepidemiological features.\ncSince 2006, STARHS is included in the HIV/STI Integrated\nSurveillance System of Catalonia, Spain.Epidemiology\nSex Transm Infect 2009; 85:106\u2013110. doi:10.1136/sti.2008.031864 109 on 3 April 2009 sti.bmj.com Downloaded from STARHS Laboratory (Microbiology Service, Hospital Universitari Germans Trias i Pujol):\nV Gonza \u00b4lez, E Martro \u00b4, L Matas, V Ausina.\nAcquisition of data: D Puente, M Granell, A Romero, I Rodrigo, A `Bosch, R Lo \u00b4pez,\nE Dopico, J Ros, R Navarro, C Rovira, T Pumarola, A Casanova, E Martro \u00b4, L Matas,\nV Gonza \u00b4lez, V Ausina, E Caballero, N Margall, J Farre \u00b4, C Toro, M Sauca, X Ort\u0131 \u00b4n ,\nM Armengual, J MaPrats, J MaEuras, M Navarro, J Ramo \u00b4n Blanco, J MaSimo\u00b4, Ma\nC Villa `, E Ma \u00b4rquez, J M Miro \u00b4, F Agu \u00a8ero, O Sued, M Lo \u00b4pez-Dieguez, L Zamora,\nJ M Gatell, E Ferrer, D Podzamczer, C Tural, B Clotet, E Ribera, J Alte `s, J Manuel\nGuadarrama, P Domingo, T Puig, V Soriano, C Bernal, P Barrufet, L Force, C Gutie \u00b4rrez,\nA Ort\u0131 \u00b4 , G Navarro, F Segura, A `Masabeu, J Vilaro \u00b4, J A Iribarren, J A Oteo, B Coll,\nC A Villaverde, S Montull, I Garcia, J del Romero, C Rodr\u0131 \u00b4 guez, R Sala, O D\u0131 \u00b4 az,K Zaragoza, F Pujol, J Saz, M Meron \u02dco, J Becerra, R Ros, A Avellaneda, M Site \u00b4, A Rafel.\nDrafting of the manuscript: A Romero, V Gonza \u00b4lez, M l Granell, L Matas, A Esteve,\nE Martro \u00b4, I Rodrigo, T Pumarola, J M Miro \u00b4, A Casanova, E Ferrer, C Tural, J del\nRomero, C Rodr\u0131 \u00b4 guez, E Caballero, E Ribera, J Casabona.\nFinal Approval: J Casabona, J Masip, N Vives, B Ortiga, A Alque \u00b4zar, A Romero, M Granell,\nD Puente, M\naJ Casado, A `Jaen, J Almeda, A Esteve, A Montoliu, N Ortega, E Puchol,\nR Mun \u02dcoz, V Espurz, I Rodrigo, A `Bosch, R Lo \u00b4pez, E Dopico, J Ros, R Navarro, C Rovira,\nT Pumarola, A Casanova, E Martro \u00b4, L Matas, V Gonza \u00b4lez, V Ausina, E Caballero, N Margall,\nJ Farre \u00b4, C Toro, M Sauca, X Ort\u0131 \u00b4 n, M Armengual, J MaPrats, J MaEuras, M Navarro,\nJ Ramo \u00b4n Blanco, J MaSimo\u00b4, MaC Villa`, E Ma \u00b4rquez, J M Miro \u00b4, F Agu \u00a8ero, O Sued,\nM Lo\u00b4pez-Dieguez, L Zamora, J M Gatell, E Ferrer, D Podzamczer, C Tural, B Clote t, E Ribera,\nJ Alte`s, J M Guadarrama, P Domingo, T Puig, V Soriano, C Bernal, P Barrufet, L Forc e,\nC Gutie \u00b4rrez, A Ort\u0131 \u00b4 , G Navarro, F Segura, A `Masabeu, J Vilaro \u00b4, J A Iribarren, J A Oteo, B Coll,\nC A Villaverde, S Montull, I Garcia, J del Romero, C Rodr\u0131 \u00b4 guez, R Sala, O D\u0131 \u00b4 az, K Zaragoza,\nF Pujol, J Saz, M Meron \u02dco, J Becerra, R Ros, A Avellaneda, M Site \u00b4, A Rafel.\nComposition of the Standardized Algorithm for Recent HIV Infections (AER IVIH)\nStudy Group:The Coordinating Center (CEEISCAT): J Casabona, J Masip, N Vives, B Ortiga , A Alque \u00b4zar,\nA Romero, M Granell, D Puente, M\naCasado, A `Jaen, J Almeda, A Esteve, A Montoliu,\nN Ortega, E Puchol, R Mun \u02dcoz, V Espurz.\nThe STARHS Laboratory (Microbiology Service, Hospital Universitari Ger mans Trias i Pujol):\nV Gonza \u00b4lez, E Martro \u00b4, L Matas, V Ausina.\nThe Peripheral Centers\u2014Primary Health Center Laboratories: I Rodrigo (Laboratori Cl\u0131 \u00b4n i c\nManso, Barcelona), A `Bosch (Laboratori Intercomarcal de l\u2019Alt Penede `s, l\u2019Anoia i el Garraf,\nIgualada), R Lo \u00b4pez (Laboratori Cl\u0131 \u00b4 nic Bon Pastor, Barcelona), E Dopico (Laboratori Cl\u0131 \u00b4n i c\nl\u2019Hospitalet de Llobregat, l\u2019Hospitalet de Llobregat), J Ros (Laborator i Cl\u0131\u00b4 nic Barcelone \u00b4s\nNord i Maresme, Badalona), R Navarro (Laboratori Cl\u0131 \u00b4 nic Cornella ` de Llobregat, Cornella ` de\nLlobregat), C Rovira (Laboratori Cl\u0131 \u00b4 nic El Maresme, Mataro \u00b4). Laboratory staff: T Pumarola\n(Hospital Cl\u0131 \u00b4 nic-IDIBAPS, University of Barcelona, Barcelona); A Casanova (Hospital\nUniversitari de Bellvitge-IDIBELL, Hospitalet de Llobregat); E Martro \u00b4, L Matas, V Gonza \u00b4lez,\nV Ausina (Hospital Universitari Germans Trias i Pujol, Badalona); E Caballero (HospitalUniversitari Vall Hebron, Barcelona); N Margall (Hospital de la Santa Creu i Sant Pau,\nBarcelona); J Farre \u00b4 (Hospital Universitari Arnau de Vilanova, Lleida); C Toro (Hospital\nCarlos III, Madrid); M Sauca (Hospital de Mataro \u00b4); X Ort\u0131 \u00b4 n (Hospital de Tortosa Verge de la\nCinta, Tortosa); M\naJose \u00b4 Armengual (Corporacio \u00b4 Sanita `ria Parc Taul\u0131 \u00b4 , Sabadell); J MaPrats\n(Hospital de Palamo \u00b4s); J MaEuras (Hospital General de Vic); Jose \u00b4 Ramo \u00b4n Blanco\n(Complejo San Millan-San Pedro de La Rioja); J MaSimo \u00b4 (Hospital Universitari de Sant\nJoan de Reus); MaC Villa ` (Hospital General de Granollers); E Ma \u00b4rquez (Hospital General de\nl\u2019Hospitalet, Hospitalet de Llobregat). Clinical staff: J M Miro \u00b4, F Agu \u00a8ero, O Sued, M Lo \u00b4pez-\nDieguez, J M Gatell, L Zamora (Hospital Cl\u0131 \u00b4 nic-IDIBAPS, University of Barcelona,\nBarcelona); E Ferrer, D Podzamczer (Hospital Universitari de Bellvitge-IDIBELL, Hospitalet\nde Llobregat); C Tural, B Clotet (Hospital Universitari Germans Trias i Pujol, Badalona);\nE Ribera (Hospital Universitari Vall Hebron, Barcelona); J Alte `s, J M Guadarrama (Hospital\nAlt Penede `s, Vilafranca); P Domingo (Hospital de la Santa Creu i Sant Pau, Barcelona);\nT Puig (Hospital Universitari Arnau de Vilanova, Lleida); V Soriano (Hospital Carlos III,\nMadrid); C Bernal (Hospital Universitario San Cecilio, Granada); P Barrufet, L Force\n(Hospital de Mataro \u00b4); C Gutie \u00b4rrez (Hospital Ramo \u00b4n y Cajal, Madrid); A Ort\u0131 \u00b4 (Hospital de\nTortosa Verge de la Cinta, Tortosa); G Navarro, F Segura (Corporacio \u00b4 Sanita `ria Parc Taul\u0131 \u00b4,\nSabadell); A `Masabeu (Hospital de Palamo \u00b4s); J Vilaro \u00b4 (Hospital General de Vic);\nJ A Iribarren (Hospital de Donostia, San Sebastia \u00b4n); J A Oteo (Complejo San Millan-San\nPedro de La Rioja); B Coll, C A Villaverde (Hospital Universitari de Sant Joan de Reus);\nS Montull (Hospital General de Granollers); I Garcia (Hospital General de l\u2019Hospitalet,\nHospitalet de Llobregat).\nSexually transmitted infections clinic: J del Romero, C Rodr\u0131 \u00b4 guez (Centro Sanitario\nSandoval, Madrid).\nCommunity-based testing sites: R Sala (Laboratori Sabater Tobella, Barcelona); O D\u0131 \u00b4a z\n(Servei d\u2019Atencio \u00b4 i Prevencio \u00b4 Sociosanita `ria: SAPS - Creu Roja, Barcelona); K Zaragoza\n(Stop Sida, Barcelona); F Pujol, J Saz (Projecte dels Noms \u2013 Joves positius, Barcelona);\nM Meron \u02dco (A`mbit Prevencio \u00b4, Barcelona); J Becerra (Associacio \u00b4 Ciutadana Antisida de\nCatalunya \u2013 ACASC, Barcelona); R Ros (Centre Jove d\u2019Anticoncepcio \u00b4 i Sexualitat \u2013 CJAS,Barcelona); A Avellaneda, M Site \u00b4 (Actua Valle `s, Sabadell); A Rafel (Associacio \u00b4 Antisida de\nLleida).REFERENCES\n1. Hamers FF, Downs AM. The changing face of the HIV epidemic in Western Europe:\nwhat are the implications for public health policies? Lancet 2004;364 :83\u201394.\n2. EuroHIV . HIV/AIDS Surveillance in Europe. End-year report 2005. Saint-Maurice:\nInstitut de Veille Sanitaire, 2006:73.\n3. Vigilancia epidemiolo \u00b4gica del VIH en Espan \u02dca: Valoracio \u00b4n de la Epidemia de VIH en\nEspan \u02dca a partir de los sistemas de notificacio \u00b4n de casos de las CCAA. Madrid:\nInstituto de Salud Carlos III, Centro Nacional de Epidemiolog\u0131 \u00b4 a, 2007.\n4. Centre d\u2019Estudis Epidemiolo `gics sobre les Infeccions de Transmissio \u00b4 Sexual\ni Sida de Catalunya (CEEISCAT) .SIVES 2005: Sistema integrat de vigila `ncia\nepidemiolo `gica del SIDA/VIH/ITS a Catalunya (SIVES): Informe anual CEESCAT .\nBarcelona: Generalitat de Catalunya, Departament de Salut, 2005:140.\n5. Janssen RS, Satten GA, Stramer SL, et al. New testing strategy to detect early HIV-\n1 infection for use in incidence estimates and for clinical and prevention purposes.JAMA 1998; 280:42\u20138.\n6. Vignoles M, Avila MM, Osimani ML, et al. HIV seroincidence estimates among at-risk\npopulations in Buenos Aires and Montevideo: use of the serologic testing algorithm forrecent HIV seroconversion. J Acquir Immune Defic Syndr 2006; 42:494\u2013500.\n7. Nash D, Bennani Y, Ramaswamy C, et al. Estimates of HIV incidence among persons\ntesting for HIV using the sensitive/less sensitive enzyme immunoassay, New York\nCity, 2001. J Acquir Immune Defic Syndr 2005;39 :102\u201311.\n8. Alves K, Shafer KP, Caseiro M, et al. Risk factors for incident HIV infection among\nanonymous HIV testing site clients in Santos, Brazil: 1996\u20131999. J Acquir Immune\nDefic Syndr 2003; 32:551\u20139.\n9. Gouws E, Williams BG, Sheppard HW, et al. High incidence of HIV-1 in South Africa\nusing a standardized algorithm for recent HIV seroconversion. J Acquir Immune Defic\nSyndr 2002;29 :531\u20135.\n10. Murphy G, Parry JV, Gupta SB, et al. Test of HIV incidence shows continuing HIV\ntransmission in homosexual/bisexual men in England and Wales. Commun Dis Public\nHealth 2001;4 :33\u20137.\n11. Gupta P, Kingsley L, Sheppard HW, et al. High incidence and prevalence of HIV-1\ninfection in high risk population in Calcutta, India. Int J STD AIDS 2003;14 :463\u20138.\n12. Schwarcz S, Weinstock H, Louie B, et al. Characteristics of persons with recently\nacquired HIV infection: application of the serologic testing algorithm for recent HIVseroconversion in 10 US cities. J Acquir Immune Defic Syndr 2007;44 :112\u20135.\n13. Kallas EG, Bassichetto KC, Oliveira SM, et al. Establishment of the serologic testing\nalgorithm for recent human immunodeficiency virus (HIV) seroconversion (STARHS)strategy in the city of Sao Paulo, Brazil. Braz J Infect Dis 2004;8 :399\u2013406.\n14. Kothe D, Byers RH, Caudill SP, et al. Performance characteristics of a new less\nsensitive HIV-1 enzyme immunoassay for use in estimating HIV seroincidence.\nJ Acquir Immune Defic Syndr 2003;33 :625\u201334.\n15. King-Spooner S. HIV prevention and the positive population. Int J STD AIDS\n1999; 92:1387\u201388.\n16. Wolitsk\ni RJ, Bailey CJ, O\u2019Leary A, et al. Self-perceived responsibility of HIV-\nseropositive men who have sex with men for preventing HIV transmission. AIDS\nBehav 2003;7 :363\u201372.\n17. Ferna `ndez L, Rifa ` B, Mun \u02dcoz R, et al. Impact of rapid HIV test introduction in\nvoluntary counseling and testing sites in Catalonia [abstract]. XVII International AIDS\nConference. Mexico: 3\u20138 August, 2008.\n18. Encuesta de salud y ha \u00b4bitos sexuales . INE y Secretar\u0131 \u00b4 a del Plan Nacional sobre el\nSida. Madrid: 2003.\n19. Folch C, Casabona J, Mun \u02dcoz R, et al. Evolucio \u00b4n de la prevalencia de infeccio \u00b4n por el VIH y\nde las conductas de riesgo en varones homo/bisexuales. Gaceta Sanit 2005; 19:294\u2013301.\n20. Vall-Mayans M, Casals M, Vives A, et al. Reemergencia de la s\u0131 \u00b4 filis infecciosa en\nvarones homosexuales y coinfeccio \u00b4n por el virus de la inmunodeficiencia humana en\nBarcelona, 2002\u20132003. Med Clin (Barc) 2006;126 :94\u20136.\n21. Casabona J, Binefa G, Folch C, et al. Sexually acquired HIV infections on the rise in\nCatalonia, Spain. Eurosurveill 2006; 11:7.\n22. Instituto Nacional de Estad\u0131 \u00b4 stica .Avance del Padro \u00b4n Municipal a 1 de enero de\n2006: datos provisionales [electronic resource]. Madrid: INE, 2006. http://www.ine.\nes/prensa/prensa.htm (accessed 13 November 2008).\n23. Fisher M, Pao D, Murphy G, et al. Serological testing algorithm shows rising HIV\nincidence in a UK cohort of men who have sex with men: 10 years application. AIDS\n2007; 21:2309\u201314.\n24. Young CL, Hu DJ, Byers R, et al. Evaluation of a sensitive/less sensitive testing\nalgorithm using the bioMe \u00b4rieux Vironostika-LS assay for detecting recent HIV-1\nsubtype B 9or E infection in Thailand. AIDS Res Hum Retroviruses 2003;19 :481\u20136.\n25. de Mendoza C, Rodriguez C, Colomina J, et al. Resistance to nonnucleoside reverse-\ntranscriptase inhibitors and prevalence of HIV type 1 non-B subtypes are increasingamong persons with recent infection in Spain. Clin Infect Dis 2005; 41:1350\u20134.\n26. Dobbs T, Kennedy S, Pau C-P, et al. Performance characteristics of the Immunoglobulin\nG-Capture BED-Enzyme Immunoassay, an assay to detect recent humanimmunodeficiency virus type 1 seroconversion. J Clin Microbiol 2004; 42:2623\u20138.\n27. Parekh BS, Kennedy MS, Dobbs T, et al. Quantitative detection of increasing HIV\ntype 1 antibodies after seroconversion: a simple assay for detecting recent HIVinfection and estimating incidence. AIDS Res Hum Retroviruses 2002;18 :295\u2013307.\n28. Jaen A, Esteve A, Miro \u00b4 JM, et al. Determinants of HIV progression and assessment\nof the optimal time to initiate highly active antiretroviral therapy: PISCIS Cohort\n(Spain). J Acquir Immune Defic Syndr 2008;47 :212\u201320.\n29. Jae \u00b4n A, Casabona J, Esteve A, et al. Clinical-epidemiological characteristics and\nantiretroviral treatment trends in a cohort of HIV infected patients. The PISCIS Project.\nMed Clin (Barc) 2005;124 :525\u201331.Epidemiology\n110 Sex Transm Infect 2009; 85:106\u2013110. doi:10.1136/sti.2008.031864 on 3 April 2009 sti.bmj.com Downloaded from M\u00c9TODOS\u00a0Y\u00a0RESULTADOS\u00a0\n -  55ART\u00cdCULO \u00a0II\u00a0\n\u00a0\n\u00a0\n\u00a0\n\u00a0\u00a0\n\u00a0\nPPrreevvaalleennccee\u00a0\u00a0ooff\u00a0\u00a0TTrraannssmmiitttteedd\u00a0\u00a0HHIIVV\u2010\u201011\u00a0\u00a0DDrruugg\u00a0\u00a0RReessiissttaannccee\u00a0\u00a0aanndd\u00a0\u00a0DDiissttrriibbuuttiioonn\u00a0\u00a0ooff\u00a0\u00a0\nHHIIVV\u2010\u201011\u00a0\u00a0SSuubbttyyppeess\u00a0\u00a0AAmmoonngg\u00a0\u00a0PPaattiieennttss\u00a0\u00a0WWiitthh\u00a0\u00a0RReecceenntt\u00a0\u00a0IInnffeeccttiioonn\u00a0\u00a0iinn\u00a0\u00a0CCaattaalloonniiaa\u00a0\u00a0\n((SSppaaiinn))\u00a0\u00a0BBeettwweeeenn\u00a0\u00a022000033\u00a0\u00a0aanndd\u00a0\u00a022000055\u00a0\n\u00a0\u00a0\u00a0\u00a0\nAnabel\u00a0Romero,\u00a0Omar\u00a0Sued,\u00a0Teresa\u00a0Puig, \u00a0Anna\u00a0Esteve, \u00a0Tom\u00e0s\u00a0Pumarola, \u00a0Jordi\u00a0Casabona, \u00a0\u00a0\nVictoria\u00a0Gonz\u00e1lez,\u00a0Lurdes\u00a0Matas, \u00a0Cristina\u00a0Tural,\u00a0Isabel\u00a0Rodrigo, \u00a0N\u00faria\u00a0Margall, \u00a0\u00a0\nPere\u00a0Domingo, \u00a0Aurora\u00a0Casanova, \u00a0Elena\u00a0Ferrer, \u00a0Estrella\u00a0Caballero, \u00a0Esteve\u00a0Ribera,\u00a0Joan\u00a0Farr\u00e9,\u00a0\nTeresa\u00a0Puig, \u00a0M\u00aa\u00a0Jos\u00e9\u00a0Armengual, \u00a0Gemma\u00a0Navarro, \u00a0Josep\u00a0M\u00aa\u00a0Prat,\u00a0\u00c0ngels\u00a0Masabeu, \u00a0\u00a0\nJosep\u00a0M\u00aa\u00a0Sim\u00f3,\u00a0Carlos\u00a0A.\u00a0Villaverde, \u00a0Pilar\u00a0Barrufet, \u00a0M\u00aa\u00a0Goretti\u00a0Sauca,\u00a0Xavier\u00a0Ortin, \u00a0\n\u00a0Amat\u00a0Ort\u00ed,\u00a0Rosa\u00a0Navarro, \u00a0Josep\u00a0M\u00aa\u00a0Euras,\u00a0Josep\u00a0Vilar\u00f3,\u00a0M\u00aa\u00a0Carme\u00a0Vill\u00e0,\u00a0Santiago\u00a0Montull, \u00a0\nConrad\u00a0Vilanova, \u00a0Ferran\u00a0Pujol,\u00a0Olga\u00a0D\u00edaz,\u00a0Jose\u00a0M.\u00a0Mir\u00f3\u00a0and\u00a0the\u00a0AERI\u00a0study\u00a0Group. \u00a0\n\u00a0\nEnferm\u00a0Infecc\u00a0Microbiol \u00a0Clin.\u00a02011\u00a0Aug\u2010Sep;29(7):482 \u20109.\u00a0\n\u00a0\u00a0\n\u00a0\u00a0\n\u00a0\n\u00a0\u00a0\n\u00a0\n\u00a0\u00a0\u00a0\n\u00a0\n\u00a0\u00a0\n\u00a0\n\u00a0\u00a0\u00a0\n\u00a0\n\u00a0\n \n  M\u00c9TODOS\u00a0Y\u00a0RESULTADOS\u00a0\n 56M\u00c9TODOS\u00a0Y\u00a0RESULTADOS\u00a0\n -  57RESUMEN \u00a0\n \nLa\u00a0vigilancia\u00a0de\u00a0las\u00a0resistencias\u00a0transmitidas\u00a0entre\u00a0los\u00a0pacien tes\u00a0que\u00a0todav\u00eda\u00a0no\u00a0han\u00a0recibido\u00a0\ntratamiento\u00a0antirretroviral\u00a0proporciona\u00a0una\u00a0informaci\u00f3n\u00a0necesaria\u00a0para\u00a0considerar\u00a0la\u00a0terapia\u00a0\nantirretroviral\u00a0 de\u00a0 elecci\u00f3n.\u00a0 En\u00a0 los\u00a0 pacientes\u00a0 con\u00a0 infecci\u00f3n\u00a0 rec iente,\u00a0 adem\u00e1s,\u00a0 conocer\u00a0 la\u00a0\nprevalencia\u00a0de\u00a0resistencias\u00a0transmitidas\u00a0es\u00a0un\u00a0indicador\u00a0sensib le\u00a0para\u00a0monitorizar\u00a0la\u00a0evoluci\u00f3n\u00a0\nde\u00a0las\u00a0cepas\u00a0de\u00a0VIH\u20101\u00a0resi stentes\u00a0en\u00a0una\u00a0poblaci\u00f3n.\u00a0\u00a0\nLos\u00a0 movimientos\u00a0 poblacionales,\u00a0 resultado\u00a0 de\u00a0 los\u00a0 fen\u00f3menos\u00a0 de\u00a0 in migraci\u00f3n\u00a0 o\u00a0 viajes\u00a0\ninternacionales,\u00a0y\u00a0los\u00a0contactos\u00a0sexuales\u00a0con\u00a0individuos\u00a0de\u00a0pa\u00ed ses\u00a0donde\u00a0los\u00a0subtipos\u00a0no\u00a0B\u00a0son\u00a0\nm\u00e1s\u00a0 prevalentes\u00a0 han\u00a0 dado\u00a0 lugar\u00a0 a\u00a0 un\u00a0 aumento\u00a0 de\u00a0 los\u00a0 subtipos\u00a0 no\u00a0 B \u00a0e n \u00a0a l g u n o s \u00a0p a \u00ed s e s \u00a0\ndesarrollados,\u00a0donde\u00a0el\u00a0subtipo\u00a0m \u00e1s\u00a0prevalente\u00a0hab\u00eda\u00a0sido\u00a0el\u00a0B. \u00a0\nLos\u00a0objetivos\u00a0de\u00a0este\u00a0estudio\u00a0han\u00a0sido\u00a0estimar\u00a0la\u00a0prevalencia\u00a0d e\u00a0cepas\u00a0de\u00a0VIH\u20101\u00a0con\u00a0resistencias\u00a0\nt r a n s m i t i d a s \u00a0a \u00a0l o s \u00a0a n t i r r e t r o v i r a l e s \u00a0y \u00a0d e s c r i b i r \u00a0l o s \u00a0s u b t i p o s \u00a0d e\u00a0 VIH\u20101\u00a0 entre\u00a0 una\u00a0 muestra\u00a0 de\u00a0\npacientes\u00a0con\u00a0infecci\u00f3n\u00a0reciente\u00a0en\u00a0Catalu\u00f1a,\u00a0entre\u00a0los\u00a0a\u00f1os\u00a020 03\u00a0y\u00a02005.\u00a0Adem\u00e1s,\u00a0tambi\u00e9n\u00a0se\u00a0\npropuso\u00a0describir\u00a0las\u00a0caracter\u00edsticas\u00a0de\u00a0estos\u00a0pacientes\u00a0en\u00a0fun ci\u00f3n\u00a0de\u00a0la\u00a0presencia\u00a0o\u00a0ausencia\u00a0de\u00a0\nresistencias\u00a0y\u00a0seg\u00fan\u00a0el\u00a0subtipo\u00a0de\u00a0VIH\u20101.\u00a0\u00a0\nD e s p u \u00e9 s \u00a0d e \u00a0i d e n t i f i c a r \u00a0l a s \u00a0m u e s t r a s \u00a0d e \u00a0p a c i e n t e s \u00a0c o n \u00a0i n f e c c i \u00f3 n \u00a0 reciente\u00a0 a\u00a0 trav\u00e9s\u00a0 del\u00a0 test\u00a0\nSTARHS\u00a0 en\u00a0 un\u00a0 estudio\u00a0 previo,\u00a0 se\u00a0 recuperaron\u00a0 aquellas\u00a0 que\u00a0 corres pond\u00edan\u00a0 a\u00a0 los\u00a0 pacientes\u00a0\nidentificados\u00a0con\u00a0infecci\u00f3n\u00a0reciente,\u00a0y\u00a0que\u00a0no\u00a0hab\u00edan\u00a0recibido\u00a0 tratamiento\u00a0antirretroviral.\u00a0Una\u00a0vez\u00a0\nrecuperadas,\u00a0se\u00a0realiz\u00f3\u00a0el\u00a0genot ipado\u00a0de\u00a0las\u00a0muestras\u00a0y\u00a0se\u00a0obtuvo\u00a0la\u00a0secuencia\u00a0FASTA\u00a0de\u00a0cada\u00a0una.\u00a0\nLas\u00a0secuencias\u00a0FASTA\u00a0se\u00a0analizaron\u00a0usando\u00a0el\u00a0programa\u00a0disponibl e\u00a0en\u00a0la\u00a0web\u00a0de\u00a0Stanford\u00a0(HIVDB\u00a0\nProgram).\u00a0 Para\u00a0 estimar\u00a0 la\u00a0 prevalencia\u00a0 de\u00a0 resistencias\u00a0 transmiti das\u00a0 se\u00a0 us\u00f3\u00a0 el\u00a0 listado\u00a0 de\u00a0\nmutaciones\u00a0publicado\u00a0por\u00a0la\u00a0OMS\u00a0en\u00a0el\u00a0a\u00f1o\u00a02009.\u00a0\u00a0\nEntre\u00a0un\u00a0total\u00a0de\u00a0182\u00a0pacientes\u00a0con\u00a0infecci\u00f3n\u00a0reciente,\u00a014\u00a0(7,7 %)\u00a0presentaron\u00a0resistencias\u00a0\ntransmitidas.\u00a0Siete\u00a0(3,8%)\u00a0ten\u00edan\u00a0resistencias\u00a0transmitidas\u00a0fre nte\u00a0a\u00a0los\u00a0ITINANs,\u00a06\u00a0(3,3%)\u00a0frente\u00a0a\u00a0\nlos\u00a0ITIANs,\u00a03\u00a0(1,6%)\u00a0frente\u00a0a\u00a0los\u00a0IPs,\u00a0y\u00a0s\u00f3lo\u00a0dos\u00a0individuos\u00a0(1 ,1%)\u00a0presentaban\u00a0resistencias\u00a0frente\u00a0\na\u00a0m\u00e1s\u00a0de\u00a0una\u00a0familia\u00a0de\u00a0f\u00e1rmacos.\u00a0No\u00a0se\u00a0encontraron\u00a0diferencias \u00a0entre\u00a0los\u00a0pacientes\u00a0infectados\u00a0\npor\u00a0cepas\u00a0con\u00a0resistencias\u00a0y\u00a0los\u00a0pacientes\u00a0infectados\u00a0por\u00a0cepas \u00a0sin\u00a0resistencias.\u00a0Un\u00a0total\u00a0de\u00a035\u00a0\npacientes\u00a0(19,2%)\u00a0estaban\u00a0infectados\u00a0por\u00a0un\u00a0subtipo\u00a0de\u00a0VIH\u20101\u00a0no \u00a0B.\u00a0Los\u00a0pacientes\u00a0infectados\u00a0por\u00a0\nsubtipos\u00a0 no\u00a0 B\u00a0 eran\u00a0 mayores\u00a0 (35,9\u00a0 vs\u00a0 32,8\u00a0 a\u00f1os),\u00a0con\u00a0mayor\u00a0frecuencia\u00a0hab\u00edan\u00a0adquirido\u00a0la\u00a0infecci\u00f3n\u00a0a\u00a0trav\u00e9s\u00a0del\u00a0uso\u00a0de\u00a0drogas\u00a0por\u00a0v\u00eda\u00a0parenteral,\u00a0y\u00a0se\u00a0h ab\u00edan\u00a0diagnosticado\u00a0con\u00a0mayor\u00a0\nfrecuencia\u00a0en\u00a0\u00e1reas\u00a0de\u00a0fuera\u00a0de\u00a0Barcelona\u00a0y\u00a0su\u00a0\u00e1rea\u00a0metropolita na.\u00a0Un\u00a017,2%\u00a0de\u00a0los\u00a0pacientes\u00a0de\u00a0\norigen\u00a0aut\u00f3ctono\u00a0estaban\u00a0infectad os\u00a0por\u00a0subtipos\u00a0de\u00a0VIH\u20101\u00a0no\u00a0B. \u00a0M\u00c9TODOS\u00a0Y\u00a0RESULTADOS\u00a0\n 58Este\u00a0estudio\u00a0es\u00a0el\u00a0primero\u00a0en\u00a0estimar\u00a0la\u00a0prevalencia\u00a0de\u00a0resiste ncias\u00a0transmitidas\u00a0en\u00a0pacientes\u00a0\ncon\u00a0infecci\u00f3n\u00a0reciente\u00a0por\u00a0VIH\u20101\u00a0en\u00a0Catalu\u00f1a,\u00a0y\u00a0los\u00a0resultados\u00a0 son\u00a0muy\u00a0similares\u00a0a\u00a0otros\u00a0estudios\u00a0\nrealizados\u00a0en\u00a0otras\u00a0regiones\u00a0de\u00a0Espa\u00f1a.\u00a0La\u00a0alta\u00a0prevalencia\u00a0de\u00a0 subtipos\u00a0no\u00a0B\u00a0entre\u00a0los\u00a0pacientes\u00a0\naut\u00f3ctonos\u00a0 sugiere\u00a0 que\u00a0 \u00e9stos\u00a0 se\u00a0 encuentran\u00a0 circulando\u00a0 entre\u00a0 nue stra\u00a0 poblaci\u00f3n\u00a0 Para\u00a0 el\u00a0\nseguimiento\u00a0adecuado\u00a0de\u00a0estos\u00a0pa r\u00e1metros\u00a0es\u00a0necesaria\u00a0la\u00a0vigila ncia\u00a0epidemiol\u00f3gica\u00a0sistem\u00e1tica\u00a0\nde\u00a0las\u00a0resistencias\u00a0transmitidas.\u00a0\u00a0\u00a0\u00a0Enferm Infecc Microbiol Clin. 2011; 29(7):482\u2013489\nwww.elsevier.es/eimc\nOriginal article\nPrevalence of Transmitted Antiretroviral Resistance and Distribution of HIV-1\nSubtypes Among Patients with Recent Infection in Catalonia (Spain) between2003 and 2005\nAnabel Romeroa,b,c,\u2666, Omar Suedd,\u2666, Teresa Puige, Anna Estevea,b, Tom\u00e0s Pumarolad, Jordi\nCasabonaa,b,c, Victoria Gonz\u00e1leza,b,f, Lurdes Matasf, Cristina Turalg, Isabel Rodrigoh, N\u00faria Margalli,\nPere Domingoi, Aurora Casanovaj, Elena Ferrerj, Estrella Caballerok, Esteve Riberak, Joan Farr\u00e9l,\nTeresa Puigl, M. Jos\u00e9 Amengualm, Gemma Navarrom, Josep M. Pratn, \u00c0ngels Masabeun, Josep M.\nSim\u00f3o, Carlos A. Villaverdeo, Pilar Barrufetp, M. Goretti Saucap, Xavier Ortinq, Amat Ort\u00edq, Rosa\nNavarror, Josep M. Eurass, Josep Vilar\u00f3s, M. Carme Vill\u00e0t, Santiago Montullt, Conrad Vilanovau,\nFerran Pujolv, Olga D\u00edazw, Jose M. Mir\u00f3d,\u2217, the AERI study Group\naCenter for Epidemiological Studies on HIV/AIDS and STI of Catalonia (CEEISCAT), Institut Catal\u00e0 d\u2019Oncologia/Health Department, Generalitat de Catalunya, Spain\nbCIBER Epidemiolog\u00eda y Salud P\u00fablica (CIBERESP), Spain\ncDepartment of Epidemiology and Evaluation, IMIM-Parc de Salut Mar, Barcelona, Spain, Department of Paediatrics, Obstetrics and Gynaecology, and Preventive Medicine, Universitat\nAut\u00f2noma de Barcelona, Barcelona, Spain\ndHospital Cl\u00ednic \u2013 IDIBAPS, University of Barcelona, Barcelona, Spain\neInstitut de Recerca de la SIDA-irsiCaixa, Badalona, Spain, Hospital Universitari Germans Trias i Pujol, Badalona, Spain\nfMicrobiology Service, Hospital Universitari Germans Trias I Pujol, Departament de Gen\u00e8tica i Microbiologia, Universitat Aut\u00f2noma de Barcelona, Badalona, Spain\ngHospital Universitari Germans Trias i Pujol, Universitat Aut\u00f2noma de Barcelona, Badalona, Spain\nhLaboratori Cl\u00ednic Manso, Barcelona, Spain\niHospital de la Santa Creu I Sant Pau, Barcelona, Spain\njHospital Universitari de Bellvitge \u2013 IDIBELL, l\u2019Hospitalet de Llobregat, Spain\nkHospital Universitari Vall d\u2019Hebron, Universitat Aut\u00f2noma de Barcelona, Barcelona, Spain\nlHospital Universitari Arnau de Vilanova, Lleida, Spain\nmCorporaci\u00f3 Sanit\u00e0ria i Universit\u00e0ria Parc Taul\u00ed, Universitat Aut\u00f2noma de Barcelona, Sabadell, Spain\nnHospital de Palam\u00f2s, Palam\u00f2s, Spain\noHospital Universitari de Sant Joan de Reus, Reus, Spain\npHospital de Matar\u00f3, Matar\u00f3, Spain\nqHospital de Tortosa Verge de la Cinta, Tortosa, Spain\nrLaboratori Cl\u00ednic Cornell\u00e0 de Llobregat, Cornell\u00e0 de Llobregat, Spain\nsHospital General de Vic, Vic, Spain\ntHospital General de Granollers, Granollers, Spain\nuLaboratori Cl\u00ednic El Maresme, Matar\u00f3\nvProjecte dels Noms \u2013 Hispanosida, Barcelona, Spain\nwServei d\u2019Atenci\u00f3 i Prevenci\u00f3 Sociosanit\u00e0ria: SAPS \u2013 Creu Roja, Barcelona, Spain\narticle info\nArticle history:\nReceived 27 August 2010Accepted 3 March 2011Available online 2 May 2011\nKeywords:Transmitted resistanceRecent infectionsHIV-1 subtypesabstract\nObjectives: The objectives of this study were to assess the prevalence of transmitted HIV-1 drug resis-\ntances (TDR) and HIV-1 subtypes in recently infected patients in Catalonia between 2003 and 2005 and\nto describe the characteristics of these patients according to the presence or absence of TDR and HIV-1subtype.Methods: After application of the Serological Testing Algorithm for Recent HIV Seroconversion (STARHS),\nresidual aliquots of serum samples from recently infected antiretroviral-na\u00efve individuals were geno-typed. FASTA sequences were analyzed using the HIVDB Program. The World Health Organization 2009List of Mutations for Surveillance of Transmitted HIV-1 Drug Resistant HIV Strains was used to estimatethe prevalence of TDR.\n\u2217Corresponding author.\nE-mail address: jmmiro@ub.edu (J.M. Mir\u00f3).\n\u2666Omar Sued and Anabel Romero have contributed equally in the design, analysis, and writing of the manuscript.\n0213-005X/$ \u2013 see front matter \u00a9 2010 Elsevier Espa\u00f1a, S.L. All rights reserved.\ndoi:10.1016/j.eimc.2011.03.001Document downloaded from http://www.elsevier.es, day 16/12/2011. This copy is for personal use. Any transmission of this document by any media or format is strictly prohibited.A. Romero et al / Enferm Infecc Microbiol Clin. 2011; 29(7):482\u2013489 483\nPalabras clave:\nResistencias transmitidasInfecciones recientesSubtipo de VIH-1Results: Of 182 recently infected patients, 14 (7.7%) presented TDR. Seven (3.8%) had genotypic evidence\nof TDR against non-nucleoside reverse transcriptase inhibitors, 6 (3.3%) against nucleoside reverse tran-\nscriptase inhibitors, 3 (1.6%) against protease inhibitors (PIs), and only 2 individuals (1.1%) presentedTDR against more than one class of drugs. Thirty-\ufb01ve (19.2%) patients were infected with a non-B HIV-1subtype.Conclusion: This is the \ufb01rst study to estimate the prevalence of TDR in recently infected patients in Cat-\nalonia. The results are similar to those of studies performed in other Spanish regions. Correct monitoringof these parameters requires systematic epidemiologic surveillance of transmitted resistance.\n\u00a9 2010 Elsevier Espa\u00f1a, S.L. All rights reserved.\nPrevalencia de resistencias primarias transmitidas y distribuci\u00f3n de subtipos\nVIH-1 en pacientes con infecci\u00f3n reciente en Catalu \u02dcna (2003-2005)\nresumen\nObjetivos\nLos objetivos de este estudio fueron evaluar la prevalencia de las resistencias primarias transmitidas (RPT)\ny de subtipos de VIH-1 en pacientes recientemente infectados en Catalu \u02dcna entre 2003 y 2005, y describir\nlas caracter\u00edsticas de estos pacientes seg\u00fan la presencia o ausencia de RPT y el subtipo de VIH-1.M\u00e9todos: Despu\u00e9s de la aplicaci\u00f3n del algoritmo de pruebas serol\u00f3gicas para la seroconversi\u00f3n reciente\nal VIH (STARHS), al\u00edcuotas residuales de las muestras de suero de individuos recientemente infectados notratados previamente con antirretrovirales fueron genotipados. Las secuencias FASTA se analizaron conel programa HIVdb. Se utiliz\u00f3 el listado de mutaciones de la Organizaci\u00f3n Mundial de la Salud del 2009para estimar la prevalencia de resistencias transmitidas.Resultados: De 182 pacientes recientemente infectados, 14 (7,7%) presentaron RPT. Siete personas (3,8%)\npresentaban evidencias genot\u00edpica de RPT a los inhibidores de la transcriptasa inversa no an\u00e1logos anucle\u00f3sidos, 6 (3,3%) frente a inhibidores de la transcriptasa inversa an\u00e1logos de nucle\u00f3sidos, 3 (1,6%)frente a los inhibidores de la proteasa, y solo 2 personas (1,1%) presentaron RPT a m\u00e1s de una familia demedicamentos. Treinta y cinco (19,2%) pacientes estaban infectados con un subtipo no-B del VIH-1.Conclusi\u00f3n: Este es el primer estudio que estima la prevalencia de RPT en pacientes recientemente infec-\ntados en Catalu \u02dcna, y los resultados son similares a los de estudios realizados en otras regiones espa \u02dcnolas.\nPara el adecuado seguimiento de estos par\u00e1metros es necesaria la vigilancia epidemiol\u00f3gica sistem\u00e1ticade las RPT.\n\u00a9 2010 Elsevier Espa \u02dcna, S.L. Todos los derechos reservados.\nIntroduction\nEmergence of transmitted HIV-1 drug resistance is well doc-\numented almost everywhere combined antiretroviral treatment\n(cART) is available. Global resistance estimates vary between 5%and 25% in primary infection, depending on study population,de\ufb01nition of resistance, cART strategy, infection status (recent orchronic), and year of evaluation.\n1,2In Spain, the rate of transmitted\nHIV-1 drug resistance has been reported to be between 7.1 and12.1%.\n3,4\nContinued surveillance of transmitted HIV-1 drug resistance\nprovides useful information on cART as a \ufb01rst-line regimen. Base-line resistance has been shown to impair the response to highlyactive antiretroviral therapy (HAART),\n5although a genotype-\nguided cART regimen can prove just as effective in patientswith primary drug resistance as in patients with wild-typevirus.\n6\nIn addition, increased population movements resulting from\nimmigration, international travel, and sexual contact with individ-uals from countries where non-B subtypes are endemic have ledto increased prevalence of these strains in developed countries.\n7\nThe presence of circulating non-B subtypes complicates the inter-pretation of tests (viral load or resistance testing) that have beendeveloped mainly for B subtypes. Many reported minor mutationsassociated with resistance by B subtypes are natural polymor-phisms in some non-B subtypes, although their impact on thesusceptibility of antiretroviral drugs has not been clari\ufb01ed todate.\nThe objectives of this study were to report the prevalence of\ntransmitted HIV-1 drug resistance and HIV-1 subtypes in patientswith recent HIV-1 infection in the area of Catalonia (Spain) between2003 and 2005 and to describe the characteristics of these patientsaccording to the presence or absence of transmitted HIV-1 drugresistance and HIV-1 subtype.\nPatients and methods\nPatients\nThe study population was composed of new HIV-1 diagnoses,\nantiretroviral-na\u00efve individuals who were identi\ufb01ed as having\nnewly diagnosed with recent HIV-1 infection between 2003 and2005 at 26 of the 28 laboratories participating in the AERI project.\n8\nWe were only able to include samples from 17 of the 26 laboratories(1 each from Badalona, L\u2019Hospitalet de Llobregat, Lleida, Sabadell,Palam\u00f2s, Reus, Tortosa, Cornell\u00e0, Granollers, and Vic, as well as 5from Barcelona and 2 from Matar\u00f3).\nThe protocol was approved by the ethics committees of all the\nparticipating centers. An infection was considered recent if thesample reacted with the sensitive enzyme immunoassay (EIA) butnot with the modi\ufb01ed less sensitive EIA (LS-EIA (ie, had low HIV-1antibody titers). Since antibody titers can fall in advanced stagesof HIV-1 infection, patients whose samples did not react and whopresented clinical criteria for AIDS were not considered recentlyinfected. All patients who had initiated cART before sampling wereexcluded from this analysis.\nSpecimen collection\nResidual aliquots of serum collected for diagnostic purposes\nwere frozen and sent by the participating laboratories to the coor-\ndinating center (Centre d\u2019Estudis Epidemiol\u00f2gics sobre les ITS i la Sidade Catalunya, CEEISCAT). After application of Serological TestingAlgorithm for Recent HIV Seroconversion (STARHS) samples wereDocument downloaded from http://www.elsevier.es, day 16/12/2011. This copy is for personal use. Any transmission of this document by any media or format is strictly prohibited.484 A. Romero et al / Enferm Infecc Microbiol Clin. 2011; 29(7):482\u2013489\n*Of the 728 samples excluded, 75.0% belonged to patients whose HIV infection was diagnosed\nmore than 6 months before sample collection, 11.1% were duplicate samples, 9.2% were HIV-\nnegative samples, 2.7% did had insufficient volume, 1.4% were negative by WB, and 0.5% were\nfrom patients aged under 18 years.   489 Samples excluded from the resistance study\n-  96 from two centers that decided not to participate in\nthe present study\n-  28 from patients with clinical criteria for AIDS\n-  9 from patients with previous ARV treatment\n-  70 from patients with insufficient sample volume\n-  286 from patients with no information about previous treatment\n224 samples eligible for the resistance study\n42 samples excluded due to lack of amplification\n182 samples analyzed4172 samples collected for the AERI project 2003-2005 \n728 samples excluded * \n3444 tested with LS-EIA \n2731 reactive\n(considered long-standing\ninfections)713 nonreactive\nFigure 1. Flowchart of samples included in our study. *Of the 728 samples excluded, 75.0% belonged to patients whose HIV infection was diagnosed more than 6 months\nbefore sample collection, 11.1% were duplicate samples, 9.2% were HIV-negative samples, 2.7% did had insuf\ufb01cient volume, 1.4% were negative by WB, and 0.5% were from\npatients aged under 18 years.\nstored at \u201370\u25e6C. The residual volumes of serum specimens from\nrecently infected treatment-na\u00efve patients were sent to the two\nlaboratories responsible for genotyping (IrsiCaixa Foundation andHospital Cl\u00ednic).\nData collection\nLaboratory staff completed a data collection form to record\nCD4\n+T-cell count, HIV-1 viral load, and previous HIV-1 test results.\nAn additional data collection form was required for each recently\ninfected case. This form was completed by the patient\u2019s physicianor a designated person and contained demographic and clinical-epidemiological variables (sex, date of birth, country of origin, dateof arrival in Spain, HIV-1 risk category, sexually transmitted infec-tions, known HIV-1 status at the time of current testing, and use ofcART).\nQuality control\nExtensive control procedures were implemented to ensure the\nquality of the data. In patients identi\ufb01ed as recent infected, their\nidenti\ufb01cation study numbers were sent to each participant centreto ensure that each included patient had not received antiretroviraltreatment. Patients for whom no information on previous cART wasavailable were excluded from the analysis.Identi\ufb01cation of recent infections\nHIV-1 positive specimens were tested at the Microbiology Ser-\nvice of Hospital Universitari Germans Trias i Pujol using a modi\ufb01ed\nversion of the Vironostika HIV-1 EIA (bioM\u00e9rieux, Durham, NorthCarolina, USA), in which sample dilution times and sample andconjugate incubation times were modi\ufb01ed to render it less sensi-tive. Recent infection was de\ufb01ned as occurring within the past 170days (95% con\ufb01dence interval [CI], 144-200).\n9Since 2000, CEEISCAT\n(Center for Epidemiological Studies on STIs/HIV/AIDS of Catalonia)and the Microbiology Service of the Hospital Universitari Germans\nTrias i Pujol have been participating in an international STARHS\nquality control program established by the Centers for Disease Con-trol and Prevention (FDA BB-IND # 8193).\nGenotyping\nHIV-1 reverse transcriptase and protease genes were genotyped\nusing the TruGene HIV-1 Genotyping Kit, (Siemens Healthcare\nDiagnostics, Barcelona, Spain) at the IrsiCaixa laboratory and theViroSeq HIV-1 Genotyping System (Abbott Molecular, Abbott Park,Illinois, USA) at the Hospital Cl\u00ednic laboratory. TruGene ampli\ufb01esfrom codon 4 to 99 in the protease gene and from codon 37 to 247in the reverse transcriptase gene. ViroSeq ampli\ufb01es codons 1 to 99in the protease gene and codons 1 to 335 in the reverse transcriptasegene.Document downloaded from http://www.elsevier.es, day 16/12/2011. This copy is for personal use. Any transmission of this document by any media or format is strictly prohibited.A. Romero et al / Enferm Infecc Microbiol Clin. 2011; 29(7):482\u2013489 485\nIn order to homogenize the sequence analyses, all FASTA\nsequences were analyzed using the HIVDB Program (available from\nhttp://hivdb.stanford.edu , August 2008) and summarized. How-\never, to calculate the prevalence of mutations associated withreduced drug susceptibility, we used the World Health Organiza-tion (WHO) 2009 List of Mutations for Surveillance of TransmittedDrug Resistant HIV Strains.\n10Viral subtypes were assessed on the\nbasis of the pol sequence using the REGA HIV-1 subtyping tool, ver-sion 2 (available from http://www.bioafrica.net/subtypetool/html/ ,\nJuly 2009). In cases where the REGA HIV-1 subtyping tool didnot assign a valid subtype, we used phylogenetic analysis. Geneticdistances and evolutionary rates were computed using a Kimura2-parameter model. Neighbour-joining phylogenetic trees of eachsubject\u2019s pol sequences were constructed using MEGA4.1. The reli-ability of phylogram clustering was assessed by bootstrappinganalyses.\nStatistical analysis\nWe calculated the proportion of the presence or absence of\ntransmitted HIV-1 drug resistance and B and non-B HIV-1 subtypes.\nWe provided the 95% CI using the normal approximation or theexact method when appropriate. Patients with or without resistantpro\ufb01les and with B or non-B HIV-1 subtypes were compared usingthe Pearson chi square test or Fisher exact test. The Mann-Whitneytest was performed for quantitative variables. The variables exam-ined were gender, age at diagnosis, route of transmission, origin,year of diagnosis, CD4\n+T-cell count, HIV-1 viral load, co-infection\nwith a sexually transmitted infection, and geographic area. Univari-ate and multivariate logistic regression models were constructedto identify the characteristics associated with infection by a non-BHIV-1 subtype.\nResults\nWe collected 4,172 samples between 2003 and 2005. After\nexcluding duplicates and patients with a previously known HIV-\n1 infection, we used LS-EIA to analyze 3,444 samples, of which713 were nonreactive. Of these, 489 were excluded for variousreasons (lack of information about previous treatment, samplesfrom 2 centers that did not participate in the study, AIDS, previousantiretroviral treatment, or insuf\ufb01cient sample volume); therefore,224 samples were eligible, and, of these, 182 were successfullygenotyped (Fig. 1). Age, gender, origin, and HIV-1 risk were sim-\nilar for the study patients and those who were excluded (data notshown). Most of the patients were male (80.8%), natives of Spain(76.2%), and the median age was 33.3 years. The main route of HIV-1 acquisition was sexual relations between men who have sex withmen (48.3%), followed by heterosexual relations (22.5%), and intra-venous drug use (13.2%). Median (interquartile range (IQR)) viralload (log\n10) was 5.0 (4.5-5.5) and median (IQR) CD4 lymphocyte\ncount was 541 cells/mm3(357-698).\nAccording to the WHO 2009 list, 7.7% (95% CI, 4.3-12.6) of\nindividuals with recent infections (14 cases) presented mutationsassociated with resistance. Seven patients (3.8%; 95% CI, 1.6%-7.8%) had evidence of resistance against non-nucleoside reversetranscriptase inhibitors (NNRTIs), 6 (3.3%; 95% CI, 1.2%-7.0%)had genotypic evidence of primary drug resistance to nucleosidereverse transcriptase inhibitors (NRTIs), 3 (1.6%; 95% CI, 0.3%-4.7%)against protease inhibitors (PIs), and only 2 (1.1%; 95% CI, 0.1%-3.9%)presented mutations associated with resistance against more than1 class of drugs. The prevalence of resistance was 10.0% (95% CI,3.8-20.5) for 2003, 6.5% (95% CI, 2.1-14.5) for 2004, and 6.7% (95%CI, 1.4-18.3) for 2005.Table 1\nPrevalence of Mutations in the Protease and Reverse Transcriptase Genes.\nMutations Frequency N (%)\nPR gene\nL10F/I/V 19 (10.4)\nA71T/V 19 (10.4)\nD30N 1 (0.5)\nK43T 1 (0.5)\nI47V 1 (0.5)\nQ58E 1 (0.5)\nV82L 1 (0.5)\nL90S 1 (0.5)\nRT geneNRTIs\nA62V 5 (2.7)\nV118I 5 (2.7)\nM41L 3 (1.6)\nG333E 3 (1.6)\nD67N/E 2 (1.1)\nL210M 2 (1.1)\nL210W 1 (0.5)\nT215D 2 (1.1)\nT215F 1 (0.5)\nK219Q/E 2 (1.1)\nT69N 1 (0.5)\nK70R 1 (0.5)\nV75A/I/T/V 1 (0.5)\nY115C 1 (0.5)\nE44A 1 (0.5)\nNNRTIs\nE138A 10 (5.5)\nV179E/D/C 7 (3.8)\nK103N 5 (2.7)\nK103R 4 (2.2)\nA98T/G 2 (1.1)\nY188L/H 2 (1.1)\nF227L/S 2 (1.1)\nV106A 1 (0.5)\nV108I 1 (0.5)\nV90I 2 (1.1)\nV106I 2 (1.1)\nMutations in bold are considered to be associated with resistance according to thelist for surveillance by WHO.\nAccording to the WHO list, the most prevalent resistance\nmutations\u2014K103N (2.7%), and M41L (1.6%)\u2014were in the reverse\ntranscriptase gene. In addition, considering mutations reported bythe HIVDB, minor mutations were common in the protein gene(L10F/I/V and A71T/V; 10.44% each), as were NNRTI-related muta-tions, such as E138A (5.49%), V179E/D/C (3.85%), and K103R (2.2%).A list with all the mutations observed is presented in Table 1.\nPatient characteristics according to the presence or absence of\ntransmitted HIV-1 drug resistance (WHO 2009 List of Mutations)are shown in Table 2. Patients with transmitted HIV-1 drug resis-\ntance were men (100.0%) with a median age of 33.6 years. Men whohave sex with men accounted for 57.1%, and 57.1% were from Spain.An STI was diagnosed in 75%, 71.4% were subtype B, 85.7% werefrom the area of Barcelona, the median viral load (log\n10) was 4.7\nand the median CD4 lymphocyte count was 476 cells/mm3. There\nwere no statistically signi\ufb01cant differences between resistant andnonresistant groups. However, immigrants (15.0%), men (9.5%), andpatients with a diagnosis of a sexually transmitted infection (8.3%)showed a higher prevalence of transmitted HIV-1 drug resistance.\nOf the 182 successfully genotyped samples, 147 (80.8%) were\nlabeled as subtype B and 35 (19.2%) were classi\ufb01ed as other sub-types. A total of 39 sequences were not ascribed by the REGA sub-typing tool and the subtype was assigned by phylogenetic analysis.The distribution of non-B subtypes was CRF02\nAG (n=11), CRF01 AE\n(n=9), G (n=3), A (n=3), F/B (n=2), G/B (n=2), D (n=1), H/B (n=1), J/K(n=1), K/G (n=1) and C (n=1). The characteristics of patients accord-ing to HIV-1 subtype are shown in Table 3. Most of the patientsDocument downloaded from http://www.elsevier.es, day 16/12/2011. This copy is for personal use. Any transmission of this document by any media or format is strictly prohibited.486 A. Romero et al / Enferm Infecc Microbiol Clin. 2011; 29(7):482\u2013489\nTable 2\nCharacteristics of patients according to the presence or absence of transmitted HIV-1 drug resistance, according the World Health Organization 2009 List of Mutations forSurveillance of Transmitted Drug Resistant HIV Strains.\nTotal Non resistant Resistant P\n182 168 (92.3) 14 (7.7)95% CI: (87.4-95.7 95% CI: 4.3-12.6\nSex\n*.075\nMale 147 (80.8) 133 (79.2) 14 (100.0)Female 35 (19.2) 35 (20.8) 0 (0.0)\nAge (years) (N=181)\n**33.3 (27.2\u201337.9) 33.3 (27.2-37.8) 33.6 (28.2-42.7) .500\n<30*69 (38.1) 65 (38.9) 4 (28.5) .677\n30-40 78 (43.1) 72 (43.1) 6 (42.9)\n40-50 21 (11.6) 19 (11.4) 2 (14.3)\n>50 13 (7.2) 11 (6.6) 2 (14.3)\nRoute of transmission*.404\nMen who have sex with men 88 (48.3) 80 (47.6) 8 (57.1)Heterosexual 41 (22.5) 37 (22.0) 4 (28.6)Intravenous drug use 24 (13.3) 22 (13.1) 2 (14.3)Others/unknown 29 (15.9) 29 (17.3) 0 (0.0)\nOrigin\n*(N=168)***.101\nNatives 128 (70.3) 120 (77.9) 8 (57.1)Immigrant 40 (29.7) 34 (22.1) 6 (42.9)\nPlasma RNA-HIV-1 (log\n10) N=162)**5.0 (4.5-5.5) 5.1 (4.5-5.6) 4.7 (4.2-5.3) .093\n<5.0*81 (50.0) 73 (48.3) 8 (72.7) .210\n>5.0 81 (50.0) 78 (51.7) 3 (27.3)\nCD4 cell count /mm3(N=154)**541 (357-698) 541 (358-6999) 476 (194-714) .582\n<350*36 (23.4) 33 (23.0) 3 (30.0) .540\n350-500 31 (20.1) 28 (19.4) 3 (30.0)\n>500 87 (56.5) 83 (57.6) 4 (40.0)\nSTI co-infection (N=96)*.147\nYes 36 (37.5) 33 (35.9) 3 (75.0)No 60 (62.5) 59 (64.1) 1 (25.0)\nHIV subtype\n*.477\nB 147 (80.8) 137 (81.5) 10 (71.4)Non B 35 (19.2) 31 (18.5) 4 (28.6)\nGeographic area\n*.624\nBarcelona 165 (90.7) 153 (91.1) 12 (85.7)\nOutside Barcelona 17 (9.3) 15 (8.9) 2 (14.3)\n*N (%);**Median and interquartile range;***P value calculated for 168 patients with available information.\nSTI co-infection: Having a diagnosis of an sexually transmitted infection within 12 months before inclusion.\nBarcelona: Includes Barcelona city and its metropolitan area.Outside Barcelona: Includes Lleida, Tortosa, Reus, Vic and Palam\u00f2s.\nwith a non-B subtype were male (71.4%) with a median age of 35.9\nyears. Spanish-born patients accounted for 64.7% and 80% werefrom the area of Barcelona. Median viral load was 5.1, median CD4cell count was 471 cells/mm\n3, 20% reported a diagnosis of STI, and\n11.4% presented transmitted HIV-1 drug resistances. Among thepatients infected by a non-B subtype, the percentage of men whohave sex with men, heterosexual individuals, and intravenous drugusers was the same for the 3 groups (28.6%). Twelve (34%) of thesepatients infected by a non-B subtype were immigrants: 5 were fromSouth America, 4 from Sub-Saharan Africa, 2 from Eastern Europe,and 1 from North Africa. The date of arrival in Spain was knownin 8 cases: 6 had arrived in Spain more than 2 years previously, 1had arrived 7 months before the HIV diagnosis, and 1 patient hadarrived just 1 month before the HIV diagnosis. When comparingindividuals carrying the B subtype with those carrying the non-Bsubtype, individuals with non-B subtypes were older (35.9 vs 32.8years), more frequently intravenous drug users (41.7%), and morefrequently from areas outside Barcelona (41.2 vs. 17.0%). These dif-ferences were statistically signi\ufb01cant ( Table 3). They also presented\na lower CD4 lymphocyte count than patients carrying the B subtype.The variables entered in the logistic regression model were age, CD4count, transmission group, and transmitted HIV-1 drug resistance.In the multivariate analysis, being over 40 years of age was the onlyfactor associated with infection by a non-B HIV-1 subtype.Discussion\nThis is the \ufb01rst prospective study to evaluate the prevalence of\ntransmitted HIV-1 drug resistances in recently infected patients inthe Autonomous Region of Catalonia, Spain. Using the 2009 WHOHIV mutations list, we were able to demonstrate a rate of drugresistance (7.7%) similar to that of previous studies in other Spanishand European regions.\n2\u20134,11\u201313In a recent meta-analysis including\n26 studies performed in Spain, the global transmitted HIV-1 drugresistance prevalence was estimated to be 10.6% between 1997 \u20132008.\n14Although this result is quite similar to ours, the revised\nstudies have used different lists of transmitted HIV-1 drug resis-tance and none of them have used the WHO 2009 list, makingdif\ufb01cult any comparison.\nWe observed that prevalence was higher in 2003 than in fol-\nlowing years (10.0 vs 6.5% in 2004 and 6.7% in 2005). Although notstatistically signi\ufb01cant, this \ufb01nding is consistent with those of otherauthors, who report a decreasing temporal trend in the prevalenceof transmitted HIV-1 drug resistances.\n2\nThe main dif\ufb01culty in analyzing genotypic information to pro-\nvide prevalence rates is to establish a comparable de\ufb01nition ofresistance.\n1,12The IAS-USA 200915list is commonly used to report\nresistance and has been developed to analyze mutations selected bythe HIV-1 B subtype. This is particularly relevant in persons infectedDocument downloaded from http://www.elsevier.es, day 16/12/2011. This copy is for personal use. Any transmission of this document by any media or format is strictly prohibited.A. Romero et al / Enferm Infecc Microbiol Clin. 2011; 29(7):482\u2013489 487\nTable 3\nCharacteristics of patients according to HIV-1 subtype.\nTotal B subtype Non B subtype P\n182 147 (80.8) 35 (19.2)\n95% CI: (74.3-86.2) 95% CI: (13.8-25.7)\nSex*.151\nMale 147 (80.8) 122 (83.0) 25 (71.4)\nFemale 35 (19.2) 25 (17.0) 10 (28.6)\nAge (years) (N=181)**33.3 (27.2\u201337.9) 32.8 (26.9-37.2) 35.9 (29.2-43.1) .017\n<30*69 (38.1) 60 (41.1) 9 (25.7) .004\n30-40 78 (43.1) 66 (45.2) 12 (34.3)\n40-50 21 (11.6) 11 (7.5) 10 (28.6)\n>50 13 (7.2) 9 (6.1) 4 (11.4)\nRoute of transmission*.009\nMen who have sex with men 88 (48.3) 78 (53.1) 10 (28.6)Heterosexual 41 (22.5) 31 (21.1) 10 (28.6)Intravenous drug use 24 (13.3) 14 (9.5) 10 (28.6)Others/unknown 29 (15.9) 24 (16.3) 5 (14.3)\nOrigin\n*(N=168)***.113\nNatives 128 (70.3) 106 (79.1) 22 (64.7)Immigrant 40 (29.7) 28 (20.9) 12 (34.3)\nPlasma RNA-HIV-1 (log\n10) (N=162)**5.0 (4.5-5.5) 5.0 (4.5-5.5) 5.1 (4.2-5.7) .935\n<5.0*81 (50.0) 67 (50.8) 14 (46.7) .840\n>5.0 81 (50.0) 65 (49.2) 16 (53.3)\nCD4 cell count /mm3(N=154)**541 (357-698) 553 (390-712) 471 (281-581) .063\n<350*36 (23.4) 25 (19.8) 11 (39.3) .059\n350-500 31 (20.1) 25 (19.8) 6 (21.4)\n>500 87 (56.5) 76 (60.3) 11 (39.3)\nSTI co-infection (N=96)*.127\nYes 36 (37.5) 33 (40.7) 3 (20.0)No 60 (62.5) 48 (59.3) 12 (80.0)\nTransmitted HIV-Drug Resistances * .477\nYes 14 (7.7) 10 (6.8) 4 (11.4)No 168 (92.3) 137 (93.2) 31 (88.6)\nGeographic area\n*.024\nBarcelona 165 (90.7) 137 (93.2) 28 (80.0)Outside Barcelona 17 (9.3) 10 (6.8) 7 (20.0)\n*N (%);**Median and interquartile range;***P value calculated for 168 patients with available information.\nSTI co-infection: Having a diagnosis of an sexually transmitted infection within 12 months before inclusion.\nBarcelona: Includes Barcelona city and its metropolitan area.Outside Barcelona: Includes Lleida, Tortosa, Reus, Vic and Palam\u00f2s.\nwith subtypes other than B, which shows many more polymor-\nphisms than the reference subtype B virus.\nAs in previous reports,4the NNRTI mutation K103N was com-\nmon in our study (5 cases). This mutation is the result of asingle-nucleotide polymorphism from wild-type K103. It is asso-ciated with a high level of resistance to nevirapine and efavirenz,although it does not affect the activity of etravirine.\n16,17The poly-\nmorphism K103R is not associated with the emergence of K103N;however, in combination with V179, it signi\ufb01cantly reduces thesusceptibility of the virus to nevirapine and efavirenz.\n\u201cMinor\u201d or \u201csecondary\u201d mutations to new-generation NNRTIs\n(mutations associated with reduced activity to etravirine) werecommon in our study. The virological response to etravirine is afunction of the number and weight of the baseline mutations. InNNRTI-experienced patients who started etravirine, darunavir, anda background regimen in the DUET studies, weighted mutationscores of 0-2, 2.5-3.5, and \u22654 were associated with a response of\n74%, 52%, and 38%, respectively.\n16\nAs in other series,1,2thymidine analog mutations (eg, M41L,\nD67N/E, L210W, T215F, K219Q/E) were less common than NNRTImutations.\nMajor PI mutations were rare (<0.5%). Although minor PI muta-\ntions were relatively common in our sample (>10% for L10F/I/V andfor D71T/V/A), they are not included in the WHO list because theyare often reported in almost all non-B subtypes.The proportion of immigrants in our sample was 23.3% in 2003,\n18.2% in 2004, and 26.7% in 2005. In Catalonia, the number of immi-grants accounting for new cases of HIV rose during the study period(31.3% in 2003, 34.0% in 2004, and 39.1% in 2005).\n18Nearly 20% of\nour patients had non-B subtypes, and although the highest preva-lence was seen in 2005 (28.9%), there were no signi\ufb01cant trendsduring the 3 years of the study. In areas outside Barcelona (Lleida,Tortosa, Reus, Vic, and Palam\u00f3s), subtypes other than B were morefrequent than in the metropolitan area of Barcelona (41.2 vs. 17.0%).In our population of recently HIV-infected patients, the percent-age of immigrants was higher in areas outside Barcelona (47.1 vs.19.6%). The prevalence of non-B subtypes among autochthonouspatients was 17.2%. This high prevalence would suggest that non-Bsubtypes are already circulating in our population. Several authorshave reported an increase in the frequency of non-B subtypesin different Spanish regions. In Madrid, the prevalence of non-Bsubtypes increased from 9% in 2000 to 32% in 2007; the num-ber of autochthonous patients infected also increased during thesame period (from 4% to 10%).\n19In Galicia, the prevalence was\n22.3% between 2000 and 2002,20and in Gran Canaria it was 22.4%\nbetween 2002 and 2005.13\nLittle is known about the clinical and biological consequences\nof infections by non-B subtypes. Differences in pathogenicity,transmissibility, or susceptibility to antiretroviral drugs amongHIV-1 subtypes have been proposed,\n21,22and there is evidenceDocument downloaded from http://www.elsevier.es, day 16/12/2011. This copy is for personal use. Any transmission of this document by any media or format is strictly prohibited.488 A. Romero et al / Enferm Infecc Microbiol Clin. 2011; 29(7):482\u2013489\nthat similar outcomes can be found in almost all the subtypes\nafter conventional anti\u2013HIV-1 treatment.23We observed resistance\nmutations to be more frequent in patients with the non-B sub-type, although this difference it is not statistically signi\ufb01cant. Inthe multivariate analysis, the only factor associated with infectionby a non-B HIV-1 subtype was being over 40 years old. However,we are not able to offer a clear explanation for this \ufb01nding, proba-bly due to the small sample size and the constraints of our currentdata.\nGiven the limitations of our study, the results should be inter-\npreted with caution. First, we only analyzed 182 of the 713potentially recent HIV-1 infections. The lack of data on antiretro-viral therapy was the most frequent cause of exclusion,\n9although\na comparison of the baseline characteristics of patients with andwithout a resistance test result suggests that our data are repre-sentative of the original study sample. Second, 21% of the samplesidenti\ufb01ed could not be ampli\ufb01ed. This was probably because sam-ples were residual aliquots from serological testing and, therefore,were not optimally stored for PCR analysis. Third, the LS-EIA used toidentify recent infections was validated in the B subtype. The resultsof this assay vary depending on the HIV-1 subtype, with a longerwindow period in non-B subtypes than in B subtypes. For circulat-ing recombinant forms (CRF01\nAE in particular), the mean window\nperiod was 356 days (95% CI, 318-402).24These data, would suggest\nthat non-B subtypes identi\ufb01ed as recent infections are presumed tohave seroconverted within the past 12 months. And fourth, we usedconventional sequencing, which underestimates minority HIV-1variants.\nDespite its limitations, our approach does have certain\nstrengths. First, it focused on recent infections, which demon-strated a higher rate of resistance than chronic infections, thusre\ufb02ecting, at least in part, the gradual disappearance of the dom-inant quasispecies over time. Second, analyzing all samples forrecent infection and resistance avoids the bias of recruiting per-sons who seek more frequent testing (usually white men who havesex with men), thus preventing extrapolation to the general HIV-1\u2013infected population. Third, the robustness of our data and thecharacteristics of the Catalonian health system (unrestricted freeaccess to HIV care and treatment) mean that there is little risk ofincluding patients with little exposure to therapy.\nIn conclusion, we observed a prevalence of transmitted HIV-1\ndrug resistance of 7.7% (95% CI, 4.3-12.6), which is consistent withresults from other parts of Europe. Furthermore, a high prevalenceof transmitted HIV-1 drug resistance driven mainly by K103N andNRTI mutations was found in Catalonia. We also showed the fea-sibility of monitoring both transmitted HIV-1 drug resistance andHIV subtypes in our setting, and the logistical pitfalls identi\ufb01ed willbe crucial if we are to improve monitoring of these parameters.Although not signi\ufb01cant, the prevalence of non-B subtypes amongrecently infected patients is increasing, and this group has the high-est prevalence of resistance. Although we could not establish aspatial or temporal relationship between immigration patterns, ourdata suggest that the non-B subtypes are already circulating in oursetting. Long-term monitoring of recent infection will allow us tobetter describe the relationship between transmitted HIV-1 drugresistance and subtypes with imported and locally acquired HIVinfection, as well as its clinical implications.\nFunding\nLa \u201cMarat\u00f3 de TV3\u201d Foundation awarded the CEEISCAT a grant\nfor the development of the AERI-HIV (Algoritme Estandartditzat per\nla detecci\u00f3 de Recent Infectats pel HIV) project for epidemiologicalresearch on AIDS using the STARHS technique (project #022010).The project was also partially funded by the Departament de Salut dela Generalitat de Catalunya (Department of Health of the Catalonian\nGovernment), Spain, and by the Fundaci\u00f3n para la Investigaci\u00f3n y\nPrevenci\u00f3n del Sida en Espa \u02dcna(Spanish Foundation for Prevention\nand Research in AIDS; FIPSE) of the National AIDS Plan Secretariat\n(Spanish Ministry of Health). Funding was also received from theCarlos III Health Institute (Madrid, Spain), the Spanish Network forAIDS Research (RIS; ISCIII-RETIC RD06/006) and the Spanish HealthResearch Fund (FIS, 04-0363). Dr. JM Mir\u00f3 holds an INT10/219Intensi\ufb01cation Research Grant (I3SNS & PRICS programs) from the\u201cInstituto de Salud Carlos III, Madrid (Spain)\u201d and the \u201cDepartamentde Salut de la Generalitat de Catalunya, Barcelona (Spain).\u201d\nCon\ufb02ict of interests\nThe authors declare no con\ufb02icts of interest related to this study.\nAcknowledgments\nWe are indebted to the study participants and we thank Judith\nDalmau and Lidia Ruiz for providing technical assistance and\nadvice.\nAppendix A.\nThe Recent HIV Infections (AERIVIH) study group includes the\nfollowing:\nCoordinating Center (CEEISCAT): Jordi Casabona, Anna Esteve,\nAnabel Romero, N\u00faria Ortega, Alexandra Montoliu, Eva Puchol,\nRafael Mu \u02dcnoz, Joan Masip, N\u00faria Vives, Berta Ortiga, Meritxell\nGranell, Diana Puente, M. Jes\u00fas Casado, \u00c0ngels Jaen, Jes\u00fas Almeda,Vanessa Espurz.\nSTARHS Laboratory (Microbiology Service, Hospital Universi-\ntari Germans Trias i Pujol): Victoria Gonz\u00e1lez, Elisa Martr\u00f3, Lurdes\nMatas and Vicenc \u00b8 Ausina.\nA.1. Peripheral Centers\nPrimary Health Care Laboratories: Isabel Rodrigo (Laboratori\nCl\u00ednic Manso, Barcelona), \u00c0ngels Bosch (Laboratori Intercomarcal\nde l\u2019Alt Pened\u00e8s, l\u2019Anoia i el Garraf, Igualada), Rosa L\u00f3pez (Labo-ratori Cl\u00ednic Bon Pastor, Barcelona), Eva Dopico (Laboratori Cl\u00ednicl\u2019Hospitalet de Llobregat,), Josep Ros (Laboratori Cl\u00ednic Barcelon\u00e9sNord i Maresme, Badalona), Rosa Navarro (Laboratori Cl\u00ednic Cor-nell\u00e0 de Llobregat), Conrad Vilanova (Laboratori Cl\u00ednic El Maresme,Matar\u00f3)\nA.2. Hospitals\nLaboratory Staff: Tom\u00e0s Pumarola (Hospital Cl\u00ednic-IDIBAPS,\nUniversity of Barcelona, Barcelona), Aurora Casanova (Hospital\nUniversitari de Bellvitge-IDIBELL, Hospitalet de Llobregat); ElisaMartro, Lurdes Matas, Victoria Gonz\u00e1lez and Vicenc \u00b8 Ausina (Hospi-tal Universitari Germans Trias i Pujol, Badalona); Estrella Caballero(Hospital Universitari Vall Hebron, Barcelona); N\u00faria Margall (Hos-pital de la Santa Creu i Sant Pau, Barcelona); Joan Farr\u00e9 (HospitalUniversitari Arnau de Vilanova, Lleida); M. Goretti Sauca (Hospitalde Matar\u00f3); Xavier Ort\u00edn (Hospital de Tortosa Verge de la Cinta, Tor-tosa); M. Jos\u00e9 Amengual (Corporaci\u00f3 Sanit\u00e0ria Parc Taul\u00ed, Sabadell);Josep M. Prat (Hospital de Palam\u00f3s); Josep M. Euras (Hospital Gen-eral de Vic); Jos\u00e9 Ram\u00f3n Blanco (Complejo San Mill\u00e1n-San Pedrode La Rioja); Josep M. Sim\u00f3 (Hospital Universitari de Sant Joan deReus); M. Carme Vill\u00e0 (Hospital General de Granollers); EugeniaM\u00e1rquez (Hospital General de l\u2019Hospitalet, Hospitalet de Llobregat).\nClinical Staff: Josep M. Mir\u00f3, Fernando Ag\u00fcero, Omar Sued,\nMaria L\u00f3pez-Di\u00e9guez and Jos\u00e9 M. Gatell (Hospital Cl\u00ednic-IDIBAPS,Document downloaded from http://www.elsevier.es, day 16/12/2011. This copy is for personal use. Any transmission of this document by any media or format is strictly prohibited.A. Romero et al / Enferm Infecc Microbiol Clin. 2011; 29(7):482\u2013489 489\nUniversity of Barcelona, Barcelona); Elena Ferrer and Daniel\nPodzamczer (Hospital Universitari de Bellvitge-IDIBELL, Hospitaletde Llobregat); Cristina Tural and Bonaventura Clotet (Hospital Uni-versitari Germans Trias i Pujol, Badalona); Esteve Ribera (HospitalUniversitari Vall Hebron, Barcelona); Jordi Alt\u00e8s and Jos\u00e9 ManuelGuadarrama (Hospital Alt Pened\u00e8s, Vilafranca); Pere Domingo(Hospital de la Santa Creu i Sant Pau, Barcelona); Teresa Puig (Hospi-tal Universitari Arnau de Vilanova, Lleida); Carmen Bernal (HospitalUniversitario San Cecilio, Granada); Pilar Barrufet and Llu\u00eds Force(Hospital de Matar\u00f3); Carolina Guti\u00e9rrez (Hospital Ram\u00f3n y Cajal,Madrid); Amat Ort\u00ed (Hospital de Tortosa Verge de la Cinta, Tor-tosa); Gemma Navarro and Ferran Segura (Corporaci\u00f3 Sanit\u00e0riaParc Taul\u00ed, Sabadell); \u00c0ngels masabeu (Hospital de Palam\u00f3s); JosepVilar\u00f3 (Hospital General de Vic);Jos\u00e9 Antonio Iribarren (Hospital deDonostia, San Sebasti\u00e1n); Jos\u00e9 Antonio Oteo (Complejo San Mill\u00e1n-San Pedro de La Rioja); Blai Coll and Carlos Alonso Villaverde;(Hospital Universitari de Sant Joan de Reus); Santiago Montull (Hos-pital General de Granollers) and Isabel Garcia (Hospital General del\u2019Hospitalet, Hospitalet de Llobregat).\nSite-testing nongovernmental organizations: Roser Sala (Lab-\noratori Sabater Tobella, Barcelona); Olga D\u00edaz (Servei d\u2019Atenci\u00f3i Prevenci\u00f3 Sociosanit\u00e0ria: SAPS - Creu Roja, Barcelona); KatiZaragoza (Stop Sida, Barcelona); Ferran Pujol and Jorge Saz (Pro-jecte dels Noms \u2013 Joves positius, Barcelona); Merc\u00e8 Mero \u02dcno (\u00c0mbit\nPrevenci\u00f3, Barcelona); Jasmina Becerra (Associaci\u00f3 Ciutadana Anti-sida de Catalunya \u2013 ACASC, Barcelona); Rosa Ros (Centre Joved\u2019Anticoncepci\u00f3 i Sexualitat \u2013 CJAS, Barcelona); Anna Avellanedaand Montse Sit\u00e9 (Actua Vall\u00e8s, Sabadell) and Anna Rafel (Associaci\u00f3Antisida de Lleida).\nReferences\n1. Booth CL, Geretti AM. Prevalence and determinants of transmitted\nantiretroviral drug resistance in HIV-1 infection. J Antimicrob Chemother.\n2007;59:1047\u201356.\n2. Wensing AM, van de Vijver DA, Angarano G, Asjo B, Balotta C, Boeri E, et al.\nPrevalence of drug-resistant HIV-1 variants in untreated individuals in europe:Implications for clinical management. J Infect Dis. 2005;192:958\u201366.\n3. Palacios R, Viciana I, Perez de Pedro I, de la Torre J, Ropero F, Fernandez S, et al.\nPrevalence of primary resistance mutations in patients with newly diagnosedHIV infection in the province of malaga (spain). Enferm Infecc Microbiol Clin.2008;26:141\u20135.\n4. de Mendoza C, Rodriguez C, Colomina J, Tuset C, Garcia F, Eiros JM, et al. Resis-\ntance to nonnucleoside reverse-transcriptase inhibitors and prevalence of HIVtype 1 non-B subtypes are increasing among persons with recent infection inspain. Clin Infect Dis. 2005;41:1350\u20134.\n5. Chaix ML, Desquilbet L, Descamps D, Costagliola D, Deveau C, Galimand J, et al.\nResponse to HAART in french patients with resistant HIV-1 treated at primaryinfection: ANRS resistance network. Antivir Ther. 2007;12:1305\u201310.\n6. Oette M, Kaiser R, Daumer M, Petch R, Fatkenheuer G, Carls H, et al. Primary\nHIV drug resistance and ef\ufb01cacy of \ufb01rst-line antiretroviral therapy guided byresistance testing. J Acquir Immune De\ufb01c Syndr. 2006;41:573\u201381.7. Lospitao E, Alvarez A, Soriano V, Holguin A. HIV-1 subtypes in spain: A retro-\nspective analysis from 1995 to 2003. HIV Med. 2005;6:313\u201320.\n8. Romero A, Gonz\u00e1lez V, Granell M, Matas L, Esteve A, Martr\u00f3 E, et al. Recently\nacquired HIV infections in spain (2003-2005). introduction of the serolog-ical testing algorithm for recent HIV seroconversion. Sex Transm Infect.2009;85:106\u201310.\n9. Kothe D, Byers RH, Caudill SP, Satten GA, Janssen RS, Hannon WH, et al.\nPerformance characteristics of a new less sensitive HIV-1 enzyme immunoas-say for use in estimating HIV seroincidence. J Acquir Immune De\ufb01c Syndr.2003;33:625\u201334.\n10. Bennett DE, Camacho RJ, Otelea D, Kuritzkes DR, Fleury H, Kiuchi M, et al. Drug\nresistance mutations for surveillance of transmitted HIV-1 drug-resistance:2009 update. Plos One. 2009;4:e4724.\n11. SPREAD programme. Transmission of drug-resistant HIV-1 in europe remains\nlimited to single classes. AIDS. 2008;22:625\u201335.\n12. Fox J, Hill S, Kaye S, Dustan S, McClure M, Fidler S, et al. Prevalence of primary\ngenotypic resistance in a UK centre: Comparison of primary HIV-1 and newlydiagnosed treatment-naive individuals. AIDS. 2007;21:237\u20139.\n13. S\u00e1nchez Onoro M, L\u00f3pez MJ, Santana MA, Andes JM, Campelo FA. Primary\nantiretroviral drug resistance among patients diagnosed with HIV infectionin gran canaria (spain) between 2002 and 2005. Enferm Infecc Microbiol Clin.2007;25:437\u201340.\n14. Yebra G, Holguin A. Epidemiology of drug-resistant HIV-1 transmission in naive\npatients in spain. Med Clin (Barc). 2010;135:561\u20137.\n15. Johnson VA, Brun-Vezinet F, Clotet B, Gunthard HF, Kuritzkes DR, Pillay\nD, et al. Update of the drug resistance mutations in HIV-1. Top HIV Med.2008;16:138\u201345.\n16. Vingerhoets Jea. An update of the list of NNRTI mutations associated with\ndecreased virologic response to etravirine (ETR): Multivariate analyses on thepooled DUET-1 and DUET-2 clinical trial data, in XVIIth international drugresistance workshop, Sitges, Spain. 2008.\n17. Parkin NT, Gupta S, Chappey C, Petropoulos CJ. The K101P and K103R/V179D\nmutations in human immunode\ufb01ciency virus type 1 reverse transcriptase con-fer resistance to nonnucleoside reverse transcriptase inhibitors. AntimicrobAgents Chemother. 2006;50:351\u20134.\n18. Centre d\u2019Estudis Epidemiol\u00f2gics sobre les ITS i la SIDA de Catalunya. Sistema\nintegrat de vigil\u00e0ncia epidemiol\u00f2gica del SIDA/VIH/ITS a catalunya (SIVES).Informe. Barcelona: Generalitat de Catalunya, Departament de Salut, Direcci\u00f3General de Salut P\u00fablica; 2008. Report No.: 19.\n19. Holguin A, de Mulder M, Yebra G, Lopez M, Soriano V. Increase of non-B sub-\ntypes and recombinants among newly diagnosed HIV-1 native spaniards andimmigrants in spain. Curr HIV Res. 2008;6:327\u201334.\n20. Perez-Alvarez L, Carmona R, Munoz M, Delgado E, Thomson MM, Contreras G,\net al. High incidence of non-B and recombinant HIV-1 strains in newly diag-nosed patients in galicia, spain: Study of genotypic resistance. Antivir Ther.2003;8:355\u201360.\n21. Chohan B, Lang D, Sagar M, Korber B, Lavreys L, Richardson B, et al.\nSelection for human immunode\ufb01ciency virus type 1 envelope glycosylationvariants with shorter V1-V2 loop sequences occurs during transmission ofcertain genetic subtypes and may impact viral RNA levels. J Virol. 2005;79:6528\u201331.\n22. Marozsan AJ, Moore DM, Lobritz MA, Fraundorf E, Abraha A, Reeves JD, et al.\nDifferences in the \ufb01tness of two diverse wild-type human immunode\ufb01ciencyvirus type 1 isolates are related to the ef\ufb01ciency of cell binding and entry. JVirol. 2005;79:7121\u201334.\n23. Geretti AM, Harrison L, Green H, Sabin C, Hill T, Fearnhill E, et al. Effect of\nHIV-1 subtype on virologic and immunologic response to starting highly activeantiretroviral therapy. Clin Infect Dis. 2009;48:1296\u2013305.\n24. Young CL, Hu DJ, Byers R, Vanichseni S, Young NL, Nelson R, et al. Evaluation of a\nsensitive/less sensitive testing algorithm using the bioMerieux vironostika-LSassay for detecting recent HIV-1 subtype B\u2019 or E infection in thailand. AIDS ResHum Retroviruses. 2003;19:481\u20136.Document downloaded from http://www.elsevier.es, day 16/12/2011. This copy is for personal use. Any transmission of this document by any media or format is strictly prohibited.M\u00c9TODOS\u00a0Y\u00a0RESULTADOS\u00a0\n -  67ART\u00cdCULO \u00a0III\u00a0\n\u00a0\u00a0\n\u00a0\u00a0\n\u00a0\u00a0\n\u00a0\u00a0\n\u00a0\u00a0\n\u00a0\u00a0\nCCoommppaarriissoonn\u00a0\u00a0ooff\u00a0\u00a0TTwwoo\u00a0\u00a0SSeerroollooggiiccaall\u00a0\u00a0TTeessttss\u00a0\u00a0ffoorr\u00a0\u00a0tthhee\u00a0\u00a0IIddeennttiiffiiccaattiioonn\u00a0\u00a0ooff\u00a0\u00a0RReecceenntt\u00a0\u00a0\nHHIIVV\u00a0\u00a0IInnffeeccttiioonn::\u00a0\u00a0VViirroonnoossttiikkaa\u00a0\u00a0HHIIVV\u2010\u201011\u00a0\u00a0MMiiccrrooeelliissaa\u00a0\u00a0aanndd\u00a0\u00a0BBEEDD\u00a0\u00a0CCaappttuurree\u00a0\u00a0EEnnzzyymmee\u00a0\u00a0\nIImmmmuunnooaassssaayy\u00a0\u00a0\n\u00a0\nAnabel\u00a0Romero,\u00a0Elisa\u00a0Martr\u00f3,\u00a0Victoria\u00a0Gonz\u00e1lez,,\u00a0Lurdes\u00a0Matas\u00a0and\u00a0the\u00a0AERI\u00a0study\u00a0group\u00a0\n\u00a0\nEnferm\u00a0Infecc\u00a0Microbiol \u00a0Clin.\u00a02011\u00a0Aug\u2010Sep;29(7):553 \u20105\u00a0\n\u00a0\n\u00a0\u00a0\u00a0\n\u00a0\n\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\n\u00a0\u00a0\u00a0\n\u00a0\n\u00a0\u00a0\u00a0\u00a0\u00a0M\u00c9TODOS\u00a0Y\u00a0RESULTADOS\u00a0\n 68M\u00c9TODOS\u00a0Y\u00a0RESULTADOS\u00a0\n -  69RESUMEN \u00a0\n\u00a0\nA\u00a0lo\u00a0largo\u00a0de\u00a0los\u00a0\u00faltimos\u00a0a\u00f1os\u00a0se\u00a0han\u00a0desarrollado\u00a0diferentes\u00a0tests\u00a0serol\u00f3gicos\u00a0para\u00a0detectar\u00a0\ninfecciones\u00a0recientes.\u00a0A\u00a0partir\u00a0del\u00a0a\u00f1o\u00a02007,\u00a0uno\u00a0de\u00a0estos\u00a0test s,\u00a0el\u00a0test\u00a0Vironostika,\u00a0dej\u00f3\u00a0de\u00a0estar\u00a0\ndisponible\u00a0comercialmente.\u00a0Por\u00a0ese\u00a0motivo,\u00a0nuestro\u00a0laboratorio, \u00a0que\u00a0hasta\u00a0ese\u00a0momento\u00a0hab\u00eda\u00a0\nestado\u00a0utilizando\u00a0el\u00a0test\u00a0Vironostika,\u00a0empez\u00f3\u00a0a\u00a0usar\u00a0un\u00a0nuevo\u00a0test\u00a0para\u00a0identificar\u00a0infecciones\u00a0\nrecientes.\u00a0El\u00a0test\u00a0escogido\u00a0por\u00a0nuestro\u00a0laboratorio\u00a0fue\u00a0el\u00a0BED\u2010 CEIA.\u00a0El\u00a0estudio\u00a0que\u00a0se\u00a0presenta\u00a0a\u00a0\ncontinuaci\u00f3n\u00a0se\u00a0dise\u00f1\u00f3\u00a0para\u00a0validar\u00a0que\u00a0los\u00a0resultados\u00a0obtenido s\u00a0por\u00a0ambos\u00a0tests\u00a0(Vironostika\u00a0y\u00a0\nBED\u2010CEIA)\u00a0eran\u00a0comparables\u00a0en\u00a0nuestro\u00a0medio.\u00a0\u00a0\nPara\u00a0valorar\u00a0la\u00a0concordancia\u00a0ent re\u00a0los\u00a0dos\u00a0tests,\u00a0se\u00a0selecciona ron\u00a0101\u00a0muestras\u00a0de\u00a0sueros\u00a0de\u00a0\nindividuos\u00a0VIH\u20101\u00a0positivos\u00a0y\u00a0fue ron\u00a0analizadas\u00a0por\u00a0ambos\u00a0tests. \u00a0Esta\u00a0muestra\u00a0estaba\u00a0formada\u00a0por\u00a0\n15\u00a0pacientes\u00a0con\u00a0infecci\u00f3n\u00a0reciente,\u00a045\u00a0pacientes\u00a0con\u00a0diagn\u00f3sti co\u00a0de\u00a0SIDA\u00a0(por\u00a0criterios\u00a0cl\u00ednicos\u00a0o\u00a0\npor\u00a0recuentos\u00a0de\u00a0c\u00e9lulas\u00a0CD4+\u00a0inferiores\u00a0a\u00a0200\u00a0c\u00e9lulas/\u00b5l),\u00a03\u00a0pacientes\u00a0con\u00a0infecci\u00f3n\u00a0cr\u00f3nica\u00a0(pacientes\u00a0infectados\u00a0desde\u00a0hac\u00eda\u00a0m\u00e1s\u00a0de\u00a012\u00a0meses),\u00a0y\u00a0en\u00a038\u00a0cas os\u00a0no\u00a0se\u00a0pudo\u00a0establecer\u00a0si\u00a0\npertenec\u00edan\u00a0a\u00a0individuos\u00a0con\u00a0in fecci\u00f3n\u00a0reciente,\u00a0cr\u00f3nica\u00a0o\u00a0SIDA .\u00a0\nLos\u00a0resultados\u00a0obtenidos\u00a0indicaron\u00a0que\u00a0el\u00a0acuerdo\u00a0entre\u00a0los\u00a0tes ts\u00a0Vironostika\u00a0y\u00a0BED\u2010CEIA\u00a0era\u00a0\nbueno\u00a0(\u00edndice\u00a0kappa\u00a0=\u00a00,738,\u00a0p<0,005).\u00a0Ambos\u00a0tests\u00a0clasificaron \u00a029\u00a0muestras\u00a0como\u00a0infecciones\u00a0\nrecientes\u00a0y\u00a060\u00a0como\u00a0infecciones\u00a0 cr\u00f3nicas,\u00a0mientras\u00a0que\u00a0los\u00a0resu ltados\u00a0discordantes\u00a0se\u00a0obtuvieron\u00a0\nen\u00a012\u00a0muestras.\u00a0La\u00a0sensibilidad\u00a0para\u00a0detectar\u00a0infecciones\u00a0recie ntes\u00a0fue\u00a0del\u00a093,3%\u00a0para\u00a0ambos\u00a0\ntests,\u00a0mientras\u00a0que\u00a0la\u00a0especificidad\u00a0para\u00a0detectar\u00a0infecciones\u00a0 cr\u00f3nicas\u00a0fue\u00a0del\u00a075,0%\u00a0para\u00a0el\u00a0test\u00a0\nVironostika,\u00a0y\u00a0del\u00a081,3%\u00a0para\u00a0el\u00a0test\u00a0BED\u2010CEIA.\u00a0Los\u00a0valores\u00a0predictivos\u00a0positivos\u00a0fueron\u00a060,9%\u00a0\nusando\u00a0el\u00a0test\u00a0BED\u2010CEIA\u00a0y\u00a053,8%\u00a0usando\u00a0el\u00a0Vironostika.\u00a0\nLos\u00a0resultados\u00a0obtenidos\u00a0demuestran\u00a0que\u00a0ambos\u00a0tests\u00a0identificar on\u00a0las\u00a0infecciones\u00a0recientes\u00a0\nigual\u00a0de\u00a0bien.\u00a0Sin\u00a0embargo,\u00a0el\u00a0test\u00a0Vironostika\u00a0tiende\u00a0a\u00a0clasif icar\u00a0err\u00f3neamente\u00a0m\u00e1s\u00a0individuos\u00a0\ncon\u00a0SIDA\u00a0como\u00a0reci\u00e9n\u00a0infectados.\u00a0Por\u00a0tanto,\u00a0el\u00a0test\u00a0BED\u2010CEIA\u00a0of rece\u00a0una\u00a0buena\u00a0alternativa\u00a0al\u00a0test\u00a0\nVironostika.\u00a0M\u00c9TODOS\u00a0Y\u00a0RESULTADOS\u00a0\n 70Cartas cient\u00ed\ufb01cas / Enferm Infecc Microbiol Clin. 2011; 29(7):550\u2013559 553\nA literature search with no date limits in PubMed using the\nkeywords \u201clymphomatoid granulomatosis\u201d and \u201clarynx\u201d found\nonly two reported cases where LG affects the larynx, but inboth of them, laryngeal disease was associated with pulmonaryinvolvement.\n2,3The larynx has its own lymphatic structure called\nlarynx-associated lymphoid tissue (LALT). In the subglottis, LALTis replaced throughout life by a diffuse in\ufb01ltration of strong inten-sity consisting predominantly of CD3-positive T lymphocytes withscattered CD20-positive B cells,\n4therefore LG could be originated\nin subglottic tissues.\nLG pathogenesis is unclear, but it has been linked to EBV and\nimmunode\ufb01ciency. As regards the close to 100% EBV associationwith LG and the presumed wide expression of EBV latent enco-ded proteins, it has been strongly inferred that EBV is not just aninnocent bystander in the pathogenesis of LG.\n5When dealing with\nimmunode\ufb01ciency, it has been proven that most patients with LGhave defects in cytotoxic T cell function. That would explain howLG is less rare in many immunode\ufb01ciency states.\n6In our case, CD4\ncount cell was 124 cell/ /H9262l due to a good treatment compliance with\ndiscordant response.\nMany studies have analyzed the connection between LG and\nAIDS. HIV infection is associated with an increased risk of lymp-homas by 60-165 fold even in the combined antiretroviral therapyera. Excellent outcomes with infusion therapy and concurrent ritu-ximab have been reported in the treatment of some of them.\n7\nWe report that laryngeal LG can mimic Reinke\u2019s edema in its\nearly stages. In our own experience, Reinke\u2019s edema should not betreated as a casual \ufb01nding in patients with fever of unknown originor immunode\ufb01ciency.\nOur current case was classi\ufb01ed as grade III of LG, which is histo-\nlogically considered as diffuse large B-cell malignant lymphoma,\n8\nbut the \ufb01rst biopsy was reported as polymorph lymphoid proli-feration related to a post-transplant lymphoproliferative disorder(PTLD), which can simulate a lower grade of LG. LG and PTLD areassociated with immunode\ufb01ciency and are driven by EBV. Histo-pathologically, they present a morphological spectrum spanningpolymorphic through monomorphic lymphoid proliferations.\n9\nThe distinctness of LG and PTLD has been emphasized by thedifference in the immune response. While LG has a large popu-lation of background T-cells, PTLD is recognized by a poor T-cellenviroment.\n5\nA better awareness of LG in recent years is at present allowing\nnew therapeutic tools for this disease to be developed. Rituximab, anew monoclonal antibody anti-CD20 has shown promising resultsin some cases of LG with pulmonary involvement.\n10\nBibliograf\u00eda\n1. Liebow AA, Carrington CR, Friedman PJ. Lymphomatoid granulomatosis. Hum\nPathol. 1972;3:457\u2013558.\n2. Schmalzl F, Gasser RW, Weiser G, Zur Nedden D. Lymphomatoid granulo-\nmatosis with primary manifestation in the skeletal muscular system. Klin\nWochenschr. 1982;60:311\u20136.\n3. Cohen SR, Landing BH, Siegel S, Shen S, Heuser E, Isaacs H. Lymphomatoid\ngranulomatosis in a child with acute lymphatic leukemia in remission. AnnOtol Rhinol Laryngol Suppl. 1978;87(5 Pt 2 Suppl 52):5\u201310.\n4. Kutta H, Steven P, Tillmann BN, Tsokos M, Paulsen FP. Region-speci\ufb01c\nimmunological response of the different laryngeal compartments: signi-\ufb01cance of larynx-associated lymphoid tissue. Cell Tissue Res. 2003;311:365\u201371.\n5. Wilson WH, Kingma DW, Raffeld M, Wittes RE, Jaffe ES. Associa-\ntion of lymphomatoid granulomatosis with Epstein-Barr viral infectionof B lymphocytes and response to interferon-alpha 2b. Blood. 1996;87:4531\u20137.\n6. Jaffe ES, Wilson WH. Lymphomatoid granulomatosis: pathogenesis, pathology\nand clinical implications. Cancer Surv. 1997;30:233\u201348.\n7. Gucalp A, Noy A. Spectrum of HIV lymphoma 2009. Curr Opin Hematol.\n2010;17:362\u20137.\n8. Guinee Jr DG, Perkins SL, Travis WD, Holden JA, Tripp SR, Koss MN. Prolifera-\ntion and cellular phenotype in lymphomatoid granulomatosis: implicationsof a higher proliferation index in B cells. Am J Surg Pathol. 1998;22:1093\u2013100.\n9. Saxena A, Dyker KM, Angel S, Moshynska O, Dharampaul S, Cockroft DW. Post-\ntransplant diffuse large B-cell lymphoma of \u201clymphomatoid granulomatosis\u201dtype. Virchows Arch. 2002;441:622\u20138.\n10. Moudir-Thomas C, Foulet-Roge A, Plat M, Kaswin R, Lepic P, Solal-Celigny P,\net al. Ef\ufb01cacy of rituximab in lymphomatoid granulomatosis. Rev Mal Respir.2004;21(6Pt1):1157\u201361.\nEmilio Dom\u00ednguez-Dur\u00e1na,\u2217, Rafael Luque-M\u00e1rquezb,\nMar\u00eda Fontill\u00f3n-Alberdic, Antonio Abrante-Jim\u00e9neza\naDepartamento de Otorrinolaringolog\u00eda, Hospital Universitario\nVirgen del Roc\u00edo, Sevilla, Espa \u02dcna\nbUnidad de Enfermedades Infecciosas, Hospital Universitario Virgen\ndel Roc\u00edo, Sevilla, Espa \u02dcna\ncDepartamento de Anatom\u00eda Patol\u00f3gica, Hospital Universitario\nVirgen del Roc\u00edo, Sevilla, Espa \u02dcna\n\u2217Autor para correspondencia.\nE-mail address: emiliodominguezorl@gmail.com\n(E. Dom\u00ednguez-Dur\u00e1n).\ndoi:10.1016/j.eimc.2011.02.017\nComparison of Two Serological Tests for the Identi\ufb01cation of\nRecent HIV Infection: Vironostika HIV-1 Microelisa and BEDCapture Enzyme Immunoassay\nComparaci\u00f3n de dos tests serol\u00f3gicos para la identi\ufb01caci\u00f3n\nde infecciones recientes por VIH-1: microelisa Vironostika HIV-1y enzimoinmunoensayo de captura BED\nTo the Editor:\nIdenti\ufb01cation of recent human immunode\ufb01ciency virus (HIV)\ninfection is an important tool for monitoring HIV transmission.\nDuring the last few years, several serological assays have beendeveloped for this purpose and used in cross-sectional studies.\n1\nThe serological testing algorithm for recent HIV seroconversion(STARHS) was developed in 1998\n2and used with the Abbott HIVAB\n3A11 assay (Abbott Laboratories, Abbott Park, Chicago, Illinois,USA) and with the Vironostika HIV-1 Microelisa System (bioM\u00e9-rieux SA, Marcy l\u2019Etoile, France). The sensitivity of both assays waslowered in order to obtain a negative result in specimens with lowantibody titers, such as those from individuals with a recent infec-tion. These assays are no longer available, and laboratories haveturned to new methods. The BED assay (Calypte Biomedical Cor-poration, Portland, Oregon, USA) measures anti-HIV IgG titers\n3and\nincludes a calibrator to ensure comparability of results. Further-more, the BED assay is included in an external quality programoffered by the Centers for Disease Control and Prevention (CDC,Atlanta, Georgia, USA).\nIn Catalonia, the STARHS was introduced using the Vironostika\nassay as part of the enhanced HIV/STI surveillance program in 2003.As the Vironostika assay has no longer been available since 2007,our laboratory changed to the BED assay in 2008. Our aim wasto assess whether the results obtained by both techniques werecomparable.Document downloaded from http://www.elsevier.es, day 16/12/2011. This copy is for personal use. Any transmission of this document by any media or format is strictly prohibited.554 Cartas cient\u00ed\ufb01cas / Enferm Infecc Microbiol Clin. 2011; 29(7):550\u2013559\nTable 1\nPerformance of both assays according to clinical information.\nNo. of recent infectionsaccording to assay\nGroup Total no.\nof patientsVironostika BED Both\nassays\nKnown recent HIV\ninfection15 14 14 13\nAIDS 45 12 9 7Long-standing HIV\ninfection300 0\nUnclassi\ufb01ed\na38 9 11 9\nTotal 101 35 35 29\naPatients with no clinical criteria for AIDS, without evidence of recent infection,\nneither long-standing infection.\nA total of 101 serum specimens from HIV-1\u2013positive indivi-\nduals were selected from a previous study.4The selection criteria\nwere suf\ufb01cient sample volume and minimum available clinical\nand laboratory information (CD4+T-cell count, HIV viral load, HIV\ninfection stage, previous antiretroviral treatment). Patients wereclassi\ufb01ed into three groups. The \ufb01rst group included 15 recentlyinfected individuals (sera were drawn no more than 6 months afterseroconversion in nine patients, and the rest had a diagnosis ofacute HIV infection). The second group included three patients withlong-standing infection (subjects infected for >12 months) and 45patients with a diagnosis of AIDS (clinical criteria or CD4\n+T-cell\ncount under 200 cells//H9262l). Finally, 38 specimens were unable to beclassi\ufb01ed as either recent infections, long-standing infections, orAIDS.\nThe agreement between Vironostika and BED assays was\ngood (/H9260=0.738, P<.005), which is consistent with the results\nof two published studies.\n5,6Sensitivity to detect recent infec-\ntion was 93.3% (95% CI: 68.1 \u2013 99.8) for both the Viro-nostika and the BED assays. Speci\ufb01city for detecting long-term infections was 75.0% (95% CI: 60.4 \u2013 86.4) using theVironostika, and 81.3% (95% CI: 67.4 \u2013 91.1) using theBED. Positive predictive values were 60.9% (95% CI: 38.5 \u201380.3) using the BED, and 53.8% (95% CI: 33.4 \u2013 73.4) using theVironostika. Negative predictive values were 97.5% (95% CI: 86.8 \u201399.9) using the BED, and 97.3% (95% CI: 85.8 \u2013 99.9) using the Viro-nostika. Table 1 shows the samples identi\ufb01ed as recent infections by\nboth BED and Vironostika according to their clinical characteristicsand laboratory information.\nThe BED assay correctly classi\ufb01ed a greater proportion of recent\ninfections and patients with AIDS than Vironostika. These resultsare similar to those of a previous study,\n6in which the Vironostika\nkit also tended to misclassify more individuals with long-standinginfections or AIDS as recently infected in a comparison with theavidity index method.\n7The misclassi\ufb01cation of patients with AIDS\nor CD4+T-cell counts \u2264200 cells//H9262l is explained by the low anti-\nHIV IgG titers. Hence the importance of excluding those samplesbelonging to patients ful\ufb01lling these criteria from STARHS testingwhen this information is available.\nThe BED assay offers several advantages over the Vironostika:\ni) it has been reported to have better reproducibility, since it isbased on the HIV IgG/non-HIV IgG ratio and uses a simple 1:100dilution;\n8ii) the BED assay can also be automated providing more\nprecise results than the Vironostika assay, which is performedmanually; and iii) the window period of the Vironostika assaydiffers for B and non-B HIV-1 subtypes, whereas these differen-ces are less pronounced with the BED.\n9For all those reasons, the\nBED assay offers a good alternative to the discontinued Vironostikaassay.Funding\nThis work was supported by the \u201cLa Marat\u00f3 de TV3\u201d Foun-\ndation grant for the development of the AERI-HIV (AlgoritmeEstandarditzat per la detecci\u00f3 de Recent Infectats pel VIH) pro-ject for epidemiological research on AIDS by applying the STARHStechnique (project #022010). This work was partially fundedby the Direcci\u00f3 General de Salut P\u00fablica de la Generalitat deCatalunya and by the Fundaci\u00f3n para la Investigaci\u00f3n y Preven-ci\u00f3n del Sida en Espa \u02dcna (FIPSE, Madrid, Spain, National AIDS\nPlan Secretariat of the Spanish Ministry of Health) and grantCD05/00258 (EM) (post-doctoral training contracts) from the\u201cMinisterio de Sanidad y Consumo\u201d, within the \u201cPlan Nacionalde Investigaci\u00f3n cient\u00ed\ufb01ca, Desarrollo e Innovaci\u00f3n Tecnol\u00f3gica(I+D+I)\u201d.\nThe authors acknowledge partial funding of this research from\nthe CIBER Epidemiolog\u00eda y Salud P\u00fablica (CIBERESP), Spain\u201d.\nAcknowledgements\nWe thank Joanne V Mei (Centers for Disease Control and Pre-\nvention, Atlanta, Georgia, USA) for technical assistance and advice.\nWe would also like to thank Thomas O \u02c7\u0131Boyle for his assistance with\nthe English version of the manuscript.\nAppendix.\nThe Recent HIV Infections (AERIVIH) study group includes the\nfollowing:\nCoordinating Center (CEEISCAT): Jordi Casabona, Anna Esteve,\nAnabel Romero, N\u00faria Ortega, Alexandra Montoliu, Eva Puchol,\nRafael Mu \u02dcnoz, Joan Masip, N\u00faria Vives, Berta Ortiga, Meritxell Gra-\nnell, Diana Puente, M. Jes\u00fas Casado, \u00c0ngels Jaen, Jes\u00fas Almeda,Vanessa Espurz.\nSTARHS Laboratory (Microbiology Service, Hospital Universi-\ntari Germans Trias i Pujol): Victoria Gonz\u00e1lez, Elisa Martr\u00f3, Lurdes\nMatas and Vicenc \u00b8 Ausina\nPeripheral CentersPrimary Health Care Laboratories: Isabel Rodrigo (Laboratori\nCl\u00ednic Manso, Barcelona), \u00c0ngels Bosch (Laboratori Intercomarcalde l\u2019Alt Pened\u00e8s, l\u2019Anoia i el Garraf, Igualada), Rosa L\u00f3pez (Labo-ratori Cl\u00ednic Bon Pastor, Barcelona), Eva Dopico (Laboratori Cl\u00ednicl\u2019Hospitalet de Llobregat,), Josep Ros (Laboratori Cl\u00ednic Barcelon\u00e9sNord i Maresme, Badalona), Rosa Navarro (Laboratori Cl\u00ednic Corne-ll\u00e0 de Llobregat), Conrad Vilanova (Laboratori Cl\u00ednic El Maresme,Matar\u00f3)\nHospitalsLaboratory Staff: Tom\u00e0s Pumarola (Hospital Cl\u00ednic-IDIBAPS,\nUniversity of Barcelona, Barcelona), Aurora Casanova (HospitalUniversitari de Bellvitge-IDIBELL, Hospitalet de Llobregat); ElisaMartr\u00f3, Lurdes Matas, Victoria Gonz\u00e1lez and Vicenc \u00b8 Ausina (Hospi-tal Universitari Germans Trias i Pujol, Badalona); Estrella Caballero(Hospital Universitari Vall Hebron, Barcelona); N\u00faria Margall (Hos-pital de la Santa Creu i Sant Pau, Barcelona); Joan Farr\u00e9 (HospitalUniversitari Arnau de Vilanova, Lleida); M. Goretti Sauca (Hos-pital de Matar\u00f3); Xavier Ort\u00edn (Hospital de Tortosa Verge dela Cinta, Tortosa); M. Jos\u00e9 Amengual (Corporaci\u00f3 Sanit\u00e0ria ParcTaul\u00ed, Sabadell); Josep M. Prat (Hospital de Palam\u00f3s); Josep M.Euras (Hospital General de Vic); Jos\u00e9 Ram\u00f3n Blanco (HospitalSan Pedro - CIBIR La Rioja); Josep M. Sim\u00f3 (Hospital Univer-sitari de Sant Joan de Reus); Carlos Toro (Hospital Carlos III,Madrid) M. Carme Vill\u00e0 (Hospital General de Granollers); EugeniaM\u00e1rquez (Hospital General de l\u2019Hospitalet, Hospitalet de Llobre-gat).\nClinical Staff: Josep M. Mir\u00f3, Fernando Ag\u00fcero, Omar Sued,\nMar\u00eda L\u00f3pez-Di\u00e9guez and Jos\u00e9 M. Gatell (Hospital Cl\u00ednic-IDIBAPS,Document downloaded from http://www.elsevier.es, day 16/12/2011. This copy is for personal use. Any transmission of this document by any media or format is strictly prohibited.Cartas cient\u00ed\ufb01cas / Enferm Infecc Microbiol Clin. 2011; 29(7):550\u2013559 555\nUniversity of Barcelona, Barcelona); Elena Ferrer and Daniel Pod-\nzamczer (Hospital Universitari de Bellvitge-IDIBELL, Hospitalet deLlobregat); Cristina Tural and Bonaventura Clotet (Hospital Uni-versitari Germans Trias i Pujol, Badalona); Esteve Ribera (HospitalUniversitari Vall Hebron, Barcelona); Jordi Alt\u00e8s and Jos\u00e9 ManuelGuadarrama (Hospital Alt Pened\u00e8s, Vilafranca); Pere Domingo(Hospital de la Santa Creu i Sant Pau, Barcelona); Teresa Puig (Hospi-tal Universitari Arnau de Vilanova, Lleida); Carmen Bernal (HospitalUniversitario San Cecilio, Granada); Pilar Barrufet and Llu\u00eds Force(Hospital de Matar\u00f3); Carolina Guti\u00e9rrez (Hospital Ram\u00f3n y Cajal,Madrid); Amat Ort\u00ed (Hospital de Tortosa Verge de la Cinta, Tor-tosa); Gemma Navarro and Ferran Segura (Corporaci\u00f3 Sanit\u00e0ria ParcTaul\u00ed, Sabadell); \u00c0ngels Masabeu (Hospital de Palam\u00f3s); VicenteSoriano (Hospital Carlos III, Madrid); Josep Vilar\u00f3 (Hospital Generalde Vic);Jos\u00e9 Antonio Iribarren (Hospital de Donostia, San Sebas-ti\u00e1n); Jos\u00e9 Antonio Oteo (Hospital San Pedro - CIBIR La Rioja); BlaiColl and Carlos Alonso Villaverde; (Hospital Universitari de SantJoan de Reus); Santiago Montull (Hospital General de Granollers)and Isabel Garcia (Hospital General de l\u2019Hospitalet, Hospitalet deLlobregat).\nSexually transmitted infections clinic: Carmen Rodr\u00edguez and\nJorge del Romero (Centro Sanitario Sandoval, Madrid)\nSite-testing nongovernmental organizations: Roser Sala\n(Laboratori Sabater Tobella, Barcelona); Olga D\u00edaz (Servei d\u2019Atenci\u00f3i Prevenci\u00f3 Sociosanit\u00e0ria: SAPS - Creu Roja, Barcelona); Kati Zara-goza (Stop Sida, Barcelona); Ferran Pujol and Jorge Saz (Projectedels Noms \u2013 Joves positius, Barcelona); Merc\u00e8 Mero \u02dcno (\u00c0mbit\nPrevenci\u00f3, Barcelona); Jasmina Becerra (Associaci\u00f3 Ciutadana Anti-sida de Catalunya \u2013 ACASC, Barcelona); Rosa Ros (Centre Joved\u2019Anticoncepci\u00f3 i Sexualitat \u2013 CJAS, Barcelona); Anna Avellanedaand Montse Sit\u00e9 (Actua Vall\u00e8s, Sabadell) and Anna Rafel (Associaci\u00f3Antisida de Lleida).\nBibliograf\u00eda\n1. Guy R, Gold J, Calleja JM, Kim AA, Parekh B, Busch M, et al. Accuracy of serological\nassays for detection of recent infection with HIV and estimation of population\nincidence: A systematic review. Lancet Infect Dis. 2009;9:747\u201359.\n2. Janssen RS, Satten GA, Stramer SL, Rawal BD, O\u2019Brien TR, Weiblen BJ, et al. New\ntesting strategy to detect early HIV-1 infection for use in incidence estimatesand for clinical and prevention purposes. JAMA. 1998;280:42\u20138.\n3. Rawal BD, Degula A, Lebedeva L, Janssen RS, Hecht FM, Sheppard HW, et al.\nDevelopment of a new less-sensitive enzyme immunoassay for detection of earlyHIV-1 infection. J Acquir Immune De\ufb01c Syndr. 2003;33:349\u201355.4. Romero A, Gonz\u00e1lez V, Granell M, Matas L, Esteve A, Martro E, et al. Recently\nacquired HIV infections in spain (2003-2005). introduction of the serolo-gical testing algorithm for recent HIV seroconversion. Sex Transm Infect.2009;85:106\u201310.\n5. Truong HM, Kellogg T, Louie B, Klausner J, Dilley J, McFarland W. Recent HIV-1\ninfection detection: Comparison of incidence estimates derived by laboratoryassays and repeat testing data. J Acquir Immune De\ufb01c Syndr. 2009;51:502\u20135.\n6. Gupta SB, Murphy G, Koenig E, Adon C, Beyrer C, Celentano D, et al. Comparison\nof methods to detect recent HIV type 1 infection in cross-sectionally collectedspecimens from a cohort of female sex workers in the Dominican Republic. AIDSRes Hum Retroviruses. 2007;23:1475\u201380.\n7. Martro E, Suligoi B, Gonzalez V, Bossi V, Esteve A, Mei J, et al. Comparison\nof the avidity index method and the serologic testing algorithm for recenthuman immunode\ufb01ciency virus (HIV) seroconversion, two methods using a sin-gle serum sample for identi\ufb01cation of recent HIV infections. J Clin Microbiol.2005;43:6197\u20139.\n8. Suligoi B, Massi M, Galli C, Sciandra M, Di Sora F, Pezzotti P, et al. Identifying\nrecent HIV infections using the avidity index and an automated enzyme immu-noassay. J Acquir Immune De\ufb01c Syndr. 2003;32:424\u20138.\n9. Dobbs T, Kennedy S, Pau CP, McDougal JS, Parekh BS. Performance characteristics\nof the immunoglobulin G-capture BED-enzyme immunoassay, an assay to detectrecent human immunode\ufb01ciency virus type 1 seroconversion. J Clin Microbiol.2004;42:2623\u20138.\nAnabel Romeroa,b,c,d,\u2217,2, Elisa Martr\u00f3c,e,2,\nVictoria Gonz\u00e1leza,c,e, Lurdes Matasc,e, the AERI Study group\u2666\naCenter for Epidemiological Studies on HIV/AIDS and STI of Catalonia\n(CEEISCAT), Institut Catal\u00e0 d\u2019Oncologia/Health Department,\nGeneralitat de Catalunya, Spain\nbDepartment of Epidemiology and Evaluation, IMIM-Parc de Salut\nMar, Barcelona, Spain\ncCIBER Epidemiolog\u00eda y Salud P\u00fablica (CIBERESP),\nSpain\ndDepartment of Pediatrics, Obstetrics and Gynecology, and\nPreventive Medicine, Universitat Aut\u00f2noma de Barcelona, Barcelona,Spain\neMicrobiology Service, Fundaci\u00f3 Institut d\u2019Investigaci\u00f3 en Ci\u00e8ncies\nde la Salut Germans Trias i Pujol, Hospital Universitari Germans Triasi Pujol, Universitat Aut\u00f2noma de Barcelona, Badalona, Spain\n\u2217Corresponding author.\nE-mail address: aromero@imim.es (A. Romero).\n\u2666SeeAppendix.\n2AR and EM are equal contributors.\ndoi:10.1016/j.eimc.2011.02.016\nEnfermedad meningoc\u00f3cica invasiva por Neisseria meningitidis\ndel serogrupo Y\nInvasive meningococcal disease due to Neisseria meningitidis\nserogroup Y\nSr. Editor:\nLos aislados de Neisseria meningitidis del serogrupo Y son muy\npoco frecuentes en nuestro medio. Se presenta un caso de bacte-\nriemia y neumon\u00eda causada por este microorganismo.\nVar\u00f3n de 17 a \u02dcnos, natural de Bolivia con residencia en Espa \u02dcna\ndesde hace 5 a \u02dcnos, que acude a urgencias en Marzo de 2010. Al\ningreso present\u00f3 cefalea, congesti\u00f3n nasal, rinorrea verdosa y \ufb01e-bre de hasta 38,8\n\u25e6C de tres d\u00edas de evoluci\u00f3n. En la exploraci\u00f3n\nf\u00edsica el paciente estaba bien orientado, sin signos men\u00edngeos nilesiones cut\u00e1neas. La presi\u00f3n arterial era de 100/66 mmHg, no pre-sentaba afectaci\u00f3n cardiocirculatoria y la radiograf\u00eda de torax inicialno mostr\u00f3 n\u00f3dulos ni consolidaciones. El hemograma de urgenciamostraba 16800 leucocitos/mm\n3; el 90,3% neutr\u00f3\ufb01los, 3,5% linfo-\ncitos, 0, 2% eosin\u00f3\ufb01los y 323000 plaquetas/mm3. La PCR era de\n3.27 mg/L. Como antecedentes personales destacaba haber sidosometido a una amigdalectomia un mes antes del ingreso.\nSe realiz\u00f3 una punci\u00f3n lumbar que dio salida a un l\u00edquido claro y\nacelular, con tinci\u00f3n de Gram en la que no se observaban ni c\u00e9lulasni bacterias, cuyo cultivo \ufb01nalmente result\u00f3 negativo.\nA su llegada a planta, unas horas m\u00e1s tarde, el paciente se\nencuentra estable, y se procede a la extracci\u00f3n de hemoculti-vos. El paciente presentaba tos productiva y esputo herrumbroso,objetiv\u00e1ndose en una nueva radiograf\u00eda de t\u00f3rax una afectaci\u00f3nparenquimatosa de tipo alveolar en el l\u00f3bulo inferior izquierdo. Porlo que se inici\u00f3 antibioterapia con levo\ufb02oxacino.\nA las 28 horas de incubaci\u00f3n, en los hemocultivos se aisl\u00f3 N.\nmeningitidis serogrupo Y, genosubtipo VR1:5-1; VR2: 10-4, sensible\na cefotaxima (concentraci\u00f3n inhibitoria m\u00ednima 0,003 mg/l), mero-penem, cipro\ufb02oxacino, levo\ufb02oxacino, cloranfenicol y rifampicina.\nTras interrogar a la familia se con\ufb01rma que el paciente hab\u00eda\ncompletado el calendario vacunal de la Comunidad Aut\u00f3noma deMadrid, incluida la vacuna frente a meningococo C.Document downloaded from http://www.elsevier.es, day 16/12/2011. This copy is for personal use. Any transmission of this document by any media or format is strictly prohibited.M\u00c9TODOS\u00a0Y\u00a0RESULTADOS\u00a0\n 74M\u00c9TODOS\u00a0Y\u00a0RESULTADOS\u00a0\n -  75ART\u00cdCULO \u00a0IV\u00a0\n\u00a0\n\u00a0\n\u00a0\n\u00a0\u00a0\n\u00a0\nIIddeennttiiffiiccaattiioonn\u00a0\u00a0ooff\u00a0\u00a0rreecceenntt\u00a0\u00a0HHIIVV\u2010\u201011\u00a0\u00a0iinnffeeccttiioonn\u00a0\u00a0aammoonngg\u00a0\u00a0nneewwllyy\u00a0\u00a0ddiiaaggnnoosseedd\u00a0\u00a0ccaasseess\u00a0\u00a0\niinn\u00a0\u00a0CCaattaalloonniiaa,,\u00a0\u00a0SSppaaiinn\u00a0\u00a0((22000066\u2010\u201022000088))\u00a0\u00a0\n\u00a0\u00a0\nAnabel\u00a0Romero,\u00a0Victoria\u00a0Gonz\u00e1lez,\u00a0Anna\u00a0Esteve, \u00a0Elisa\u00a0Martr\u00f3,\u00a0Lurdes\u00a0Matas,\u00a0Cristina\u00a0Tural,\u00a0\nTom\u00e0s\u00a0Pumarola, \u00a0Aurora\u00a0Casanova, \u00a0Elena\u00a0Ferrer, \u00a0Estrella\u00a0Caballero, \u00a0Esteve\u00a0Ribera,\u00a0\nN\u00faria\u00a0Margall, \u00a0Pere\u00a0Domingo, \u00a0Joan\u00a0Farr\u00e9,\u00a0Tersa\u00a0Puig, \u00a0M\u00aa\u00a0Goretti\u00a0Sauca,\u00a0\u00a0\nPilar\u00a0Barrufet, \u00a0M\u00aa\u00a0Jos\u00e9\u00a0Amengual, \u00a0Gemma\u00a0Navarro, \u00a0Maria\u00a0Navarro, \u00a0Josep\u00a0Vilar\u00f3,\u00a0\nXavier\u00a0Ort\u00edn, \u00a0Amat\u00a0Ort\u00ed,\u00a0Ferran\u00a0Pujol,\u00a0Josep\u00a0M\u00aa\u00a0Prat,\u00a0\u00c0ngels\u00a0Massabeu, \u00a0Josep\u00a0M\u00aa\u00a0Sim\u00f3,\u00a0\u00a0\nCarlos\u00a0A\u00a0Villaverde, \u00a0Miguel\u00a0\u00c1ngel\u00a0Ben\u00edtez, \u00a0Isabel\u00a0Garcia, \u00a0Olga\u00a0D\u00edaz,\u00a0Jassmina \u00a0Becerra,\u00a0\u00a0\nRosa\u00a0Ros,\u00a0Roser\u00a0Sala,\u00a0Isabel\u00a0Rodrigo, \u00a0Josep\u00a0M\u00aa\u00a0Mir\u00f3,\u00a0Jordi\u00a0Casabona \u00a0\u00a0\nand\u00a0the\u00a0AERI\u00a0Studygroup. \u00a0\u00a0\n\u00a0\u00a0\nEur\u00a0J\u00a0Public\u00a0Health.\u00a02012\u00a0Dec;22(6):802 \u20108\u00a0\n\u00a0M\u00c9TODOS\u00a0Y\u00a0RESULTADOS\u00a0\n 76M\u00c9TODOS\u00a0Y\u00a0RESULTADOS\u00a0\n -  77RESUMEN \u00a0\n\u00a0\nEn\u00a0la\u00a0mayor\u00eda\u00a0de\u00a0pa\u00edses\u00a0europeos,\u00a0la\u00a0vigilancia\u00a0de\u00a0la\u00a0epidemia\u00a0 de\u00a0VIH/SIDA\u00a0se\u00a0basa\u00a0en\u00a0la\u00a0\ndeclaraci\u00f3n\u00a0de\u00a0los\u00a0nuevos\u00a0diagn\u00f3sticos\u00a0de\u00a0VIH.\u00a0Catalu\u00f1a\u00a0dispone \u00a0de\u00a0un\u00a0sistema\u00a0voluntario\u00a0de\u00a0\nnotificaci\u00f3n\u00a0de\u00a0nuevos\u00a0diagn\u00f3stico s\u00a0de\u00a0VIH,\u00a0implementado\u00a0desde\u00a0 el\u00a0a\u00f1o\u00a02001\u00a0y\u00a0obligatorio\u00a0a\u00a0\npartir\u00a0 del\u00a0 a\u00f1o\u00a0 2010.\u00a0 Sin\u00a0 embargo,\u00a0 la\u00a0 informaci\u00f3n\u00a0 que\u00a0 proporciona\u00a0 el\u00a0 registro\u00a0 de\u00a0 nuevos\u00a0diagn\u00f3sticos\u00a0de\u00a0VIH\u00a0no\u00a0refleja\u00a0los\u00a0patrones\u00a0actuales\u00a0de\u00a0transmi si\u00f3n\u00a0del\u00a0VIH,\u00a0ya\u00a0que\u00a0entre\u00a0los\u00a0\nnuevos\u00a0diagn\u00f3sticos\u00a0se\u00a0pueden\u00a0en contrar\u00a0infecciones\u00a0que\u00a0ocurrie ron\u00a0hace\u00a0mucho\u00a0tiempo.\u00a0\u00a0\nLa\u00a0 cuantificaci\u00f3n\u00a0 y\u00a0 descripci\u00f3n\u00a0 de\u00a0 los\u00a0 pacientes\u00a0 con\u00a0 infecci\u00f3n\u00a0 r e c i e n t e \u00a0p o r \u00a0V I H \u00a0p u e d e \u00a0\nproporcionar\u00a0una\u00a0estimaci\u00f3n\u00a0precisa\u00a0de\u00a0la\u00a0din\u00e1mica\u00a0de\u00a0transmisi \u00f3n\u00a0del\u00a0virus.\u00a0En\u00a0este\u00a0sentido,\u00a0los\u00a0\ntests\u00a0serol\u00f3gicos\u00a0para\u00a0identific ar\u00a0infecciones\u00a0recientes\u00a0(TRIs) \u00a0han\u00a0demostrado\u00a0su\u00a0utilidad\u00a0en\u00a0la\u00a0\ndescripci\u00f3n\u00a0de\u00a0las\u00a0caracter\u00edsticas\u00a0de\u00a0las\u00a0personas\u00a0con\u00a0infecci\u00f3 n\u00a0reciente\u00a0por\u00a0VIH.\u00a0A\u00a0partir\u00a0del\u00a0a\u00f1o\u00a0\n2006,\u00a0se\u00a0ha\u00a0incorporado\u00a0la\u00a0identificaci\u00f3n\u00a0de\u00a0las\u00a0infecciones\u00a0re cientes\u00a0mediante\u00a0TRIs\u00a0entre\u00a0los\u00a0\nnuevos\u00a0diagn\u00f3sticos\u00a0de\u00a0VIH\u00a0de\u00a0un\u00a0grupo\u00a0de\u00a0hospitales\u00a0y\u00a0centros\u00a0 de\u00a0cribado\u00a0alternativos\u00a0situados\u00a0\nen\u00a0Catalu\u00f1a,\u00a0como\u00a0parte\u00a0del\u00a0Sistema\u00a0Integrado\u00a0de\u00a0Vigilancia\u00a0Epi demiol\u00f3gica\u00a0del\u00a0SIDA/VIH/ITS\u00a0\n(SIVES).\u00a0\u00a0\nEn\u00a0el\u00a0estudio\u00a0que\u00a0se\u00a0presenta\u00a0a\u00a0continuaci\u00f3n,\u00a0se\u00a0comparan\u00a0las\u00a0c aracter\u00edsticas\u00a0de\u00a0los\u00a0pacientes\u00a0\nidentificados\u00a0 con\u00a0 infecci\u00f3n\u00a0 reciente\u00a0 con\u00a0 aquellos\u00a0 que\u00a0 presentab an\u00a0 infecci\u00f3n\u00a0 cr\u00f3nica,\u00a0 para\u00a0\ndeterminar\u00a0los\u00a0factores\u00a0asocia dos\u00a0con\u00a0la\u00a0infecci\u00f3n\u00a0reciente.\u00a0\nEl\u00a0TRI\u00a0se\u00a0aplic\u00f3\u00a0en\u00a0muestras\u00a0de\u00a0suero\u00a0de\u00a0pacientes\u00a0que\u00a0recibier on\u00a0el\u00a0diagn\u00f3stico\u00a0de\u00a0VIH\u00a0entre\u00a0\nlos\u00a0a\u00f1os\u00a02006\u00a0y\u00a02008.\u00a0Las\u00a0muestras\u00a0se\u00a0obtuvieron\u00a0durante\u00a0los\u00a0pr imeros\u00a0seis\u00a0meses\u00a0despu\u00e9s\u00a0del\u00a0\ndiagn\u00f3stico\u00a0de\u00a0VIH.\u00a0Las\u00a0muestras\u00a0de\u00a0pacientes\u00a0con\u00a0criterios\u00a0cl\u00ednicos\u00a0de\u00a0SIDA\u00a0o\u00a0recuentos\u00a0de\u00a0c\u00e9lulas\u00a0CD4+\u00a0inferiores\u00a0a\u00a0200\u00a0c\u00e9lulas/\u03bcl\u00a0no\u00a0se\u00a0analizaron\u00a0con\u00a0el\u00a0TRI,\u00a0ya\u00a0que\u00a0correspond\u00edan\u00a0a\u00a0pacientes\u00a0con\u00a0enfermedad\u00a0avanzada.\u00a0Las\u00a0muestras\u00a0de\u00a0suero\u00a0no\u00a0fue ron\u00a0extra\u00eddas\u00a0expresamente\u00a0\npara\u00a0el\u00a0estudio,\u00a0sino\u00a0que\u00a0se\u00a0recuperaron\u00a0las\u00a0al\u00edcuotas\u00a0sobrante s\u00a0que\u00a0hab\u00edan\u00a0sido\u00a0extra\u00eddas\u00a0con\u00a0\nprop\u00f3sitos\u00a0diagn\u00f3sticos\u00a0en\u00a0los\u00a0laboratorios\u00a0participantes.\u00a0\u00a0\nDel\u00a0total\u00a0de\u00a0nuevos\u00a0diagn\u00f3sticos\u00a0 de\u00a0VIH,\u00a0el\u00a079,9%\u00a0eran\u00a0hombres\u00a0 (mediana\u00a0de\u00a0edad\u00a035,4\u00a0a\u00f1os),\u00a0\nel\u00a038,7%\u00a0eran\u00a0de\u00a0origen\u00a0inmigrante,\u00a0el\u00a048,9%\u00a0de\u00a0las\u00a0transmision es\u00a0se\u00a0produjeron\u00a0entre\u00a0HSH,\u00a0y\u00a0el\u00a0\n10,6%\u00a0presentaron\u00a0otra\u00a0ITS\u00a0durante\u00a0el\u00a0a\u00f1o\u00a0previo\u00a0al\u00a0diagn\u00f3stico \u00a0de\u00a0VIH.\u00a0El\u00a0porcentaje\u00a0global\u00a0de\u00a0\ninfecci\u00f3n\u00a0reciente\u00a0fue\u00a0del\u00a023,0%,\u00a0y\u00a0se\u00a0observ\u00f3\u00a0un\u00a0aumento\u00a0signi ficativo\u00a0durante\u00a0el\u00a0periodo\u00a0de\u00a0\nestudio.\u00a0En\u00a0el\u00a0a\u00f1o\u00a02006\u00a0el\u00a0porcentaje\u00a0de\u00a0infecciones\u00a0reciente\u00a0f ue\u00a0del\u00a018,1%,\u00a0mientras\u00a0que\u00a0en\u00a0el\u00a0\na\u00f1o\u00a02008\u00a0el\u00a0porcentaje\u00a0de\u00a0infecciones\u00a0recientes\u00a0aument\u00f3\u00a0hasta\u00a0e l\u00a026,2%.\u00a0Entre\u00a0los\u00a0pacientes\u00a0\noriginarios\u00a0de\u00a0Am\u00e9rica\u00a0del\u00a0Sur,\u00a0 el\u00a0porcentaje\u00a0de\u00a0infecciones\u00a0re cientes\u00a0fue\u00a0m\u00e1s\u00a0alto\u00a0(27,6%).\u00a0En\u00a0el\u00a0M\u00c9TODOS\u00a0Y\u00a0RESULTADOS\u00a0\n 78grupo\u00a0de\u00a0pacientes\u00a0de\u00a0origen\u00a0inmigrante\u00a0identificados\u00a0con\u00a0infec ci\u00f3n\u00a0reciente,\u00a0y\u00a0cuya\u00a0fecha\u00a0de\u00a0\nllegada\u00a0a\u00a0Espa\u00f1a\u00a0era\u00a0conocida,\u00a0se\u00a0 observ\u00f3\u00a0que\u00a0el\u00a080%\u00a0llevaban\u00a0e n\u00a0nuestro\u00a0pa\u00eds\u00a0m\u00e1s\u00a0de\u00a0un\u00a0a\u00f1o.\u00a0\u00a0\u00a0\nLos\u00a0factores\u00a0que\u00a0se\u00a0asociaron\u00a0a\u00a0la\u00a0infecci\u00f3n\u00a0reciente\u00a0fue\u00a0la\u00a0ad quisici\u00f3n\u00a0de\u00a0la\u00a0infecci\u00f3n\u00a0a\u00a0trav\u00e9s\u00a0\ndel\u00a0contracto\u00a0sexual\u00a0entre\u00a0HSH\u00a0(Odds\u00a0ratio[OR]:\u00a02,0),\u00a0en\u00a0compar aci\u00f3n\u00a0con\u00a0adquirir\u00a0la\u00a0infecci\u00f3n\u00a0a\u00a0\ntrav\u00e9s\u00a0de\u00a0relaciones\u00a0heterosexuales,\u00a0y\u00a0tener\u00a0menos\u00a0de\u00a030\u00a0a\u00f1os\u00a0d e\u00a0edad\u00a0(OR:\u00a05,9),\u00a0en\u00a0comparaci\u00f3n\u00a0\ncon\u00a0tener\u00a0m\u00e1s\u00a0de\u00a050\u00a0a\u00f1os.\u00a0\nEn\u00a0este\u00a0estudio\u00a0se\u00a0ha\u00a0observado\u00a0el\u00a0mayor\u00a0porcentaje\u00a0de\u00a0infeccio nes\u00a0recientes\u00a0entre\u00a0los\u00a0HSH\u00a0\n(31%),\u00a0sugiriendo\u00a0una\u00a0mayor\u00a0incidencia\u00a0o,\u00a0tal\u00a0vez,\u00a0una\u00a0mayor\u00a0de manda\u00a0de\u00a0pruebas\u00a0de\u00a0cribado\u00a0de\u00a0\nVIH.\u00a0Los\u00a0resultados\u00a0sugieren\u00a0que\u00a0muchas\u00a0de\u00a0las\u00a0infecciones\u00a0por\u00a0 VIH\u00a0en\u00a0la\u00a0poblaci\u00f3n\u00a0inmigrante\u00a0\npodr\u00edan\u00a0haber\u00a0sido\u00a0adquiridas\u00a0lo calmente.\u00a0Otro\u00a0resultado\u00a0releva nte\u00a0del\u00a0estudio\u00a0es\u00a0el\u00a0aumento\u00a0\nsignificativo\u00a0del\u00a0porcentaje\u00a0de\u00a0infecciones\u00a0recientes\u00a0a\u00a0lo\u00a0larg o\u00a0del\u00a0periodo\u00a0de\u00a0estudio.\u00a0Conocer\u00a0la\u00a0\ninformaci\u00f3n\u00a0sobre\u00a0el\u00a0n\u00famero\u00a0de\u00a0p ruebas\u00a0de\u00a0VIH\u00a0realizadas\u00a0para\u00a0c ada\u00a0individuo\u00a0ser\u00eda\u00a0muy\u00a0\u00fatil\u00a0\npara\u00a0interpretar\u00a0correctamente\u00a0los\u00a0datos\u00a0de\u00a0los\u00a0individuos\u00a0con\u00a0 infecci\u00f3n\u00a0reciente.\u00a0Por\u00a0tanto,\u00a0los\u00a0\nsistemas\u00a0 para\u00a0 la\u00a0 monitorizaci\u00f3n\u00a0 de\u00a0 la\u00a0 epidemia\u00a0 de\u00a0 VIH\u00a0 deber\u00edan\u00a0 incluir\u00a0 ambos\u00a0 par\u00e1metros:\u00a0\ninfecciones\u00a0recientes\u00a0y\u00a0n\u00famero \u00a0de\u00a0pruebas\u00a0VIH\u00a0realizadas.\u00a0....................................................... ................................ ............... ................\nIdentification of recent HIV-1 infection among newly\ndiagnosed cases in Catalonia, Spain (2006\u201308)\nAnabel Romero1,2,3,4, Victoria Gonza \u00b4lez1,2,5, Anna Esteve1,2, Elisa Martro \u00b42,5, Lurdes Matas2,5,\nCristina Tural6, Toma `s Pumarola7, Aurora Casanova8, Elena Ferrer8, Estrella Caballero9,\nEsteve Ribera9,N u\u00b4ria Margall10, Pere Domingo10, Joan Farre \u00b411, Teresa Puig11, M\u00aaGoretti Sauca12,\nPilar Barrufet12, M\u00aaJose \u00b4Amengual13, Gemma Navarro13, Maria Navarro14, Josep Vilaro \u00b414,\nXavier Ort\u0131 \u00b4n15, Amat Ort\u0131 \u00b415, Ferran Pujol16, Josep M Prat17,A`ngels Massabeu17, Josep M Simo \u00b418,\nCarlos Alonso Villaverde18, Miguel A \u00b4ngel Ben\u0131 \u00b4tez19, Isabel Garcia20, Olga D\u0131 \u00b4az21,\nJasmina Becerra22, Rosa Ros23, Roser Sala24, Isabel Rodrigo25, Jose \u00b4M Miro \u00b426, Jordi Casabona1,2,3,\nthe AERI Study group*\n1 Centre d\u2019Estudis Epidemiolo `gics sobre les Infeccions de Transmissio \u00b4Sexual i Sida de Catalunya (CEEISCAT), Institut Catala `d\u2019Oncologia,\nDepartament de Salut, Generalitat de Catalunya, Badalona, Spain\n2 CIBER Epidemiolog\u0131 \u00b4a y Salud Pu \u00b4blica (CIBERESP), Spain\n3 Department of Paediatrics, Obstetrics and Gynaecology, and Preventive Medicine, Universitat Auto `noma de Barcelona, Spain\n4 Department of Epidemiology and Evaluation, IMIM- Parc de Salut Mar, Barcelona, Spain\n5 Departament de Gene `tica i Microbiologia, Microbiology Service, Hospital Universitari Germans Trias i Pujol, Universitat Auto `noma de\nBarcelona, Badalona, Spain\n6 Hospital Universitari Germans Trias i Pujol, Universitat Auto \u00b4noma de Barcelona, Badalona, Spain\n7 Hospital Cl\u0131 \u00b4nic \u2013 CRESIB, University of Barcelona, Barcelona, Spain\n8 Hospital Universitari de Bellvitge \u2013 IDIBELL, l\u2019Hospitalet de Llobregat, Spain9 Hospital Universitari Vall Hebron, Universitat Auto \u00b4noma de Barcelona, Barcelona, Spain\n10 Hospital de la Santa Creu i Sant Pau, Barcelona, Spain11 Hospital Universitari Arnau de Vilanova, Lleida, Spain12 Hospital de Mataro \u00b4, Mataro \u00b4, Spain\n13 Corporacio \u00b4Sanitaria Parc Taul\u0131 \u00b4, Sabadell, Spain\n14 Hospital General de Vic, Vic, Spain15 Hospital Verge de la Cinta, Tortosa, Spain16 Projecte dels NOMS-Hispanosida, Barcelona, Spain17 Hospital de Palamo \u00b4s, Palamo \u00b4s, Spain\n18 Hospital Universitari Sant Joan de Reus, Reus, Spain\n19 Hospital de Vilafranca, Vilafranca del Penede \u00b4s, Spain\n20 Hospital General de l\u2019Hospitalet, l\u2019Hospitalet de Llobregat, Spain\n21 SAPS, Barcelona, Spain22 ACASC, Barcelona, Spain23 CJAS, Barcelona, Spain24 Laboratori Sabater Tobella, Barcelona, Spain25 Laboratori Cl\u0131 \u00b4nic Manso, Barcelona, Spain\n26 Hospital Cl\u0131 \u00b4nic- IDIBAPS, University of Barcelona, Barcelona, Spain\n*The members of the AERI Study group are included in the Acknowledgements section.\nCorrespondence: Anabel Romero, Department of Epidemiology and Evaluation, IMIM- Parc de Salut Mar, Barcelona, Passeig Mar\u0131 \u00b4tim\n25-29, Barcelona 08003, Spain, tel: +34 93 248 3636, fax: +34 93 248 3496, e-mail: aromero@imim.es\nReceived 11 May 2011, accepted 5 November 2011\nBackground: Quantification and description of patients recently infected by HIV can provide an accurate estimate of the\ndynamics of HIV transmission. Between 2006 and 2008 in Catalonia, we estimated the prevalence of recent HIV infection\namong newly diagnosed cases, described the epidemiological characteristics of the infection according to whether it wasrecent, long-standing or advanced, and identified factors associated with recent infection. Methods: A Test for Recent\nInfection (TRI) was performed in serum samples from patients newly diagnosed with HIV. Two different TRI were used: theVironostika-LS assay (January 2006\u2013May 2007) and the BED-CEIA CEIA (June 2007 onwards). Samples were obtained within thefirst 6 months of diagnosis. Patients whose samples tested positive in the TRI were considered recently infected. Results: Of\n1125 newly diagnosed patients, 79.9% were men (median age, 35.4 years), 38.7% were born outside Spain, 48.9% were men\nwho have sex with men (MSM) and 10.6% presented other sexually transmitted infections. The overall percentage of recent\ninfection was 23.0%, which increased significantly, from 18.1% in 2006 to 26.2% in 2008. This percentage was higher forpatients from South America (27.6%). Factors associated with recent infection were acquiring infection through sexualcontact between MSM [odds ratio (OR) 2.0; 95% confidence interval (95% CI) 1.1\u20133.9], compared with acquiring infection\nthrough heterosexual relations and being under 30 years of age (OR 5.9; 95% CI 1.9\u201317.4), compared with being over\n50 years of age. Conclusion: The highest percentage of recent infection was identified in MSM, suggesting either a higher\nincidence or a greater frequency of HIV testing. Information regarding testing patterns is necessary to correctly interpret data\nfrom recently infected individuals. Systems to monitor the HIV epidemic should include both parameters.\n....................................................... ................................ ............... ................European Journal of Public Health , 1\u20137\n/C223The Author 2011. Published by Oxford University Press on behalf of the European Public Health Association. All rights reserved.\ndoi:10.1093/eurpub/ckr179 The European Journal of Public Health Advance Access published December 8, 2011 by guest on December 12, 2011 http://eurpub.oxfordjournals.org/ Downloaded from Introduction\nIn most European countries, HIV/AIDS surveillance is based\non reporting new diagnoses of HIV infection. In Spain, 15\nautonomous regions report new cases to the Newly DiagnosedHIV-infected Individuals Information System, which is currentlybeing implemented.\n1In one of these regions, Catalonia, voluntary\nreporting of newly diagnosed HIV infections was implemented inJanuary 2001 and became mandatory in 2010.\n2Given the varying\nand often long delays between HIV infection and diagnosis,information systems based on new diagnoses do not reflectcurrent patterns of HIV transmission dynamics.\nFor over a decade, laboratory-based methods have been applied\nfor the identification of recent HIV infections.\n3,4Several countries\nhave begun to monitor recent infections using Tests for RecentInfection (TRI). These assays are based on the principle that theantibody response to HIV infection matures over time and that\nimmunological biomarkers of HIV disease progression can be used\nto distinguish recent from non-recent HIV infection. In France,recent infection has been routinely monitored at national levelsince 2003 by applying a TRI to all new HIV diagnoses.\n5Other\nEuropean countries have also included this approach as a part of\ntheir surveillance system.6Using TRI, the Centers for Diseases\nControl and Prevention provided the first direct estimates of the\nincidence of HIV in the USA.7In 2003, the Serological Testing\nAlgorithm for Recent HIV Seroconversion was introduced inCatalonia as a feasibility study\n8and since 2006, has been applied\nin all newly identified cases of HIV infection in a network ofcentres as part of the Integrated Surveillance System of Catalonia(SIVES).\nThe aims of this study were to estimate the prevalence of recent\nHIV infection among newly diagnosed cases, to describe theepidemiological characteristics of the infection according towhether it was recent, long-standing or advanced, and to identifythe factors associated with recent infection in 14 hospitals and8 voluntary and counselling testing sites (VCTS) in Catalonia.\nMethods\nStudy period\nFrom January 2006 to December 2008.\nStudy population\nNewly identified cases of HIV infection in the participating centres,\nwhich represent /C2450% of all the new HIV notifications collected\nby the voluntary reporting system.\nSettings\nSamples were collected from 16 laboratories: 14 in hospitaloutpatient clinics and 2 other laboratories which collected\nsamples from the 8 VCTS. All the laboratories are in Catalonia(5 in Barcelona, 5 in the metropolitan area of Barcelona and 6in other cities in Catalonia) and all volunteered to participate.\nInclusion criteria\nAll patients newly diagnosed with HIV at the participating centreswere included. Serum samples had to be obtained within the first6 months of newly diagnosed HIV infection. All patients were aged/C2116 years and gave their written informed consent to participate.\nSpecimen collection\nResidual volumes of serum specimens collected for diagnosticpurposes were sent by the participating laboratories to thecoordinating centre (Centre for Epidemiological Studies on HIV/AIDS and STI of Catalonia (CEEISCAT)). Aliquots were identified\nby a study number (no personal identifiers were used).\nLaboratory methods\nSamples were analysed at the Microbiology Service of the HospitalUniversitari Germans Trias i Pujol. First, samples were analysed to\ndetect the presence of HIV-specific antibodies using a conventionalsensitive enzyme immunoassay (EIA) (Anti-HIV TETRA Elisa,\nBiotest, Dreieich, Germany) to ensure that they were all from\nHIV-positive patients. Samples from patients with a CD4\n+T-cell\ncount <200 cells/ ml and/or clinical criteria for AIDS (patients with\nadvanced HIV disease) were not tested. We designed a specificrecent infection testing algorithm to identify cases of recentinfection ( figure 1).\nDuring the study period, our laboratory used two different TRIs:\nthe Vironostika-LS assay (January 2006\u2013May 2007) and theBED-CEIA (June 2007 onwards). The performance characteristics\nof Vironostika-LS and BED-CEIA have been described else-\nwhere,\n9,10and both techniques showed good consistency.11\nMoreover, in order to assess whether the results obtained by\neach assay were comparable in our setting, we performed a local\nstudy, which provided consistent results. In that study we foundthat the agreement among both assays was good ( /C20= 0.738,\nP< 0.005). Both techniques identified recent infection equally\nwell.\n12However, Vironostika-LS is based on subtype B antigens\nand, consequently, performs differently with B and non-B\nsubtypes.13\nEthics\nThe ethics committees of the participating centres approved the\nprotocol. All personal identifiers were removed from the samplesthat were sent to the coordinating centre with a study number.\nOnly the recruitment centre had access to personal identifiers.\nInterpretation of results\nRecent infection: patients whose samples were positive in the TRI.\nLong-standing infection: patients whose samples were negative\nin the TRI.\nAdvanced HIV disease: patients with a CD4+T-cell count\n<200 cells/ ml and/or clinical criteria for AIDS.\nNewly diagnosed case of HIV \ninfection\n\u2264200 cells/ ml\n>200 cells/ ml\nYes\nNoAdvanced disease \nAIDS-defining\nillness Advanced disease \nLong-standing infection \nPositiveNegative\nRecent infectionCD4 count \nTest for Recent \nInfection\nFigure 1 Algoritm for the application of the TRI2o f7 European Journal of Public Health by guest on December 12, 2011 http://eurpub.oxfordjournals.org/ Downloaded from Data collection\nLaboratory staff completed a data collection form to record CD4+\nT-cell counts, HIV viral load and previous HIV serological testing\nresults. The patient\u2019s physician or a person designated by thephysician completed a second data collection form to recorddemographic and clinical\u2013epidemiological variables (sex, date ofbirth, country of origin, date of arrival in Spain, sexual orientation,use of injected drugs, sexually transmitted infections (STI), HIVserologic status at the time of diagnosis and use of antiretrovirals).\nPatients born outside Spain were considered immigrants.\nClinical and laboratory data from the closest date to the HIVdiagnosis were reported.\nIn order to ascertain whether the immigrants were infected in\nSpain, or whether they had acquired the infection before their\narrival in Spain, the date of arrival was collected whenever\npossible. If patients were identified as recently infected and hadbeen in Spain for >12 months (from the date of the HIVdiagnosis), they were considered to have acquired the infectionin Spain. On the contrary, if they were identified as recentlyinfected and had been in Spain for <6 months, they wereconsidered to have acquired the infection before arrival in Spain.If patients with advanced HIV disease or long-standing infection\nhad arrived <12 months (from the date of HIV diagnosis), they\nwere considered to have acquired the infection outside Spain.\nStatistical analysis\nThe percentage of recent infection was calculated as the number ofsamples identified as recent by the TRI divided by the total numberof new diagnoses and the 95% confidence interval (95% CI) wasestimated using the exact method. The Mantel test was applied toassess the presence of any significant trend during the study period.The Pearson\u2019s /C31\n2test or the Fisher\u2019s exact test were applied asappropriate to compare demographic characteristics, such as sex,\ncountry of origin, transmission group and presence of other STIs\nbetween the three study groups (recent infection, long-standinginfection and advanced HIV disease). Moreover, quantitative\nvariables were compared using the Mann\u2013Whitney U test. In\norder to identify risk factors associated with recent infection,univariate and multivariate and logistic regression models were\nconstructed adjusting for the type of centre and the geographic\narea. The odds ratio (OR) and its 95% CI were calculated.The statistical analysis was performed using SPSS 17.0.\nResults\nWe collected 1456 samples, of which 331 did not meet the\ninclusion criteria and were excluded from the study. Out of the\n1125 specimens, 1047 (93.1%) were obtained from hospitals andthe remainder were from the VCTS (6.9%). The characteristics of\npatients with newly diagnosed HIV infection are shown in table 1 .\nMost of them were male (79.9%), with a median age of 35.4 years[interquartile range (IQR): 29.5\u201343.4], 48.9% were men who have\nsex with men (MSM), 38.7% were immigrants, mostly from SouthAmerica (50.8%) and 10.6% had reported an STI diagnosis during\nthe 12 months before HIV diagnosis. Most of STI reported were\nreported as non-specified syphilis (55.5%).\nPatients with advanced HIV disease accounted for 29.7% of the\nsamples and, after performing the TRI in 791 samples, we obtaineda prevalence of recent infection of 23.0% (95% CI 20.6\u201325.6)(figure 2 ). The percentage of recent infection increased year by\nyear: 18.1% (95% CI 14.1\u201322.8) in 2006, 23.8% (95% CI 19.8\u201328.2) in 2007 and 26.2% (95% CI 21.9\u201330.9) in 2008 (P = 0.012\nfor linear trend).\nIn patients with newly diagnosed HIV infection, characteristics\nsuch as sex, age and transmission group differ significantly for\npatients identified as having recent infection, long-standing\nTable 1 Characteristics of newly diagnosed cases of HIV infection stratified by type of infection (Catalonia, 2006\u201308)\nNewly diagnosed cases,\nN(%)Recent,N(%)Long-standing,N(%)Advanced,N(%)P-value\na\n1125 (100.0) 259 (23.0) 532 (47.3) 334 (29.7)\nSex ( n= 1125)c0.042\nMen 899 (79.9) 221 (24.6) 417 (46.4) 261 (29.0)Women 226 (20.1) 38 (16.8) 115 (50.9) 73 (32.3)\nAge\nb(n= 1125)c(years) 35.4 (29.5\u201343.4) 32.5 (28.1\u201338.6) 33.9 (29.1\u201341.4) 40.1 (32.3\u201348.1) <0.001\n<30 310 (27.6) 88 (28.4) 160 (51.6) 62 (20.0)\n30\u201340 443 (39.4) 121 (27.3) 218 (49.2) 104 (23.5)\n40\u201350 243 (21.6) 40 (16.5) 108 (44.6) 95 (39.3)\n>50 129 (11.5) 10 (7.8) 46 (35.7) 73 (56.6)\nPlace of birth ( N= 1067)c0.443\nSpanish-born 654 (61.3) 150 (22.9) 357 (46.9) 197 (30.1)Immigrants 413 (38.7) 92 (22.3) 195 (47.2) 126 (30.5)\nSouth America 210 (50.8) 58 (27.6) 100 (47.6) 52 (24.8)Sub-Saharan Africa 84 (20.3) 10 (11.9) 38 (45.2) 36 (42.9)Central and western Europe 32 (7.7) 6 (18.8) 19 (59.4) 7 (21.9)North Africa and Middle East 18 (4.4) 4 (22.2) 11 (61.1) 3 (16.7)Eastern Europe and Russia 24 (5.8) 6 (25.0) 7 (29.2) 11 (45.8)Asia 7 (1.7) 1 (14.3) 4 (57.3) 2 (28.6)North America 6 (1.5) 3 (50.0) 2 (33.3) 1 (16.7)\nUnknown 32 (7.7) 4 (12.5) 14 (43.8) 14 (43.8)\nTransmission group ( n= 1117)\nc<0.001\nMen who have sex with men 550 (48.9) 171 (31.1) 282 (51.3) 97 (17.6)\nHeterosexual relations 436 (38.8) 67 (15.4) 185 (42.4) 184 (42.2)Injecting drug users 53 (4.7) 7 (13.2) 25 (47.2) 21 (39.6)Others/non-qualified risk 78 (6.9) 13 (16.7) 35 (44.9) 30 (38.5)\nSexually transmitted infections\nd(n= 940)c0.113\nYes 119 (10.6) 33 (27.2) 62 (52.1) 24 (20.2)No 821 (73.0) 191 (23.3) 390 (47.6) 240 (29.3)\na:P -value: Pearson\u2019s or Fisher\u2019s exact test, except for median age, where the Mann\u2013Whitney U test was used.\nb: Median and interquartile range.\nc: Number of samples with available information for each variable.d: Sexually transmitted infection diagnosed during the 12 months before inclusion.Identification of recent HIV-1 infection in Catalonia, Spain 3o f7 by guest on December 12, 2011 http://eurpub.oxfordjournals.org/ Downloaded from infection or advanced disease ( table 1 ). Recent infection was more\nfrequent in men than in women (24.6% vs. 16.8%), and median\nage was 32.5 years for patients with recent infection, 33.9 years for\npatients with long-standing infection and 40.1 years for patients\nwith advanced HIV disease ( P< 0.001). In MSM, 31.1% of\ninfections were identified as recent, whereas in the other transmis-\nsion groups the percentage ranges from 13.2% to 16.7%. Patients\nwith an STI diagnosed within the 12 months before the HIVdiagnosis tended to present recent infection more frequently\nthan those without (27.2% vs. 23.3%).\nOf the 413 immigrants, the date of their arrival in Spain was\ncollected in 238 cases: median time from arrival to HIV diagnosis\nwas 36.4 months (IQR 11.9\u201377.6). Among these 238 patients, 60were recently infected, 120 had long-standing infection and 58 had\nadvanced HIV disease. Of the 60 recently infected patients, 48\n(80%) had arrived in Spain over 12 months before their HIVdiagnosis. Of the 58 patients with advanced HIV disease and the\n120 patients with long-standing infection, 24.1 and 29.1%, respect-\nively, had arrived in Spain <12 months before. The percentage of\nrecent infection was different according to origin, namely, higher\namong patients from South America than for Spanish-bornpatients (27.6% vs. 22.9%). In contrast, this percentage was\nmuch lower for Sub-Saharan patients (11.9%).\nThe factors associated with recent infection were described using\nunivariate and multivariate logistic regression models ( table 2 ).\nIn the univariate model, two factors were found to be associated\nwith recent infection\u2014age and transmission group\u2014and both\nremained in the multivariate model. Transmission between MSM\nwas associated with recent infection (OR 2.0; 95% CI 1.1\u20133.9),compared with acquiring infection through heterosexual\nrelations. Recent infection was less frequent among patients\n>50 years, with an OR of 0.2 (95% CI 0.1\u20130.5), compared withpatients aged <30 years.\nDiscussion\nThe percentage of recent infections among newly diagnosed casesof HIV infection in Catalonia grew during the study period from18.1% (58 out of 320) in 2006 to 26.2% (103 out of 393) in 2008.The factors associated with recent infection were acquiring\ninfection through sexual contact between MSM and aged\n<30 years.\nA previous study, performed during 2003\u201305 in several centres\nin Spain, reported the prevalence of recent infection to be 19.2%,\n8\nwhich is lower than the overall prevalence of recent infectionsreported in the present study (23.0%). As some of the centresinvolved in the two studies are not the same, the results are notdirectly comparable; however, when recent infections in the\nCatalonian centres participating in both studies were taken into\naccount, the percentage of recent infections was 19.5% in 2003\u201305.Therefore, our results indicate that the percentage of recentinfection increased in our study population and that the\ndifference was statistically significant ( P< 0.01). This increase is\nconsistent with the decrease in the percentage of patients\nidentified with advanced HIV disease in the PISCIS cohort (aprospective cohort study of HIV-infected patients) and thevoluntary reporting of newly diagnosed HIV infection.\n2\nIn France, reporting of newly diagnosed HIV infection has been\nmandatory since 2003, and serology testing for recent infection hasbeen applied at the population level since then. Le Vu et al .\n13\nrecently reported percentages of recent infection of 24.8% in2006, 26.4% in 2007 and 27.0% in 2008. Although our percentagesof recent infection obtained were slightly lower, the increasingtrend is similar in both studies.\nOur study population represents /C2450% of all the new HIV\nnotifications collected by the regional surveillance system duringthe same period.\n2Data from this surveillance information system\nshow that the characteristics of our study population are\nquite similar to those of all new diagnoses of HIV infection in\nCatalonia. However, it appears that MSM might have beenslightly overrepresented in our study (48.9%), since in the HIVreporting system, the percentage of MSM among newly diagnosed\ncases between 2006 and 2008 was 42.7%. On the contrary, the\npercentage of immigrants in our study (38.7%) was lower thanthat observed in the HIV reporting system (43.1%). Therefore,since the HIV reporting system was not mandatory during thestudy period, these data are not representative of the population\nof newly diagnosed cases of HIV infection in Catalonia.Patients with advanced HIV \ndisease\nN=334 (29.7%)Samples tested using the TRI \nN=791\nPatients with long-standing \ninfections\nN=532 (47.3%) Patients with recent infection \nN=259 (23.0%)Samples collected \nN=1456\nSamples excluded* \nN=331\nFigure 2 Study flowchart. /C3: Patients whose HIV infection was diagnosed >6 months before sample collection (78.2%), insufficient\nsample volume (9.1%), duplicate samples (5.4%), no informed consent (3.6%), infected by HIV type 2 (0.9%), HIV-negative samples\n(0.6%) and age <16 years (0.3%)4o f7 European Journal of Public Health by guest on December 12, 2011 http://eurpub.oxfordjournals.org/ Downloaded from The highest percentage of recent infection was found in MSM,\na variable identified by logistic regression as being associated with\nrecent infection. There are several explanations for this finding.\nFirst, it is known that MSM undergo testing more often than\nother groups. A survey by our research team in a population ofpatients newly diagnosed with HIV infection revealed that 65.0% of\nMSM had been tested at least once before diagnosis, whereas this\npercentage was lower for patients who became infected through\nheterosexual relations (28.3%). Moreover, the median number of\nHIV tests taken was 3.0 for MSM and 1.0 for patients who acquiredthe infection through heterosexual relations (PISCIS Cohort\nStudy). This behaviour may be due to a higher self-perception of\nrisk for HIV infection in this group, but also to public health inter-ventions, such as those performed in venues where information and\nrapid testing for HIV are provided to MSM.\n14These patients are\nreferred to hospital if they test positive. In addition, the introduc-\ntion of rapid tests in VCTS represents an improvement in access to\ntesting facilities and, consequently, has enabled more people to be\ntested15and referred to hospital if they test positive. In our area,\ncommunity-based testing services specifically targeting MSM are\nmore common than in the general population. As these patients\nare tested more frequently, the probability of being identified as\nrecently infected increases. Second, several studies have recently\nreported an increase in risk behaviour among MSM.16\u201318Third,\nthe recent increase in the prevalence of STI is yet another\nindicator of risk behaviour, pointing to an increased likelihood of\nHIV transmission.19,20Fourth, it is noteworthy that MSM is the\nonly transmission group that experienced a significant increase\n(>5%) in the number of HIV diagnoses in the reporting system.2\nTaken together, these findings\u2014increase in risk behaviour and STI\nand a high percentage of recent infection\u2014suggest that the inci-\ndence of HIV may actually be rising among MSM.\nOur results show that age is associated with recent infection:\nrecently infected individuals are younger than those with\nadvanced HIV disease. The probability of being identified asrecently infected is higher for younger patients, as the time from\ninfection to diagnosis is usually shorter in younger people.\nPercentages of recent infection in patients who became infected\nthrough heterosexual relations (15.4%) and in injecting drug users\n(13.2%) were lower than those observed in MSM (31.1%),although, noticeably, the prevalence of recent infection in thefirst two groups increased during the study period, especially in2008. This increase could reflect an increase in the incidence ofHIV in those groups. However, when the time trend was analysed\nby transmission group, the differences were not statistically\nsignificant.\nA comparison of percentages of recent infection in immigrant\nand Spanish-born patients revealed that the percentage of recentinfections was similar among immigrants. The percentage of recent\ninfections differed significantly according to the country of origin.\nFor patients from South America (50.8% of our immigrantpopulation), the prevalence of recent infection was higher than\nin patients from Sub-Saharan Africa (20.3% of our immigrant\npopulation). This difference between the two populations lies inthe transmission group. The percentage of MSM was higher in\nSouth American patients, whereas heterosexual transmission was\nmore prevalent in Sub-Saharan patients. In our study population,\nthe percentage of MSM among the newly diagnosed cases of\nHIV was 67.6% for patients from South America and 0% forSub-Saharan patients. These data are consistent with epidemio-\nlogical data reported in both areas.\n21As mentioned above, MSM\nundergo testing more often than heterosexual individuals, thus\nmaking it more likely that they will be identified as recently\ninfected. Although age was also associated with recent infection,\nwe did not find significant differences between the two groups(sub-Saharan and South American patients): median age was\n31.1 years in patients from South America and 31.4 years in\nthose from Sub-Saharan Africa. Nonetheless, other factors mayhave affected our results.\nTo ascertain whether recent infections were imported or\nacquired locally, we recorded the date of arrival in Spain. This\ninformation was available for 60 patients identified as recently\ninfected and 48 (80%) had arrived in Spain more than 1 yearbefore they were diagnosed with HIV, suggesting that a substantial\nnumber of the recent HIV infections observed among immigrants\nare locally acquired. On the other hand, among the 58 patientswith advanced HIV disease for whom the arrival date was\nrecorded, 14 (24%) had arrived in Spain <1 year before they\nwere diagnosed with HIV, suggesting that these patients were\nalready infected when they first arrived in Spain. However, the\nfinding cannot be extrapolated, given the limited informationabout the arrival date.Table 2 Factors associated with recent infection (univariate and multivariate logistic regression models)\nUnivariate Multivariatea\nOR (95% CI) P-value OR (95% CI)aP-value\nSex ( n= 1125)b\nMale 1.6 (1.1\u20132.4) 0.014\nFemale\nPlace of birth ( n= 1067)b\nSpanish-born 1.0 (0.8\u20131.4) 0.802\nImmigrants\nAge ( n= 1125)b(years) <0.001 <0.001\n<30\n30\u201340 0.9 (0.7\u20131.3) 0.746 1.0 (0.7\u20131.3) 0.811\n40\u201350 0.5 (0.3\u20130.7) 0.001 0.5 (0.4\u20130.8) 0.005\n>50 0.2 (0.1\u20130.4) <0.001 0.2 (0.1\u20130.5) <0.001\nTransmission group ( n= 1117)b<0.001 <0.001\nHeterosexual relationsMen who have sex with men 2.5 (1.8\u20133.4) <0.001 2.0 (1.1\u20133.9) 0.027\nInjection drug users 0.8 (0.4\u20131.9) 0.679 0.9 (0.5\u20131.8) 0.805\nOthers/non-qualified risk 1.1 (0.6\u20132.1) 0.771 0.8 (0.3\u20132.1) 0.575\nSexually transmitted infections\nc(n= 940)b\nYes 1.3 (0.8\u20132.0) 0.286\nNo\na: The multivariate logistic regression model was adjusted for the type of centre and the geographic\narea. The OR and its 95% CI were calculated.b: Number of samples with available information for each variable.\nc: Sexually transmitted infection diagnosed during the 12 months before inclusion.Identification of recent HIV-1 infection in Catalonia, Spain 5o f7 by guest on December 12, 2011 http://eurpub.oxfordjournals.org/ Downloaded from Our study has several limitations. First, the small number of\nparticipating centres means that our findings cannot be\nextrapolated to the general HIV-positive population. Whereas\nour sample size represents nearly 50% of all HIV-positive\npatients in Catalonia and the characteristics of these patients arequite similar, it cannot be assumed to be representative.\nThe limitations of the serological assays for recent infections are\nwell known. These tests have reasonable sensitivity for the\ndetection of recent HIV infection, but can missclassify established\ninfections as recent.\n22However, by excluding patients with\nadvanced HIV disease from testing, we avoided missclassifyingthem as recently infected. In addition, we used two different\ntests: the Vironostika-LS assay and the BED-CEIA. Although\nseemingly a limitation, the results for both tests were consistent.\n12\nThe Vironostika assay has a longer window period in samples from\npatients with non-B subtypes.23Despite the increasing prevalence\nof non-B subtypes in our setting,24,25we do not believe that this\nlimitation has greatly affected our results, given that the percentage\nof samples identified by the Vironostika assay as recent is small\n(only 4%). The BED assay has a similar window period for\nHIV subtypes A\u2013E.10,26\nIn Catalonia, the Recent Infection Testing Algorithm has been\nincorporated into the surveillance system. Identification of factorsassociated with recent infection provides useful information about\ncurrent transmission patterns. In order to improve programmes\nfor prevention and control of HIV and STI, data from recent\ninfection surveillance should be included. In the light of our\nfindings, prevention campaigns targeting MSM should reinforcethe need to reduce sexual risk behaviours, however, the represen-\ntativeness of the samples available to be analysed using the TRI,\nadditional information about testing patterns is needed to enable a\nmore accurate interpretation of these data. We suggest that\nsurveillance systems should include information about testing\npatterns and recent infections.\nAcknowledgements\nThe Recent HIV Infections (AERIVIH) Study Group includes the\nfollowing: Coordinating Centre (CEEISCAT): Anabel Romero,Rafael Mun \u02dcoz, Nu \u00b4ria Ortega, Alexandra Montoliu, Anna Esteve\nand Jordi Casabona; STARHS Laboratory (Microbiology Service,Hospital Universitari Germans Trias i Pujol): Victoria Gonza \u00b4lez,\nElisa Martro \u00b4and Lurdes Matas; Peripheral centres: Josep M\naMiro\u00b4,\nToma `s Pumarola and Mar\u0131 \u00b4aL o\u00b4pez-Die \u00b4guez (H. Cl\u0131 \u00b4nic i Provincial\nde Barcelona); Aurora Casanova and Elena Ferrer (H. BellvitgePr\u0131\u00b4nceps d\u2019Espanya\u2014Barcelona); Cristina Tural (H. Universitari\nGermans Trias i Pujol\u2014Badalona); Estrella Caballero, Esteve\nRibera (H. General Vall Hebron\u2014Barcelona); Nu \u00b4ria Margall,\nPere Domingo (H. De la Santa Creu i Sant Pau\u2014Barcelona);Joan Farre \u00b4and Teresa Puig (H. Universitari Arnau de\nVilanova\u2014Lleida); M\naGoretti Sauca and MaPilar Barrufet\n(H. De Mataro \u00b4); Xavier Ort\u0131 \u00b4n and Amat Ort\u0131 \u00b4(H. Verge de la\nCinta\u2014Tortosa); MaJose\u00b4Armengual, Gemma Navarro and\nFerran Segura (Consorci Hospitalari del Parc Taul\u0131 \u00b4\u2014Sabadell);\nJosep MaPrat and A `ngels Masabeu (H. de Palamo \u00b4s); Marian\nNavarro and Josep Vilaro \u00b4(H. General de Vic); Josep MaSimo\u00b4,\nCarlos Alonso Villaverde and Blai Coll (H. Universitari Sant Joan\nde Reus), Eugenia Ma `rquez and Isabel Garcia (Hospital general de\nL\u2019Hospitalet); Miguel A \u00b4ngel Ben\u0131 \u00b4tez, Alba Cebollero and Manuel\nGuadarrama (H. De Vilafranca) Voluntary and Counseling TestingSites; Isabel Rodrigo (Lab. Cl\u0131 \u00b4nic de Manso), Roser Sala (Lab.\nSabater Tobella), Olga D\u0131 \u00b4az (SAPS), Kati Zaragoza (Stop Sida),\nMerce `Meron \u02dco( A `mbit Dona), Jorge Saz and Ferran Pujol\n(Projecte dels Noms\u2014Hispanosida), Jasmina Becerra (ACASC),Rosa Ros (CJAS), Anna Avellaneda, Montse Site \u00b4(Actua Valle `s),\nAnna Rafel (Associacio \u00b4Antisida Lleida).\nDr Miro \u00b4was a recipient of an INT10/219 Intensification\nResearch Grant (I3SNS & PRICS programs) from the Institutode Salud Carlos III, Madrid,Spain, and the Departament de Salutde la Generalitat de Catalunya, Barcelona, Spain. Hospital Clinic of\nBarcelona (Spain) data were supported in part by Ministerio de\nSanidad y Consumo, Instituto de Salud Carlos III, and the Spanish\nNetwork for the Research in Infectious Diseases (REIPI RD06/\n0008), Madrid, Spain\nFunding\nDireccio \u00b4General de Salut Pu \u00b4blica de la Generalitat de Catallunya\n(in part); the Fundacio \u00b4n para la Investigacio \u00b4n y Prevencio \u00b4n del\nSida en Espan \u02dca (FIPSE, Madrid, Spain, National AIDS Plan\nSecretariat of the Spanish Ministry of Health, in part); theCentres for Diseases Control and Prevention (CDC) provided\nthe samples for the quality control programme (FDA BB-IND\n#8193).\nConflicts of interest : None declared.\nKey points\n/C15Percentage of recent infections increased from 18.1% in\n2006 to 26.1% in 2008. This increase may also reflect an\nincrease in the incidence of HIV infection.\n/C15The highest percentage of recent infections was identified\nin MSM (31.1%), suggesting that the incidence of HIV is\nhigher in this group or the demand for diagnostic tests ishigher.\n/C15Many HIV infections among immigrants may be locally\nacquired.\nReferences\n1 Oliva J, Galindo S, Vives N, et al. Delayed diagnosis of HIV infection in Spain.\nEnferm Infecc Microbiol Clin 2010;28:583\u20139.\n2 Centre for Epidemiological Studies on Sexually Transmitted Infections and HIV/\nAIDS of Catalonia. d Estudis. SIVES 2010: Integrated AIDS/HIV/STI Surveillance\nSystem of Catalonia (SIVES): biennial epidemiological report . Barcelona:\nGeneralitat de Catalunya, Departament de Salut, 2011, (Technical document\nCEEISCAT: 20).\n3 Janssen RS, Satten GA, Stramer SL, et al. New testing strategy to detect early\nHIV-1 infection for use in incidence estimates and for clinical and preventionpurposes. JAMA 1998;280:42\u20138.\n4 Murphy G, Parry JV. Assays for the detection of recent infections with human\nimmunodeficiency virus type 1. Euro Surveill 2008;13:18966.\n5 Semaille C, Cazein F, Pillonel J, et al. Four years of surveillance of recent HIV\ninfections at country level, France, mid 2003 - 2006: Experience and perspectives.Euro Surveill 2008;13:18968.\n6 Health Protect Agency. Identification of recent HIV infection, UK. Available at:\nhttp://www.hpa.org.uk/web/HPAweb&Page&HPAwebAutoListName/Page/1201094588911 (6 December 2011, date last accessed).\n7 Hall HI, Song R, Rhodes P, et al. Estimation of HIV incidence in the United\nStates. JAMA 2008;300:520\u20139.\n8 Romero A, Gonzalez V, Granell M, et al. Recently acquired HIV infection in Spain\n(2003-2005): Introduction of the serological testing algorithm for recent HIVseroconversion. Sex Transm Infect 2009;85:106\u201310.\n9 Kothe D, Byers RH, Caudill SP, et al. Performance characteristics of a new less\nsensitive HIV-1 enzyme immunoassay for use in estimating HIV seroincidence.J Acquir Immune Defic Syndr 2003;33:625\u201334.\n10 Dobbs T, Kennedy S, Pau CP, et al. Performance characteristics of the im-\nmunoglobulin G-capture BED-enzyme immunoassay, an assay to detect recenthuman immunodeficiency virus type 1 seroconversion. J Clin Microbiol\n2004;42:2623\u20138.\n11 Gupta SB, Murphy G, Koenig E, et al. Comparison of methods to detect recent\nHIV type 1 infection in cross-sectionally collected specimens from a cohort of6o f7 European Journal of Public Health by guest on December 12, 2011 http://eurpub.oxfordjournals.org/ Downloaded from female sex workers in the Dominican Republic. AIDS Res Hum Retroviruses\n2007;23:1475\u201380.\n12 Romero A, Martro E, Gonza \u00b4lez V, et al. Comparison of two serological tests for\nthe identification of recent HIV infection: Vironostika HIV-1 microelisa and BED\ncapture enzyme immunoassay. Enferm Infecc Microbiol Clin 2011;29:553\u20135.\n13 Le Vu S, Le Strat Y, Barin F, et al. Population-based HIV-1 incidence in France,\n2003-08: a modelling analysis. Lancet Infect Dis 2010;10:682\u20137.\n14 Hurtado I, Alastrue I, Garcia de Olalla P, et al. Preventive intervention in\nvenues for interaction used by men who have sex with men. Gac Sanit\n2010;24:78\u201380.\n15 Fernandez-Lopez L, Rifa B, Pujol F, et al. Impact of the introduction of rapid HIV\ntesting in the voluntary counselling and testing sites network of Catalonia, Spain.\nInt J STD AIDS 2010;21:388\u201391.\n16 Folch C, Casabona J, Munoz R, et al. Increase in the prevalence of HIV and in\nassociated risk behaviors in men who have sex with men: 12 years of behavioral\nsurveillance surveys in Catalonia (Spain). Gac Sanit 2010;24:40\u20136.\n17 Folch C, Munoz R, Zaragoza K, Casabona J. Sexual risk behaviour and its\ndeterminants among men who have sex with men in Catalonia, Spain. Euro\nSurveill 2009;14:19415.\n18 Sullivan PS, Hamouda O, Delpech V, et al. Reemergence of the HIV epidemic\namong men who have sex with men in North America, western Europe, and\nAustralia, 1996-2005. Ann Epidemiol 2009;19:423\u201331.19 Vall-Mayans M, Caballero E, Sanz B. The emergence of lymphogranuloma\nvenereum in Europe. Lancet 2009;374:356.\n20 Casabona Barbara J, Binefa i Rodriguez G, Folch Toda C, et al. Sexually\nacquired HIV infections on the rise in Catalonia, Spain. Euro Surveill\n2006;11:E060720.5.\n21 UNAIDS. Global Report UNAIDS on the global AIDS epidemic: Joint United\nNations Programme on HIV/AIDS (UNAIDS). Geneva, Switzerland, 2010.\n22 Guy R, Gold J, Calleja JM, et al. Accuracy of serological assays for detection of\nrecent infection with HIV and estimation of population incidence: a systematic\nreview. Lancet Infect Dis 2009;9:747\u201359.\n23 Young CL, Hu DJ, Byers R, et al. Evaluation of a sensitive/less sensitive\ntesting algorithm using the bioMerieux vironostika-LS assay for detecting recent\nHIV-1 subtype B\u2019 or E infection in Thailand. AIDS Res Hum Retroviruses\n2003;19:481\u20136.\n24 Romero A, Sued O, Puig T, et al. Prevalence of transmitted HIV-1 drug resistance\nand distribution of HIV-1 subtypes among patients with recent infection inCatalonia (Spain) between 2003 and 2005. Enferm Infecc Microbiol Clin\n2011;29:482\u20139.\n25 Lospitao E, Alvarez A, Soriano V, Holguin A. HIV-1 subtypes in Spain: a\nretrospective analysis from 1995 to 2003. HIV Med 2005;6:313\u201320.\n26 Parekh BS, McDougal JS. New approaches for detecting recent HIV-1 infection.\nAIDS Rev 2001;3:183\u201393.Identification of recent HIV-1 infection in Catalonia, Spain 7o f7 by guest on December 12, 2011 http://eurpub.oxfordjournals.org/ Downloaded from \u00a0\n 86\u00a0\n -  87\u00a0\n\u00a0\n\u00a0\n\u00a0\n\u00a0\u00a0\n\u00a0\n\u00a0\u00a0\n\u00a0\n\u00a0\n\u00a0\n\u00a0\u00a0\n\u00a0\nANEXO\u00a0\n\u00a0\n\u00a0\u00a0\u00a0\u00a0\n 88ANEXO\u00a0\n -  89Estimaci\u00f3n \u00a0de\u00a0la\u00a0incidencia \u00a0mediante \u00a0el\u00a0uso\u00a0de\u00a0tests\u00a0 serol\u00f3gicos \u00a0para\u00a0\nidentificar \u00a0infecciones \u00a0recientes \u00a0\nA\u00a0pesar\u00a0de\u00a0la\u00a0importancia\u00a0de\u00a0la\u00a0incidencia\u00a0como\u00a0un\u00a0indicador\u00a0en \u00a0Salud\u00a0P\u00fablica,\u00a0la\u00a0mayor\u00eda\u00a0de\u00a0\nprogramas\u00a0preventivos\u00a0y\u00a0sistemas\u00a0de\u00a0vigilancia\u00a0se\u00a0centran\u00a0en\u00a0medir\u00a0la\u00a0prevalencia\u00a0de\u00a0VIH\u00a0en\u00a0una\u00a0\npoblaci\u00f3n,\u00a0es\u00a0decir,\u00a0la\u00a0proporci\u00f3n\u00a0actual\u00a0de\u00a0personas\u00a0que\u00a0viven \u00a0con\u00a0la\u00a0infecci\u00f3n\u00a0por\u00a0VIH.\u00a0Aunque\u00a0\nla\u00a0prevalencia\u00a0es\u00a0un\u00a0\u00edndice\u00a0\u00fatil\u00a0en\u00a0Salud\u00a0P\u00fablica,\u00a0no\u00a0refleja\u00a0d e\u00a0manera\u00a0directa\u00a0la\u00a0tasa\u00a0de\u00a0la\u00a0\ntransmisi\u00f3n\u00a0 actual\u00a0 de\u00a0 VIH,\u00a0 ya\u00a0 qu e\u00a0 puede\u00a0 estar\u00a0 confundida\u00a0 por\u00a0 otros\u00a0 factores\u00a0 como\u00a0 son\u00a0 la\u00a0\nsupervivencia\u00a0de\u00a0los\u00a0pacientes,\u00a0los\u00a0patrones\u00a0de\u00a0migraci\u00f3n\u00a0y\u00a0las\u00a0tasas\u00a0de\u00a0nacimiento.\u00a0Hay\u00a0que\u00a0enfatizar\u00a0adem\u00e1s\u00a0que\u00a0el\u00a0efecto\u00a0de\u00a0la\u00a0supervivencia\u00a0sobre\u00a0la\u00a0pre valencia\u00a0se\u00a0ha\u00a0visto\u00a0fuertemente\u00a0\nincrementado\u00a0con\u00a0el\u00a0\u00e9xito\u00a0de\u00a0las\u00a0terapias\u00a0antirretrovirales\u00a0en\u00a0 los\u00a0pa\u00edses\u00a0con\u00a0acceso\u00a0al\u00a0tratamiento\u00a0\n(113).\u00a0\nLa\u00a0estimaci\u00f3n\u00a0de\u00a0la\u00a0tasa\u00a0de\u00a0incidencia\u00a0en\u00a0una\u00a0determinada\u00a0poblaci\u00f3n\u00a0requiere\u00a0el\u00a0seguimiento\u00a0a\u00a0\nlo\u00a0largo\u00a0del\u00a0tiempo\u00a0de\u00a0individuos\u00a0que\u00a0no\u00a0est\u00e1n\u00a0infectados\u00a0por\u00a0e l\u00a0VIH\u00a0pero\u00a0que\u00a0se\u00a0consideran\u00a0a\u00a0\nriesgo\u00a0 de\u00a0 adquirir\u00a0 la\u00a0 infecci\u00f3n.\u00a0 No\u00a0 obstante,\u00a0 la\u00a0 implementaci\u00f3n \u00a0d e \u00a0e s t e \u00a0t i p o \u00a0d e \u00a0e s t u d i o s , \u00a0\ndenominados\u00a0cohortes\u00a0de\u00a0pacientes\u00a0seronegativos,\u00a0presenta\u00a0dific ultades\u00a0y\u00a0limitaciones.\u00a0Por\u00a0un\u00a0\nlado\u00a0requieren\u00a0importantes\u00a0recur sos\u00a0log\u00edsticos\u00a0para\u00a0asegurar\u00a0que\u00a0se\u00a0minimizan\u00a0las\u00a0p\u00e9rdidas\u00a0de\u00a0\nseguimiento\u00a0de\u00a0los\u00a0pacientes\u00a0incluidos\u00a0en\u00a0el\u00a0estudio.\u00a0A\u00a0su\u00a0vez, \u00a0este\u00a0intenso\u00a0seguimiento,\u00a0a\u00a0menudo\u00a0\nimplica\u00a0consejos\u00a0para\u00a0reducir\u00a0conductas\u00a0de\u00a0riesgo\u00a0u\u00a0otras\u00a0medid as\u00a0preventivas\u00a0lo\u00a0que\u00a0limita\u00a0la\u00a0\nvalidez\u00a0de\u00a0las\u00a0estimaciones\u00a0de\u00a0i ncidencia\u00a0o\u00a0su\u00a0extrapolaci\u00f3n\u00a0a\u00a0la\u00a0poblaci\u00f3n\u00a0general.\u00a0\u00a0\nE n \u00a0e s t e \u00a0c o n t e x t o , \u00a0l a \u00a0v e n t a j a \u00a0d e \u00a0l a \u00a0u t i l i z a c i \u00f3 n \u00a0d e \u00a0l o s \u00a0T R I s \u00a0p a r a \u00a0 obtener\u00a0 estimaciones\u00a0 de\u00a0\nincidencia\u00a0del\u00a0VIH\u00a0radica,\u00a0precisamente,\u00a0en\u00a0dos\u00a0aspectos\u00a0claves ,\u00a0como\u00a0son\u00a0la\u00a0poblaci\u00f3n\u00a0a\u00a0la\u00a0que\u00a0se\u00a0\naccede\u00a0y\u00a0el\u00a0dise\u00f1o\u00a0del\u00a0estudio\u00a0que\u00a0se\u00a0lleva\u00a0a\u00a0cabo\u00a0en\u00a0ella.\u00a0Est as\u00a0caracter\u00edsticas\u00a0determinan\u00a0que\u00a0su\u00a0\naplicaci\u00f3n\u00a0habitual\u00a0sea\u00a0en\u00a0poblaciones\u00a0a\u00a0riesgo\u00a0definidas\u00a0en\u00a0el \u00a0contexto\u00a0de\u00a0vigilancia\u00a0centinela,\u00a0en\u00a0\nsistemas\u00a0de\u00a0vigilancia\u00a0basados\u00a0en\u00a0los\u00a0nuevos\u00a0diagn\u00f3sticos\u00a0de\u00a0VI H\u00a0e\u00a0incluso\u00a0en\u00a0poblaci\u00f3n\u00a0general\u00a0\n(94,\u00a095,\u00a0114,\u00a0115).\u00a0En\u00a0cualquiera\u00a0de\u00a0estos\u00a0dos\u00a0contextos\u00a0anteri ores,\u00a0el\u00a0dise\u00f1o\u00a0del\u00a0estudio\u00a0es\u00a0de\u00a0\ntipo\u00a0transversal.\u00a0\nJanssen\u00a0 bas\u00e1ndose\u00a0 en\u00a0 la\u00a0 relaci\u00f3n\u00a0 epidemiol\u00f3gica\u00a0 que\u00a0 existe\u00a0 entre\u00a0 la\u00a0 prevalencia\u00a0 (p)\u00a0 la\u00a0\nincidencia\u00a0(I)\u00a0y\u00a0el\u00a0tiempo\u00a0de\u00a0 duraci\u00f3n\u00a0de\u00a0la\u00a0infecci\u00f3n\u00a0(T),\u00a0\u00a0\np = \u00a0 I \u00a0 x \u00a0 T , \u00a0\u00a0\u00a0\u00a0\u00a0\u00a0( 1 ) \u00a0\nformula\u00a0la\u00a0estrategia\u00a0a\u00a0seguir\u00a0para\u00a0la\u00a0estimaci\u00f3n\u00a0de\u00a0la\u00a0inciden cia\u00a0del\u00a0VIH\u00a0aplicando\u00a0los\u00a0resultados\u00a0\nde\u00a0clasificaci\u00f3n\u00a0del\u00a0test\u00a0STARHS\u00a0 en\u00a0muestras\u00a0procedentes\u00a0de\u00a0un\u00a0 estudio\u00a0transversal\u00a0(72).\u00a0En\u00a0su\u00a0\nformulaci\u00f3n\u00a0 la\u00a0 estimaci\u00f3n\u00a0 de\u00a0 la\u00a0 incidencia\u00a0 consiste\u00a0 en\u00a0 dividir\u00a0 el\u00a0 n\u00famero\u00a0 de\u00a0 individuos\u00a0\nidentificados\u00a0como\u00a0infecciones\u00a0recientes\u00a0(R)\u00a0por\u00a0el\u00a0n\u00famero\u00a0de\u00a0individuos\u00a0susceptibles,\u00a0es\u00a0decir,\u00a0el\u00a0n\u00famero\u00a0de\u00a0individuos\u00a0con\u00a0un\u00a0resultado\u00a0negativo\u00a0del\u00a0EIA\u00a0convencional\u00a0(N)\u00a0m\u00e1s\u00a0el\u00a0n\u00famero\u00a0de\u00a0ANEXO\u00a0\n 90infecciones\u00a0recientes\u00a0(R).\u00a0Esta\u00a0cantidad\u00a0se\u00a0anualiza\u00a0mediante\u00a0u n\u00a0factor\u00a0constante\u00a0que\u00a0tiene\u00a0en\u00a0\ncuenta\u00a0el\u00a0per\u00edodo\u00a0ventana\u00a0medio\u00a0del\u00a0test\u00a0(w):\u00a0\nI\u00a0=\u00a0R\u00a0/\u00a0(N\u00a0+\u00a0R)\u00a0x\u00a0365/w.\u00a0 \u00a0\u00a0\u00a0( 2 ) \u00a0\nAsimismo,\u00a0se\u00a0propone\u00a0c\u00f3mo\u00a0estimar\u00a0el\u00a0intervalo\u00a0de\u00a0confianza\u00a0aso ciado\u00a0a\u00a0la\u00a0incidencia\u00a0as\u00ed\u00a0como\u00a0\nuna\u00a0modificaci\u00f3n\u00a0de\u00a0la\u00a0f\u00f3rmula\u00a0(1)\u00a0para\u00a0tener\u00a0en\u00a0cuenta\u00a0la\u00a0exis tencia\u00a0de\u00a0m\u00faltiples\u00a0muestras\u00a0\nprocedentes\u00a0de\u00a0un\u00a0mismo\u00a0individuo.\u00a0\u00a0\nDesde\u00a0 esta\u00a0 primera\u00a0 aproximaci\u00f3n\u00a0 hasta\u00a0 la\u00a0 fecha\u00a0 encontramos\u00a0 en\u00a0 l a\u00a0 literatura\u00a0 numerosos\u00a0\nestudios\u00a0evaluando\u00a0la\u00a0precisi\u00f3n\u00a0de\u00a0las\u00a0estimaciones\u00a0de\u00a0incidenc ia\u00a0obtenidas\u00a0mediante\u00a0la\u00a0f\u00f3rmula\u00a0\nde\u00a0Janssen\u00a0(98,\u00a0116).\u00a0La\u00a0motivaci\u00f3n\u00a0de\u00a0estos\u00a0trabajos\u00a0ha\u00a0sido\u00a0s iempre\u00a0cuantificar\u00a0el\u00a0impacto\u00a0en\u00a0las\u00a0\nestimaciones\u00a0del\u00a0error\u00a0de\u00a0clasifi caci\u00f3n\u00a0(\u0404)\u00a0que,\u00a0en\u00a0mayor\u00a0o\u00a0men or\u00a0magnitud,\u00a0existe\u00a0siempre\u00a0al\u00a0\nconsiderar\u00a0 un\u00a0 test\u00a0 de\u00a0 identificaci\u00f3n\u00a0 de\u00a0 infecci\u00f3n\u00a0 reciente.\u00a0 Est e\u00a0 debate\u00a0 ha\u00a0 conducido\u00a0 a\u00a0 la\u00a0\npublicaci\u00f3n\u00a0de\u00a0propuestas\u00a0alternativas\u00a0a\u00a0la\u00a0f\u00f3rmula\u00a0(1),\u00a0como\u00a0s on\u00a0la\u00a0de\u00a0Hargrove\u00a0(117),\u00a0McDougal\u00a0\n(118)\u00a0y\u00a0McWalter\u00a0(119).\u00a0En\u00a0definitiva,\u00a0todas\u00a0estas\u00a0propuestas\u00a0p retenden\u00a0corregir\u00a0el\u00a0n\u00famero\u00a0de\u00a0\nindividuos\u00a0 considerados\u00a0 como\u00a0 reci entes\u00a0 entre\u00a0 el\u00a0 total\u00a0 de\u00a0 muestr as\u00a0 positivas\u00a0 (P).\u00a0 Las\u00a0 gu\u00edas\u00a0\nactuales,\u00a0no\u00a0obstante,\u00a0recomiendan\u00a0utilizar\u00a0la\u00a0aproximaci\u00f3n\u00a0de\u00a0 McWalter:\u00a0\u00a0\nI=\u00a0\u00a0(\u00a0R\u00a0\u2010\u00a0\u0404\u00a0x\u00a0P\u00a0)\u00a0/\u00a0(\u00a01\u2010\u00a0\u0404\u00a0)\u00a0x\u00a0w\u00a0x\u00a0N,\u00a0 \u00a0 \u00a0 (3)\u00a0\nque\u00a0expresa\u00a0la\u00a0incidencia\u00a0(I)\u00a0como\u00a0la\u00a0tasa\u00a0\u00a0instant\u00e1nea,\u00a0o\u00a0su\u00a0e xpresi\u00f3n\u00a0como\u00a0riesgo\u00a0anual\u00a0de\u00a0\ninfecci\u00f3n\u00a0con\u00a0la\u00a0siguiente\u00a0f\u00f3rmula\u00a0de\u00a0conversi\u00f3n:\u00a0\nIa\u00a0 = \u00a0 1 \u2010 e x p \u00a0 ( \u2010 \u00a0 I \u00a0 ) . \u00a0 \u00a0\u00a0\u00a0\u00a0\u00a0( 4 ) \u00a0\nLos\u00a0 primeros\u00a0 estudios\u00a0 que\u00a0 usaron\u00a0 los\u00a0 TRIs\u00a0 para\u00a0 estimar\u00a0 incidenc ia\u00a0 se\u00a0 realizaron\u00a0 en\u00a0\npoblaciones\u00a0centinela,\u00a0reclutando\u00a0los\u00a0participantes\u00a0en\u00a0cl\u00ednicas\u00a0de\u00a0ITS\u00a0(120,\u00a0121),\u00a0o\u00a0bien\u00a0en\u00a0centros\u00a0\nque\u00a0ofrecen\u00a0la\u00a0prueba\u00a0del\u00a0VIH\u00a0de\u00a0manera\u00a0an\u00f3nima\u00a0(122).\u00a0Las\u00a0inci dencias\u00a0estimadas\u00a0oscilaban\u00a0\nentre\u00a01,1\u00a0y\u00a03,0\u00a0infecciones\u00a0/100\u00a0 personas\u2010a\u00f1o,\u00a0encontr\u00e1ndose\u00a0la s\u00a0incidencias\u00a0m\u00e1s\u00a0altas\u00a0entre\u00a0la\u00a0\npoblaci\u00f3n\u00a0de\u00a0hombres\u00a0que\u00a0practican\u00a0sexo\u00a0con\u00a0hombres.\u00a0Posteriorm ente,\u00a0tambi\u00e9n\u00a0se\u00a0centraron\u00a0en\u00a0\notras\u00a0poblaciones\u00a0como\u00a0los\u00a0UDVP\u00a0 o\u00a0las\u00a0mujeres\u00a0embarazadas\u00a0(114, \u00a0123).En\u00a0el\u00a0estudio\u00a0realizado\u00a0\ne n \u00a0A t l a n t a \u00a0e n t r e \u00a0m u j e r e s \u00a0e m b a r a z adas\u00a0 la\u00a0 incidencia\u00a0 estimada\u00a0 fue \u00a0i n f e r i o r , \u00a0t a n \u00a0s \u00f3 l o \u00a0d e \u00a00 , 2 4 \u00a0\ninfecciones/\u00a0 100\u00a0 personas\u2010a\u00f1o\u00a0 (123).\u00a0 Por\u00a0 otro\u00a0 lado,\u00a0en\u00a0el\u00a0estud io\u00a0realizado\u00a0entre\u00a0poblaci\u00f3n\u00a0\nUDVP,\u00a0 en\u00a0 el\u00a0 primer\u00a0 periodo\u00a0 del\u00a0 estudio,\u00a0 de\u00a0 1990\u00a0 a\u00a0 1995\u00a0 la\u00a0 incid encia\u00a0 estimada\u00a0 fue\u00a0 3,1\u00a0\ninfecciones/\u00a0 100\u00a0 personas\u2010a\u00f1o,\u00a0 mientras\u00a0 que\u00a0 en\u00a0 el\u00a0 siguiente\u00a0 periodo,\u00a0 de\u00a0 1996\u00a0 a\u00a0 2002,\u00a0 la\u00a0incidencia\u00a0disminuy\u00f3\u00a0hasta\u00a00,9 \u00a0infecciones/\u00a0100\u00a0personas\u2010a\u00f1o.\u00a0\nEn\u00a0 los\u00a0 pa\u00edses\u00a0 africanos\u00a0 de\u00a0 la\u00a0 regi\u00f3n\u00a0 Subsahariana\u00a0 se\u00a0 han\u00a0 realiz ado\u00a0 numerosos\u00a0 estudios\u00a0\nestimando\u00a0 incidencia,\u00a0 usando\u00a0 TRIs.\u00a0 Las\u00a0 estimaciones\u00a0 obtenidas\u00a0 o s c i l a n \u00a0e n t r e \u00a02 , 0 \u00a0y \u00a01 7 , 0 % \u00a0\ninfecciones/personas\u2010a\u00f1o\u00a0(124).\u00a0En\u00a0general,\u00a0tambi\u00e9n\u00a0se\u00a0observa\u00a0un\u00a0descenso\u00a0en\u00a0el\u00a0tiempo\u00a0en\u00a0las\u00a0\ntasas\u00a0de\u00a0incidencia\u00a0(Tabla\u00a05).\u00a0ANEXO\u00a0\n -  91En\u00a0Estados\u00a0Unidos,\u00a0en\u00a0el\u00a0a\u00f1o\u00a02008\u00a0 publicaron\u00a0un\u00a0estudio\u00a0en\u00a0el\u00a0q ue\u00a0proporcionaban\u00a0la\u00a0primera\u00a0\nestimaci\u00f3n\u00a0 directa\u00a0 de\u00a0 incidencia\u00a0 de\u00a0 VIH,\u00a0 a\u00a0 nivel\u00a0 poblacional,\u00a0 u sando\u00a0 la\u00a0 informaci\u00f3n\u00a0 sobre\u00a0\ninfecciones\u00a0recientes\u00a0obtenida\u00a0med iante\u00a0el\u00a0test\u00a0BED\u2010CEIA.\u00a0Para\u00a0 el\u00a0a\u00f1o\u00a02006\u00a0estimaron\u00a0que\u00a039.400\u00a0\npersonas\u00a0fueron\u00a0diagnosticadas\u00a0de \u00a0VIH.\u00a0De\u00a0entre\u00a0todas\u00a0ellas,\u00a0an alizaron\u00a06.864\u00a0muestras\u00a0con\u00a0el\u00a0\ntest\u00a0BED\u2010CEIA,\u00a0y\u00a0obtuvieron\u00a02.133\u00a0casos\u00a0de\u00a0infecciones\u00a0reciente s\u00a0(31%).\u00a0A\u00a0partir\u00a0de\u00a0estos\u00a0datos,\u00a0\nextrapolaron\u00a0que\u00a0el\u00a0n\u00famero\u00a0total\u00a0de\u00a0nuevas\u00a0infecciones\u00a0producidas\u00a0en\u00a0el\u00a0a\u00f1o\u00a02006\u00a0fue\u00a0de\u00a056.300,\u00a0\nsuponiendo\u00a0una\u00a0tasa\u00a0de\u00a0incidencia\u00a0de\u00a022,8\u00a0nuevas\u00a0infecciones\u00a0por\u00a0cada\u00a0100.000\u00a0personas\u00a0(94).\u00a0\nEn\u00a0 Francia,\u00a0 tambi\u00e9n\u00a0 han\u00a0 calculado \u00a0 la\u00a0 incidencia\u00a0 de\u00a0 VIH\u00a0 a\u00a0 nivel\u00a0 poblacional\u00a0 usando\u00a0 la\u00a0\ninformaci\u00f3n\u00a0obtenida\u00a0a\u00a0partir\u00a0de\u00a0la\u00a0aplicaci\u00f3n\u00a0del\u00a0test\u00a0IDE\u2010V3. \u00a0En\u00a0el\u00a0a\u00f1o\u00a02008\u00a0estimaron\u00a0un\u00a0total\u00a0\nde\u00a06.480\u00a0nuevos\u00a0diagn\u00f3sticos\u00a0de\u00a0VIH\u00a0y\u00a06.940\u00a0nuevas\u00a0infecciones\u00a0 de\u00a0VIH.\u00a0La\u00a0incidencia\u00a0estimada\u00a0\nfue\u00a0de\u00a017\u00a0nuevas\u00a0infecciones\u00a0 por\u00a0cada\u00a0100.000\u00a0personas\u00a0(95).\u00a0\n\u00a0\nTabla\u00a05.\u00a0 Estimaciones \u00a0de\u00a0incidencia \u00a0de\u00a0VIH,\u00a0usando\u00a0tests\u00a0serol\u00f3gicos \u00a0para\u00a0identificar \u00a0infecciones \u00a0\nrecientes\u00a0\u00a0\u00a0 *%\u00a0personas\u2010a\u00f1o \u00a0\n\u00a0\nA\u00a0continuaci\u00f3n,\u00a0se\u00a0presenta\u00a0el\u00a0trabajo\u00a0que\u00a0tiene\u00a0como\u00a0objetivo\u00a0 utilizar\u00a0los\u00a0tests\u00a0serol\u00f3gicos\u00a0para\u00a0\nidentificar\u00a0infecciones\u00a0recientes\u00a0 para\u00a0obtener\u00a0estimaciones\u00a0de\u00a0 la\u00a0incidencia\u00a0de\u00a0VIH\u00a0en\u00a0nuestro\u00a0\nmedio.\u00a0Este\u00a0trabajo\u00a0est\u00e1\u00a0pendien te\u00a0de\u00a0publicaci\u00f3n,\u00a0y\u00a0se\u00a0present a\u00a0como\u00a0parte\u00a0no\u00a0fundamental\u00a0de\u00a0\nesta\u00a0tesis.\u00a0Lugar\u00a0 T\u00e9cnica\u00a0 Poblaci\u00f3n\u00a0 Tipo\u00a0de\u00a0centro\u00a0 Periodo\u00a0 Incidencia*\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 Referencia \u00a0\nAmsterdam\u00a0 Abbott\u00a0 HSH\u00a0 Cl\u00ednica\u00a0ITS\u00a0 1991\u00a0\u2010\u00a02001\u00a0 3,00\u00a0 Dukers\u00a0NH\u00a0 et\u00a0al.\u00a0\u00a0\nReino\u00a0Unido\u00a0Abbott/\u00a0\nVironostika\u00a0HSH\u00a0 Cl\u00ednica\u00a0ITS\u00a0 1995\u00a0\u2010\u00a02001\u00a0 2,45\u00a0 Murphy\u00a0G\u00a0et \u00a0al.\u00a0\u00a0\nSan\u00a0Francisco\u00a0Abbott/\u00a0\nVironostika\u00a0Poblaci\u00f3n\u00a0\nque\u00a0acude\u00a0a\u00a0\nlos\u00a0centros\u00a0\nan\u00f3nimos\u00a0de\u00a0\ncribado\u00a0\u00a0Centros\u00a0an\u00f3nimos\u00a0\nde\u00a0cribado\u00a0de\u00a0VIH\u00a01996\u20101998\u00a0 1,1\u00a0y\u00a01,9\u00a0en\u00a0H SH\u00a0 McFarland\u00a0W\u00a0 et\u00a0al.\u00a0\u00a0\nLisboa\u00a0 Avidez\u00a0Poblaci\u00f3n\u00a0\nheterosexual\u00a0Cl\u00ednica\u00a0ITS\u00a0 2004\u00a0 3,3\u00a0 Cortes\u00a0Martins\u00a0H\u00a0 et\u00a0al.\u00a0\u00a0\nSan\u00a0\nPetesburgo\u00a0BED\u2010CEIA\u00a0 UDVP\u00a0 Centros\u00a0de\u00a0s alud\u00a0 2005\u20102008\u00a0 18,7\u00a0 Niccolai\u00a0LM\u00a0 et\u00a0al.\u00a0\u00a0\u00a0\nAtlanta\u00a0 BED\u2010CEIA\u00a0Mujeres\u00a0\nembarazadas\u00a0Cl\u00ednica\u00a0prenatal\u00a0 1991\u20101998\u00a0 0,24\u00a0 Nesheim\u00a0S\u00a0 et\u00a0al.\u00a0\u00a0\n1990\u20101995\u00a0 3,1\u00a0New\u00a0York\u00a0 Vironostika\u00a0 UDVP\u00a0Centro\u00a0de\u00a0\ndesintoxicaci\u00f3n\u00a0 1996\u20102002\u00a0 0,9\u00a0Des\u00a0Jarlais\u00a0DC\u00a0 et\u00a0al.\u00a0\u00a0\nAdis\u00a0Abeba\u00a0\n(Etiop\u00eda)\u00a0BED\u2010CEIA\u00a0Mujeres\u00a0\nembarazadas\u00a0Cl\u00ednica\u00a0Prenatal\u00a0 1995\u00a0\u2010\u00a02003\u00a07,7\u00a0(1995)\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\n2,0\u00a0(2003)\u00a0Wolday\u00a0D \u00a0et\u00a0al.\u00a0\u00a0\nSur\u00a0\u00c1frica\u00a0 BED\u2010CEIA\u00a0Poblaci\u00f3n\u00a0\ngeneral\u00a0Poblacional\u00a0 2003\u00a0\u2010\u00a02006\u00a0 3,03\u00a0 \u2010\u00a03,19\u00a0 B\u00e4rnighausen\u00a0T\u00a0 et\u00a0al\u00a0\nEEUU\u00a0 BED\u2010CEIA\u00a0Poblaci\u00f3n\u00a0\ngeneral\u00a0Poblacional\u00a0 2006\u00a0 0,0228\u00a0 Hall\u00a0I\u00a0et\u00a0al.\u00a0\u00a0\nFrancia\u00a0 IDE\u2010V3\u00a0Poblaci\u00f3n\u00a0\ngeneral\u00a0Poblacional\u00a0 2008\u00a0 0,017\u00a0 Le\u00a0Vu\u00a0S\u00a0 et\u00a0al.\u00a0\u00a0ANEXO\u00a0\n 92Approximation \u00a0to\u00a0HIV\u00a0incidence\u00a0 using\u00a0 tests\u00a0 for\u00a0recent\u00a0infection \u00a0in\u00a0the\u00a0\nHIV\u00a0Surveillance \u00a0System\u00a0of\u00a0Catalonia, \u00a0Spain.\u00a0\u00a0\n\u00a0\nA\u00a0Esteve1,2,3,4,\u00a0A\u00a0Romero4,5,\u00a0V\u00a0Gonz\u00e1lez1,2,3,\u00a0C\u00a0N\u00a0J\u00a0Campbell1,\u00a0L\u00a0Fern\u00e1ndez\u2010L\u00f3pez1,\u00a0J\u00a0Casabona1,2,3,4\u00a0\nand\u00a0the\u00a0AERI\u00a0Study\u00a0Group.\u00a0\n1\u00a0Centre\u00a0d'Estudis\u00a0Epidemiol\u00f2gics\u00a0sobre\u00a0les\u00a0Infeccions\u00a0de\u00a0Transm issi\u00f3\u00a0Sexual\u00a0i\u00a0Sida\u00a0de\u00a0Catalunya\u00a0\n(CEEISCAT).\u00a0Institut\u00a0Catal\u00e0\u00a0d\u2019Oncologia\u00a0(ICO).\u00a0Ag\u00e8ncia\u00a0de\u00a0Salut \u00a0P\u00fablica\u00a0de\u00a0Catalunya\u00a0(ASPCAT),\u00a0\nEspanya\u00a0\n2\u00a0CIBER\u00a0Epidemiolog\u00eda\u00a0y\u00a0Salud\u00a0P \u00fablica\u00a0(CIBERESP),\u00a0Espanya\u00a0\n3\u00a0Institut\u00a0d'Investigaci\u00f3\u00a0Germans\u00a0Trias\u00a0i\u00a0Pujol\u00a0(IGTP),\u00a0Badalona, \u00a0Espanya\u00a0\n4\u00a0Departament\u00a0 de\u00a0Pediatria,\u00a0d\u2019Obst etr\u00edcia\u00a0 i\u00a0 Ginecologia\u00a0 i\u00a0 de\u00a0 Medi cina\u00a0 Preventiva,\u00a0 Universitat\u00a0\nAut\u00f2noma\u00a0de\u00a0Barcelona,\u00a0Bella terra,\u00a0Barcelona,\u00a0Espanya\u00a0\n5\u00a0Ag\u00e8ncia\u00a0de\u00a0Qualitat\u00a0i\u00a0Avaluaci\u00f3 \u00a0Sanit\u00e0ries\u00a0de\u00a0Catalunya\u00a0(AQuAS),\u00a0Espanya\u00a0\n\u00a0\nRunning\u00a0 head:\u00a0HIV\u00a0incidence\u00a0in\u00a0Catalonia,\u00a0Spain\u00a0(2003\u20102008)\u00a0\nWords\u00a0in\u00a0Abstract:\u00a0 310\u00a0 \u00a0 Words\u00a0in\u00a0the\u00a0manuscript: \u00a02,924\u00a0\nTables:\u00a02\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 Figures:\u00a00\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 Key\u00a0words:\u00a0Recent\u00a0infection,\u00a0HIV;\u00a0Incide nce;\u00a0Test\u00a0for\u00a0recent\u00a0infection\u00a0\nThis\u00a0study\u00a0was\u00a0presented\u00a0in\u00a0part\u00a0at\u00a0the\u00a0Congress\u00a0of\u00a0the\u00a0Socieda d\u00a0Espa\u00f1ola\u00a0de\u00a0Epidemiolog\u00eda\u00a0\n(SEE),\u00a0Madrid,\u00a0Spain;\u00a0October\u00a06\u20108,\u00a02011.\u00a0\u00a0\nCorresponding \u00a0author:\u00a0\u00a0\nAnna\u00a0Esteve\u00a0Center\u00a0for\u00a0Epidemiological\u00a0Studies\u00a0on\u00a0Sexually\u00a0Transmitted\u00a0Infections\u00a0and\u00a0HIV/AIDS\u00a0of\u00a0Catalonia\u00a0\n(CEEISCAT\u2010\u00a0ICO).\u00a0\nHospital\u00a0Universitari\u00a0Germans\u00a0Trias\u00a0i\u00a0Pujol\u00a0\nCtra.\u00a0de\u00a0Canyet,\u00a0s/n.\u00a008916\u00a0Badalona,\u00a0SPAIN\u00a0\naesteve@iconcologia.net\n\u00a0\nphone:\u00a0+34\u00a0934\u00a0978\u00a0891;\u00a0fax\u00a0+34\u00a0934\u00a0978\u00a0889\u00a0\nCompeting\u00a0 interests: \u00a0None\u00a0declared \u00a0\nData:\u00a027/05/2014\u00a0\n\u00a0\n\u00a0\n\u00a0\u00a0\n\u00a0ANEXO\u00a0\n -  93RESUMEN\u00a0\nIntroducci\u00f3n: \u00a0 En\u00a0 Catalu\u00f1a,\u00a0 desde\u00a0 el\u00a0 a\u00f1o\u00a0 2003,\u00a0 en\u00a0 el\u00a0 contexto\u00a0 del\u00a0 Sistema\u00a0 Int egrado\u00a0 de\u00a0\nVigilancia\u00a0Epidemiol\u00f3gica\u00a0del\u00a0VIH,\u00a0se\u00a0realiza\u00a0la\u00a0identificaci\u00f3n \u00a0de\u00a0infecciones\u00a0recientes\u00a0entre\u00a0los\u00a0\nnuevos\u00a0 diagn\u00f3sticos\u00a0 de\u00a0 VIH\u00a0 mediante\u00a0 el\u00a0 uso\u00a0 de\u00a0 los\u00a0 algoritmos\u00a0 para\u00a0 identificar\u00a0 infecciones\u00a0\nrecientes.\u00a0Identificar\u00a0las\u00a0infe cciones\u00a0recientes\u00a0bas\u00e1ndose\u00a0en\u00a0l a\u00a0aplicaci\u00f3n\u00a0de\u00a0tests\u00a0serol\u00f3gicos\u00a0\npermite\u00a0estimar\u00a0la\u00a0incidencia\u00a0a\u00a0partir\u00a0de\u00a0f\u00f3rmulas\u00a0dise\u00f1adas\u00a0espec\u00edficamente\u00a0para\u00a0ese\u00a0prop\u00f3sito.\u00a0\nEl\u00a0objetivo\u00a0de\u00a0este\u00a0trabajo\u00a0fue\u00a0estimar\u00a0la\u00a0incidencia\u00a0de\u00a0VIH\u00a0en tre\u00a0los\u00a0nuevos\u00a0diagn\u00f3sticos\u00a0de\u00a0VIH\u00a0\nidentificados\u00a0en\u00a0una\u00a0red\u00a0de\u00a0hospitales\u00a0y\u00a0centros\u00a0de\u00a0cribado\u00a0alternativos\u00a0situados\u00a0en\u00a0Catalu\u00f1a,\u00a0entre\u00a0los\u00a0a\u00f1os\u00a02003\u00a0y\u00a02008.\u00a0\nM\u00e9todos: \u00a0Se\u00a0incluyeron\u00a0muestras\u00a0de\u00a0nuevos\u00a0diagn\u00f3sticos\u00a0de\u00a0VIH\u00a0procedent es\u00a0de\u00a011\u00a0hospitales\u00a0\ny\u00a0 6\u00a0 centros\u00a0 de\u00a0 cribado\u00a0 alternativos.\u00a0 Durante\u00a0 el\u00a0 periodo\u00a0 de\u00a0 estu dio\u00a0 se\u00a0 utilizaron\u00a0 dos\u00a0 tests\u00a0\ndiferentes.\u00a0Desde\u00a0el\u00a0a\u00f1o\u00a02003\u00a0hasta\u00a0el\u00a02006\u00a0se\u00a0us\u00f3\u00a0el\u00a0Vironostika,\u00a0y\u00a0a\u00a0partir\u00a0del\u00a0a\u00f1o\u00a02007,\u00a0debido\u00a0\na\u00a0que\u00a0el\u00a0test\u00a0Vironostika\u00a0dej\u00f3\u00a0de\u00a0estar\u00a0disponible\u00a0comercialmen te,\u00a0se\u00a0us\u00f3\u00a0el\u00a0test\u00a0BED\u2010CEIA.\u00a0Los\u00a0\nresultados\u00a0de\u00a0un\u00a0estudio\u00a0previo, \u00a0nos\u00a0indicaron\u00a0que\u00a0la\u00a0concordan cia\u00a0entre\u00a0ambos\u00a0tests\u00a0era\u00a0buena.\u00a0\nEn\u00a0el\u00a0algoritmo\u00a0dise\u00f1ado\u00a0para\u00a0identificar\u00a0infecciones\u00a0recientes ,\u00a0las\u00a0muestras\u00a0correspondientes\u00a0a\u00a0\npacientes\u00a0con\u00a0enfermedad\u00a0avanzada\u00a0de\u00a0VIH\u00a0(pacientes\u00a0con\u00a0criteri os\u00a0cl\u00ednicos\u00a0de\u00a0SIDA\u00a0o\u00a0recuentos\u00a0\nde\u00a0c\u00e9lulas\u00a0CD4+\u00a0inferiores\u00a0a\u00a0 200\u00a0c\u00e9lulas/\u03bcl)\u00a0se\u00a0consideraron\u00a0qu e\u00a0correspond\u00edan\u00a0a\u00a0infecciones\u00a0no\u00a0\nrecientes.\u00a0Para\u00a0estimar\u00a0la\u00a0incid encia\u00a0de\u00a0VIH\u00a0se\u00a0us\u00f3\u00a0el\u00a0m\u00e9todo\u00a0p ropuesto\u00a0por\u00a0McWalter.\u00a0Este\u00a0\nm\u00e9todo\u00a0consiste\u00a0en\u00a0dividir\u00a0el\u00a0n\u00famero\u00a0de\u00a0infecciones\u00a0recientes\u00a0( IR)\u00a0por\u00a0el\u00a0n\u00famero\u00a0de\u00a0muestras\u00a0\ncon\u00a0un\u00a0resultado\u00a0negativo\u00a0en\u00a0un\u00a0test\u00a0VIH\u00a0est\u00e1ndar,\u00a0de\u00a0esta\u00a0mane ra:\u00a0I=\u00a0\u00a0(\u00a0IR\u00a0\u2010\u00a0\u0404\u00a0x\u00a0P\u00a0)\u00a0/\u00a0(\u00a01\u2010\u00a0\u0404\u00a0)\u00a0x\u00a0w\u00a0x\u00a0\nN,\u00a0 donde\u00a0 \u0404\u00a0 representa\u00a0 la\u00a0 tasa\u00a0 de\u00a0 falsos\u00a0 positivos\u00a0 del\u00a0 algoritmo \u00a0 para\u00a0 identificar\u00a0 infecciones\u00a0\nrecientes,\u00a0la\u00a0P\u00a0es\u00a0el\u00a0n\u00famero\u00a0total\u00a0de\u00a0personas\u00a0VIH\u00a0positivas\u00a0,\u00a0 la\u00a0w\u00a0es\u00a0el\u00a0periodo\u00a0ventana\u00a0del\u00a0test\u00a0\npara\u00a0detectar\u00a0infecciones\u00a0reciente s,\u00a0y\u00a0la\u00a0N\u00a0es\u00a0el\u00a0n\u00famero\u00a0de\u00a0personas\u00a0VIH\u00a0negativas.\u00a0\nResultados:\u00a0En\u00a0el\u00a0periodo\u00a0de\u00a0estudio,\u00a0se\u00a0 analizaron\u00a0un\u00a0total\u00a0de\u00a02.642\u00a0mues tras\u00a0de\u00a0pacientes\u00a0\nque\u00a0fueron\u00a0diagnosticados\u00a0por\u00a0VIH\u00a0entre\u00a0los\u00a0a\u00f1os\u00a02003\u00a0y\u00a02008.\u00a0D e\u00a0estas\u00a02.642\u00a0muestras,\u00a0despu\u00e9s\u00a0\nde\u00a0aplicar\u00a0el\u00a0algoritmo\u00a0para\u00a0ide ntificar\u00a0infecciones\u00a0recientes, \u00a0518\u00a0(19,6%)\u00a0se\u00a0identificaron\u00a0como\u00a0\ninfecciones\u00a0recientes.\u00a0La\u00a0incidencia\u00a0de\u00a0VIH\u00a0estimada\u00a0para\u00a0el\u00a0pe riodo\u00a02003\u00a0\u2013\u00a02008\u00a0fue\u00a0de\u00a00,46\u00a0\ncasos\u00a0de\u00a0nuevas\u00a0infecciones\u00a0por\u00a0 cada\u00a0100\u00a0personas/a\u00f1o.\u00a0Se\u00a0observ\u00f3\u00a0un\u00a0aumento\u00a0de\u00a0la\u00a0incidencia\u00a0\ndurante\u00a0el\u00a0periodo\u00a0de\u00a0estudio\u00a0global,\u00a0aumentando\u00a0significativamente\u00a0de\u00a00,31\u00a0nuevas\u00a0infecciones\u00a0\npor\u00a0cada\u00a0100\u00a0personas/a\u00f1o\u00a0en\u00a0el\u00a0 a\u00f1o\u00a02005,\u00a0a\u00a00,73\u00a0por\u00a0cada\u00a0100\u00a0p ersonas/a\u00f1o\u00a0en\u00a0el\u00a0a\u00f1o\u00a02008.\u00a0\u00a0\u00a0\u00a0 \u00a0\nConclusiones:\u00a0Estimar\u00a0la\u00a0incidencia\u00a0es\u00a0necesario\u00a0para\u00a0conocer\u00a0la\u00a0evoluci\u00f3n\u00a0de\u00a0la\u00a0epidemia\u00a0por\u00a0\nVIH\u00a0en\u00a0nuestro\u00a0medio.\u00a0Este\u00a0trabajo\u00a0supone\u00a0la\u00a0primera\u00a0estimaci\u00f3n \u00a0de\u00a0incidencia\u00a0de\u00a0VIH,\u00a0usando\u00a0los\u00a0\nalgoritmos\u00a0para\u00a0identificar\u00a0infecciones\u00a0recientes\u00a0en\u00a0Catalu\u00f1a.\u00a0 Los\u00a0resultados\u00a0obtenidos\u00a0sugieren\u00a0\nque\u00a0la\u00a0incidencia\u00a0de\u00a0VIH\u00a0est\u00e1\u00a0aumentando\u00a0en\u00a0nuestro\u00a0medio.\u00a0\u00a0ANEXO\u00a0\n 94ABSTRACT\u00a0\n\u00a0\nBackground:\u00a0 In\u00a0Catalonia\u00a0(Spain)\u00a0since\u00a0year\u00a02003\u00a0recent\u00a0infection\u00a0testing\u00a0a lgorithms\u00a0(RITA)\u00a0\nh a v e \u00a0b e e n \u00a0i n c o r p o r a t e d \u00a0t o \u00a0t h e \u00a0I n t egrated\u00a0 Surveillance\u00a0 System\u00a0 on \u00a0A I D S , \u00a0H I V \u00a0a n d \u00a0S e x u a l l y \u00a0\nTransmitted\u00a0Infections\u00a0in\u00a0Catalonia.\u00a0This\u00a0approach,\u00a0based\u00a0on\u00a0a\u00a0 laboratory\u00a0assay\u00a0able\u00a0to\u00a0identify\u00a0\nrecent\u00a0 infections\u00a0 (RI)\u00a0 among\u00a0 HIV\u00a0 diagnoses,\u00a0 allows\u00a0 us\u00a0 to\u00a0 infer\u00a0 HIV\u00a0 incidence\u00a0 from\u00a0 a\u00a0 cross\u2010\nsectional\u00a0survey\u00a0testing.\u00a0We\u00a0aim\u00a0to\u00a0estimate\u00a0the\u00a0HIV\u00a0incidence\u00a0 in\u00a0the\u00a0subpopulation\u00a0tested\u00a0for\u00a0HIV\u00a0\nin\u00a0Catalonia\u00a0(Spain)\u00a0from\u00a02003\u00a0to\u00a02008\u00a0by\u00a0using\u00a0data\u00a0from\u00a0the\u00a0H IV\u00a0Surveillance\u00a0system\u00a0and\u00a0\nRITAs.\u00a0Methods: \u00a0We\u00a0evaluated\u00a0with\u00a0RITA\u00a0all\u00a0the\u00a0samples\u00a0with\u00a0a\u00a0new\u00a0HIV\u00a0diagnosis \u00a0from\u00a0a\u00a0network\u00a0of\u00a011\u00a0\nhospitals\u00a0and\u00a06\u00a0voluntary\u00a0counselling\u00a0testing\u00a0sites\u00a0during\u00a02003 \u20102008\u00a0(AERI\u00a0Study).\u00a0The\u00a0HIV\u00a0\nTesting\u00a0Surveillance\u00a0System\u00a0of\u00a0Catalonia\u00a0provided\u00a0as\u00a0aggregated\u00a0data\u00a0the\u00a0number\u00a0of\u00a0diagnostic\u00a0tests\u00a0with\u00a0positive\u00a0or\u00a0negative\u00a0result\u00a0performed\u00a0by\u00a0the\u00a0partici pating\u00a0centres.\u00a0We\u00a0approximate\u00a0HIV\u00a0\nincidence\u00a0 using\u00a0 a\u00a0 modification\u00a0 of\u00a0 the\u00a0 McWalter\u2019s\u00a0 approach\u00a0 takin g\u00a0 into\u00a0 account\u00a0 the\u00a0\nmisclassification\u00a0rate\u00a0and\u00a0other\u00a0calibration\u00a0parameters.\u00a0Compar ison\u00a0of\u00a0HIV\u00a0incidence\u00a0between\u00a0\ntimes\u00a0periods\u00a0were\u00a0evaluated\u00a0using\u00a0the\u00a0incidence\u00a0ratio\u00a0(IR)\u00a0and \u00a0their\u00a095%\u00a0confidence\u00a0interval\u00a0\n(CI).\u00a0\u00a0Results:\u00a0Out\u00a0of\u00a0the\u00a02,642\u00a0new\u00a0HIV\u00a0diagnoses,\u00a0518\u00a0were\u00a0classified\u00a0as\u00a0RI\u00a0( 19.6%).\u00a0By\u00a0year,\u00a0this\u00a0\npercentage\u00a0increases\u00a0from\u00a017.4%\u00a0to\u00a026.0%\u00a0(p<0.05).\u00a0The\u00a0FRR\u00a0of\u00a0t he\u00a0recent\u00a0infection\u00a0algorithm\u00a0\nwas\u00a0 locally\u00a0 estimated\u00a0 in\u00a0 3.8%\u00a0 (coefficient\u00a0 of\u00a0 variation\u00a0 of\u00a0 15.7 %).\u00a0 The\u00a0 HIV\u00a0 incidence\u00a0 was\u00a0\nestimated\u00a0in\u00a00.46\u00a0cases\u00a0of\u00a0new\u00a0i nfections\u00a0per\u00a0100/year\u00a0during\u00a0the\u00a0study\u00a0period\u00a02003\u20102008\u00a0(95%\u00a0\nCI:\u00a00.39\u20100.53).\u00a0Annually,\u00a0the\u00a0HIV\u00a0incidence\u00a0varied\u00a0increasing\u00a0s ignificantly\u00a0from\u00a00.31\u00a0(95%\u00a0CI:\u00a0\n0.22\u20100.51)\u00a0new\u00a0infections\u00a0per\u00a0 100/year\u00a0in\u00a02005\u00a0to\u00a00.73\u00a0(95%\u00a0CI: \u00a00.55\u20100.90)\u00a0per\u00a0100/year\u00a0in\u00a02008\u00a0\n(IR=2.34,\u00a095%\u00a0CI\u00a0[1.51\u20103.18]).\u00a0Conclusions: \u00a0Our\u00a0data\u00a0suggest\u00a0that\u00a0HIV\u00a0incidence\u00a0might\u00a0be\u00a0increasing\u00a0from\u00a020 06\u00a0to\u00a02008\u00a0in\u00a0our\u00a0\nsetting.\u00a0However,\u00a0at\u00a0a\u00a0population\u00a0level\u00a0these\u00a0results\u00a0should\u00a0be\u00a0confirmed\u00a0taking\u00a0into\u00a0account\u00a0\ninformation\u00a0on\u00a0HIV\u00a0testing\u00a0patterns.\n\u00a0\u00a0\n\u00a0\n\u00a0\u00a0\n\u00a0\n\u00a0\u00a0\u00a0ANEXO\u00a0\n -  95INTRODUCTION \u00a0\nA\u00a0key\u00a0component\u00a0of\u00a0an\u00a0HIV\u00a0surveillance\u00a0system\u00a0is\u00a0to\u00a0estimate\u00a0th e\u00a0rate\u00a0of\u00a0occurrence\u00a0of\u00a0new\u00a0\ninfections\u00a0in\u00a0a\u00a0given\u00a0population.\u00a0Since\u00a0the\u00a0beginning\u00a0of\u00a0the\u00a0ep idemic,\u00a0several\u00a0approaches\u00a0and\u00a0\nmethods\u00a0 have\u00a0 been\u00a0 proposed\u00a0 to\u00a0 estimate\u00a0 HIV\u00a0 incidence,\u00a0 each\u00a0 one\u00a0 presenting\u00a0 specific\u00a0\nmethodological\u00a0 challenges.\u00a0 Approaches\u00a0 developed\u00a0 during\u00a0 the\u00a0 last \u00a0 fifteen\u00a0 years\u00a0 based\u00a0 upon\u00a0\nlaboratory\u00a0assays\u00a0to\u00a0identify\u00a0recent\u00a0infection\u00a0(RI)\u00a0have\u00a0become \u00a0particularly\u00a0useful\u00a0from\u00a0the\u00a0public\u00a0\nhealth\u00a0perspective\u00a0(1\u00a0\u2010\u00a04).\u00a0With\u00a0this\u00a0assay\u00a0approach\u00a0to\u00a0identif y\u00a0RI\u00a0among\u00a0HIV\u00a0diagnoses\u00a0from\u00a0a\u00a0\nsingle\u00a0cross\u2010sectional\u00a0survey,\u00a0it\u00a0is\u00a0possible\u00a0to\u00a0estimate\u00a0HIV\u00a0incidence\u00a0using\u00a0formulae\u00a0specifically\u00a0\ndevised\u00a0for\u00a0this\u00a0purpose\u00a0based\u00a0on\u00a0the\u00a0classic\u00a0epidemiological\u00a0p rinciple\u00a0of\u00a0Incidence\u00a0=\u00a0prevalence\u00a0\nx\u00a0duration\u00a0(1,\u00a02).\u00a0\nSerological\u00a0assays\u00a0used\u00a0as\u00a0tests \u00a0for\u00a0recent\u00a0HIV\u00a0infection\u00a0(TRIs )\u00a0are\u00a0based\u00a0on\u00a0the\u00a0principle\u00a0that\u00a0\nimmune\u00a0responses\u00a0to\u00a0HIV\u00a0develop\u00a0over\u00a0time\u00a0in\u00a0such\u00a0a\u00a0way\u00a0that\u00a0a\u00a0 mean\u00a0response\u00a0could\u00a0be\u00a0derived\u00a0\n(4).\u00a0Variation\u00a0in\u00a0individual\u00a0immune\u00a0responses,\u00a0however,\u00a0leads\u00a0t he\u00a0currently\u00a0available\u00a0TRIs\u00a0to\u00a0\nmisclassify\u00a0a\u00a0proportion\u00a0of\u00a0people\u00a0with\u00a0long\u2010standing\u00a0HIV\u00a0infection\u00a0as\u00a0 recent\u00a0(5).\u00a0In\u00a0order\u00a0to\u00a0\nminimize\u00a0the\u00a0impact\u00a0of\u00a0this\u00a0phenomenon,\u00a0it\u00a0is\u00a0recommended\u00a0that\u00a0individual\u00a0information\u00a0about\u00a0the\u00a0diagnosis\u00a0of\u00a0AIDS,\u00a0CD4+\u00a0T\u00a0cell\u00a0count\u00a0and\u00a0antiretroviral\u00a0tre atment\u00a0(ART)\u00a0be\u00a0collected\u00a0and\u00a0this\u00a0\ninformation\u00a0be\u00a0combined\u00a0with\u00a0TRI\u00a0assay\u00a0results\u00a0into\u00a0a\u00a0recent\u00a0in fection\u00a0testing\u00a0algorithm\u00a0(RITA)\u00a0\n(6).\u00a0However,\u00a0since\u00a0a\u00a0proportion\u00a0of\u00a0long\u2010standing\u00a0individuals\u00a0could\u00a0be\u00a0still\u00a0be\u00a0misclassified\u00a0as\u00a0\nrecent,\u00a0guidelines\u00a0(6)\u00a0recommend\u00a0estimating\u00a0the\u00a0false\u00a0recent\u00a0ra te\u00a0(FRR)\u00a0and\u00a0using\u00a0the\u00a0FRR\u00a0in\u00a0the\u00a0\ncalculation\u00a0of\u00a0incidence\u00a0using \u00a0McWalter\u2019s\u00a0formulae\u00a0(7).\u00a0\u00a0\nIn\u00a0Europe\u00a0many\u00a0countries\u00a0have\u00a0already\u00a0incorporated\u00a0TRIs\u00a0into\u00a0th eir\u00a0HIV\u00a0surveillance\u00a0systems\u00a0\n(8\u00a0\u2013\u00a011).\u00a0In\u00a0France\u00a0routine\u00a0national\u00a0incidence\u00a0testing\u00a0with\u00a0ser ologic\u00a0testing\u00a0methods\u00a0has\u00a0been\u00a0\ndone\u00a0since\u00a02003\u00a0as\u00a0a\u00a0part\u00a0of\u00a0national\u00a0HIV\u00a0case\u00a0surveillance\u00a0(12 ).\u00a0Similarly,\u00a0in\u00a0the\u00a0United\u00a0States,\u00a0\nthe\u00a0Centers\u00a0for\u00a0Disease\u00a0Control\u00a0(CDC)\u00a0and\u00a0Prevention\u00a0implemente d\u00a0a\u00a0National\u00a0HIV\u00a0Incidence\u00a0\nSurveillance\u00a0System\u00a0in\u00a02007\u00a0(13,\u00a014).\u00a0Recently,\u00a0in\u00a0the\u00a0region\u00a0o f\u00a0Lazio\u00a0in\u00a0Italy,\u00a0similar\u00a0methods\u00a0\n(15)\u00a0have\u00a0been\u00a0adopted\u00a0in\u00a0order\u00a0 to\u00a0report\u00a0HIV\u00a0incidence\u00a0(16).\u00a0\u00a0\nSpain\u00a0is\u00a0the\u00a0western\u00a0European\u00a0country\u00a0with\u00a0the\u00a0eighth\u00a0highest\u00a0r ate\u00a0of\u00a0HIV\u00a0infections\u00a0newly\u00a0\ndiagnosed\u00a0 after\u00a0 Portugal\u00a0 and\u00a0 Ireland,\u00a0 representing\u00a0 an\u00a0 annual\u00a0 rate\u00a0 of\u00a0 7.9\u00a0 cases\u00a0 per\u00a0 100,000\u00a0population\u00a0(17).\u00a0In\u00a0Catalonia,\u00a0the\u00a0dynamics\u00a0and\u00a0incidence\u00a0rates \u00a0are\u00a0similar\u00a0to\u00a0the\u00a0rest\u00a0of\u00a0Spain,\u00a0\nwhere\u00a0the\u00a0epidemic\u00a0was\u00a0initially\u00a0driven\u00a0by\u00a0intravenous\u00a0drug\u00a0use rs\u00a0and\u00a0subsequently\u00a0spread\u00a0due\u00a0\nto\u00a0 sexual\u00a0 transmission.\u00a0 Between\u00a0 2001\u00a0 and\u00a0 2008,\u00a0 5,506\u00a0 newly\u00a0 diagnosed\u00a0 cases\u00a0 of\u00a0 HIV\u00a0 were\u00a0reported,\u00a0 with\u00a0 an\u00a0 annual\u00a0 global\u00a0 rate\u00a0 of\u00a0 12\u00a0 cases\u00a0 per\u00a0 100,000\u00a0 population,\u00a0 predominantly\u00a0 in\u00a0heterosexuals\u00a0(43.3%),\u00a0followed\u00a0by\u00a0men\u00a0who\u00a0have\u00a0sex\u00a0with\u00a0men\u00a0(M SM)\u00a0(36.1%)\u00a0and\u00a0injecting\u00a0\ndrug\u00a0users\u00a0(14.6%)\u00a0(18).\u00a0ANEXO\u00a0\n 96The\u00a0implementation\u00a0of\u00a0the\u00a0laborat ory\u00a0procedures\u00a0led\u00a0us\u00a0to\u00a0desig n\u00a0a\u00a0study\u00a0in\u00a02001\u00a0aimed\u00a0at\u00a0\nassessing\u00a0the\u00a0viability\u00a0of\u00a0introducing\u00a0recent\u00a0infection\u00a0testing \u00a0algorithms\u00a0(RITAs)\u00a0to\u00a0distinguish\u00a0\nbetween\u00a0 recent\u00a0 and\u00a0 long\u2010standing\u00a0 infections\u00a0 among\u00a0 new\u00a0 HIV\u00a0 diagn oses\u00a0 in\u00a0 our\u00a0 setting\u00a0 (ref:\u00a0\nRomero\u00a02009).\u00a0Since\u00a0the\u00a0study\u00a0demonstrated\u00a0the\u00a0viability\u00a0of\u00a0RIT A\u00a0implementation,\u00a0a\u00a0broader\u00a0\nsentinel\u00a0surveillance\u00a0system\u00a0for\u00a0RI\u00a0was\u00a0established\u00a0in\u00a02006,\u00a0ap plying\u00a0RITA\u00a0to\u00a0newly\u00a0identified\u00a0\ncases\u00a0of\u00a0HIV\u00a0infection\u00a0from\u00a0a\u00a0network\u00a0of\u00a011\u00a0hospitals\u00a0and\u00a06\u00a0vol untary\u00a0counselling\u00a0testing\u00a0sites\u00a0\n(VCTS)\u00a0 (19,\u00a0 20)\u00a0 as\u00a0 part\u00a0 of\u00a0 the\u00a0 Integrated\u00a0 Surveillance\u00a0 System\u00a0 o n\u00a0 AIDS,\u00a0 HIV\u00a0 and\u00a0 Sexually\u00a0\nTransmitted\u00a0Infections\u00a0in\u00a0Catalonia\u00a0(18).\u00a0\u00a0\nThe\u00a0objective\u00a0of\u00a0the\u00a0present\u00a0study\u00a0is\u00a0to\u00a0provide\u00a0an\u00a0approximati on\u00a0to\u00a0HIV\u00a0incidence\u00a0in\u00a0the\u00a0\nsubpopulation\u00a0tested\u00a0for\u00a0HIV\u00a0by\u00a0combining\u00a0data\u00a0from\u00a0the\u00a0HIV\u00a0sur veillance\u00a0system\u00a0and\u00a0TRI\u00a0in\u00a0\nCatalonia\u00a0(Spain).\u00a0\n\u00a0\nMETHODS \u00a0\nStudy\u00a0period\u00a0\nFrom\u00a0January\u00a02003\u00a0to\u00a0December\u00a02008.\u00a0\nStudy\u00a0population \u00a0\nThe\u00a0population\u00a0tested\u00a0for\u00a0HIV\u00a0in\u00a0Catalonia\u00a0.\u00a0\nSettings\u00a0\nAll\u00a0patients\u00a0newly\u00a0diagnosed\u00a0of\u00a0HIV\u00a0infection\u00a0in\u00a0a\u00a0network\u00a0of\u00a01 1\u00a0hospitals\u00a0and\u00a06\u00a0voluntary\u00a0\ncounselling\u00a0testing\u00a0sites\u00a0(VCTs)\u00a0participating\u00a0in\u00a0the\u00a0AERI\u00a0Stud y,\u00a0a\u00a0multicentre\u00a0study\u00a0which\u00a0started\u00a0\nin\u00a02003.\u00a0Characteristics\u00a0and\u00a0methods\u00a0of\u00a0the\u00a0study\u00a0have\u00a0been\u00a0pre viously\u00a0described\u00a0(19,\u00a020).\u00a0All\u00a0the\u00a0\nlaboratories\u00a0are\u00a0in\u00a0Catalonia\u00a0(10\u00a0within\u00a0in\u00a0the\u00a0metropolitan\u00a0ar ea\u00a0of\u00a0Barcelona,\u00a0and\u00a03\u00a0in\u00a0other\u00a0\ncities\u00a0in\u00a0Catalonia)\u00a0and\u00a0all\u00a0volunteered\u00a0to\u00a0participate.\u00a0Serum\u00a0samples\u00a0were\u00a0to\u00a0be\u00a0obtained\u00a0within\u00a0the\u00a0first\u00a06\u00a0months\u00a0of\u00a0newly\u00a0diagnosed\u00a0HIV\u00a0infection\u00a0and\u00a0all\u00a0pat ients\u00a0were\u00a0\u226516\u00a0years\u00a0old\u00a0.\u00a0Patients\u00a0\ngave\u00a0their\u00a0written\u00a0informed\u00a0consent\u00a0to\u00a0participate\u00a0from\u00a02006\u00a0onwards.\u00a0Newly\u00a0identified\u00a0cases\u00a0of\u00a0H I V \u00a0i n f e c t i o n \u00a0i n \u00a0t h e \u00a0p a r t i c i p a t i n g \u00a0c e n t r e s \u00a0r e p r e s e n t e d \u00a0a p p r o x i m ately\u00a0 50%\u00a0 of\u00a0 all\u00a0 new\u00a0 HIV\u00a0\nnotifications\u00a0to\u00a0the\u00a0Catala n\u00a0HIV\u00a0reporting\u00a0system.\u00a0\nSpecimen \u00a0collection \u00a0\nResidual\u00a0volumes\u00a0of\u00a0serum\u00a0specimens\u00a0collected\u00a0for\u00a0diagnostic\u00a0pu rposes\u00a0were\u00a0sent\u00a0by\u00a0the\u00a0\nparticipating\u00a0 laboratories\u00a0 to\u00a0 the\u00a0 coordinating\u00a0 centre\u00a0 (Centre\u00a0 f or\u00a0 Epidemiological\u00a0 Studies\u00a0 on\u00a0\nHIV/AIDS\u00a0and\u00a0STI\u00a0of\u00a0Catalonia\u00a0[CEEISCAT]).\u00a0Aliquots\u00a0were\u00a0identi fied\u00a0by\u00a0a\u00a0unique\u00a0study\u00a0number\u00a0\n(no\u00a0personal\u00a0identifiers\u00a0were\u00a0used).\u00a0\n\u00a0\n\u00a0ANEXO\u00a0\n -  97Recent\u00a0infection \u00a0testing\u00a0algorithm \u00a0(RITA)\u00a0\nSamples\u00a0were\u00a0analysed\u00a0at\u00a0the\u00a0Mi crobiology\u00a0Service\u00a0of\u00a0the\u00a0Hospit al\u00a0Universitari\u00a0Germans\u00a0Trias\u00a0i\u00a0\nPujol.\u00a0First,\u00a0samples\u00a0were\u00a0analysed\u00a0to\u00a0detect\u00a0the\u00a0presence\u00a0of\u00a0H IV\u2010specific\u00a0antibodies\u00a0using\u00a0a\u00a0\nconventional\u00a0 sensitive\u00a0 enzyme\u00a0 immunoassay\u00a0 (EIA)\u00a0 (Anti\u2010HIV\u00a0 TETRA\u00a0E l i s a , \u00a0B i o t e s t , \u00a0D r e i e i c h , \u00a0\nGermany)\u00a0to\u00a0ensure\u00a0that\u00a0they\u00a0were\u00a0all\u00a0from\u00a0HIV\u2010positive\u00a0patients.\u00a0During\u00a0the\u00a0period\u00a02003\u20102005\u00a0\nwe\u00a0used\u00a0a\u00a0specific\u00a0RITA\u00a0in\u00a0which\u00a0all\u00a0specimens\u00a0meeting\u00a0the\u00a0incl usion\u00a0criteria\u00a0were\u00a0tested\u00a0with\u00a0the\u00a0\nTRI.\u00a0Conversely,\u00a0during\u00a0the\u00a0following\u00a0period\u00a0of\u00a02006\u20102008,\u00a0thos e\u00a0samples\u00a0from\u00a0patients\u00a0with\u00a0a\u00a0\nCD4+\u00a0T\u00a0cell\u00a0count\u00a0<200\u00a0cells/\u03bcL\u00a0and/or\u00a0clinical\u00a0criteria\u00a0for\u00a0AIDS\u00a0were\u00a0not\u00a0tested\u00a0with\u00a0the\u00a0TRI\u00a0but\u00a0were\u00a0directly\u00a0classified\u00a0as\u00a0patients\u00a0with\u00a0advanced\u00a0HIV\u00a0disease. \u00a0Moreover,\u00a0during\u00a0the\u00a0study\u00a0period\u00a0\nthe\u00a0laboratory\u00a0used\u00a02\u00a0different\u00a0TRI:\u00a0the\u00a0Vironostika\u2010LS\u00a0assay\u00a0( January\u00a02003\u00a0to\u00a0May\u00a02007)\u00a0and\u00a0the\u00a0\nBED\u2010CEIA\u00a0(June\u00a02007\u00a0onwards).\u00a0The\u00a0performance\u00a0characteristics\u00a0o f\u00a0Vironostika\u2010LS\u00a0and\u00a0BED\u2010\nCEIA\u00a0have\u00a0been\u00a0described\u00a0elsewhere\u00a0(21,\u00a022),\u00a0and\u00a0both\u00a0technique s\u00a0showed\u00a0good\u00a0consistency\u00a0in\u00a0\nour\u00a0setting\u00a0(23).\u00a0The\u00a0mean\u00a0window\u00a0period\u00a0of\u00a0both\u00a0techniques\u00a0was \u00a0170\u00a0days\u00a0for\u00a0the\u00a0Vironostika\u00a0\nassay\u00a0and\u00a0155\u00a0days\u00a0for\u00a0the\u00a0BED\u2010CEIA.\u00a0Quality\u00a0control\u00a0was\u00a0assure d\u00a0by\u00a0participation\u00a0as\u00a0national\u00a0\nrepresentatives\u00a0 in\u00a0 the\u00a0 internati onal\u00a0 program\u00a0 of\u00a0 quality\u00a0 control \u00a0f o r \u00a0t h e \u00a0S e r o l o g i c a l \u00a0T e s t i n g \u00a0\nAlgorithm\u00a0for\u00a0Seroconversions\u00a0(STARHS)\u00a0established\u00a0by\u00a0the\u00a0CDC\u00a0( FDA/BB\u2010IND\u00a0#8193)\u00a0since\u00a0\n1999.\u00a0\nData\u00a0 Collection \u00a0\nData\u00a0collection\u00a0occurred\u00a0as\u00a0a\u00a0two\u2010stage\u00a0process.\u00a0Laboratory\u00a0sta ff\u00a0identified\u00a0newly\u00a0diagnosed\u00a0\nindividuals\u00a0and\u00a0completed\u00a0a\u00a0data \u00a0collection\u00a0form\u00a0to\u00a0record\u00a0CD4+ \u00a0T\u2010cell\u00a0counts,\u00a0HIV\u00a0viral\u00a0load\u00a0and\u00a0\nprevious\u00a0HIV\u00a0serological\u00a0testing\u00a0results.\u00a0Once\u00a0the\u00a0person\u00a0was\u00a0under\u00a0the\u00a0care\u00a0of\u00a0a\u00a0physician,\u00a0a\u00a0second\u00a0data\u00a0collection\u00a0round\u00a0to\u00a0record\u00a0demographic\u00a0and\u00a0clinical \u2010epidemiological\u00a0variables\u00a0at\u00a0the\u00a0\ntime\u00a0of\u00a0diagnosis\u00a0(or\u00a0the\u00a0closest\u00a0available\u00a0date)\u00a0was\u00a0undertaken.\u00a0For\u00a0centres\u00a0participating\u00a0in\u00a0the\u00a0\nPISCIS\u00a0cohort,\u00a0this\u00a0second\u00a0dataset\u00a0was\u00a0extracted\u00a0from\u00a0the\u00a0centr e\u2019s\u00a0clinical\u00a0database,\u00a0whereas\u00a0for\u00a0\ncentres\u00a0not\u00a0participation\u00a0in\u00a0PISCIS,\u00a0a\u00a0form\u00a0was\u00a0completed\u00a0by\u00a0the\u00a0clinician\u00a0or\u00a0designated\u00a0person\u00a0\nfrom\u00a0the\u00a0clinical\u00a0record.\u00a0The\u00a0HIV\u00a0Testing\u00a0Surveillance\u00a0System\u00a0of\u00a0Catalonia\u00a0provided\u00a0the\u00a0annual\u00a0\nnumber\u00a0 of\u00a0 diagnostic\u00a0 tests\u00a0 with\u00a0 positive\u00a0 or\u00a0 negative\u00a0 result\u00a0 per f o r m e d \u00a0a n d \u00a0r e p o r t e d \u00a0b y \u00a0t h e \u00a0\nparticipating\u00a0centres\u00a0(18).\u00a0\nStatistical \u00a0analysis\u00a0\nThe\u00a0percentage\u00a0of\u00a0recent\u00a0infection\u00a0was\u00a0calculated\u00a0as\u00a0the\u00a0number \u00a0of\u00a0samples\u00a0identified\u00a0as\u00a0recent\u00a0\nby\u00a0the\u00a0TRI\u00a0divided\u00a0by\u00a0the\u00a0total\u00a0number\u00a0of\u00a0new\u00a0diagnoses,\u00a0and\u00a0th eir\u00a095%\u00a0confidence\u00a0interval\u00a0(CI)\u00a0\nwas\u00a0estimated\u00a0using\u00a0the\u00a0exact\u00a0method.\u00a0The\u00a0Mantel\u00a0test\u00a0was\u00a0appli ed\u00a0to\u00a0assess\u00a0the\u00a0presence\u00a0of\u00a0any\u00a0\ns i g n i f i c a n t \u00a0t r e n d \u00a0d u r i n g \u00a0t h e \u00a0s t u d y \u00a0p e r i o d . \u00a0T o \u00a0e s t i m a t e \u00a0H I V \u00a0i n c i dence\u00a0 from\u00a0 RITA\u00a0 we\u00a0 applied\u00a0\nMcWalter\u2019s\u00a0approach\u00a0(7)\u00a0which\u00a0essentially\u00a0divides\u00a0the\u00a0number\u00a0of \u00a0samples\u00a0identified\u00a0as\u00a0RI\u00a0by\u00a0the\u00a0ANEXO\u00a0\n 98number\u00a0 of\u00a0 samples\u00a0 with\u00a0 a\u00a0 negative\u00a0 result\u00a0 in\u00a0 the\u00a0 conventional\u00a0 EI A \u00a0te st\u00a0(N),\u00a0a s\u00a0f o llo ws: \u00a0HI V \u00a0\nIncidence\u00a0=\u00a0(\u00a0RI\u00a0\u2010\u00a0\u0404\u00a0x\u00a0P\u00a0)\u00a0/\u00a0(\u00a01\u2010\u00a0\u0404\u00a0)\u00a0x\u00a0w\u00a0x\u00a0N,\u00a0where\u00a0w\u00a0is\u00a0the\u00a0m ean\u00a0RITA\u00a0duration\u00a0in\u00a0units\u00a0of\u00a0years,\u00a0\u0404\u00a0\nis\u00a0the\u00a0false\u00a0recent\u00a0rate\u00a0(FRR)\u00a0of\u00a0the\u00a0RITA,\u00a0a\u00a0calibration\u00a0param eter\u00a0which\u00a0corrects\u00a0for\u00a0the\u00a0number\u00a0\nof\u00a0misclassified\u00a0samples,\u00a0and\u00a0P\u00a0is\u00a0the\u00a0number\u00a0of\u00a0HIV\u2010positive\u00a0c ases.\u00a0Since\u00a0the\u00a0number\u00a0newly\u00a0\ndiagnosed\u00a0HIV\u2010infections\u00a0tested\u00a0with\u00a0RITA\u00a0(P)\u00a0represented\u00a040\u201050 %\u00a0of\u00a0the\u00a0number\u00a0of\u00a0HIV\u2010positive\u00a0\nsamples\u00a0(P*)\u00a0reported\u00a0to\u00a0the\u00a0HIV\u00a0Testing\u00a0Surveillance\u00a0System,\u00a0w e\u00a0rescaled\u00a0the\u00a0counts\u00a0of\u00a0negative\u00a0\nHIV\u00a0tests\u00a0used\u00a0in\u00a0the\u00a0incidence\u00a0calculation\u00a0(N)\u00a0proportionally\u00a0 from\u00a0the\u00a0total\u00a0number\u00a0of\u00a0negative\u00a0\nt e s t \u00a0r e p o r t e d \u00a0( N * ) \u00a0u s i n g \u00a0t h e \u00a0e x p r e s s i o n \u00a0N \u00a0= \u00a0N * \u00a0x \u00a0( P / P * ) . \u00a0T h e \u00a0( F RR)\u00a0 was\u00a0 estimated\u00a0 as\u00a0 the\u00a0\nproportion\u00a0of\u00a0specimens\u00a0classified\u00a0by\u00a0the\u00a0RITA\u00a0as\u00a0RI\u00a0among\u00a0thos e\u00a0known\u00a0to\u00a0be\u00a0long\u2010standing\u00a0or\u00a0\nadvanced\u00a0infections.\u00a0Since\u00a0two\u00a0di fferent\u00a0TRI\u00a0were\u00a0used\u00a0during\u00a0y ear\u00a02007,\u00a0it\u00a0was\u00a0calculated\u00a0using\u00a0\nthe\u00a0mean\u00a0RITA\u00a0duration\u00a0as\u00a0the\u00a0average\u00a0of\u00a0the\u00a0window\u00a0periods\u00a0of\u00a0the\u00a0two\u00a0assays\u00a0(162.5\u00a0days).\u00a0\nI n c i d e n c e \u00a0r a t i o \u00a0( I R ) \u00a0a n d \u00a0i t s \u00a09 5 % \u00a0C I \u00a0w e r e \u00a0r e p o r t e d \u00a0t o \u00a0c o m p a r e \u00a0t h e\u00a0 HIV\u00a0 incidence\u00a0 between\u00a0\ndifferent\u00a0time\u00a0periods.\u00a0The\u00a0calculations\u00a0of\u00a0incidence\u00a0were\u00a0done \u00a0using\u00a0the\u00a0spreadsheet\u00a0ABIE\u00a0v1.0\u00a0\navailable\u00a0at\u00a0the\u00a0SACEMA\u2019s\u00a0web\u00a0site.\u00a0Ethics\u00a0\nThe\u00a0 ethics\u00a0 committees\u00a0 of\u00a0 the\u00a0 participating\u00a0 centres\u00a0 approved\u00a0 the \u00a0 protocol.\u00a0 All\u00a0 personal\u00a0\nidentifiers\u00a0were\u00a0removed\u00a0from\u00a0the\u00a0samples,\u00a0which\u00a0were\u00a0sent\u00a0to\u00a0t he\u00a0coordinating\u00a0centre\u00a0with\u00a0a\u00a0\nstudy\u00a0number.\u00a0Only\u00a0the\u00a0recruitment\u00a0centre\u00a0had\u00a0access\u00a0to\u00a0persona l\u00a0identifiers\u00a0in\u00a0order\u00a0to\u00a0enable\u00a0\nrecord\u00a0linkage\u00a0for\u00a0subsequent\u00a0ep idemiological\u00a0and\u00a0clinical\u00a0data\u00a0collection.\n\u00a0\n\u00a0\nRESULTS \u00a0\nBetween\u00a02003\u00a0and\u00a02008,\u00a0the\u00a0total\u00a0number\u00a0of\u00a0patients\u00a0participati ng\u00a0in\u00a0the\u00a0centre\u2019s\u00a0network\u00a0\nstudy\u00a0(AERI\u00a0project)\u00a0was\u00a02,853. \u00a0Of\u00a0these,\u00a0211\u00a0(8%)\u00a0were\u00a0exclude d\u00a0from\u00a0the\u00a0study\u00a0mainly\u00a0because\u00a0\nthey\u00a0did\u00a0not\u00a0meet\u00a0inclusion\u00a0criteria\u00a0(19,\u00a020).\u00a0Out\u00a0of\u00a0the\u00a0remai ning\u00a02,642\u00a0new\u00a0HIV\u00a0diagnosis,\u00a0518\u00a0\nwere\u00a0classified\u00a0as\u00a0RI\u00a0with\u00a0the\u00a0RITA\u00a0(19.6%).\u00a0The\u00a0percentage\u00a0of\u00a0 RI\u00a0increased\u00a0significantly\u00a0(p<0.05)\u00a0\nfrom\u00a017.4%\u00a0in\u00a02003\u00a0to\u00a026. 0%\u00a0in\u00a02008\u00a0(Table\u00a01).\u00a0\u00a0\nO v e r a l l , \u00a0t h e \u00a0t o t a l \u00a0n u m b e r \u00a0o f \u00a0t e s t s \u00a0r e p o r t e d \u00a0b y \u00a0p a r t i c i p a t i n g \u00a0c e n t r e s \u00a0t o \u00a0t h e \u00a0H I V \u00a0T e s t i n g \u00a0\nSurveillance\u00a0System\u00a0of\u00a0Catalonia\u00a0during\u00a02003\u20102008\u00a0was\u00a0458,443,\u00a0 of\u00a0which\u00a05,648\u00a0(1.23%)\u00a0were\u00a0\npositive.\u00a0The\u00a0number\u00a0of\u00a0tests\u00a0with\u00a0a\u00a0negative\u00a0result\u00a0increased\u00a0 from\u00a053,073\u00a0in\u00a02003\u00a0up\u00a0to\u00a091,566\u00a0\nin\u00a02008\u00a0and,\u00a0conversely,\u00a0the\u00a0percentage\u00a0of\u00a0positive\u00a0tests\u00a0durin g\u00a0the\u00a0study\u00a0period\u00a0varied\u00a0from\u00a0a\u00a0\nhigh\u00a0of\u00a01.42%\u00a0in\u00a02003\u00a0through\u00a0a\u00a0low\u00a0of\u00a01.08%\u00a0in\u00a02006\u00a0to\u00a01.39%\u00a0i n\u00a02008\u00a0(Table\u00a01).\u00a0\u00a0\nCharacteristics\u00a0of\u00a0the\u00a0participants\u00a0by\u00a0study\u00a0period\u00a0are\u00a0describ ed\u00a0in\u00a0Table\u00a02.\u00a0Most\u00a0of\u00a0samples\u00a0\nincluded\u00a0were\u00a0collected\u00a0in\u00a0hospit als,\u00a0from\u00a0male\u00a0patients\u00a0infected\u00a0throguh\u00a0MSM\u00a0relations,\u00a0with\u00a0\nages\u00a0between\u00a030\u00a0and\u00a050.\u00a0In\u00a0both\u00a0study\u00a0periods\u00a0percentages\u00a0of\u00a0im migrants\u00a0were\u00a0quite\u00a0similar.\u00a0ANEXO\u00a0\n -  99Estimates\u00a0of\u00a0the\u00a0FRR\u00a0corresponding\u00a0to\u00a0the\u00a0study\u00a0period\u00a02003\u2010200 5\u00a0are\u00a0based\u00a0on\u00a0430\u00a0samples.\u00a0\nFifteen\u00a0were\u00a0classified\u00a0as\u00a0RI\u00a0resulting\u00a0in\u00a0a\u00a0FRR\u00a0of\u00a03.5%\u00a0(coeff icient\u00a0of\u00a0variation=25.4%).\u00a0Estimates\u00a0\nof\u00a0the\u00a0FRR\u00a0derived\u00a0during\u00a0the\u00a0study\u00a0period\u00a02006\u20102008\u00a0were\u00a0simil ar;\u00a0out\u00a0of\u00a0the\u00a0593\u00a0long\u2010standing\u00a0\ninfections\u00a024\u00a0were\u00a0classified\u00a0as\u00a0RI,\u00a0giving\u00a0a\u00a0FRR\u00a0of\u00a04.0%\u00a0(coef ficient\u00a0of\u00a0variation=20.0%).\u00a0A\u00a0final\u00a0\nFRR\u00a0estimate\u00a0was\u00a0obtained\u00a0from\u00a0pooling\u00a0data\u00a0of\u00a0the\u00a0two\u00a0time\u00a0per iods,\u00a0resulting\u00a0in\u00a0a\u00a0FRR=3.8%\u00a0\n(coefficient\u00a0of\u00a0variation=15.7%).\u00a0\u00a0\nHIV\u00a0incidence\u00a0for\u00a0the\u00a0period\u00a02003\u20102008\u00a0was\u00a0estimated\u00a0to\u00a0be\u00a00.46 \u00a0new\u00a0infections\u00a0per\u00a0100/year\u00a0\n(95%\u00a0CI:\u00a00.39\u20100.53).\u00a0HIV\u00a0incidenc e\u00a0varied\u00a0during\u00a0this\u00a0period,\u00a0i ncreasing\u00a0significantly\u00a0from\u00a00.31\u00a0\n(95%\u00a0 CI:\u00a0 0.22\u20100.41)\u00a0 new\u00a0 infecti ons\u00a0 per\u00a0 100/year\u00a0 in\u00a0 2005\u00a0 to\u00a0 0.73 \u00a0 (95%\u00a0 CI:\u00a0 0.55\u20100.90)\u00a0 per\u00a0\n100/year\u00a0in\u00a02008\u00a0(Table\u00a01),\u00a0(IR=2. 34,\u00a095%\u00a0CI\u00a0[1.51\u20103.18]).\u00a0When \u00a0stratified\u00a0by\u00a0study\u00a0period,\u00a0the\u00a0\nHIV\u00a0incidence\u00a0was\u00a0estimated\u00a0to \u00a0be\u00a00.40%\u00a0(95%\u00a0CI:\u00a00.32\u20100.47%)\u00a0an d\u00a00.55%\u00a0(95%\u00a0CI:\u00a00.45\u20100.65%)\u00a0\nnew\u00a0 infections\u00a0 per\u00a0 year\u00a0 during\u00a0 2003\u20102005\u00a0 and\u00a0 2006\u20102008,\u00a0 respect ively.\u00a0 Incidence\u00a0 was\u00a0\nsignificantly\u00a0higher\u00a0in\u00a0the\u00a0last \u00a0period\u00a0(IR=1.39,\u00a095%\u00a0CI\u00a0[1.10\u2010 1.69]).\u00a0\n\u00a0\nDISCUSSION \u00a0\nThe\u00a0present\u00a0study\u00a0estimates\u00a0the\u00a0incidence\u00a0of\u00a0new\u00a0HIV\u00a0infections \u00a0among\u00a0a\u00a0population\u00a0of\u00a0people\u00a0\nwho\u00a0undergo\u00a0HIV\u00a0testing\u00a0in\u00a0a\u00a0network\u00a0of\u00a0voluntary\u00a0counselling\u00a0a nd\u00a0testing\u00a0services\u00a0and\u00a0hospitals\u00a0\nin\u00a0Catalonia\u00a0(Spain)\u00a0for\u00a0the\u00a0period\u00a02003\u00a0to\u00a02008.\u00a0These\u00a0estimat es\u00a0are\u00a0derived\u00a0from\u00a0serological\u00a0\ntests\u00a0for\u00a0recent\u00a0infection,\u00a0indiv idual\u00a0clinical\u00a0data\u00a0and\u00a0inform ation\u00a0provided\u00a0from\u00a0the\u00a0HIV\u00a0Testing\u00a0\nSurveillance\u00a0System\u00a0of\u00a0Catalonia.\u00a0HIV\u00a0incidence\u00a0in\u00a0this\u00a0populat ion\u00a0was\u00a0estimated\u00a0at\u00a00.5\u00a0new\u00a0HIV\u00a0\ninfections\u00a0per\u00a0100\u00a0persons/year.\u00a0\u00a0\nDuring\u00a0the\u00a0study\u00a0period\u00a0a\u00a0trend\u00a0toward\u00a0an\u00a0increase\u00a0in\u00a0the\u00a0annua l\u00a0HIV\u00a0incidence\u00a0was\u00a0found\u00a0\nbetween\u00a02005\u00a0and\u00a02008.\u00a0This\u00a0rise\u00a0is\u00a0driven\u00a0by\u00a0an\u00a0increase\u00a0in\u00a0th e\u00a0percentage\u00a0of\u00a0recent\u00a0infections\u00a0\nover\u00a0the\u00a0number\u00a0of\u00a0negative\u00a0tests.\u00a0Several\u00a0possible\u00a0reasons\u00a0could\u00a0explain\u00a0this\u00a0increment.\u00a0First\u00a0of\u00a0\nall,\u00a0the\u00a0ratio\u00a0of\u00a0new\u00a0diagnosis\u00a0tested\u00a0by\u00a0the\u00a0RITA\u00a0to\u00a0the\u00a0total\u00a0number\u00a0of\u00a0HIV\u00a0positive\u00a0tests\u00a0\noscillates\u00a0over\u00a0the\u00a0study\u00a0period\u00a0which\u00a0might\u00a0have\u00a0an\u00a0impact\u00a0on\u00a0 the\u00a0accuracy\u00a0of\u00a0the\u00a0incidence\u00a0\nestimates\u00a0and\u00a0cannot\u00a0be\u00a0lightly\u00a0dismissed.\u00a0Secondly,\u00a0changes\u00a0in \u00a0the\u00a0algorithm\u00a0used\u00a0during\u00a0the\u00a0\nstudy\u00a0 may\u00a0 have\u00a0 resulted\u00a0 in\u00a0 altered\u00a0 classification\u00a0 of\u00a0 recent\u00a0 or\u00a0 long\u2010standing\u00a0 infection.\u00a0\nNevertheless,\u00a0estimated\u00a0FRRs\u00a0during\u00a0the\u00a0two\u00a0study\u00a0periods\u00a0were\u00a0 similar\u00a0and\u00a0previous\u00a0studies\u00a0\nconducted\u00a0 in\u00a0 our\u00a0 setting\u00a0 reported\u00a0 that\u00a0 the\u00a0 Vironostika\u00a0 and\u00a0 BED\u2010 C E I A \u00a0a s s a y s \u00a0s h o w e d \u00a0g o o d \u00a0\nagreement\u00a0 and\u00a0 similar\u00a0 sensitivity\u00a0 (23).\u00a0 Thirdly,\u00a0 changes\u00a0 in\u00a0 tes tin g \u00a0b e h a v io u r\u00a0m a y \u00a0a f f e ct\u00a0th e \u00a0\nproportion\u00a0of\u00a0people\u00a0with\u00a0recent\u00a0infection\u00a0during\u00a0the\u00a0study\u00a0per iod.\u00a0A\u00a0rise\u00a0in\u00a0the\u00a0demand\u00a0for\u00a0tests\u00a0\nwas\u00a0seen\u00a0during\u00a0the\u00a0study\u00a0period\u00a0in\u00a0the\u00a0testing\u00a0surveillance\u00a0da ta\u00a0coinciding\u00a0with\u00a0the\u00a0widespread\u00a0\nintroduction\u00a0into\u00a0VCTs\u00a0of\u00a0rapid\u00a0HIV\u00a0tests\u00a0(the\u00a0probability\u00a0of\u00a0identifying\u00a0recent\u00a0increases)\u00a0(24).\u00a0ANEXO\u00a0\n 100Coupled\u00a0with\u00a0a\u00a0rise\u00a0in\u00a0a\u00a0demand\u00a0for\u00a0tests,\u00a0we\u00a0see\u00a0that\u00a0MSM\u00a0are\u00a0 more\u00a0likely\u00a0to\u00a0be\u00a0repeat\u00a0testers\u00a0\n(mainly\u00a0through\u00a0VCTs),\u00a0with\u00a0a\u00a0median\u00a0number\u00a0of\u00a0tests\u00a0prior\u00a0to\u00a0d iagnosis\u00a0of\u00a04\u00a0as\u00a0compared\u00a0to\u00a01.5\u00a0\nin\u00a0MSM\u00a0(25).\u00a0\nFinally,\u00a0these\u00a0results\u00a0may\u00a0reflect\u00a0real\u00a0increases\u00a0in\u00a0risk\u00a0behav iours\u00a0among\u00a0MSM\u00a0(26,\u00a027).\u00a0This\u00a0\nobservation\u00a0would\u00a0be\u00a0consistent\u00a0with\u00a0observed\u00a0increases\u00a0in\u00a0prim ary\u00a0and\u00a0secondary\u00a0syphilis\u00a0\ndiagnoses\u00a0from\u00a02000\u20102005\u00a0(28)\u00a0and\u00a0o ther\u00a0studies\u00a0from\u00a0around\u00a0Eur ope\u00a0(29,\u00a030)\u00a0showing\u00a0rises\u00a0in\u00a0\nboth\u00a0directly\u00a0measured\u00a0risk\u00a0behaviour\u00a0and\u00a0STIs\u00a0indicating\u00a0high\u00a0 risk\u00a0behaviour.\u00a0Moreover,\u00a0it\u00a0is\u00a0\nconsistent\u00a0with\u00a0results\u00a0of\u00a0the\u00a0ITACA\u00a0Cohort,\u00a0a\u00a0prospective\u00a0long itudinal\u00a0study\u00a0of\u00a0HIV\u00a0negative\u00a0MSM\u00a0\nrecruited\u00a0among\u00a0clients\u00a0of\u00a0a\u00a0Community\u00a0Based\u00a0HIV\u00a0and\u00a0other\u00a0STI\u00a0 detection\u00a0centre\u00a0in\u00a0Barcelona,\u00a0\nwhere\u00a0preliminary\u00a0results\u00a0showed\u00a0that\u00a0directly\u00a0measured\u00a0HIV\u00a0incidence\u00a0has\u00a0a\u00a0trend\u00a0toward\u00a0\nincrease\u00a0(3\u00a0per\u00a0100/year\u00a0in\u00a02006\u20102008\u00a0and\u00a04.35%\u00a0in\u00a02009\u20102010)\u00a0( 31).\u00a0Furthermore,\u00a0estimates\u00a0\nderived\u00a0 from\u00a0 the\u00a0 Estimation\u00a0 and\u00a0 Projection\u00a0 Package\u00a0 (EPP)\u00a0 and\u00a0 Sp ectrum\u00a0 developed\u00a0 by\u00a0 the\u00a0\nUNAIDS\u00a0(32,\u00a033)\u00a0also\u00a0disclose\u00a0an\u00a0increase\u00a0of\u00a0the\u00a0HIV\u00a0incidence\u00a0 in\u00a0the\u00a0general\u00a0population\u00a0aged\u00a0\nmore\u00a0than\u00a015\u00a0years\u00a0old\u00a0in\u00a0Catalonia,\u00a0rising\u00a0from\u00a00.1\u00a0per\u00a01,000/ year\u00a0in\u00a02003\u20102005\u00a0to\u00a00.2\u00a0per\u00a0\n1,000/year\u00a0in\u00a02006\u20102008\u00a0(18,\u00a034),\u00a0al though\u00a0this\u00a0model\u00a0relies\u00a0on \u00a0many\u00a0similar\u00a0inputs.\u00a0\nLimitations\u00a0 in\u00a0 this\u00a0 study\u00a0 centre\u00a0 on\u00a0 changes\u00a0 in\u00a0 methods\u00a0 during\u00a0 the\u00a0 study\u00a0 period\u00a0 and\u00a0 the\u00a0\ncompleteness\u00a0 of\u00a0 surveillance\u00a0 data \u00a0a v a i l a b l e \u00a0t o \u00a0e s t i m a t e \u00a0i n c i d e n ce.\u00a0 The\u00a0 use\u00a0 of\u00a0 two\u00a0 different\u00a0\nalgorithms\u00a0and\u00a0laboratory\u00a0assays\u00a0has\u00a0been\u00a0discussed\u00a0above\u00a0with\u00a0 the\u00a0exception\u00a0of\u00a0our\u00a0adoption\u00a0of\u00a0\na\u00a0mean\u00a0window\u00a0period.\u00a0While\u00a0there\u00a0is\u00a0no\u00a0guidance\u00a0in\u00a0the\u00a0literat ure\u00a0on\u00a0combining\u00a0different\u00a0assays\u00a0\nse q u e n tia lly \u00a0in \u00a0a \u00a0sin g le \u00a0stu dy ,\u00a0we \u00a0f e e l\u00a0th a t\u00a0th is\u00a0pra g m a tic\u00a0a pp roach\u00a0 is\u00a0reasonable\u00a0given\u00a0the\u00a0\ncomparability\u00a0otherwise\u00a0discussed\u00a0above.\u00a0Estimates\u00a0of\u00a0the\u00a0FRR\u00a0c ould\u00a0be\u00a0improved\u00a0in\u00a0our\u00a0setting\u00a0\nwith\u00a0the\u00a0adoption\u00a0a\u00a0new\u00a0TRI\u00a0(Avidity\u00a0index)\u00a0as\u00a0recommended\u00a0by\u00a0s ome\u00a0authors\u00a0(5)\u00a0and\u00a0by\u00a0\ns y s t e m a t i c \u00a0a n d \u00a0p e r i o d i c \u00a0e s t i m a t i o n \u00a0o f \u00a0t h e \u00a0F R R \u00a0i n \u00a0a \u00a0s u f f i c i e n t l y \u00a0l a r g e \u00a0s a m p l e , \u00a0i n c l u d i n g \u00a0i n \u00a0\nsubgroups.\u00a0\u00a0\nData\u00a0on\u00a0negative\u00a0tests\u00a0required\u00a0for\u00a0estimating\u00a0incidence\u00a0is\u00a0in\u00a0 aggregate\u00a0form. \u00a0The\u00a0principal\u00a0\nimplications\u00a0of\u00a0this\u00a0are\u00a0that\u00a0we\u00a0are\u00a0unable\u00a0to\u00a0provide\u00a0estimates\u00a0of\u00a0incidence\u00a0by\u00a0age,\u00a0sex\u00a0or\u00a0risk\u00a0\ngroup\u00a0 and\u00a0 we\u00a0 cannot\u00a0 eliminate\u00a0 repeat\u00a0 testers\u00a0 from\u00a0 the\u00a0 denominat or.\u00a0 About\u00a0 half\u00a0 of\u00a0 all\u00a0 new\u00a0\ndiagnoses\u00a0are\u00a0not\u00a0tested\u00a0with\u00a0RITA\u00a0and\u00a0these\u00a0we\u00a0have\u00a0considered \u00a0to\u00a0be\u00a0randomly\u00a0distributed.\u00a0\nAnother\u00a0limitation\u00a0is\u00a0that\u00a0changes\u00a0in\u00a0the\u00a0prevalence\u00a0of\u00a0non\u2010B\u00a0suptypes\u00a0were\u00a0not\u00a0measured\u00a0which\u00a0\nm a y \u00a0i m p a c t \u00a0u p o n \u00a0t h e \u00a0F R R , \u00a0s i n c e \u00a0t h e \u00a0p e r f o r m a n c e \u00a0o f \u00a0i n c i d e n c e \u00a0a s s ays\u00a0 has\u00a0 not\u00a0 been\u00a0 widely\u00a0\nassessed\u00a0in\u00a0non\u2010B\u00a0subtypes\u00a0(35).\u00a0\nRecently\u00a0a\u00a0new\u00a0estimator\u00a0has\u00a0been\u00a0proposed\u00a0(36).\u00a0Using\u00a0this\u00a0for mulae\u00a0we\u00a0found\u00a0slightly\u00a0higher\u00a0\nrates\u00a0of\u00a0HIV\u00a0incidence\u00a0(data\u00a0not \u00a0shown),\u00a0but\u00a0consistent\u00a0with\u00a0th e\u00a0reported\u00a0trends.\u00a0\u00a0\n\u00a0ANEXO\u00a0\n -  101Caution\u00a0should\u00a0be\u00a0exercised\u00a0in\u00a0extrapolating\u00a0these\u00a0results\u00a0to\u00a0t he\u00a0general\u00a0population\u00a0given\u00a0that\u00a0\nthe\u00a0frequency\u00a0of\u00a0testing\u00a0of\u00a0some\u00a0over\u2010represented\u00a0groups\u00a0in\u00a0our \u00a0study\u00a0(e.g.\u00a0MSM)\u00a0is\u00a0known\u00a0to\u00a0be\u00a0\nhigher,\u00a0increasing\u00a0the\u00a0likelihood\u00a0of\u00a0identifying\u00a0RI\u00a0in\u00a0comparis on\u00a0to\u00a0other\u00a0groups\u00a0(37).\u00a0In\u00a0fact,\u00a0\ndespite\u00a0the\u00a0insufficient\u00a0sample\u00a0size\u00a0to\u00a0reliably\u00a0report\u00a0HIV\u00a0inc idence\u00a0estimates\u00a0from\u00a0VCTS\u00a0alone,\u00a0\nthe\u00a0observed\u00a0data\u00a0suggest\u00a0higher\u00a0rates\u00a0of\u00a0recent\u00a0infection,\u00a0con sistent\u00a0with\u00a0the\u00a0high\u00a0proportion\u00a0of\u00a0\nVCTS\u00a0users\u00a0who\u00a0are\u00a0MSM.\u00a0In\u00a0considering\u00a0the\u00a0applicability\u00a0of\u00a0the se\u00a0sentinel\u00a0surveillance\u00a0results\u00a0to\u00a0\nthe\u00a0HIV\u2010tested\u00a0subpopulation,\u00a0however,\u00a0we\u00a0conclude\u00a0that\u00a0since\u00a0the\u00a0number\u00a0of\u00a0new\u00a0HIV\u00a0diagnoses\u00a0\ntested\u00a0 with\u00a0 RITA\u00a0 in\u00a0 our\u00a0 study\u00a0 represented\u00a0 approximately\u00a0 50%\u00a0 of\u00a0 all\u00a0 new\u00a0 HIV\u00a0 notifications\u00a0\ncollected\u00a0by\u00a0the\u00a0HIV\u00a0Reporting\u00a0System,\u00a0and\u00a0that\u00a0their\u00a0epidemiol ogical\u00a0characteristics\u00a0did\u00a0not\u00a0\ndiffer\u00a0from\u00a0those\u00a0presented\u00a0by\u00a0the\u00a0new\u00a0HIV\u00a0diagnosis\u00a0in\u00a0Catalonia,\u00a0the\u00a0estimated\u00a0rate\u00a0of\u00a0might\u00a0be\u00a0\nreliably\u00a0indicative\u00a0of\u00a0the\u00a0real\u00a0rate\u00a0in\u00a0this\u00a0subpopulation.\u00a0\u00a0\nIn\u00a0order\u00a0to\u00a0improve\u00a0the\u00a0generali sability\u00a0of\u00a0our\u00a0incidence\u00a0estimates,\u00a0we\u00a0would\u00a0need\u00a0to\u00a0be\u00a0able\u00a0to\u00a0\nestimate\u00a0the\u00a0probability\u00a0of\u00a0testing\u00a0for\u00a0HIV\u00a0in\u00a0the\u00a0year\u00a0after\u00a0i nfection\u00a0but\u00a0the\u00a0aggregate\u00a0testing\u00a0data\u00a0\nin\u00a0 the\u00a0 current\u00a0 surveillance\u00a0 system\u00a0 precludes\u00a0 this\u00a0 at\u00a0 present.\u00a0 Moreover,\u00a0 having\u00a0 available\u00a0individual\u00a0information\u00a0about\u00a0testing\u00a0behaviour\u00a0would\u00a0allow\u00a0us\u00a0t o\u00a0estimated\u00a0HIV\u00a0incidence\u00a0at\u00a0\nregional\u00a0level\u00a0using\u00a0models\u00a0that\u00a0 account\u00a0for\u00a0the\u00a0effect\u00a0of\u00a0test ing\u00a0practices\u00a0(15,\u00a016).\u00a0\nIn\u00a0conclusion,\u00a0estimates\u00a0of\u00a0HIV\u00a0incidence\u00a0derived\u00a0from\u00a0RITA\u00a0have\u00a0proved\u00a0a\u00a0useful\u00a0tool\u00a0to\u00a0\nanalyse\u00a0the\u00a0current\u00a0dynamic\u00a0of\u00a0th e\u00a0epidemic\u00a0in\u00a0Catalonia,\u00a0and\u00a0a re\u00a0being\u00a0routinely\u00a0used\u00a0to\u00a0enhance\u00a0\nthe\u00a0HIV\u00a0Surveillance\u00a0System.\u00a0To\u00a0our\u00a0knowledge,\u00a0this\u00a0is\u00a0the\u00a0firs t\u00a0application\u00a0of\u00a0the\u00a0RITA\u00a0technique\u00a0\nto\u00a0estimate\u00a0HIV\u00a0incidence\u00a0in\u00a0Spain,\u00a0contributing\u00a0to\u00a0establish\u00a0t he\u00a0magnitude\u00a0of\u00a0new\u00a0infection\u00a0\nduring\u00a0the\u00a0study\u00a0period\u00a0and\u00a0reporting\u00a0data\u00a0suggesting\u00a0that\u00a0HIV\u00a0 incidence\u00a0is\u00a0increasing\u00a0in\u00a0our\u00a0\nsetting.\u00a0To\u00a0fully\u00a0experience\u00a0the\u00a0benefit\u00a0of\u00a0using\u00a0TRI\u00a0in\u00a0the\u00a0HI V\u00a0Surveillance\u00a0System\u00a0of\u00a0Catalonia\u00a0\nwould\u00a0 be\u00a0 advisable\u00a0 to\u00a0 have\u00a0 information\u00a0 about\u00a0 the\u00a0 testing\u00a0 practi ces\u00a0 of\u00a0 newly\u00a0 diagnosed\u00a0\nindividuals,\u00a0so\u00a0HIV\u00a0incidence\u00a0es timates\u00a0could\u00a0be\u00a0obtained\u00a0at\u00a0a\u00a0 regional\u00a0level.\n\u00a0\n\u00a0\nFunding\u00a0\n\u2018\u2018La\u00a0Marat\u00f3\u00a0de\u00a0TV3\u2019\u2019\u00a0Foundation\u00a0awarded\u00a0the\u00a0CEEISCAT\u00a0a\u00a0grant\u00a0fo r\u00a0the\u00a0development\u00a0of\u00a0the\u00a0AERI\u2010\nHIV\u00a0 (Algoritme\u00a0 Estandartditzat\u00a0 per\u00a0 la\u00a0 detecci\u00f3\u00a0 de\u00a0 Recent\u00a0 Infect ats\u00a0 pel\u00a0 VIH)\u00a0 project\u00a0 for\u00a0\nepidemiological\u00a0research\u00a0on\u00a0AIDS\u00a0by\u00a0applying\u00a0the\u00a0STARHS\u00a0techniq ue\u00a0(project\u00a0#022010).\u00a0This\u00a0\nwork\u00a0was\u00a0partially\u00a0funded\u00a0by\u00a0the \u00a0Direcci\u00f3\u00a0General\u00a0de\u00a0Salut\u00a0P\u00fabl ica\u00a0de\u00a0la\u00a0Generalitat\u00a0de\u00a0Catallunya\u00a0\nand\u00a0by\u00a0the\u00a0Fundaci\u00f3n\u00a0para\u00a0la\u00a0Investigaci\u00f3n\u00a0y\u00a0Prevenci\u00f3n\u00a0del\u00a0Sid a\u00a0en\u00a0Espa\u00f1a\u00a0(FIPSE,\u00a0Madrid,\u00a0\nSpain,\u00a0National\u00a0AIDS\u00a0Plan\u00a0Secretariat\u00a0of\u00a0the\u00a0Spanish\u00a0Ministry\u00a0o f\u00a0Health).\u00a0The\u00a0Centers\u00a0for\u00a0Diseases\u00a0\nControl\u00a0and\u00a0Prevention\u00a0(CDC)\u00a0provided\u00a0the\u00a0samples\u00a0for\u00a0the\u00a0quali ty\u00a0control\u00a0programme\u00a0(FDA\u00a0BB\u2010\nIND\u00a0#8193).\u00a0ANEXO\u00a0\n 102The\u00a0Recent\u00a0HIV\u00a0Infections \u00a0(AERIVIH)\u00a0 Study\u00a0Group\u00a0includes\u00a0 the\u00a0following:\u00a0\u00a0\nCoordinating \u00a0Center\u00a0(CEEISCAT): \u00a0\u00a0\nAnabel\u00a0Romero,\u00a0Colin\u00a0Campbell,\u00a0Rafael\u00a0Mu\u00f1oz,\u00a0N\u00faria\u00a0Ortega,\u00a0Alexandra\u00a0Montoliu,\u00a0Anna\u00a0Esteve,\u00a0\nand\u00a0Jordi\u00a0Casabona\u00a0STARHS\u00a0 Laboratory \u00a0(Microbiology \u00a0Service,\u00a0Hospital \u00a0Universitari \u00a0Germans \u00a0Trias\u00a0i\u00a0Pujol):\u00a0\u00a0\nVictoria\u00a0Gonz\u00e1lez,\u00a0Elisa\u00a0Martr\u00f3,\u00a0and\u00a0Lurdes\u00a0Matas\u00a0Peripheral \u00a0centres:\u00a0J o s e p \u00a0M \u00aa \u00a0M i r \u00f3 , \u00a0T o m \u00e0 s \u00a0P u m a r o l a \u00a0a n d \u00a0M a r \u00ed a \u00a0L \u00f3 p e z \u2010 D i \u00e9 g u e z \u00a0( H . \u00a0C l \u00ed n ic\u00a0 i\u00a0\nProvincial\u00a0de\u00a0Barcelona);\u00a0Aurora\u00a0Casanova\u00a0and\u00a0Elena\u00a0Ferrer\u00a0(H.\u00a0 Bellvitge\u00a0Pr\u00ednceps\u00a0d\u2019Espanya\u00a0\u2010\u00a0\nBarcelona);\u00a0Cristina\u00a0Tural\u00a0(H.\u00a0Universitari\u00a0Germans\u00a0Trias\u00a0i\u00a0Puj ol\u00a0\u2010\u00a0Badalona);\u00a0Estrella\u00a0Caballero,\u00a0\nEsteve\u00a0Ribera\u00a0(H.\u00a0General\u00a0Vall\u00a0 Hebron\u00a0\u2010\u00a0Barcelona);\u00a0\u00a0N\u00faria\u00a0Marg all,\u00a0Pere\u00a0Domingo\u00a0(H.\u00a0De\u00a0la\u00a0Santa\u00a0\nCreu\u00a0i\u00a0Sant\u00a0Pau\u00a0\u2010\u00a0Barcelona);\u00a0Joan\u00a0Farr\u00e9\u00a0and\u00a0Teresa\u00a0Puig\u00a0(H.\u00a0Un iversitari\u00a0Arnau\u00a0de\u00a0Vilanova\u2010\u00a0\nLleida);\u00a0M\u00aa\u00a0Goretti\u00a0Sauca\u00a0and\u00a0M\u00aaPilar\u00a0Barrufet\u00a0(H.\u00a0De\u00a0Matar\u00f3);\u00a0\u00a0Xavier\u00a0Ort\u00edn\u00a0and\u00a0\u00a0Amat\u00a0Ort\u00ed\u00a0(H.\u00a0\nVerge\u00a0de\u00a0la\u00a0Cinta\u00a0\u2013\u00a0Tortosa);\u00a0M\u00aa\u00a0Jos\u00e9\u00a0Armengual,\u00a0Gemma\u00a0Navarro\u00a0 and\u00a0Ferran\u00a0Segura\u00a0(Consorci\u00a0\nHospitalari\u00a0del\u00a0Parc\u00a0Taul\u00ed\u00a0\u2013\u00a0Saba dell);\u00a0Josep\u00a0M\u00aa\u00a0Prat\u00a0and\u00a0\u00c0ngel s\u00a0Masabeu\u00a0(H.\u00a0de\u00a0Palam\u00f3s);\u00a0\u00a0Marian\u00a0\nNavarro\u00a0and\u00a0Josep\u00a0Vilar\u00f3\u00a0(H.\u00a0General\u00a0de\u00a0Vic);\u00a0Josep\u00a0M\u00aa\u00a0Sim\u00f3,\u00a0Carlos\u00a0Alonso\u00a0Villaverde\u00a0and\u00a0Blai\u00a0Coll\u00a0(H.\u00a0Universitari\u00a0Sant\u00a0Joan\u00a0de\u00a0Reus),\u00a0Eugenia\u00a0M\u00e0rquez\u00a0and\u00a0I sabel\u00a0Garcia\u00a0(Hospital\u00a0general\u00a0de\u00a0\nL\u2019Hospitalet);\u00a0Miguel\u00a0\u00c1ngel\u00a0Ben\u00edtez,\u00a0Alba\u00a0Cebollero\u00a0and\u00a0Manuel\u00a0 Guadarrama\u00a0(H.\u00a0De\u00a0Vilafranca).\u00a0\nVoluntary \u00a0and\u00a0Counseling \u00a0Testing\u00a0Sites:\u00a0Isabel\u00a0Rodrigo\u00a0(Lab.\u00a0Cl\u00ednic\u00a0de\u00a0Manso),\u00a0Roser\u00a0Sala\u00a0(Lab.\u00a0\nSabater\u00a0Tobella),\u00a0\u00a0Olga\u00a0D\u00edaz\u00a0(SAPS),\u00a0\u00a0Kati\u00a0Zaragoza\u00a0(Stop\u00a0Sida) ,\u00a0\u00a0Merc\u00e8\u00a0Mero\u00f1o\u00a0(\u00c0mbit\u00a0Dona),\u00a0\nJorge\u00a0Saz\u00a0and\u00a0Ferran\u00a0Pujol\u00a0(Proje cte\u00a0dels\u00a0Noms\u00a0\u2013\u00a0Hispanosida),\u00a0 Jasmina\u00a0Becerra\u00a0(ACASC),\u00a0\u00a0Rosa\u00a0\nRos\u00a0(CJAS),\u00a0Anna\u00a0Avellaneda,\u00a0Mont se\u00a0Sit\u00e9\u00a0(Actua\u00a0Vall\u00e8s),\u00a0Anna\u00a0R afel\u00a0(Associaci\u00f3\u00a0Antisida\u00a0Lleida).\u00a0\n\u00a0\n\u00a0\n\u00a0\u00a0\n\u00a0\n\u00a0\n\u00a0\n\u00a0\u00a0\n\u00a0\n\u00a0\n\u00a0ANEXO\u00a0\n -  103REFERENCES \u00a0\n1.\u00a0Brookmeyer\u00a0R,\u00a0Quinn\u00a0TC.\u00a0Estimati on\u00a0of\u00a0current\u00a0human\u00a0immunodeficiency\u00a0virus\u00a0incidence\u00a0rates\u00a0from\u00a0a\u00a0\ncross\u2010sectional\u00a0survey\u00a0using\u00a0ear ly\u00a0diagnostic\u00a0tests.\u00a0Am\u00a0J\u00a0Epide miol.\u00a01995;141(2):166\u2013172.\u00a0\n2.\u00a0Janssen\u00a0RS,\u00a0Satten\u00a0GA,\u00a0Stramer\u00a0SL ,\u00a0Rawal\u00a0BD,\u00a0O'Brien\u00a0TR,\u00a0Weible n\u00a0BJ,\u00a0Hecht\u00a0FM,\u00a0Jack\u00a0N,\u00a0Cleghorn\u00a0FR,\u00a0\nKahn\u00a0JO,\u00a0Chesney\u00a0MA,\u00a0Busch\u00a0MP.\u00a0New\u00a0testing\u00a0strategy\u00a0to\u00a0detect\u00a0early\u00a0HIV\u20101\u00a0infection\u00a0for\u00a0use\u00a0in\u00a0incidence\u00a0\nestimates\u00a0and\u00a0for\u00a0clinical\u00a0and\u00a0prevention\u00a0purposes.\u00a0JAMA\u00a01998;\u00a0 280(1):42\u20108 \u00a0\n3.\u00a0Busch\u00a0MP,\u00a0Pilcher\u00a0CD,\u00a0Mastro\u00a0TD, \u00a0et\u00a0al.\u00a0Beyond\u00a0detuning:\u00a010\u00a0yea rs\u00a0of\u00a0progress\u00a0and\u00a0new\u00a0challenges\u00a0in\u00a0the\u00a0\ndevelopment\u00a0and\u00a0application\u00a0of\u00a0assays\u00a0for\u00a0HIV\u00a0incidence\u00a0estimat ion.\u00a0AIDS.\u00a02010;24(18):2763\u20102771. \u00a0\n4.\u00a0Murphy\u00a0G,\u00a0Parry\u00a0JV.\u00a0Assays\u00a0for\u00a0the\u00a0detection\u00a0of\u00a0recent\u00a0infectio ns\u00a0with\u00a0human\u00a0immunodeficiency\u00a0virus\u00a0\ntype\u00a01.\u00a0Euro\u00a0Surveill\u00a02008;\u00a013:pii:18966 \u00a0\n5.\u00a0Mastro\u00a0TD,\u00a0Kim\u00a0AA,\u00a0Hallett\u00a0T,\u00a0Rehle\u00a0T,\u00a0Welte\u00a0A,\u00a0Laeyendecker\u00a0O, \u00a0et\u00a0al.\u00a0Estimating\u00a0HIV\u00a0incidence\u00a0in\u00a0\npopulations\u00a0using\u00a0tests\u00a0for\u00a0recent\u00a0infection:\u00a0Issues,\u00a0challenge s\u00a0and\u00a0the\u00a0way\u00a0forward.\u00a0\u2010\u00a0J\u00a0HIV\u00a0AIDS\u00a0Surveill\u00a0\nEpidemiol.2010\u00a0Jan\u00a01;2(1):1\u201014.(1930\u20106768\u00a0(Electronic)). \u00a0\n6.\u00a0UNAIDS/WHO\u00a0Working\u00a0group\u00a0on\u00a0Globa l\u00a0HIV/AIDS\u00a0and\u00a0STI\u00a0Surveillanc e.\u00a0When\u00a0and\u00a0how\u00a0to\u00a0use\u00a0assays\u00a0for\u00a0\nrecent\u00a0infection\u00a0to\u00a0estimate\u00a0HIV\u00a0incidence\u00a0at\u00a0a\u00a0population\u00a0leve l.\u00a0Geneva:\u00a0WHO\u00a0Press;\u00a02011. \u00a0\n7.\u00a0McWalter\u00a0TA,\u00a0Welte\u00a0A.\u00a0Relating\u00a0recent\u00a0infection\u00a0prevalence\u00a0to\u00a0i ncidence\u00a0with\u00a0a\u00a0sub\u2010population\u00a0of\u00a0assay\u00a0\nnon\u2010progressors.\u00a0J\u00a0Math\u00a0Biol.\u00a02010;60(5):687\u2013710. \u00a0\n8.\u00a0Health\u00a0Protection\u00a0Agency.\u00a0HIV\u00a0in\u00a0the\u00a0United\u00a0Kingdom:\u00a02011\u00a0Repor t.\u00a0London:\u00a0Health\u00a0Protection\u00a0Services,\u00a0\nColindale.\u00a0November\u00a02011.\u00a0\n9.\u00a0Cortes\u00a0Martins\u00a0H,\u00a0Paixao\u00a0M.\u00a0Settings\u00a0for\u00a0identifying\u00a0recent\u00a0HIV\u00a0infections:\u00a0the\u00a0Portuguese\u00a0experience.\u00a0EuroSurveill\u00a0[Internet].\u00a02008\u00a0Se pt.\u00a04\u00a0[cited\u00a0 2010\u00a0Jul.\u00a020];13(36).\u00a0pii:18974.\u00a0\n10.\u00a0B\u00e4tzing\u2010Feigenbaum\u00a0J,\u00a0Loschen\u00a0S, \u00a0Gohlke\u2010Micknis\u00a0S,\u00a0Zimmermann\u00a0R ,\u00a0Herrmann\u00a0A,\u00a0Kamga\u00a0Wambo\u00a0O,\u00a0et\u00a0\nal.\u00a0Country\u2010wide\u00a0HIV\u00a0incidence\u00a0study\u00a0complementing\u00a0HIV\u00a0surveill ance\u00a0in\u00a0Germany.\u00a0Euro\u00a0Surveill\u00a02008;\u00a0\n13:pii:18971.\u00a0\n11.\u00a0Semaille\u00a0C,\u00a0Cazein\u00a0F,\u00a0Pillonel\u00a0J,\u00a0Lot\u00a0F,\u00a0Le\u00a0Vu\u00a0S,\u00a0Pinget\u00a0R,\u00a0Des enclos\u00a0J,\u00a0Barin\u00a0F.\u00a0Four\u00a0years\u00a0of\u00a0surveillance\u00a0of\u00a0\nrecent\u00a0HIV\u00a0infections\u00a0at\u00a0country\u00a0level,\u00a0France,\u00a0mid\u00a02003\u00a0\u2010\u00a02006 :\u00a0experience\u00a0and\u00a0perspectives.\u00a0Euro\u00a0\nSurveill.\u00a02008\u00a0Sep\u00a04;13(36).\u00a0pii:\u00a018968.\u00a0\n12.\u00a0Le\u00a0Vu\u00a0S,\u00a0Le\u00a0Strat\u00a0Y,\u00a0Barin\u00a0F,\u00a0Pillonel\u00a0J,\u00a0Cazein\u00a0F,\u00a0Bousquet\u00a0V, \u00a0et\u00a0al.\u00a0Population\u2010based\u00a0HIV\u20101\u00a0incidence\u00a0in\u00a0\nfrance,\u00a02003\u201008:\u00a0A\u00a0modelling\u00a0analysis.\u00a0Lancet\u00a0Infect\u00a0Dis.\u00a02010\u00a0 Oct;10(10):682\u20107.\u00a0\n13.\u00a0Lee\u00a0LM,\u00a0McKenna\u00a0MT.\u00a0Monitoring\u00a0th e\u00a0incidence\u00a0of\u00a0HIV\u00a0infection\u00a0i n\u00a0the\u00a0United\u00a0States.\u00a0Public\u00a0Health\u00a0Rep.\u00a0\n2007;122\u00a0Suppl\u00a01:72\u20109.\u00a0\n14.\u00a0Hall\u00a0HI,\u00a0Song\u00a0R,\u00a0Rhodes\u00a0P,\u00a0Prejean\u00a0J,\u00a0An\u00a0Q,\u00a0Lee\u00a0LM,\u00a0et\u00a0al.\u00a0Esti mation\u00a0of\u00a0HIV\u00a0incidence\u00a0 in\u00a0the\u00a0United\u00a0States.\u00a0\nJAMA\u00a02008;\u00a0300:520\u20109.\u00a0\n15.\u00a0Karon\u00a0JM,\u00a0Song\u00a0R,\u00a0Brookmeyer\u00a0R,\u00a0K aplan\u00a0EH,\u00a0Hall\u00a0HI.\u00a0Estimating\u00a0 HIV\u00a0incidence\u00a0in\u00a0the\u00a0United\u00a0States\u00a0from\u00a0\nHIV/AIDS\u00a0surveillance\u00a0data\u00a0and\u00a0b iomarker\u00a0HIV\u00a0test\u00a0results.\u00a0Stat \u00a0Med.\u00a02008\u00a0Oct\u00a015; 27(23):4617\u201033.\u00a0\n16.\u00a0Mammone\u00a0et\u00a0al.\u00a0HIV\u00a0incidence\u00a0esti mate\u00a0combining\u00a0HIV/AIDS\u00a0surveillance,\u00a0testing\u00a0history\u00a0information\u00a0\nand\u00a0HIV\u00a0test\u00a0to\u00a0identify\u00a0recent\u00a0i nfections\u00a0in\u00a0Lazio,\u00a0Italy.\u00a0BMC \u00a0Infectious\u00a0Diseases\u00a02012;\u00a012:65.\u00a0ANEXO\u00a0\n 10417.\u00a0European\u00a0 Centre\u00a0 for\u00a0 Disease\u00a0 Prevention\u00a0 and\u00a0 Control\u00a0 (ECDC).\u00a0 Mapp i n g \u00a0o f \u00a0H I V / S T I \u00a0b e h a v i o u r a l \u00a0\nsurveillance\u00a0in\u00a0Europe.\u00a0ECDC\u00a0tech nical\u00a0report.\u00a0Stockholm:\u00a0ECDC; \u00a02009.\u00a0\n18.\u00a0Centre\u00a0 for\u00a0 Epidemiolog ical\u00a0 Studies\u00a0 on\u00a0 Sexually\u00a0 Transmitted\u00a0 Infe c t i o n s \u00a0a n d \u00a0H I V / A I D S \u00a0o f \u00a0C a t a l o n i a . \u00a0\nd\u2019Estudis.\u00a0 SIVES\u00a0 2010:\u00a0 Integrated\u00a0 AIDS/HIV/STI\u00a0 Surveillance\u00a0 Sys tem\u00a0 of\u00a0 Catalonia\u00a0 (SIVES):\u00a0biennial\u00a0\nepidemiological\u00a0report.\u00a0Barcelona:\u00a0Generalitat\u00a0de\u00a0Catalunya,\u00a0De partament\u00a0de\u00a0Salut;\u00a02011.\u00a0(Technical\u00a0\ndocument\u00a0CEEISCAT:\u00a020).\u00a0Availabel\u00a0at\u00a0 http://www.ceescat.org/Index_Ing.htm .\u00a0\n19.\u00a0Romero\u00a0A,\u00a0Gonzalez\u00a0V,\u00a0Granell\u00a0M,\u00a0Matas\u00a0L,\u00a0Esteve\u00a0A,\u00a0Martro\u00a0E,\u00a0e t\u00a0al.\u00a0Recently\u00a0acquire d\u00a0HIV\u00a0infection\u00a0in\u00a0\nSpain\u00a0(2003\u20102005):\u00a0Introduction\u00a0of\u00a0the\u00a0serological\u00a0testing\u00a0algo rithm\u00a0for\u00a0recent\u00a0HIV\u00a0seroconversion.\u00a0Sex\u00a0\nTransm\u00a0Infect.\u00a02009\u00a0Apr;85(2):106\u201010.\u00a0\n20.\u00a0Romero\u00a0A,\u00a0Gonz\u00e1lez\u00a0V,\u00a0Esteve\u00a0A,\u00a0Martr\u00f3\u00a0E,\u00a0Matas\u00a0L,\u00a0Tural\u00a0C,\u00a0et\u00a0 al.\u00a0Identification\u00a0of\u00a0re cent\u00a0HIV\u20101\u00a0infection\u00a0\namong\u00a0newly\u00a0diagnosed\u00a0cases\u00a0in\u00a0 Catalonia,\u00a0Spain\u00a0(2006\u201008).\u00a0Eur\u00a0J\u00a0Public\u00a0Health.\u00a0 2012\u00a0Dec;22(6):802\u20108.\u00a0\n21.\u00a0Kothe\u00a0D,\u00a0Byers\u00a0RH,\u00a0Caudill\u00a0SP,\u00a0Satten\u00a0GA,\u00a0Janssen\u00a0RS,\u00a0Hannon\u00a0WH ,\u00a0et\u00a0al.\u00a0Performance\u00a0characteristics\u00a0of\u00a0a\u00a0\nnew\u00a0less\u00a0sensitive\u00a0HIV\u20101\u00a0enzyme\u00a0 immunoassay\u00a0for\u00a0use\u00a0in\u00a0estimati ng\u00a0HIV\u00a0seroincidence .\u00a0J\u00a0Acquir\u00a0Immune\u00a0\nDefic\u00a0Syndr.\u00a02003\u00a0Aug\u00a015;33(5):625\u201034.\u00a0\n22.\u00a0Parekh\u00a0BS,\u00a0Kennedy\u00a0MS,\u00a0Dobbs\u00a0T,\u00a0Pau\u00a0CP,\u00a0Byers\u00a0R,\u00a0Green\u00a0T,\u00a0et\u00a0al .\u00a0Quantitative\u00a0detection\u00a0of\u00a0increasing\u00a0HIV\u00a0\ntype\u00a01\u00a0antibodies\u00a0after\u00a0seroconversion:\u00a0a\u00a0simple\u00a0assay\u00a0for\u00a0dete cting\u00a0recent\u00a0HIV\u00a0infection\u00a0and\u00a0estimating\u00a0\nincidence.\u00a0AIDS\u00a0Res\u00a0Hum\u00a0Re troviruses.\u00a02002;\u00a018:295\u2013307.\u00a0\n23.\u00a0Romero\u00a0A,\u00a0Martro\u00a0E,\u00a0Gonz\u00e1lez\u00a0V,\u00a0Matas\u00a0L,\u00a0AERI\u00a0Study\u00a0Group.\u00a0Comp arison\u00a0of\u00a0two\u00a0serological\u00a0tests\u00a0for\u00a0the\u00a0\nidentification\u00a0 of\u00a0 recent\u00a0 HIV\u00a0 inf e c t i o n : \u00a0V i r o n o s t i k a \u2010 L S \u00a0H I V \u2010 1 \u00a0m i c r o e l i s a \u00a0a n d \u00a0B E D \u00a0c a p t u r e \u00a0e n z y m e \u00a0\nimmunoassay.\u00a0Enferm\u00a0Infecc\u00a0Microb iol\u00a0Clin.\u00a0Enferm\u00a0Infecc\u00a0Microb iol\u00a0Clin.\u00a02011\u00a0Aug\u2010Sep;29(7):553\u20105.\u00a0\n24.\u00a0Fern\u00e0ndez\u2010Lopez\u00a0L,\u00a0Rif\u00e0\u00a0B,\u00a0Pujol \u00a0F,\u00a0Becerra\u00a0J,\u00a0P\u00e9rez\u00a0M,\u00a0Mero\u00f1o\u00a0 M,\u00a0Zaragoza\u00a0K,\u00a0Rafel\u00a0A,\u00a0D\u00edaz\u00a0O,\u00a0Avellaneda\u00a0\nA,\u00a0Casado\u00a0MJ,\u00a0Gim\u00e9nez\u00a0A,\u00a0Casabon a\u00a0J.\u00a0Impact\u00a0of\u00a0the\u00a0introduction \u00a0of\u00a0rapid\u00a0HIV\u00a0testing\u00a0in\u00a0the\u00a0Voluntary\u00a0\nCounselling\u00a0and\u00a0Testing \u00a0sites\u00a0network\u00a0of\u00a0Ca talonia,\u00a0Spain.\u00a0Int\u00a0 J\u00a0STD\u00a0AIDS.\u00a02010\u00a0Jun ;21(6):388\u201091.\u00a0\n25.\u00a0Campbell\u00a0C,\u00a0Esteve\u00a0A,\u00a0and\u00a0Casabona\u00a0J\u00a0on\u00a0behalf\u00a0of\u00a0the\u00a0PISCIS\u00a0Cohort\u00a0Study\u00a0Group.\u00a0\u00a0Development\u00a0of\u00a0a\u00a0\ncomposite\u00a0 behaviour\u00a0 risk\u00a0 score\u00a0 to\u00a0 assess\u00a0 behaviour\u00a0 change\u00a0 assoc iated\u00a0 with\u00a0 HIV\u00a0 diagnosis.\u00a0 Poster\u00a0\npresentation\u00a0at\u00a0the\u00a018th\u00a0International\u00a0Workshop\u00a0on\u00a0HIV\u00a0Observat ional\u00a0Databases.\u00a0Sitges,\u00a0Spain\u00a027th\u2010\n29th\u00a0March\u00a02014.\u00a0\n26.\u00a0Folch\u00a0C,\u00a0Munoz\u00a0R,\u00a0Zaragoza\u00a0K,\u00a0Casabona\u00a0J.\u00a0Sexual\u00a0risk\u00a0behaviour \u00a0and\u00a0its\u00a0determinants\u00a0among\u00a0men\u00a0who\u00a0\nhave\u00a0sex\u00a0with\u00a0men\u00a0in\u00a0Catalonia,\u00a0Spain.\u00a0Euro\u00a0Surveill\u00a02009;14:19 415.\u00a0\n27.\u00a0Folch\u00a0C,\u00a0Casabona\u00a0J,\u00a0Munoz\u00a0R,\u00a0et\u00a0al.\u00a0Increase\u00a0in\u00a0the\u00a0prevalence \u00a0of\u00a0HIV\u00a0and\u00a0in\u00a05\u00a0associated\u00a0risk\u00a0behaviors\u00a0\nin\u00a0men\u00a0who\u00a0have\u00a0sex\u00a0with\u00a0men:\u00a012\u00a0years\u00a0of\u00a0behavioral\u00a0surveillan ce\u00a0surveys\u00a0in\u00a0Catalonia\u00a0(Spain).\u00a0Gac\u00a0\nSanit\u00a02010;24:40\u20136.\u00a0\n28.\u00a0Sullivan\u00a0PS,\u00a0Hamouda\u00a0O,\u00a0Delpech\u00a0V,\u00a0Geduld\u00a0JE,\u00a0Prejean\u00a0J,\u00a0Semail le\u00a0C,\u00a0et\u00a0al.\u00a0Reemergence\u00a0of\u00a0the\u00a0HIV\u00a0\nepidemic\u00a0among\u00a0men\u00a0who\u00a0have\u00a0sex\u00a0with\u00a0men\u00a0in\u00a0North\u00a0America,\u00a0west ern\u00a0Europe,\u00a0and\u00a0Australia,\u00a01996\u2010\n2005.\u00a0Ann\u00a0Epidemiol.\u00a0 2009\u00a0Jun;19(6):423\u201031.\u00a0\n29.\u00a0Van\u00a0de\u00a0Laar\u00a0MJ.\u00a0HIV/AIDS\u00a0and\u00a0other\u00a0STI\u00a0in\u00a0men\u00a0who\u00a0have\u00a0sex\u00a0with \u00a0men\u2010\u2010a\u00a0continuous\u00a0challenge\u00a0for\u00a0\npublic\u00a0health.\u00a0Euro\u00a0 Surveill\u00a02009\u00a0;14(47):19423\u00a0ANEXO\u00a0\n -  10530.\u00a0European\u00a0Centre\u00a0for\u00a0Disease\u00a0Prevention\u00a0and\u00a0Control.\u00a0STI\u00a0and\u00a0HIV\u00a0prevention\u00a0in\u00a0men\u00a0who\u00a0have\u00a0sex\u00a0with\u00a0\nmen\u00a0in\u00a0Europe.\u00a0Stockholm:\u00a0ECDC;\u00a02013.\u00a0\n31.\u00a0Ferrer\u00a0L,\u00a0Esteve\u00a0A,\u00a0Meulbroek\u00a0M,\u00a0Loureiro\u00a0E,\u00a0Ditzel\u00a0E,\u00a0Folch\u00a0C, \u00a0Pujol\u00a0F,\u00a0Saz\u00a0J,\u00a0Taboada\u00a0H,\u00a0Casabona\u00a0J.\u00a0High\u00a0\nincidence\u00a0among\u00a0MSM\u00a0in\u00a0Barcelona ,\u00a0Catalonia:\u00a0The\u00a0ITACA\u00a0Cohort.\u00a0 \u00a0FEMP\u00a02011:\u00a0The\u00a0Future\u00a0of\u00a0European\u00a0\nPrevention\u00a0among\u00a0MSM.\u00a010\u00a0&\u00a011\u00a0November\u00a02011\u00a0Stockholm,\u00a0Sweden.\u00a0\n32.\u00a0Stover\u00a0J,\u00a0Johnson\u00a0P,\u00a0Hallett\u00a0T,\u00a0Marston\u00a0M,\u00a0Becquet\u00a0R,\u00a0Timaeus\u00a0I M.\u00a0The\u00a0Spectrum\u00a0projection\u00a0package:\u00a0\nimprovements\u00a0in\u00a0estimating\u00a0incidence\u00a0by\u00a0age\u00a0and\u00a0sex,\u00a0mother\u2010to\u2010 child\u00a0transmission,\u00a0HIV\u00a0progression\u00a0in\u00a0\nchildren\u00a0and\u00a0double\u00a0orphans.\u00a0Sex\u00a0Transm\u00a0Infect.\u00a02010\u00a0Dec;86\u00a0Sup pl\u00a02:ii16\u201021.\u00a0\u00a0\n33.\u00a0Brown\u00a0T,\u00a0Bao\u00a0L,\u00a0Raftery\u00a0AE,\u00a0Salomon\u00a0JA,\u00a0Baggaley\u00a0RF,\u00a0Stover\u00a0J,\u00a0 Gerland\u00a0P.\u00a0Modelling\u00a0H IV\u00a0epidemics\u00a0in\u00a0the\u00a0\nantiretroviral\u00a0era:\u00a0the\u00a0UNAIDS\u00a0Estimation\u00a0and\u00a0Projection\u00a0packag e\u00a02009.\u00a0Sex\u00a0Transm\u00a0Infect.\u00a02010\u00a0Dec;86\u00a0\nSuppl\u00a02:ii3\u201010.\u00a0doi:\u00a010.1136/sti.2010.044784.\u00a0Epub\u00a02010\u00a0Oct\u00a06.\u00a0\n34.\u00a0Campbell\u00a0C,\u00a0Esteve\u00a0A,\u00a0and\u00a0Casabona\u00a0J\u00a0on\u00a0behalf\u00a0of\u00a0the\u00a0PISCIS\u00a0Co hort\u00a0Study\u00a0Group.\u00a0\u00a0Reconstruction\u00a0of\u00a0the\u00a0\nHIV\u00a0 epidemic\u00a0 in\u00a0 Catalonia\u00a0 and\u00a0 projection\u00a0 for\u00a0 the\u00a0 years\u00a0 2012\u2010201 7.\u00a0 Poster\u00a0 presentation\u00a0 at\u00a0 the\u00a0 XI\u00a0\nInternational\u00a0AIDS\u00a0Impact.\u00a0Barcelona,\u00a0Spain\u00a0September\u00a029th\u2010Octo ber\u00a02nd\u00a02013.\u00a0\n35.\u00a0Young\u00a0CL,\u00a0Hu\u00a0DJ,\u00a0Byers\u00a0R,\u00a0et\u00a0al.\u00a0Evaluation\u00a0of\u00a0a\u00a0sensitive/less\u00a0sensitive\u00a0testing\u00a0algorithm\u00a0using\u00a0the\u00a0bioMerieux\u00a0vironostika\u2010LS\u00a0assay\u00a0 for\u00a0detecting\u00a0recent\u00a0HIV\u20101\u00a0subt ype\u00a0B\u2019\u00a0or\u00a0E\u00a0infection\u00a0in\u00a0Thailand.\u00a0AIDS\u00a0\nRes\u00a0Hum\u00a0Retroviruses\u00a02003;19:481\u20136.\u00a0\n36.\u00a0Kassanjee\u00a0 R,\u00a0 McWalter\u00a0 TA,\u00a0 B\u00e4rnighausen\u00a0 T,\u00a0 Welte\u00a0 A.\u00a0A\u00a0 new\u00a0 genera l\u00a0 biomarker\u2010based\u00a0 incidence\u00a0\nestimator.\u00a0 Epidemiology .\u00a02012;\u00a0in\u00a0press.\u00a0\n37.\u00a0M\u00a0Takano,\u00a0M\u00a0Okada,\u00a0S\u00a0Oka,\u00a0and\u00a0Y\u00a0Wagatsuma.\u00a0The\u00a0relationship\u00a0bet ween\u00a0HIV\u00a0testing\u00a0and\u00a0CD4\u00a0counts\u00a0at\u00a0\nHIV\u00a0diagnosis\u00a0among\u00a0newly\u00a0diagnos ed\u00a0HIV\u20101\u00a0patients\u00a0in\u00a0Japan\u00a0.\u00a0I nt\u00a0J\u00a0STD\u00a0AIDS\u00a0April\u00a02012\u00a023:262\u2014266.\u00a0\n\u00a0\n\u00a0\n\u00a0\u00a0\u00a0\u00a0\n\u00a0\n\u00a0\u00a0\u00a0\u00a0\u00a0\n\u00a0\n\u00a0\u00a0\u00a0\u00a0ANEXO\u00a0\n 106Table\u00a01.\u00a0Annual\u00a0HIV\u00a0incidence \u00a0estimates\u00a0 Catalonia, \u00a02003\u20102008.\u00a0\n\u00a0\nYear\u00a0\u00a0 HIV\u00a0incidence\u00a0per\u00a0\u00a0\n100/year\u00a0New\u00a0HIV\u00a0\ndiagnoses\u00a0\nRITA\u00a0tested\u00a0\n(1)\u00a0Identified\u00a0Recent\u00a0\ninfections\u00a0(1)\u00a0\u00a0\nN\u00a0(%)\u00a0HIV\u00a0\nNegative\u00a0tests\u00a0(2)\u00a0HIV\u00a0positive\u00a0\ntests\u00a0(2)\u00a0\nN\u00a0(%)\u00a0RITA\u00a0\ntested/HIV+\u00a0\n(%)\u00a0\n2003\u00a0\n2004\u00a0\n2005\u00a0\n2006\u00a02007\u00a0\n2008\u00a00.46\u00a0(0.31\u20100.61)\u00a0\n0.44\u00a0(0.32\u20100.55)\u00a0\n0.31\u00a0(0.22\u20100.41)\u00a0\n0.37\u00a0(0.24\u20100.49)\u00a00.54\u00a0(0.40\u20100.68)\u00a0\n0.73\u00a0(0.55\u20100.90)\u00a0373\u00a0\n568\u00a0\n577\u00a0\n320\u00a0412\u00a0\n392\u00a065\u00a0(17.4)\u00a0\n106\u00a0(18.7)\u00a0\n89\u00a0(15.4)\u00a0\n58\u00a0(18.1)\u00a098\u00a0(23.8)\u00a0\n102\u00a0(26.0)\u00a053,073\u00a069,707\u00a0\n74,913\u00a0\n78,334\u00a085,202\u00a0\n91,566\u00a0766\u00a0(1.42)\u00a0\n882\u00a0(1.25)\u00a0\n866\u00a0(1.14)\u00a0\n857\u00a0(1.08)\u00a0990\u00a0(1.15)\u00a0\n1,287\u00a0(1.39)\u00a00.49\u00a00.64\u00a0\n0.67\u00a0\n0.37\u00a00.42\u00a0\n0.30\u00a0\nTotal\u00a0 0.46\u00a0(0.39\u20100.53)\u00a0 2,642\u00a0 518\u00a0(19.6)\u00a0 452,795\u00a0 5,648\u00a0(1.23)\u00a0 0. 46\u00a0\n(1)\u00a0Data\u00a0from\u00a0the\u00a0AERI\u00a0project\u00a0\n(2)\u00a0Aggregated\u00a0data\u00a0reported\u00a0to\u00a0the\u00a0HIV\u00a0testing\u00a0surveillance\u00a0system \u00a0in\u00a0Catalonia\u00a0\n \n ANEXO\u00a0\n -  107Table\u00a02.\u00a0Characteristics \u00a0of\u00a0the\u00a0samples \u00a0included \u00a0in\u00a0the\u00a0AERI\u00a0Study\u00a0by\u00a0period\u00a0and\u00a0the\u00a0HIV\u00a0\npositive\u00a0samples \u00a0reported \u00a0to\u00a0the\u00a0HIV\u00a0Testing\u00a0surveillance\u00a0 System.\u00a0\n \n\u00a0 2003\u20102005\u00a0 2006\u20102008\u00a0\n\u00a0 Identified\u00a0\nRecent\u00a0\ninfections\u00a0(1)\u00a0New\u00a0HIV\u00a0\ndiagnoses\u00a0\nRITA\u00a0tested\u00a0(1)\u00a0HIV\u00a0positive\u00a0\ntests\u00a0(2)\u00a0Identified\u00a0\nRecent\u00a0\ninfections\u00a0(1)\u00a0New\u00a0HIV\u00a0\ndiagnoses\u00a0\nRITA\u00a0tested\u00a0(1)\u00a0HIV\u00a0positive\u00a0\ntests\u00a0(2)\u00a0\nType\u00a0of\u00a0centre\u00a0\nHospitals\u00a0\nVCTS\u00a0\u00a0\n243\u00a0(92.5)\u00a0\n17\u00a0(7.5)\u00a0\u00a0\n1,483\u00a0(94.7)\u00a0\n80\u00a0(6.0)\u00a0\u00a0\n2,425\u00a0(96.5)\u00a0\n89\u00a0(3.5)\u00a0\u00a0\n236\u00a0(91.5)\u00a0\n22\u00a0(8.5)\u00a0\u00a0\n1,046\u00a0(93.0)\u00a0\n78\u00a0(7.0)\u00a0\u00a0\n2,906\u00a0(92.7)\u00a0\n228\u00a0(7.3)\u00a0\nGender\u00a0\nFemale\u00a0\nMale\u00a0\u00a0\n41\u00a0(15.2)\u00a0\n219\u00a0(84.8)\u00a0\u00a0\nNA\u00a0NA\u00a0\u00a0\n666\u00a0(26.5)\u00a0\n1,848\u00a0(73.5) \u00a0\u00a0\n38\u00a0(14.7)\u00a0\n221\u00a0(85.3)\u00a0\u00a0\n226\u00a0(20.1)\u00a0898\u00a0(79.9)\u00a0\u00a0\n724\u00a0(23.1)\u00a0\n2,410\u00a0(76.9)\u00a0\nRisk\u00a0group\u00a0\nHomosexual\u00a0\nHeterosexual\u00a0\nIDU\u00a0\u00a0\n120\u00a0(49.7)\u00a0\n76\u00a0(31.5)\u00a045\u00a0(18.6)\u00a0\u00a0\nNA\u00a0\nNA\u00a0\nNA\u00a0\u00a0\nNA\u00a0\nNA\u00a0\nNA\u00a0\u00a0\n171\u00a0(69.8)\u00a0\n67\u00a0(27.3)\u00a0\n7\u00a0(2.9)\u00a0\u00a0\n550\u00a0(52.9)\u00a0\n436\u00a0(42.0)\u00a0\n53\u00a0(5.1)\u00a0\u00a0\nNA\u00a0NA\u00a0\nNA\u00a0\nAge\u00a0\n<30\u00a0\n30\u201050\u00a0\n>50\u00a0\u00a0\n96\u00a0(37.5)\u00a0\n142\u00a0(55.5)\u00a0\n18\u00a0(7.0\u00a0)\u00a0\u00a0\nNA\u00a0\nNA\u00a0\nNA\u00a0\u00a0\n618\u00a0(24.6)\u00a0\n1,692\u00a0(67.3)\u00a0\n204\u00a0(8.1)\u00a0\u00a0\n88\u00a0(34.0)\u00a0\n160\u00a0(62.2)\u00a0\n10\u00a0(3.8)\u00a0\u00a0\n310\u00a0(27.6)\u00a0\n686\u00a0(61.0)\u00a0\n129\u00a0(11.4)\u00a0\u00a0\n807\u00a0(25.7)\u00a0\n2,038\u00a0(65.0)\u00a0\n288\u00a0(9.3)\u00a0\nOrigin\u00a0\nSpanish\u2010born\u00a0Immigrants\u00a0\u00a0\n164\u00a0(72.9)\u00a0\n61\u00a0(27.1)\u00a0\u00a0\nNA\u00a0NA\u00a0\u00a0\nNA\u00a0NA\u00a0\u00a0\n150\u00a0(62.0)\u00a0\n92\u00a0(38.0)\u00a0\u00a0\n654\u00a0(61.3)\u00a0413\u00a0(38.7)\u00a0\u00a0\nNA\u00a0NA\u00a0\nTotal\u00a0 260\u00a0 1,518\u00a0 2,514\u00a0 258\u00a0 1,124\u00a0 3,134\u00a0\n(1)\u00a0Data\u00a0from\u00a0the\u00a0AERI\u00a0project;(2)\u00a0Aggregated\u00a0data\u00a0reported\u00a0to\u00a0the\u00a0HIV\u00a0testing\u00a0surveillance\u00a0system \u00a0in\u00a0Catalonia;\u00a0\u00a0\nNA:\u00a0not\u00a0available\u00a0IDU:\u00a0injection\u00a0drug\u00a0users\u00a0\nData\u00a0presented\u00a0are\u00a0N\u00a0and\u00a0pe rcentages\u00a0in\u00a0brackets\u00a0(%)\n\u00a0\u00a0\n 108 \n -  109\u00a0\n\u00a0\n\u00a0\n\u00a0\n\u00a0\u00a0\n\u00a0\n\u00a0\u00a0\n\u00a0\n\u00a0\n\u00a0\n\u00a0\u00a0\n\u00a0\nDISCUSI\u00d3N\u00a0\n\u00a0\n\u00a0\u00a0\u00a0\u00a0\n\u00a0\n\u00a0\u00a0\n 110DISCUSI\u00d3N\u00a0\n -  1111.\u00a0Resumen \u00a0global\u00a0 de\u00a0los\u00a0resultados\u00a0\nLos\u00a0resultados\u00a0principales\u00a0de\u00a0lo s\u00a0trabajos\u00a0presentados\u00a0en\u00a0esta\u00a0 tesis\u00a0son\u00a0los\u00a0siguientes:\u00a0\n1.\u00a0La\u00a0aplicaci\u00f3n\u00a0de\u00a0los\u00a0tests\u00a0serol\u00f3gicos\u00a0para\u00a0la\u00a0identificaci\u00f3 n\u00a0de\u00a0infecciones\u00a0recientes\u00a0es\u00a0\nfactible\u00a0en\u00a0nuestro\u00a0medio.\u00a0\n2.\u00a0Gracias\u00a0 a\u00a0 la\u00a0 aplicaci\u00f3n\u00a0 de\u00a0 estos\u00a0 tests,\u00a0 ha\u00a0 sido\u00a0 posible\u00a0 desc ribir\u00a0 las\u00a0 caracter\u00edsticas\u00a0\nepidemiol\u00f3gicas\u00a0de\u00a0las\u00a0personas\u00a0 con\u00a0infecci\u00f3n\u00a0reciente\u00a0por\u00a0VIH. \u00a0\n3.\u00a0Desde\u00a0el\u00a0a\u00f1o\u00a02006\u00a0la\u00a0identificaci\u00f3n\u00a0de\u00a0infecciones\u00a0recientes \u00a0mediante\u00a0tests\u00a0serol\u00f3gicos\u00a0\nest\u00e1\u00a0incorporada\u00a0en\u00a0el\u00a0Sistema\u00a0Integrado\u00a0de\u00a0Vigilancia\u00a0Epidemiol\u00f3gica\u00a0del\u00a0VIH\u00a0en\u00a0Catalu\u00f1a.\u00a0\n4.\u00a0La\u00a0prevalencia\u00a0de\u00a0infecci\u00f3n\u00a0reciente\u00a0present\u00f3\u00a0una\u00a0tendencia\u00a0 al\u00a0aumento\u00a0a\u00a0lo\u00a0largo\u00a0del\u00a0\nperiodo\u00a02003\u00a0\u2013\u00a02008.\u00a0\n5.\u00a0Los\u00a0factores\u00a0asociados\u00a0a\u00a0la\u00a0infecci\u00f3n\u00a0reciente\u00a0fueron\u00a0la\u00a0tra nsmisi\u00f3n\u00a0a\u00a0trav\u00e9s\u00a0de\u00a0relaciones\u00a0\nentre\u00a0HSH\u00a0y\u00a0tener\u00a0menos \u00a0de\u00a030\u00a0a\u00f1os\u00a0de\u00a0edad.\u00a0\n6.\u00a0 \u00a0Es\u00a0probable\u00a0que\u00a0la\u00a0mayor\u00eda\u00a0de\u00a0las\u00a0infecciones\u00a0en\u00a0los\u00a0pacien tes\u00a0de\u00a0origen\u00a0inmigrante\u00a0se\u00a0\nhayan\u00a0producido\u00a0localmente.\u00a0\n7.\u00a0Por\u00a0primera\u00a0vez\u00a0se\u00a0ha\u00a0estimado\u00a0la\u00a0prevalencia\u00a0de\u00a0resistencias\u00a0transmitidas\u00a0y\u00a0de\u00a0subtipos\u00a0\nno\u00a0B\u00a0en\u00a0pacientes\u00a0con\u00a0infecci\u00f3n\u00a0re ciente\u00a0por\u00a0VIH\u20101\u00a0en\u00a0Catalu\u00f1a. \u00a0\n8.\u00a0No\u00a0 se\u00a0 observaron\u00a0 diferencias\u00a0 en\u00a0 las\u00a0 caracter\u00edsticas\u00a0 cl\u00ednico\u2010 epidemiol\u00f3gicas\u00a0 de\u00a0 los\u00a0\npacientes\u00a0recientemente\u00a0infectados\u00a0por\u00a0VIH\u20101\u00a0seg\u00fan\u00a0la\u00a0presencia \u00a0o\u00a0ausencia\u00a0de\u00a0resistencias\u00a0\ntransmitidas.\u00a0\n9.\u00a0Los\u00a0pacientes\u00a0recientemente\u00a0infectados\u00a0por\u00a0subtipos\u00a0de\u00a0VIH\u20101\u00a0no\u00a0B\u00a0eran\u00a0mayores,\u00a0con\u00a0\nm\u00e1s\u00a0frecuencia\u00a0se\u00a0hab\u00edan\u00a0infectado\u00a0por\u00a0transmisi\u00f3n\u00a0parenteral\u00a0y \u00a0hab\u00edan\u00a0sido\u00a0diagnosticado\u00a0en\u00a0\n\u00e1reas\u00a0de\u00a0fuera\u00a0de\u00a0Barcelona.\u00a0\n10.\u00a0Los\u00a0tests\u00a0serol\u00f3gicos\u00a0para\u00a0identificar\u00a0infecciones\u00a0reciente s\u00a0utilizados\u00a0en\u00a0los\u00a0trabajos\u00a0que\u00a0\nconforman\u00a0esta\u00a0tesis,\u00a0el\u00a0Vironosti ka\u2010LS\u00a0y\u00a0el\u00a0BED\u2010CEIA,\u00a0presentan\u00a0una\u00a0concordancia\u00a0buena.\u00a0\n11.\u00a0\u00a0Ambos\u00a0tests\u00a0presentaron\u00a0la\u00a0misma\u00a0sensibilidad,\u00a0mientras\u00a0qu e\u00a0el\u00a0test\u00a0Vironostika\u2010LS\u00a0\npresent\u00f3\u00a0una\u00a0especificidad\u00a0menor\u00a0que\u00a0el\u00a0BED\u2010CEIA.\u00a0\n12.\u00a0Se\u00a0ha\u00a0realizado\u00a0la\u00a0primera\u00a0estimaci\u00f3n\u00a0de\u00a0incidencia\u00a0de\u00a0VIH\u00a0 usando\u00a0los\u00a0tests\u00a0serol\u00f3gicos\u00a0\npara\u00a0identificar\u00a0infecciones\u00a0recientes\u00a0en\u00a0Catalu\u00f1a.\u00a0\n13.\u00a0Se\u00a0observ\u00f3\u00a0un\u00a0aumento\u00a0de\u00a0la\u00a0incidencia\u00a0de\u00a0VIH\u00a0durante\u00a0el\u00a0pe riodo\u00a0de\u00a0estudio\u00a02003\u00a0\u2013\n2008.\u00a0\n\u00a0\u00a0\n\u00a0\n\u00a0DISCUSI\u00d3N\u00a0\n 1122.\u00a0Discusi\u00f3n \u00a0global\u00a0\nY a \u00a0q u e \u00a0l a \u00a0d i s c u s i \u00f3 n \u00a0e s p e c \u00ed f i c a \u00a0p a r a \u00a0c a d a \u00a0u n o \u00a0d e \u00a0l o s \u00a0t r a b a j o s \u00a0q u e\u00a0 conforman\u00a0 esta\u00a0 tesis\u00a0 se\u00a0\nencuentra\u00a0en\u00a0los\u00a0art\u00edculos\u00a0presentados\u00a0previamente,\u00a0a\u00a0continuac i\u00f3n,\u00a0se\u00a0presenta\u00a0la\u00a0discusi\u00f3n\u00a0\nglobal\u00a0de\u00a0los\u00a0resultados\u00a0obtenid os\u00a0en\u00a0los\u00a0trabajos\u00a0de\u00a0esta\u00a0tesi s.\u00a0Dentro\u00a0de\u00a0esta\u00a0discusi\u00f3n\u00a0global\u00a0\ntambi\u00e9n\u00a0se\u00a0incluyen\u00a0los\u00a0resultad os\u00a0presentados\u00a0en\u00a0el\u00a0trabajo\u00a0an exo\u00a0de\u00a0esta\u00a0tesis.\u00a0\n\u00a0\nA\u00a0trav\u00e9s\u00a0del\u00a0proyecto\u00a0AERI,\u00a0la\u00a0identificaci\u00f3n\u00a0de\u00a0infecciones\u00a0re cientes\u00a0mediante\u00a0el\u00a0test\u00a0STARHS\u00a0\nse\u00a0introdujo\u00a0por\u00a0primera\u00a0vez\u00a0en\u00a0Espa\u00f1a\u00a0en\u00a0el\u00a0a\u00f1o\u00a02003.\u00a0Este\u00a0pro yecto\u00a0demostr\u00f3\u00a0la\u00a0viabilidad\u00a0de\u00a0\nimplementar\u00a0este\u00a0test\u00a0en\u00a0nuestro\u00a0medio,\u00a0y\u00a0permiti\u00f3\u00a0cuantificar\u00a0la\u00a0magnitud\u00a0de\u00a0las\u00a0infecciones\u00a0\nrecientes,\u00a0as\u00ed\u00a0como\u00a0describir\u00a0las\u00a0caracter\u00edsticas\u00a0de\u00a0los\u00a0pacien tes\u00a0reci\u00e9n\u00a0infectados\u00a0por\u00a0VIH\u00a0entre\u00a0\nlos\u00a0a\u00f1os\u00a02003\u00a0y\u00a02005.\u00a0Adem\u00e1s\u00a0de\u00a0poner\u00a0de\u00a0relieve\u00a0el\u00a0perfil\u00a0de\u00a0l a\u00a0poblaci\u00f3n\u00a0entre\u00a0la\u00a0cual\u00a0el\u00a0VIH\u00a0se\u00a0\ne s t \u00e1 \u00a0t r a n s m i t i e n d o , \u00a0s e \u00a0o b s e r v \u00f3 \u00a0q u e \u00a0l a s \u00a0i n f e c c i o n e s \u00a0r e c i e n t e s \u00a0s e \u00a0 detectaban\u00a0 en\u00a0 una\u00a0 mayor\u00a0\nproporci\u00f3n\u00a0en\u00a0los\u00a0centros\u00a0de\u00a0at enci\u00f3n\u00a0primaria\u00a0(21,5%),\u00a0los\u00a0cen tros\u00a0alternativos\u00a0de\u00a0cribado\u00a0\n(21,3%)\u00a0y\u00a0las\u00a0cl\u00ednicas\u00a0de\u00a0ITS\u00a0(23,4%),\u00a0respecto\u00a0a\u00a0los\u00a0hospitale s\u00a0(16,5%).\u00a0Este\u00a0hallazgo\u00a0indica\u00a0que\u00a0\nlos\u00a0pacientes\u00a0acuden\u00a0con\u00a0mayor\u00a0frecuencia\u00a0a\u00a0primaria,\u00a0cl\u00ednicas\u00a0 de\u00a0ITS\u00a0o\u00a0centros\u00a0de\u00a0cribado\u00a0\nalternativo,\u00a0poco\u00a0tiempo\u00a0despu\u00e9s \u00a0de\u00a0producirse\u00a0la\u00a0infecci\u00f3n,\u00a0mo tivados\u00a0por\u00a0una\u00a0percepci\u00f3n\u00a0de\u00a0\nriesgo\u00a0 o,\u00a0 tal\u00a0 vez,\u00a0 por\u00a0 s\u00edntomas\u00a0 relacionados\u00a0 con\u00a0 la\u00a0 primoinfecc i\u00f3n.\u00a0 Estos\u00a0 resultados\u00a0 han\u00a0\ncontribuido\u00a0a\u00a0aportar\u00a0evidencia\u00a0cient\u00edfica,\u00a0al\u00a0cuantificar\u00a0la\u00a0magnitud\u00a0de\u00a0las\u00a0infecciones\u00a0recientes,\u00a0\nseg\u00fan\u00a0 su\u00a0 distribuci\u00f3n\u00a0 en\u00a0 cada\u00a0 \u00e1mbito\u00a0 asistencial.\u00a0 Esta\u00a0 informac i\u00f3n\u00a0 est\u00e1\u00a0 contribuyendo\u00a0\nactualmente\u00a0 a\u00a0 orientar\u00a0 las\u00a0 pol\u00edt icas\u00a0 sanitarias\u00a0 sobre\u00a0 el\u00a0 diagn\u00f3 s t i c o \u00a0p r e c o z \u00a0d e l \u00a0V I H \u00a0e n \u00a0e l \u00a0\nDepartament\u00a0de\u00a0Salut\u00a0de\u00a0Catalu\u00f1a,\u00a0ayudando\u00a0a\u00a0dise\u00f1ar\u00a0intervenci ones\u00a0preventivas\u00a0adecuadas\u00a0y\u00a0\nproporcionadas,\u00a0de\u00a0acuerdo\u00a0con\u00a0la \u00a0evidencia\u00a0cient\u00edfica\u00a0reportad a\u00a0(125).\u00a0\u00a0\nGracias\u00a0a\u00a0la\u00a0experiencia\u00a0del\u00a0proyecto\u00a0AERI\u00a02003\u00a0\u2013\u00a02005,\u00a0fue\u00a0pos ible\u00a0consolidar\u00a0los\u00a0circuitos\u00a0de\u00a0\nrecogida\u00a0de\u00a0informaci\u00f3n\u00a0cl\u00ednica\u00a0y\u00a0de\u00a0muestras\u00a0de\u00a0suero\u00a0de\u00a0los\u00a0p acientes\u00a0identificados\u00a0como\u00a0\nnuevos\u00a0diagn\u00f3sticos\u00a0de\u00a0VIH.\u00a0Este\u00a0hecho,\u00a0junto\u00a0a\u00a0la\u00a0estrecha\u00a0col aboraci\u00f3n\u00a0del\u00a0CEEISCAT\u00a0con\u00a0el\u00a0\nlaboratorio\u00a0de\u00a0microbiolog\u00eda\u00a0del \u00a0Hospital\u00a0Germans\u00a0Trias\u00a0i\u00a0Pujol\u00a0en\u00a0la\u00a0aplicaci\u00f3n\u00a0de\u00a0los\u00a0tests\u00a0\nserol\u00f3gicos\u00a0para\u00a0identificar\u00a0rec i\u00e9n\u00a0infectados,\u00a0permiti\u00f3\u00a0incorporar\u00a0los\u00a0algoritmos\u00a0de\u00a0identificaci\u00f3n\u00a0\nde\u00a0infecciones\u00a0recientes\u00a0en\u00a0el\u00a0Sistema\u00a0Integrado\u00a0de\u00a0Vigilancia\u00a0 Epidemiol\u00f3gica\u00a0del\u00a0VIH\u00a0en\u00a0Catalu\u00f1a\u00a0\na\u00a0partir\u00a0del\u00a0a\u00f1o\u00a02006.\u00a0\nLa\u00a0 aplicaci\u00f3n\u00a0 rutinaria\u00a0 en\u00a0 el\u00a0 sistema\u00a0 de\u00a0 vigilancia\u00a0 epidemiol\u00f3g ica\u00a0 del\u00a0 VIH\u00a0 ha\u00a0 permitido\u00a0\nidentificar\u00a0cuales\u00a0son\u00a0los\u00a0factores\u00a0de\u00a0riesgo\u00a0asociados\u00a0a\u00a0la\u00a0in fecci\u00f3n\u00a0reciente\u00a0entre\u00a0los\u00a0nuevos\u00a0\ndiagn\u00f3sticos\u00a0de\u00a0VIH.\u00a0En\u00a0el\u00a0per\u00edodo\u00a02006\u00a0\u2010\u00a02008,\u00a0se\u00a0identificaron\u00a0como\u00a0factores\u00a0asociados\u00a0a\u00a0la\u00a0\ninfecci\u00f3n\u00a0reciente\u00a0infectarse\u00a0a\u00a0trav\u00e9s\u00a0de\u00a0relaciones\u00a0sexuales\u00a0entre\u00a0HSH\u00a0y\u00a0tener\u00a0menos\u00a0de\u00a030\u00a0a\u00f1os\u00a0\nde\u00a0 edad.\u00a0 La\u00a0 transmisi\u00f3n\u00a0 entre\u00a0 HSH\u00a0 present\u00f3\u00a0 una\u00a0 OR\u00a0 de\u00a0 2,0,\u00a0 respe cto\u00a0 a\u00a0 la\u00a0 transmisi\u00f3n\u00a0DISCUSI\u00d3N\u00a0\n -  113heterosexual.\u00a0El\u00a0mayor\u00a0riesgo\u00a0de\u00a0ser\u00a0identificado\u00a0como\u00a0reci\u00e9n\u00a0i nfectado\u00a0en\u00a0la\u00a0poblaci\u00f3n\u00a0HSH\u00a0\npuede\u00a0explicarse\u00a0por\u00a0distintos\u00a0motivos.\u00a0En\u00a0primer\u00a0lugar,\u00a0se\u00a0ha\u00a0 observado\u00a0una\u00a0mayor\u00a0frecuencia\u00a0\nde\u00a0realizaci\u00f3n\u00a0del\u00a0test\u00a0de\u00a0cribado\u00a0de\u00a0VIH\u00a0en\u00a0la\u00a0poblaci\u00f3n\u00a0HSH\u00a0( 44).\u00a0Esta\u00a0mayor\u00a0frecuencia\u00a0puede\u00a0\ns e r \u00a0d e b i d a \u00a0a \u00a0u n a \u00a0m a y o r \u00a0p e r c e p c i \u00f3 n \u00a0d e \u00a0r i e s g o \u00a0p o r \u00a0p a r t e \u00a0d e \u00a0e s t a \u00a0p oblaci\u00f3n,\u00a0 pero\u00a0 tambi\u00e9n\u00a0 a\u00a0\nintervenciones\u00a0preventivas\u00a0de\u00a0sal ud\u00a0p\u00fablica\u00a0dirigidas\u00a0espec\u00edficamente\u00a0a\u00a0esta\u00a0poblaci\u00f3n\u00a0(126),\u00a0as\u00ed\u00a0\ncomo\u00a0a\u00a0la\u00a0introducci\u00f3n\u00a0de\u00a0la\u00a0prueba\u00a0r\u00e1pida\u00a0del\u00a0VIH\u00a0(127).\u00a0Pero, \u00a0por\u00a0otro\u00a0lado,\u00a0en\u00a0los\u00a0\u00faltimos\u00a0a\u00f1os\u00a0\ntambi\u00e9n\u00a0se\u00a0ha\u00a0observado\u00a0un\u00a0aumento\u00a0de\u00a0las\u00a0conductas\u00a0de\u00a0riesgo\u00a0e ntre\u00a0los\u00a0HSH\u00a0(128\u2010130),\u00a0lo\u00a0cual\u00a0\npodr\u00eda\u00a0hacer\u00a0aumentar\u00a0la\u00a0inciden cia\u00a0de\u00a0VIH\u00a0en\u00a0este\u00a0colectivo.\u00a0\u00a0\nLa\u00a0edad\u00a0tambi\u00e9n\u00a0se\u00a0asoci\u00f3\u00a0con\u00a0la \u00a0infecci\u00f3n\u00a0reciente.\u00a0La\u00a0infecci \u00f3n\u00a0reciente\u00a0fue\u00a0menos\u00a0frecuente\u00a0\nentre\u00a0los\u00a0pacientes\u00a0mayores\u00a0de\u00a050\u00a0a\u00f1os,\u00a0con\u00a0una\u00a0OR\u00a0de\u00a00,2,\u00a0en\u00a0comparaci\u00f3n\u00a0con\u00a0los\u00a0pacientes\u00a0de\u00a0\nedad\u00a0 inferior\u00a0 a\u00a0 30\u00a0 a\u00f1os.\u00a0 Los\u00a0 individuos\u00a0 m\u00e1s\u00a0 j\u00f3venes\u00a0 tienen\u00a0 una\u00a0 mayor\u00a0 probabilidad\u00a0 de\u00a0ser\u00a0\nidentificados\u00a0 como\u00a0 reci\u00e9n\u00a0 infectados,\u00a0 ya\u00a0 que\u00a0 el\u00a0 tiempo\u00a0 que\u00a0 ocur r e \u00a0d e s d e \u00a0e l \u00a0m o m e n t o \u00a0d e \u00a0l a \u00a0\ninfecci\u00f3n\u00a0hasta\u00a0el\u00a0diagn\u00f3stico\u00a0es\u00a0m\u00e1s\u00a0corto\u00a0cuanto\u00a0m\u00e1s\u00a0joven\u00a0es \u00a0el\u00a0paciente.\u00a0Por\u00a0otro\u00a0lado,\u00a0se\u00a0ha\u00a0\nobservado\u00a0que\u00a0los\u00a0HSH\u00a0m\u00e1s\u00a0j\u00f3vene s\u00a0tienen\u00a0m\u00e1s\u00a0conductas\u00a0de\u00a0riesg o\u00a0que\u00a0los\u00a0HSH\u00a0de\u00a0m\u00e1s\u00a0edad\u00a0\n(128),\u00a0por\u00a0lo\u00a0que\u00a0la\u00a0mayor\u00a0frecuencia\u00a0de\u00a0infecci\u00f3n\u00a0reciente\u00a0pod r\u00eda\u00a0corresponderse\u00a0tambi\u00e9n\u00a0con\u00a0\nuna\u00a0mayor\u00a0incidencia\u00a0entre\u00a0l os\u00a0individuos\u00a0m\u00e1s\u00a0j\u00f3venes.\u00a0\u00a0\nLa\u00a0prevalencia\u00a0de\u00a0infecci\u00f3n\u00a0reciente\u00a0present\u00f3\u00a0una\u00a0tendencia\u00a0cre ciente\u00a0a\u00a0lo\u00a0largo\u00a0de\u00a0todo\u00a0el\u00a0\nperiodo\u00a0estudiado,\u00a0pasando\u00a0de\u00a0 19,2%\u00a0en\u00a0el\u00a0periodo\u00a02003\u00a0\u2013\u00a02005\u00a0a \u00a023,0%\u00a0en\u00a0el\u00a0periodo\u00a02006\u00a0\u2013\u00a0\n2008.\u00a0En\u00a0el\u00a0\u00faltimo\u00a0informe\u00a0epidemiol\u00f3gico\u00a0del\u00a0Sistema\u00a0Integrado\u00a0de\u00a0Vigilancia\u00a0Epidemiol\u00f3gica\u00a0de\u00a0\nla\u00a0SIDA/VIH/ITS\u00a0de\u00a0Catalu\u00f1a,\u00a0el\u00a0 porcentaje\u00a0de\u00a0infecciones\u00a0recie ntes\u00a0aument\u00f3\u00a0hasta\u00a0el\u00a032,4%\u00a0en\u00a0el\u00a0\na\u00f1o\u00a02009\u00a0(44).\u00a0Esta\u00a0tendencia\u00a0creciente\u00a0es\u00a0consistente\u00a0con\u00a0la\u00a0d isminuci\u00f3n\u00a0del\u00a0porcentaje\u00a0de\u00a0\ndiagn\u00f3stico\u00a0tard\u00edo\u00a0entre\u00a0los\u00a0nuevos\u00a0diagn\u00f3sticos\u00a0de\u00a0VIH\u00a0en\u00a0Cata lu\u00f1a:\u00a0el\u00a0porcentaje\u00a0de\u00a0pacientes\u00a0\ndiagnosticados\u00a0tard\u00edamente\u00a0disminuy\u00f3\u00a0del\u00a057,5%\u00a0en\u00a0el\u00a01998\u00a0al\u00a044 ,4%\u00a0en\u00a0el\u00a02010\u00a0y\u00a0al\u00a038,3%\u00a0en\u00a0el\u00a0\n2011\u00a0(44).\u00a0Por\u00a0otro\u00a0lado,\u00a0esta\u00a0tendencia\u00a0creciente\u00a0de\u00a0la\u00a0preval encia\u00a0de\u00a0infecci\u00f3n\u00a0reciente\u00a0tambi\u00e9n\u00a0\nse\u00a0ha\u00a0observado\u00a0en\u00a0un\u00a0estudio\u00a0realizado\u00a0en\u00a0Francia\u00a0(95),\u00a0pasand o\u00a0del\u00a024,8%\u00a0en\u00a0el\u00a02006\u00a0al\u00a027,0%\u00a0\nen\u00a0el\u00a02008.\u00a0\u00a0\nLa\u00a0prevalencia\u00a0de\u00a0infecci\u00f3n\u00a0reciente\u00a0fue\u00a0similar\u00a0en\u00a0los\u00a0pacient es\u00a0de\u00a0origen\u00a0inmigrante\u00a0(22,3%)\u00a0\ny\u00a0 en\u00a0 los\u00a0 de\u00a0 origen\u00a0 aut\u00f3ctono\u00a0 (22,9%).\u00a0 Sin\u00a0 embargo,\u00a0 la\u00a0 prevalenc ia\u00a0 de\u00a0 infecci\u00f3n\u00a0 reciente,\u00a0\nobservada\u00a0seg\u00fan\u00a0los\u00a0distintos\u00a0lugares\u00a0de\u00a0origen,\u00a0fue\u00a0mayor\u00a0en\u00a0l os\u00a0pacientes\u00a0procedentes\u00a0de\u00a0\nAm\u00e9rica\u00a0del\u00a0Sur\u00a0(27,6%)\u00a0que\u00a0en\u00a0los\u00a0pacientes\u00a0aut\u00f3ctonos\u00a0(22,9%).\u00a0En\u00a0cambio,\u00a0en\u00a0los\u00a0pacientes\u00a0\nprocedentes\u00a0de\u00a0\u00c1frica\u00a0Subsahariana\u00a0el\u00a0porcentaje\u00a0de\u00a0infecciones \u00a0recientes\u00a0fue\u00a0mucho\u00a0menor\u00a0\n(11,9%).\u00a0Estas\u00a0diferencias\u00a0radic an\u00a0en\u00a0el\u00a0modo\u00a0de\u00a0transmisi\u00f3n\u00a0de l\u00a0VIH,\u00a0ya\u00a0que\u00a0entre\u00a0los\u00a0pacientes\u00a0\nprocedentes\u00a0de\u00a0Am\u00e9rica\u00a0del\u00a0Sur\u00a0el\u00a0porcentaje\u00a0de\u00a0HSH\u00a0fue\u00a0mucho\u00a0m ayor\u00a0(67,6%) que\u00a0en\u00a0los\u00a0\npacientes\u00a0de\u00a0\u00c1frica\u00a0Subsahariana,\u00a0en\u00a0los\u00a0que\u00a0no\u00a0se\u00a0identific\u00f3\u00a0ninguna\u00a0transmisi\u00f3n\u00a0entre\u00a0HSH.\u00a0DISCUSI\u00d3N\u00a0\n 114Estos\u00a0datos\u00a0son\u00a0consistentes\u00a0con\u00a0la\u00a0informaci\u00f3n\u00a0reportada\u00a0sobre \u00a0la\u00a0epidemiolog\u00eda\u00a0de\u00a0la\u00a0infecci\u00f3n\u00a0\npor\u00a0VIH\u00a0en\u00a0ambas\u00a0\u00e1reas\u00a0(38).\u00a0\nLa\u00a0aplicaci\u00f3n\u00a0de\u00a0los\u00a0tests\u00a0serol \u00f3gicos\u00a0para\u00a0identificar\u00a0infecciones\u00a0recientes\u00a0puede\u00a0ayudar\u00a0a\u00a0\nestablecer\u00a0si\u00a0la\u00a0infecci\u00f3n\u00a0por\u00a0VIH\u00a0en\u00a0los\u00a0pacientes\u00a0de\u00a0origen\u00a0i nmigrante\u00a0fue\u00a0importada\u00a0o\u00a0bien\u00a0fue\u00a0\ncontra\u00edda\u00a0localmente.\u00a0Para\u00a0los\u00a0pacientes\u00a0de\u00a0origen\u00a0inmigrante\u00a0s e\u00a0recogi\u00f3\u00a0la\u00a0fecha\u00a0de\u00a0llegada\u00a0a\u00a0\nEspa\u00f1a.\u00a0Aunque\u00a0esta\u00a0informaci\u00f3n\u00a0no\u00a0se\u00a0pudo\u00a0obtener\u00a0en\u00a0todos\u00a0los \u00a0casos,\u00a0los\u00a0resultados\u00a0sugieren\u00a0\nque\u00a0la\u00a0mayor\u00eda\u00a0de\u00a0inmigrantes\u00a0identificados\u00a0como\u00a0reci\u00e9n\u00a0infecta dos\u00a0adquirieron\u00a0la\u00a0infecci\u00f3n\u00a0en\u00a0\nnuestro\u00a0pa\u00eds,\u00a0ya\u00a0que\u00a0llevaban\u00a0en \u00a0\u00e9l\u00a0m\u00e1s\u00a0de\u00a012\u00a0meses\u00a0cuando\u00a0recibieron\u00a0el\u00a0diagn\u00f3stico\u00a0de\u00a0VIH.\u00a0\u00a0\u00a0\nGracias\u00a0a\u00a0la\u00a0utilizaci\u00f3n\u00a0de\u00a0los\u00a0tests\u00a0serol\u00f3gicos\u00a0para\u00a0la\u00a0ident ificaci\u00f3n\u00a0de\u00a0infecciones\u00a0recientes\u00a0\npor\u00a0VIH,\u00a0para\u00a0el\u00a0periodo\u00a02003\u00a0\u2013\u00a02005,\u00a0fue\u00a0posible\u00a0realizar\u00a0el\u00a0p rimer\u00a0estudio\u00a0de\u00a0resistencias\u00a0\ntransmitidas\u00a0en\u00a0pacientes\u00a0con\u00a0infecci\u00f3n\u00a0reciente\u00a0por\u00a0VIH\u00a0en\u00a0Cat alu\u00f1a.\u00a0El\u00a0valor\u00a0estimado\u00a0de\u00a0la\u00a0\nprevalencia\u00a0(7,7%)\u00a0fue\u00a0similar\u00a0al\u00a0de\u00a0otros\u00a0estudios\u00a0europeos\u00a0(6 0,\u00a0131,\u00a0132)\u00a0y\u00a0espa\u00f1oles\u00a0(133\u2010\n135).\u00a0Es\u00a0importante\u00a0destacar\u00a0que\u00a0este\u00a0tipo\u00a0de\u00a0estudios\u00a0habitual mente\u00a0se\u00a0realizan\u00a0en\u00a0pacientes\u00a0\nque\u00a0se\u00a0acaban\u00a0de\u00a0diagnosticar\u00a0y\u00a0que\u00a0no\u00a0han\u00a0recibido\u00a0tratamiento \u00a0previo,\u00a0pero\u00a0existen\u00a0muy\u00a0pocos\u00a0\nen\u00a0los\u00a0que\u00a0la\u00a0infecci\u00f3n\u00a0se\u00a0haya\u00a0adquirido\u00a0recientemente\u00a0(131,\u00a0134).\u00a0Este\u00a0hecho\u00a0le\u00a0a\u00f1ade\u00a0valor\u00a0al\u00a0\nestudio,\u00a0ya\u00a0que\u00a0la\u00a0medida\u00a0de\u00a0la\u00a0 prevalencia\u00a0de\u00a0resistencias\u00a0tra nsmitidas\u00a0en\u00a0una\u00a0poblaci\u00f3n\u00a0es\u00a0m\u00e1s\u00a0\nprecisa\u00a0si\u00a0se\u00a0realiza\u00a0en\u00a0pacientes\u00a0con\u00a0infecci\u00f3n\u00a0reciente.\u00a0En\u00a0l os\u00a0pacientes\u00a0infectados\u00a0con\u00a0cepas\u00a0de\u00a0\nVIH\u00a0resistentes\u00a0al\u00a0tratamiento\u00a0antirretroviral,\u00a0en\u00a0ausencia\u00a0de\u00a0 presi\u00f3n\u00a0farmacol\u00f3gica,\u00a0con\u00a0el\u00a0paso\u00a0\ndel\u00a0tiempo,\u00a0las\u00a0cepas\u00a0minoritarias\u00a0 wild\u00a0type,\u00a0llegar\u00e1n\u00a0a\u00a0ser\u00a0la\u00a0cuasiespecie\u00a0mayoritaria,\u00a0ya\u00a0que\u00a0\ntienen\u00a0un\u00a0mayor\u00a0 fitness\u00a0que\u00a0las\u00a0cepas\u00a0con\u00a0resistencias\u00a0(31).\u00a0\u00a0\nLa\u00a0prevalencia\u00a0de\u00a0resistencias\u00a0transmitidas\u00a0fue\u00a0m\u00e1s\u00a0alta\u00a0en\u00a0el\u00a0 a\u00f1o\u00a02003\u00a0(10,0%)\u00a0que\u00a0en\u00a0los\u00a0\nsiguientes\u00a0a\u00f1os\u00a0del\u00a0estudio\u00a0(6, 5%\u00a0en\u00a0el\u00a02004\u00a0y\u00a06,7%\u00a0en\u00a0el\u00a02005) .\u00a0Este\u00a0descenso,\u00a0aunque\u00a0no\u00a0\nmostr\u00f3\u00a0ser\u00a0estad\u00edsticamente\u00a0sign ificativo,\u00a0es\u00a0consistente\u00a0con\u00a0l os\u00a0resultados\u00a0de\u00a0otros\u00a0estudios\u00a0\neuropeos\u00a0que\u00a0muestran\u00a0una\u00a0tendencia\u00a0temporal\u00a0decreciente\u00a0(131).\u00a0\nEn\u00a0el\u00a0mismo\u00a0periodo\u00a02003\u00a0\u2013\u00a02005,\u00a0tambi\u00e9n\u00a0se\u00a0describieron\u00a0por\u00a0pr imera\u00a0vez\u00a0en\u00a0Catalu\u00f1a\u00a0los\u00a0\nsubtipos\u00a0de\u00a0VIH\u20101\u00a0circulantes\u00a0entre\u00a0los\u00a0pacientes\u00a0reci\u00e9n\u00a0infectados.\u00a0La\u00a0prevalencia\u00a0de\u00a0subtipos\u00a0no\u00a0B\u00a0(19,2%)\u00a0fue\u00a0similar\u00a0a\u00a0los\u00a0valores\u00a0reportados\u00a0en\u00a0otros\u00a0estudio s\u00a0espa\u00f1oles\u00a0(65,\u00a0135,\u00a0136),\u00a0y\u00a0\nligeramente\u00a0superior\u00a0al\u00a0valor\u00a0reportado\u00a0en\u00a0un\u00a0estudio\u00a0de\u00a0la\u00a0coh orte\u00a0espa\u00f1ola\u00a0CoRIS\u00a0(15,2%)\u00a0(61).\u00a0\nSe\u00a0observ\u00f3\u00a0un\u00a0elevado\u00a0porcentaje\u00a0de\u00a0subtipos\u00a0no\u00a0B\u00a0entre\u00a0los\u00a0pac ientes\u00a0reci\u00e9n\u00a0infectados\u00a0de\u00a0origen\u00a0\naut\u00f3ctono.\u00a0Este\u00a0hallazgo\u00a0indica\u00a0que\u00a0los\u00a0subtipos\u00a0no\u00a0B\u00a0se\u00a0encuen tran\u00a0actualmente\u00a0circulando\u00a0entre\u00a0\nnuestra\u00a0poblaci\u00f3n\u00a0de\u00a0reci\u00e9n\u00a0infectados\u00a0por\u00a0VIH.\u00a0Aunque\u00a0no\u00a0fue\u00a0e stad\u00edsticamente\u00a0significativo,\u00a0\ntambi\u00e9n\u00a0 se\u00a0 observ\u00f3\u00a0 un\u00a0 aumento\u00a0 de\u00a0 la\u00a0 prevalencia\u00a0 de\u00a0 subtipos\u00a0 no\u00a0 B \u00a0a \u00a0l o \u00a0l a r g o \u00a0d e l \u00a0p e r i o d o \u00a0\nestudiado,\u00a0que\u00a0podr\u00eda\u00a0estar\u00a0relacionado\u00a0con\u00a0el\u00a0aumento\u00a0de\u00a0la\u00a0po blaci\u00f3n\u00a0inmigrante\u00a0en\u00a0nuestro\u00a0\nmedio\u00a0durante\u00a0este\u00a0per\u00edodo\u00a0(44).\u00a0DISCUSI\u00d3N\u00a0\n -  115En\u00a0el\u00a0periodo\u00a0de\u00a0estudio\u00a02003\u00a0\u2013\u00a02005\u00a0se\u00a0us\u00f3\u00a0el\u00a0algoritmo\u00a0STARHS\u00a0para\u00a0identificar\u00a0infecciones\u00a0\nrecientes,\u00a0mediante\u00a0el\u00a0test\u00a0Vironostika\u2010LS\u00a0(73).\u00a0El\u00a0test\u00a0Virono stika\u2010LS\u00a0dej\u00f3\u00a0de\u00a0estar\u00a0disponible\u00a0\ncomercialmente\u00a0 en\u00a0 el\u00a0 a\u00f1o\u00a0 2007,\u00a0 y\u00a0 fue\u00a0 sustituido\u00a0 por\u00a0 test\u00a0 BED\u2010CEIA\u00a0 (74).\u00a0 Ambos\u00a0 tests\u00a0 han\u00a0\ndemostrado\u00a0 tener\u00a0 una\u00a0 concordancia\u00a0 buena\u00a0 (\u03ba=0,738),\u00a0 por\u00a0 lo\u00a0 que\u00a0 s e\u00a0 puede\u00a0 afirmar\u00a0 que\u00a0 los\u00a0\nresultados\u00a0obtenidos\u00a0a\u00a0lo\u00a0largo\u00a0de\u00a0los\u00a0dos\u00a0periodos\u00a0de\u00a0estudio\u00a0 (2003\u00a0\u2013\u00a02005\u00a0y\u00a02006\u00a0\u2013\u00a02008)\u00a0son\u00a0\ncomparables.\u00a0 Aunque\u00a0 el\u00a0 test\u00a0 Vir onostika\u00a0 clasificaba\u00a0 m\u00e1s\u00a0 pacient es\u00a0 con\u00a0 SIDA\u00a0 como\u00a0 reci\u00e9n\u00a0\ninfectados,\u00a0el\u00a0hecho\u00a0de\u00a0incluir\u00a0informaci\u00f3n\u00a0cl\u00ednica\u00a0(diagn\u00f3stic o\u00a0de\u00a0SIDA\u00a0y\u00a0recuento\u00a0de\u00a0c\u00e9lulas\u00a0\nCD4+)\u00a0al\u00a0algoritmo\u00a0de\u00a0identificaci\u00f3n\u00a0de\u00a0infecciones\u00a0recientes\u00a0p ermiti\u00f3\u00a0aumentar\u00a0la\u00a0especificidad,\u00a0\nobteni\u00e9ndose\u00a0 una\u00a0 tasa\u00a0 de\u00a0 error\u00a0 del\u00a0 3,8%,\u00a0un\u00a0valor\u00a0aceptable\u00a0seg \u00fan\u00a0las\u00a0gu\u00edas\u00a0recientemente\u00a0\npublicadas\u00a0por\u00a0el\u00a0ECDC\u00a0(137)\u00a0y\u00a0la\u00a0OMS\u00a0(89).\u00a0\nEl\u00a0uso\u00a0de\u00a0algoritmos\u00a0serol\u00f3gicos \u00a0para\u00a0la\u00a0identificaci\u00f3n\u00a0de\u00a0infecciones\u00a0recientes\u00a0en\u00a0un\u00a0sistema\u00a0\npoblacional\u00a0de\u00a0vigilancia\u00a0epidemiol\u00f3gica\u00a0del\u00a0VIH\u00a0permite\u00a0estimar\u00a0la\u00a0incidencia\u00a0de\u00a0manera\u00a0menos\u00a0\ncostosa,\u00a0respecto\u00a0los\u00a0estudios\u00a0de\u00a0cohortes\u00a0en\u00a0pacientes\u00a0seroneg ativos.\u00a0En\u00a0nuestro\u00a0medio,\u00a0se\u00a0\nestim\u00f3\u00a0la\u00a0incidencia\u00a0de\u00a0VIH\u00a0para\u00a0el\u00a0periodo\u00a02003\u00a0\u2013\u00a02008\u00a0y\u00a0el\u00a0va lor\u00a0obtenido\u00a0fue\u00a0de\u00a00,46\u00a0nuevas\u00a0\ninfecciones\u00a0por\u00a0cada\u00a0100\u00a0personas/a\u00f1o.\u00a0Se\u00a0observ\u00f3\u00a0que\u00a0la\u00a0incide ncia\u00a0se\u00a0manten\u00eda\u00a0estable\u00a0en\u00a0el\u00a0\nperiodo\u00a02003\u00a0\u2013\u00a02005,\u00a0y\u00a0present\u00f3\u00a0una\u00a0ligera\u00a0tendencia\u00a0al\u00a0aumento \u00a0durante\u00a0el\u00a0periodo\u00a02006\u00a0\u2013\u00a0\n2008;\u00a0pasando\u00a0de\u00a00,31,\u00a0en\u00a0el\u00a0a \u00f1o\u00a02005,\u00a0a\u00a00,73,\u00a0en\u00a0el\u00a0a\u00f1o\u00a02008.\u00a0 Este\u00a0aumento\u00a0es\u00a0consistente\u00a0con\u00a0\nlos\u00a0resultados\u00a0de\u00a0otros\u00a0estudios\u00a0realizados\u00a0en\u00a0nuestro\u00a0contexto \u00a0(44),\u00a0aunque\u00a0deber\u00eda\u00a0confirmarse\u00a0\ncon\u00a0estimaciones\u00a0que\u00a0tengan\u00a0en\u00a0cuenta\u00a0el\u00a0patr\u00f3n\u00a0de\u00a0realizaci\u00f3n\u00a0 de\u00a0la\u00a0prueba\u00a0del\u00a0VIH\u00a0de\u00a0las\u00a0\npersonas\u00a0identificadas\u00a0como\u00a0reci\u00e9n\u00a0infectadas.\u00a0\n3.\u00a0Limitaciones \u00a0\nLos\u00a0estudios\u00a0que\u00a0conforman\u00a0esta\u00a0tesis\u00a0doctoral\u00a0presentan\u00a0cierta s\u00a0limitaciones.\u00a0En\u00a0relaci\u00f3n\u00a0con\u00a0\nlas\u00a0 limitaciones\u00a0 propias\u00a0 de\u00a0 los\u00a0 TRIs,\u00a0 (comentadas\u00a0 en\u00a0 el\u00a0 apartad o\u00a0 correspondiente\u00a0 de\u00a0 la\u00a0\nintroducci\u00f3n),\u00a0 se\u00a0 ha\u00a0 intentado\u00a0 minimizar\u00a0 el\u00a0 posible\u00a0 error\u00a0 de\u00a0 clasificaci\u00f3n\u00a0 de\u00a0 muestras\u00a0\ncorrespondientes\u00a0 a\u00a0 pacientes\u00a0 con\u00a0 infecci\u00f3n\u00a0 avanzada\u00a0 como\u00a0 infecc iones\u00a0 recientes\u00a0 usando\u00a0 la\u00a0\ninformaci\u00f3n\u00a0cl\u00ednica\u00a0y\u00a0de\u00a0laboratorio\u00a0disponible.\u00a0\u00a0\nEl\u00a0circuito\u00a0del\u00a0diagn\u00f3stico\u00a0de\u00a0VIH\u00a0frecuentemente\u00a0se\u00a0inicia\u00a0en\u00a0 el\u00a0centro\u00a0de\u00a0cribado\u00a0alternativo,\u00a0\ny,\u00a0en\u00a0caso\u00a0de\u00a0resultado\u00a0positivo\u00a0en\u00a0la\u00a0prueba\u00a0de\u00a0cribado,\u00a0el\u00a0pa ciente\u00a0es\u00a0derivado\u00a0al\u00a0hospital\u00a0para\u00a0\nconfirmar\u00a0el\u00a0diagn\u00f3stico.\u00a0En\u00a0nuestro\u00a0estudio\u00a0han\u00a0participado\u00a0ce ntros\u00a0de\u00a0cribado\u00a0y\u00a0hospitales,\u00a0de\u00a0\nmanera\u00a0 que\u00a0 es\u00a0 posible\u00a0 haber\u00a0 reclu t a d o \u00a0u n \u00a0m i s m o \u00a0p a c i e n t e \u00a0a \u00a0t r a v \u00e9 s\u00a0 del\u00a0 centro\u00a0 de\u00a0 cribado\u00a0\nalternativo\u00a0y\u00a0tambi\u00e9n\u00a0a\u00a0trav\u00e9s\u00a0d el\u00a0hospital.\u00a0Para\u00a0evitar\u00a0tener\u00a0 pacientes\u00a0duplicados\u00a0en\u00a0los\u00a0an\u00e1lisis,\u00a0\nse\u00a0 realizaron\u00a0 b\u00fasqueda\u00a0 de\u00a0 duplicados\u00a0 por\u00a0 sexo\u00a0 y\u00a0 fecha\u00a0 de\u00a0 nacimi ento,\u00a0 y\u00a0 en\u00a0 aquellos\u00a0 casos\u00a0\ndetectados\u00a0como\u00a0posibles\u00a0duplicados\u00a0se\u00a0consult\u00f3\u00a0con\u00a0el\u00a0hospital \u00a0para\u00a0confirmar\u00a0que\u00a0se\u00a0trataba\u00a0\nrealmente\u00a0de\u00a0un\u00a0duplicado\u00a0y,\u00a0en\u00a0ese\u00a0caso,\u00a0se\u00a0exclu\u00eda\u00a0del\u00a0an\u00e1lis is.\u00a0\u00a0DISCUSI\u00d3N\u00a0\n 116En\u00a0el\u00a0primer\u00a0art\u00edculo,\u00a0no\u00a0se\u00a0pudo\u00a0obtener\u00a0informaci\u00f3n\u00a0cl\u00ednico\u2010e pidemiol\u00f3gica\u00a0de\u00a0los\u00a0pacientes\u00a0\nidentificados\u00a0con\u00a0infecci\u00f3n\u00a0cr\u00f3nica,\u00a0por\u00a0lo\u00a0que\u00a0no\u00a0se\u00a0pudieron\u00a0 identificar\u00a0los\u00a0factores\u00a0asociados\u00a0a\u00a0\nla\u00a0infecci\u00f3n\u00a0reciente.\u00a0Por\u00a0otro\u00a0lado,\u00a0de\u00a0las\u00a0muestras\u00a0recogidas \u00a0por\u00a0los\u00a0laboratorios\u00a0de\u00a0atenci\u00f3n\u00a0\nprimaria\u00a0fue\u00a0muy\u00a0dif\u00edcil\u00a0recuperar\u00a0informaci\u00f3n\u00a0epidemiol\u00f3gica.\u00a0 A\u00a0partir\u00a0de\u00a0esa\u00a0experiencia,\u00a0para\u00a0\nel\u00a0siguiente\u00a0estudio,\u00a0se\u00a0limit\u00f3\u00a0la\u00a0participaci\u00f3n\u00a0a\u00a0los\u00a0centros\u00a0 en\u00a0los\u00a0que\u00a0se\u00a0pod\u00eda\u00a0asegurar\u00a0la\u00a0\nobtenci\u00f3n\u00a0de\u00a0la\u00a0informaci\u00f3n\u00a0cl\u00ednico\u2010epidemiol\u00f3gica\u00a0del\u00a0paciente .\u00a0A\u00fan\u00a0as\u00ed,\u00a0fue\u00a0dif\u00edcil\u00a0de\u00a0obtener\u00a0\nalgunas\u00a0de\u00a0las\u00a0variables\u00a0de\u00a0la\u00a0encuesta\u00a0cl\u00ednico\u2010epidemiol\u00f3gica, \u00a0como\u00a0la\u00a0fecha\u00a0de\u00a0llegada\u00a0a\u00a0nuestro\u00a0\npa\u00eds,\u00a0en\u00a0el\u00a0caso\u00a0de\u00a0los\u00a0pacientes\u00a0inmigrantes,\u00a0o\u00a0el\u00a0diagn\u00f3stico\u00a0previo\u00a0de\u00a0infecciones\u00a0de\u00a0transmisi\u00f3n\u00a0\nsexual.\u00a0\nEn\u00a0el\u00a0segundo\u00a0art\u00edculo,\u00a0a\u00a0pesar\u00a0de\u00a0haber\u00a0identificado\u00a0un\u00a0n\u00famero \u00a0considerable\u00a0de\u00a0infecciones\u00a0\nrecientes,\u00a0s\u00f3lo\u00a0se\u00a0pudo\u00a0obtener\u00a0el\u00a0genotipado\u00a0de\u00a0menos\u00a0de\u00a0la\u00a0mi tad\u00a0de\u00a0\u00e9stas.\u00a0Esto\u00a0es\u00a0debido\u00a0a\u00a0que\u00a0\ne n \u00a0m u c h o s \u00a0c a s o s \u00a0n o \u00a0s e \u00a0p u d o \u00a0a s e g u r a r \u00a0q u e \u00a0e l \u00a0p a c i e n t e \u00a0n o \u00a0h a b \u00ed a \u00a0r e cibido\u00a0 tratamiento\u00a0\nantirretroviral\u00a0previo,\u00a0y\u00a0se\u00a0tuvieron\u00a0que\u00a0excluir\u00a0del\u00a0estudio.\u00a0 En\u00a0relaci\u00f3n\u00a0al\u00a0genotipado\u00a0de\u00a0las\u00a0\nmuestras,\u00a0 se\u00a0 usaron\u00a0 t\u00e9cnicas\u00a0 convencionales\u00a0 de\u00a0 secuenciaci\u00f3n,\u00a0 q ue\u00a0 pueden\u00a0 infraestimar\u00a0 las\u00a0\nvariantes\u00a0de\u00a0VIH\u20101\u00a0minoritarias.\u00a0\u00a0\nPara\u00a0el\u00a0estudio\u00a0de\u00a0la\u00a0comparaci\u00f3n\u00a0de\u00a0los\u00a0dos\u00a0TRIs,\u00a0hubiera\u00a0sido \u00a0deseable\u00a0poder\u00a0disponer\u00a0de\u00a0\nm\u00e1s\u00a0muestras\u00a0con\u00a0informaci\u00f3n\u00a0cl\u00ednica\u00a0y\u00a0de\u00a0laboratorio\u00a0que\u00a0nos\u00a0a seguraran\u00a0su\u00a0clasificaci\u00f3n\u00a0como\u00a0\ninfecciones\u00a0recientes,\u00a0cr\u00f3nica s\u00a0o\u00a0enfermedad\u00a0avanzada.\u00a0\nUna\u00a0limitaci\u00f3n\u00a0com\u00fan\u00a0a\u00a0todos\u00a0los\u00a0estudios,\u00a0es\u00a0la\u00a0representatividad\u00a0de\u00a0la\u00a0muestra.\u00a0Para\u00a0poder\u00a0\nextrapolar\u00a0 con\u00a0 total\u00a0confianza\u00a0los\u00a0resultados\u00a0a\u00a0toda\u00a0la\u00a0poblaci \u00f3n\u00a0de\u00a0nuevos\u00a0diagn\u00f3sticos,\u00a0se\u00a0\ndeber\u00eda\u00a0poder\u00a0asegurar\u00a0que\u00a0los\u00a0pacientes\u00a0incluidos\u00a0en\u00a0los\u00a0estud ios\u00a0son\u00a0representativos\u00a0de\u00a0todos\u00a0\nlos\u00a0nuevos\u00a0diagn\u00f3sticos\u00a0de\u00a0VIH\u00a0d e\u00a0Catalu\u00f1a.\u00a0Para\u00a0ello\u00a0se\u00a0deber\u00eda\u00a0dise\u00f1ar\u00a0un\u00a0muestreo\u00a0asegurando\u00a0\nque\u00a0sea\u00a0representativo\u00a0de\u00a0toda\u00a0la\u00a0poblaci\u00f3n\u00a0de\u00a0nuevos\u00a0diagn\u00f3sti cos.\u00a0La\u00a0recogida\u00a0de\u00a0muestras\u00a0fue\u00a0\nrealizada\u00a0 por\u00a0 los\u00a0 laboratorios\u00a0 que\u00a0 decidieron,\u00a0 de\u00a0 manera\u00a0 volunt aria,\u00a0 participar\u00a0 en\u00a0 nuestros\u00a0\nestudios.\u00a0Aunque\u00a0no\u00a0es\u00a0posible\u00a0asegurar\u00a0que\u00a0la\u00a0muestra\u00a0sea\u00a0repr esentativa\u00a0de\u00a0toda\u00a0la\u00a0poblaci\u00f3n\u00a0\nde\u00a0nuevos\u00a0diagn\u00f3sticos\u00a0de\u00a0VIH,\u00a0s\u00ed\u00a0se\u00a0puede\u00a0decir\u00a0que\u00a0en\u00a0el\u00a0estu dio\u00a0AERI\u00a02003\u20102005\u00a0participaron\u00a0\ndiferentes\u00a0tipos\u00a0de\u00a0centros\u00a0(atenci\u00f3n\u00a0primaria,\u00a0hospitales,\u00a0cen tros\u00a0de\u00a0cribado\u00a0alternativos\u00a0y\u00a0una\u00a0\ncl\u00ednica\u00a0 de\u00a0 ITS),\u00a0 y\u00a0 en\u00a0 el\u00a0 AERI\u00a0 2006\u20102008\u00a0 el\u00a0 n\u00famero\u00a0 de\u00a0 pacientes\u00a0 incluidos\u00a0 representa\u00a0\naproximadamente\u00a0 un\u00a0 50%\u00a0 del\u00a0 total\u00a0 de\u00a0 nuevos\u00a0 diagn\u00f3sticos\u00a0 reporta dos\u00a0 en\u00a0 Catalu\u00f1a\u00a0 para\u00a0 el\u00a0\nperiodo\u00a0estudio.\u00a0Adem\u00e1s,\u00a0aunque\u00a0la\u00a0mayor\u00eda\u00a0de\u00a0pacientes\u00a0incluid os\u00a0provienen\u00a0de\u00a0los\u00a0centros\u00a0\nsituados\u00a0en\u00a0Barcelona\u00a0y\u00a0su\u00a0\u00e1mbito\u00a0metropolitano,\u00a0tambi\u00e9n\u00a0partic ipan\u00a0algunos\u00a0centros\u00a0situados\u00a0en\u00a0\ndistintos\u00a0puntos\u00a0de\u00a0Catalu\u00f1a.\u00a0\u00a0\n\u00a0\u00a0DISCUSI\u00d3N\u00a0\n -  1174.\u00a0Conclusi\u00f3n\u00a0 final\u00a0\u00a0\nD e s p u \u00e9 s \u00a0d e \u00a0m \u00e1 s \u00a0d e \u00a03 0 \u00a0a \u00f1 o s \u00a0d e s d e \u00a0l o s \u00a0p r i m e r o s \u00a0c a s o s \u00a0d e \u00a0S I D A , \u00a0l a \u00a0 investigaci\u00f3n\u00a0 cl\u00ednica\u00a0 y\u00a0\nbiol\u00f3gica\u00a0ha\u00a0logrado\u00a0el\u00a0desarrollo\u00a0de\u00a0f\u00e1rmacos\u00a0que\u00a0han\u00a0reducido\u00a0la\u00a0mortalidad\u00a0y\u00a0mejorado\u00a0la\u00a0\ncalidad\u00a0de\u00a0vida\u00a0de\u00a0las\u00a0personas\u00a0infectadas\u00a0por\u00a0VIH.\u00a0A\u00fan\u00a0as\u00ed,\u00a0ha y\u00a0que\u00a0tener\u00a0presente\u00a0que\u00a0las\u00a0\npersonas\u00a0infectadas\u00a0por\u00a0VIH\u00a0necesitan\u00a0seguir\u00a0los\u00a0tratamientos\u00a0a \u00a0lo\u00a0largo\u00a0de\u00a0toda\u00a0su\u00a0vida,\u00a0por\u00a0lo\u00a0\nque\u00a0 puede\u00a0 ser\u00a0 considerada\u00a0 como\u00a0 u na\u00a0 enfermedad\u00a0 cr\u00f3nica.\u00a0 Adem\u00e1s\u00a0 d e\u00a0 los\u00a0 posibles\u00a0 efectos\u00a0\nadversos\u00a0 de\u00a0 los\u00a0 tratamientos,\u00a0 es \u00a0 importante\u00a0 tener\u00a0 en\u00a0 considerac i \u00f3 n \u00a0e l \u00a0e l e v a d o \u00a0c o s t e \u00a0d e \u00a0l o s \u00a0\nmismos,\u00a0por\u00a0lo\u00a0que\u00a0la\u00a0prevenci\u00f3n\u00a0de\u00a0la\u00a0transmisi\u00f3n\u00a0del\u00a0VIH\u00a0debe \u00a0ser\u00a0considerada\u00a0como\u00a0parte\u00a0\nfundamental\u00a0 en\u00a0 la\u00a0 deseable\u00a0 erradicaci\u00f3n\u00a0 de\u00a0 la\u00a0 epidemia.\u00a0 En\u00a0 este \u00a0s e n t i d o , \u00a0e l \u00a0d i s e \u00f1 o \u00a0d e \u00a0l a s \u00a0\nactividades\u00a0preventivas\u00a0debe\u00a0ser\u00a0apropiado\u00a0para\u00a0incidir\u00a0en\u00a0aque llas\u00a0poblaciones\u00a0en\u00a0las\u00a0que\u00a0el\u00a0\nvirus\u00a0se\u00a0est\u00e1\u00a0transmitiendo\u00a0actualmente.\u00a0La\u00a0identificaci\u00f3n\u00a0de\u00a0i nfecciones\u00a0recientes\u00a0mediante\u00a0TRIs\u00a0\npermite\u00a0obtener\u00a0una\u00a0descripci\u00f3n\u00a0precisa\u00a0de\u00a0los\u00a0patrones\u00a0de\u00a0tran smisi\u00f3n\u00a0actual\u00a0del\u00a0virus.\u00a0Esta\u00a0\ninformaci\u00f3n,\u00a0una\u00a0vez\u00a0incorporada\u00a0a\u00a0las\u00a0estrategias\u00a0de\u00a0prevenci\u00f3n,\u00a0puede\u00a0evitar\u00a0que\u00a0se\u00a0produzcan\u00a0\nnuevas\u00a0infecciones. \u00a0\nLa\u00a0monitorizaci\u00f3n\u00a0de\u00a0las\u00a0infecciones\u00a0recientes\u00a0por\u00a0VIH\u00a0en\u00a0Catal u\u00f1a,\u00a0mediante\u00a0la\u00a0aplicaci\u00f3n\u00a0de\u00a0\nlos\u00a0 algoritmos\u00a0 para\u00a0 identificar\u00a0 infecciones\u00a0 recientes,\u00a0 ha\u00a0 permi tido\u00a0 entender\u00a0 los\u00a0 patrones\u00a0 de\u00a0\ntransmisi\u00f3n\u00a0 del\u00a0 VIH\u00a0 actuales.\u00a0 Esta\u00a0 informaci\u00f3n\u00a0 debe\u00a0 contribuir\u00a0 a\u00a0 dirigir\u00a0 los\u00a0 esfuerzos\u00a0 en\u00a0\nprevenci\u00f3n\u00a0de\u00a0un\u00a0modo\u00a0m\u00e1s\u00a0efectiv o,\u00a0con\u00a0el\u00a0objetivo\u00a0final\u00a0de\u00a0di sminuir\u00a0la\u00a0transmisi\u00f3n\u00a0del\u00a0VIH.\u00a0Por\u00a0\ntanto,\u00a0es\u00a0necesario\u00a0mantener\u00a0y\u00a0consolidar\u00a0la\u00a0monitorizaci\u00f3n\u00a0de\u00a0 las\u00a0infecciones\u00a0recientes\u00a0en\u00a0los\u00a0\nsistemas\u00a0de\u00a0vigilancia\u00a0del\u00a0VIH,\u00a0siguiendo\u00a0las\u00a0recomendaciones\u00a0t \u00e9cnicas\u00a0proporcionadas\u00a0por\u00a0el\u00a0\nECDC\u00a0(137)\u00a0y\u00a0la\u00a0OMS\u00a0(89),\u00a0para\u00a0poder\u00a0ofrecer\u00a0resultados\u00a0v\u00e1lidos \u00a0y\u00a0comparables\u00a0a\u00a0nivel\u00a0europeo\u00a0y\u00a0\nmundial.\u00a0\n\u00a0\u00a0\n\u00a0\n\u00a0\n\u00a0\u00a0\u00a0\n\u00a0\u00a0\n 118 \n -  119\u00a0\n\u00a0\n\u00a0\n\u00a0\n\u00a0\u00a0\n\u00a0\n\u00a0\u00a0\n\u00a0\n\u00a0\n\u00a0\n\u00a0\u00a0\n\u00a0\nCONCLUSIONES \u00a0\n\u00a0\n\u00a0\u00a0\u00a0\u00a0\n\u00a0\n\u00a0\u00a0\u00a0\u00a0\n\u00a0\u00a0\n 120CONCLUSIONES\u00a0\n -  121\uf0b7\uf020Los\u00a0resultados\u00a0de\u00a0la\u00a0aplicaci\u00f3n\u00a0de\u00a0algoritmos\u00a0de\u00a0identificaci\u00f3n \u00a0de\u00a0infecciones\u00a0recientes\u00a0\nbasados\u00a0en\u00a0t\u00e9cnicas\u00a0de\u00a0laboratorio\u00a0en\u00a0\u00a0los\u00a0nuevos\u00a0diagn\u00f3sticos\u00a0 de\u00a0VIH\u00a0han\u00a0mostrado\u00a0la\u00a0\nviabilidad\u00a0y\u00a0utilidad\u00a0de\u00a0la\u00a0introducci\u00f3n\u00a0de\u00a0esta\u00a0t\u00e9cnica\u00a0en\u00a0nue stro\u00a0medio,\u00a0y\u00a0constituyen\u00a0la\u00a0\nprimera\u00a0experiencia\u00a0realizada\u00a0en \u00a0Espa\u00f1a\u00a0desde\u00a0su\u00a0introducci\u00f3n\u00a0e n\u00a0el\u00a0a\u00f1o\u00a02003.\u00a0\n\uf0b7\uf020El\u00a0estudio\u00a0piloto\u00a0realizado\u00a0en\u00a0c entros\u00a0espa\u00f1oles\u00a0durante\u00a0el\u00a0per \u00edodo\u00a02003\u20102005\u00a0estableci\u00f3\u00a0\nque\u00a0la\u00a0prevalencia\u00a0de\u00a0infecci\u00f3n\u00a0reciente\u00a0era\u00a0del\u00a019,2%,\u00a0una\u00a0estimaci\u00f3n\u00a0muy\u00a0similar\u00a0a\u00a0la\u00a0\nreportada\u00a0en\u00a0otros\u00a0estudios\u00a0real izados\u00a0en\u00a0Francia\u00a0o\u00a0Estados\u00a0Unidos.\u00a0\n\uf0b7\uf020Este\u00a0estudio\u00a0tambi\u00e9n\u00a0permiti\u00f3\u00a0describir\u00a0el\u00a0perfil\u00a0epidemiol\u00f3gico\u00a0de\u00a0las\u00a0personas\u00a0reci\u00e9n\u00a0\ninfectadas,\u00a0siendo\u00a0\u00e9stas\u00a0mayoritariamente\u00a0hombres\u00a0(79,8%),\u00a0de\u00a0origen\u00a0espa\u00f1ol\u00a0(73,5%),\u00a0\ndel\u00a0grupo\u00a0de\u00a0hombres\u00a0que\u00a0tienen\u00a0sexo\u00a0con\u00a0hombres\u00a0(62,5%)\u00a0y\u00a0con\u00a0 una\u00a0edad\u00a0mediana\u00a0de\u00a0\n33\u00a0a\u00f1os.\u00a0\n\uf0b7\uf020Las\u00a0diferencias\u00a0observadas\u00a0en\u00a0la \u00a0prevalencia\u00a0de\u00a0infecci\u00f3n\u00a0reciente\u00a0seg\u00fan\u00a0el\u00a0tipo\u00a0de\u00a0centro,\u00a0\nsugirieron\u00a0 que\u00a0 los\u00a0 individuos\u00a0 infectados\u00a0 recientemente\u00a0 acuden\u00a0 a \u00a0 atenci\u00f3n\u00a0 primaria\u00a0\n(21,5%),\u00a0cl\u00ednicas\u00a0de\u00a0infecciones\u00a0de\u00a0Transmisi\u00f3n\u00a0Sexual\u00a0(23,4%)\u00a0 y\u00a0centros\u00a0de\u00a0cribado\u00a0\nalternativos\u00a0(21,3%)\u00a0con\u00a0mayor\u00a0frecuencia\u00a0que\u00a0a\u00a0los\u00a0hospitales\u00a0 (16,5%),\u00a0motivados\u00a0por\u00a0\nuna\u00a0 percepci\u00f3n\u00a0 de\u00a0 riesgo\u00a0 o,\u00a0 tal\u00a0 vez,\u00a0 por\u00a0 presentar\u00a0 s\u00edntomas\u00a0 rel acionados\u00a0 con\u00a0 la\u00a0\nprimoinfecci\u00f3n. \u00a0\n\uf0b7\uf020\u00a0El\u00a0dise\u00f1o\u00a0y\u00a0consolidaci\u00f3n\u00a0de\u00a0circuitos\u00a0de\u00a0recogida\u00a0de\u00a0informac i\u00f3n\u00a0y\u00a0de\u00a0muestras\u00a0de\u00a0los\u00a0\nnuevos\u00a0 diagn\u00f3sticos\u00a0 de\u00a0 VIH\u00a0 que\u00a0 se\u00a0 estableci\u00f3\u00a0 entre\u00a0 los\u00a0 centros\u00a0 participantes\u00a0 y\u00a0 los\u00a0\nlaboratorios\u00a0 ha\u00a0 permitido\u00a0 incorp orar\u00a0 los\u00a0 algoritmos\u00a0 de\u00a0 identifi caci\u00f3n\u00a0 de\u00a0 infecciones\u00a0\nrecientes\u00a0en\u00a0el\u00a0Sistema\u00a0Integrado\u00a0de\u00a0Vigilancia\u00a0Epidemiol\u00f3gica\u00a0 del\u00a0VIH\u00a0en\u00a0Catalu\u00f1a\u00a0a\u00a0\npartir\u00a0del\u00a0a\u00f1o\u00a02006.\u00a0\n\uf0b7\uf020Su\u00a0 aplicaci\u00f3n\u00a0 rutinaria\u00a0 en\u00a0 un\u00a0 sistema\u00a0 nacional\u00a0 de\u00a0 vigilancia\u00a0 ep idemiol\u00f3gica\u00a0 del\u00a0 VIH\u00a0\npermite,\u00a0entre\u00a0otros\u00a0aspectos,\u00a0identificar\u00a0cuales\u00a0son\u00a0los\u00a0facto res\u00a0de\u00a0riesgo\u00a0asociados\u00a0a\u00a0la\u00a0\ninfecci\u00f3n\u00a0reciente\u00a0entre\u00a0los\u00a0n uevos\u00a0diagn\u00f3sticos\u00a0de\u00a0VIH.\u00a0\n\uf0b7\uf020En\u00a0el\u00a0per\u00edodo\u00a02006\u20102008,\u00a0entre\u00a0los\u00a0hombres\u00a0que\u00a0tienen\u00a0sexo\u00a0con\u00a0 hombres,\u00a0el\u00a031,1%\u00a0se\u00a0\nidentificaron\u00a0como\u00a0infecciones\u00a0recientes,\u00a0siendo\u00a0este\u00a0porcentaje\u00a0mayor\u00a0que\u00a0en\u00a0grupo\u00a0se\u00a0las\u00a0transmisiones\u00a0heterosexuales\u00a0(15,4%)\u00a0y\u00a0en\u00a0el\u00a0de\u00a0\u00a0las\u00a0produc idas\u00a0a\u00a0trav\u00e9s\u00a0del\u00a0uso\u00a0de\u00a0\ndrogas\u00a0por\u00a0v\u00eda\u00a0parenteral\u00a0(13,2%). \u00a0\n\uf0b7\uf020La\u00a0 adquisici\u00f3n\u00a0 de\u00a0 la\u00a0 infecci\u00f3n\u00a0 entre\u00a0 los\u00a0 hombres\u00a0 que\u00a0 tienen\u00a0 sex o\u00a0 con\u00a0 hombres\u00a0 se\u00a0\nidentific\u00f3\u00a0como\u00a0un\u00a0factor\u00a0asocia do\u00a0a\u00a0la\u00a0infecci\u00f3n\u00a0reciente,\u00a0pre sentando\u00a0un\u00a0riesgo\u00a0dos\u00a0veces\u00a0\nmayor\u00a0respecto\u00a0al\u00a0grupo\u00a0de\u00a0transmisi\u00f3n\u00a0heterosexual. \u00a0CONCLUSIONES\u00a0\n 122\uf0b7\uf020La\u00a0asociaci\u00f3n\u00a0observada\u00a0entre\u00a0infecci\u00f3n\u00a0reciente\u00a0y\u00a0transmisi\u00f3n\u00a0 entre\u00a0los\u00a0hombres\u00a0que\u00a0\ntienen\u00a0sexo\u00a0con\u00a0hombres\u00a0sugiere\u00a0que\u00a0la\u00a0incidencia\u00a0de\u00a0VIH\u00a0es\u00a0may or\u00a0en\u00a0este\u00a0grupo,\u00a0aunque\u00a0\ntambi\u00e9n\u00a0puede\u00a0explicarse\u00a0por\u00a0una\u00a0mayor\u00a0frecuencia\u00a0de\u00a0realizaci\u00f3 n\u00a0del\u00a0test\u00a0de\u00a0cribado\u00a0\npara\u00a0la\u00a0detecci\u00f3n\u00a0de\u00a0la\u00a0infecci\u00f3n\u00a0por\u00a0VIH.\u00a0\u00a0\n\uf0b7\uf020La\u00a0prevalencia\u00a0de\u00a0infecci\u00f3n\u00a0reciente\u00a0en\u00a0el\u00a0periodo\u00a02006\u20102008\u00a0fu e\u00a0del\u00a023,0%,\u00a0siendo\u00a0el\u00a0\naumento\u00a0 observado\u00a0 respecto\u00a0 al\u00a0 periodo\u00a0 anterior\u00a0 consistente\u00a0 con\u00a0 la\u00a0 disminuci\u00f3n\u00a0 del\u00a0\nporcentaje\u00a0de\u00a0diagn\u00f3stico\u00a0tard\u00edo\u00a0entre\u00a0los\u00a0nuevos\u00a0diagn\u00f3sticos\u00a0 de\u00a0VIH\u00a0en\u00a0Catalu\u00f1a\u00a0para\u00a0el\u00a0\nmismo\u00a0periodo.\u00a0\n\uf0b7\uf020\u00a0La\u00a0infecci\u00f3n\u00a0reciente\u00a0fue\u00a0m\u00e1s\u00a0frecuente\u00a0en\u00a0hombres\u00a0que\u00a0en\u00a0muje res\u00a0(24,6%\u00a0vs.\u00a016,8%),\u00a0y\u00a0\nmucho\u00a0mayor\u00a0en\u00a0los\u00a0individuos\u00a0menores\u00a0de\u00a030\u00a0a\u00f1os\u00a0(28,4%)\u00a0que\u00a0en \u00a0los\u00a0individuos\u00a0de\u00a0m\u00e1s\u00a0\nde\u00a050\u00a0a\u00f1os\u00a0(7,8%). \u00a0\n\uf0b7\uf020La\u00a0prevalencia\u00a0de\u00a0infecci\u00f3n\u00a0reciente\u00a0fue\u00a0mayor\u00a0en\u00a0los\u00a0pacientes \u00a0procedentes\u00a0de\u00a0Am\u00e9rica\u00a0\ndel\u00a0Sur\u00a0(27,6%)\u00a0que\u00a0en\u00a0los\u00a0pacientes\u00a0de\u00a0origen\u00a0aut\u00f3ctono\u00a0(22,9% ).\u00a0En\u00a0cambio,\u00a0en\u00a0los\u00a0\npacientes\u00a0procedentes\u00a0de\u00a0\u00c1frica\u00a0 Sub\u2010sahariana\u00a0la\u00a0prevalencia\u00a0de \u00a0infecci\u00f3n\u00a0reciente\u00a0fue\u00a0\nmucho\u00a0menor\u00a0(11,9%).\u00a0\n\uf0b7\uf020Las\u00a0diferencias\u00a0en\u00a0las\u00a0prevalencias\u00a0de\u00a0infecci\u00f3n\u00a0reciente\u00a0obser vadas,\u00a0seg\u00fan\u00a0el\u00a0origen,\u00a0\nradican\u00a0 en\u00a0 el\u00a0 grupo\u00a0 de\u00a0 transmisi\u00f3n,\u00a0 ya\u00a0 que\u00a0 el\u00a0 porcentaje\u00a0 de\u00a0 HSH \u00a0f u e \u00a0m a y o r \u00a0e n \u00a0l o s \u00a0\npacientes\u00a0de\u00a0Am\u00e9rica\u00a0del\u00a0Sur\u00a0(67, 6%)\u00a0que\u00a0en\u00a0los\u00a0pacientes\u00a0de\u00a0\u00c1f rica\u00a0Subsahariana\u00a0(0,0%). \u00a0\n\uf0b7\uf020L a \u00a0a p l i c a c i \u00f3 n \u00a0d e \u00a0l o s \u00a0t e s t s \u00a0s e r o l \u00f3gicos\u00a0 para\u00a0 identificar\u00a0 infecci ones\u00a0 recientes\u00a0 por\u00a0 VIH\u00a0\ncombinada\u00a0con\u00a0la\u00a0informaci\u00f3n\u00a0epidemiol\u00f3gica\u00a0adecuada\u00a0permite\u00a0es clarecer\u00a0si\u00a0la\u00a0infecci\u00f3n\u00a0\npor\u00a0 VIH\u00a0 en\u00a0 los\u00a0 pacientes\u00a0 de\u00a0 origen\u00a0 inmigrante\u00a0 fue\u00a0 importada\u00a0 o\u00a0 bien\u00a0 fue\u00a0 contra\u00edda\u00a0\nlocalmente. \u00a0\n\uf0b7\uf020Los\u00a0 resultados\u00a0 sugieren\u00a0 que\u00a0 la\u00a0 mayor\u00eda\u00a0 de\u00a0 inmigrantes\u00a0 identificados\u00a0 como\u00a0 reci\u00e9n\u00a0\ninfectados\u00a0adquirieron\u00a0la\u00a0infecci\u00f3n\u00a0en\u00a0nuestro\u00a0pa\u00eds,\u00a0ya\u00a0que\u00a0lle vaban\u00a0en\u00a0\u00e9l\u00a0m\u00e1s\u00a0de\u00a012\u00a0meses\u00a0\ncuando\u00a0recibieron\u00a0el\u00a0diagn\u00f3stico\u00a0de\u00a0VIH,\u00a0poniendo\u00a0de\u00a0manifiesto\u00a0la\u00a0vulnerabilidad\u00a0de\u00a0la\u00a0\npoblaci\u00f3n\u00a0inmigrante\u00a0frente\u00a0la\u00a0infecci\u00f3n\u00a0por\u00a0VIH\u00a0en\u00a0nuestro\u00a0med io.\u00a0\n\uf0b7\uf020\u00a0El\u00a0uso\u00a0de\u00a0algoritmos\u00a0serol\u00f3gicos\u00a0para\u00a0la\u00a0identificaci\u00f3n\u00a0de\u00a0inf ecciones\u00a0recientes\u00a0en\u00a0un\u00a0\nsistema\u00a0nacional\u00a0de\u00a0vigilancia\u00a0epidemiol\u00f3gica\u00a0del\u00a0VIH\u00a0permite\u00a0e stimar\u00a0la\u00a0incidencia\u00a0de\u00a0\nVIH\u00a0 de\u00a0 manera\u00a0 menos\u00a0 costosa\u00a0 log\u00edstica\u00a0 y\u00a0 econ\u00f3micamente,\u00a0 respect o\u00a0 los\u00a0 estudios\u00a0 de\u00a0\ncohortes\u00a0en\u00a0pacientes\u00a0seronegativos. \u00a0CONCLUSIONES\u00a0\n -  123\uf0b7\uf020\u00a0La\u00a0 aproximaci\u00f3n\u00a0 a\u00a0 la\u00a0 incidencia\u00a0 de\u00a0 VIH\u00a0 mediante\u00a0 tests\u00a0 serol\u00f3gi cos\u00a0 para\u00a0 identificar\u00a0\ninfecciones\u00a0recientes\u00a0present\u00f3\u00a0una\u00a0ligera\u00a0tendencia\u00a0al\u00a0aumento\u00a0 durante\u00a0el\u00a0per\u00edodo\u00a02006\u2010\n2008.\u00a0\n\uf0b7\uf020Este\u00a0aumento,\u00a0aunque\u00a0es\u00a0consistente\u00a0con\u00a0los\u00a0resultados\u00a0de\u00a0otros \u00a0estudios\u00a0realizados\u00a0en\u00a0\nnuestro\u00a0contexto,\u00a0deber\u00eda\u00a0confirmarse\u00a0con\u00a0estimaciones\u00a0que\u00a0teng an\u00a0en\u00a0cuenta\u00a0el\u00a0patr\u00f3n\u00a0\nde\u00a0realizaci\u00f3n\u00a0de\u00a0la\u00a0prueba\u00a0del \u00a0VIH\u00a0de\u00a0las\u00a0infecciones\u00a0reciente s.\u00a0\n\uf0b7\uf020\u00a0La\u00a0 utilizaci\u00f3n\u00a0 de\u00a0 tests\u00a0 serol\u00f3g icos\u00a0 para\u00a0 la\u00a0 identificaci\u00f3n\u00a0 de\u00a0 infecciones\u00a0 recientes\u00a0 ha\u00a0\npermitido\u00a0 obtener\u00a0 estimaciones\u00a0 de\u00a0 la\u00a0 prevalencia\u00a0 de\u00a0 resistencia s\u00a0 transmitidas\u00a0 en\u00a0\nCatalu\u00f1a\u00a0en\u00a0la\u00a0poblaci\u00f3n\u00a0de\u00a0pacientes\u00a0con\u00a0infecci\u00f3n\u00a0reciente,\u00a0u na\u00a0informaci\u00f3n\u00a0m\u00e1s\u00a0precisa\u00a0\nque\u00a0en\u00a0el\u00a0conjunto\u00a0de\u00a0nuevos\u00a0diagn\u00f3sticos\u00a0de\u00a0VIH. \u00a0\n\uf0b7\uf020En\u00a0Catalu\u00f1a,\u00a0para\u00a0el\u00a0periodo\u00a02003\u20132005,\u00a0la\u00a0prevalencia\u00a0de\u00a0resis tencias\u00a0transmitidas\u00a0entre\u00a0\nlos\u00a0 pacientes\u00a0 con\u00a0 infecci\u00f3n\u00a0 recien t e \u00a0f u e \u00a07 , 7 % , \u00a0u n \u00a0v a l o r \u00a0s i m i l a r \u00a0a l \u00a0d e \u00a0o t r o s \u00a0e s t u d i o s \u00a0\nrealizados\u00a0en\u00a0Espa\u00f1a\u00a0y\u00a0en\u00a0Europa.\u00a0 \u00a0\n\uf0b7\uf020La\u00a0prevalencia\u00a0de\u00a0resistencias\u00a0t ransmitidas\u00a0mostr\u00f3\u00a0una\u00a0tendenci a\u00a0al\u00a0descenso,\u00a0de\u00a010,0%\u00a0\nen\u00a0el\u00a0a\u00f1o\u00a02003\u00a0a\u00a06,7%\u00a0en\u00a0el\u00a0a\u00f1o\u00a02005,\u00a0siendo\u00a0este\u00a0hallazgo\u00a0cons istente\u00a0con\u00a0los\u00a0resultados\u00a0\nde\u00a0otros\u00a0estudios\u00a0europeos\u00a0que\u00a0m uestran\u00a0una\u00a0tendencia\u00a0temporal\u00a0decreciente. \u00a0\n\uf0b7\uf020\u00a0Adem\u00e1s,\u00a0la\u00a0prevalencia\u00a0de\u00a0subtipos\u00a0de\u00a0VIH\u20101\u00a0no\u00a0B\u00a0entre\u00a0los\u00a0pac ientes\u00a0con\u00a0infecci\u00f3n\u00a0\nr e c i e n t e \u00a0f u e \u00a0d e l \u00a01 9 , 2 % , \u00a0u n \u00a0v a l o r \u00a0s u p e r i o r \u00a0a l \u00a0r e p o r t a d o \u00a0e n \u00a0u n \u00a0e s tudio\u00a0 de\u00a0 la\u00a0 cohorte\u00a0\nespa\u00f1ola\u00a0(12,2%),\u00a0pero\u00a0similar\u00a0al\u00a0de\u00a0otros\u00a0estudios\u00a0realizados\u00a0 en\u00a0Galicia\u00a0(22,3%)\u00a0y\u00a0Gran\u00a0\nCanaria\u00a0(22,4%).\u00a0\u00a0\n\uf0b7\uf020El\u00a0elevado\u00a0porcentaje\u00a0de\u00a0subtipos\u00a0no\u00a0B\u00a0entre\u00a0los\u00a0pacientes\u00a0reci \u00e9n\u00a0infectados\u00a0\u00a0de\u00a0origen\u00a0\naut\u00f3ctono\u00a0(17,2%)\u00a0sugiere\u00a0que\u00a0los\u00a0subtipos\u00a0no\u00a0B\u00a0se\u00a0encuentran\u00a0a ctualmente\u00a0circulando\u00a0\nentre\u00a0nuestra\u00a0poblaci\u00f3n\u00a0de\u00a0r eci\u00e9n\u00a0infectados\u00a0por\u00a0VIH.\u00a0\n\uf0b7\uf020Adem\u00e1s,\u00a0el\u00a0aumento\u00a0de\u00a0este\u00a0porcentaje\u00a0a\u00a0lo\u00a0largo\u00a0del\u00a0periodo\u00a0de \u00a0estudio\u00a0podr\u00eda\u00a0estar\u00a0\nrelacionado\u00a0con\u00a0el\u00a0aumento\u00a0de\u00a0la\u00a0poblaci\u00f3n\u00a0inmigrante\u00a0en\u00a0nuestr o\u00a0medio\u00a0durante\u00a0este\u00a0\nper\u00edodo.\u00a0\n\uf0b7\uf020Los\u00a0resultados\u00a0de\u00a0la\u00a0evaluaci\u00f3n\u00a0de\u00a0los\u00a0tests\u00a0Vironostika\u00a0y\u00a0BED\u2010CEIA,\u00a0utilizados\u00a0en\u00a0nuestro\u00a0\nmedio\u00a0a\u00a0lo\u00a0largo\u00a0de\u00a0los\u00a0a\u00f1os\u00a02003\u00a0\u2010\u00a02008,\u00a0indican\u00a0que\u00a0el\u00a0grado\u00a0 de\u00a0acuerdo\u00a0entre\u00a0ambos\u00a0\ntests\u00a0es\u00a0bueno\u00a0y,\u00a0por\u00a0tanto,\u00a0\u00a0los\u00a0resultados\u00a0obtenidos\u00a0por\u00a0amba s\u00a0t\u00e9cnicas\u00a0a\u00a0lo\u00a0largo\u00a0de\u00a0los\u00a0\ndos\u00a0per\u00edodos\u00a0de\u00a0estudio\u00a0son\u00a0comparables. \u00a0CONCLUSIONES\u00a0\n 124\uf0b7\uf020Los\u00a0dos\u00a0tests\u00a0identifican\u00a0con\u00a0la\u00a0misma\u00a0sensibilidad\u00a0las\u00a0infecci ones\u00a0recientes,\u00a0aunque\u00a0el\u00a0\nVironostika\u00a0 presenta\u00a0 una\u00a0 menor\u00a0 especificidad\u00a0 que\u00a0 el\u00a0 BED\u2010CEIA,\u00a0 y a\u00a0 que\u00a0 clasifica\u00a0 con\u00a0\nmayor\u00a0frecuencia\u00a0pacientes\u00a0con\u00a0SIDA\u00a0como\u00a0infectados\u00a0recientemente.\u00a0 \u00a0\n\uf0b7\uf020\u00a0Esta\u00a0menor\u00a0especificidad\u00a0no\u00a0debe\u00a0haber\u00a0afectado\u00a0los\u00a0resultados \u00a0obtenidos\u00a0al\u00a0aplicar\u00a0\nnuestro\u00a0 algoritmo\u00a0 de\u00a0 identificaci\u00f3n\u00a0 de\u00a0 infecciones\u00a0 recientes,\u00a0 y a\u00a0 que\u00a0 las\u00a0 muestras\u00a0 de\u00a0\npacientes\u00a0con\u00a0SIDA\u00a0no\u00a0son\u00a0an alizadas\u00a0mediante\u00a0el\u00a0test. \u00a0\n\uf0b7\uf020El\u00a0uso\u00a0combinado\u00a0de\u00a0un\u00a0test\u00a0serol\u00f3gico\u00a0para\u00a0identificar\u00a0infecciones\u00a0recientes\u00a0junto\u00a0con\u00a0la\u00a0\ninformaci\u00f3n\u00a0cl\u00ednica\u00a0(diagn\u00f3stico\u00a0de\u00a0SIDA\u00a0y\u00a0recuento\u00a0de\u00a0c\u00e9lulas\u00a0 CD4+)\u00a0dio\u00a0lugar\u00a0a\u00a0un\u00a0\nalgoritmo\u00a0 de\u00a0 clasificaci\u00f3n\u00a0 que\u00a0 present\u00f3\u00a0 una\u00a0 tasa\u00a0 de\u00a0 error\u00a0 del\u00a0 3 ,8%\u00a0 (coeficiente\u00a0 de\u00a0\nvariaci\u00f3n\u00a015,7%),\u00a0un\u00a0valor\u00a0acepta ble\u00a0seg\u00fan\u00a0las\u00a0gu\u00edas\u00a0publicadas\u00a0por\u00a0el\u00a0ECDC\u00a0y\u00a0la\u00a0OMS.\u00a0\u00a0\n\uf0b7\uf020La\u00a0monitorizaci\u00f3n\u00a0de\u00a0las\u00a0infecciones\u00a0recientes\u00a0por\u00a0VIH\u00a0en\u00a0Catal u\u00f1a\u00a0permite\u00a0entender\u00a0los\u00a0\npatrones\u00a0 de\u00a0 transmisi\u00f3n\u00a0 del\u00a0 VIH\u00a0 actuales\u00a0 contribuyendo\u00a0 a\u00a0 dirigir\u00a0 los\u00a0 esfuerzos\u00a0 en\u00a0\nprevenci\u00f3n\u00a0de\u00a0un\u00a0modo\u00a0m\u00e1s\u00a0efectivo\u00a0con\u00a0el\u00a0objetivo\u00a0final\u00a0de\u00a0dis minuir\u00a0la\u00a0transmisi\u00f3n\u00a0del\u00a0\nVIH.\u00a0\n\u00a0\n\u00a0\n\u00a0\n\u00a0\n\u00a0\n\u00a0\n\u00a0\u00a0\n\u00a0\n\u00a0\u00a0\n -  125\u00a0\n\u00a0\n\u00a0\n\u00a0\n\u00a0\n\u00a0\u00a0\n\u00a0\n\u00a0\u00a0\n\u00a0\n\u00a0\u00a0\u00a0\n\u00a0\nRECOMENDACIONES \u00a0\n\u00a0\n\u00a0\u00a0\n\u00a0\n\u00a0\u00a0\n\u00a0\n\u00a0\u00a0\u00a0\n\u00a0\n\u00a0\u00a0\u00a0\n\u00a0\n\u00a0\u00a0\u00a0\n 126RECOMENDACIONES\u00a0\n -  127\uf0b7\uf020Los\u00a0 sistemas\u00a0 de\u00a0 vigilancia\u00a0 de\u00a0 nuevos\u00a0 diagn\u00f3sticos\u00a0 de\u00a0 VIH\u00a0 deber\u00ed an\u00a0 incorporar\u00a0 la\u00a0\nidentificaci\u00f3n\u00a0de\u00a0infecciones\u00a0reci entes\u00a0mediante\u00a0tests\u00a0serol\u00f3gi cos\u00a0como\u00a0una\u00a0t\u00e9cnica\u00a0de\u00a0\nrutina,\u00a0 por\u00a0 ser\u00a0 una\u00a0 herramienta\u00a0 q ue,\u00a0 distinguiendo\u00a0 las\u00a0 infecciones\u00a0 recientes\u00a0 de\u00a0 las\u00a0\nantiguas,\u00a0permite\u00a0conocer\u00a0cuales\u00a0 son\u00a0los\u00a0patrones\u00a0de\u00a0transmisi\u00f3 n\u00a0del\u00a0VIH\u00a0actuales.\u00a0\u00a0\n\uf0b7\uf020La\u00a0 identificaci\u00f3n\u00a0 de\u00a0 infecciones\u00a0 recientes\u00a0 mediante\u00a0 tests\u00a0 serol \u00f3gicos\u00a0 debe\u00a0 hacerse\u00a0\nsiguiendo\u00a0 las\u00a0 recomendaciones\u00a0 t\u00e9 cnicas\u00a0 proporcionadas\u00a0 por\u00a0 el\u00a0 EC DC\u00a0 y\u00a0 la\u00a0 OMS,\u00a0 para\u00a0\u00a0\npoder\u00a0ofrecer\u00a0resultados\u00a0v\u00e1lidos \u00a0y\u00a0comparables\u00a0a\u00a0nivel\u00a0europeo\u00a0 y\u00a0mundial.\u00a0\n\uf0b7\uf020\u00a0En\u00a0Catalu\u00f1a,\u00a0el\u00a0Departament\u00a0de\u00a0Salut\u00a0debe\u00a0mantener\u00a0la\u00a0particip aci\u00f3n\u00a0de\u00a0los\u00a0centros\u00a0que\u00a0\nactualmente\u00a0est\u00e1n\u00a0colaborando\u00a0en\u00a0el\u00a0sistema\u00a0de\u00a0identificaci\u00f3n\u00a0d e\u00a0infecciones\u00a0recientes\u00a0\nmediante\u00a0tests\u00a0serol\u00f3gicos,\u00a0as\u00ed\u00a0como\u00a0promover\u00a0la\u00a0participaci\u00f3n\u00a0 de\u00a0nuevos\u00a0centros,\u00a0lo\u00a0que\u00a0\npermitir\u00e1\u00a0aumentar\u00a0la\u00a0representatividad\u00a0de\u00a0este\u00a0sistema. \u00a0\n\uf0b7\uf020Para\u00a0mejorar\u00a0la\u00a0interpretaci\u00f3n\u00a0de \u00a0los\u00a0resultados\u00a0obtenidos\u00a0de\u00a0l a\u00a0aplicaci\u00f3n\u00a0de\u00a0los\u00a0tests\u00a0\nserol\u00f3gicos\u00a0para\u00a0la\u00a0identificaci \u00f3n\u00a0de\u00a0infecciones\u00a0recientes\u00a0bas ada\u00a0en\u00a0nuevos\u00a0diagn\u00f3sticos\u00a0\nd e \u00a0V I H , \u00a0a s \u00ed \u00a0c o m o \u00a0o b t e n e r \u00a0e s t i m a c i o n e s \u00a0d e \u00a0i n c i d e n c i a \u00a0d e \u00a0V I H \u00a0p o b l acional,\u00a0 se\u00a0 deber\u00eda\u00a0\nincorporar\u00a0al\u00a0sistema\u00a0la\u00a0recogida\u00a0rutinaria\u00a0de\u00a0informaci\u00f3n\u00a0sobr e\u00a0el\u00a0patr\u00f3n\u00a0de\u00a0testaje\u00a0\nindividual\u00a0de\u00a0los\u00a0pacientes\u00a0diagnosticados. \u00a0\n\uf0b7\uf020Debido\u00a0a\u00a0la\u00a0mayor\u00a0prevalencia\u00a0de\u00a0infecci\u00f3n\u00a0reciente\u00a0en\u00a0atenci\u00f3n \u00a0primaria,\u00a0cl\u00ednicas\u00a0de\u00a0ITS\u00a0y\u00a0\nlos\u00a0 centros\u00a0 de\u00a0 cribado\u00a0 alternati vos,\u00a0 es\u00a0 necesario\u00a0 promover\u00a0 la\u00a0 r ealizaci\u00f3n\u00a0 del\u00a0 test\u00a0 de\u00a0\ncribado\u00a0del\u00a0VIH\u00a0en\u00a0atenci\u00f3n\u00a0primaria\u00a0y\u00a0cl\u00ednicas\u00a0de\u00a0ITS,\u00a0as\u00ed\u00a0com o\u00a0reforzar\u00a0y\u00a0mantener\u00a0la\u00a0\nactividad\u00a0de\u00a0los\u00a0centros\u00a0de\u00a0cribado\u00a0alternativos,\u00a0para\u00a0aumentar \u00a0el\u00a0diagn\u00f3stico\u00a0precoz\u00a0del\u00a0\nVIH.\u00a0\u00a0\n\uf0b7\uf020La\u00a0mayor\u00a0prevalencia\u00a0de\u00a0infecci\u00f3n\u00a0reciente\u00a0entre\u00a0las\u00a0personas\u00a0q ue\u00a0se\u00a0han\u00a0infectado\u00a0a\u00a0\ntrav\u00e9s\u00a0de\u00a0relaciones\u00a0entre\u00a0HSH\u00a0sugiere\u00a0que\u00a0la\u00a0incidencia\u00a0podr\u00eda \u00a0estar\u00a0aumentando\u00a0en\u00a0ese\u00a0\ngrupo,\u00a0tal\u00a0y\u00a0como\u00a0tambi\u00e9n\u00a0se\u00a0observa\u00a0en\u00a0los\u00a0datos\u00a0de\u00a0una\u00a0cohort e\u00a0de\u00a0HSH\u00a0seronegativos\u00a0a\u00a0\nriesgo\u00a0de\u00a0contraer\u00a0la\u00a0infecci\u00f3n\u00a0reclutados\u00a0en\u00a0base\u00a0comunitaria\u00a0 en\u00a0Barcelona,\u00a0por\u00a0lo\u00a0que\u00a0se\u00a0\nevidencia\u00a0la\u00a0necesidad\u00a0reforzar\u00a0 los\u00a0programas\u00a0de\u00a0prevenci\u00f3n\u00a0dirigidos\u00a0a\u00a0este\u00a0colectivo.\u00a0 \u00a0\u00a0\n\uf0b7\uf020La\u00a0mayor\u00eda\u00a0de\u00a0inmigrantes\u00a0identificados\u00a0como\u00a0reci\u00e9n\u00a0infectados\u00a0 por\u00a0VIH\u00a0han\u00a0adquirido\u00a0la\u00a0\ninfecci\u00f3n\u00a0 localmente.\u00a0 Esta\u00a0 informaci\u00f3n\u00a0 deber\u00eda\u00a0 incorporarse\u00a0 a\u00a0 l as\u00a0 campa\u00f1as\u00a0 de\u00a0\nprevenci\u00f3n\u00a0para\u00a0evitar\u00a0que\u00a0se\u00a0produzcan\u00a0nuevas\u00a0infecciones\u00a0en\u00a0e sta\u00a0nueva\u00a0poblaci\u00f3n\u00a0\nvulnerable.\u00a0 \u00a0\n\u00a0\n\u00a0RECOMENDACIONES\u00a0\n 128\uf0b7\uf020Para\u00a0conocer\u00a0la\u00a0evoluci\u00f3n\u00a0de\u00a0la\u00a0pr evalencia\u00a0de\u00a0resistencias\u00a0tra nsmitidas\u00a0y\u00a0de\u00a0subtipos\u00a0no\u00a0\nB\u00a0 en\u00a0 nuestro\u00a0 medio\u00a0 es\u00a0 necesario\u00a0 que\u00a0 los\u00a0 sistemas\u00a0 de\u00a0 vigilancia\u00a0 incorporen\u00a0 la\u00a0\nmonitorizaci\u00f3n\u00a0de\u00a0las\u00a0resistencias\u00a0transmitidas\u00a0en\u00a0los\u00a0paciente s\u00a0infectados\u00a0recientemente\u00a0\npor\u00a0VIH,\u00a0tal\u00a0y\u00a0como\u00a0recomienda\u00a0la\u00a0OMS.\u00a0\n\uf0b7\uf020Para\u00a0 aumentar\u00a0 la\u00a0 especificidad\u00a0 d el\u00a0 actual\u00a0 algoritmo\u00a0 de\u00a0 identificaci\u00f3n\u00a0 de\u00a0 infecciones\u00a0\nrecientes\u00a0basado\u00a0en\u00a0el\u00a0test\u00a0BED, \u00a0es\u00a0recomendable\u00a0incorporar\u00a0un\u00a0 segundo\u00a0test\u00a0serol\u00f3gico,\u00a0\npreferiblemente\u00a0el\u00a0test\u00a0de\u00a0avidez,\u00a0tal\u00a0y\u00a0como\u00a0recomiendan\u00a0las\u00a0gu\u00edas\u00a0m\u00e1s\u00a0recientes\u00a0de\u00a0la\u00a0\nOMS\u00a0y\u00a0el\u00a0ECDC.\u00a0\u00a0\n\uf0b7\uf020A \u00a0p e s a r \u00a0d e \u00a0q u e \u00a0l o s \u00a0t e s t s \u00a0s e r o l \u00f3 g i c o s \u00a0p a r a \u00a0i d e n t i f i c a r \u00a0i n f e c c i o n es\u00a0 recientes\u00a0 fueron\u00a0\ndise\u00f1ados\u00a0para\u00a0usarse\u00a0a\u00a0nivel\u00a0poblacional,\u00a0si\u00a0se\u00a0aumenta\u00a0la\u00a0esp ecificidad\u00a0del\u00a0algoritmo\u00a0se\u00a0\npodr\u00eda\u00a0plantear\u00a0la\u00a0posibilidad\u00a0d e\u00a0proporcionar\u00a0el\u00a0resultado\u00a0a\u00a0l os\u00a0pacientes.\u00a0\n\u00a0\n\u00a0\u00a0\n -  129BIBLIOGRAF\u00cdA \u00a0\n1.\u00a0Gatell\u00a0JM,\u00a0Clotet\u00a0B,\u00a0Podzamczer\u00a0D,\u00a0Miro\u00a0JM,\u00a0Mallolas\u00a0J.\u00a0Gu\u00eda \u00a0pr\u00e1ctica\u00a0del\u00a0sida.\u00a0cl\u00ednica,\u00a0diagn\u00f3stico\u00a0y\u00a0\ntratamiento.\u00a09th\u00a0ed.\u00a0Elsevier\u00a0Do yma,\u00a0editor.\u00a0Barcelona:\u00a0Masson;\u00a02007.\u00a0\u00a0\n2.\u00a0 Taylor\u00a0 BS,\u00a0 Hammer\u00a0 SM.\u00a0 The\u00a0 challenge\u00a0 of\u00a0 HIV\u20101\u00a0 subtype\u00a0 diversi ty.\u00a0 N\u00a0 Engl\u00a0 J\u00a0 Med.\u00a0 2008\u00a0 Oct\u00a0\n30;359(18):1965\u20106.\u00a0\u00a0\n3.\u00a0Hahn\u00a0BH,\u00a0Shaw\u00a0GM,\u00a0De\u00a0Cock\u00a0KM,\u00a0Sharp\u00a0PM.\u00a0AIDS\u00a0as\u00a0a\u00a0zoonosis:\u00a0 Scientific\u00a0and\u00a0public\u00a0health\u00a0implications.\u00a0\nScience.\u00a02000\u00a0Jan\u00a0 28;287(5453):607\u201014.\u00a0\u00a0\n4.\u00a0Hemelaar\u00a0J,\u00a0Gouws\u00a0E,\u00a0Ghys\u00a0PD,\u00a0Osmanov\u00a0S.\u00a0Global\u00a0and\u00a0regional \u00a0distribution\u00a0of\u00a0HIV\u20101 \u00a0genetic\u00a0subtypes\u00a0and\u00a0\nrecombinants\u00a0in\u00a02004.\u00a0AIDS. \u00a02006\u00a0Oct\u00a024;20(16):W13\u201023.\u00a0\u00a0\n5.\u00a0Casabona\u00a0J.\u00a0Epidemi ologic\u00a0aspects\u00a0of\u00a0the\u00a0transmission\u00a0of\u00a0HIV .\u00a0Rev\u00a0Clin\u00a0Esp.\u00a01988\u00a0Oct;183(6):313\u20107.\u00a0\u00a0\n6.\u00a0Osmond\u00a0DH.\u00a0Epidemiology\u00a0and\u00a0t ransmission.\u00a0In:\u00a0Cohen\u00a0PT,\u00a0Sand e\u00a0MA,\u00a0Volberding\u00a0P,\u00a0editor.\u00a0The\u00a0AIDS\u00a0\nknowledge\u00a0base.\u00a0Third\u00a0ed.\u00a0San\u00a0Fr ancisco:\u00a0Lippincott\u00a0Williams\u00a0&\u00a0Wilkins;\u00a01999.\u00a0\u00a0\n7.\u00a0Lifson\u00a0AR,\u00a0Castro\u00a0KG,\u00a0McCray\u00a0E,\u00a0Jaffe\u00a0HW.\u00a0National\u00a0surveilla nce\u00a0of\u00a0AIDS\u00a0in\u00a0health\u00a0care\u00a0workers.\u00a0JAMA.\u00a0\n1986\u00a0Dec\u00a019;256(23):3231\u20104.\u00a0\u00a08.\u00a0McCray\u00a0E.\u00a0Occupational\u00a0risk\u00a0of \u00a0the\u00a0acquired\u00a0i mmunodeficiency\u00a0syndrome\u00a0among\u00a0health\u00a0care\u00a0workers.\u00a0N\u00a0\nEngl\u00a0J\u00a0Med.\u00a01986\u00a0Ap r\u00a024;314(17):1127\u201032.\u00a0\u00a0\n9 . \u00a0C e n t e r s \u00a0f o r \u00a0D i s e a s e \u00a0C o n t r o l \u00a0( C D C ) . \u00a0A p p a r e n t \u00a0t r a n s m i s s i o n \u00a0o f \u00a0 human\u00a0 T\u2010lymphotrophic\u00a0 virus\u00a0 type\u00a0\nIII/lymphadenopathy\u2010associated\u00a0vir us\u00a0from\u00a0a\u00a0child\u00a0to\u00a0a\u00a0mother\u00a0p roviding\u00a0health\u00a0care.\u00a0MMWR\u00a0Morb\u00a0Mortal\u00a0\nWkly\u00a0Rep.\u00a01986\u00a0Feb\u00a07;35(5):76\u20109.\u00a0\u00a010.\u00a0Wahn\u00a0V,\u00a0Kramer\u00a0HH,\u00a0Voit\u00a0T,\u00a0Bruster\u00a0HT,\u00a0Scrampical\u00a0B,\u00a0Scheid \u00a0A.\u00a0Horizontal\u00a0transmission\u00a0of\u00a0HIV\u00a0\ninfection\u00a0between\u00a0two\u00a0sibling s.\u00a0Lancet.\u00a01986\u00a0Sep\u00a020;2(8508):694 .\u00a0\u00a0\n11.\u00a0Winkelstein\u00a0W,Jr,\u00a0Lyman\u00a0DM,\u00a0Padian\u00a0N,\u00a0Grant\u00a0R,\u00a0Samuel\u00a0M,\u00a0Wi ley\u00a0JA,\u00a0et\u00a0al.\u00a0Sexual\u00a0practices\u00a0and\u00a0risk\u00a0of\u00a0\ninfection\u00a0by\u00a0the\u00a0human\u00a0immunodefi ciency\u00a0virus.\u00a0the\u00a0san\u00a0francisc o\u00a0men's\u00a0health\u00a0study.\u00a0JAMA.\u00a01987\u00a0Jan\u00a0\n16;257(3):321\u20105.\u00a0\u00a012.\u00a0Moss\u00a0AR,\u00a0Osmond\u00a0D,\u00a0Bacchetti\u00a0P,\u00a0Chermann\u00a0JC,\u00a0et\u00a0al.\u00a0Risk\u00a0fa ctors\u00a0for\u00a0AIDS\u00a0and\u00a0HIV\u00a0seropositivity\u00a0in\u00a0\nhomosexual\u00a0men.\u00a0\u2010\u00a0Am\u00a0J\u00a0Epi demiol.1987\u00a0Jun;125(6):1035\u201047.\u00a0\u00a0\n13.\u00a0Ward\u00a0H,\u00a0Ronn\u00a0M.\u00a0Contribution\u00a0of\u00a0sexually\u00a0transmitted\u00a0infections\u00a0to\u00a0the\u00a0sexual\u00a0transmission\u00a0of\u00a0HIV.\u00a0Curr\u00a0\nOpin\u00a0HIV\u00a0AIDS.\u00a02010\u00a0Jul;5(4):305\u201010.\u00a0\u00a0\n1 4 . \u00a0L a t i f \u00a0A S , \u00a0K a t z e n s t e i n \u00a0D A , \u00a0B a s s e t t \u00a0M T , \u00a0H o u s t o n \u00a0S , \u00a0E m m a n u e l \u00a0J C,\u00a0 Marowa\u00a0 E.\u00a0 Genital\u00a0 ulcers\u00a0 and\u00a0\ntransmission\u00a0of\u00a0HIV\u00a0among\u00a0couples\u00a0in\u00a0zimbabwe.\u00a0AIDS.\u00a01989\u00a0Aug;3 (8):519\u201023.\u00a0\u00a0\n1 5 . \u00a0B e r t o l l i \u00a0J , \u00a0S t \u00a0L o u i s \u00a0M E , \u00a0S i m o n d s \u00a0R J , \u00a0N i e b u r g \u00a0P , \u00a0e t \u00a0a l . \u00a0E s t i mating\u00a0 the\u00a0 timing\u00a0 of\u00a0 mother\u2010to\u2010child\u00a0\ntransmission\u00a0of\u00a0human\u00a0immunodefi ciency\u00a0virus\u00a0in\u00a0a\u00a0breast\u2010feedin g\u00a0population\u00a0in\u00a0kinshasa,\u00a0zaire.\u00a0\u2010\u00a0J\u00a0Infect\u00a0\nDis.1996\u00a0Oct;174(4):722\u20106.\u00a0\u00a016.\u00a0Schacker\u00a0T,\u00a0Collier\u00a0AC,\u00a0Hughes\u00a0J,\u00a0Shea\u00a0T,\u00a0Corey\u00a0L.\u00a0Clinical \u00a0and\u00a0epidemiologic\u00a0features\u00a0of\u00a0primary\u00a0HIV\u00a0\ninfection.\u00a0Ann\u00a0Intern\u00a0Med .\u00a01996\u00a0Aug\u00a015;125(4):257\u201064.\u00a0\u00a0\u00a0\n 13017.\u00a0Piatak\u00a0M,Jr,\u00a0Saag\u00a0MS,\u00a0Yang\u00a0LC,\u00a0Clark\u00a0SJ,\u00a0Kappes\u00a0JC,\u00a0Luk\u00a0KC, \u00a0et\u00a0al.\u00a0High\u00a0levels\u00a0of\u00a0HIV\u20101\u00a0in\u00a0plasma\u00a0during\u00a0all\u00a0\nstages\u00a0of\u00a0infection\u00a0determined\u00a0b y\u00a0competitive\u00a0PCR.\u00a0Science.\u00a0199 3\u00a0Mar\u00a019;259(5102):1749\u201054.\u00a0\u00a0\n18.\u00a0Koup\u00a0RA,\u00a0Safrit\u00a0JT,\u00a0Cao\u00a0Y,\u00a0Andrews\u00a0CA,\u00a0McLeod\u00a0G,\u00a0Borkowsky\u00a0 W,\u00a0et\u00a0al.\u00a0Temporal\u00a0association\u00a0of\u00a0cellular\u00a0\nimmune\u00a0responses\u00a0with\u00a0the\u00a0initial\u00a0control\u00a0of\u00a0viremia\u00a0in\u00a0primary \u00a0human\u00a0immunodeficiency\u00a0virus\u00a0type\u00a01\u00a0\nsyndrome.\u00a0J\u00a0Virol.\u00a0 1994\u00a0Jul;68(7):4650\u20105.\u00a0\u00a0\n19.\u00a0Lee\u00a0JC,\u00a0Boechat\u00a0MI,\u00a0Belzer\u00a0M,\u00a0Church\u00a0JA,\u00a0De\u00a0Ville\u00a0J,\u00a0Nielse n\u00a0K,\u00a0et\u00a0al.\u00a0Thymic\u00a0volume,\u00a0T\u2010cell\u00a0populations,\u00a0\nand\u00a0parameters\u00a0of\u00a0thymopoiesis\u00a0i n\u00a0adolescent\u00a0and\u00a0adult\u00a0survivors\u00a0of\u00a0HIV\u00a0infection\u00a0acquired\u00a0in\u00a0infancy.\u00a0\nAIDS.\u00a02006\u00a0Mar\u00a021;20(5):667\u201074.\u00a0\u00a0\n20.\u00a01993\u00a0revised\u00a0classification\u00a0system\u00a0for\u00a0HIV\u00a0infection\u00a0and\u00a0ex panded\u00a0surveillance\u00a0case\u00a0definition\u00a0for\u00a0AIDS\u00a0\namong\u00a0adolescents\u00a0and\u00a0adults.\u00a0MMWR\u00a0Recomm\u00a0Rep.\u00a01992\u00a0Dec\u00a018;41(R R\u201017):1\u201019.\u00a0\u00a0\n2 1 . \u00a0S o r i a n o \u00a0V , \u00a0G u t i e r r e z \u00a0M , \u00a0B r a v o \u00a0R . \u00a0S e r o l o g i c a l \u00a0d i a g n o s i s \u00a0o f \u00a0H IV\u20101\u00a0 infection].\u00a0 Rev\u00a0 Clin\u00a0 Esp.\u00a0 1994\u00a0\nJul;194(7):558\u201067.\u00a0\u00a022.\u00a0Damond\u00a0F,\u00a0Gueudin\u00a0M,\u00a0Pueyo\u00a0S, \u00a0Farfara\u00a0I,\u00a0Robertson\u00a0DL,\u00a0Desc amps\u00a0D,\u00a0et\u00a0al.\u00a0Plasma\u00a0RNA\u00a0viral\u00a0load\u00a0in\u00a0\nhuman\u00a0 immunodeficiency\u00a0 virus\u00a0 type\u00a0 2\u00a0 subtype\u00a0 A\u00a0 and\u00a0 subtype\u00a0 B\u00a0 inf ections.\u00a0 J\u00a0 Clin\u00a0 Microbiol.\u00a0 2002\u00a0\nOct;40(10):3654\u20109.\u00a0\u00a0\n23.\u00a0Fiebig\u00a0EW,\u00a0Wright\u00a0DJ,\u00a0Rawal\u00a0BD,\u00a0Garrett\u00a0PE,\u00a0Schumacher\u00a0RT,\u00a0 Peddada\u00a0L,\u00a0et\u00a0al.\u00a0Dynamics\u00a0of\u00a0HIV\u00a0viremia\u00a0\nand\u00a0antibody\u00a0seroconversion\u00a0in\u00a0p lasma\u00a0donors:\u00a0Implications\u00a0for\u00a0 diagnosis\u00a0and\u00a0staging\u00a0of\u00a0primary\u00a0HIV\u00a0\ninfection.\u00a0AIDS.\u00a02003\u00a0Sep\u00a05;17(13):1871\u20109.\u00a0\u00a0\n24.\u00a0Cohen\u00a0MS,\u00a0Shaw\u00a0GM,\u00a0McMichael\u00a0AJ,\u00a0Haynes\u00a0BF.\u00a0MEDICAL\u00a0PROGRES S\u00a0acute\u00a0HIV\u20101\u00a0infection.\u00a0N\u00a0Engl\u00a0J\u00a0\nMed.\u00a02011\u00a0MAY\u00a019;364(20):1943\u201054.\u00a0\u00a025.\u00a0Fischl\u00a0MA,\u00a0Richman\u00a0DD,\u00a0Grieco\u00a0MH,\u00a0Gottlieb\u00a0MS,\u00a0Volberding\u00a0P A,\u00a0Laskin\u00a0OL,\u00a0et\u00a0al.\u00a0The\u00a0efficacy\u00a0of\u00a0\nazidothymidine\u00a0(AZT)\u00a0in\u00a0the\u00a0treatment\u00a0of\u00a0patients\u00a0with\u00a0AIDS\u00a0and \u00a0AIDS\u2010related\u00a0complex.\u00a0A\u00a0double\u2010blind,\u00a0\nplacebo\u2010controlled\u00a0trial.\u00a0N\u00a0E ngl\u00a0J\u00a0Med.\u00a01987\u00a0 Jul\u00a023;317(4):185\u2010 91.\u00a0\u00a0\n26.\u00a0S.J.\u00a0Flint,\u00a0L.W.\u00a0Enquist,\u00a0V.R .\u00a0Racaniello,\u00a0A.M.Skalka.\u00a0Prin ciples\u00a0of\u00a0virology.\u00a03\u00aa\u00a0ed.\u00a0US:\u00a0American\u00a0Society\u00a0for\u00a0\nMicrobiology;\u00a02009.\u00a0\u00a027.\u00a0Lalezari\u00a0JP,\u00a0Henry\u00a0K,\u00a0O'Hearn\u00a0M,\u00a0Montaner\u00a0JS,\u00a0Piliero\u00a0PJ,\u00a0Trottier\u00a0B,\u00a0et\u00a0al.\u00a0Enfuvirtide,\u00a0an\u00a0HIV\u20101\u00a0fusion\u00a0\ni n h i b i t o r , \u00a0f o r \u00a0d r u g \u2010 r e s i s t a n t \u00a0H I V \u00a0i n f e c t i o n \u00a0i n \u00a0n o r t h \u00a0a n d \u00a0s o u t h \u00a0 america.\u00a0 N\u00a0 Engl\u00a0 J\u00a0 Med.\u00a0 2003\u00a0 May\u00a0\n29;348(22):2175\u201085.\u00a0\u00a0\n28.\u00a0Dorr\u00a0P,\u00a0Westby\u00a0M,\u00a0Dobbs\u00a0S,\u00a0Griffin\u00a0P,\u00a0Irvine\u00a0B,\u00a0Macartney\u00a0M ,\u00a0et\u00a0al.\u00a0Maraviroc\u00a0(UK\u2010427,857),\u00a0a\u00a0potent,\u00a0\no r a l l y \u00a0b i o a v a i l a b l e , \u00a0a n d \u00a0s e l e c t i ve\u00a0 small\u2010molecule\u00a0 inhibitor\u00a0 of\u00a0 chemokine\u00a0 receptor\u00a0 CCR5\u00a0 with\u00a0 broad\u2010\nspectrum\u00a0 anti\u2010human\u00a0 immunodeficiency\u00a0 virus\u00a0 type\u00a0 1\u00a0 activity.\u00a0 Ant imicrob\u00a0 Agents\u00a0 Chemother.\u00a0 2005\u00a0\nNov;49(11):4721\u201032.\u00a0\u00a029.\u00a0Detels\u00a0R,\u00a0Munoz\u00a0A,\u00a0McFarlane\u00a0G,\u00a0Kingsley\u00a0LA,\u00a0et\u00a0al.\u00a0Effecti veness\u00a0of\u00a0potent\u00a0antiretroviral\u00a0therapy\u00a0on\u00a0time\u00a0\nto\u00a0AIDS\u00a0and\u00a0death\u00a0in\u00a0men\u00a0with\u00a0known\u00a0HIV\u00a0infection\u00a0duration.\u00a0mul ticenter\u00a0AIDS\u00a0cohort\u00a0study\u00a0investigators.\u00a0\u2010\u00a0\nJAMA.1998\u00a0Nov\u00a04;280(17):1497\u2010503.\u00a0\u00a03 0 . \u00a0J a c o b s o n \u00a0L P , \u00a0L i \u00a0R , \u00a0P h a i r \u00a0J , \u00a0M a r g o l i c k \u00a0J B , \u00a0e t \u00a0a l . \u00a0E v a l u a t i o n \u00a0 of\u00a0 the\u00a0 effectiveness\u00a0 of\u00a0 highly\u00a0 active\u00a0\nantiretroviral\u00a0therapy\u00a0in\u00a0person s\u00a0with\u00a0human\u00a0immunodeficiency\u00a0v irus\u00a0using\u00a0biomarker\u2010based\u00a0equivalence\u00a0\nof\u00a0disease\u00a0progression.\u00a0\u2010\u00a0Am\u00a0J \u00a0Epidemiol.2002\u00a0Apr\u00a015;155(8):760 \u201070.\u00a0\u00a0\u00a0\n -  13131.\u00a0Clotet\u00a0B,\u00a0Men\u00e9ndez\u2010Arias\u00a0L,\u00a0Schapiro\u00a0JM,\u00a0Kuritzkes\u00a0DR,\u00a0Burg er\u00a0D,\u00a0Telenti\u00a0A,\u00a0et\u00a0al.\u00a0Guide\u00a0to\u00a0management\u00a0\nof\u00a0HIV\u00a0drug\u00a0resistance ,\u00a0antiretrovirals\u00a0pharmacokinetics\u00a0and\u00a0vi ral\u00a0hepatitis\u00a0in\u00a0HIV\u00a0infected\u00a0subjects.\u00a08th\u00a0ed.\u00a0\nFundaci\u00f3\u00a0Lluita\u00a0contra\u00a0la\u00a0SIDA,\u00a0editor.\u00a0Spain:\u00a0;\u00a02008.\u00a0\u00a0\n32.\u00a0Alencar\u00a0CS,\u00a0Nishiya\u00a0AS,\u00a0Ferreira\u00a0S,\u00a0Giret\u00a0MT,\u00a0Diaz\u00a0RS,\u00a0Sabi no\u00a0EC.\u00a0Evaluation\u00a0of\u00a0primary\u00a0resistance\u00a0to\u00a0HIV\u00a0\nentry\u00a0inhibitors\u00a0among\u00a0brazilian \u00a0patients\u00a0failing\u00a0reverse\u00a0trans criptase/protease\u00a0inhibitors\u00a0treatment\u00a0reveal\u00a0\nhigh\u00a0 prevalence\u00a0 of\u00a0 maraviroc\u00a0 resistance\u2010related\u00a0 mutations.\u00a0 AIDS \u00a0 Res\u00a0 Hum\u00a0 Retroviruses.\u00a0 2010\u00a0\nDec;26(12):1267\u201071.\u00a0\u00a033.\u00a0Leung\u00a0PH,\u00a0Chen\u00a0JH,\u00a0Wong\u00a0KH,\u00a0Chan\u00a0KC,\u00a0Lam\u00a0HY,\u00a0Cheng\u00a0VC,\u00a0et\u00a0a l.\u00a0High\u00a0prevalence\u00a0of\u00a0primary\u00a0enfuvirtide\u00a0\n(ENF)\u00a0 resistance\u2010associated\u00a0 mutations\u00a0 in\u00a0 HIV\u20101\u2010infected\u00a0 patient s\u00a0 in\u00a0 hong\u00a0 kong.\u00a0 J\u00a0 Clin\u00a0 Virol.\u00a0 2010\u00a0\nMar;47(3):273\u20105.\u00a0\u00a034.\u00a0Mantovani\u00a0NP,\u00a0Azevedo\u00a0RG,\u00a0Rabelato\u00a0JT,\u00a0Sanabani\u00a0S,\u00a0Diaz\u00a0RS, \u00a0Komninakis\u00a0SC.\u00a0Analyses\u00a0of\u00a0transmitted\u00a0\nresistance\u00a0and\u00a0selective\u00a0pressure\u00a0in\u00a0HIV\u20101\u00a0naive\u00a0patients\u00a0to\u00a0ra ltegravir\u00a0and\u00a0failure\u00a0HAART\u00a0in\u00a0sao\u00a0paulo,\u00a0\nbrazil.\u00a0J\u00a0Clin\u00a0Microbiol.\u00a02012\u00a0Mar\u00a07.\u00a0\u00a035.\u00a0Centers\u00a0for\u00a0Disease\u00a0Control\u00a0(CDC).\u00a0Pneumocystis\u00a0pneumonia\u2010\u2010 los\u00a0angeles.\u00a0MMWR\u00a0Morb\u00a0Mortal\u00a0Wkly\u00a0\nRep.\u00a01981\u00a0Jun\u00a05;30(21):250\u20102.\u00a0\u00a036.\u00a0 Gottlieb\u00a0 MS,\u00a0 Schroff\u00a0 R,\u00a0 Schanker\u00a0 HM,\u00a0 Weisman\u00a0 JD,\u00a0 Fan\u00a0 PT,\u00a0 Wo lf\u00a0 RA,\u00a0 et\u00a0 al.\u00a0 Pneumocystis\u00a0 carinii\u00a0\npneumonia\u00a0and\u00a0mucosal\u00a0candidiasis\u00a0in\u00a0previously\u00a0healthy\u00a0homosex ual\u00a0men:\u00a0Evidence\u00a0of\u00a0a\u00a0new\u00a0acquired\u00a0\ncellular\u00a0immunodeficiency.\u00a0N\u00a0 Engl\u00a0J\u00a0Med.\u00a01981\u00a0Dec\u00a010;305(24):14 25\u201031.\u00a0\u00a0\n37.\u00a0Geneve:\u00a0ONUSIDA\u00a0O.\u00a0AIDS\u00a0epidemia\u00a0update:\u00a0December\u00a02009.\u00a0\u00a0\u00a0\n38.\u00a0Joint\u00a0United\u00a0Nations\u00a0Programme \u00a0on\u00a0HIV/AIDS\u00a0(UNAIDS).\u00a0GLOBAL \u00a0REPORT\u00a0UNAIDS\u00a0REPORT\u00a0ON\u00a0THE\u00a0\nGLOBAL\u00a0AIDS\u00a0EPIDEMIC\u00a0|\u00a02013.\u00a0WHO\u00a0Library\u00a0Cataloguing\u2010in\u2010Publica tion\u00a0Data;\u00a02013.\u00a0\u00a0\n39.\u00a0Quinn\u00a0TC.\u00a0HIV\u00a0epidemiology\u00a0and\u00a0the\u00a0effects\u00a0of\u00a0antiviral\u00a0the rapy\u00a0on\u00a0long\u2010term\u00a0consequences.\u00a0AIDS.\u00a02008\u00a0\nSep;22\u00a0Suppl\u00a03:S7\u201012.\u00a0\u00a040.\u00a0Sullivan\u00a0PS,\u00a0Hamouda\u00a0O,\u00a0Delpech\u00a0V,\u00a0Geduld\u00a0JE,\u00a0Prejean\u00a0J,\u00a0Se maille\u00a0C,\u00a0et\u00a0al.\u00a0Reemergence\u00a0of\u00a0the\u00a0HIV\u00a0\nepidemic\u00a0among\u00a0men\u00a0who\u00a0have\u00a0sex\u00a0with\u00a0men\u00a0in\u00a0north\u00a0america,\u00a0west ern\u00a0europe,\u00a0and\u00a0australia,\u00a01996\u20102005.\u00a0\nAnn\u00a0Epidemiol.\u00a02009\u00a0 Jun;19(6):423\u201031.\u00a0\u00a0\n41.\u00a0van\u00a0de\u00a0Laar\u00a0MJ,\u00a0Likatavicius\u00a0G,\u00a0Stengaard\u00a0AR,\u00a0Donoghoe\u00a0MC.\u00a0 HIV/AIDS\u00a0surveillance\u00a0in\u00a0europe:\u00a0Update\u00a0\n2007.\u00a0Euro\u00a0Surveill.\u00a02008\u00a0Dec\u00a011;13(50):19066.\u00a0\u00a042.\u00a0Houweling\u00a0H,\u00a0Wiessing\u00a0LG,\u00a0Hamers\u00a0FF,\u00a0Termorshuizen\u00a0F,\u00a0et\u00a0al .\u00a0An\u00a0age\u2010period\u2010cohort\u00a0analysis\u00a0of\u00a050,875\u00a0\nAIDS\u00a0cases\u00a0among\u00a0injecting\u00a0drug\u00a0 users\u00a0in\u00a0europe.\u00a0\u00a0Int\u00a0J\u00a0Epidemi ol.1999\u00a0Dec;28(6):1141\u20108.\u00a0\u00a0\n43.\u00a0Centro\u00a0Nacional\u00a0de\u00a0Epidemiolog\u00eda.\u00a0Vigilancia\u00a0epidemiol\u00f3gica \u00a0del\u00a0VIH\u00a0en\u00a0Espa\u00f1a.\u00a0Nuevos\u00a0Diagn\u00f3sticos\u00a0de\u00a0\nVIH\u00a0en\u00a0Espa\u00f1a.\u00a0Periodo\u00a02003\u00a0\u20102009.\u00a0Instituto\u00a0de\u00a0Salud\u00a0Carlos\u00a0ii i:\u00a0Actualizaci\u00f3n\u00a030\u00a0de\u00a0junio\u00a0de\u00a02010\u00a0\nNoviembre,\u00a02010.\u00a0\u00a044.\u00a0Centre\u00a0d'Estudis\u00a0Epidemiol\u00f2gics\u00a0sobre\u00a0les\u00a0ITS\u00a0i\u00a0la\u00a0SIDA\u00a0de\u00a0 Catalunya.\u00a0Sistema\u00a0integrat\u00a0de\u00a0vigil\u00e0ncia\u00a0\nepidemiol\u00f2gica\u00a0 del\u00a0 SIDA/VIH/ITS\u00a0 a\u00a0 catalunya\u00a0 (SIVES).\u00a0 Informe.\u00a0 Barcelona:\u00a0 Generalitat\u00a0 de\u00a0 Catalunya,\u00a0\nDepartament\u00a0de\u00a0Salut,\u00a0Direcci\u00f3\u00a0General\u00a0de\u00a0Salut\u00a0P\u00fablica;\u00a02013.\u00a0 Report\u00a0No.:\u00a021.\u00a0\u00a0\n45.\u00a0Egger\u00a0M,\u00a0May\u00a0M,\u00a0Chene\u00a0G,\u00a0Phillips\u00a0AN,\u00a0et\u00a0al.\u00a0Prognosis\u00a0of\u00a0H IV\u20101\u2010infected\u00a0patients\u00a0starting\u00a0highly\u00a0active\u00a0\nantiretroviral\u00a0therapy:\u00a0A\u00a0collabo rative\u00a0analysis\u00a0of\u00a0prospective \u00a0studies.\u00a0\u2010\u00a0Lancet.2002\u00a0Jul\u00a013;360(9327):119\u2010\n29.\u00a0\u00a0\u00a0\n 13246.\u00a0Phillips\u00a0A,\u00a0Pezzotti\u00a0P.\u00a0Short\u2010 term\u00a0risk\u00a0of\u00a0AIDS\u00a0according\u00a0t o\u00a0current\u00a0CD4\u00a0cell\u00a0count\u00a0and\u00a0viral\u00a0load\u00a0in\u00a0\nantiretroviral\u00a0drug\u2010naive\u00a0indivi duals\u00a0and\u00a0those\u00a0treated\u00a0in\u00a0the\u00a0 monotherapy\u00a0era.\u00a0\u2010\u00a0A IDS.2004\u00a0Jan\u00a02;18(1):51\u2010\n8.\u00a0\u00a0\n47.\u00a0Jaen\u00a0A,\u00a0Esteve\u00a0A,\u00a0Miro\u00a0JM,\u00a0Tural\u00a0C,\u00a0Montoliu\u00a0A,\u00a0Ferrer\u00a0E,\u00a0e t\u00a0al.\u00a0Determinants\u00a0of\u00a0HIV\u00a0progression\u00a0and\u00a0\nassessment\u00a0of\u00a0the\u00a0optimal\u00a0time\u00a0to\u00a0initiate\u00a0highly\u00a0active\u00a0antire troviral\u00a0therapy:\u00a0PISCIS\u00a0cohort\u00a0(Spain).\u00a0J\u00a0\nAcquir\u00a0Immune\u00a0Defic\u00a0Syndr.\u00a02008\u00a0Feb\u00a01;47(2):212\u201020.\u00a0\u00a048.\u00a0Marks\u00a0G,\u00a0Crepaz\u00a0N,\u00a0Senterfitt\u00a0JW,\u00a0Janssen\u00a0RS,\u00a0et\u00a0al.\u00a0Meta\u2010a nalysis\u00a0of\u00a0high\u2010risk\u00a0sexual\u00a0behavior\u00a0in\u00a0persons\u00a0\naware\u00a0and\u00a0unaware\u00a0they\u00a0are\u00a0infected\u00a0with\u00a0HIV\u00a0in\u00a0the\u00a0united\u00a0stat es:\u00a0Implications\u00a0for\u00a0HIV\u00a0prevention\u00a0\nprograms.\u00a0\u2010\u00a0J\u00a0Acquir\u00a0Immune\u00a0Def ic\u00a0Syndr.2005\u00a0Aug\u00a01;39(4):446\u201053 .\u00a0\u00a0\n49.\u00a0Antinori\u00a0A,\u00a0Coenen\u00a0T,\u00a0Costagiola\u00a0D,\u00a0Dedes\u00a0N,\u00a0et\u00a0al.\u00a0Late\u00a0pr esentation\u00a0of\u00a0HIV\u00a0infection:\u00a0A\u00a0consensus\u00a0\ndefinition.\u00a0\u2010\u00a0HIV\u00a0Med.2011\u00a0Jan;12(1):61\u20104.\u00a0\u00a0\n50.\u00a0Registros\u00a0Auton\u00f3micos\u00a0de\u00a0Casos\u00a0de\u00a0SIDA.\u00a0Centro\u00a0Nacional\u00a0de\u00a0 Epidemiolog\u00eda.\u00a0Vigilancia\u00a0Epidemiol\u00f3gica\u00a0\ndel\u00a0SIDA\u00a0en\u00a0Espa\u00f1a.\u00a0Registro\u00a0Nac ional\u00a0de\u00a0casos\u00a0de\u00a0SIDA.\u00a0Actuali zaci\u00f3n\u00a0a\u00a030\u00a0de\u00a0junio\u00a0de\u00a02010.\u00a0\u00a0\n51.\u00a0Caro\u2010Murillo\u00a0AM,\u00a0Gutierrez\u00a0F,\u00a0Manuel\u00a0Ramos\u00a0J,\u00a0Sobrino\u00a0P,\u00a0Mi ro\u00a0JM,\u00a0Lopez\u2010Cortes\u00a0LF,\u00a0et\u00a0al.\u00a0HIV\u00a0infection\u00a0\nin\u00a0immigrants\u00a0in\u00a0spain:\u00a0Epidemiol ogical\u00a0characteristics\u00a0and\u00a0cli nical\u00a0presentation\u00a0in\u00a0the\u00a0CoRIS\u00a0cohort\u00a0(2004\u2010\n2006).\u00a0Enferm\u00a0Infecc\u00a0Microbiol\u00a0 Clin.\u00a02009\u00a0Aug\u2010Sep;27(7):380\u20108.\u00a0 \u00a0\n52.\u00a0Booth\u00a0CL,\u00a0Geretti\u00a0AM.\u00a0Prevalence\u00a0and\u00a0determinants\u00a0of\u00a0transm itted\u00a0antiretroviral\u00a0drug\u00a0resistance\u00a0in\u00a0HIV\u2010\n1\u00a0infection.\u00a0J\u00a0Antimicrob\u00a0Ch emother.\u00a02007\u00a0Jun;59(6):1047\u201056.\u00a0\u00a0\n53.\u00a0Sax\u00a0PE,\u00a0Islam\u00a0R,\u00a0Walensky\u00a0RP,\u00a0Losina\u00a0E,\u00a0et\u00a0al.\u00a0Should\u00a0resis tance\u00a0testing\u00a0be\u00a0performed\u00a0for\u00a0treatment\u2010\nnaive\u00a0HIV\u2010infected\u00a0patients?\u00a0A\u00a0cost\u2010effectiveness\u00a0analysis.\u00a0\u2010\u00a0C lin\u00a0Infect\u00a0Dis.2005\u00a0Nov\u00a01;41(9):1316\u201023.\u00a0\u00a0\n54.\u00a0Hammer\u00a0SM,\u00a0Saag\u00a0MS,\u00a0Schechter\u00a0M,\u00a0Montaner\u00a0JSG,\u00a0et\u00a0al.\u00a0Treat ment\u00a0for\u00a0adult\u00a0HIV\u00a0infection:\u00a02006\u00a0\nrecommendations\u00a0of\u00a0the\u00a0internatio nal\u00a0AIDS\u00a0society\u2010USA\u00a0panel.\u00a0\u2010\u00a0 JAMA.2006\u00a0Aug\u00a016;296(7):827\u201043.\u00a0\u00a0\n55.\u00a0Rockstroh\u00a0JK,\u00a0Bhagani\u00a0S,\u00a0Benhamou\u00a0Y,\u00a0Bruno\u00a0R,\u00a0et\u00a0al.\u00a0Europe an\u00a0AIDS\u00a0clinical\u00a0society\u00a0(EACS)\u00a0guidelines\u00a0\nfor\u00a0the\u00a0clinical\u00a0management\u00a0and\u00a0treatment\u00a0of\u00a0chronic\u00a0hepatitis\u00a0 B\u00a0and\u00a0C\u00a0coinfection\u00a0in\u00a0HI V\u2010infected\u00a0adults.\u00a0\u2010\u00a0\nHIV\u00a0Med.2008\u00a0Feb;9(2):82\u20108.\u00a0\u00a056.\u00a0[National\u00a0consensus\u00a0document\u00a0by\u00a0GESIDA/National\u00a0aids\u00a0plan\u00a0o n\u00a0antiretroviral\u00a0treatment\u00a0in\u00a0adults\u00a0\ninfected\u00a0by\u00a0the\u00a0human\u00a0immunodeficiency\u00a0virus\u00a0(january\u00a02011\u00a0upda te)].\u00a0\u2010\u00a0Enferm\u00a0Infecc\u00a0Microbiol\u00a0Clin.2011\u00a0\nMar;29(3):209.e1\u2010103.\u00a0\u00a057.\u00a0 de\u00a0 Mendoza\u00a0 C,\u00a0 Rodriguez\u00a0 C,\u00a0 Eir os\u00a0 JM,\u00a0 Colomina\u00a0 J,\u00a0 Garcia\u00a0 F,\u00a0 Leiva\u00a0 P,\u00a0 et\u00a0 al.\u00a0 Antiretroviral\u00a0\nrecommendations\u00a0may\u00a0influence\u00a0the\u00a0rate\u00a0of\u00a0transmission\u00a0of\u00a0drug\u2010 resistant\u00a0HIV\u00a0type\u00a01.\u00a0Clin\u00a0Infect\u00a0Dis.\u00a02005\u00a0\nJul\u00a015;41(2):227\u201032.\u00a0\u00a058.\u00a0Johnson\u00a0VA,\u00a0Brun\u2010Vezinet\u00a0F,\u00a0Clotet\u00a0B,\u00a0Gunthard\u00a0HF,\u00a0Kuritzke s\u00a0DR,\u00a0Pillay\u00a0D,\u00a0et\u00a0al.\u00a0Update\u00a0of\u00a0the\u00a0drug\u00a0\nresistance\u00a0mutations\u00a0in\u00a0HIV\u20101. \u00a0Top\u00a0HIV\u00a0Med.\u00a02008\u00a0Dec;16(5):138\u2010 45.\u00a0\u00a0\n59.\u00a0Bennett\u00a0DE,\u00a0Camacho\u00a0RJ,\u00a0Otelea\u00a0D,\u00a0Kuritzkes\u00a0DR,\u00a0Fleury\u00a0H,\u00a0Kiuchi\u00a0M,\u00a0et\u00a0al.\u00a0Drug\u00a0resistance\u00a0mutations\u00a0for\u00a0\nsurveillance\u00a0of\u00a0transmitted\u00a0HIV\u2010 1\u00a0drug\u2010resistance:\u00a02009\u00a0update. \u00a0PLoS\u00a0One.\u00a02009;4(3):e4724.\u00a0\u00a0\n60.\u00a0SPREAD\u00a0programme.\u00a0Transmission\u00a0of\u00a0drug\u2010resistant\u00a0HIV\u20101\u00a0in\u00a0e urope\u00a0remains\u00a0limited\u00a0to\u00a0single\u00a0classes.\u00a0\nAIDS.\u00a02008\u00a0Mar\u00a012;22(5):625\u201035.\u00a0\u00a0\u00a0\n -  13361.\u00a0Garcia\u00a0F,\u00a0Perez\u2010Cachafeiro\u00a0S,\u00a0Guillot\u00a0V,\u00a0Alvarez\u00a0M,\u00a0et\u00a0al.\u00a0 Transmission\u00a0of\u00a0HIV\u00a0drug\u00a0resistance\u00a0and\u00a0non\u2010B\u00a0\nsubtype\u00a0 distribution\u00a0 in\u00a0 the\u00a0 span ish\u00a0 cohort\u00a0 of\u00a0 antiretroviral\u00a0 tr eatment\u00a0 naive\u00a0 HIV\u2010infected\u00a0 individuals\u00a0\n(CoRIS).\u00a0\u2010\u00a0Antiviral\u00a0Res.2011\u00a0Aug;91(2):150\u20103.\u00a0\u00a0\n62.\u00a0Yebra\u00a0G,\u00a0Holguin\u00a0A.\u00a0Epidemiol ogy\u00a0of\u00a0drug\u2010resistant\u00a0HIV\u20101\u00a0tr ansmission\u00a0in\u00a0naive\u00a0patients\u00a0in\u00a0spain.\u00a0Med\u00a0\nClin\u00a0(Barc).\u00a02010\u00a0Oct\u00a016;135(12):561\u20107.\u00a0\u00a0\n63.\u00a0Hamers\u00a0RL,\u00a0Wallis\u00a0CL,\u00a0Kityo\u00a0C,\u00a0Siwale\u00a0M,\u00a0et\u00a0al.\u00a0HIV\u20101\u00a0drug\u00a0 resistance\u00a0in\u00a0antiretroviral\u2010naive\u00a0individuals\u00a0\nin\u00a0sub\u2010saharan\u00a0africa\u00a0after\u00a0rollout\u00a0of\u00a0antiretroviral\u00a0therapy:\u00a0 A\u00a0multicentre\u00a0observational\u00a0study.\u00a0\u2010\u00a0Lancet\u00a0\nInfect\u00a0Dis.2011\u00a0Oct;11(10):750\u20109.\u00a0\u00a0\n64.\u00a0 de\u00a0 Mendoza\u00a0 C,\u00a0 Rodriguez\u00a0 C,\u00a0 C olomina\u00a0 J,\u00a0 Gutierrez\u00a0 F,\u00a0 Aguiler a\u00a0 A,\u00a0 Garc\u00eda\u00a0 F,\u00a0 et\u00a0 al.\u00a0\u00a0\nHIV\u20101\u00a0 non\u2010B\u00a0 subtypes\u00a0 are\u00a0 increasing\u00a0 in\u00a0 native\u00a0 recent\u00a0 seroconverters\u00a0 in\u00a0\nspain\u00a0 while\u00a0 transmission\u00a0 of\u00a0 drug\u00a0 resistance\u00a0 mutations\u00a0 is\u00a0 droppi ng.\u00a0 7th\u00a0 European\u00a0\nHIVDrugResistanceWorkshop.\u00a02009\u00a0 Mar\u00a025\u00a0\u2010\u00a027,\u00a0Stockholm,\u00a0Sweeden.\u00a0\u00a0\n65.\u00a0Holguin\u00a0A,\u00a0de\u00a0Mulder\u00a0M,\u00a0Yebra\u00a0G,\u00a0Lopez\u00a0M,\u00a0Soriano\u00a0V.\u00a0Increa se\u00a0of\u00a0non\u2010B\u00a0subtypes\u00a0and\u00a0recombinants\u00a0\namong\u00a0newly\u00a0diagnosed\u00a0HIV\u20101\u00a0native\u00a0spaniards\u00a0and\u00a0immigrants\u00a0in\u00a0 spain.\u00a0Curr\u00a0HIV\u00a0Res.\u00a02008\u00a0Jun;6(4):327\u2010\n34.\u00a0\u00a0\n66.\u00a0Lospitao\u00a0E,\u00a0Alvarez\u00a0A,\u00a0Soriano\u00a0V,\u00a0Holguin\u00a0A.\u00a0HIV\u20101\u00a0subtypes \u00a0in\u00a0spain:\u00a0A\u00a0retrospective\u00a0analysis\u00a0from\u00a01995\u00a0\nto\u00a02003.\u00a0HIV\u00a0Med.\u00a02005\u00a0Sep;6(5):313\u201020.\u00a0\u00a0\n67.\u00a0Brookmeyer\u00a0R,\u00a0Quinn\u00a0TC.\u00a0Estimation\u00a0of\u00a0current\u00a0human\u2010immunod eficiency\u2010virus\u00a0incidence\u00a0rates\u00a0from\u00a0a\u00a0\ncross\u2010sectional\u00a0survey\u00a0using\u00a0ear ly\u00a0diagnostic\u2010tests.\u00a0Am\u00a0J\u00a0Epide miol.\u00a01995\u00a0JAN\u00a015;141(2):166\u201072.\u00a0\u00a0\n68.\u00a0Busch\u00a0MP,\u00a0Glynn\u00a0SA,\u00a0Stramer\u00a0SL,\u00a0Strong\u00a0DM,\u00a0Caglioti\u00a0S,\u00a0Wrig ht\u00a0DJ,\u00a0et\u00a0al.\u00a0A\u00a0new\u00a0strategy\u00a0for\u00a0estimating\u00a0\nrisks\u00a0of\u00a0transfusion\u2010transmitted\u00a0 viral\u00a0infections\u00a0based\u00a0on\u00a0rate s\u00a0of\u00a0detection\u00a0of\u00a0rece ntly\u00a0infected\u00a0donors.\u00a0\nTransfusion.\u00a02005\u00a0FEB;45(2):254\u201064.\u00a0\u00a069.\u00a0Pilcher\u00a0CD,\u00a0Fiscus\u00a0SA,\u00a0Nguyen\u00a0TQ,\u00a0Foust\u00a0E,\u00a0Wolf\u00a0L,\u00a0Williams\u00a0D,\u00a0et\u00a0al.\u00a0Detection\u00a0of\u00a0acute\u00a0infections\u00a0during\u00a0\nHIV\u00a0testing\u00a0in\u00a0north\u00a0carolina .\u00a0N\u00a0Engl\u00a0J\u00a0Med.\u00a02005\u00a0MAY\u00a05;352(18) :1873\u201083.\u00a0\u00a0\n70.\u00a0Le\u00a0Vu\u00a0S,\u00a0Pillonel\u00a0J,\u00a0Semaille\u00a0C,\u00a0Bernillon\u00a0P,\u00a0Le\u00a0Strat\u00a0Y,\u00a0M eyer\u00a0L,\u00a0et\u00a0al.\u00a0Principles\u00a0and\u00a0uses\u00a0of\u00a0HIV\u00a0incidence\u00a0\nestimation\u00a0from\u00a0recent\u00a0infection \u00a0testing\u2010\u2010a\u00a0review.\u00a0Euro\u00a0Survei ll.\u00a02008\u00a0Sep\u00a04;13(36):18969.\u00a0\u00a0\n71.\u00a0Murphy\u00a0G,\u00a0Parry\u00a0JV.\u00a0Assays\u00a0for\u00a0the\u00a0detection\u00a0of\u00a0recent\u00a0infe ctions\u00a0with\u00a0human\u00a0immunodeficiency\u00a0virus\u00a0\ntype\u00a01.\u00a0Euro\u00a0Surveill. \u00a02008\u00a0Sep\u00a04;13(36):18966.\u00a0\u00a0\n72.\u00a0Janssen\u00a0RS,\u00a0Satten\u00a0GA,\u00a0Strame r\u00a0SL,\u00a0Rawal\u00a0BD,\u00a0O'Brien\u00a0TR,\u00a0We iblen\u00a0BJ,\u00a0et\u00a0al.\u00a0New\u00a0testing\u00a0strategy\u00a0to\u00a0\ndetect\u00a0early\u00a0HIV\u20101\u00a0infection\u00a0for \u00a0use\u00a0in\u00a0incidence\u00a0estimates\u00a0and \u00a0for\u00a0clinical\u00a0and\u00a0prevention\u00a0purposes.\u00a0JAMA.\u00a0\n1998\u00a0Jul\u00a01;280(1):42\u20108.\u00a0\u00a0\n73.\u00a0Kothe\u00a0D,\u00a0Byers\u00a0RH,\u00a0Caudill\u00a0 SP,\u00a0Satten\u00a0GA,\u00a0Janssen\u00a0RS,\u00a0Hanno n\u00a0WH,\u00a0et\u00a0al.\u00a0Performance\u00a0characteristics\u00a0of\u00a0a\u00a0\nnew\u00a0less\u00a0sensitive\u00a0HIV\u20101\u00a0enzyme\u00a0 immunoassay\u00a0for\u00a0use\u00a0in\u00a0estimati ng\u00a0HIV\u00a0seroincidence.\u00a0J\u00a0Acquir\u00a0Immune\u00a0\nDefic\u00a0Syndr.\u00a02003\u00a0Aug\u00a015;33(5):625\u201034.\u00a0\u00a074.\u00a0Parekh\u00a0BS,\u00a0Kennedy\u00a0MS,\u00a0Dobbs\u00a0T,\u00a0Pau\u00a0CP,\u00a0Byers\u00a0R,\u00a0Green\u00a0T,\u00a0e t\u00a0al.\u00a0Quantitative\u00a0detection\u00a0of\u00a0increasing\u00a0\nHIV\u00a0 type\u00a0 1\u00a0 antibodies\u00a0 after\u00a0 seroconversion:\u00a0 A\u00a0 simple\u00a0 assay\u00a0 for\u00a0 detecting\u00a0 recent\u00a0 HIV\u00a0 infection\u00a0 and\u00a0\nestimating\u00a0incidence.\u00a0AIDS\u00a0Res \u00a0Hum\u00a0Retroviruses.\u00a02002\u00a0Mar\u00a01;18( 4):295\u2010307.\u00a0\u00a0\n75.\u00a0 Calypte\u00a0Biomedical\u00a0Corporatio n.\u00a0Product\u00a0inse rt\u00a0for:\u00a0Calypte (R)\u00a0HIV\u20101\u00a0BED\u00a0incidence\u00a0EIA.\u00a0enzyme\u00a0\nimmunoassay\u00a0for\u00a0population\u00a0estimates\u00a0of\u00a0HIV\u20101\u00a0incidence.\u00a0In\u00a0pre ss\u00a02004.\u00a0\u00a0\u00a0\n 13476.\u00a0 Parekh\u00a0 BS,\u00a0 McDougal\u00a0 JS.\u00a0 New\u00a0 approaches\u00a0 for\u00a0 detecting\u00a0 recent \u00a0 HIV\u20101\u00a0 infection.\u00a0 AIDS\u00a0 Rev.\u00a0 2001\u00a0\n2001;3:183\u201093.\u00a0\u00a0\n77.\u00a0Guy\u00a0R,\u00a0Gold\u00a0J,\u00a0Calleja\u00a0JM,\u00a0Kim \u00a0AA,\u00a0Parekh\u00a0B,\u00a0Busch\u00a0M,\u00a0et\u00a0al .\u00a0Accuracy\u00a0of\u00a0serological\u00a0 assays\u00a0for\u00a0detection\u00a0of\u00a0\nrecent\u00a0infection\u00a0with\u00a0HIV\u00a0and\u00a0es timation\u00a0of\u00a0population\u00a0incidenc e:\u00a0A\u00a0systematic\u00a0review.\u00a0Lancet\u00a0Infect\u00a0Dis.\u00a0\n2009\u00a0Dec;9(12):747\u201059.\u00a0\u00a0\n78.\u00a0Suligoi\u00a0B,\u00a0Massi\u00a0M,\u00a0Galli\u00a0C,\u00a0Sciandra\u00a0M,\u00a0Di\u00a0Sora\u00a0F,\u00a0Pezzott i\u00a0P,\u00a0et\u00a0al.\u00a0Identifying\u00a0recent\u00a0HIV\u00a0infections\u00a0using\u00a0\nthe\u00a0 avidity\u00a0 index\u00a0 and\u00a0 an\u00a0 automated\u00a0 enzyme\u00a0 immunoassay.\u00a0 J\u00a0 Acquir\u00a0 Immune\u00a0 Defic\u00a0 Syndr.\u00a0 2003\u00a0 Apr\u00a0\n1;32(4):424\u20108.\u00a0\u00a0\n79.\u00a0Martro\u00a0E,\u00a0Suligoi\u00a0B,\u00a0Gonzalez\u00a0V,\u00a0Bossi\u00a0V,\u00a0Esteve\u00a0A,\u00a0Mei\u00a0J,\u00a0 et\u00a0al.\u00a0Comparison\u00a0of\u00a0the\u00a0avidity\u00a0index\u00a0method\u00a0\nand\u00a0the\u00a0serologic\u00a0testing\u00a0algorithm\u00a0for\u00a0recent\u00a0human\u00a0immunodefi ciency\u00a0virus\u00a0(HIV)\u00a0seroconversion,\u00a0two\u00a0\nmethods\u00a0using\u00a0a\u00a0single\u00a0serum\u00a0samp le\u00a0for\u00a0identification\u00a0of\u00a0recent\u00a0HIV\u00a0infections.\u00a0J\u00a0Clin\u00a0Microbiol.\u00a02005\u00a0\nDec;43(12):6197\u20109.\u00a0\u00a0\n80.\u00a0Barin\u00a0F,\u00a0Meyer\u00a0L,\u00a0Lancar\u00a0R,\u00a0Deveau\u00a0C,\u00a0Gharib\u00a0M,\u00a0Laporte\u00a0A,\u00a0 et\u00a0al.\u00a0Development\u00a0and\u00a0validation\u00a0of\u00a0an\u00a0\nimmunoassay\u00a0for\u00a0identification\u00a0o f\u00a0recent\u00a0human\u00a0immunodeficiency \u00a0virus\u00a0type\u00a01\u00a0infections\u00a0and\u00a0its\u00a0use\u00a0on\u00a0\ndried\u00a0serum\u00a0spots.\u00a0J\u00a0Clin\u00a0Microbiol.\u00a02005\u00a0Sep;43(9):4441\u20107.\u00a0\u00a081.\u00a0Mastro\u00a0TD,\u00a0Kim\u00a0AA,\u00a0Hallett\u00a0T,\u00a0Rehle\u00a0T,\u00a0Welte\u00a0A,\u00a0Laeyendecker\u00a0O,\u00a0et\u00a0al.\u00a0Estimating\u00a0HIV\u00a0incidence\u00a0in\u00a0\npopulations\u00a0using\u00a0tests\u00a0for\u00a0recent\u00a0infection:\u00a0Issues,\u00a0challenge s\u00a0and\u00a0the\u00a0way\u00a0forward.\u00a0\u2010\u00a0J\u00a0HIV\u00a0AIDS\u00a0Surveill\u00a0\nEpidemiol.2010\u00a0Jan\u00a01;2(1):1\u201014.\u00a0\u00a0\n82.\u00a0Young\u00a0CL,\u00a0Hu\u00a0DJ,\u00a0Byers\u00a0R,\u00a0Van ichseni\u00a0S,\u00a0Young\u00a0NL,\u00a0Nelson\u00a0R, \u00a0et\u00a0al.\u00a0Evaluation\u00a0of\u00a0a\u00a0sensitive/less\u00a0sensitive\u00a0\ntesting\u00a0algorithm\u00a0using\u00a0the\u00a0bioMerieux\u00a0vironostika\u2010LS\u00a0assay\u00a0for \u00a0detecting\u00a0recent\u00a0HIV\u20101\u00a0subtype\u00a0B'\u00a0or\u00a0E\u00a0\ninfection\u00a0in\u00a0thailand.\u00a0AIDS\u00a0Res\u00a0Hum\u00a0Retroviruses.\u00a02003\u00a0Jun;19(6 ):481\u20106.\u00a0\u00a0\n83.\u00a0 Parekh\u00a0 BS,\u00a0 Hanson\u00a0 DL,\u00a0 Hargrove\u00a0 J,\u00a0 Branson\u00a0 B,\u00a0 et\u00a0 al.\u00a0 Determination\u00a0 of\u00a0 mean\u00a0 recency\u00a0 period\u00a0 for\u00a0\nestimation\u00a0of\u00a0HIV\u00a0type\u00a01\u00a0incidence\u00a0with\u00a0the\u00a0BED\u2010capture\u00a0EIA\u00a0in\u00a0 persons\u00a0infected\u00a0with\u00a0diverse\u00a0subtypes.\u00a0\u2010\u00a0\nAIDS\u00a0Res\u00a0Hum\u00a0Retroviru ses.2011\u00a0Mar;27(3):265\u201073.\u00a0\u00a0\n84.\u00a0Lange\u00a0JM,\u00a0Paul\u00a0DA,\u00a0Huisman\u00a0HG,\u00a0de\u00a0Wolf\u00a0F,\u00a0et\u00a0al.\u00a0Persistent \u00a0HIV\u00a0antigenaemia\u00a0and\u00a0decline\u00a0of\u00a0HIV\u00a0core\u00a0\nantibodies\u00a0associated\u00a0with\u00a0transi tion\u00a0to\u00a0AIDS.\u00a0Br\u00a0Med\u00a0J\u00a0(Clin\u00a0Res\u00a0Ed).1986\u00a0Dec\u00a06;293(6560):1459\u201062.\u00a0\u00a0\n85.\u00a0Gupta\u00a0SB,\u00a0Murphy\u00a0G,\u00a0Koenig\u00a0E,\u00a0Adon\u00a0C,\u00a0Beyrer\u00a0C,\u00a0Celentano\u00a0D ,\u00a0et\u00a0al.\u00a0Comparison\u00a0of\u00a0methods\u00a0to\u00a0detect\u00a0\nrecent\u00a0HIV\u00a0type\u00a01\u00a0infection\u00a0in\u00a0c ross\u2010sectionally\u00a0collected\u00a0spec imens\u00a0from\u00a0a\u00a0cohort\u00a0of\u00a0female\u00a0sex\u00a0workers\u00a0in\u00a0\nthe\u00a0dominican\u00a0republic.\u00a0AIDS\u00a0Re s\u00a0Hum\u00a0Retroviruses.\u00a02007\u00a0Dec;23(12):1475\u201080.\u00a0\u00a0\n86.\u00a0Incidence\u00a0Assay\u00a0Critical\u00a0Path,Working\u00a0Group.\u00a0More\u00a0and\u00a0bette r\u00a0information\u00a0to\u00a0tackle\u00a0HIV\u00a0epidemics:\u00a0\nTowards\u00a0improved\u00a0HIV\u00a0incidence \u00a0assays.\u00a0PLoS\u00a0Med.\u00a02011\u00a006/14;8(6 ):e1001045.\u00a0\u00a0\n87.\u00a0Laeyendecker\u00a0O,\u00a0Oliver\u00a0M,\u00a0Owe n\u00a0S,\u00a0Kirk\u00a0G,\u00a0Mehta\u00a0S,\u00a0Koblin\u00a0B ,\u00a0et\u00a0al.\u00a0Improved\u00a0precis ion\u00a0of\u00a0cross\u2010sectional\u00a0\nHIV\u00a0incidence\u00a0testing\u00a0using\u00a0a\u00a0multi\u2010assay\u00a0algorithm\u00a0that\u00a0includes\u00a0BED\u00a0and\u00a0an\u00a0avidity\u00a0assay\u00a0with\u00a0modified\u00a0assay\u00a0cut\u2010offs.\u00a017th\u00a0Conference\u00a0on\u00a0Retroviruses\u00a0and\u00a0Opportunist ic\u00a0Infections,\u00a0San\u00a0Francisco.\u00a02010;Poster\u00a0\n#935.\u00a0\u00a0\n88.\u00a0Laeyendecker\u00a0O,\u00a0Brookmeyer\u00a0R,\u00a0Mullis\u00a0C,\u00a0Donnell\u00a0D,\u00a0Lingappa \u00a0J,\u00a0Celum\u00a0C,\u00a0et\u00a0al.\u00a0Specificity\u00a0of\u00a0four\u00a0\nlaboratory\u00a0approaches\u00a0for\u00a0cross\u2010se ctional\u00a0HIV\u00a0incidence\u00a0determi nation:\u00a0Analysis\u00a0of\u00a0samples\u00a0from\u00a0adults\u00a0\nwith\u00a0 known\u00a0 non\u2010recent\u00a0 HIV\u00a0 infection\u00a0 from\u00a0 five\u00a0 african\u00a0 countries .\u00a0 AIDS\u00a0 Res\u00a0 Hum\u00a0 Retroviruses.2012\u00a0\nOct;28(10):1177\u201083.\u00a089.\u00a0UNAIDS/WHO\u00a0Working\u00a0group\u00a0on\u00a0Global\u00a0HIV/AIDS\u00a0and\u00a0STI\u00a0Surveil lance.\u00a0When\u00a0and\u00a0how\u00a0to\u00a0use\u00a0assays\u00a0\nfor\u00a0recent\u00a0infection\u00a0to\u00a0estimate \u00a0HIV\u00a0incidence\u00a0at\u00a0a\u00a0population\u00a0 level.\u00a0Geneva:\u00a0WHO\u00a0Press;\u00a02011.\u00a0\u00a0\u00a0\n -  13590.\u00a0Braunstein\u00a0SL,\u00a0Nash\u00a0D,\u00a0Kim\u00a0AA,\u00a0Ford\u00a0K,\u00a0et\u00a0al.\u00a0Dual\u00a0testing\u00a0 algorithm\u00a0of\u00a0BED\u2010CEIA\u00a0and\u00a0AxSYM\u00a0avidity\u00a0\nindex\u00a0assays\u00a0performs\u00a0best\u00a0in\u00a0identifying\u00a0recent\u00a0HIV\u00a0infection\u00a0 in\u00a0a\u00a0sample\u00a0of\u00a0rwandan\u00a0sex\u00a0workers.\u00a0PLoS\u00a0\nOne.2011\u00a0Apr\u00a012;6(4):e18402.\u00a0\u00a0\n9 1 . \u00a0B a t z i n g \u2010 F e i g e n b a u m \u00a0J , \u00a0L o s c h e n \u00a0S , \u00a0G o h l k e \u2010 M i c k n i s \u00a0S , \u00a0H i n t s c h e \u00a0B , \u00a0R a u s c h \u00a0M , \u00a0H i l l e n b r a n d \u00a0H , \u00a0e t \u00a0a l . \u00a0\nImplications\u00a0of\u00a0and\u00a0perspectives\u00a0on\u00a0HIV\u00a0surveillance\u00a0using\u00a0a\u00a0se rological\u00a0method\u00a0to\u00a0measure\u00a0recent\u00a0HIV\u00a0\ninfections\u00a0in\u00a0newly\u00a0diagnosed\u00a0individuals:\u00a0Results\u00a0from\u00a0a\u00a0pilot \u00a0study\u00a0in\u00a0berlin,\u00a0germany,\u00a0in\u00a02005\u20102007.\u00a0HIV\u00a0\nMed.\u00a02009\u00a0Apr;10(4):209\u201018.\u00a0\u00a0\n92.\u00a0Semaille\u00a0C,\u00a0Cazein\u00a0F,\u00a0Pillonel\u00a0J,\u00a0Lot\u00a0F,\u00a0Le\u00a0Vu\u00a0S,\u00a0Pinget\u00a0R,\u00a0et\u00a0al.\u00a0Four\u00a0years\u00a0of\u00a0surveillance\u00a0of\u00a0recent\u00a0HIV\u00a0\ninfections\u00a0at\u00a0country\u00a0level,\u00a0france,\u00a0mid\u00a02003\u00a0\u2010\u00a02006:\u00a0Experienc e\u00a0and\u00a0perspectives.\u00a0Euro\u00a0Surveill.\u00a02008\u00a0Sep\u00a0\n4;13(36):18968.\u00a0\u00a0\n93.\u00a0Karon\u00a0JM,\u00a0Song\u00a0R,\u00a0Brookmeyer\u00a0R,\u00a0Kaplan\u00a0EH,\u00a0Hall\u00a0HI.\u00a0Estimat ing\u00a0HIV\u00a0incidence\u00a0in\u00a0the\u00a0united\u00a0states\u00a0from\u00a0\nHIV/AIDS\u00a0surveillance\u00a0data\u00a0and\u00a0b iomarker\u00a0HIV\u00a0test\u00a0results.\u00a0Stat \u00a0Med.\u00a02008\u00a0Oct\u00a015;27(23):4617\u201033.\u00a0\u00a0\n94.\u00a0Hall\u00a0HI,\u00a0Song\u00a0R,\u00a0Rhodes\u00a0P,\u00a0Prejean\u00a0J,\u00a0An\u00a0Q,\u00a0Lee\u00a0LM,\u00a0et\u00a0al.\u00a0 Estimation\u00a0of\u00a0HIV\u00a0incidenc e\u00a0in\u00a0the\u00a0united\u00a0states.\u00a0\nJAMA.\u00a02008\u00a0Aug\u00a06;300(5):520\u20109.\u00a0\u00a0\n95.\u00a0Le\u00a0Vu\u00a0S,\u00a0Le\u00a0Strat\u00a0Y,\u00a0Barin\u00a0F,\u00a0Pillonel\u00a0J,\u00a0Cazein\u00a0F,\u00a0Bousquet\u00a0V,\u00a0et\u00a0al.\u00a0Population\u2010based\u00a0HIV\u20101\u00a0incidence\u00a0in\u00a0\nfrance,\u00a02003\u201008:\u00a0A\u00a0modelling\u00a0analysis.\u00a0Lancet\u00a0Infect\u00a0Dis.\u00a02010\u00a0 Oct;10(10):682\u20107.\u00a0\u00a0\n96.\u00a0Oyugi\u00a0JO,\u00a0Oyugi\u00a0FJ,\u00a0Otieno\u00a0CA,\u00a0Jaoko\u00a0W,\u00a0Bwayo\u00a0JJ,\u00a0Anzala\u00a0O. \u00a0Serologic\u00a0testing\u00a0algorithm\u00a0for\u00a0recent\u00a0HIV\u00a0\nseroconversion\u00a0in\u00a0estimating\u00a0inci dence\u00a0of\u00a0HIV\u20101\u00a0among\u00a0adults\u00a0vi siting\u00a0a\u00a0VCT\u00a0centre\u00a0at\u00a0a\u00a0kenyan\u00a0tertiary\u00a0\nhealth\u00a0institution.\u00a0East\u00a0Afr\u00a0Med\u00a0J.\u00a02009\u00a0May;86(5):212\u20108.\u00a0\u00a0\n97.\u00a0Thiede\u00a0H,\u00a0Jenkins\u00a0RA,\u00a0Carey\u00a0JW,\u00a0Hutcheson\u00a0R,\u00a0Thomas\u00a0KK,\u00a0Sta ll\u00a0RD,\u00a0et\u00a0al.\u00a0Determinants\u00a0of\u00a0recent\u00a0HIV\u00a0\ninfection\u00a0among\u00a0seattle\u2010area\u00a0men \u00a0who\u00a0have\u00a0sex\u00a0with\u00a0men.\u00a0Am\u00a0J\u00a0Pu blic\u00a0Health.\u00a02008\u00a0May\u00a029.\u00a0\u00a0\n98.\u00a0White\u00a0E,\u00a0Goldbaum\u00a0G,\u00a0Goodreau\u00a0S,\u00a0Lumley\u00a0T,\u00a0et\u00a0al.\u00a0Interpopu lation\u00a0variation\u00a0in\u00a0HIV\u00a0testing\u00a0promptness\u00a0\nm a y \u00a0i n t r o d u c e \u00a0b i a s \u00a0i n \u00a0H I V \u00a0i n c i d e n c e \u00a0e s t i m a t e s \u00a0u s i n g \u00a0t h e \u00a0s e r o l o g i c \u00a0t e s t i n g \u00a0a l g o r i t h m \u00a0f o r \u00a0r e c e n t \u00a0H I V \u00a0\nseroconversion.\u00a0\u2010\u00a0Sex\u00a0Transm\u00a0 Infect.2010\u00a0Aug;86(4):254\u20107.\u00a0\u00a0\n99.\u00a0Schwarcz\u00a0S,\u00a0Weinstock\u00a0H,\u00a0Louie\u00a0B,\u00a0Kellogg\u00a0T,\u00a0Douglas\u00a0J,\u00a0Lal ota\u00a0M,\u00a0et\u00a0al.\u00a0Characteristics\u00a0of\u00a0persons\u00a0with\u00a0\nrecently\u00a0 acquired\u00a0 HIV\u00a0 infection: \u00a0A p p l i c a t i o n \u00a0o f \u00a0t h e \u00a0s e r o l o g i c \u00a0t e s t i n g \u00a0a l g o r i t h m \u00a0f o r \u00a0r e c e n t \u00a0H I V \u00a0\nseroconversion\u00a0in\u00a010\u00a0US\u00a0cities.\u00a0J \u00a0Acquir\u00a0Immune\u00a0Defic\u00a0Syndr.\u00a020 07\u00a0Jan\u00a01;44(1):112\u20105.\u00a0\u00a0\n100.\u00a0Fisher\u00a0M,\u00a0Pao\u00a0D,\u00a0Murphy\u00a0G,\u00a0Dean\u00a0G,\u00a0McElborough\u00a0D,\u00a0Homer\u00a0G, \u00a0et\u00a0al.\u00a0Serological\u00a0testing\u00a0algorithm\u00a0\nshows\u00a0rising\u00a0HIV\u00a0incidence\u00a0in\u00a0a\u00a0UK\u00a0cohort\u00a0of\u00a0men\u00a0who\u00a0have\u00a0sex\u00a0w ith\u00a0men:\u00a010\u00a0years\u00a0application.\u00a0AIDS.\u00a02007\u00a0\nNov\u00a012;21(17):2309\u201014.\u00a0\u00a0\n101.\u00a0Semaille\u00a0C,\u00a0Cazein\u00a0F,\u00a0Lot\u00a0F,\u00a0Pillonel\u00a0J,\u00a0Le\u00a0Vu\u00a0S,\u00a0Le\u00a0Strat \u00a0Y,\u00a0et\u00a0al.\u00a0Recently\u00a0acquired\u00a0HIV\u00a0infection\u00a0in\u00a0men\u00a0\nwho\u00a0have\u00a0sex\u00a0with\u00a0men\u00a0(MSM)\u00a0in \u00a0france,\u00a02003\u20102008.\u00a0Euro\u00a0Surveill .\u00a02009\u00a0Dec\u00a03;14(48):19425.\u00a0\u00a0\n102.\u00a0Bassichetto\u00a0KC,\u00a0Bergamaschi\u00a0DP,\u00a0Oliveira\u00a0SM,\u00a0Deienno\u00a0MC,\u00a0B ortolato\u00a0R,\u00a0de\u00a0Rezende\u00a0HV,\u00a0et\u00a0al.\u00a0Elevated\u00a0\nrisk\u00a0 for\u00a0 HIV\u20101\u00a0 infection\u00a0 in\u00a0 adol escents\u00a0 and\u00a0 young\u00a0 adults\u00a0 in\u00a0 sao \u00a0 paulo,\u00a0 brazil.\u00a0 PLoS\u00a0 ONE.\u00a0 2008\u00a0 Jan\u00a0\n9;3(1):e1423.\u00a0\u00a0103.\u00a0Mermin\u00a0J,\u00a0Musinguzi\u00a0J,\u00a0Opio\u00a0A,\u00a0Kirungi\u00a0W,\u00a0Ekwaru\u00a0JP,\u00a0Hladi k\u00a0W,\u00a0et\u00a0al.\u00a0Risk\u00a0factors\u00a0for\u00a0recent\u00a0HIV\u00a0\ninfection\u00a0in\u00a0uganda.\u00a0JAMA.\u00a02008\u00a0Aug\u00a06;300(5):540\u20109.\u00a0\u00a0104.\u00a0Hu\u00a0DJ,\u00a0Vanichseni\u00a0S,\u00a0Mock\u00a0PA,\u00a0Young\u00a0NL,\u00a0Dobbs\u00a0T,\u00a0Byers\u00a0RH, Jr,\u00a0et\u00a0al.\u00a0HIV\u00a0type\u00a01\u00a0incidence\u00a0estimates\u00a0by\u00a0\ndetection\u00a0of\u00a0recent\u00a0infection\u00a0from\u00a0a\u00a0cross\u2010sectional\u00a0sampling\u00a0o f\u00a0injection\u00a0drug\u00a0users\u00a0in\u00a0bangkok:\u00a0Use\u00a0of\u00a0the\u00a0\nIgG\u00a0capture\u00a0BED\u00a0enzyme\u00a0immunoassa y.\u00a0AIDS\u00a0Res\u00a0Hum\u00a0Retroviruses.\u00a0 2003\u00a0Sep;19(9):727\u201030.\u00a0\u00a0\u00a0\n 136105.\u00a0Taylor\u00a0MM,\u00a0Hawkins\u00a0K,\u00a0Gonzalez\u00a0A,\u00a0Buchacz\u00a0K,\u00a0Aynalem\u00a0G,\u00a0Sm ith\u00a0LV,\u00a0et\u00a0al.\u00a0Use\u00a0of\u00a0the\u00a0serologic\u00a0testing\u00a0\nalgorithm\u00a0for\u00a0recent\u00a0HIV\u00a0seroconversion\u00a0(STARHS)\u00a0to\u00a0identify\u00a0re cently\u00a0acquired\u00a0HIV\u00a0infections\u00a0in\u00a0men\u00a0with\u00a0\nearly\u00a0syphilis\u00a0in\u00a0Los\u00a0Angeles\u00a0cou nty.\u00a0J\u00a0Acquir\u00a0Immune\u00a0Defic\u00a0Syndr.\u00a02005\u00a0Apr\u00a015;38(5):505\u20108.\u00a0\u00a0\n106.\u00a0Cortes\u00a0Martins\u00a0H,\u00a0Paixao\u00a0M.\u00a0Settings\u00a0for\u00a0identifying\u00a0recen t\u00a0HIV\u00a0infections:\u00a0The\u00a0portuguese\u00a0experience.\u00a0\nEuro\u00a0Surveill.\u00a02008\u00a0Sep\u00a04;13(36):18974.\u00a0\u00a0\n107.\u00a0Niccolai\u00a0LM,\u00a0Verevochkin\u00a0SV,\u00a0 Toussova\u00a0OV,\u00a0Whi te\u00a0E,\u00a0et\u00a0al.\u00a0Estimates\u00a0of\u00a0HIV\u00a0incidence\u00a0among\u00a0drug\u00a0users\u00a0\nin\u00a0St.\u00a0Petersburg,\u00a0Russia:\u00a0Continued\u00a0growth\u00a0of\u00a0a\u00a0rapidly\u00a0expand ing\u00a0epidemic.\u00a0Eur\u00a0J\u00a0Public\u00a0Health.2011\u00a0\nOct;21(5):613\u20109.\u00a0\u00a0\n108.\u00a0Garrett\u00a0N,\u00a0Lattimore\u00a0S,\u00a0Gilbart\u00a0V,\u00a0Aghaizu\u00a0A,\u00a0Mensah\u00a0G,\u00a0Tosswill\u00a0J,\u00a0et\u00a0al.\u00a0The\u00a0recent\u00a0infection\u00a0testing\u00a0\nalgorithm\u00a0(RITA)\u00a0in\u00a0clinical\u00a0practice:\u00a0A\u00a0survey\u00a0of\u00a0HIV\u00a0clinicia ns\u00a0in\u00a0England\u00a0and\u00a0Northern\u00a0Ireland.\u00a0HIV\u00a0\nMed.2012\u00a0Aug;13(7):444\u20107.\u00a0\u00a0\n109.\u00a0Jayaraman\u00a0GC,\u00a0Archibald\u00a0CP,\u00a0Kim\u00a0J,\u00a0Rekart\u00a0ML,\u00a0Singh\u00a0AE,\u00a0Ha rmen\u00a0S,\u00a0et\u00a0al.\u00a0A\u00a0population\u2010based\u00a0approach\u00a0\nt o \u00a0d e t e r m i n e \u00a0t h e \u00a0p r e v a l e n c e \u00a0o f \u00a0t r a n s m i t t e d \u00a0d r u g \u2010 r e s i s t a n t \u00a0H I V \u00a0a mong\u00a0 recent\u00a0 versus\u00a0 established\u00a0 HIV\u00a0\ninfections:\u00a0 Results\u00a0 from\u00a0 the\u00a0 canadian\u00a0 HIV\u00a0 strain\u00a0 and\u00a0 drug\u00a0 resistance\u00a0 surveillance\u00a0 program.\u00a0 J\u00a0 Acquir\u00a0\nImmune\u00a0Defic\u00a0Syndr.\u00a02006\u00a0May;42(1):86\u201090.\u00a0\u00a0\n110.\u00a0Murillo\u00a0W,\u00a0Paz\u2010Bailey\u00a0G,\u00a0Morales\u00a0S,\u00a0Monterroso\u00a0E,\u00a0et\u00a0al.\u00a0T ransmitted\u00a0drug\u00a0resistance\u00a0and\u00a0type\u00a0of\u00a0\ninfection\u00a0in\u00a0newly\u00a0diagnosed\u00a0HIV \u20101\u00a0individuals\u00a0i n\u00a0honduras.\u00a0J\u00a0Clin\u00a0Virol.2010\u00a0Dec;49(4):239\u201044.\u00a0\u00a0\n111.\u00a0Hurt\u00a0CB,\u00a0McCoy\u00a0SI,\u00a0Kuruc\u00a0J,\u00a0Nelson\u00a0JA,\u00a0et\u00a0al.\u00a0Transmitted\u00a0 antiretroviral\u00a0drug\u00a0resistance\u00a0among\u00a0acute\u00a0\nand\u00a0recent\u00a0HIV\u00a0infections\u00a0in\u00a0North\u00a0Carolina\u00a0from\u00a01998\u00a0to\u00a02007.\u00a0 \u2010\u00a0Antivir\u00a0Ther.2009;14(5):673\u20108.\u00a0\u00a0\n112.\u00a0Wang\u00a0MJ,\u00a0Duan\u00a0S,\u00a0Xiang\u00a0LF,\u00a0Yang\u00a0Y,\u00a0et\u00a0al.\u00a0[Study\u00a0on\u00a0the\u00a0drug\u00a0resistance\u00a0situation\u00a0among\u00a0recently\u00a0\ninfected\u00a0HIV\u20101\u00a0patients\u00a0in\u00a0dehon g].\u00a0\u2010\u00a0Zhonghua\u00a0Liu\u00a0Xing\u00a0Bing\u00a0Xu e\u00a0Za\u00a0Zhi.2008\u00a0Sep;29(9):905\u20108.\u00a0\u00a0\n113.\u00a0 Antiretroviral\u00a0 Therapy\u00a0 Cohort \u00a0 Collaboration.\u00a0 Life\u00a0 expectan cy\u00a0 of\u00a0 individuals\u00a0 on\u00a0 combination\u00a0\nantiretroviral\u00a0therapy\u00a0in\u00a0high\u2010i ncome\u00a0countries:\u00a0A\u00a0collaborativ e\u00a0analysis\u00a0of\u00a014\u00a0cohort\u00a0studies.\u00a0Lancet.\u00a02008\u00a0\nJul\u00a026;372(9635):293\u20109.\u00a0\u00a0\n114.\u00a0Des\u00a0Jarlais\u00a0DC,\u00a0Perlis\u00a0T,\u00a0Arasteh\u00a0K,\u00a0Torian\u00a0LV,\u00a0Beatrice\u00a0S,\u00a0Milliken\u00a0J,\u00a0et\u00a0al.\u00a0HIV\u00a0inc idence\u00a0among\u00a0injection\u00a0\ndrug\u00a0users\u00a0in\u00a0New\u00a0York\u00a0city,\u00a01990\u00a0to\u00a02002:\u00a0Use\u00a0of\u00a0serologic\u00a0tes t\u00a0algorithm\u00a0to\u00a0assess\u00a0expansion\u00a0of\u00a0HIV\u00a0\nprevention\u00a0services.\u00a0Am\u00a0J\u00a0Publ ic\u00a0Health.\u00a02005\u00a0Aug;95(8):1439\u201044 .\u00a0\u00a0\n115.\u00a0Kim\u00a0AA,\u00a0Hallett\u00a0T,\u00a0Stover\u00a0J,\u00a0Gouws\u00a0E,\u00a0et\u00a0al.\u00a0Estimating\u00a0HI V\u00a0incidence\u00a0among\u00a0adults\u00a0in\u00a0Kenya\u00a0and\u00a0\nUganda:\u00a0A\u00a0systematic\u00a0comparison\u00a0 of\u00a0multiple\u00a0methods.\u00a0\u2010\u00a0PLoS\u00a0One .2011\u00a0Mar\u00a07;6(3):e17535.\u00a0\u00a0\n116.\u00a0Kellogg\u00a0TA,\u00a0Loeb\u00a0L,\u00a0Dilley\u00a0J,\u00a0Adler\u00a0B,\u00a0Louie\u00a0BT,\u00a0McFarland \u00a0W.\u00a0Comparison\u00a0of\u00a0three\u00a0methods\u00a0to\u00a0measure\u00a0\nHIV\u00a0incidence\u00a0among\u00a0persons\u00a0seek ing\u00a0voluntary,\u00a0anonymous\u00a0counse ling\u00a0and\u00a0testing.\u00a0J\u00a0 Acquir\u00a0Immune\u00a0Defic\u00a0\nSyndr.\u00a02005\u00a0May\u00a01;39(1):112\u201020.\u00a0\u00a0117.\u00a0Hargrove\u00a0JW,\u00a0Humphrey\u00a0JH,\u00a0Mutasa\u00a0K,\u00a0Parekh\u00a0BS,\u00a0McDougal\u00a0JS ,\u00a0Ntozini\u00a0R,\u00a0et\u00a0al.\u00a0Improved\u00a0HIV\u20101\u00a0\nincidence\u00a0estimates\u00a0using\u00a0the\u00a0BED\u00a0capture\u00a0enzyme\u00a0immunoassay.\u00a0A IDS.\u00a02008\u00a0Feb\u00a019;22(4):511\u20108.\u00a0\u00a0\n118.\u00a0McDougal\u00a0JS.\u00a0BED\u00a0estimates\u00a0of\u00a0HIV\u00a0incidence\u00a0must\u00a0be\u00a0adjust ed.\u00a0AIDS.\u00a02009\u00a0Sep\u00a024;23(15):2064,5;\u00a0\nauthor\u00a0reply\u00a02066\u20108.\u00a0\u00a0119.\u00a0McWalter\u00a0TA,\u00a0Welte\u00a0A.\u00a0Relating\u00a0recent\u00a0infection\u00a0prevalence \u00a0to\u00a0incidence\u00a0with\u00a0a\u00a0sub\u2010population\u00a0of\u00a0\nassay\u00a0non\u2010progressors.\u00a0\u2010\u00a0J\u00a0Math\u00a0Biol.2010\u00a0May;60(5):687\u2010710.\u00a0\u00a0\u00a0\n -  137120.\u00a0Dukers\u00a0NH,\u00a0Spaargaren\u00a0J,\u00a0Geskus\u00a0RB,\u00a0Beijnen\u00a0J,\u00a0et\u00a0al.\u00a0HIV\u00a0 incidence\u00a0on\u00a0the\u00a0increase\u00a0among\u00a0homosexual\u00a0\nmen\u00a0attending\u00a0an\u00a0amsterdam\u00a0sexually\u00a0transmitted\u00a0disease\u00a0clinic: \u00a0Using\u00a0a\u00a0novel\u00a0approach\u00a0for\u00a0detecting\u00a0\nrecent\u00a0infections.\u00a0\u2010\u00a0AIDS.2002\u00a0Jul\u00a05;16(10):F19\u201024.\u00a0\u00a0\n121.\u00a0Murphy\u00a0G,\u00a0Charlett\u00a0A,\u00a0Jordan\u00a0LF,\u00a0Osner\u00a0N,\u00a0Gill\u00a0ON,\u00a0Parry\u00a0J V.\u00a0HIV\u00a0incidence\u00a0appears\u00a0constant\u00a0in\u00a0men\u00a0\nwho\u00a0 have\u00a0 sex\u00a0 with\u00a0 men\u00a0 despite\u00a0 widespread\u00a0 use\u00a0 of\u00a0 effective\u00a0 antir etroviral\u00a0 therapy.\u00a0 AIDS.\u00a0 2004\u00a0 Jan\u00a0\n23;18(2):265\u201072.\u00a0\u00a0122.\u00a0McFarland\u00a0W,\u00a0Busch\u00a0MP,\u00a0Kellogg\u00a0TA,\u00a0Rawal\u00a0BD,\u00a0et\u00a0al.\u00a0Detect ion\u00a0of\u00a0early\u00a0HIV\u00a0infecti on\u00a0and\u00a0estimation\u00a0of\u00a0\nincidence\u00a0using\u00a0a\u00a0sensitive/less\u2010sensitive\u00a0enzyme\u00a0immunoassay\u00a0t esting\u00a0strategy\u00a0at\u00a0anonymous\u00a0counseling\u00a0\nand\u00a0testing\u00a0sites\u00a0in\u00a0san\u00a0francis co.\u00a0J\u00a0Acquir\u00a0Immune\u00a0Defic\u00a0Syndr .1999\u00a0Dec\u00a015;22(5):484\u20109.\u00a0\u00a0\n123.\u00a0Nesheim\u00a0S,\u00a0Parekh\u00a0B,\u00a0Sullivan\u00a0K,\u00a0Bulterys\u00a0M,\u00a0Dobbs\u00a0T,\u00a0Lind say\u00a0M,\u00a0et\u00a0al.\u00a0Temporal\u00a0trends\u00a0in\u00a0HIV\u00a0type\u00a01\u00a0\nincidence\u00a0 among\u00a0 inner\u2010city\u00a0 childbearing\u00a0 women\u00a0 in\u00a0 Atlanta:\u00a0 Use\u00a0 o f\u00a0 the\u00a0 IgG\u2010capture\u00a0 BED\u2010enzyme\u00a0\nimmunoassay.\u00a0AIDS\u00a0Res\u00a0Hum\u00a0Retr oviruses.\u00a02005\u00a0Jun;21(6):537\u201044.\u00a0 \u00a0\n124.\u00a0Braunstein\u00a0SL,\u00a0van\u00a0de\u00a0Wijgert,Janneke\u00a0H.H.M.,\u00a0Nash\u00a0D.\u00a0HIV\u00a0 incidence\u00a0in\u00a0Sub\u2010saharan\u00a0Africa:\u00a0A\u00a0review\u00a0of\u00a0\navailable\u00a0 data\u00a0 with\u00a0 implications\u00a0 for\u00a0 surveillance\u00a0 and\u00a0 preventio n\u00a0 planning.\u00a0 \u2010\u00a0 AIDS\u00a0 Rev.2009\u00a0 Jul\u2010\nSep;11(3):140\u201056.\u00a0\u00a0125.\u00a0L'Ag\u00e8ncia\u00a0de\u00a0Salut\u00a0P\u00fablica\u00a0 promour\u00e0\u00a0el\u00a0diagn\u00f2stic\u00a0preco\u00e7\u00a0d el\u00a0VIH\u00a0en\u00a0l'\u00e0mbit\u00a0assistencial\u00a0[Nota\u00a0de\u00a0\npremsa].\u00a0 Barcelona:\u00a0 Generalitat\u00a0 de\u00a0 Catalunya.\u00a0 29\u201011\u20102013.\u00a0 Dispo nible\u00a0\na:http://premsa.gencat.cat/pres_fsvp/AppJava/notapremsavw/detall.do?id=233369\n\u00a0\n126.\u00a0Hurtado\u00a0I,\u00a0Alastrue\u00a0I,\u00a0Garc\u00eda\u00a0de\u00a0Olalla\u00a0P,\u00a0et\u00a0al.\u00a0Preventi ve\u00a0intervention\u00a0in\u00a0venues\u00a0for\u00a0interaction\u00a0used\u00a0by\u00a0\nmen\u00a0who\u00a0have\u00a0sex\u00a0with\u00a0men. \u00a0Gac\u00a0Sanit\u00a02010;\u00a024:\u00a078\u201080.\u00a0\n127.\u00a0Fernandez\u2010Lopez\u00a0L,\u00a0Rifa\u00a0B,\u00a0Pujol\u00a0F,\u00a0et\u00a0al.\u00a0Impact\u00a0of\u00a0the\u00a0introduction\u00a0of\u00a0rapid\u00a0HIV\u00a0testing\u00a0in\u00a0the\u00a0\nvoluntary\u00a0counselling\u00a0and\u00a0testing \u00a0sites\u00a0network\u00a0of\u00a0Catalonia,\u00a0S pain.\u00a0Int\u00a0J\u00a0STD\u00a0AIDS\u00a02010;21:388\u201091.\u00a0\n128.\u00a0Folch\u00a0C,\u00a0Casabona\u00a0J,\u00a0Munoz\u00a0R,\u00a0et\u00a0al.\u00a0Increase\u00a0in\u00a0the\u00a0preva lence\u00a0of\u00a0HIV\u00a0and\u00a0in\u00a0associated\u00a0risk\u00a0behaviors\u00a0\nin\u00a0men\u00a0who\u00a0have\u00a0sex\u00a0with\u00a0men:\u00a012\u00a0years\u00a0of\u00a0behavioral\u00a0surveillan ce\u00a0surveys\u00a0in\u00a0Catalonia\u00a0(Spain).\u00a0Gac\u00a0Sanit\u00a0\n2010;24:40\u20136.\u00a0\n\u00a0129.\u00a0Folch\u00a0C,\u00a0Munoz\u00a0R,\u00a0Zaragoza\u00a0K,\u00a0Casabona\u00a0J.\u00a0Sexual\u00a0risk\u00a0beha viour\u00a0and\u00a0its\u00a0determinants\u00a0among\u00a0men\u00a0who\u00a0\nhave\u00a0sex\u00a0with\u00a0men\u00a0in\u00a0Catalonia,\u00a0Spain.\u00a0Euro\u00a0Surveill\u00a02009;14:19 415.\u00a0\n\u00a0130.\u00a0Sullivan\u00a0PS,\u00a0Hamouda\u00a0O,\u00a0Delpech\u00a0V,\u00a0et\u00a0al.\u00a0Reemergence\u00a0of\u00a0t he\u00a0HIV\u00a0epidemic\u00a0among\u00a0men\u00a0who\u00a0have\u00a0sex\u00a0\nwith\u00a0men\u00a0in\u00a0North\u00a0America,\u00a0wes tern\u00a0Europe,\u00a0and\u00a0Australia,\u00a01996\u2010 2005.\u00a0Ann\u00a0Epidem iol\u00a02009;19:423\u201331.  \n\u00a0\n131.\u00a0Wensing\u00a0AM,\u00a0van\u00a0de\u00a0Vijver\u00a0DA,\u00a0Angarano\u00a0G,\u00a0Asjo\u00a0B,\u00a0Balotta\u00a0 C,\u00a0Boeri\u00a0E,\u00a0et\u00a0al.\u00a0Prevalence\u00a0of\u00a0drug\u2010\nresistant\u00a0HIV\u20101\u00a0variants\u00a0in\u00a0untreated\u00a0individuals\u00a0in\u00a0europe:\u00a0Im plications\u00a0for\u00a0clinical\u00a0 management.\u00a0J\u00a0Infect\u00a0\nDis.\u00a02005;192:958\u201366\u00a0\n\u00a0\n132.\u00a0Fox\u00a0J,\u00a0Hill\u00a0S,\u00a0Kaye\u00a0S,\u00a0Dustan\u00a0S,\u00a0McClure\u00a0M,\u00a0Fidler\u00a0S,\u00a0et\u00a0a l.\u00a0Prevalence\u00a0of\u00a0primary\u00a0g enotypic\u00a0resistance\u00a0in\u00a0a\u00a0\nU K \u00a0c e n t r e : \u00a0C o m p a r i s o n \u00a0o f \u00a0p r i m a r y \u00a0H I V \u2010 1 \u00a0a n d \u00a0n e w l y \u00a0d i a g n o s e d \u00a0t r e a tment\u2010naive\u00a0 individuals.\u00a0 AIDS.\u00a0\n2007;21:237\u20139.\u00a0\u00a0133.\u00a0Palacios\u00a0R,\u00a0Viciana\u00a0I,\u00a0Perez\u00a0de\u00a0Pedro\u00a0I,\u00a0de\u00a0la\u00a0Torre\u00a0J,\u00a0Ropero\u00a0F,\u00a0Fernandez\u00a0S,\u00a0et\u00a0al.\u00a0Prevalence\u00a0of\u00a0primary\u00a0resistance\u00a0mutations\u00a0in\u00a0patients\u00a0with\u00a0newly\u00a0diagnosed\u00a0HIV\u00a0infec tion\u00a0in\u00a0the\u00a0province\u00a0of\u00a0Malaga\u00a0(Spain).\u00a0\nEnferm\u00a0Infecc\u00a0Microbiol\u00a0Clin.2008;26:141\u20135.\u00a0\u00a0134.\u00a0de\u00a0Mendoza\u00a0C,\u00a0Rodriguez\u00a0C,\u00a0Colomina\u00a0J,\u00a0Tuset\u00a0C,\u00a0Garcia\u00a0F,\u00a0 Eiros\u00a0JM,\u00a0et\u00a0al.\u00a0Resistance\u00a0to\u00a0nonnucleoside\u00a0\nreverse\u2010transcriptase\u00a0 inhibitors \u00a0a n d \u00a0p r e v a l e n c e \u00a0o f \u00a0H I V \u00a0t y p e \u00a01 \u00a0n on\u2010B\u00a0 subtypes\u00a0 are\u00a0 increasing\u00a0 among\u00a0\npersons\u00a0with\u00a0recent\u00a0infection\u00a0in \u00a0Spain.\u00a0Clin\u00a0Infect\u00a0Dis.\u00a02005;4 1:1350\u20134.\u00a0\u00a0\n 138 \n135.\u00a0 S\u00e1nchez\u00a0 Onoro\u00a0 M,\u00a0 L\u00f3pez\u00a0 MJ,\u00a0 Santana\u00a0 MA,\u00a0 Andes\u00a0 JM,\u00a0 Campelo\u00a0 FA.\u00a0 Primary\u00a0 antiretroviral\u00a0 drug\u00a0\nresistance\u00a0among\u00a0patients\u00a0diagno sed\u00a0with\u00a0HIV\u00a0infection\u00a0in\u00a0Gran\u00a0Canaria\u00a0(Spain)\u00a0between\u00a02002\u00a0and\u00a02005.\u00a0\nEnferm\u00a0Infecc\u00a0Microbiol\u00a0Clin.\u00a02007;25:437\u201340.\u00a0\u00a0136.\u00a0Perez\u2010Alvarez\u00a0L,\u00a0Carmona\u00a0R,\u00a0Munoz\u00a0M,\u00a0Delgado\u00a0E,\u00a0Thomson\u00a0MM ,\u00a0Contreras\u00a0G,\u00a0et\u00a0al.\u00a0High\u00a0incidence\u00a0of\u00a0\nnon\u2010B\u00a0and\u00a0recombinant\u00a0HIV\u20101\u00a0strai ns\u00a0in\u00a0newly\u00a0diagnosed\u00a0patients \u00a0in\u00a0Galicia,\u00a0Spain:\u00a0Study\u00a0of\u00a0genotypic\u00a0\nresistance.\u00a0Antivir\u00a0Ther.\u00a02003;8:355\u201360.\u00a0\u00a0\n137.\u00a0European\u00a0Centre\u00a0for\u00a0Disease\u00a0Prevention\u00a0and\u00a0Control.\u00a0Monito ring\u00a0recently\u00a0acquired\u00a0HIV\u00a0infections\u00a0in\u00a0\nthe\u00a0European\u00a0context.\u00a0Stockholm:\u00a0ECDC;\u00a02013\u00a0\n\u00a0\n\u00a0\n\u00a0\n\u00a0\n\u00a0\n\u00a0\u00a0\u00a0", "language": "PDF", "image": "PDF", "pagetype": "PDF", "links": "PDF"}